#Variation	ClinVar Variation Id	Allele Registry Id	HGVS Expressions	HGNC Gene Symbol	Disease	Mondo Id	Mode of Inheritance	Assertion	Applied Evidence Codes (Met)	Applied Evidence Codes (Not Met)	Summary of interpretation	PubMed Articles	Expert Panel	Guideline	Approval Date	Published Date	Retracted	Evidence Repo Link	Uuid
NM_000277.2(PAH):c.1A>G (p.Met1Val)	586	CA114360	NM_000277.2:c.1A>G, NC_000012.12:g.102917130T>C, CM000674.2:g.102917130T>C, NC_000012.11:g.103310908T>C, CM000674.1:g.103310908T>C, NC_000012.10:g.101835038T>C, NG_008690.1:g.5473A>G, NG_008690.2:g.46281A>G, NM_000277.1:c.1A>G, XM_011538422.1:c.1A>G, NM_001354304.1:c.1A>G, XM_017019370.2:c.1A>G, NM_000277.3:c.1A>G, ENST00000307000.7:c.-147A>G, ENST00000546844.1:c.1A>G, ENST00000547319.1:n.312A>G, ENST00000549111.5:n.97A>G, ENST00000551337.5:c.1A>G, ENST00000551988.5:n.90A>G, ENST00000553106.5:c.1A>G, ENST00000635500.1:n.29-4232A>G, NM_000277.2(PAH):c.1A>G (p.Met1Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PS3	PVS1	PAH-specific ACMG/AMP criteria applied: PM2: gnomAD MAF=0.00002; PP4_Moderate: Seen in PKU patients. BH4 disorders ruled out. (PMID:2574002); PS3: <3% (PMID:9450897). PM3: Detected in trans with known pathogenic variants. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM3, PP4_Moderate, PS3). Updated to reflect new PVS1 recommendations.	2574002, 2574002, 9450897	Phenylketonuria VCEP		2019-03-23	2019-05-10	false	https://erepo.genome.network/evrepo/ui/classification/CA114360/MONDO:0009861/006	89f04437-ed5d-4735-8c4a-a9b1d91d10ea
NM_000277.2(PAH):c.806delT (p.Ile269Thrfs)	102844	CA229778	NM_000277.2:c.806delT, NC_000012.12:g.102852851del, CM000674.2:g.102852851del, NC_000012.11:g.103246629del, CM000674.1:g.103246629del, NC_000012.10:g.101770759del, NG_008690.1:g.69752del, NG_008690.2:g.110560del, NM_000277.1:c.806del, XM_011538422.1:c.806del, NM_000277.2:c.806del, NM_001354304.1:c.806del, NM_000277.3:c.806del, ENST00000307000.7:c.791del, ENST00000549247.6:n.565del, ENST00000553106.5:c.806del, NM_000277.2(PAH):c.806delT (p.Ile269Thrfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4		PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Extremely low frequency. gnomAD MAF=0.00007.; PP4: Detected in a PKU patient. BH4 deficiency not assessed. (PMID:9012412). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4).	9012412	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229778/MONDO:0009861/006	f5d8dc3f-dba0-4dc9-98cd-4a22b6a11a83
NM_000277.2(PAH):c.561G>A (p.Trp187Ter)	102736	CA229624	NM_000277.2:c.561G>A, NC_000012.12:g.102855281C>T, CM000674.2:g.102855281C>T, NC_000012.11:g.103249059C>T, CM000674.1:g.103249059C>T, NC_000012.10:g.101773189C>T, NG_008690.1:g.67322G>A, NG_008690.2:g.108130G>A, NM_000277.1:c.561G>A, XM_011538422.1:c.561G>A, NM_001354304.1:c.561G>A, XM_017019370.2:c.561G>A, NM_000277.3:c.561G>A, ENST00000307000.7:c.546G>A, ENST00000549111.5:n.657G>A, ENST00000551988.5:n.582G>A, ENST00000553106.5:c.561G>A, NM_000277.2(PAH):c.561G>A (p.Trp187Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PP4_Moderate, PM2		PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: Extremely low frequency in gnomAD. MAF=0.00002.; PP4_Moderate: Detected in 3 chromosomes of patients with PAH deficiency. BH4 deficiency ruled out. (PMID:8268925). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate).	8268925	Phenylketonuria VCEP		2018-08-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229624/MONDO:0009861/006	c75a3cc6-1a5e-4837-b431-6e2b2a14c0b1
NM_000277.2(PAH):c.503delA (p.Tyr168Serfs)	102705	CA229588	NM_000277.2:c.503delA, NC_000012.12:g.102866602del, CM000674.2:g.102866602del, NC_000012.11:g.103260380del, CM000674.1:g.103260380del, NC_000012.10:g.101784510del, NG_008690.1:g.56001del, NG_008690.2:g.96809del, NM_000277.1:c.503del, XM_011538422.1:c.503del, NM_000277.2:c.503del, NM_001354304.1:c.503del, XM_017019370.2:c.503del, NM_000277.3:c.503del, ENST00000307000.7:c.488del, ENST00000549111.5:n.599del, ENST00000551988.5:n.530+10860del, ENST00000553106.5:c.503del, NM_000277.2(PAH):c.503delA (p.Tyr168Serfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4		PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Extremely low frequency. ExAC MAF: 0.00001.; PP4: Detected in PKU patient in international phase II clinical trial for sapropterin. (PMID:23430918). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4).	23430918	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229588/MONDO:0009861/006	7a494430-377e-4473-a5f7-e0698ec51cab
NM_000277.2(PAH):c.1089delG (p.Lys363Asnfs)	102518	CA229336	NM_000277.2:c.1089delG, NC_000012.12:g.102843756del, CM000674.2:g.102843756del, NC_000012.11:g.103237534del, CM000674.1:g.103237534del, NC_000012.10:g.101761664del, NG_008690.1:g.78847del, NG_008690.2:g.119655del, NM_000277.1:c.1089del, XM_011538422.1:c.1032del, NM_000277.2:c.1089del, NM_001354304.1:c.1089del, NM_000277.3:c.1089del, ENST00000307000.7:c.1074del, ENST00000549247.6:n.848del, ENST00000551114.2:n.751del, ENST00000553106.5:c.1089del, ENST00000635477.1:n.193del, ENST00000635528.1:n.604del, NM_000277.2(PAH):c.1089delG (p.Lys363Asnfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4		PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP4: Detected in a patient with Classical PKU. (PMID:8659548). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4).	8659548	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229336/MONDO:0009861/006	f73ce257-c08b-40ce-845f-012c6403252c
NM_000277.2(PAH):c.1055delG (p.Gly352Valfs)	102498	CA229311	NM_000277.2:c.1055delG, NC_000012.12:g.102844347del, CM000674.2:g.102844347del, NC_000012.11:g.103238125del, CM000674.1:g.103238125del, NC_000012.10:g.101762255del, NG_008690.1:g.78257del, NG_008690.2:g.119065del, NM_000277.1:c.1055del, XM_011538422.1:c.998del, NM_000277.2:c.1055del, NM_001354304.1:c.1055del, NM_000277.3:c.1055del, ENST00000307000.7:c.1040del, ENST00000549247.6:n.814del, ENST00000551114.2:n.717del, ENST00000553106.5:c.1055del, ENST00000635477.1:n.159del, ENST00000635528.1:n.570del, NM_000277.2(PAH):c.1055delG (p.Gly352Valfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4		PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Extremely low frequency in ExAC, MAF=0.00002.; PP4: Identified in a pair of siblings with PKU. (PMID:7913581). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4).	7913581	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229311/MONDO:0009861/006	65776af0-77ed-41ec-9999-612a44a636b2
NM_000277.2(PAH):c.1024delG (p.Ala342Hisfs)	102475	CA229279	NM_000277.2:c.1024delG, NC_000012.12:g.102844378del, CM000674.2:g.102844378del, NC_000012.11:g.103238156del, CM000674.1:g.103238156del, NC_000012.10:g.101762286del, NG_008690.1:g.78226del, NG_008690.2:g.119034del, NM_000277.1:c.1024del, XM_011538422.1:c.967del, NM_000277.2:c.1024del, NM_001354304.1:c.1024del, NM_000277.3:c.1024del, ENST00000307000.7:c.1009del, ENST00000549247.6:n.783del, ENST00000551114.2:n.686del, ENST00000553106.5:c.1024del, ENST00000635477.1:n.128del, ENST00000635528.1:n.539del, NM_000277.2(PAH):c.1024delG (p.Ala342Hisfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PP4_Moderate, PM2		PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PVS1: Frameshift variant; PP4_Moderate: Reported in patients with PAH deficiency. Bh4 defects excluded. (PMID:9634518). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4_Moderate).	9634518	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229279/MONDO:0009861/006	4cc2d322-d860-4209-b3df-63e58bac3b07
NM_000277.2(PAH):c.912+1G>A	92752	CA220591	NM_000277.2:c.912+1G>A, NC_000012.12:g.102851686C>T, CM000674.2:g.102851686C>T, NC_000012.11:g.103245464C>T, CM000674.1:g.103245464C>T, NC_000012.10:g.101769594C>T, NG_008690.1:g.70917G>A, NG_008690.2:g.111725G>A, NM_000277.1:c.912+1G>A, XM_011538422.1:c.912+1G>A, NM_001354304.1:c.912+1G>A, NM_000277.3:c.912+1G>A, ENST00000307000.7:c.897+1G>A, ENST00000549247.6:n.671+1G>A, ENST00000551114.2:n.574+1G>A, ENST00000553106.5:c.912+1G>A, ENST00000635477.1:n.73+1G>A, NM_000277.2(PAH):c.912+1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4		PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency. ExAC MAF=0.00006.; PVS1: Canonical +1 splice site; PP4: Detected in 5 patients with classical PKU. (PMID:8659548). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4).	8659548	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA220591/MONDO:0009861/006	f8b8c165-463e-4138-88c6-316879bdcf67
NM_000277.2(PAH):c.331C>T (p.Arg111Ter)	581	CA251526	NM_000277.2:c.331C>T, NC_000012.12:g.102894756G>A, CM000674.2:g.102894756G>A, NC_000012.11:g.103288534G>A, CM000674.1:g.103288534G>A, NC_000012.10:g.101812664G>A, NG_008690.1:g.27847C>T, NG_008690.2:g.68655C>T, NM_000277.1:c.331C>T, XM_011538422.1:c.331C>T, NM_001354304.1:c.331C>T, XM_017019370.2:c.331C>T, NM_000277.3:c.331C>T, ENST00000307000.7:c.316C>T, ENST00000546844.1:c.331C>T, ENST00000548928.1:n.253C>T, ENST00000549111.5:n.427C>T, ENST00000550978.6:n.315C>T, ENST00000551337.5:c.331C>T, ENST00000551988.5:n.420C>T, ENST00000553106.5:c.331C>T, NM_000277.2(PAH):c.331C>T (p.Arg111Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PVS1, PM3_Very Strong	PM2	PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PP4_Moderate: Seen in multiple Chinese PKU patients. BH4 deficiency excluded. (PMID:1301187; PMID:2816939; PMID:9860305); PM3_very-strong: Detected in trans with 6 known pathogenic variants: p.R158Q; p.R241C; p.R243Q; p.E280K; p.Y356*; p.R413P (PMID:15503242, 26322415). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PP4_Moderate, PM3_very-strong).	9860305, 1301187, 2816939, 26322415, 15503242	Phenylketonuria VCEP		2019-04-09	2019-04-09	false	https://erepo.genome.network/evrepo/ui/classification/CA251526/MONDO:0009861/006	a0f4f502-3d14-496e-92b6-b2160d5d9013
NM_000277.2(PAH):c.472C>T (p.Arg158Trp)	102693	CA229570	NM_000277.2:c.472C>T, NC_000012.12:g.102866633G>A, CM000674.2:g.102866633G>A, NC_000012.11:g.103260411G>A, CM000674.1:g.103260411G>A, NC_000012.10:g.101784541G>A, NG_008690.1:g.55970C>T, NG_008690.2:g.96778C>T, NM_000277.1:c.472C>T, XM_011538422.1:c.472C>T, NM_001354304.1:c.472C>T, XM_017019370.2:c.472C>T, NM_000277.3:c.472C>T, ENST00000307000.7:c.457C>T, ENST00000549111.5:n.568C>T, ENST00000551988.5:n.530+10829C>T, ENST00000553106.5:c.472C>T, NM_000277.2(PAH):c.472C>T (p.Arg158Trp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2, PP3, PS3, PM3_Strong		PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency. ExAC MAF=0.00019.; PP3: Predicted deleterious in SIFT, Polyphen-2, MutationTaster. REVEL=0.939; PS3: 2% mutant enzyme activity in BioPKU; PP4_Moderate: Detected in at least 3 patients with PAH deficiency. BH4 deficiency ruled out in 1 patient. (PMID:1307609; PMID:10429004; PMID:9634518); PM3_Strong: Detected with 3 pathogenic/likely pathogenic variants (PMID:14681498; PMID:23430918). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PP4_Moderate, PM3_Strong).	9634518, 1307609, 10429004, 23430918, 14681498	Phenylketonuria VCEP		2018-08-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229570/MONDO:0009861/006	faad1844-5076-4b6f-b671-eeb06035449a
NM_000277.2(PAH):c.526C>T (p.Arg176Ter)	102723	CA275338	NM_000277.2:c.526C>T, NC_000012.12:g.102855316G>A, CM000674.2:g.102855316G>A, NC_000012.11:g.103249094G>A, CM000674.1:g.103249094G>A, NC_000012.10:g.101773224G>A, NG_008690.1:g.67287C>T, NG_008690.2:g.108095C>T, NM_000277.1:c.526C>T, XM_011538422.1:c.526C>T, NM_001354304.1:c.526C>T, XM_017019370.2:c.526C>T, NM_000277.3:c.526C>T, ENST00000307000.7:c.511C>T, ENST00000549111.5:n.622C>T, ENST00000551988.5:n.547C>T, ENST00000553106.5:c.526C>T, NM_000277.2(PAH):c.526C>T (p.Arg176Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4_Moderate, PM3_Strong		PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: ExAC MAF: 0.00010; PP4_Moderate: BH4 defect excluded in all patients in Liu 2015. Identified in 6 patients in this study (PMID:10394930; PMID:26600521); PM3_Strong: Identified in 6 patients, in trans with R243Q and R241C (both pathogenic) (PMID:26600521). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate, PM3_Strong).	10394930, 26600521, 26600521	Phenylketonuria VCEP		2018-08-13	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA275338/MONDO:0009861/006	08d51386-af9e-4de1-8e7b-0dc6c2252c91
NM_000277.2(PAH):c.169G>A (p.Glu57Lys)	92737	CA220578	NM_000277.2:c.169G>A, NC_000012.12:g.102894918C>T, CM000674.2:g.102894918C>T, NC_000012.11:g.103288696C>T, CM000674.1:g.103288696C>T, NC_000012.10:g.101812826C>T, NG_008690.1:g.27685G>A, NG_008690.2:g.68493G>A, NM_000277.1:c.169G>A, XM_011538422.1:c.169G>A, NM_001354304.1:c.169G>A, XM_017019370.2:c.169G>A, NM_000277.3:c.169G>A, ENST00000307000.7:c.154G>A, ENST00000546844.1:c.169G>A, ENST00000548677.2:n.256G>A, ENST00000548928.1:n.91G>A, ENST00000549111.5:n.265G>A, ENST00000550978.6:n.153G>A, ENST00000551337.5:c.169G>A, ENST00000551988.5:n.258G>A, ENST00000553106.5:c.169G>A, ENST00000635500.1:n.137G>A, NM_000277.2(PAH):c.169G>A (p.Glu57Lys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4_Moderate, PM3_Supporting	PP3	PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency. ESP MAF=0.00012.; PP4_Moderate: Detected in a patient with mild HPA. Assessment of the PAH, PTS, and QDPR genes was performed. (PMID:21147011); PM3-supporting: Detected with V388M, pathogenic in ClinVar, but parental testing not performed. (PMID:21147011). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_supporting).	21147011, 21147011	Phenylketonuria VCEP		2019-04-26	2019-04-26	false	https://erepo.genome.network/evrepo/ui/classification/CA220578/MONDO:0009861/006	1afec1b2-0d05-412d-b7b8-5253350ff838
NM_000277.2(PAH):c.581T>C (p.Leu194Pro)	102742	CA229633	NM_000277.2:c.581T>C, NC_000012.12:g.102855261A>G, CM000674.2:g.102855261A>G, NC_000012.11:g.103249039A>G, CM000674.1:g.103249039A>G, NC_000012.10:g.101773169A>G, NG_008690.1:g.67342T>C, NG_008690.2:g.108150T>C, NM_000277.1:c.581T>C, XM_011538422.1:c.581T>C, NM_001354304.1:c.581T>C, XM_017019370.2:c.581T>C, NM_000277.3:c.581T>C, ENST00000307000.7:c.566T>C, ENST00000549111.5:n.677T>C, ENST00000553106.5:c.581T>C, NM_000277.2(PAH):c.581T>C (p.Leu194Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PP3, PM3_Strong		PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. gnomAD MAF:0.00004.; PP3: Predicted deleterious in SIFT, Polyphen-2, MutationTaster. REVEL=0.899; PM3_Strong: Detected in trans with V245A and R261X, both pathogenic (PMID:7981714; PMID:16601866); PP4_Moderate: Detected in 3 patients (1 HPA, 1 PKU). BH4 deficiency excluded in 2 patients. (PMID:8533759; PMID:7981714; PMID:9012412; PMID:16601866). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM3_Strong, PP4_Moderate).	9012412, 16601866, 8533759, 7981714, 16601866, 7981714	Phenylketonuria VCEP		2018-08-13	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229633/MONDO:0009861/006	434f1539-4967-4ff7-abc2-e2ff3ca9ecbe
NM_000277.2(PAH):c.533A>G (p.Glu178Gly)	92746	CA273110	NM_000277.2:c.533A>G, NC_000012.12:g.102855309T>C, CM000674.2:g.102855309T>C, NC_000012.11:g.103249087T>C, CM000674.1:g.103249087T>C, NC_000012.10:g.101773217T>C, NG_008690.1:g.67294A>G, NG_008690.2:g.108102A>G, ENST00000553106.6:c.533A>G, ENST00000307000.7:c.518A>G, ENST00000549111.5:n.629A>G, ENST00000551988.5:n.554A>G, ENST00000553106.5:c.533A>G, NM_000277.1:c.533A>G, XM_011538422.1:c.533A>G, NM_001354304.1:c.533A>G, XM_017019370.2:c.533A>G, NM_000277.3:c.533A>G, NM_001354304.2:c.533A>G, NM_000277.2(PAH):c.533A>G (p.Glu178Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2_Supporting, PM3_Strong, PP3_Moderate, PS3_Supporting		The c.533A>G variant in PAH is a missense variant predicted to cause substitution of glutamine by glycine at amino acid 178 (p.Glu178Gly).  At least 5 patients with this variant displayed serum Phe levels > 6.5â€“10 mg/dl which is highly specific for PAH deficiency; BH4 deficiency was excluded (PP4_moderate, PMID: 18299955, PMID:9634518). Of those individuals, 4 probands were compound heterozygous for the variant and a pathogenic variant and 1 proband was compound heterozygous with a likely pathogenic variant (phase unknown, 2.25 points). The population allele frequency in gnomAD v4.1 is 0.00003965 which is lower than the ClinGen PAH VCEP threshold (<0.0002) for PM2_Supporting, meeting this criterion (PM2_Supporting).  The results from in silico predictors [REVEL=0.841], predict a damaging effect on PAH function (PP3_moderate). Enzyme activity assay showed 39% residual phenylalanine hydroxylase activity indicating that this variant impacts protein function (PMID:17935162)(PS3_supporting).  In summary, this variant meets criteria to be classified as pathogenic for PAH deficiency in an autosomal recessive manner based on the ACMG/AMP criteria applied, as specified by the ClinGen PAH Expert Panel: PM2_supporting, PP3_moderate, PS3_supporting, PP4_Moderate, PM3_Strong (version 2.0, 11/16/2024).		Phenylketonuria VCEP		2025-04-18	2025-04-18	false	https://erepo.genome.network/evrepo/ui/classification/CA273110/MONDO:0009861/006	9cbb36d6-2daf-4507-b947-3a692ec4d9e7
NM_000277.2(PAH):c.1242C>T (p.Tyr414=)	102577	CA200893	NM_000277.2:c.1242C>T, NC_000012.12:g.102840473G>A, CM000674.2:g.102840473G>A, NC_000012.11:g.103234251G>A, CM000674.1:g.103234251G>A, NC_000012.10:g.101758381G>A, NG_008690.1:g.82130C>T, NG_008690.2:g.122938C>T, NM_000277.1:c.1242C>T, XM_011538422.1:c.1185C>T, NM_001354304.1:c.1242C>T, NM_000277.3:c.1242C>T, ENST00000307000.7:c.1227C>T, ENST00000551114.2:n.904C>T, ENST00000553106.5:c.1242C>T, ENST00000635477.1:n.346C>T, ENST00000635528.1:n.757C>T, NM_000277.2(PAH):c.1242C>T (p.Tyr414=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BS2, BS1	BP4	PAH-specific ACMG/AMP criteria applied: BS1: MAF=0.01361 in ENF from gnomAD; BS2: 19 homozygotes in gnomAD. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BS2).		Phenylketonuria VCEP		2018-08-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA200893/MONDO:0009861/006	349736d7-05a8-4ec0-9b30-04fa24dd5529
NM_000277.2(PAH):c.1278T>C (p.Asn426=)	92732	CA145978	NM_000277.2:c.1278T>C, NC_000012.12:g.102840437A>G, CM000674.2:g.102840437A>G, NC_000012.11:g.103234215A>G, CM000674.1:g.103234215A>G, NC_000012.10:g.101758345A>G, NG_008690.1:g.82166T>C, NG_008690.2:g.122974T>C, NM_000277.1:c.1278T>C, XM_011538422.1:c.1221T>C, NM_001354304.1:c.1278T>C, NM_000277.3:c.1278T>C, ENST00000307000.7:c.1263T>C, ENST00000551114.2:n.940T>C, ENST00000553106.5:c.1278T>C, ENST00000635477.1:n.382T>C, ENST00000635528.1:n.793T>C, NM_000277.2(PAH):c.1278T>C (p.Asn426=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BP4, BA1		PAH-specific ACMG/AMP criteria applied: BA1: MAF=0.16641; BP4: no impact on gene in SIFT, Polyphen2, MutationTaster. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1, BP4).		Phenylketonuria VCEP		2018-08-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA145978/MONDO:0009861/006	66eeb668-a8a7-49cb-a6cd-26afcc800972
NM_000277.2(PAH):c.355C>T (p.Pro119Ser)	92741	CA220582	NM_000277.2:c.355C>T, NC_000012.12:g.102877548G>A, CM000674.2:g.102877548G>A, NC_000012.11:g.103271326G>A, CM000674.1:g.103271326G>A, NC_000012.10:g.101795456G>A, NG_008690.1:g.45055C>T, NG_008690.2:g.85863C>T, NM_000277.1:c.355C>T, XM_011538422.1:c.355C>T, NM_001354304.1:c.355C>T, XM_017019370.2:c.355C>T, NM_000277.3:c.355C>T, ENST00000307000.7:c.340C>T, ENST00000549111.5:n.451C>T, ENST00000550978.6:n.339C>T, ENST00000551337.5:c.355C>T, ENST00000551988.5:n.444C>T, ENST00000553106.5:c.355C>T, NM_000277.2(PAH):c.355C>T (p.Pro119Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PP3, PM3_Strong	PM2	PAH-specific ACMG/AMP criteria applied: PP3: in silico analysis supportive of damaging effect; PM3_Strong: In trans with R261Q (PMID 21147011), and in trans with IVS2+1G>A (PMID 12655554) (PMID:21147011; PMID:12655554); PP4_Moderate: BH4 deficiency excluded (PMID:21147011). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PM3_Strong, PP4_Moderate).	21147011, 12655554, 21147011	Phenylketonuria VCEP		2018-07-29	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA220582/MONDO:0009861/006	38a183ee-7e53-4c24-a250-50958f390c78
NM_000277.2(PAH):c.299A>G (p.His100Arg)	306914	CA6748985	NM_000277.2:c.299A>G, NC_000012.12:g.102894788T>C, CM000674.2:g.102894788T>C, NC_000012.11:g.103288566T>C, CM000674.1:g.103288566T>C, NC_000012.10:g.101812696T>C, NG_008690.1:g.27815A>G, NG_008690.2:g.68623A>G, NM_000277.1:c.299A>G, XM_011538422.1:c.299A>G, NM_001354304.1:c.299A>G, XM_017019370.2:c.299A>G, NM_000277.3:c.299A>G, ENST00000307000.7:c.284A>G, ENST00000546844.1:c.299A>G, ENST00000548928.1:n.221A>G, ENST00000549111.5:n.395A>G, ENST00000550978.6:n.283A>G, ENST00000551337.5:c.299A>G, ENST00000551988.5:n.388A>G, ENST00000553106.5:c.299A>G, NM_000277.2(PAH):c.299A>G (p.His100Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM3, PP4, BP4	PM2	PAH-specific ACMG/AMP criteria applied: BP4: In silico overwhelmingly predict benign. REVEL = 0.553; PP4: Detected in a patient with non PKU hyperphe (PMID:11244681); PM3: H100R detected with IVS10 (PMID:11244681). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BP4, PP4, PM3).	11244681, 11244681	Phenylketonuria VCEP		2018-08-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA6748985/MONDO:0009861/006	a445bf0d-e08f-4300-b282-53c974544d50
NM_000277.1:c.772C>T	590340	CA6748843	NM_000277.1:c.772C>T, NC_000012.12:g.102852885G>A, CM000674.2:g.102852885G>A, NC_000012.11:g.103246663G>A, CM000674.1:g.103246663G>A, NC_000012.10:g.101770793G>A, NG_008690.1:g.69718C>T, NG_008690.2:g.110526C>T, XM_011538422.1:c.772C>T, NM_000277.2:c.772C>T, NM_001354304.1:c.772C>T, NM_000277.3:c.772C>T, ENST00000307000.7:c.757C>T, ENST00000549247.6:n.531C>T, ENST00000553106.5:c.772C>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Benign	BS1, BP7	PM2	PAH-specific ACMG/AMP criteria applied: BS1: > PAH specific guidelines of AF-0.0002 (0.02%); BP7: No deleterious effect predicted.. In summary this variant meets criteria to be classified as likely benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BP7).		Phenylketonuria VCEP		2018-08-13	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA6748843/MONDO:0009861/006	254ed141-a219-404a-8c94-1fd2aceb8103
NM_000277.2(PAH):c.963C>T (p.Leu321=)	102911	CA229873	NM_000277.2:c.963C>T, NC_000012.12:g.102846901G>A, CM000674.2:g.102846901G>A, NC_000012.11:g.103240679G>A, CM000674.1:g.103240679G>A, NC_000012.10:g.101764809G>A, NG_008690.1:g.75702C>T, NG_008690.2:g.116510C>T, NM_000277.1:c.963C>T, XM_011538422.1:c.913-2470C>T, NM_001354304.1:c.963C>T, NM_000277.3:c.963C>T, ENST00000307000.7:c.948C>T, ENST00000549247.6:n.722C>T, ENST00000551114.2:n.625C>T, ENST00000553106.5:c.963C>T, ENST00000635477.1:n.74-2470C>T, ENST00000635528.1:n.478C>T, NM_000277.2(PAH):c.963C>T (p.Leu321=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BS2, BS3_Supporting, BS1, BP7		PAH-specific ACMG/AMP criteria applied: BS1: >0.02% as set by the PAH specific specifications; BP7: ; BS3_Supporting: cDNA method demonstrates 98% and intinic system demonstrates 81% residual enzyme activity; BS2: 38 homozygotes in gnomAD. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BP7, BS3_Supporting, BS2).		Phenylketonuria VCEP		2018-07-29	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229873/MONDO:0009861/006	31e57f08-7be8-46c7-902d-8429b753f57c
NM_000277.2(PAH):c.500A>G (p.Asn167Ser)	102703	CA229585	NM_000277.2:c.500A>G, NC_000012.12:g.102866605T>C, CM000674.2:g.102866605T>C, NC_000012.11:g.103260383T>C, CM000674.1:g.103260383T>C, NC_000012.10:g.101784513T>C, NG_008690.1:g.55998A>G, NG_008690.2:g.96806A>G, NM_000277.1:c.500A>G, XM_011538422.1:c.500A>G, NM_001354304.1:c.500A>G, XM_017019370.2:c.500A>G, NM_000277.3:c.500A>G, ENST00000307000.7:c.485A>G, ENST00000549111.5:n.596A>G, ENST00000551988.5:n.530+10857A>G, ENST00000553106.5:c.500A>G, NM_000277.2(PAH):c.500A>G (p.Asn167Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4, BS1	PP3	PAH-specific ACMG/AMP criteria applied: PP4: N167S was observed in 1 case (genotype N167S/-) with benign persistent hyperphenylalaninemia (200-600 uM). (PMID:11385716); BS1: gnomAD MAF: 0.01461. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4, BS1).	11385716	Phenylketonuria VCEP		2018-08-13	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229585/MONDO:0009861/006	33e1f5d5-20ab-45d2-8dcd-4eba431a8642
NM_000277.2(PAH):c.464G>C (p.Arg155Pro)	102687	CA229561	NM_000277.2:c.464G>C, NC_000012.12:g.102866641C>G, CM000674.2:g.102866641C>G, NC_000012.11:g.103260419C>G, CM000674.1:g.103260419C>G, NC_000012.10:g.101784549C>G, NG_008690.1:g.55962G>C, NG_008690.2:g.96770G>C, NM_000277.1:c.464G>C, XM_011538422.1:c.464G>C, NM_001354304.1:c.464G>C, XM_017019370.2:c.464G>C, NM_000277.3:c.464G>C, ENST00000307000.7:c.449G>C, ENST00000549111.5:n.560G>C, ENST00000551988.5:n.530+10821G>C, ENST00000553106.5:c.464G>C, NM_000277.2(PAH):c.464G>C (p.Arg155Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		PAH-specific ACMG/AMP criteria applied: PM2: absent from ExAC, gnomAD, 1000G, ESP. PAGE MAF=0.00066; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.967; PP4_Moderate: Detected in a patient with classic PKU. Cofactor deficiency excluded. (PMID:10679941); PM3: Detected in trans with R408W (P) (PMID:10679941). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3).	10679941, 10679941	Phenylketonuria VCEP		2018-08-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229561/MONDO:0009861/006	a532eae1-862f-4d90-b69e-5e590a9f7512
NM_000277.2(PAH):c.511G>A (p.Gly171Arg)	102716	CA229598	NM_000277.2:c.511G>A, NC_000012.12:g.102855331C>T, CM000674.2:g.102855331C>T, NC_000012.11:g.103249109C>T, CM000674.1:g.103249109C>T, NC_000012.10:g.101773239C>T, NG_008690.1:g.67272G>A, NG_008690.2:g.108080G>A, NM_000277.1:c.511G>A, XM_011538422.1:c.511G>A, NM_001354304.1:c.511G>A, XM_017019370.2:c.511G>A, NM_000277.3:c.511G>A, ENST00000307000.7:c.496G>A, ENST00000549111.5:n.607G>A, ENST00000551988.5:n.532G>A, ENST00000553106.5:c.511G>A, NM_000277.2(PAH):c.511G>A (p.Gly171Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2, PP4_Moderate, PP3, PM3_Strong		PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.966; PP4_Moderate: Detected in PKU patients. BH4 deficiency assessed. Upgraded per ClinGen PAH EP. (PMID:26600521; PMID:23430918); PM3_Strong: Detected with c.611A>G (P/LP) and R408W (P). Upgraded per ClinGen SVI workgroup. (PMID:23430918; PMID:26600521). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong).	23430918, 26600521, 26600521, 23430918	Phenylketonuria VCEP		2018-08-10	2019-05-04	false	https://erepo.genome.network/evrepo/ui/classification/CA229598/MONDO:0009861/006	0dbfb1dc-9c9b-4fbe-b1a1-37b190aafe51
NM_000277.2(PAH):c.158G>A (p.Arg53His)	102601	CA229447	NM_000277.2:c.158G>A, NC_000012.12:g.102912801C>T, CM000674.2:g.102912801C>T, NC_000012.11:g.103306579C>T, CM000674.1:g.103306579C>T, NC_000012.10:g.101830709C>T, NG_008690.1:g.9802G>A, NG_008690.2:g.50610G>A, NM_000277.1:c.158G>A, XM_011538422.1:c.158G>A, NM_001354304.1:c.158G>A, XM_017019370.2:c.158G>A, NM_000277.3:c.158G>A, ENST00000307000.7:c.143G>A, ENST00000546844.1:c.158G>A, ENST00000548677.2:n.245G>A, ENST00000548928.1:n.80G>A, ENST00000549111.5:n.254G>A, ENST00000550978.6:n.142G>A, ENST00000551337.5:c.158G>A, ENST00000551988.5:n.247G>A, ENST00000553106.5:c.158G>A, ENST00000635500.1:n.126G>A, NM_000277.2(PAH):c.158G>A (p.Arg53His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM3, PP4_Moderate, BS1	PP3	PAH-specific ACMG/AMP criteria applied: BS1: MAF=0.01596 in ExAC (138/8648) and 0.0104 in gnomAD (265/18868 with 3 homozygotes); PP4_moderate: Detected in multiple patients with hyperphenylalaninemia, BH4 deficiency excluded (PMID:24401910, 26322415); PM3: Detected in trans with pathogenic variant p.R243Q. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, PP4_moderate, PM3).	24401910, 26322415, 24401910, 26322415	Phenylketonuria VCEP		2019-04-08	2019-04-08	false	https://erepo.genome.network/evrepo/ui/classification/CA229447/MONDO:0009861/006	0b0aa28d-6844-4b34-a270-410f26ce9504
NM_000277.2(PAH):c.535T>A (p.Tyr179Asn)	102729	CA229613	NM_000277.2:c.535T>A, NC_000012.12:g.102855307A>T, CM000674.2:g.102855307A>T, NC_000012.11:g.103249085A>T, CM000674.1:g.103249085A>T, NC_000012.10:g.101773215A>T, NG_008690.1:g.67296T>A, NG_008690.2:g.108104T>A, NM_000277.1:c.535T>A, XM_011538422.1:c.535T>A, NM_001354304.1:c.535T>A, XM_017019370.2:c.535T>A, NM_000277.3:c.535T>A, ENST00000307000.7:c.520T>A, ENST00000549111.5:n.631T>A, ENST00000551988.5:n.556T>A, ENST00000553106.5:c.535T>A, NM_000277.2(PAH):c.535T>A (p.Tyr179Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.929; PP4_Moderate: Detected in 1 PKU patient, primary BH4 deficiency excluded. Upgraded per ClinGen PAH EP. (PMID:23430918); PM3: Detected with c.1066-11G>A (P) (PMID:23430918). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3).	23430918, 23430918	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229613/MONDO:0009861/006	1530f57a-9096-4f98-a934-15ce8f576c73
NM_000277.2(PAH):c.842+3G>C	102871	CA229814	NM_000277.2:c.842+3G>C, NC_000012.12:g.102852812C>G, CM000674.2:g.102852812C>G, NC_000012.11:g.103246590C>G, CM000674.1:g.103246590C>G, NC_000012.10:g.101770720C>G, NG_008690.1:g.69791G>C, NG_008690.2:g.110599G>C, NM_000277.1:c.842+3G>C, XM_011538422.1:c.842+3G>C, NM_001354304.1:c.842+3G>C, NM_000277.3:c.842+3G>C, ENST00000307000.7:c.827+3G>C, ENST00000549247.6:n.601+3G>C, ENST00000553106.5:c.842+3G>C, ENST00000635477.1:n.3+3G>C, NM_000277.2(PAH):c.842+3G>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PM3_Strong		PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in gnomAD+ExAC (MAF=0.00006). Absent from 1000G, ESP.; PP4_Moderate: Detected in Costa Rican and 1 Spanish PKU patients, exclusion of defects in tetrahydrobiopterine metabolism. (PMID:8860005; PMID:8981952); PM3_Strong: Detected in trans with I269L and R408W, known pathogenic variants. (PMID:9521426; PMID:23430918). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_Strong).	8860005, 8981952, 9521426, 23430918	Phenylketonuria VCEP		2018-09-11	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229814/MONDO:0009861/006	ad7649c8-a5c0-4598-8404-91fbd76346b9
NM_000277.2(PAH):c.500A>T (p.Asn167Ile)	92743	CA220584	NM_000277.2:c.500A>T, NC_000012.12:g.102866605T>A, CM000674.2:g.102866605T>A, NC_000012.11:g.103260383T>A, CM000674.1:g.103260383T>A, NC_000012.10:g.101784513T>A, NG_008690.1:g.55998A>T, NG_008690.2:g.96806A>T, NM_000277.1:c.500A>T, XM_011538422.1:c.500A>T, NM_001354304.1:c.500A>T, XM_017019370.2:c.500A>T, NM_000277.3:c.500A>T, ENST00000307000.7:c.485A>T, ENST00000549111.5:n.596A>T, ENST00000551988.5:n.530+10857A>T, ENST00000553106.5:c.500A>T, NM_000277.2(PAH):c.500A>T (p.Asn167Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PM3_Strong	PP3	PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC (MAF=0.00003). Absent from gnomAD, 1000G, ESP; PP4_Moderate: Found in a French patient with HPA and 2 unrelated UK patients. BH4 deficiencies not assessed/reported. Seen in 1 German patient, Cofactor deficiency was excluded by the BH4 test. 1 Spanish patient, a defect in the synthesis or regeneration pathways of 6R-BH4 was ruled out by analyzing urinary pterin levels and measuring dihydropteridine reductase activity. (PMID:26666653; PMID:9012412; PMID:10679941); PM3_Strong: Patient 664 with genotype N167I/Rl58Q (Pathogenic in ClinVar). Detected with G272X and R408W, known pathogenic variants. (PMID:24368688; PMID:26666653). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_Strong).	9012412, 10679941, 26666653, 24368688, 26666653	Phenylketonuria VCEP		2018-08-28	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA220584/MONDO:0009861/006	a49cb655-9cb0-4fac-959d-26d4290227d6
NM_000277.2(PAH):c.506G>A (p.Arg169His)	102706	CA286505	NM_000277.2:c.506G>A, NC_000012.12:g.102866599C>T, CM000674.2:g.102866599C>T, NC_000012.11:g.103260377C>T, CM000674.1:g.103260377C>T, NC_000012.10:g.101784507C>T, NG_008690.1:g.56004G>A, NG_008690.2:g.96812G>A, NM_000277.1:c.506G>A, XM_011538422.1:c.506G>A, NM_001354304.1:c.506G>A, XM_017019370.2:c.506G>A, NM_000277.3:c.506G>A, ENST00000307000.7:c.491G>A, ENST00000549111.5:n.602G>A, ENST00000551988.5:n.530+10863G>A, ENST00000553106.5:c.506G>A, NM_000277.2(PAH):c.506G>A (p.Arg169His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM3_Strong	PM2, PP3	PAH-specific ACMG/AMP criteria applied: PP4_Moderate: This variant has been reported in multiple mild hyperphenylalaninaemia (MHP) patients, with BH4 defects excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:10234516); PM3_Strong: Detected with P281L and A403V, both pathogenic variants (PMID:10234516). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_Strong).	10234516, 10234516	Phenylketonuria VCEP		2018-08-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA286505/MONDO:0009861/006	7b1098c0-cd76-4492-9b41-16cbd8f9ddc3
NM_000277.2(PAH):c.350C>T (p.Thr117Ile)	120273	CA267651	NM_000277.2:c.350C>T, NC_000012.12:g.102894737G>A, CM000674.2:g.102894737G>A, NC_000012.11:g.103288515G>A, CM000674.1:g.103288515G>A, NC_000012.10:g.101812645G>A, NG_008690.1:g.27866C>T, NG_008690.2:g.68674C>T, NM_000277.1:c.350C>T, XM_011538422.1:c.350C>T, NM_001354304.1:c.350C>T, XM_017019370.2:c.350C>T, NM_000277.3:c.350C>T, ENST00000307000.7:c.335C>T, ENST00000546844.1:c.350C>T, ENST00000548928.1:n.272C>T, ENST00000549111.5:n.446C>T, ENST00000550978.6:n.334C>T, ENST00000551337.5:c.350C>T, ENST00000551988.5:n.439C>T, ENST00000553106.5:c.350C>T, NM_000277.2(PAH):c.350C>T (p.Thr117Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2	PM5, PP3	PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC& gnomAD (MAF 0.00018). Absent from 1000G, ESP. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2).		Phenylketonuria VCEP		2018-09-28	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA267651/MONDO:0009861/006	4112e5b8-c121-471a-a34f-9da03e769a2b
NM_000277.2(PAH):c.1068C>A (p.Tyr356Ter)	92729	CA273107	NM_000277.2:c.1068C>A, NC_000012.12:g.102843777G>T, CM000674.2:g.102843777G>T, NC_000012.11:g.103237555G>T, CM000674.1:g.103237555G>T, NC_000012.10:g.101761685G>T, NG_008690.1:g.78826C>A, NG_008690.2:g.119634C>A, NM_000277.1:c.1068C>A, XM_011538422.1:c.1011C>A, NM_001354304.1:c.1068C>A, NM_000277.3:c.1068C>A, ENST00000307000.7:c.1053C>A, ENST00000549247.6:n.827C>A, ENST00000551114.2:n.730C>A, ENST00000553106.5:c.1068C>A, ENST00000635477.1:n.172C>A, ENST00000635528.1:n.583C>A, NM_000277.2(PAH):c.1068C>A (p.Tyr356Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2, PVS1, PM3_Strong		PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: gnomAD MAF 0.00017; PP4_Moderate: Detected in PKU patients (PMID:25894915); PM3_Strong: in trans with p.W326X (Pathogenic), and IVS4-1G>A (Pathogenic). (PMID:25894915). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate, PM3_Strong).	25894915, 25894915	Phenylketonuria VCEP		2018-08-13	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA273107/MONDO:0009861/006	6f390ad4-1675-4f3f-9b2d-eb81f608dc3b
NM_000277.2(PAH):c.818C>T (p.Ser273Phe)	598	CA229785	NM_000277.2:c.818C>T, NC_000012.12:g.102852839G>A, CM000674.2:g.102852839G>A, NC_000012.11:g.103246617G>A, CM000674.1:g.103246617G>A, NC_000012.10:g.101770747G>A, NG_008690.1:g.69764C>T, NG_008690.2:g.110572C>T, NM_000277.1:c.818C>T, XM_011538422.1:c.818C>T, NM_001354304.1:c.818C>T, NM_000277.3:c.818C>T, ENST00000307000.7:c.803C>T, ENST00000549247.6:n.577C>T, ENST00000553106.5:c.818C>T, NM_000277.2(PAH):c.818C>T (p.Ser273Phe)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2, PP4_Moderate, PP3, PM3_Strong	PM5	PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC and gnomAD (1 allele); PP3: Deleterious effect predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.978; PP4_Moderate: S273F was detected in in Northern Ireland, Belgium/French, Western Scotland, and New South Wales PKU patients. BH4 deficiency was assessed in 1 study. Upgraded per ClinGen Metabolic workgroup. (PMID:1671881; PMID:8533759; PMID:9012412; PMID:24368688); PM3_Strong: Seen with 2 known pathogenic mutations: I65T, R408W. Upgraded based on SVI worgroup recommendations and approved PAH guidelines (PMID:24368688). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong).	1671881, 24368688, 9012412, 8533759, 24368688	Phenylketonuria VCEP		2018-08-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229785/MONDO:0009861/006	75b9eddc-e554-4f4c-91a7-976ac6c27ba2
NM_000277.2(PAH):c.194T>C (p.Ile65Thr)	636	CA251544	NM_000277.2:c.194T>C, NC_000012.12:g.102894893A>G, CM000674.2:g.102894893A>G, NC_000012.11:g.103288671A>G, CM000674.1:g.103288671A>G, NC_000012.10:g.101812801A>G, NG_008690.1:g.27710T>C, NG_008690.2:g.68518T>C, NM_000277.1:c.194T>C, XM_011538422.1:c.194T>C, NM_001354304.1:c.194T>C, XM_017019370.2:c.194T>C, NM_000277.3:c.194T>C, ENST00000307000.7:c.179T>C, ENST00000546844.1:c.194T>C, ENST00000548677.2:n.281T>C, ENST00000548928.1:n.116T>C, ENST00000549111.5:n.290T>C, ENST00000550978.6:n.178T>C, ENST00000551337.5:c.194T>C, ENST00000551988.5:n.283T>C, ENST00000553106.5:c.194T>C, ENST00000635500.1:n.162T>C, NM_000277.2(PAH):c.194T>C (p.Ile65Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM3_Very Strong, PS3	PM5, PM2, PP1, PS1	PAH-specific ACMG/AMP criteria applied: PM3_VeryStrong: Detected with Y414C (P), R408W (P), P281L (P), IVS10nt-11 (P), R252W (P/LP), and R243Q(P). (PMID:12501224; PMID:1301201; PMID:10767174); PP3: Predicted dleterious in SIZFT, Polyphen2, MutationTaster. REVEL=0.985; PP4_Moderate: Detected in a patient with mild PKU. BH4 deficiency excluded. Upgraded per ClinGen PAH EP. (PMID:12501224); PS3: 25% mutant enzyme activity in COS cells as compared in wt (PMID:1301201). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM3_VeryStrong, PP3, PP4_Moderate, PS3).	12501224, 21871829, 10767174, 1301201, 12501224, 1301201	Phenylketonuria VCEP		2018-04-21	2019-04-08	true	https://erepo.genome.network/evrepo/ui/classification/CA251544/MONDO:0009861/006	633ef5e6-95c8-4ff5-88b2-6cf22b99158b
NM_000277.2(PAH):c.812A>T (p.His271Leu)	120287	CA267675	NM_000277.2:c.812A>T, NC_000012.12:g.102852845T>A, CM000674.2:g.102852845T>A, NC_000012.11:g.103246623T>A, CM000674.1:g.103246623T>A, NC_000012.10:g.101770753T>A, NG_008690.1:g.69758A>T, NG_008690.2:g.110566A>T, NM_000277.1:c.812A>T, XM_011538422.1:c.812A>T, NM_001354304.1:c.812A>T, NM_000277.3:c.812A>T, ENST00000307000.7:c.797A>T, ENST00000549247.6:n.571A>T, ENST00000553106.5:c.812A>T, NM_000277.2(PAH):c.812A>T (p.His271Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4_Moderate, PM2, PP3	PM5	PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Predicted deleterious in SIFT, Polyphen2, MutationTaster. REVEL=0.957; PP4_Moderate: H271L seen in a Chinese PKU patient. BH4 deficiencies excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:26503515). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate).	26503515	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA267675/MONDO:0009861/006	d8dab33d-d9aa-45d0-8e54-f50e90d27dd5
NM_000277.2(PAH):c.310_318delGCCACTGTC (p.Ala104_Val106del)	92740	CA220580	NM_000277.2:c.310_318delGCCACTGTC, NC_000012.12:g.102894769_102894777del, CM000674.2:g.102894769_102894777del, NC_000012.11:g.103288547_103288555del, CM000674.1:g.103288547_103288555del, NC_000012.10:g.101812677_101812685del, NG_008690.1:g.27826_27834del, NG_008690.2:g.68634_68642del, NM_000277.1:c.310_318del, XM_011538422.1:c.310_318del, NM_000277.2:c.310_318del, NM_001354304.1:c.310_318del, XM_017019370.2:c.310_318del, NM_000277.3:c.310_318del, ENST00000307000.7:c.295_303del, ENST00000546844.1:c.310_318del, ENST00000548928.1:n.232_240del, ENST00000549111.5:n.406_414del, ENST00000550978.6:n.294_302del, ENST00000551337.5:c.310_318del, ENST00000551988.5:n.399_407del, ENST00000553106.5:c.310_318del, NM_000277.2(PAH):c.310_318delGCCACTGTC (p.Ala104_Val106del)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM4, PM2, PP4		PAH-specific ACMG/AMP criteria applied: PM2: Identified a single time in gnomAD (4.06e-06) and absent in ExAC; PM4: p.Ala104_Val106del; PP4: Single patient picked up on NBS with no confirmation studies, no clinical info, no Phe levels, etc. (PMID:27308838). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM4, PP4).	27308838	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA220580/MONDO:0009861/006	6d2dd44e-13de-406f-a230-bfe8aa3f0740
NM_000277.2(PAH):c.205_210dup (p.Ser70_Arg71insProSer)	120271	CA267647	NM_000277.2:c.205_210dup, NM_000277.1:c.206_211dup, XM_011538422.1:c.206_211dup, NM_000277.2:c.206_211dup, NM_001354304.1:c.206_211dup, XM_017019370.2:c.206_211dup, NM_000277.3:c.206_211dup, ENST00000307000.7:c.191_196dup, ENST00000546844.1:c.206_211dup, ENST00000548677.2:n.293_298dup, ENST00000548928.1:n.128_133dup, ENST00000549111.5:n.302_307dup, ENST00000550978.6:n.190_195dup, ENST00000551337.5:c.206_211dup, ENST00000551988.5:n.295_300dup, ENST00000553106.5:c.206_211dup, ENST00000635500.1:n.174_179dup, NC_000012.12:g.102894877_102894882dup, CM000674.2:g.102894877_102894882dup, NC_000012.11:g.103288655_103288660dup, CM000674.1:g.103288655_103288660dup, NC_000012.10:g.101812785_101812790dup, NG_008690.1:g.27722_27727dup, NG_008690.2:g.68530_68535dup, NM_000277.2(PAH):c.205_210dup (p.Ser70_Arg71insProSer)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM4, PM2		PAH-specific ACMG/AMP criteria applied: PM2: chr12-103288654--GAGAAG; Absent from population databases; PM4: in-frame insertion. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM4).		Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA267647/MONDO:0009861/006	4b73962a-e05e-466d-b474-fa8e50ec1626
NM_000277.2(PAH):c.800A>T (p.Gln267Leu)	225135	CA354145	NM_000277.2:c.800A>T, NC_000012.12:g.102852857T>A, CM000674.2:g.102852857T>A, NC_000012.11:g.103246635T>A, CM000674.1:g.103246635T>A, NC_000012.10:g.101770765T>A, NG_008690.1:g.69746A>T, NG_008690.2:g.110554A>T, NM_000277.1:c.800A>T, XM_011538422.1:c.800A>T, NM_001354304.1:c.800A>T, NM_000277.3:c.800A>T, ENST00000307000.7:c.785A>T, ENST00000549247.6:n.559A>T, ENST00000553106.5:c.800A>T, NM_000277.2(PAH):c.800A>T (p.Gln267Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4_Moderate, PP3	PM5	PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. Extremely low frequency in ExAC and gnomAD ( 0.00001, 0.000004063); PP3: Predicted deleterious in SIFT, Polyphen2, MutationTaster. REVEL=0.975; PP4_Moderate: Q267L found in 1 Japanese PKU allele and in 1 Chinese PKU patient. Analysis of dihydropteridine reductase activity in red blood cells, biopterin loading test and/or pteridine analysis in urine was performed in the Japanese study. Upgraded per ClinGen Metabolic workgroup. (PMID:21307867; PMID:24078561; PMID:26503515). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate).	21307867, 26503515, 24078561	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA354145/MONDO:0009861/006	0f298658-69d4-402a-a0d1-47973a683451
NM_000277.2(PAH):c.745C>T (p.Leu249Phe)	102821	CA273356	NM_000277.2:c.745C>T, NC_000012.12:g.102852912G>A, CM000674.2:g.102852912G>A, NC_000012.11:g.103246690G>A, CM000674.1:g.103246690G>A, NC_000012.10:g.101770820G>A, NG_008690.1:g.69691C>T, NG_008690.2:g.110499C>T, NM_000277.1:c.745C>T, XM_011538422.1:c.745C>T, NM_001354304.1:c.745C>T, NM_000277.3:c.745C>T, ENST00000307000.7:c.730C>T, ENST00000549247.6:n.504C>T, ENST00000553106.5:c.745C>T, NM_000277.2(PAH):c.745C>T (p.Leu249Phe)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2, PP3, PM3_Very Strong	PM5, PS3	PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. Extremely low frequency in ExAC and gnomAD (0.00004065); PP3: Deleterious effect predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.981; PP4_Moderate: L249F was seen 3 times in HPA patients associated with 2 different haplotypes. DHPR defeciency was excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:8533759); PM3_VeryStrong: Seen with R261X, A309V, V388M, R261Q. All Pathogenic/Likely Pathogenic in ClinVar. Upgraded per ClinGen SVI Workgroup (PMID:21871829; PMID:24765287). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_VeryStrong).	8533759, 24765287, 21871829	Phenylketonuria VCEP		2018-08-12	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA273356/MONDO:0009861/006	6807a54c-cde9-445c-b30f-9d4a3fbbdc85
NM_000277.2(PAH):c.707-7A>T	102795	CA180267	NM_000277.2:c.707-7A>T, NC_000012.12:g.102852957T>A, CM000674.2:g.102852957T>A, NC_000012.11:g.103246735T>A, CM000674.1:g.103246735T>A, NC_000012.10:g.101770865T>A, NG_008690.1:g.69646A>T, NG_008690.2:g.110454A>T, NM_000277.1:c.707-7A>T, XM_011538422.1:c.707-7A>T, NM_001354304.1:c.707-7A>T, NM_000277.3:c.707-7A>T, ENST00000307000.7:c.692-7A>T, ENST00000549247.6:n.459A>T, ENST00000553106.5:c.707-7A>T, NM_000277.2(PAH):c.707-7A>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BP4, BA1		PAH-specific ACMG/AMP criteria applied: BA1: Highest MAF=0.10514 in 1000G. 35 homozygotes in ExAC; BP4: HSF: No significant splicing motif alteration detected. This mutation has probably no impact on splicing. CADD=1.163344. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1, BP4).		Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA180267/MONDO:0009861/006	ef426544-d234-401a-81e4-5e2f6a9ded0a
NM_000277.2(PAH):c.829T>G (p.Tyr277Asp)	603	CA251534	NM_000277.2:c.829T>G, NC_000012.12:g.102852828A>C, CM000674.2:g.102852828A>C, NC_000012.11:g.103246606A>C, CM000674.1:g.103246606A>C, NC_000012.10:g.101770736A>C, NG_008690.1:g.69775T>G, NG_008690.2:g.110583T>G, NM_000277.1:c.829T>G, XM_011538422.1:c.829T>G, NM_001354304.1:c.829T>G, NM_000277.3:c.829T>G, ENST00000307000.7:c.814T>G, ENST00000549247.6:n.588T>G, ENST00000553106.5:c.829T>G, NM_000277.2(PAH):c.829T>G (p.Tyr277Asp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PP3, PS3	PM5	The c.829T>G (p.Tyr277Asp) variant in PAH has been reported in 2 individuals with Classic PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 8268925; PMID: 23500595). This variant has an extremely low allele frequency (1/121400) in ExAC (PM2; http://exac.broadinstitute.org). This variant has 0% enzyme activity (PS3; http://www.biopku.org/centralStore/biopku/PAH%20activity.pdf). This variant was detected in trans with L48S (Pathogenic in ClinVar) (PM3; PMID: 23500595). Computational prediction tools and conservation analysis suggest that the c.829T>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3	23500595, 23500595, 8268925	Phenylketonuria VCEP		2018-08-05	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA251534/MONDO:0009861/006	ac3ebdc5-43ab-403b-8ef9-27fff7d691ba
NM_000277.2(PAH):c.735G>A (p.Val245=)	92748	CA145982	NM_000277.2:c.735G>A, NC_000012.12:g.102852922C>T, CM000674.2:g.102852922C>T, NC_000012.11:g.103246700C>T, CM000674.1:g.103246700C>T, NC_000012.10:g.101770830C>T, NG_008690.1:g.69681G>A, NG_008690.2:g.110489G>A, NM_000277.1:c.735G>A, XM_011538422.1:c.735G>A, NM_001354304.1:c.735G>A, NM_000277.3:c.735G>A, ENST00000307000.7:c.720G>A, ENST00000549247.6:n.494G>A, ENST00000553106.5:c.735G>A, NM_000277.2(PAH):c.735G>A (p.Val245=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BS2, BP4, BA1		The c.735G>A (p.Val245=) variant in PAH has a MAF of 0.29058 in ExAC (BA1; http://exac.broadinstitute.org) with 6,524 homozygotes (BS2). This is a synonymous variant, predicted tolerated and benign in SIFT, Polyphen. MutationTaster predicted polymorphism with no abrogation of splice sites (BP4). In summary, this variant meets criteria to be classified as benign.		Phenylketonuria VCEP		2018-04-24	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA145982/MONDO:0009861/006	9cca2153-6d64-4ab3-923e-39673d123cd3
NM_000277.2(PAH):c.842+1G>A	599	CA229811	NM_000277.2:c.842+1G>A, NC_000012.12:g.102852814C>T, CM000674.2:g.102852814C>T, NC_000012.11:g.103246592C>T, CM000674.1:g.103246592C>T, NC_000012.10:g.101770722C>T, NG_008690.1:g.69789G>A, NG_008690.2:g.110597G>A, NM_000277.1:c.842+1G>A, XM_011538422.1:c.842+1G>A, NM_001354304.1:c.842+1G>A, NM_000277.3:c.842+1G>A, ENST00000307000.7:c.827+1G>A, ENST00000549247.6:n.601+1G>A, ENST00000553106.5:c.842+1G>A, ENST00000635477.1:n.3+1G>A, NM_000277.2(PAH):c.842+1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PM2, PP4		PAH-specific ACMG/AMP criteria applied: PVS1: Canonical +1 splice site; PM2: gnomAD MAF 0.00008; PP4: Reported in 3 PKU populations: Slovak, Germany, Italy (PMID:1671810; PMID:10394930; PMID:23764561); PM3: (PMID:20188615; PMID:24941924). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4, PM3).	24941924, 20188615, 23764561, 10394930, 1671810	Phenylketonuria VCEP		2018-08-13	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229811/MONDO:0009861/006	4d4f7818-81d9-4893-8bdd-a751be9a75e9
NM_000277.2(PAH):c.734T>C (p.Val245Ala)	632	CA114372	NM_000277.2:c.734T>C, NC_000012.12:g.102852923A>G, CM000674.2:g.102852923A>G, NC_000012.11:g.103246701A>G, CM000674.1:g.103246701A>G, NC_000012.10:g.101770831A>G, NG_008690.1:g.69680T>C, NG_008690.2:g.110488T>C, NM_000277.1:c.734T>C, XM_011538422.1:c.734T>C, NM_001354304.1:c.734T>C, NM_000277.3:c.734T>C, ENST00000307000.7:c.719T>C, ENST00000549247.6:n.493T>C, ENST00000553106.5:c.734T>C, NM_000277.2(PAH):c.734T>C (p.Val245Ala)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM5, PP4_Moderate, PM3_Very Strong	PM2, PP3, PS3	PAH-specific ACMG/AMP criteria applied: PM5: V245L Pathogenic; PP4_Moderate: Seen in at least 7 MHP patients. Exclusion of a defect in tetrahydrobiopterin metabolism. Upgraded per ClinGen Metabolic Workgroup. (PMID:7981714; PMID:9298832; PMID:9634518); PM3_VeryStrong: V245A detected with IVS-12nt1, R252W, L194P (both P/LP), R408W (Path). Upgraded per ClinGen SVI Workgroup (PMID:7981714; PMID:9298832; PMID:8088845). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM5, PP4_Moderate, PM3_VeryStrong).	9634518, 7981714, 9298832, 7981714, 9298832, 8088845, 11161839	Phenylketonuria VCEP		2018-09-28	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA114372/MONDO:0009861/006	0129bef0-6e1d-4f6b-8e4e-2c05721902af
NM_000277.2(PAH):c.1033G>A (p.Ala345Thr)	102483	CA229291	NM_000277.2:c.1033G>A, NC_000012.12:g.102844368C>T, CM000674.2:g.102844368C>T, NC_000012.11:g.103238146C>T, CM000674.1:g.103238146C>T, NC_000012.10:g.101762276C>T, NG_008690.1:g.78235G>A, NG_008690.2:g.119043G>A, NM_000277.1:c.1033G>A, XM_011538422.1:c.976G>A, NM_001354304.1:c.1033G>A, NM_000277.3:c.1033G>A, ENST00000307000.7:c.1018G>A, ENST00000549247.6:n.792G>A, ENST00000551114.2:n.695G>A, ENST00000553106.5:c.1033G>A, ENST00000635477.1:n.137G>A, ENST00000635528.1:n.548G>A, NM_000277.2(PAH):c.1033G>A (p.Ala345Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM5, PM2, PP4_Moderate, PP3		PAH-specific ACMG/AMP criteria applied: PM2: Absent from controls in ExaC, 100 Genomes, ESP, and gnomAD; PP3: Deleterious effected predicted by SIFT, Polyphen2, and MutationTaster; PM5: A345S (Variant ID 102484) predicted pathogenic in ClinVar; PP4_Moderate: Found in two individuals with Classic PKU on exon 10.Urinary pterin analysis and dihydropteridine reductase (DHPR) assay were performed t (PMID:15503242); PM3: Found in trans with R243Q (pathogenic in ClinVar). (PMID:15503242). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM5, PP4_Moderate, PM3).	15503242, 15503242	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229291/MONDO:0009861/006	e8f41b26-818c-4003-b73f-0be5c4dcd234
NM_000277.2(PAH):c.1199+1G>C	102557	CA274088	NM_000277.2:c.1199+1G>C, NC_000012.12:g.102843645C>G, CM000674.2:g.102843645C>G, NC_000012.11:g.103237423C>G, CM000674.1:g.103237423C>G, NC_000012.10:g.101761553C>G, NG_008690.1:g.78958G>C, NG_008690.2:g.119766G>C, NM_000277.1:c.1199+1G>C, XM_011538422.1:c.1142+1G>C, NM_001354304.1:c.1199+1G>C, NM_000277.3:c.1199+1G>C, ENST00000307000.7:c.1184+1G>C, ENST00000549247.6:n.958+1G>C, ENST00000551114.2:n.861+1G>C, ENST00000553106.5:c.1199+1G>C, ENST00000635477.1:n.303+1G>C, ENST00000635528.1:n.714+1G>C, NM_000277.2(PAH):c.1199+1G>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PM2, PP4_Moderate		PAH-specific ACMG/AMP criteria applied: PM2: 8.1e-6 allele frequency in GnomAD, not found in any other databases; PM3: [c.898G>T];[c.1199+1G>C] in a patient with mild hyperphe (180umol/L); PP4_Moderate: Single patient in Sterl 2013, BH4 defect excluded. Also identified in multiple other patients (7 publications linked through ClinVar) (PMID:22526846); PVS1: +1 canonical splice site. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM3, PP4_Moderate, PVS1).	22526846	Phenylketonuria VCEP		2018-08-27	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA274088/MONDO:0009861/006	97e81c3d-c06f-476a-b576-a37317f3f512
NM_000277.2(PAH):c.47_48delCT (p.Ser16Terfs)	102696	CA229574	NM_000277.2:c.47_48delCT, NC_000012.12:g.102917087_102917088del, CM000674.2:g.102917087_102917088del, NC_000012.11:g.103310865_103310866del, CM000674.1:g.103310865_103310866del, NC_000012.10:g.101834995_101834996del, NG_008690.1:g.5519_5520del, NG_008690.2:g.46327_46328del, NM_000277.1:c.47_48del, XM_011538422.1:c.47_48del, NM_000277.2:c.47_48del, NM_001354304.1:c.47_48del, XM_017019370.2:c.47_48del, NM_000277.3:c.47_48del, ENST00000307000.7:c.-101_-100del, ENST00000546844.1:c.47_48del, ENST00000547319.1:n.358_359del, ENST00000549111.5:n.143_144del, ENST00000550978.6:n.31_32del, ENST00000551337.5:c.47_48del, ENST00000551988.5:n.136_137del, ENST00000553106.5:c.47_48del, ENST00000635500.1:n.29-4186_29-4185del, NM_000277.2(PAH):c.47_48delCT (p.Ser16Terfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PM2, PP4	PP3	PAH-specific ACMG/AMP criteria applied: PM2: ExAC:8.238e-06; gnomAD:0.000004062; 1000G + ESP: absent; PVS1: Null variant- frameshift. Subject to nonsense mediated decay.; PM3: found in trans with L48S (VarID608, Pathogenic) (PMID:8535445); PP4: 47delCT found in 1 patient with moderate PKU. BH4 deficiency not ruled out. (PMID:8535445). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PM3, PP4).	8535445, 8535445	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229574/MONDO:0009861/006	88d14684-a7c2-4bfb-9ec0-2e5bc851b285
NM_000277.1(PAH):c.967_969delACA (p.Thr323del)	102913	CA229876	NM_000277.1:c.967_969delACA, NC_000012.12:g.102846895_102846897del, CM000674.2:g.102846895_102846897del, NC_000012.11:g.103240673_103240675del, CM000674.1:g.103240673_103240675del, NC_000012.10:g.101764803_101764805del, NG_008690.1:g.75706_75708del, NG_008690.2:g.116514_116516del, NM_000277.1:c.967_969del, XM_011538422.1:c.913-2466_913-2464del, NM_000277.2:c.967_969del, NM_001354304.1:c.967_969del, NM_000277.3:c.967_969del, ENST00000307000.7:c.952_954del, ENST00000549247.6:n.726_728del, ENST00000551114.2:n.629_631del, ENST00000553106.5:c.967_969del, ENST00000635477.1:n.74-2466_74-2464del, ENST00000635528.1:n.482_484del, NM_000277.1(PAH):c.967_969delACA (p.Thr323del)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM4, PP4_Moderate, PM2, PM3_Strong		PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in gnomAD: 0.000008131; PM4: Protein length change as a results of in-frame deletion; PP4_Moderate: T323del found in 2 PKU patients. BH4 deficiency excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:21147011); PM3_Strong: T323del detected with P281 in 1 PKU patient, and L48S in another PKU patient. Both pathogenic. Upgraded per ClinGen SVI Workgroup. (PMID:21147011). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM4, PP4_Moderate, PM3_Strong).	21147011, 21147011	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229876/MONDO:0009861/006	415850ec-8284-4760-a5cc-4383c207b56f
NM_000277.1(PAH):c.983C>T (p.Thr328Ile)	281073	CA10603804	NM_000277.1:c.983C>T, NC_000012.12:g.102844418G>A, CM000674.2:g.102844418G>A, NC_000012.11:g.103238196G>A, CM000674.1:g.103238196G>A, NC_000012.10:g.101762326G>A, NG_008690.1:g.78185C>T, NG_008690.2:g.118993C>T, XM_011538422.1:c.926C>T, NM_000277.2:c.983C>T, NM_001354304.1:c.983C>T, NM_000277.3:c.983C>T, ENST00000307000.7:c.968C>T, ENST00000549247.6:n.742C>T, ENST00000551114.2:n.645C>T, ENST00000553106.5:c.983C>T, ENST00000635477.1:n.87C>T, ENST00000635528.1:n.498C>T, NM_000277.1(PAH):c.983C>T (p.Thr328Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP3	PM5	PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Predicted deleterious in SIFT, PolyPhen2, Mutation Taster. REVEL=0.952. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3).		Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA10603804/MONDO:0009861/006	7adf378c-7393-4f5a-8666-38c92a10a292
NM_000277.1:c.842+4A>G	439228	CA16020870	NM_000277.1:c.842+4A>G, NC_000012.12:g.102852811T>C, CM000674.2:g.102852811T>C, NC_000012.11:g.103246589T>C, CM000674.1:g.103246589T>C, NC_000012.10:g.101770719T>C, NG_008690.1:g.69792A>G, NG_008690.2:g.110600A>G, XM_011538422.1:c.842+4A>G, NM_000277.2:c.842+4A>G, NM_001354304.1:c.842+4A>G, NM_000277.3:c.842+4A>G, ENST00000307000.7:c.827+4A>G, ENST00000549247.6:n.601+4A>G, ENST00000553106.5:c.842+4A>G, ENST00000635477.1:n.3+4A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		PAH-specific ACMG/AMP criteria applied: PP3: HSF: Broken WT Donor Site, New Donor Site. MaxEnt: Broken WT Donor Site.; PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP4_Moderate: IVS7+4A>G seen in 2 PKU patients. BH4 deficiency was ruled out. Upgraded per ClinGen PAH EP. (PMID:21147011); PM3: Detected in trans with A300S, pathogenic in ClinVar (PMID:21147011). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PM2, PP4_Moderate, PM3).	21147011, 21147011	Phenylketonuria VCEP		2018-08-12	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA16020870/MONDO:0009861/006	d91a71b3-b17d-4148-8b40-c1de9c400e78
NM_000277.1(PAH):c.441+5G>T	92742	CA273112	NM_000277.1:c.441+5G>T, NC_000012.12:g.102877457C>A, CM000674.2:g.102877457C>A, NC_000012.11:g.103271235C>A, CM000674.1:g.103271235C>A, NC_000012.10:g.101795365C>A, NG_008690.1:g.45146G>T, NG_008690.2:g.85954G>T, XM_011538422.1:c.441+5G>T, NM_000277.2:c.441+5G>T, NM_001354304.1:c.441+5G>T, XM_017019370.2:c.441+5G>T, NM_000277.3:c.441+5G>T, ENST00000307000.7:c.426+5G>T, ENST00000549111.5:n.537+5G>T, ENST00000550978.6:n.430G>T, ENST00000551988.5:n.530+5G>T, ENST00000553106.5:c.441+5G>T, NM_000277.1(PAH):c.441+5G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2, PP4_Moderate, PP3, PS3, PM3_Strong	PM5	The c.441+5G>T variant in PAH has been reported on >17 PKU alleles (BH4 deficiency excluded). (PP4_Moderate; PMID: 17935162; PMID: 23514811). This variant has an extremely low allele frequency (0.00002886) in gnomAD (PM2; http://gnomad.broadinstitute.org). This variant has 0% enzyme activity (PS3; http://www.biopku.org). This variant was detected in trans with IVS10-11g>a and p.V388M (Pathogenic in ClinVar) (PM3_Strong; PMID: 23514811). Computational prediction tools and conservation analysis suggest that the c.441+5G>T variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3_Strong	17935162, 23514811, 23514811	Phenylketonuria VCEP		2018-05-24	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA273112/MONDO:0009861/006	674e662c-0350-403f-afef-a3cb5a47ced4
NM_000277.1(PAH):c.1222C>T (p.Arg408Trp)	577	CA251523	NM_000277.1:c.1222C>T, NC_000012.12:g.102840493G>A, CM000674.2:g.102840493G>A, NC_000012.11:g.103234271G>A, CM000674.1:g.103234271G>A, NC_000012.10:g.101758401G>A, NG_008690.1:g.82110C>T, NG_008690.2:g.122918C>T, XM_011538422.1:c.1165C>T, NM_000277.2:c.1222C>T, NM_001354304.1:c.1222C>T, NM_000277.3:c.1222C>T, ENST00000307000.7:c.1207C>T, ENST00000551114.2:n.884C>T, ENST00000553106.5:c.1222C>T, ENST00000635477.1:n.326C>T, ENST00000635528.1:n.737C>T, NM_000277.1(PAH):c.1222C>T (p.Arg408Trp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PS3, PM3_Strong	PM2	PAH-specific ACMG/AMP criteria applied: PP3: ; PS3: PMID 17935162: Table 1: p.Arg408Trp 1.85% WT activity PMID 25596310: 1.3% activity of WT (Table S4) (PMID:25596310; PMID:17935162); PP4_Moderate: most common PAH mutation in cohort; exclude BH4 deficiency. (PMID:25596310; PMID:9634518); PM3_Strong: Detected with IVS12+1G>A, M1V (Pathogenic/LP) (PMID:9634518; PMID:1971147; PMID:1609797). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PS3, PP4_Moderate, PM3_Strong).	9634518, 25596310, 25596310, 17935162, 1971147, 9634518, 1609797	Phenylketonuria VCEP		2018-08-06	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA251523/MONDO:0009861/006	0dbc6b3d-662c-424c-bca8-7346f4312024
NM_000277.1(PAH):c.814G>T (p.Gly272Ter)	596	CA251532	NM_000277.1:c.814G>T, NC_000012.12:g.102852843C>A, CM000674.2:g.102852843C>A, NC_000012.11:g.103246621C>A, CM000674.1:g.103246621C>A, NC_000012.10:g.101770751C>A, NG_008690.1:g.69760G>T, NG_008690.2:g.110568G>T, XM_011538422.1:c.814G>T, NM_000277.2:c.814G>T, NM_001354304.1:c.814G>T, NM_000277.3:c.814G>T, ENST00000307000.7:c.799G>T, ENST00000549247.6:n.573G>T, ENST00000553106.5:c.814G>T, NM_000277.1(PAH):c.814G>T (p.Gly272Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4		PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. Extrememly low frequency in ExAC, gnomAD (MAF= 0.00006, 0.0003093); PVS1: Nonsense variant. Predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay.; PP4: G272X found on one allele of a patient with classic PKU (PMID:1975559). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4).	1975559	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA251532/MONDO:0009861/006	f7c77032-c599-46f3-9086-0bb73eb5c0c1
NM_000277.2(PAH):c.311C>A (p.Ala104Asp)	102650	CA229515	NM_000277.2:c.311C>A, NC_000012.12:g.102894776G>T, CM000674.2:g.102894776G>T, NC_000012.11:g.103288554G>T, CM000674.1:g.103288554G>T, NC_000012.10:g.101812684G>T, NG_008690.1:g.27827C>A, NG_008690.2:g.68635C>A, NM_000277.1:c.311C>A, XM_011538422.1:c.311C>A, NM_001354304.1:c.311C>A, XM_017019370.2:c.311C>A, NM_000277.3:c.311C>A, ENST00000307000.7:c.296C>A, ENST00000546844.1:c.311C>A, ENST00000548928.1:n.233C>A, ENST00000549111.5:n.407C>A, ENST00000550978.6:n.295C>A, ENST00000551337.5:c.311C>A, ENST00000551988.5:n.400C>A, ENST00000553106.5:c.311C>A, NM_000277.2(PAH):c.311C>A (p.Ala104Asp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2, PS3, PM3_Strong	PP3	PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency: 0.00009 in gnomAD; PS3: 26% PAH enzyme activity; PM3_Strong: Detected with Y414C, pathogenic in ClinVar and V245L (P/LP) (PMID:9429153; PMID:24368688). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PS3, PM3_Strong).	9429153, 24368688	Phenylketonuria VCEP		2018-08-07	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229515/MONDO:0009861/006	86ce59a8-cc5a-46f9-9b96-2254638db653
NM_000277.3(PAH):c.1066-11G>A	607	CA251538	NM_000277.3:c.1066-11G>A, NC_000012.12:g.102843790C>T, CM000674.2:g.102843790C>T, NC_000012.11:g.103237568C>T, CM000674.1:g.103237568C>T, NC_000012.10:g.101761698C>T, NG_008690.1:g.78813G>A, NG_008690.2:g.119621G>A, ENST00000553106.6:c.1066-11G>A, ENST00000307000.7:c.1051-11G>A, ENST00000549247.6:n.825-11G>A, ENST00000551114.2:n.728-11G>A, ENST00000553106.5:c.1066-11G>A, ENST00000635477.1:c.170-11G>A, ENST00000635528.1:n.581-11G>A, NM_000277.1:c.1066-11G>A, XM_011538422.1:c.1009-11G>A, NM_000277.2:c.1066-11G>A, NM_001354304.1:c.1066-11G>A, NM_001354304.2:c.1066-11G>A, NM_000277.3(PAH):c.1066-11G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM3_Very Strong, PVS1_Strong	PM2, PP3, BP4, BA1, PS3, BS1	The c.1066-11G>A variant in PAH occurs within intron 10. It is predicted to impact splicing of biologically-relevant-exon 11/13. This prediction is confirmed by RT-PCR analysis which showed an in-frame insertion of Gly, Leu, Gln between exon 10 and 11 (PMID: 1769645). Nonsense mediated decay does not occur, but the resulting protein has no enzymatic activity (altered region is critical to protein function, PVS1_strong). At least one patient with this variant displayed blood Phe > 30 mg/dl, which is highly specific for PAH deficiency (PMID: 8990013). BH4 deficiency was ruled out in 1 study (PMID: 23500595). This variant has been detected in at least 23 individuals with PAH deficiency. Of those individuals, 15 were compound heterozygous for the variant and a pathogenic variant [p.R252W, p.R243X, p.R261Q (4 patients), p.R270K, p.I65T (2 patients); 5.5 points] (PMID: 23500595; PMID: 8990013) (PM3_Very strong). The population allele frequency in gnomAD v4 is 0.0003248, which is higher than the PAH VCEP cutoff for PM2 (<0.0002). In summary, this variant meets criteria to be classified as pathogenic for PAH deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen PAH VCEP: PVS1_strong, PP4_Moderate, PM3_very-strong. (VCEPspecifications version 2; 12/06/24)		Phenylketonuria VCEP		2024-12-30	2024-12-31	false	https://erepo.genome.network/evrepo/ui/classification/CA251538/MONDO:0009861/006	2470a255-3083-4956-9ff7-176203d54920
NM_000277.1(PAH):c.1243G>A (p.Asp415Asn)	617	CA114364	NM_000277.1:c.1243G>A, NC_000012.12:g.102840472C>T, CM000674.2:g.102840472C>T, NC_000012.11:g.103234250C>T, CM000674.1:g.103234250C>T, NC_000012.10:g.101758380C>T, NG_008690.1:g.82131G>A, NG_008690.2:g.122939G>A, XM_011538422.1:c.1186G>A, NM_000277.2:c.1243G>A, NM_001354304.1:c.1243G>A, NM_000277.3:c.1243G>A, ENST00000307000.7:c.1228G>A, ENST00000551114.2:n.905G>A, ENST00000553106.5:c.1243G>A, ENST00000635477.1:n.347G>A, ENST00000635528.1:n.758G>A, NM_000277.1(PAH):c.1243G>A (p.Asp415Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2, PP4_Moderate, PM3_Very Strong	PM5, PP3, PS3	The c.1243G>A (p.Asp415Asn) variant in PAH has been reported in 3 patients with Hyperphenylalaninemia (BH4 deficiency excluded). (PP4_Moderate; PMID: 1358789). This variant has an extremely low allele frequency (0.0001097 in gnomAD) (PM2; http://gnomad.broadinstitute.org). This variant was detected in trans with R408W, F39L, Y414C, IVS10-11G>A (Pathogenic in ClinVar) (PM3_Very-strong; PMID: 1358789; PMID: 12501224; PMID: 18299955). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_Very-strong	1358789, 1358789, 18299955, 12501224, 11161839	Phenylketonuria VCEP		2018-08-12	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA114364/MONDO:0009861/006	d8d2e477-0bfe-4136-9489-617a94f7fda6
NM_000277.1(PAH):c.781C>T (p.Arg261Ter)	610	CA229757	NM_000277.1:c.781C>T, NC_000012.12:g.102852876G>A, CM000674.2:g.102852876G>A, NC_000012.11:g.103246654G>A, CM000674.1:g.103246654G>A, NC_000012.10:g.101770784G>A, NG_008690.1:g.69727C>T, NG_008690.2:g.110535C>T, XM_011538422.1:c.781C>T, NM_000277.2:c.781C>T, NM_001354304.1:c.781C>T, NM_000277.3:c.781C>T, ENST00000307000.7:c.766C>T, ENST00000549247.6:n.540C>T, ENST00000553106.5:c.781C>T, NM_000277.1(PAH):c.781C>T (p.Arg261Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PP4		PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PP4: Detected in 2 unrelated patients (PMID:1682234); PM3: Detected with H170D, pathogenic (PMID:11385716). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PP4, PM3).	11385716, 1682234	Phenylketonuria VCEP		2018-08-05	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229757/MONDO:0009861/006	a79e0701-cceb-4823-a816-a3acbb89f1b7
NM_000277.2(PAH):c.1315+1G>A	576	CA251522	NM_000277.2:c.1315+1G>A, NC_000012.12:g.102840399C>T, CM000674.2:g.102840399C>T, NC_000012.11:g.103234177C>T, CM000674.1:g.103234177C>T, NC_000012.10:g.101758307C>T, NG_008690.1:g.82204G>A, NG_008690.2:g.123012G>A, NM_000277.1:c.1315+1G>A, XM_011538422.1:c.1258+1G>A, NM_001354304.1:c.1315+1G>A, NM_000277.3:c.1315+1G>A, ENST00000307000.7:c.1300+1G>A, ENST00000551114.2:n.977+1G>A, ENST00000553106.5:c.1315+1G>A, ENST00000635477.1:n.419+1G>A, ENST00000635528.1:n.830+1G>A, NM_000277.2(PAH):c.1315+1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PVS1, PS3		PAH-specific ACMG/AMP criteria applied: PS3: abolishes PAH activity due to protein instability (PMID:17935162; PMID:3615198); PM3: (PMID:24941924); PP4_Moderate: Reported in Galician PAH deficiency population. BH4 deficiency ruled out. (PMID:23500595); PVS1: Canonical +1 splice site. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PS3, PM3, PP4_Moderate, PVS1).	24941924, 23500595, 17935162, 3615198	Phenylketonuria VCEP		2018-08-05	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA251522/MONDO:0009861/006	a0e84b26-03d1-42c0-a937-859d45d287e0
NM_000277.1(PAH):c.1241A>G (p.Tyr414Cys)	593	CA114362	NM_000277.1:c.1241A>G, NC_000012.12:g.102840474T>C, CM000674.2:g.102840474T>C, NC_000012.11:g.103234252T>C, CM000674.1:g.103234252T>C, NC_000012.10:g.101758382T>C, NG_008690.1:g.82129A>G, NG_008690.2:g.122937A>G, XM_011538422.1:c.1184A>G, NM_000277.2:c.1241A>G, NM_001354304.1:c.1241A>G, NM_000277.3:c.1241A>G, ENST00000307000.7:c.1226A>G, ENST00000551114.2:n.903A>G, ENST00000553106.5:c.1241A>G, ENST00000635477.1:n.345A>G, ENST00000635528.1:n.756A>G, NM_000277.1(PAH):c.1241A>G (p.Tyr414Cys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM5, PP4_Moderate, PP3, PM3_Very Strong, PS3	PM2	PAH-specific ACMG/AMP criteria applied: PM5: c.1240T>C likely pathogenic in ClinVar; PP3: All computational evidence supports deleterious effect. REVEL=0.982; PS3: 50% activity, 50% immunoreactivity (PMID:2044609); PM3_VeryStrong: Patient #41 p.R408W / p.Y414C, Phe 744 @dx and two homozygous individuals. Total of 9 patients with this variant (PMID:22526846; PMID:17935162; PMID:9399896; PMID:21871829; PMID:26542770); PP4_Moderate: BH4 defect excluded in all patients (PMID:22526846). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM5, PP3, PS3, PM3_VeryStrong, PP4_Moderate).	22526846, 21871829, 26542770, 9399896, 17935162, 22526846, 2044609	Phenylketonuria VCEP		2018-07-27	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA114362/MONDO:0009861/006	52c5efc0-4153-4bd6-a94a-132ad01f1d73
NM_000277.1(PAH):c.782G>A (p.Arg261Gln)	582	CA251528	NM_000277.1:c.782G>A, NC_000012.12:g.102852875C>T, CM000674.2:g.102852875C>T, NC_000012.11:g.103246653C>T, CM000674.1:g.103246653C>T, NC_000012.10:g.101770783C>T, NG_008690.1:g.69728G>A, NG_008690.2:g.110536G>A, XM_011538422.1:c.782G>A, NM_000277.2:c.782G>A, NM_001354304.1:c.782G>A, NM_000277.3:c.782G>A, ENST00000307000.7:c.767G>A, ENST00000549247.6:n.541G>A, ENST00000553106.5:c.782G>A, NM_000277.1(PAH):c.782G>A (p.Arg261Gln)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM3_Very Strong, PS3	PM2	PAH-specific ACMG/AMP criteria applied: PP3: tools predict damaging; PS3: 15.5-30% activity (PMID:2014036; PMID:25596310); PM3_VeryStrong: L48S, R408W, S349P, R243X (PMID:25596310; PMID:17935162); PP4_Moderate: (PMID:25596310). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PS3, PM3_VeryStrong, PP4_Moderate).	25596310, 25596310, 17935162, 25596310, 2014036	Phenylketonuria VCEP		2018-08-13	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA251528/MONDO:0009861/006	9e4b6d0e-936a-4cbe-a237-e66213b685d4
NM_000277.1(PAH):c.1238G>C (p.Arg413Pro)	592	CA229414	NM_000277.1:c.1238G>C, NC_000012.12:g.102840477C>G, CM000674.2:g.102840477C>G, NC_000012.11:g.103234255C>G, CM000674.1:g.103234255C>G, NC_000012.10:g.101758385C>G, NG_008690.1:g.82126G>C, NG_008690.2:g.122934G>C, XM_011538422.1:c.1181G>C, NM_000277.2:c.1238G>C, NM_001354304.1:c.1238G>C, NM_000277.3:c.1238G>C, ENST00000307000.7:c.1223G>C, ENST00000551114.2:n.900G>C, ENST00000553106.5:c.1238G>C, ENST00000635477.1:n.342G>C, ENST00000635528.1:n.753G>C, NM_000277.1(PAH):c.1238G>C (p.Arg413Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PP3, PS3		PAH-specific ACMG/AMP criteria applied: PS3: In vitro expression of altered protein in COS cells produces severe decrease of PAH activity (<3%); PM2: Extremely low frequency. ExAC MAF=0.00012; PP4_Moderate: Detected in PKU patients, BH4 deficiency excluded; PP3: Predicted deleterious in SIFT, Polyphen-2, MutationTaster. REVEL=0.895; PM3: Detected with V388M (pathogenic) in 2 patients (PMID:9860305; PMID:21307867). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PS3, PM2, PP4_Moderate, PP3, PM3).	21307867, 9860305	Phenylketonuria VCEP		2018-08-05	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229414/MONDO:0009861/006	ce8fbaf1-f9e2-43cc-ac9c-6b77a1fd68a0
NM_000277.1(PAH):c.208_210delTCT (p.Ser70del)	102632	CA229490	NM_000277.1:c.207_209delTTC, NM_000277.1:c.206_208delCTT, NM_000277.1:c.208_210delTCT, NM_000277.1:c.208_210del, XM_011538422.1:c.208_210del, NM_000277.2:c.208_210del, NM_001354304.1:c.208_210del, XM_017019370.2:c.208_210del, NM_000277.3:c.208_210del, ENST00000307000.7:c.193_195del, ENST00000546844.1:c.208_210del, ENST00000548677.2:n.295_297del, ENST00000548928.1:n.130_132del, ENST00000549111.5:n.304_306del, ENST00000550978.6:n.192_194del, ENST00000551337.5:c.208_210del, ENST00000551988.5:n.297_299del, ENST00000553106.5:c.208_210del, ENST00000635500.1:n.176_178del, NC_000012.12:g.102894879_102894881del, CM000674.2:g.102894879_102894881del, NC_000012.11:g.103288657_103288659del, CM000674.1:g.103288657_103288659del, NC_000012.10:g.101812787_101812789del, NG_008690.1:g.27724_27726del, NG_008690.2:g.68532_68534del, NM_000277.1(PAH):c.208_210delTCT (p.Ser70del)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM4, PM3, PM2, PP4, PS3		PAH-specific ACMG/AMP criteria applied: PP4: Phe>120 umol/L with PKU (PMID:25456745); PM3: In trans with: c.842+2T>A (P, ClinGen) (PMID:25456745); PS3: 0% in BioPKU; PM2: Extremely low frequency. ExAC MAF=0.00012; PM4: In frame deletion. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4, PM3, PS3, PM2, PM4).	25456745, 25456745	Phenylketonuria VCEP		2018-08-05	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229490/MONDO:0009861/006	ea84cf1d-348b-4e04-a809-550ce2b8d111
NM_000277.1(PAH):c.1223G>A (p.Arg408Gln)	612	CA229404	NM_000277.1:c.1223G>A, NC_000012.12:g.102840492C>T, CM000674.2:g.102840492C>T, NC_000012.11:g.103234270C>T, CM000674.1:g.103234270C>T, NC_000012.10:g.101758400C>T, NG_008690.1:g.82111G>A, NG_008690.2:g.122919G>A, XM_011538422.1:c.1166G>A, NM_000277.2:c.1223G>A, NM_001354304.1:c.1223G>A, NM_000277.3:c.1223G>A, ENST00000307000.7:c.1208G>A, ENST00000551114.2:n.885G>A, ENST00000553106.5:c.1223G>A, ENST00000635477.1:n.327G>A, ENST00000635528.1:n.738G>A, NM_000277.1(PAH):c.1223G>A (p.Arg408Gln)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PS3, PM3_Strong	PM2	PAH-specific ACMG/AMP criteria applied: PM3_Strong: In trans with R408W, IVS4-1G>A, R241C (ClinGen, P) (PMID:1312992; PMID:14722928); PP3: ; PS3: Mutant enzyme activity of 46% in BioPKU (PMID:9860305); PP4_Moderate: ~830 uml/L w/o BH4 deficiency & 823 umol/L, BH4 status unknown (PMID:9860305; PMID:1312992). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM3_Strong, PP3, PS3, PP4_Moderate).	1312992, 9860305, 9860305, 14722928, 1312992	Phenylketonuria VCEP		2018-08-05	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229404/MONDO:0009861/006	f5c357c3-eebd-4738-b8e9-b9c74e4aa9f4
NM_000277.2(PAH):c.289A>C (p.Ile97Leu)	376937	CA6748987	NM_000277.2:c.289A>C, NC_000012.12:g.102894798T>G, CM000674.2:g.102894798T>G, NC_000012.11:g.103288576T>G, CM000674.1:g.103288576T>G, NC_000012.10:g.101812706T>G, NG_008690.1:g.27805A>C, NG_008690.2:g.68613A>C, NM_000277.1:c.289A>C, XM_011538422.1:c.289A>C, NM_001354304.1:c.289A>C, XM_017019370.2:c.289A>C, NM_000277.3:c.289A>C, ENST00000307000.7:c.274A>C, ENST00000546844.1:c.289A>C, ENST00000548928.1:n.211A>C, ENST00000549111.5:n.385A>C, ENST00000550978.6:n.273A>C, ENST00000551337.5:c.289A>C, ENST00000551988.5:n.378A>C, ENST00000553106.5:c.289A>C, NM_000277.2(PAH):c.289A>C (p.Ile97Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4, BP4	PM2	PAH-specific ACMG/AMP criteria applied: BP4: Tolerated in SIFT, benign in Polyphen-2, Polymorphism in MutationTaster. REVEL=0.511; PP4: Seen in patient with mild HPA (PMID:17627389). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BP4, PP4).	17627389	Phenylketonuria VCEP		2018-08-07	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA6748987/MONDO:0009861/006	c5437297-1b67-4097-ba03-479a5330c664
NM_000277.1(PAH):c.1162G>A (p.Val388Met)	619	CA251543	NM_000277.1:c.1162G>A, NC_000012.12:g.102843683C>T, CM000674.2:g.102843683C>T, NC_000012.11:g.103237461C>T, CM000674.1:g.103237461C>T, NC_000012.10:g.101761591C>T, NG_008690.1:g.78920G>A, NG_008690.2:g.119728G>A, XM_011538422.1:c.1105G>A, NM_000277.2:c.1162G>A, NM_001354304.1:c.1162G>A, NM_000277.3:c.1162G>A, ENST00000307000.7:c.1147G>A, ENST00000549247.6:n.921G>A, ENST00000551114.2:n.824G>A, ENST00000553106.5:c.1162G>A, ENST00000635477.1:n.266G>A, ENST00000635528.1:n.677G>A, NM_000277.1(PAH):c.1162G>A (p.Val388Met)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PM2, PP4, PP3, PS3		PAH-specific ACMG/AMP criteria applied: PM2: Extremely low in ExAC and 1000 genomes (PMID:9860305); PS3: PAH activity in COS cell expression system 15% (PMID:9860305); PM3: Compound het with severe mutation (PMID:9860305); PP3: ; PP4: Reported in patient with classic PKU (PMID:9860305). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PS3, PM3, PP3, PP4).	9860305, 9860305, 9860305, 9860305	Phenylketonuria VCEP		2018-08-05	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA251543/MONDO:0009861/006	c18b654a-1bd0-428b-b43f-2711b92f28a1
NM_000277.1(PAH):c.688G>A (p.Val230Ile)	102784	CA286506	NM_000277.1:c.688G>A, NC_000012.12:g.102855154C>T, CM000674.2:g.102855154C>T, NC_000012.11:g.103248932C>T, CM000674.1:g.103248932C>T, NC_000012.10:g.101773062C>T, NG_008690.1:g.67449G>A, NG_008690.2:g.108257G>A, XM_011538422.1:c.688G>A, NM_000277.2:c.688G>A, NM_001354304.1:c.688G>A, XM_017019370.2:c.688G>A, NM_000277.3:c.688G>A, ENST00000307000.7:c.673G>A, ENST00000549111.5:n.784G>A, ENST00000553106.5:c.688G>A, NM_000277.1(PAH):c.688G>A (p.Val230Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM3_Very Strong	PM5, PM2, PP3, PS3	PAH-specific ACMG/AMP criteria applied: PP4_Moderate: V2301 seen in 1 patient with PAH deficiency. BH4 deficiency ruled out. Upgraded per ClinGen Metabolism WG. (PMID:8268925); PM3_VeryStrong: Detected in trans with IVS 10-11G>A, L48S, R408W, E390G). Upgraded per ClinGen SVI Workgroup. (PMID:15943553; PMID:21147011). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_VeryStrong).	8268925, 21147011, 15943553, 11161839, 17924342	Phenylketonuria VCEP		2018-08-12	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA286506/MONDO:0009861/006	08c0af15-2212-42d9-841c-0a5e84d6838d
NM_000277.1(PAH):c.1139C>T (p.Thr380Met)	628	CA114369	NM_000277.1:c.1139C>T, NC_000012.12:g.102843706G>A, CM000674.2:g.102843706G>A, NC_000012.11:g.103237484G>A, CM000674.1:g.103237484G>A, NC_000012.10:g.101761614G>A, NG_008690.1:g.78897C>T, NG_008690.2:g.119705C>T, XM_011538422.1:c.1082C>T, NM_000277.2:c.1139C>T, NM_001354304.1:c.1139C>T, NM_000277.3:c.1139C>T, ENST00000307000.7:c.1124C>T, ENST00000549247.6:n.898C>T, ENST00000551114.2:n.801C>T, ENST00000553106.5:c.1139C>T, ENST00000635477.1:n.243C>T, ENST00000635528.1:n.654C>T, NM_000277.1(PAH):c.1139C>T (p.Thr380Met)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM3_Very Strong, PS3	PM5, PM2	The c.1139C>T (p.Thr380Met) variant in PAH has been reported in 1 patient with PAH deficiency (BH4 deficiency excluded). (PP4_Moderate; PMID: 8268925). This variant has 28% enzyme activity (PS3; PMID: 27620137). This variant was detected in trans with multiple known pathogenic variants: R408W, R261Q, I65T, F299C (PM3_Very-strong; PMID: 7981714). Computational prediction tools and conservation analysis suggest that the c.1139C>T variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3_Very-strong	8268925, 7981714, 27620137	Phenylketonuria VCEP		2018-10-01	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA114369/MONDO:0009861/006	95c70134-5e17-4767-a5b4-84155f4374bd
NM_000277.1(PAH):c.442-1G>A	594	CA229550	NM_000277.1:c.442-1G>A, NC_000012.12:g.102866664C>T, CM000674.2:g.102866664C>T, NC_000012.11:g.103260442C>T, CM000674.1:g.103260442C>T, NC_000012.10:g.101784572C>T, NG_008690.1:g.55939G>A, NG_008690.2:g.96747G>A, XM_011538422.1:c.442-1G>A, NM_000277.2:c.442-1G>A, NM_001354304.1:c.442-1G>A, XM_017019370.2:c.442-1G>A, NM_000277.3:c.442-1G>A, ENST00000307000.7:c.427-1G>A, ENST00000549111.5:n.538-1G>A, ENST00000551988.5:n.530+10798G>A, ENST00000553106.5:c.442-1G>A, NM_000277.1(PAH):c.442-1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PP4_Moderate, PM2	PM3, PS3	PAH-specific ACMG/AMP criteria applied: PM2: Not present in ExAC or 1000 genomes (PMID:9860305); PVS1: Canonical -1 splice site where LOF is a known mechanism of disease, exon skipping disrupts reading frame, and is predicted to undergo NMD. Coding exon 5 is present in biologically-relevant transcript. PP4_Moderate: Reported in a mild PKU patient. BH4 deficiency assessed. (PMID:14681498). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4_Moderate).	21307867, 14681498, 14681498, 9860305, 14681498	Phenylketonuria VCEP		2019-04-09	2019-04-09	false	https://erepo.genome.network/evrepo/ui/classification/CA229550/MONDO:0009861/006	aa4ba2e7-5604-4e53-ad0b-f24f7ed4339c
NM_000277.1(PAH):c.721C>T (p.Arg241Cys)	102803	CA273357	NM_000277.1:c.721C>T, NC_000012.12:g.102852936G>A, CM000674.2:g.102852936G>A, NC_000012.11:g.103246714G>A, CM000674.1:g.103246714G>A, NC_000012.10:g.101770844G>A, NG_008690.1:g.69667C>T, NG_008690.2:g.110475C>T, XM_011538422.1:c.721C>T, NM_000277.2:c.721C>T, NM_001354304.1:c.721C>T, NM_000277.3:c.721C>T, ENST00000307000.7:c.706C>T, ENST00000549247.6:n.480C>T, ENST00000553106.5:c.721C>T, NM_000277.1(PAH):c.721C>T (p.Arg241Cys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2, PP4_Moderate, PP3, PS3, PM3_Strong	PM5	PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC (0.00014) and gnomAD (0.0001301); PP3: Deleterious effect predicted in SIFT, PolyPhen2, MutationTaster; PP4_Moderate: Seen in multiple PKU patients. BH4 deficiency excluded in 2 patients. Upgraded per ClinGen Metabolic Workgroup. (PMID:8222245; PMID:11142755); PM3_Strong: R241C seen once in trans with R413P, and once with R243Q, both pathogenic. Upgraded per ClinGen SVI Workgroup. (PMID:11142755); PS3: In vitro PAH R241C mutant was found to have 25% PAH activity of normal. In vivo phenylalanine breath test measured a decreased level in R241C homozygote. (PMID:15319459; PMID:7915167). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong, PS3).	11142755, 8222245, 15319459, 7915167, 11142755	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA273357/MONDO:0009861/006	dd8fcc3c-dde1-42d4-a0f2-31bbafa786a5
NM_000277.1(PAH):c.722G>A (p.Arg241His)	102804	CA286507	NM_000277.1:c.722G>A, NC_000012.12:g.102852935C>T, CM000674.2:g.102852935C>T, NC_000012.11:g.103246713C>T, CM000674.1:g.103246713C>T, NC_000012.10:g.101770843C>T, NG_008690.1:g.69668G>A, NG_008690.2:g.110476G>A, XM_011538422.1:c.722G>A, NM_000277.2:c.722G>A, NM_001354304.1:c.722G>A, NM_000277.3:c.722G>A, ENST00000307000.7:c.707G>A, ENST00000549247.6:n.481G>A, ENST00000553106.5:c.722G>A, NM_000277.1(PAH):c.722G>A (p.Arg241His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM5, PP4_Moderate, PM2, PP3, PM3_Strong		PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC, gnomAD, 1000G, ESP (0.000077- 0.0001518); PP3: Predicted deleterious in SIFT, PolyPhen2, MutationTaster; PM5: R241C (VarID 102803) is Pathogenic in ClinVar based on 3 submitters; PP4_Moderate: R241H seen in 1 PKU patient. BH4 deficiency ruled out. Upgraded per ClinGen Metabolism WG. (PMID:8268925); PM3_Strong: R241H detected in trans with pathogenic variants (IVS10, R408W, R252W). Upgraded per ClinGen SVI Workgroup. (PMID:9429153). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM5, PP4_Moderate, PM3_Strong).	8268925, 9429153	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA286507/MONDO:0009861/006	86e24192-6435-4be3-a366-79ac5a804969
NM_000277.1(PAH):c.1208C>T (p.Ala403Val)	92731	CA273106	NM_000277.1:c.1208C>T, NC_000012.12:g.102840507G>A, CM000674.2:g.102840507G>A, NC_000012.11:g.103234285G>A, CM000674.1:g.103234285G>A, NC_000012.10:g.101758415G>A, NG_008690.1:g.82096C>T, NG_008690.2:g.122904C>T, XM_011538422.1:c.1151C>T, NM_000277.2:c.1208C>T, NM_001354304.1:c.1208C>T, NM_000277.3:c.1208C>T, ENST00000307000.7:c.1193C>T, ENST00000551114.2:n.870C>T, ENST00000553106.5:c.1208C>T, ENST00000635477.1:n.312C>T, ENST00000635528.1:n.723C>T, NM_000277.1(PAH):c.1208C>T (p.Ala403Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM3_Very Strong, PS3	PM5, PM2, PP3	PAH-specific ACMG/AMP criteria applied: PP4_Moderate: Seen on 3 PKU alleles, BH4 deficiency was ruled out. Upgraded per ClinGen Metabolic WG. (PMID:8268925); PM3_VeryStrong: A403V found with 4 pathogenic variants . Upgraded per ClinGen SVI workgroup. (PMID:9429153); PS3: In vitro A403V mutant protein activity was ~43% wt. (PMID:21820508). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_VeryStrong, PS3).	8268925, 9429153, 21820508	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA273106/MONDO:0009861/006	e8a0e1ef-d616-4dfe-a24e-30a901afa80f
NM_000277.1(PAH):c.1197A>T (p.Val399=)	601	CA229379	NM_000277.1:c.1197A>T, NC_000012.12:g.102843648T>A, CM000674.2:g.102843648T>A, NC_000012.11:g.103237426T>A, CM000674.1:g.103237426T>A, NC_000012.10:g.101761556T>A, NG_008690.1:g.78955A>T, NG_008690.2:g.119763A>T, XM_011538422.1:c.1140A>T, NM_000277.2:c.1197A>T, NM_001354304.1:c.1197A>T, NM_000277.3:c.1197A>T, ENST00000307000.7:c.1182A>T, ENST00000549247.6:n.956A>T, ENST00000551114.2:n.859A>T, ENST00000553106.5:c.1197A>T, ENST00000635477.1:n.301A>T, ENST00000635528.1:n.712A>T, NM_000277.1(PAH):c.1197A>T (p.Val399=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PS3	PM5	The c.1197A>T (p.Val399=) variant in PAH has been reported on 7 alleles of PKU patients (BH4 deficiency excluded). (PP4_Moderate; PMID: 23271928; PMID: 11214902). This variant has an extremely low allele frequency (0.000004064) in gnomAD (PM2; http://gnomAD.broadinstitute.org). This variant induces post-transcriptional skipping of exon 11 (PS3; PMID: 11214902). This variant was detected in trans with R408W (Pathogenic in ClinVar) (PM3; PMID: 11214902). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate	11214902, 11214902, 23271928, 11214902	Phenylketonuria VCEP		2018-07-28	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229379/MONDO:0009861/006	2e857d40-9a55-4adc-a5f1-92f85b42ab6a
NM_000277.1(PAH):c.1169A>G (p.Glu390Gly)	625	CA114367	NM_000277.1:c.1169A>G, NC_000012.12:g.102843676T>C, CM000674.2:g.102843676T>C, NC_000012.11:g.103237454T>C, CM000674.1:g.103237454T>C, NC_000012.10:g.101761584T>C, NG_008690.1:g.78927A>G, NG_008690.2:g.119735A>G, XM_011538422.1:c.1112A>G, NM_000277.2:c.1169A>G, NM_001354304.1:c.1169A>G, NM_000277.3:c.1169A>G, ENST00000307000.7:c.1154A>G, ENST00000549247.6:n.928A>G, ENST00000551114.2:n.831A>G, ENST00000553106.5:c.1169A>G, ENST00000635477.1:n.273A>G, ENST00000635528.1:n.684A>G, NM_000277.1(PAH):c.1169A>G (p.Glu390Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2, PP3, PM3_Very Strong	PS3	The c.1169A>G (p.Glu390Gly) variant in PAH has been reported on at least 47 alleles, most often with Mild Hyperphenylalaninemia. (BH4 deficiency excluded). (PP4_Moderate; PMID: 8088845; PMID: 21147011). This variant has an extremely low allele frequency (MAF=0.00018 in gnomAD) (PM2; http://gnomAD.broadinstitute.org). This variant was detected in trans with IVS-12nt1, L333F (Pathogenic in ClinVar) + 8 homozygotes (PM3_Very-strong; PMID: 10479481; PMID: 21147011; PMID: 8088845). Computational prediction tools and conservation analysis suggest that the c.1169A>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_Very-strong	8088845, 21147011, 10479481, 8088845, 21147011, 10479481, 21147011	Phenylketonuria VCEP		2018-10-01	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA114367/MONDO:0009861/006	4917956e-57f9-44fe-959a-f93a579f02f2
NM_000277.1(PAH):c.898G>T (p.Ala300Ser)	92751	CA273108	NM_000277.1:c.898G>T, NC_000012.12:g.102851701C>A, CM000674.2:g.102851701C>A, NC_000012.11:g.103245479C>A, CM000674.1:g.103245479C>A, NC_000012.10:g.101769609C>A, NG_008690.1:g.70902G>T, NG_008690.2:g.111710G>T, XM_011538422.1:c.898G>T, NM_000277.2:c.898G>T, NM_001354304.1:c.898G>T, NM_000277.3:c.898G>T, ENST00000307000.7:c.883G>T, ENST00000549247.6:n.657G>T, ENST00000551114.2:n.560G>T, ENST00000553106.5:c.898G>T, ENST00000635477.1:n.59G>T, NM_000277.1(PAH):c.898G>T (p.Ala300Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM3_Very Strong, PS3	PM5, PM2	PAH-specific ACMG/AMP criteria applied: PP3: Deleterious in SIFT, Polyphen2, MutationTaster; PP4_Moderate: A300S found on 56/588 hyperphenylalaninemic patients, BH4 deficiency excluded. Upgraded per ClinGen Metabolic WG. (PMID:21147011); PM3_VeryStrong: Detected with c.1066-11G>A (P), R261Q(P/LP), L48S (P), R176X (P) in 20 patients. (PMID:21147011); PS3: A300S in vitro PAH activity of 31% (PMID:17935162). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PP4_Moderate, PM3_VeryStrong, PS3).	21147011, 21147011, 17935162	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA273108/MONDO:0009861/006	1cd06d79-1c2c-4338-936e-15faf0063222
NM_000277.2(PAH):c.727C>T (p.Arg243Ter)	588	CA220585	NM_000277.2:c.727C>T, NC_000012.12:g.102852930G>A, CM000674.2:g.102852930G>A, NC_000012.11:g.103246708G>A, CM000674.1:g.103246708G>A, NC_000012.10:g.101770838G>A, NG_008690.1:g.69673C>T, NG_008690.2:g.110481C>T, NM_000277.1:c.727C>T, XM_011538422.1:c.727C>T, NM_001354304.1:c.727C>T, NM_000277.3:c.727C>T, ENST00000307000.7:c.712C>T, ENST00000549247.6:n.486C>T, ENST00000553106.5:c.727C>T, NM_000277.2(PAH):c.727C>T (p.Arg243Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PS3		PAH-specific ACMG/AMP criteria applied: PVS1: nonsense variant; PS3: <1% of normal PAH activity (PMID:2014036). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PS3).	2014036	Phenylketonuria VCEP		2018-08-07	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA220585/MONDO:0009861/006	15418e53-7ae7-4fc4-8f8d-246d5db75696
NM_000277.1(PAH):c.754C>T (p.Arg252Trp)	584	CA251529	NM_000277.1:c.754C>T, NC_000012.12:g.102852903G>A, CM000674.2:g.102852903G>A, NC_000012.11:g.103246681G>A, CM000674.1:g.103246681G>A, NC_000012.10:g.101770811G>A, NG_008690.1:g.69700C>T, NG_008690.2:g.110508C>T, XM_011538422.1:c.754C>T, NM_000277.2:c.754C>T, NM_001354304.1:c.754C>T, NM_000277.3:c.754C>T, ENST00000307000.7:c.739C>T, ENST00000549247.6:n.513C>T, ENST00000553106.5:c.754C>T, NM_000277.1(PAH):c.754C>T (p.Arg252Trp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PM2, PP4, PP3, PS3	PM5	PAH-specific ACMG/AMP criteria applied: PM2: gnomAD MAF: 0.00006; PP3: tools predict damaging ; PS3: 1% residual activity (PMID:25596310; PMID:17935162); PP4: Detection of codon 252arg>trp in a patient with PAH deficiency (PMID:2574153); PM3: Detected with IVS10-11G>A, R261Q, IVS12+1, R68S (all P/LP). (PMID:18299955; PMID:11524738). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PP4, PM3).	18299955, 11524738, 2574153, 25596310, 17935162	Phenylketonuria VCEP		2018-08-13	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA251529/MONDO:0009861/006	3641e358-76ec-4492-b57b-e0456cc8d34b
NM_000277.1(PAH):c.755G>A (p.Arg252Gln)	102824	CA229743	NM_000277.1:c.755G>A, NC_000012.12:g.102852902C>T, CM000674.2:g.102852902C>T, NC_000012.11:g.103246680C>T, CM000674.1:g.103246680C>T, NC_000012.10:g.101770810C>T, NG_008690.1:g.69701G>A, NG_008690.2:g.110509G>A, XM_011538422.1:c.755G>A, NM_000277.2:c.755G>A, NM_001354304.1:c.755G>A, NM_000277.3:c.755G>A, ENST00000307000.7:c.740G>A, ENST00000549247.6:n.514G>A, ENST00000553106.5:c.755G>A, NM_000277.1(PAH):c.755G>A (p.Arg252Gln)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PP3, PS3		PAH-specific ACMG/AMP criteria applied: PM2: ; PP3: tools predict damaging; PS3: BioPKU 3% enzyme activity; 3.8% residual activity (PMID:24401910); PM3: Detected in trans with p.Pro407fs (PMID:7833954); PP4_Moderate: Detected in 2 patients with classic PKU (Phe>1.5mM). BH4 deficiency excluded (PMID:7833954; PMID:9634518). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PM3, PP4_Moderate).	7833954, 9634518, 7833954, 24401910	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229743/MONDO:0009861/006	ab854b7c-19a6-4553-ac95-af437437cddf
NM_000277.1(PAH):c.638T>C (p.Leu213Pro)	92747	CA273109	NM_000277.1:c.638T>C, NC_000012.12:g.102855204A>G, CM000674.2:g.102855204A>G, NC_000012.11:g.103248982A>G, CM000674.1:g.103248982A>G, NC_000012.10:g.101773112A>G, NG_008690.1:g.67399T>C, NG_008690.2:g.108207T>C, XM_011538422.1:c.638T>C, NM_000277.2:c.638T>C, NM_001354304.1:c.638T>C, XM_017019370.2:c.638T>C, NM_000277.3:c.638T>C, ENST00000307000.7:c.623T>C, ENST00000549111.5:n.734T>C, ENST00000553106.5:c.638T>C, NM_000277.1(PAH):c.638T>C (p.Leu213Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2, PP3, PM3_Very Strong		The c.638T>C (p.Leu213Pro) variant in PAH has been reported in in 4 patients with PAH deficiency (BH4 deficiency excluded). (PP4_Moderate; PMID: 8659548; PMID: 19292873; PMID: 21147011). This variant is absent from large population studies (PM2; http://exac.broadinstitute.org). This variant was detected in trans with c.1066-11G>A, E390G, D415N, R261X.(Pathogenic in ClinVar) (PM3_Very-strong; PMID: 19292873; PMID: 21147011; PMID: 8632937). Computational prediction tools and conservation analysis suggest that the c.638T>C variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_Very-strong	21147011, 19292873, 8659548, 8632937, 21147011, 19292873	Phenylketonuria VCEP		2018-10-01	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA273109/MONDO:0009861/006	1adb5216-c67d-4ebf-8b37-89b36d1f2625
NM_000277.1(PAH):c.926C>T (p.Ala309Val)	92753	CA220592	NM_000277.1:c.926C>T, NC_000012.12:g.102846938G>A, CM000674.2:g.102846938G>A, NC_000012.11:g.103240716G>A, CM000674.1:g.103240716G>A, NC_000012.10:g.101764846G>A, NG_008690.1:g.75665C>T, NG_008690.2:g.116473C>T, XM_011538422.1:c.913-2507C>T, NM_000277.2:c.926C>T, NM_001354304.1:c.926C>T, NM_000277.3:c.926C>T, ENST00000307000.7:c.911C>T, ENST00000549247.6:n.685C>T, ENST00000551114.2:n.588C>T, ENST00000553106.5:c.926C>T, ENST00000635477.1:n.74-2507C>T, ENST00000635528.1:n.441C>T, NM_000277.1(PAH):c.926C>T (p.Ala309Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PM2, PP4, PP3, PS3		PAH-specific ACMG/AMP criteria applied: PM2: Low frequency. 1.0e-5; PP3: All databases agree on damaging effect. REVEL=0.921; PS3: Enzyme activity = 30% (Ho, 2008) (PMID:18590700); PM3: Single patient with classic PKU, c.842C>T (pathogenic in ClinVar) / c.926C>T (PMID:26666653); PP4: Single patient with classic PKU (>1200umol/L), BH4 defect not excluded (PMID:26666653). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PM3, PP4).	26666653, 26666653, 18590700	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA220592/MONDO:0009861/006	db2881e3-3790-4e61-95e9-4ee16b4291d4
NM_000277.1(PAH):c.916A>G (p.Ile306Val)	618	CA114365	NM_000277.1:c.916A>G, NC_000012.12:g.102846948T>C, CM000674.2:g.102846948T>C, NC_000012.11:g.103240726T>C, CM000674.1:g.103240726T>C, NC_000012.10:g.101764856T>C, NG_008690.1:g.75655A>G, NG_008690.2:g.116463A>G, XM_011538422.1:c.913-2517A>G, NM_000277.2:c.916A>G, NM_001354304.1:c.916A>G, NM_000277.3:c.916A>G, ENST00000307000.7:c.901A>G, ENST00000549247.6:n.675A>G, ENST00000551114.2:n.578A>G, ENST00000553106.5:c.916A>G, ENST00000635477.1:n.74-2517A>G, ENST00000635528.1:n.431A>G, NM_000277.1(PAH):c.916A>G (p.Ile306Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PP3, PS3	PM5	PAH-specific ACMG/AMP criteria applied: PM2: MAF = 2.0e-5; PP3: Software agrees on a damaging effect.; PS3: Mutation ID#1, 18% residual enzyme activity (PMID:18590700); PM3: I306V / F55L (pathogenic in ClinVar) in a single patient with mild HPA (PMID:18299955); PP4_Moderate: BH4 defect excluded in all patients--single patient with mild hyperphe (Bercovich, 2008). (PMID:18299955). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PM3, PP4_Moderate).	18299955, 18299955, 18590700	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA114365/MONDO:0009861/006	168d68ba-4789-4c16-80f7-b3bd0197b5a8
NM_000277.1(PAH):c.520A>G (p.Ile174Val)	102720	CA229603	NM_000277.1:c.520A>G, NC_000012.12:g.102855322T>C, CM000674.2:g.102855322T>C, NC_000012.11:g.103249100T>C, CM000674.1:g.103249100T>C, NC_000012.10:g.101773230T>C, NG_008690.1:g.67281A>G, NG_008690.2:g.108089A>G, XM_011538422.1:c.520A>G, NM_000277.2:c.520A>G, NM_001354304.1:c.520A>G, XM_017019370.2:c.520A>G, NM_000277.3:c.520A>G, ENST00000307000.7:c.505A>G, ENST00000549111.5:n.616A>G, ENST00000551988.5:n.541A>G, ENST00000553106.5:c.520A>G, NM_000277.1(PAH):c.520A>G (p.Ile174Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4, PP3	PM5	PAH-specific ACMG/AMP criteria applied: PM2: Not found in any population databases; PP3: All predictors agree--damaging; PM3: Single patient IVS4+5G>T (null) / I174V (Bercovich 2008 PMID 18299955) (PMID:18299955); PP4: Two independent patients (one in Zschocke (PMID 10394930) and one in Bercovich (PMID 18299955) with "PKU". While no specific levels are mentioned, they are followed in clinic and were diagnosed with Phe >120umol/L. BH4 defect WAS NOT excluded in either paper.. In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM3, PP4).	18299955	Phenylketonuria VCEP		2018-08-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229603/MONDO:0009861/006	06092610-48ec-429d-b3f5-4e9cdd9d3209
NM_000277.1(PAH):c.508C>G (p.His170Asp)	92744	CA273111	NM_000277.1:c.508C>G, NC_000012.12:g.102866597G>C, CM000674.2:g.102866597G>C, NC_000012.11:g.103260375G>C, CM000674.1:g.103260375G>C, NC_000012.10:g.101784505G>C, NG_008690.1:g.56006C>G, NG_008690.2:g.96814C>G, XM_011538422.1:c.508C>G, NM_000277.2:c.508C>G, NM_001354304.1:c.508C>G, XM_017019370.2:c.508C>G, NM_000277.3:c.508C>G, ENST00000307000.7:c.493C>G, ENST00000549111.5:n.604C>G, ENST00000551988.5:n.530+10865C>G, ENST00000553106.5:c.508C>G, NM_000277.1(PAH):c.508C>G (p.His170Asp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2, PP4, PP3, PS3, PM3_Strong		The c.508C>G (p.His170Asp) variant in PAH has been reported in 1 patient with hyperphenylalaninemia, and 1 patient with benign persistent hyperphenylalaninemia. (PP4; PMID: 11385716). This variant has an extremely low allele frequency (0.00018) in gnomAD (PM2; http://gnomad.broadinstitute.org). This variant has 43% enzyme activity (PS3; PMID: 17935162). This variant was detected in trans with R261X, c.60+5G>T, c.1315+1G>A  (Pathogenic in ClinVar) (PM3_Strong; PMID: 11385716; PMID: 24941924). Computational prediction tools and conservation analysis suggest that the c.829T>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PS3, PM3_Strong	11385716, 17935162, 11385716, 24941924	Phenylketonuria VCEP		2018-07-28	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA273111/MONDO:0009861/006	8845817f-fc6b-4d7f-93b6-a072aeee8cba
NM_000277.2(PAH):c.490A>G (p.Ile164Val)	102698	CA229576	NM_000277.2:c.490A>G, NC_000012.12:g.102866615T>C, CM000674.2:g.102866615T>C, NC_000012.11:g.103260393T>C, CM000674.1:g.103260393T>C, NC_000012.10:g.101784523T>C, NG_008690.1:g.55988A>G, NG_008690.2:g.96796A>G, NM_000277.1:c.490A>G, XM_011538422.1:c.490A>G, NM_001354304.1:c.490A>G, XM_017019370.2:c.490A>G, NM_000277.3:c.490A>G, ENST00000307000.7:c.475A>G, ENST00000549111.5:n.586A>G, ENST00000551988.5:n.530+10847A>G, ENST00000553106.5:c.490A>G, NM_000277.2(PAH):c.490A>G (p.Ile164Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PM3_Strong	PP3	PAH-specific ACMG/AMP criteria applied: PM2: ExAC MAF: 0.00012; PP4_Moderate: Detected in patients with PKU/HPA. BH4 deficiency excluded. (PMID:11244681; PMID:23942198); PM3_Strong: Detected with D145V, A403V (Pathogenic) (PMID:11244681; PMID:23942198). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_Strong).	23942198, 11244681, 23942198, 11244681	Phenylketonuria VCEP		2018-08-13	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229576/MONDO:0009861/006	6daf45cd-bc30-4517-8391-4c64f38bea84
NM_000277.2(PAH):c.1068C>G (p.Tyr356Ter)	595	CA229327	NM_000277.2:c.1068C>G, NC_000012.12:g.102843777G>C, CM000674.2:g.102843777G>C, NC_000012.11:g.103237555G>C, CM000674.1:g.103237555G>C, NC_000012.10:g.101761685G>C, NG_008690.1:g.78826C>G, NG_008690.2:g.119634C>G, NM_000277.1:c.1068C>G, XM_011538422.1:c.1011C>G, NM_001354304.1:c.1068C>G, NM_000277.3:c.1068C>G, ENST00000307000.7:c.1053C>G, ENST00000549247.6:n.827C>G, ENST00000551114.2:n.730C>G, ENST00000553106.5:c.1068C>G, ENST00000635477.1:n.172C>G, ENST00000635528.1:n.583C>G, NM_000277.2(PAH):c.1068C>G (p.Tyr356Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4_Moderate		PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: ExAC MAF:0.00006.; PP4_Moderate: seen in classic and mild PKU patients. BH4 deficiency excluded.. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate).		Phenylketonuria VCEP		2018-08-07	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229327/MONDO:0009861/006	9025e366-1413-4d27-b5fa-3879c6f42ce5
NM_000314.6(PTEN):c.737C>T (p.Pro246Leu)	142269	CA000559	NM_000314.6:c.737C>T, NM_000314.5:c.737C>T, NM_001304717.2:c.1256C>T, NM_001304718.1:c.146C>T, XM_006717926.2:c.692C>T, XM_011539981.1:c.737C>T, XM_011539982.1:c.641C>T, XR_945791.1:n.1307C>T, NM_000314.7:c.737C>T, NM_001304717.5:c.1256C>T, NM_001304718.2:c.146C>T, ENST00000371953.7:c.737C>T, ENST00000472832.2:n.164C>T, NC_000010.11:g.87957955C>T, CM000672.2:g.87957955C>T, NC_000010.10:g.89717712C>T, CM000672.1:g.89717712C>T, NC_000010.9:g.89707692C>T, NG_007466.2:g.99517C>T, LRG_311:g.99517C>T, NM_000314.6(PTEN):c.737C>T (p.Pro246Leu)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PS4		PTEN c.737C>T (p.P246L) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2_VS: At least two proven OR one proven plus two assumed de novo observations in a patient with the disease and no family history. (PMID 23934111, internal laboratory contributor(s) SCV000222227.10)PS4: Probands with phenotype specificity score of 4-15.5. (PMID 24375884, PMID 10076877, PMID 22261759, PMID 23934111, internal laboratory contributor(s) SCV000222227.10)PM2: Absent in large sequenced populations. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000559/MONDO:0017623/003	835a14e6-4a41-47df-a1ff-271c872adf39
NM_000314.6(PTEN):c.-1170C>T	127662	CA151481	NM_000314.6:c.-1170C>T, NC_000010.11:g.87863299C>T, CM000672.2:g.87863299C>T, NC_000010.10:g.89623056C>T, CM000672.1:g.89623056C>T, NC_000010.9:g.89613036C>T, NG_007466.2:g.4862C>T, LRG_311:g.4862C>T, NG_033079.1:g.5139G>A, ENST00000706954.1:c.-17+657C>T, ENST00000688308.1:c.-17+186C>T, ENST00000445946.5:c.-812G>A, ENST00000371953.7:c.-1171C>T, ENST00000445946.3:c.-812G>A, NM_001126049.1:c.-812G>A, NM_001126049.2:c.-812G>A, NM_000314.6(PTEN):c.-1170C>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP5, BS1_Supporting	BP7, BS3, BS4, PM2, PM6, BS2, PP1, PP2, PP3, PP4, PM3, PM4, PM1, PM5, BP1, BP4, BP2, BP3, BA1, PS3, PS4, PS1, PS2	PTEN c.-1170C>T (NC_000010.10:g. 89623056C>T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1_P: Allele frequency of 0.0002477 (0.02477%, 16/64,586 alleles) in the European subpopulation of the gnomAD cohort. (PMID 27535533)BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributor(s) SCV000149466.6, SCV000184146.1)		PTEN VCEP		2020-03-23	2020-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA151481/MONDO:0017623/003	8c50af60-fe53-4c9b-b60a-3735d21c8645
NM_000314.6(PTEN):c.209+3A>T	185989	CA000135	NM_000314.6:c.209+3A>T, NM_000314.5:c.209+3A>T, NM_001304717.2:c.728+3A>T, NM_001304718.1:c.-541-5486A>T, XM_006717926.2:c.165-5486A>T, XM_011539981.1:c.209+3A>T, XM_011539982.1:c.113+3A>T, XR_945789.1:n.921+3A>T, XR_945790.1:n.921+3A>T, XR_945791.1:n.921+3A>T, NM_000314.7:c.209+3A>T, NM_001304717.5:c.728+3A>T, NM_001304718.2:c.-541-5486A>T, NM_000314.8:c.209+3A>T, ENST00000371953.7:c.209+3A>T, ENST00000498703.1:n.35+3A>T, ENST00000610634.1:c.107+3A>T, NC_000010.11:g.87925560A>T, CM000672.2:g.87925560A>T, NC_000010.10:g.89685317A>T, CM000672.1:g.89685317A>T, NC_000010.9:g.89675297A>T, NG_007466.2:g.67122A>T, LRG_311:g.67122A>T, NM_000314.6(PTEN):c.209+3A>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP3	PM2, PM6, PVS1, BP5, BP7, BS1, BS3, BS4, PP2, PP1, BS2, PM4, PM1, PM5, BA1, BP4, BP2, PS3, PS1, PS2, PS4	PTEN c.209+3A>T (IVS3+3A>T) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populationsPP3: At least 2 out of 3 in silico models predict a splicing impact.		PTEN VCEP		2020-03-23	2020-03-30	false	https://erepo.genome.network/evrepo/ui/classification/CA000135/MONDO:0017623/003	049d3e03-b5ad-4a47-92e9-ee077179049a
NM_000314.6(PTEN):c.235G>A (p.Ala79Thr)	41682	CA000358	NM_000314.6:c.235G>A, NM_000314.5:c.235G>A, NM_001304717.2:c.754G>A, NM_001304718.1:c.-516G>A, XM_006717926.2:c.190G>A, XM_011539981.1:c.235G>A, XM_011539982.1:c.139G>A, XR_945789.1:n.947G>A, XR_945790.1:n.947G>A, XR_945791.1:n.947G>A, NM_000314.7:c.235G>A, NM_001304717.5:c.754G>A, NM_001304718.2:c.-516G>A, ENST00000371953.7:c.235G>A, ENST00000498703.1:n.61G>A, ENST00000610634.1:c.133G>A, NC_000010.11:g.87931071G>A, CM000672.2:g.87931071G>A, NC_000010.10:g.89690828G>A, CM000672.1:g.89690828G>A, NC_000010.9:g.89680808G>A, NG_007466.2:g.72633G>A, LRG_311:g.72633G>A, NM_000314.6(PTEN):c.235G>A (p.Ala79Thr)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS2_Supporting, BS1, PP2		PTEN c.235G>A (p.A79T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0045 (0.45%, 9/1984 alleles) in the GME variome. (PMID 27428751)BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (Internal laboratory contributor(s) SCV000222198.12)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP		2018-04-06	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000358/MONDO:0017623/003	0340272b-ab4c-4672-94b8-40e0525d8eda
NM_000314.6(PTEN):c.304_306dupAAA (p.Lys102_Pro103insLys)	142681	CA169101	NM_000314.6:c.304_306dupAAA, NM_000314.5:c.304_306dup, NM_000314.6:c.304_306dup, NM_001304717.2:c.823_825dup, NM_001304718.1:c.-447_-445dup, XM_006717926.2:c.259_261dup, XM_011539981.1:c.304_306dup, XM_011539982.1:c.208_210dup, XR_945789.1:n.1016_1018dup, XR_945790.1:n.1016_1018dup, XR_945791.1:n.1016_1018dup, NM_000314.7:c.304_306dup, NM_001304717.5:c.823_825dup, NM_001304718.2:c.-447_-445dup, ENST00000371953.7:c.304_306dup, ENST00000498703.1:n.130_132dup, ENST00000610634.1:c.202_204dup, NC_000010.11:g.87933063_87933065dup, CM000672.2:g.87933063_87933065dup, NC_000010.10:g.89692820_89692822dup, CM000672.1:g.89692820_89692822dup, NC_000010.9:g.89682800_89682802dup, NG_007466.2:g.74625_74627dup, LRG_311:g.74625_74627dup, NM_000314.6(PTEN):c.304_306dupAAA (p.Lys102_Pro103insLys)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2		PTEN c.304_306dupAAA (p.K102_P103insK) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).		PTEN VCEP		2017-11-08	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA169101/MONDO:0017623/003	742e08c9-7bda-4006-95f1-22f34ec0d9e1
NM_000314.6(PTEN):c.1052_1054delTAG (p.Val351del)	127687	CA000271	NM_000314.6:c.1052_1054delTAG, NC_000010.11:g.87965312_87965314del, CM000672.2:g.87965312_87965314del, NC_000010.10:g.89725069_89725071del, CM000672.1:g.89725069_89725071del, NC_000010.9:g.89715049_89715051del, NG_007466.2:g.106874_106876del, LRG_311:g.106874_106876del, NM_000314.5:c.1052_1054del, NM_000314.6:c.1052_1054del, NM_001304717.2:c.1571_1573del, NM_001304718.1:c.461_463del, XM_006717926.2:c.1007_1009del, XM_011539982.1:c.956_958del, XR_945791.1:n.1622_1624del, NM_000314.7:c.1052_1054del, NM_001304717.5:c.1571_1573del, NM_001304718.2:c.461_463del, NM_000314.8:c.1052_1054del, ENST00000371953.7:c.1052_1054del, NM_000314.6(PTEN):c.1052_1054delTAG (p.Val351del)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2, BS3_Supporting	PVS1, PM6, BS4, BS1, BP7, BP5, BS2, PP3, PP2, PP1, PM5, PM1, PM4, BP2, BP4, BA1, PS4, PS2, PS1, PS3	PTEN c.1052_1054delTAG (p.Val351del) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533). BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	29706350	PTEN VCEP		2020-03-23	2020-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA000271/MONDO:0017623/003	ba4a2bab-161e-445b-a38c-7ef4639e08a9
NM_000314.6(PTEN):c.1171C>T (p.Pro391Ser)	187673	CA000118	NM_000314.6:c.1171C>T, NC_000010.11:g.87965431C>T, CM000672.2:g.87965431C>T, NC_000010.10:g.89725188C>T, CM000672.1:g.89725188C>T, NC_000010.9:g.89715168C>T, NG_007466.2:g.106993C>T, LRG_311:g.106993C>T, NM_000314.5:c.1171C>T, NM_001304717.2:c.1690C>T, NM_001304718.1:c.580C>T, XM_006717926.2:c.1126C>T, XM_011539982.1:c.1075C>T, XR_945791.1:n.1741C>T, NM_000314.7:c.1171C>T, NM_001304717.5:c.1690C>T, NM_001304718.2:c.580C>T, NM_000314.8:c.1171C>T, ENST00000371953.7:c.1171C>T, NM_000314.6(PTEN):c.1171C>T (p.Pro391Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2, BS3, PP2	PM6, PVS1, BS4, BS1, BP7, BP5, PP1, PP3, BS2, PM5, PM1, PM4, BA1, BP2, BP4, PS4, PS2, PS1, PS3	PTEN c.1171C>T (p.Pro391Ser)PTEN c.1171C>T (p.Pro391Ser) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3: Missense variants with both lipid phosphatase activity AND results from a second assay appropriate to the protein domain demonstrating no statistically significant difference from wild type. (PMID 30993208, 29785012, 29706350)	29785012, 29706350, 30993208	PTEN VCEP		2020-03-23	2020-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA000118/MONDO:0017623/003	2353f24f-8466-46ea-838d-a36a749f6a49
NM_000314.6(PTEN):c.-764G>A	7844	CA000567	NM_000314.6:c.-764G>A, NC_000010.11:g.87863705G>A, CM000672.2:g.87863705G>A, NC_000010.10:g.89623462G>A, CM000672.1:g.89623462G>A, NC_000010.9:g.89613442G>A, NG_007466.2:g.5268G>A, LRG_311:g.5268G>A, NG_033079.1:g.4733C>T, ENST00000371953.8:c.-765G>A, ENST00000371953.7:c.-765G>A, ENST00000610634.1:c.-867G>A, NM_000314.5:c.-764G>A, NM_001304717.2:c.-245G>A, NM_001304718.1:c.-1469G>A, NM_000314.7:c.-764G>A, NM_001304717.5:c.-245G>A, NM_001304718.2:c.-1469G>A, NM_000314.8:c.-765G>A, NM_000314.8(PTEN):c.-765G>A, NM_000314.6(PTEN):c.-764G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance		PM2	PTEN c.-765G>A (AKA c.-764G>A, NC_000010.10:g.89623462G>A) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).No criteria currently apply to this variant.		PTEN VCEP		2021-10-29	2021-10-29	false	https://erepo.genome.network/evrepo/ui/classification/CA000567/MONDO:0017623/003	1c091a56-7fdb-41a4-9573-e48254ef08b7
NM_000314.6(PTEN):c.44G>A (p.Arg15Lys)	404147	CA16613142	NM_000314.6:c.44G>A, NC_000010.11:g.87864513G>A, CM000672.2:g.87864513G>A, NC_000010.10:g.89624270G>A, CM000672.1:g.89624270G>A, NC_000010.9:g.89614250G>A, NG_007466.2:g.6075G>A, LRG_311:g.6075G>A, NG_033079.1:g.3925C>T, ENST00000700029.2:c.44G>A, ENST00000710265.1:c.44G>A, ENST00000472832.3:c.44G>A, ENST00000688922.2:c.44G>A, ENST00000700021.1:c.44G>A, ENST00000700022.1:c.44G>A, ENST00000706954.1:c.44G>A, ENST00000706955.1:c.44G>A, ENST00000686459.1:c.44G>A, ENST00000688158.1:c.44G>A, ENST00000688308.1:c.44G>A, ENST00000693560.1:c.563G>A, ENST00000371953.8:c.44G>A, ENST00000371953.7:c.44G>A, ENST00000462694.1:n.46G>A, ENST00000487939.1:n.65G>A, ENST00000610634.1:c.-59G>A, ENST00000618586.1:n.13G>A, NM_000314.5:c.44G>A, NM_001304717.2:c.563G>A, NM_001304718.1:c.-662G>A, XM_006717926.2:c.44G>A, XM_011539981.1:c.44G>A, XR_945789.1:n.756G>A, XR_945790.1:n.756G>A, XR_945791.1:n.756G>A, NM_000314.7:c.44G>A, NM_001304717.5:c.563G>A, NM_001304718.2:c.-662G>A, NM_000314.8:c.44G>A, NM_000314.6(PTEN):c.44G>A (p.Arg15Lys)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PP2, PS3_Moderate, PM6_Strong, PM2_Supporting	PVS1, BS1, BS3, BS4, BP5, BP7, BS2, PP3, PP1, PP4, PM3, PM4, PM1, PM5, BA1, BP4, BP1, BP2, BP3, PS4, PS2, PS1	NM_000314.8(PTEN):c.44G>A (p.Arg15Lys) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.1.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2_P: Absent in large sequenced populations (PMID 27535533). PM6_S: One proband with presumed de novo occurrence (maternity/paternity not confirmed) for a patient with highly specific phenotype. (internal laboratory contributor: SCV000573362.4)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PS3_M: Functional studies supportive of a damaging effect on the gene or gene product. Score of this variant = -1.65 (â‰¤ -1.11) on a high throughput phosphatase assay (PMID:29706350).	29706350, 29785012	PTEN VCEP		2024-04-05	2024-04-10	false	https://erepo.genome.network/evrepo/ui/classification/CA16613142/MONDO:0017623/003	9b8faad8-e78a-4d2f-8805-210367466752
NM_000314.6(PTEN):c.78C>T (p.Thr26=)	184104	CA000203	NM_000314.6:c.78C>T, NC_000010.11:g.87864547C>T, CM000672.2:g.87864547C>T, NC_000010.10:g.89624304C>T, CM000672.1:g.89624304C>T, NC_000010.9:g.89614284C>T, NG_007466.2:g.6109C>T, LRG_311:g.6109C>T, NG_033079.1:g.3891G>A, NM_000314.5:c.78C>T, NM_001304717.2:c.597C>T, NM_001304718.1:c.-628C>T, XM_006717926.2:c.78C>T, XM_011539981.1:c.78C>T, XR_945789.1:n.790C>T, XR_945790.1:n.790C>T, XR_945791.1:n.790C>T, NM_000314.7:c.78C>T, NM_001304717.5:c.597C>T, NM_001304718.2:c.-628C>T, NM_000314.8:c.78C>T, ENST00000371953.7:c.78C>T, ENST00000462694.1:n.80C>T, ENST00000487939.1:n.99C>T, ENST00000610634.1:c.-25C>T, ENST00000618586.1:n.47C>T, NM_000314.6(PTEN):c.78C>T (p.Thr26=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2, BP7	PVS1, PM6, BP5, BS1, BS3, BS4, BS2, PP1, PP2, PP3, PM4, PM1, PM5, BP4, BP2, BA1, PS3, PS1, PS2, PS4	PTEN c.78C>T (p.T26=) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533). BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP		2020-03-23	2020-03-30	false	https://erepo.genome.network/evrepo/ui/classification/CA000203/MONDO:0017623/003	5ae8d67a-b184-476c-878e-aef6ec246a56
NM_000314.8(PTEN):c.165-1G>A	187590	CA000129	NM_000314.8:c.165-1G>A, NC_000010.11:g.87925512G>A, CM000672.2:g.87925512G>A, NC_000010.10:g.89685269G>A, CM000672.1:g.89685269G>A, NC_000010.9:g.89675249G>A, NG_007466.2:g.67074G>A, LRG_311:g.67074G>A, ENST00000700029.2:c.165-1G>A, ENST00000710265.1:c.165-1G>A, ENST00000472832.3:c.165-1G>A, ENST00000688158.2:n.900-1G>A, ENST00000688922.2:c.165-1G>A, ENST00000700021.1:c.165-5534G>A, ENST00000700022.1:c.165-1G>A, ENST00000706954.1:c.165-1G>A, ENST00000706955.1:c.*200-1G>A, ENST00000686459.1:c.165-1G>A, ENST00000688158.1:c.*276-1G>A, ENST00000688308.1:c.165-1G>A, ENST00000688922.1:c.34-1G>A, ENST00000693560.1:c.684-1G>A, ENST00000371953.8:c.165-1G>A, ENST00000371953.7:c.165-1G>A, ENST00000610634.1:c.63-1G>A, NM_000314.5:c.165-1G>A, NM_000314.6:c.165-1G>A, NM_001304717.2:c.684-1G>A, NM_001304718.1:c.-541-5534G>A, XM_006717926.2:c.165-5534G>A, XM_011539981.1:c.165-1G>A, XM_011539982.1:c.69-1G>A, XR_945789.1:n.877-1G>A, XR_945790.1:n.877-1G>A, XR_945791.1:n.877-1G>A, NM_000314.7:c.165-1G>A, NM_001304717.5:c.684-1G>A, NM_001304718.2:c.-541-5534G>A, NM_000314.8(PTEN):c.165-1G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2_Supporting, PS4_Moderate, PVS1_Strong	PM6, BS1, BS3, BS4, BP5, BP7, BS2, PP1, PP2, PP3, PP4, PM3, PM4, PM1, PM5, BA1, BP1, BP4, BP2, BP3, PS2, PS3, PS1	NM_000314.8(PTEN):c.165-1G>A meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.1.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1_Strong: in-frame but truncated/altered region is critical to protein function. PM2_P: Absent in large sequenced populations in the gnomAD cohort. (PMID 27535533).PS4_P: Probands with phenotype specificity score of 1-1.5. (PMID: 21659347).		PTEN VCEP		2024-04-05	2024-04-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000129/MONDO:0017623/003	8c8c1292-baf8-4fcd-abbf-e22a7793a5dd
NM_000314.6(PTEN):c.80-1G>C	189462	CA000586	NM_000314.6:c.80-1G>C, NC_000010.11:g.87894024G>C, CM000672.2:g.87894024G>C, NC_000010.10:g.89653781G>C, CM000672.1:g.89653781G>C, NC_000010.9:g.89643761G>C, NG_007466.2:g.35586G>C, LRG_311:g.35586G>C, NM_000314.5:c.80-1G>C, NM_001304717.2:c.599-1G>C, NM_001304718.1:c.-626-1G>C, XM_006717926.2:c.80-1G>C, XM_011539981.1:c.80-1G>C, XM_011539982.1:c.68+13586G>C, XR_945789.1:n.792-1G>C, XR_945790.1:n.792-1G>C, XR_945791.1:n.792-1G>C, NM_000314.7:c.80-1G>C, NM_001304717.5:c.599-1G>C, NM_001304718.2:c.-626-1G>C, NM_000314.8:c.80-1G>C, ENST00000371953.7:c.80-1G>C, ENST00000462694.1:n.82-1G>C, ENST00000610634.1:c.-23-1G>C, NM_000314.6(PTEN):c.80-1G>C	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2, PVS1	PM6, BS4, BS3, BS1, BP7, BP5, PP3, PP2, PP1, BS2, PM5, PM1, PM4, BA1, BP2, BP4, PS4, PS2, PS1, PS3	PTEN 80-1G>C (IVS1-1G>C) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations		PTEN VCEP		2020-03-23	2020-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA000586/MONDO:0017623/003	2f607d68-ce7c-4110-9640-98a0992a2d02
NM_000314.6(PTEN):c.987_990delTAAA (p.Asn329Lysfs)	189441	CA000656	NM_000314.6:c.987_990delTAAA, NM_000314.5:c.987_990del, NM_000314.6:c.987_990del, NM_001304717.2:c.1506_1509del, NM_001304718.1:c.396_399del, XM_006717926.2:c.942_945del, XM_011539981.1:c.987_990del, XM_011539982.1:c.891_894del, XR_945791.1:n.1557_1560del, NM_000314.7:c.987_990del, NM_001304717.5:c.1506_1509del, NM_001304718.2:c.396_399del, ENST00000371953.7:c.987_990del, ENST00000472832.2:n.414_417del, NC_000010.11:g.87961079_87961082del, CM000672.2:g.87961079_87961082del, NC_000010.10:g.89720836_89720839del, CM000672.1:g.89720836_89720839del, NC_000010.9:g.89710816_89710819del, NG_007466.2:g.102641_102644del, LRG_311:g.102641_102644del, NM_000314.6(PTEN):c.987_990delTAAA (p.Asn329Lysfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PVS1, PS4_Supporting		PTEN c.987_990delTAAA (p.N329KfsX14) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 10232405)		PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000656/MONDO:0017623/003	e41ad782-4c9c-4ae6-ba02-ec2e11c967fc
NM_000314.6(PTEN):c.892C>T (p.Gln298Ter)	187657	CA000219	NM_000314.6:c.892C>T, NC_000010.11:g.87960984C>T, CM000672.2:g.87960984C>T, NC_000010.10:g.89720741C>T, CM000672.1:g.89720741C>T, NC_000010.9:g.89710721C>T, NG_007466.2:g.102546C>T, LRG_311:g.102546C>T, NM_000314.5:c.892C>T, NM_001304717.2:c.1411C>T, NM_001304718.1:c.301C>T, XM_006717926.2:c.847C>T, XM_011539981.1:c.892C>T, XM_011539982.1:c.796C>T, XR_945791.1:n.1462C>T, NM_000314.7:c.892C>T, NM_001304717.5:c.1411C>T, NM_001304718.2:c.301C>T, ENST00000371953.7:c.892C>T, ENST00000472832.2:n.319C>T, NM_000314.6(PTEN):c.892C>T (p.Gln298Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PVS1, PS4_Supporting		PTEN c.892C>T (p.Q298X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 23470840)		PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000219/MONDO:0017623/003	f890d81d-90ed-4411-a0fd-a89669dd616a
NM_000314.6(PTEN):c.964A>T (p.Lys322Ter)	185213	CA000235	NM_000314.6:c.964A>T, NC_000010.11:g.87961056A>T, CM000672.2:g.87961056A>T, NC_000010.10:g.89720813A>T, CM000672.1:g.89720813A>T, NC_000010.9:g.89710793A>T, NG_007466.2:g.102618A>T, LRG_311:g.102618A>T, NM_000314.5:c.964A>T, NM_001304717.2:c.1483A>T, NM_001304718.1:c.373A>T, XM_006717926.2:c.919A>T, XM_011539981.1:c.964A>T, XM_011539982.1:c.868A>T, XR_945791.1:n.1534A>T, NM_000314.7:c.964A>T, NM_001304717.5:c.1483A>T, NM_001304718.2:c.373A>T, NM_000314.8:c.964A>T, ENST00000371953.7:c.964A>T, ENST00000472832.2:n.391A>T, NM_000314.6(PTEN):c.964A>T (p.Lys322Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1, PM2	PM6, BS4, BS3, BS1, BP7, BP5, BS2, PP3, PP2, PP1, PM5, PM1, PM4, BP2, BP4, BA1, PS4, PS2, PS1, PS3	PTEN c.964A>T (p.Lys322Ter) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations		PTEN VCEP		2020-03-23	2020-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA000235/MONDO:0017623/003	bfdfbf81-6f26-43f8-aa4b-bbb17ebaf54a
NM_000314.6(PTEN):c.511C>T (p.Gln171Ter)	189411	CA000494	NM_000314.6:c.511C>T, NM_000314.5:c.511C>T, NM_001304717.2:c.1030C>T, NM_001304718.1:c.-81C>T, XM_006717926.2:c.466C>T, XM_011539981.1:c.511C>T, XM_011539982.1:c.415C>T, XR_945789.1:n.1382C>T, XR_945790.1:n.1499C>T, XR_945791.1:n.1205-5717C>T, NM_000314.7:c.511C>T, NM_001304717.5:c.1030C>T, NM_001304718.2:c.-81C>T, ENST00000371953.7:c.511C>T, NC_000010.11:g.87952136C>T, CM000672.2:g.87952136C>T, NC_000010.10:g.89711893C>T, CM000672.1:g.89711893C>T, NC_000010.9:g.89701873C>T, NG_007466.2:g.93698C>T, LRG_311:g.93698C>T, NM_000314.6(PTEN):c.511C>T (p.Gln171Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PVS1, PS4_Moderate		PTEN c.511C>T (p.Q171X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 22595938)PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 17043057, PMID 22595938)		PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000494/MONDO:0017623/003	276b536d-e9cf-488e-a7bf-d2d8d0b119b6
NM_000314.6(PTEN):c.50_51delAA (p.Gln17Argfs)	141654	CA000167	NM_000314.6:c.50_51delAA, NM_000314.5:c.50_51del, NM_000314.6:c.50_51del, NM_001304717.2:c.569_570del, NM_001304718.1:c.-656_-655del, XM_006717926.2:c.50_51del, XM_011539981.1:c.50_51del, XR_945789.1:n.762_763del, XR_945790.1:n.762_763del, XR_945791.1:n.762_763del, NM_000314.7:c.50_51del, NM_001304717.5:c.569_570del, NM_001304718.2:c.-656_-655del, ENST00000371953.7:c.50_51del, ENST00000462694.1:n.52_53del, ENST00000487939.1:n.71_72del, ENST00000610634.1:c.-53_-52del, ENST00000618586.1:n.19_20del, NC_000010.11:g.87864519_87864520del, CM000672.2:g.87864519_87864520del, NC_000010.10:g.89624276_89624277del, CM000672.1:g.89624276_89624277del, NC_000010.9:g.89614256_89614257del, NG_007466.2:g.6081_6082del, LRG_311:g.6081_6082del, NG_033079.1:g.3918_3919del, NM_000314.6(PTEN):c.50_51delAA (p.Gln17Argfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PVS1, PS4_Supporting		PTEN c.50_51delAA (p.Q17RfsX26) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 20223021)	20223021	PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000167/MONDO:0017623/003	2b40684d-92f4-40ce-8062-ffd5a0278fbd
NM_000314.6(PTEN):c.1026+32T>G	92810	CA000255	NM_000314.6:c.1026+32T>G, NC_000010.11:g.87961150T>G, CM000672.2:g.87961150T>G, NC_000010.10:g.89720907T>G, CM000672.1:g.89720907T>G, NC_000010.9:g.89710887T>G, NG_007466.2:g.102712T>G, LRG_311:g.102712T>G, NM_000314.5:c.1026+32T>G, NM_001304717.2:c.1545+32T>G, NM_001304718.1:c.435+32T>G, XM_006717926.2:c.981+32T>G, XM_011539981.1:c.1026+32T>G, XM_011539982.1:c.930+32T>G, XR_945791.1:n.1596+32T>G, NM_000314.7:c.1026+32T>G, NM_001304717.5:c.1545+32T>G, NM_001304718.2:c.435+32T>G, ENST00000371953.7:c.1026+32T>G, ENST00000472832.2:n.485T>G, NM_000314.6(PTEN):c.1026+32T>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1		PTEN c.1026+32T>G (IVS8+32T>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.374 (37.4%, 102,771/274,696 alleles) in the gnomAD cohort. (PMID 27535533)		PTEN VCEP		2016-09-14	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000255/MONDO:0017623/003	30a41c35-daf4-47cc-b83c-ccf0c557f631
NM_000314.6(PTEN):c.801+23G>A	92829	CA000585	NM_000314.6:c.801+23G>A, NM_000314.5:c.801+23G>A, NM_001304717.2:c.1320+23G>A, NM_001304718.1:c.210+23G>A, XM_006717926.2:c.756+23G>A, XM_011539981.1:c.801+23G>A, XM_011539982.1:c.705+23G>A, XR_945791.1:n.1371+23G>A, NM_000314.7:c.801+23G>A, NM_001304717.5:c.1320+23G>A, NM_001304718.2:c.210+23G>A, ENST00000371953.7:c.801+23G>A, ENST00000472832.2:n.228+23G>A, NC_000010.11:g.87958042G>A, CM000672.2:g.87958042G>A, NC_000010.10:g.89717799G>A, CM000672.1:g.89717799G>A, NC_000010.9:g.89707779G>A, NG_007466.2:g.99604G>A, LRG_311:g.99604G>A, NM_000314.6(PTEN):c.801+23G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS1, BP4		PTEN c.801+23G>A (IVS7+23G>A) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0024 (0.24%, 58/24,016 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)BP4: Intronic variant where at least 2 out of 3 in silico models predict no splicing impact.		PTEN VCEP		2018-09-26	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000585/MONDO:0017623/003	742d7bc7-fc1a-47ac-b7fb-3be400cfe09f
NM_000314.6(PTEN):c.254-39G>T	92818	CA000368	NM_000314.6:c.254-39G>T, NC_000010.11:g.87932974G>T, CM000672.2:g.87932974G>T, NC_000010.10:g.89692731G>T, CM000672.1:g.89692731G>T, NC_000010.9:g.89682711G>T, NG_007466.2:g.74536G>T, LRG_311:g.74536G>T, NM_000314.5:c.254-39G>T, NM_001304717.2:c.773-39G>T, NM_001304718.1:c.-497-39G>T, XM_006717926.2:c.209-39G>T, XM_011539981.1:c.254-39G>T, XM_011539982.1:c.158-39G>T, XR_945789.1:n.966-39G>T, XR_945790.1:n.966-39G>T, XR_945791.1:n.966-39G>T, NM_000314.7:c.254-39G>T, NM_001304717.5:c.773-39G>T, NM_001304718.2:c.-497-39G>T, ENST00000371953.7:c.254-39G>T, ENST00000498703.1:n.80-39G>T, ENST00000610634.1:c.152-39G>T, NM_000314.6(PTEN):c.254-39G>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS1, BP7, BP4		PTEN c.254-39G>T (IVS4-39G>T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0064 (0.64%, 112/17,490 alleles) in the South Asian subpopulation of the gnomAD cohort. (PMID 27535533)BP4: Intronic variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is intronic and at or beyond +7/-21, nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP		2016-12-14	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000368/MONDO:0017623/003	e0072965-9b20-4fa8-bfab-2ec93223849b
NM_000314.6(PTEN):c.165-13_165-10delGTTT	189425	CA059366	NM_000314.6:c.165-13_165-10delGTTT, NC_000010.11:g.87925500_87925503del, CM000672.2:g.87925500_87925503del, NC_000010.10:g.89685257_89685260del, CM000672.1:g.89685257_89685260del, NC_000010.9:g.89675237_89675240del, NG_007466.2:g.67062_67065del, LRG_311:g.67062_67065del, NM_000314.5:c.165-13_165-10del, NM_000314.6:c.165-13_165-10del, NM_001304717.2:c.684-13_684-10del, NM_001304718.1:c.-541-5546_-541-5543del, XM_006717926.2:c.165-5546_165-5543del, XM_011539981.1:c.165-13_165-10del, XM_011539982.1:c.69-13_69-10del, XR_945789.1:n.877-13_877-10del, XR_945790.1:n.877-13_877-10del, XR_945791.1:n.877-13_877-10del, NM_000314.7:c.165-13_165-10del, NM_001304717.5:c.684-13_684-10del, NM_001304718.2:c.-541-5546_-541-5543del, ENST00000371953.7:c.165-13_165-10del, ENST00000610634.1:c.63-13_63-10del, NM_000314.6(PTEN):c.165-13_165-10delGTTT	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS1, BP4		PTEN c.165-13_165-10delGTTT (IVS2-13_IVS2-10delGTTT) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0049 (0.49%, 112/22,776 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533) BP4: Intronic variant where at least 2 out of 3 in silico models predict no splicing impact.		PTEN VCEP		2016-12-14	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA059366/MONDO:0017623/003	a81bf7b8-305b-4704-bf65-95e6aa54b5ba
NM_000314.6(PTEN):c.493-2A>G	141485	CA000478	NM_000314.6:c.493-2A>G, NC_000010.11:g.87952116A>G, CM000672.2:g.87952116A>G, NC_000010.10:g.89711873A>G, CM000672.1:g.89711873A>G, NC_000010.9:g.89701853A>G, NG_007466.2:g.93678A>G, LRG_311:g.93678A>G, NM_000314.5:c.493-2A>G, NM_001304717.2:c.1012-2A>G, NM_001304718.1:c.-99-2A>G, XM_006717926.2:c.448-2A>G, XM_011539981.1:c.493-2A>G, XM_011539982.1:c.397-2A>G, XR_945789.1:n.1364-2A>G, XR_945790.1:n.1481-2A>G, XR_945791.1:n.1205-5737A>G, NM_000314.7:c.493-2A>G, NM_001304717.5:c.1012-2A>G, NM_001304718.2:c.-99-2A>G, ENST00000371953.7:c.493-2A>G, NM_000314.6(PTEN):c.493-2A>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1, PM2, PM6_Strong		PTEN c.493-2A>G (IVS5-2A>G) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000222118.9)PM2: Absent in large sequenced populations.		PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000478/MONDO:0017623/003	e71dcbfe-0aed-4400-9ea2-5ec0ef78a666
NM_000314.6(PTEN):c.79+35C>T	92827	CA000576	NM_000314.6:c.79+35C>T, NC_000010.11:g.87864583C>T, CM000672.2:g.87864583C>T, NC_000010.10:g.89624340C>T, CM000672.1:g.89624340C>T, NC_000010.9:g.89614320C>T, NG_007466.2:g.6145C>T, LRG_311:g.6145C>T, NG_033079.1:g.3855G>A, NM_000314.5:c.79+35C>T, NM_001304717.2:c.598+35C>T, NM_001304718.1:c.-627+35C>T, XM_006717926.2:c.79+35C>T, XM_011539981.1:c.79+35C>T, XR_945789.1:n.791+35C>T, XR_945790.1:n.791+35C>T, XR_945791.1:n.791+35C>T, NM_000314.7:c.79+35C>T, NM_001304717.5:c.598+35C>T, NM_001304718.2:c.-627+35C>T, ENST00000371953.7:c.79+35C>T, ENST00000462694.1:n.81+35C>T, ENST00000487939.1:n.100+35C>T, ENST00000610634.1:c.-24+35C>T, ENST00000618586.1:n.83C>T, NM_000314.6(PTEN):c.79+35C>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BS3, BS1		PTEN c.79+35C>T (IVS1+35C>T) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.00178 (1.78%, 492/277,200 alleles) in the gnomAD cohort. (PMID 27535533) BS3: Intronic variant with RNA, mini-gene, or other splicing assay demonstrating no splicing impact. (PMID 17636424)		PTEN VCEP		2016-09-14	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000576/MONDO:0017623/003	e8d81f24-56b8-4bfb-82c1-e3c4bb305db9
NM_000314.6(PTEN):c.1104T>C (p.Asp368=)	138835	CA000293	NM_000314.6:c.1104T>C, NM_000314.5:c.1104T>C, NM_001304717.2:c.1623T>C, NM_001304718.1:c.513T>C, XM_006717926.2:c.1059T>C, XM_011539982.1:c.1008T>C, XR_945791.1:n.1674T>C, NM_000314.7:c.1104T>C, NM_001304717.5:c.1623T>C, NM_001304718.2:c.513T>C, ENST00000371953.7:c.1104T>C, NC_000010.11:g.87965364T>C, CM000672.2:g.87965364T>C, NC_000010.10:g.89725121T>C, CM000672.1:g.89725121T>C, NC_000010.9:g.89715101T>C, NG_007466.2:g.106926T>C, LRG_311:g.106926T>C, NM_000314.6(PTEN):c.1104T>C (p.Asp368=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP7, BS1, BP4		PTEN c.1104T>C (p.D368=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0057 (0.57%, 130/22,966 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP		2016-09-14	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000293/MONDO:0017623/003	044a4a6a-4939-4e73-8b9d-ff941b58e27d
NM_000314.6(PTEN):c.360A>C (p.Ala120=)	189426	CA000412	NM_000314.6:c.360A>C, NC_000010.11:g.87933119A>C, CM000672.2:g.87933119A>C, NC_000010.10:g.89692876A>C, CM000672.1:g.89692876A>C, NC_000010.9:g.89682856A>C, NG_007466.2:g.74681A>C, LRG_311:g.74681A>C, NM_000314.5:c.360A>C, NM_001304717.2:c.879A>C, NM_001304718.1:c.-391A>C, XM_006717926.2:c.315A>C, XM_011539981.1:c.360A>C, XM_011539982.1:c.264A>C, XR_945789.1:n.1072A>C, XR_945790.1:n.1072A>C, XR_945791.1:n.1072A>C, NM_000314.7:c.360A>C, NM_001304717.5:c.879A>C, NM_001304718.2:c.-391A>C, ENST00000371953.7:c.360A>C, ENST00000498703.1:n.186A>C, ENST00000610634.1:c.258A>C, NM_000314.6(PTEN):c.360A>C (p.Ala120=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP7, BP4		PTEN c.360A>C (p.A120=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP		2016-12-14	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000412/MONDO:0017623/003	53c09c9e-b77c-4949-8aef-58bcb3346e87
NM_000314.6(PTEN):c.132C>T (p.Gly44=)	92813	CA000318	NM_000314.6:c.132C>T, NM_000314.5:c.132C>T, NM_001304717.2:c.651C>T, NM_001304718.1:c.-574C>T, XM_006717926.2:c.132C>T, XM_011539981.1:c.132C>T, XM_011539982.1:c.68+13639C>T, XR_945789.1:n.844C>T, XR_945790.1:n.844C>T, XR_945791.1:n.844C>T, NM_000314.7:c.132C>T, NM_001304717.5:c.651C>T, NM_001304718.2:c.-574C>T, ENST00000371953.7:c.132C>T, ENST00000462694.1:n.134C>T, ENST00000610634.1:c.30C>T, NC_000010.11:g.87894077C>T, CM000672.2:g.87894077C>T, NC_000010.10:g.89653834C>T, CM000672.1:g.89653834C>T, NC_000010.9:g.89643814C>T, NG_007466.2:g.35639C>T, LRG_311:g.35639C>T, NM_000314.6(PTEN):c.132C>T (p.Gly44=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS2_Supporting, BS1, BP7, BP5		PTEN c.132C>T (p.G44=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.167 (1.67%, 463/276,792 alleles) in the gnomAD cohort. (PMID 27535533)BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (Internal laboratory contributor(s) SCV000212700.3)BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributor(s) SCV000212700.3)BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP		2016-11-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000318/MONDO:0017623/003	4fa0530f-2999-441d-b303-9451e343e97b
NM_000314.6(PTEN):c.75G>A (p.Leu25=)	184505	CA000197	NM_000314.6:c.75G>A, NC_000010.11:g.87864544G>A, CM000672.2:g.87864544G>A, NC_000010.10:g.89624301G>A, CM000672.1:g.89624301G>A, NC_000010.9:g.89614281G>A, NG_007466.2:g.6106G>A, LRG_311:g.6106G>A, NG_033079.1:g.3894C>T, ENST00000686459.1:c.75G>A, ENST00000688158.1:c.75G>A, ENST00000688308.1:c.75G>A, ENST00000693560.1:c.594G>A, ENST00000371953.8:c.75G>A, ENST00000371953.7:c.75G>A, ENST00000462694.1:n.77G>A, ENST00000487939.1:n.96G>A, ENST00000610634.1:c.-28G>A, ENST00000618586.1:n.44G>A, NM_000314.5:c.75G>A, NM_001304717.2:c.594G>A, NM_001304718.1:c.-631G>A, XM_006717926.2:c.75G>A, XM_011539981.1:c.75G>A, XR_945789.1:n.787G>A, XR_945790.1:n.787G>A, XR_945791.1:n.787G>A, NM_000314.7:c.75G>A, NM_001304717.5:c.594G>A, NM_001304718.2:c.-631G>A, NM_000314.8:c.75G>A, NM_000314.8(PTEN):c.75G>A (p.Leu25=), NM_000314.6(PTEN):c.75G>A (p.Leu25=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP7, BS3, PM2_Supporting	PM6, PVS1, BP5, BS1, BS4, PP2, PP3, PP1, PP4, BS2, PM5, PM4, PM1, PM3, BP1, BP4, BP3, BP2, BA1, PS1, PS3, PS4, PS2	NM_000314.8(PTEN):c.75G>A (p.Leu25=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS3: Synonymous variant with RNA, mini-gene, or other splicing assay demonstrating no splicing impact. (internal laboratory contributor)BP7: Variant is synonymous and no splicing impact is predicted.PM2_P: Absent in gnomAD.Using the Bayesian point system (PMID: 29300386) for this variant with conflicting evidence: 1 benign strong, 1 benign supporting and 1 pathogenic supporting codes get -4 + (-1) + 1 points; total is â€“ 4 (likely benign).		PTEN VCEP		2023-10-11	2023-10-18	false	https://erepo.genome.network/evrepo/ui/classification/CA000197/MONDO:0017623/003	e5e35031-cdfe-44ec-ad5e-0f3892c0a7b1
NM_000314.6(PTEN):c.18A>G (p.Lys6=)	233415	CA10578903	NM_000314.6:c.18A>G, NM_000314.5:c.18A>G, NM_001304717.2:c.537A>G, NM_001304718.1:c.-688A>G, XM_006717926.2:c.18A>G, XM_011539981.1:c.18A>G, XR_945789.1:n.730A>G, XR_945790.1:n.730A>G, XR_945791.1:n.730A>G, NM_000314.7:c.18A>G, NM_001304717.5:c.537A>G, NM_001304718.2:c.-688A>G, ENST00000371953.7:c.18A>G, ENST00000462694.1:n.20A>G, ENST00000487939.1:n.39A>G, ENST00000610634.1:c.-85A>G, NC_000010.11:g.87864487A>G, CM000672.2:g.87864487A>G, NC_000010.10:g.89624244A>G, CM000672.1:g.89624244A>G, NC_000010.9:g.89614224A>G, NG_007466.2:g.6049A>G, LRG_311:g.6049A>G, NG_033079.1:g.3951T>C, NM_000314.6(PTEN):c.18A>G (p.Lys6=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP7, BP4		PTEN c.18A>G (p.L6=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP		2016-10-12	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA10578903/MONDO:0017623/003	747804f8-133a-4807-9f7e-4c8798e82ee5
NM_000314.6(PTEN):c.-1311T>C	127667	CA287476	NM_000314.6:c.-1311T>C, NC_000010.11:g.87863158T>C, CM000672.2:g.87863158T>C, NC_000010.10:g.89622915T>C, CM000672.1:g.89622915T>C, NC_000010.9:g.89612895T>C, NG_007466.2:g.4721T>C, LRG_311:g.4721T>C, NG_033079.1:g.5280A>G, NM_001126049.1:c.-671A>G, ENST00000371953.7:c.-1312T>C, ENST00000445946.3:c.-671A>G, NM_000314.6(PTEN):c.-1311T>C	KLLN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1		PTEN c.-1311T>C (NC_000010.10:g.89622915T>C) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.0142 (1.42%, 23/1618 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)		PTEN VCEP		2017-06-02	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA287476/MONDO:0017623/003	eb4d52da-5b73-477e-9890-d8c613ea7ae5
NM_000314.6(PTEN):c.-1059C>G	189520	CA300594	NM_000314.6:c.-1059C>G, NC_000010.11:g.87863410C>G, CM000672.2:g.87863410C>G, NC_000010.10:g.89623167C>G, CM000672.1:g.89623167C>G, NC_000010.9:g.89613147C>G, NG_007466.2:g.4973C>G, LRG_311:g.4973C>G, NG_033079.1:g.5028G>C, NM_001126049.1:c.-923G>C, ENST00000371953.7:c.-1060C>G, ENST00000445946.3:c.-923G>C, NM_000314.6(PTEN):c.-1059C>G	KLLN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1		PTEN c.-1059C>G (NC_000010.10:g.89623167C>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.0138 (1.38%, 120/8698 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)		PTEN VCEP		2016-09-14	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA300594/MONDO:0017623/003	271c91d3-d627-42bf-86bc-ba9a7f7f2189
NM_000314.6(PTEN):c.-1026C>A	138836	CA000105	NM_000314.6:c.-1026C>A, NM_000314.5:c.-1026C>A, NM_001304717.2:c.-507C>A, NM_001304718.1:c.-1731C>A, ENST00000371953.7:c.-1027C>A, ENST00000610634.1:c.-1129C>A, NC_000010.11:g.87863443C>A, CM000672.2:g.87863443C>A, NC_000010.10:g.89623200C>A, CM000672.1:g.89623200C>A, NC_000010.9:g.89613180C>A, NG_007466.2:g.5006C>A, LRG_311:g.5006C>A, NG_033079.1:g.4995G>T, NM_000314.6(PTEN):c.-1026C>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP5, BS2_Supporting, BS1		PTEN c.-1026C>A (NC_000010.10:g.89623200C>A) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0056 (0.56%, 173/30,898 alleles) in the gnomAD cohort. (PMID 27535533)BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (Internal laboratory contributor(s) SCV000171228.5)BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributor(s) SCV000171228.5)		PTEN VCEP		2016-11-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000105/MONDO:0017623/003	b70739f7-4e4b-4678-8c1b-43aa0547db91
NM_000314.8(PTEN):c.521A>G (p.Tyr174Cys)	220007	CA349032	NM_000314.8:c.521A>G, NC_000010.11:g.87952146A>G, CM000672.2:g.87952146A>G, NC_000010.10:g.89711903A>G, CM000672.1:g.89711903A>G, NC_000010.9:g.89701883A>G, NG_007466.2:g.93708A>G, LRG_311:g.93708A>G, ENST00000686459.1:c.*107A>G, ENST00000688158.1:c.*632A>G, ENST00000688308.1:c.521A>G, ENST00000688922.1:c.442A>G, ENST00000693560.1:c.1040A>G, ENST00000371953.8:c.521A>G, ENST00000371953.7:c.521A>G, NM_000314.5:c.521A>G, NM_000314.6:c.521A>G, NM_001304717.2:c.1040A>G, NM_001304718.1:c.-71A>G, XM_006717926.2:c.476A>G, XM_011539981.1:c.521A>G, XM_011539982.1:c.425A>G, XR_945789.1:n.1392A>G, XR_945790.1:n.1509A>G, XR_945791.1:n.1205-5707A>G, NM_000314.7:c.521A>G, NM_001304717.5:c.1040A>G, NM_001304718.2:c.-71A>G, NM_000314.8(PTEN):c.521A>G (p.Tyr174Cys)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PP3, PP2, PM2_Supporting, PS4_Supporting, PS2	BP4	NM_000314.8(PTEN):c.521A>G (p.Tyr174Cys) variant meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000602123.1)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (Internal laboratory contributor(s) SCV000602123.1).PM2_P: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PP3: REVEL score > 0.7 (score=0.978).		PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA349032/MONDO:0017623/003	3905138e-990e-4b30-b0aa-96ad556248ac
NM_000314.6(PTEN):c.801+1delG	404140	CA16613026	NM_000314.6:c.801+1delG, NC_000010.11:g.87958020del, CM000672.2:g.87958020del, NC_000010.10:g.89717777del, CM000672.1:g.89717777del, NC_000010.9:g.89707757del, NG_007466.2:g.99582del, LRG_311:g.99582del, NM_000314.5:c.801+1del, NM_000314.6:c.801+1del, NM_001304717.2:c.1320+1del, NM_001304718.1:c.210+1del, XM_006717926.2:c.756+1del, XM_011539981.1:c.801+1del, XM_011539982.1:c.705+1del, XR_945791.1:n.1371+1del, NM_000314.7:c.801+1del, NM_001304717.5:c.1320+1del, NM_001304718.2:c.210+1del, NM_000314.8:c.801+1del, ENST00000371953.7:c.801+1del, ENST00000472832.2:n.228+1del, NM_000314.6(PTEN):c.801+1delG	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PVS1, PS4_Supporting	PM6, BS4, BS3, BS1, BP7, BP5, PP1, PP3, PP2, BS2, PM5, PM1, PM4, BA1, BP2, BP4, PS2, PS1, PS3	PTEN c.801+1delG (IVS7+1delG) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populationsPS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 23335809)	23335809	PTEN VCEP		2020-03-23	2020-03-25	false	https://erepo.genome.network/evrepo/ui/classification/CA16613026/MONDO:0017623/003	d8470abc-cd84-4dd7-aa9d-def2c9c878aa
NM_000314.6(PTEN):c.-903G>A	138837	CA000628	NM_000314.6:c.-903G>A, NM_000314.5:c.-903G>A, NM_001304717.2:c.-384G>A, NM_001304718.1:c.-1608G>A, ENST00000371953.7:c.-904G>A, ENST00000610634.1:c.-1006G>A, NC_000010.11:g.87863566G>A, CM000672.2:g.87863566G>A, NC_000010.10:g.89623323G>A, CM000672.1:g.89623323G>A, NC_000010.9:g.89613303G>A, NG_007466.2:g.5129G>A, LRG_311:g.5129G>A, NG_033079.1:g.4872C>T, NM_000314.6(PTEN):c.-903G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1		PTEN c.-903G>A (NC_000010.10:g.89623323G>A) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.011 (1.1%, 343/30,808 alleles) in the gnomAD cohort. (PMID 27535533)		PTEN VCEP		2016-09-14	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000628/MONDO:0017623/003	b7b13ffa-c41f-4c0e-9db4-dd26cede580d
NM_000314.6(PTEN):c.-9C>G	92808	CA000663	NM_000314.6:c.-9C>G, NC_000010.11:g.87864461C>G, CM000672.2:g.87864461C>G, NC_000010.10:g.89624218C>G, CM000672.1:g.89624218C>G, NC_000010.9:g.89614198C>G, NG_007466.2:g.6023C>G, LRG_311:g.6023C>G, NG_033079.1:g.3977G>C, NM_000314.5:c.-9C>G, NM_001304717.2:c.511C>G, NM_001304718.1:c.-714C>G, XM_006717926.2:c.-9C>G, XM_011539981.1:c.-9C>G, XR_945789.1:n.704C>G, XR_945790.1:n.704C>G, XR_945791.1:n.704C>G, NM_000314.7:c.-9C>G, NM_001304717.5:c.511C>G, NM_001304718.2:c.-714C>G, ENST00000371953.7:c.-9C>G, ENST00000487939.1:n.13C>G, ENST00000610634.1:c.-111C>G, NM_000314.6(PTEN):c.-9C>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1		PTEN c.-9C>G (NC_000010.10:g.89624218C>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.048 (4.8%, 903/18,870 alleles) in the East Asian subpopulation of the gnomAD cohort. (PMID 27535533)		PTEN VCEP		2016-11-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000663/MONDO:0017623/003	d1c7275d-fc3f-4feb-b749-4a6562cbc2d9
NM_000314.6(PTEN):c.209+4_209+7delAGTA	92816	CA220637	NM_000314.6:c.209+4_209+7delAGTA, NC_000010.11:g.87925561_87925564del, CM000672.2:g.87925561_87925564del, NC_000010.10:g.89685318_89685321del, CM000672.1:g.89685318_89685321del, NC_000010.9:g.89675298_89675301del, NG_007466.2:g.67123_67126del, LRG_311:g.67123_67126del, NM_000314.5:c.209+4_209+7del, NM_000314.6:c.209+4_209+7del, NM_001304717.2:c.728+4_728+7del, NM_001304718.1:c.-541-5485_-541-5482del, XM_006717926.2:c.165-5485_165-5482del, XM_011539981.1:c.209+4_209+7del, XM_011539982.1:c.113+4_113+7del, XR_945789.1:n.921+4_921+7del, XR_945790.1:n.921+4_921+7del, XR_945791.1:n.921+4_921+7del, NM_000314.7:c.209+4_209+7del, NM_001304717.5:c.728+4_728+7del, NM_001304718.2:c.-541-5485_-541-5482del, ENST00000371953.7:c.209+4_209+7del, ENST00000498703.1:n.35+4_35+7del, ENST00000610634.1:c.107+4_107+7del, NM_000314.6(PTEN):c.209+4_209+7delAGTA	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PP1_Moderate, PM6_Strong, PS4_Supporting, PS3		PTEN c.209+4_209+7delAGTA (IVS3+4_IVS3+7delAGTA) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: RNA, mini-gene, or other assay shows impact on splicing. (PMID 28677221)PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (Internal laboratory contributor(s))PM2: Absent in large sequenced populations (PMID 27535533).PP1_M: Co-segregation with disease in multiple affected family members, with 5 or 6 meioses observed. (Internal laboratory contributor(s))PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 28677221, internal laboratory contributor(s) SCV000273868.4)		PTEN VCEP		2017-12-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA220637/MONDO:0017623/003	9b41938e-76e1-469c-a782-0fabdaceb60c
NM_000314.6(PTEN):c.802-2A>T	142423	CA000591	NM_000314.6:c.802-2A>T, NC_000010.11:g.87960892A>T, CM000672.2:g.87960892A>T, NC_000010.10:g.89720649A>T, CM000672.1:g.89720649A>T, NC_000010.9:g.89710629A>T, NG_007466.2:g.102454A>T, LRG_311:g.102454A>T, NM_000314.5:c.802-2A>T, NM_001304717.2:c.1321-2A>T, NM_001304718.1:c.211-2A>T, XM_006717926.2:c.757-2A>T, XM_011539981.1:c.802-2A>T, XM_011539982.1:c.706-2A>T, XR_945791.1:n.1372-2A>T, NM_000314.7:c.802-2A>T, NM_001304717.5:c.1321-2A>T, NM_001304718.2:c.211-2A>T, ENST00000371953.7:c.802-2A>T, ENST00000472832.2:n.229-2A>T, NM_000314.6(PTEN):c.802-2A>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1, PM2, PS4_Supporting		PTEN c.802-2A>T (IVS7-2A>T) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (Internal laboratory contributor(s), SCV000222230.9)		PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000591/MONDO:0017623/003	0b5afc39-258a-4c7d-8a60-f765e5c2eaf2
NM_000314.6(PTEN):c.1026+1G>A	183722	CA000103	NM_000314.6:c.1026+1G>A, NM_000314.5:c.1026+1G>A, NM_001304717.2:c.1545+1G>A, NM_001304718.1:c.435+1G>A, XM_006717926.2:c.981+1G>A, XM_011539981.1:c.1026+1G>A, XM_011539982.1:c.930+1G>A, XR_945791.1:n.1596+1G>A, NM_000314.7:c.1026+1G>A, NM_001304717.5:c.1545+1G>A, NM_001304718.2:c.435+1G>A, ENST00000371953.7:c.1026+1G>A, ENST00000472832.2:n.454G>A, NC_000010.11:g.87961119G>A, CM000672.2:g.87961119G>A, NC_000010.10:g.89720876G>A, CM000672.1:g.89720876G>A, NC_000010.9:g.89710856G>A, NG_007466.2:g.102681G>A, LRG_311:g.102681G>A, NM_000314.6(PTEN):c.1026+1G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PVS1, PS4_Moderate		PTEN c.1026+1G>A (IVS8+1G>A) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4) (PMID 28677221).PM2: Absent in large sequenced populations (PMID 27535533).PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 28677221, internal laboratory contributor(s) SCV000212764.4)		PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000103/MONDO:0017623/003	9a0535ed-2b90-4309-917f-cbcce2549f2a
NM_000314.6(PTEN):c.103A>G (p.Met35Val)	231916	CA10578906	NM_000314.6:c.103A>G, NC_000010.11:g.87894048A>G, CM000672.2:g.87894048A>G, NC_000010.10:g.89653805A>G, CM000672.1:g.89653805A>G, NC_000010.9:g.89643785A>G, NG_007466.2:g.35610A>G, LRG_311:g.35610A>G, ENST00000700029.2:c.103A>G, ENST00000710265.1:c.103A>G, ENST00000472832.3:c.103A>G, ENST00000688158.2:n.899+13610A>G, ENST00000688922.2:c.103A>G, ENST00000700021.1:c.103A>G, ENST00000700022.1:c.103A>G, ENST00000706954.1:c.103A>G, ENST00000706955.1:c.*138A>G, ENST00000686459.1:c.103A>G, ENST00000688158.1:c.*275+13610A>G, ENST00000688308.1:c.103A>G, ENST00000693560.1:c.622A>G, ENST00000371953.8:c.103A>G, ENST00000371953.7:c.103A>G, ENST00000462694.1:n.105A>G, ENST00000610634.1:c.1A>G, NM_000314.5:c.103A>G, NM_001304717.2:c.622A>G, NM_001304718.1:c.-603A>G, XM_006717926.2:c.103A>G, XM_011539981.1:c.103A>G, XM_011539982.1:c.68+13610A>G, XR_945789.1:n.815A>G, XR_945790.1:n.815A>G, XR_945791.1:n.815A>G, NM_000314.7:c.103A>G, NM_001304717.5:c.622A>G, NM_001304718.2:c.-603A>G, NM_000314.8:c.103A>G, NM_000314.8(PTEN):c.103A>G (p.Met35Val), NM_000314.6(PTEN):c.103A>G (p.Met35Val)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PS3_Supporting, PP3, PP2, PM2_Supporting, PS4_Supporting	BP5, BP7, BS1, BS3, BS4, PM6, PVS1, PP4, PP1, BS2, PM3, PM4, PM1, PM5, BA1, BP4, BP1, BP2, BP3, PS1	NM_000314.8(PTEN):c.103A>G (p.Met35Val) meets criteria to be classified as Pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2_VS: At least two proven de novo observations in a patient with the disease and no family history. (internal laboratory contributors: SCV000275912.7, SCV000565444.8).PS3_P: Abnormal in vitro cellular assay or transgenic model with phenotype different from wild type that does not meet PS3 (Post et al. 2020 PMID: 32350270: pAKT levels similar to C124S).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID: 27531073, internal laboratory contributor: SCV000275912.7).PM2_P: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PP3: REVEL score > 0.7 (score of this variant =0.953)		PTEN VCEP		2024-02-09	2024-03-04	false	https://erepo.genome.network/evrepo/ui/classification/CA10578906/MONDO:0017623/003	4f6345e3-25b1-48cd-9697-1a5624715071
NM_000314.6(PTEN):c.389G>A (p.Arg130Gln)	7829	CA000437	NM_000314.6:c.389G>A, NC_000010.11:g.87933148G>A, CM000672.2:g.87933148G>A, NC_000010.10:g.89692905G>A, CM000672.1:g.89692905G>A, NC_000010.9:g.89682885G>A, NG_007466.2:g.74710G>A, LRG_311:g.74710G>A, ENST00000700029.2:c.389G>A, ENST00000710265.1:c.389G>A, ENST00000472832.3:c.389G>A, ENST00000688158.2:n.1124G>A, ENST00000688922.2:c.*219G>A, ENST00000700021.1:c.344G>A, ENST00000700022.1:c.389G>A, ENST00000700029.1:c.223G>A, ENST00000706954.1:c.389G>A, ENST00000706955.1:c.*424G>A, ENST00000686459.1:c.389G>A, ENST00000688158.1:c.*500G>A, ENST00000688308.1:c.389G>A, ENST00000688922.1:c.310G>A, ENST00000693560.1:c.908G>A, ENST00000371953.8:c.389G>A, ENST00000371953.7:c.389G>A, ENST00000498703.1:n.215G>A, ENST00000610634.1:c.287G>A, NM_000314.5:c.389G>A, NM_001304717.2:c.908G>A, NM_001304718.1:c.-362G>A, XM_006717926.2:c.344G>A, XM_011539981.1:c.389G>A, XM_011539982.1:c.293G>A, XR_945789.1:n.1101G>A, XR_945790.1:n.1101G>A, XR_945791.1:n.1101G>A, NM_000314.7:c.389G>A, NM_001304717.5:c.908G>A, NM_001304718.2:c.-362G>A, NM_000314.8:c.389G>A, NM_000314.6(PTEN):c.389G>A (p.Arg130Gln)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PM6_Very Strong, PP2, PM1, PS3, PS4		PTEN c.389G>A (p.R130Q) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM6_VS: At least four assumed de novo observations in a patient with the disease and no family history. (PMID 22595938, PMID 22327138, internal laboratory contributor(s) SCV000222111.11)PS3: Phosphatase activity <50% of wild type (PMID 10866302)PS4: Probands with phenotype specificity score of 4-15.5 (PMID 26798346, PMID 17526801, PMID 23335809, PMID 22266152)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP		2017-10-18	2024-09-23	false	https://erepo.genome.network/evrepo/ui/classification/CA000437/MONDO:0017623/003	844aa93c-ba66-4b09-825a-8e5e0fb0a775
NM_000314.6(PTEN):c.407G>A (p.Cys136Tyr)	189406	CA000451	NM_000314.6:c.407G>A, NC_000010.11:g.87933166G>A, CM000672.2:g.87933166G>A, NC_000010.10:g.89692923G>A, CM000672.1:g.89692923G>A, NC_000010.9:g.89682903G>A, NG_007466.2:g.74728G>A, LRG_311:g.74728G>A, NM_000314.5:c.407G>A, NM_001304717.2:c.926G>A, NM_001304718.1:c.-344G>A, XM_006717926.2:c.362G>A, XM_011539981.1:c.407G>A, XM_011539982.1:c.311G>A, XR_945789.1:n.1119G>A, XR_945790.1:n.1119G>A, XR_945791.1:n.1119G>A, NM_000314.7:c.407G>A, NM_001304717.5:c.926G>A, NM_001304718.2:c.-344G>A, ENST00000371953.7:c.407G>A, ENST00000498703.1:n.233G>A, ENST00000610634.1:c.305G>A, NM_000314.6(PTEN):c.407G>A (p.Cys136Tyr)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PS4_Supporting, PS3, PS2		PTEN c.407G>A (p.C136Y) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000222113.9)PS3: Phosphatase activity <50% of wild-type OR RNA, mini-gene, or other assay shows impact on splicing. (PMID 10866302)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Probands with specificity score of 1-1.5. (PMID 9735393, internal laboratory contributor(s) SCV000222113.9)		PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000451/MONDO:0017623/003	11de4e4a-dc77-4323-92c5-151d4868419d
NM_000314.6(PTEN):c.517C>T (p.Arg173Cys)	189500	CA000498	NM_000314.6:c.517C>T, NC_000010.11:g.87952142C>T, CM000672.2:g.87952142C>T, NC_000010.10:g.89711899C>T, CM000672.1:g.89711899C>T, NC_000010.9:g.89701879C>T, NG_007466.2:g.93704C>T, LRG_311:g.93704C>T, NM_000314.5:c.517C>T, NM_001304717.2:c.1036C>T, NM_001304718.1:c.-75C>T, XM_006717926.2:c.472C>T, XM_011539981.1:c.517C>T, XM_011539982.1:c.421C>T, XR_945789.1:n.1388C>T, XR_945790.1:n.1505C>T, XR_945791.1:n.1205-5711C>T, NM_000314.7:c.517C>T, NM_001304717.5:c.1036C>T, NM_001304718.2:c.-75C>T, ENST00000371953.7:c.517C>T, NM_000314.6(PTEN):c.517C>T (p.Arg173Cys)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PP1, PS4_Moderate, PS3		PTEN c.517C>T (p.R173C) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2_VS: At least two proven OR one proven plus two assumed de novo observations in a patient with the disease and no family history. (PMID 17526800, PMID 22628360, internal laboratory contributor(s) SCV000222220.10)PS3: Phosphatase activity <50% of wild type. (PMID 10866302)PM2: Absent in large sequenced populations (PMID 27535533).PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 22628360, PMID 17526800, PMID 17526801)PP1: Co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed. (PMID 22628360)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP		2017-10-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000498/MONDO:0017623/003	8f2c1cdc-0442-4dc1-ace0-ee811465348e
NM_000314.6(PTEN):c.395G>A (p.Gly132Asp)	92822	CA000444	NM_000314.6:c.395G>A, NC_000010.11:g.87933154G>A, CM000672.2:g.87933154G>A, NC_000010.10:g.89692911G>A, CM000672.1:g.89692911G>A, NC_000010.9:g.89682891G>A, NG_007466.2:g.74716G>A, LRG_311:g.74716G>A, ENST00000371953.8:c.395G>A, ENST00000371953.7:c.395G>A, ENST00000498703.1:n.221G>A, ENST00000610634.1:c.293G>A, NM_000314.5:c.395G>A, NM_001304717.2:c.914G>A, NM_001304718.1:c.-356G>A, XM_006717926.2:c.350G>A, XM_011539981.1:c.395G>A, XM_011539982.1:c.299G>A, XR_945789.1:n.1107G>A, XR_945790.1:n.1107G>A, XR_945791.1:n.1107G>A, NM_000314.7:c.395G>A, NM_001304717.5:c.914G>A, NM_001304718.2:c.-356G>A, NM_000314.8:c.395G>A, NM_000314.8(PTEN):c.395G>A (p.Gly132Asp), NM_000314.6(PTEN):c.395G>A (p.Gly132Asp)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PS4, PS3		PTEN c.395G>A (p.Gly132Asp) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29706350, PMID 32350270)PS4: Probands with phenotype specificity score of 4-15.5 (PMID 25288137, PMID 23335809, PMID 23470840, internal laboratory contributor(s) SCV000279163)PM2: Absent in large sequenced populations (PMID 27535533)PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000279163)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	25288137, 23470840, 23335809, 32350270, 29706350	PTEN VCEP		2021-10-29	2021-10-29	false	https://erepo.genome.network/evrepo/ui/classification/CA000444/MONDO:0017623/003	9c15b246-ef9f-4f55-a246-126b49710717
NM_000314.8(PTEN):c.-799G>C	127674	CA000581	NM_000314.8:c.-799G>C, NC_000010.11:g.87863671G>C, CM000672.2:g.87863671G>C, NC_000010.10:g.89623428G>C, CM000672.1:g.89623428G>C, NC_000010.9:g.89613408G>C, NG_007466.2:g.5234G>C, LRG_311:g.5234G>C, NG_033079.1:g.4767C>G, ENST00000700029.2:c.-799G>C, ENST00000710265.1:c.-799G>C, ENST00000706954.1:c.-16-783G>C, ENST00000706955.1:c.-799G>C, ENST00000688158.1:c.-799G>C, ENST00000688308.1:c.-17+558G>C, ENST00000693560.1:c.-279G>C, ENST00000371953.8:c.-799G>C, ENST00000371953.7:c.-799G>C, ENST00000610634.1:c.-901G>C, NM_000314.5:c.-798G>C, NM_000314.6:c.-798G>C, NM_001304717.2:c.-279G>C, NM_001304718.1:c.-1503G>C, NM_000314.7:c.-798G>C, NM_001304717.5:c.-279G>C, NM_001304718.2:c.-1503G>C, NM_000314.8(PTEN):c.-799G>C	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance		BS1, BS3, PM2	PTEN c.-798G>C (NC_000010.10:g.89623428G>C) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).No criteria currently apply to this variant.		PTEN VCEP		2025-03-07	2025-10-08	false	https://erepo.genome.network/evrepo/ui/classification/CA000581/MONDO:0017623/003	400140b3-b081-46b3-8b10-03492bb903d0
NM_000314.6(PTEN):c.*10delT	189424	CA000290	NM_000314.6:c.*10delT, NC_000010.11:g.87965482del, CM000672.2:g.87965482del, NC_000010.10:g.89725239del, CM000672.1:g.89725239del, NC_000010.9:g.89715219del, NG_007466.2:g.107044del, LRG_311:g.107044del, ENST00000371953.8:c.*10del, ENST00000371953.7:c.*10del, NM_000314.5:c.*10del, NM_000314.6:c.*10del, NM_001304717.2:c.*10del, NM_001304718.1:c.*10del, XM_006717926.2:c.*10del, XM_011539982.1:c.*10del, XR_945791.1:n.1792del, NM_000314.7:c.*10del, NM_001304717.5:c.*10del, NM_001304718.2:c.*10del, NM_000314.8:c.*10del, NM_000314.8(PTEN):c.*10del, NM_000314.6(PTEN):c.*10delT	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance		PM2	PTEN c.*10del (NC_000010.10:g.89725239delT) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).No criteria currently apply to this variant.		PTEN VCEP		2021-10-29	2021-10-29	false	https://erepo.genome.network/evrepo/ui/classification/CA000290/MONDO:0017623/003	e5c0aa16-de66-441e-9ef7-cda008c2cef7
NM_000314.6(PTEN):c.534_535delTAinsAT (p.Tyr178Ter)	7824	CA000509	NM_000314.6:c.534_535delTAinsAT, NC_000010.11:g.87952159_87952160delinsAT, CM000672.2:g.87952159_87952160delinsAT, NC_000010.10:g.89711916_89711917delinsAT, CM000672.1:g.89711916_89711917delinsAT, NC_000010.9:g.89701896_89701897delinsAT, NG_007466.2:g.93721_93722delinsAT, LRG_311:g.93721_93722delinsAT, NM_000314.5:c.534_535delinsAT, NM_000314.6:c.534_535delinsAT, NM_001304717.2:c.1053_1054delinsAT, NM_001304718.1:c.-58_-57delinsAT, XM_006717926.2:c.489_490delinsAT, XM_011539981.1:c.534_535delinsAT, XM_011539982.1:c.438_439delinsAT, XR_945789.1:n.1405_1406delinsAT, XR_945790.1:n.1522_1523delinsAT, XR_945791.1:n.1205-5694_1205-5693delinsAT, NM_000314.7:c.534_535delinsAT, NM_001304717.5:c.1053_1054delinsAT, NM_001304718.2:c.-58_-57delinsAT, ENST00000371953.7:c.534_535delinsAT, NM_000314.6(PTEN):c.534_535delTAinsAT (p.Tyr178Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1, PM2, PS4_Supporting		PTEN c.534_535delTAinsAT (p.Y178X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 9832032, PMID 23335809)		PTEN VCEP		2018-04-06	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000509/MONDO:0017623/003	ebef4811-dc36-4625-bd07-ea516d1cad7e
NM_000314.6(PTEN):c.-1142C>T	127661	CA151480	NM_000314.6:c.-1142C>T, NM_001126049.1:c.-840G>A, ENST00000371953.7:c.-1143C>T, ENST00000445946.3:c.-840G>A, NC_000010.11:g.87863327C>T, CM000672.2:g.87863327C>T, NC_000010.10:g.89623084C>T, CM000672.1:g.89623084C>T, NC_000010.9:g.89613064C>T, NG_007466.2:g.4890C>T, LRG_311:g.4890C>T, NG_033079.1:g.5111G>A, NM_000314.6(PTEN):c.-1142C>T	KLLN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS1, BP2		PTEN c.-1142C>T (NC_000010.10:g.89623084C>T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0049 (0.49%, 8/1622 alleles) in the East Asian subpopulation of the gnomAD cohort. (PMID 27535533) BP2: Observed in trans with a pathogenic or likely pathogenic PTEN variant, at least three observations in cis and/or phase unknown with different pathogenic/likely pathogenic PTEN variants. (Internal laboratory contributors SCV000187279.1, SCV000149465.6)		PTEN VCEP		2018-04-06	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA151480/MONDO:0017623/003	b49fa554-1a60-419c-8931-6cdc5564285c
NM_000314.6(PTEN):c.469G>T (p.Glu157Ter)	7814	CA000467	NM_000314.6:c.469G>T, NC_000010.11:g.87933228G>T, CM000672.2:g.87933228G>T, NC_000010.10:g.89692985G>T, CM000672.1:g.89692985G>T, NC_000010.9:g.89682965G>T, NG_007466.2:g.74790G>T, LRG_311:g.74790G>T, NM_000314.5:c.469G>T, NM_001304717.2:c.988G>T, NM_001304718.1:c.-282G>T, XM_006717926.2:c.424G>T, XM_011539981.1:c.469G>T, XM_011539982.1:c.373G>T, XR_945789.1:n.1181G>T, XR_945790.1:n.1181G>T, XR_945791.1:n.1181G>T, NM_000314.7:c.469G>T, NM_001304717.5:c.988G>T, NM_001304718.2:c.-282G>T, ENST00000371953.7:c.469G>T, ENST00000498703.1:n.295G>T, ENST00000610634.1:c.367G>T, NM_000314.6(PTEN):c.469G>T (p.Glu157Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PVS1, PS4_Supporting		PTEN c.469G>T (p.E157X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 8071972)		PTEN VCEP		2018-10-30	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000467/MONDO:0017623/003	c8a8caba-2251-491c-8758-14da15b51065
NM_000314.6(PTEN):c.40dupA (p.Arg14Lysfs)	7834	CA254258	NM_000314.6:c.40dupA, NC_000010.11:g.87864509dup, CM000672.2:g.87864509dup, NC_000010.10:g.89624266dup, CM000672.1:g.89624266dup, NC_000010.9:g.89614246dup, NG_007466.2:g.6071dup, LRG_311:g.6071dup, NG_033079.1:g.3932dup, NM_000314.5:c.40dup, NM_000314.6:c.40dup, NM_001304717.2:c.559dup, NM_001304718.1:c.-666dup, XM_006717926.2:c.40dup, XM_011539981.1:c.40dup, XR_945789.1:n.752dup, XR_945790.1:n.752dup, XR_945791.1:n.752dup, NM_000314.7:c.40dup, NM_001304717.5:c.559dup, NM_001304718.2:c.-666dup, ENST00000371953.7:c.40dup, ENST00000462694.1:n.42dup, ENST00000487939.1:n.61dup, ENST00000610634.1:c.-63dup, ENST00000618586.1:n.9dup, NM_000314.6(PTEN):c.40dupA (p.Arg14Lysfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1, PM6, PM2, PS4_Supporting		PTEN c.40dupA (p.R14Kfs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 10777358)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 10777358)		PTEN VCEP		2018-04-06	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA254258/MONDO:0017623/003	d7cc25c0-43b3-408c-8e19-6aab8d40a4f1
NM_000314.6(PTEN):c.510T>A (p.Ser170Arg)	7815	CA000492	NM_000314.6:c.510T>A, NC_000010.11:g.87952135T>A, CM000672.2:g.87952135T>A, NC_000010.10:g.89711892T>A, CM000672.1:g.89711892T>A, NC_000010.9:g.89701872T>A, NG_007466.2:g.93697T>A, LRG_311:g.93697T>A, ENST00000371953.8:c.510T>A, ENST00000371953.7:c.510T>A, NM_000314.5:c.510T>A, NM_001304717.2:c.1029T>A, NM_001304718.1:c.-82T>A, XM_006717926.2:c.465T>A, XM_011539981.1:c.510T>A, XM_011539982.1:c.414T>A, XR_945789.1:n.1381T>A, XR_945790.1:n.1498T>A, XR_945791.1:n.1205-5718T>A, NM_000314.7:c.510T>A, NM_001304717.5:c.1029T>A, NM_001304718.2:c.-82T>A, NM_000314.8:c.510T>A, NM_000314.8(PTEN):c.510T>A (p.Ser170Arg), NM_000314.6(PTEN):c.510T>A (p.Ser170Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PP1, PP2, PS3, PS4_Moderate		PTEN c.510T>A (p.Ser170Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 17942903, PMID 10866302, PMID 9256433, PMID 21828076PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 17526800, PMID 23335809, PMID 30528446)PM2: Absent in large sequenced populations (PMID 27535533)PP1: Co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed. (PMID 17526800, PMID 9241266)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP		2021-10-29	2021-10-29	false	https://erepo.genome.network/evrepo/ui/classification/CA000492/MONDO:0017623/003	67ade3e6-3038-4022-903b-9caf929577ba
NM_000314.6(PTEN):c.368A>G (p.His123Arg)	7816	CA000418	NM_000314.6:c.368A>G, NC_000010.11:g.87933127A>G, CM000672.2:g.87933127A>G, NC_000010.10:g.89692884A>G, CM000672.1:g.89692884A>G, NC_000010.9:g.89682864A>G, NG_007466.2:g.74689A>G, LRG_311:g.74689A>G, ENST00000371953.8:c.368A>G, ENST00000371953.7:c.368A>G, ENST00000610634.1:c.266A>G, NM_000314.5:c.368A>G, NM_001304717.2:c.887A>G, NM_001304718.1:c.-383A>G, XM_006717926.2:c.323A>G, XM_011539981.1:c.368A>G, XM_011539982.1:c.272A>G, NM_000314.7:c.368A>G, NM_001304717.5:c.887A>G, NM_001304718.2:c.-383A>G, NM_000314.8:c.368A>G, NM_000314.6(PTEN):c.368A>G (p.His123Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PM1, PS3		PTEN c.368A>G (p.His123Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29706350)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 10234502)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	29706350	PTEN VCEP		2021-04-29	2021-04-29	false	https://erepo.genome.network/evrepo/ui/classification/CA000418/MONDO:0017623/003	4ed5aa0a-d183-4c08-b6f6-23ffb9904a78
NM_000314.6(PTEN):c.520T>A (p.Tyr174Asn)	142220	CA000501	NM_000314.6:c.520T>A, NC_000010.11:g.87952145T>A, CM000672.2:g.87952145T>A, NC_000010.10:g.89711902T>A, CM000672.1:g.89711902T>A, NC_000010.9:g.89701882T>A, NG_007466.2:g.93707T>A, LRG_311:g.93707T>A, ENST00000371953.8:c.520T>A, ENST00000371953.7:c.520T>A, NM_000314.5:c.520T>A, NM_001304717.2:c.1039T>A, NM_001304718.1:c.-72T>A, XM_006717926.2:c.475T>A, XM_011539981.1:c.520T>A, XM_011539982.1:c.424T>A, XR_945789.1:n.1391T>A, XR_945790.1:n.1508T>A, XR_945791.1:n.1205-5708T>A, NM_000314.7:c.520T>A, NM_001304717.5:c.1039T>A, NM_001304718.2:c.-72T>A, NM_000314.8:c.520T>A, NM_000314.8(PTEN):c.520T>A (p.Tyr174Asn), NM_000314.6(PTEN):c.520T>A (p.Tyr174Asn)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2, PP2, PS3		PTEN c.520T>A (p.Tyr174Asn) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 10866302, PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	29706350	PTEN VCEP		2021-10-29	2021-10-29	false	https://erepo.genome.network/evrepo/ui/classification/CA000501/MONDO:0017623/003	58b7be5a-c98e-4344-9f4f-cff2dd70911d
NM_206933.2(USH2A):c.15562A>G (p.Ser5188Gly)	48468	CA143409	NM_206933.2:c.15562A>G, NC_000001.11:g.215625828T>C, CM000663.2:g.215625828T>C, NC_000001.10:g.215799170T>C, CM000663.1:g.215799170T>C, NC_000001.9:g.213865793T>C, NG_009497.1:g.802569A>G, NM_206933.3:c.15562A>G, ENST00000307340.7:c.15562A>G, NM_206933.2(USH2A):c.15562A>G (p.Ser5188Gly)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BA1		The filtering allele frequency of the p.Ser5188Gly variant in the USH2A gene is 6.8% (2200/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-17	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA143409/MONDO:0019501/005	6ea1fef2-f5b3-4739-8738-c6bf29fea20a
NM_004086.2(COCH):c.355G>A (p.Ala119Thr)	6613	CA253893	NM_004086.2:c.355G>A, NC_000014.9:g.30878926G>A, CM000676.2:g.30878926G>A, NC_000014.8:g.31348132G>A, CM000676.1:g.31348132G>A, NC_000014.7:g.30417883G>A, NG_008211.2:g.9392G>A, ENST00000216361.9:c.550G>A, ENST00000396618.9:c.355G>A, ENST00000555117.2:c.355G>A, ENST00000643575.1:c.355G>A, ENST00000643697.1:n.600G>A, ENST00000644874.2:c.355G>A, ENST00000216361.8:c.355G>A, ENST00000396618.7:c.355G>A, ENST00000460581.6:c.19G>A, ENST00000475087.5:c.355G>A, ENST00000553772.5:c.239+1198G>A, ENST00000553833.5:n.509G>A, ENST00000555881.5:c.83-1526G>A, ENST00000556908.5:c.307G>A, ENST00000557065.1:c.156-497G>A, NM_001135058.1:c.355G>A, NR_038356.1:n.1618-2374C>T, XM_011536539.1:c.355G>A, NM_001347720.1:c.550G>A, XM_017021071.1:c.550G>A, XM_024449506.1:c.355G>A, NM_004086.3:c.355G>A, NM_001135058.2:c.355G>A, NM_001347720.2:c.550G>A, NM_004086.2(COCH):c.355G>A (p.Ala119Thr)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Uncertain Significance	BS3_Supporting	BP7, BP5, BS1, BS4, PP3, PP2, PP1, PP4, BS2, PM4, PM5, PM1, PM3, PVS1, PM2, PM6, BP4, BP1, BP3, BP2, BA1, PS1, PS4, PS2, PS3	The c.355G>A (NM_004086.3) variant in COCH gene is a missense variant predicted to cause substitution of alanine by threonine at amino acid 119 p.(Ala119Thr). The highest population minor allele frequency in gnomAD v.4  is 0.08199% (7/44876 alleles) in the East Asian population (PM2_Supporting, BS1, and BA1 are not met). The computational Revel gives a score of 0.394,  which is neither above nor below the thresholds predicting a damaging or benign impact on COCH function. Functional studies show no differences between wild-type and p.A119T variant cochlin localization and secretion (PMID: 25230692) (BS3_Supporting). In summary, this variant meets the criteria to be classified as uncertain significance for  autosomal dominant nonsyndromic hearing loss based on the ACMG/AMPcriteria applied, as specified by the ClinGen ClinGen Hearing Loss VCEP: (BS3_Supporting) (Hearing Loss VCEP specifications version 2; 8/26/2025)	25230692, 14512963	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2025-08-26	2025-09-23	false	https://erepo.genome.network/evrepo/ui/classification/CA253893/MONDO:0019497/005	cb0a2192-d76a-4556-a2d3-b0f2d2569f1e
NM_206933.2(USH2A):c.15297+3A>G	48459	CA143392	NM_206933.2:c.15297+3A>G, NC_000001.11:g.215634456T>C, CM000663.2:g.215634456T>C, NC_000001.10:g.215807798T>C, CM000663.1:g.215807798T>C, NC_000001.9:g.213874421T>C, NG_009497.1:g.793941A>G, NM_206933.3:c.15297+3A>G, ENST00000307340.7:c.15297+3A>G, NM_206933.2(USH2A):c.15297+3A>G	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BA1	BP5, BP7, BS4, BS1, BS2, PP4, PP1, PP3, PM3, PM1, PM4, PM5, PM6, PM2, PVS1, BP2, BP3, BP4, PS3, PS2, PS4, PS1	The filtering allele frequency of the c.15297+3A>G variant in the USH2A gene is 0.99% (265/24032) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-14	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA143392/MONDO:0019501/005	801f4ee3-5d91-4c86-ba72-2ecc81250c22
NM_004004.5:c.677T>A	585322	CA387460663	NM_004004.5:c.677T>A, NC_000013.11:g.20188905A>T, CM000675.2:g.20188905A>T, NC_000013.10:g.20763044A>T, CM000675.1:g.20763044A>T, NC_000013.9:g.19661044A>T, NG_008358.1:g.9071T>A, ENST00000382844.2:c.677T>A, ENST00000382848.5:c.677T>A, ENST00000382844.1:c.677T>A, ENST00000382848.4:c.677T>A, XM_011535049.1:c.677T>A, XM_011535049.2:c.677T>A, NM_004004.6:c.677T>A, NM_004004.6(GJB2):c.677T>A (p.Val226Asp)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PM2_Supporting	BP5, BP7, BS1, BS3, BS4, PP1, PP4, PP3, PP2, BS2, PM5, PM4, PM3, PM1, PVS1, PM6, BP3, BP4, BP1, BP2, BA1, PS1, PS3, PS4, PS2	The NM_004004.6:c.677T>A variant in GJB2 is a missense variant predicted to cause substitution of valine by aspartic acid at amino acid 226 (p.Val226Asp). The variant was absent from gnomAD v2.1.1 meeting PM2_Supporting. The REVEL computational prediction analysis tool produced a score of 0.57 (PP3/BP4 not met). This variant has been identified in a heterozygous state in one individual with sensorineural hearing loss (PMID: 20201936). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for autosomal recessive nonsyndromic hearing loss. ACMG/AMP criteria applied as specified by the ClinGen Hearing Loss VCEP: PM2_Supporting (ClinGen Hearing Loss VCEP specifications version 2; 8/22/2023).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-08-22	2024-01-10	false	https://erepo.genome.network/evrepo/ui/classification/CA387460663/MONDO:0019497/005	3727aeaa-7c6e-4712-b0f1-b1eea47c7b7f
NM_004004.5:c.653G>A	585327	CA6904216	NM_004004.5:c.653G>A, NC_000013.11:g.20188929C>T, CM000675.2:g.20188929C>T, NC_000013.10:g.20763068C>T, CM000675.1:g.20763068C>T, NC_000013.9:g.19661068C>T, NG_008358.1:g.9047G>A, ENST00000382844.2:c.653G>A, ENST00000382848.5:c.653G>A, ENST00000382844.1:c.653G>A, ENST00000382848.4:c.653G>A, XM_011535049.1:c.653G>A, XM_011535049.2:c.653G>A, NM_004004.6:c.653G>A, NM_004004.6(GJB2):c.653G>A (p.Cys218Tyr)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PP3, PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, PM6, PVS1, BP4, BP1, BP3, BP2, BA1, PS1, PS4, PS3, PS2	The NM_004004.6:c.653G>A variant in GJB2 is a missense variant predicted to cause substitution of cysteine by tyrosine at amino acid 218 (p.Cys218Tyr). The highest minor allele frequency in gnomAD v.2.1.1 is 0.00178% (2/112164) of European (non-Finnish) population which is a low enough frequency to award PM2_Supporting. The REVEL computational prediction analysis tool produced a score of 0.817 meeting PP3. The variant has been identified in a heterozygous state in one individual with sensorineural hearing loss (PMID: 17666888). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for autosomal recessive nonsyndromic hearing loss. ACMG/AMP criteria applied as specified by the ClinGen Hearing Loss VCEP: PM2_Supporting, PP3 (ClinGen Hearing Loss VCEP specifications version 2; 8/22/2023).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-08-22	2024-01-10	false	https://erepo.genome.network/evrepo/ui/classification/CA6904216/MONDO:0019497/005	95f36c60-61b5-4f1a-ba52-8297f08592ec
NM_004004.5(GJB2):c.235delC (p.Leu79Cysfs)	17014	CA127025	NM_004004.5:c.235delC, NM_004004.5:c.235del, NC_000013.11:g.20189349del, CM000675.2:g.20189349del, NC_000013.10:g.20763488del, CM000675.1:g.20763488del, NC_000013.9:g.19661488del, NG_008358.1:g.8629del, XM_011535049.1:c.235del, XM_011535049.2:c.235del, NM_004004.6:c.235del, ENST00000382844.1:c.235del, ENST00000382848.4:c.235del, NM_004004.5(GJB2):c.235delC (p.Leu79Cysfs)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	BS1, PM3_Very Strong, PS3_Moderate, PVS1	PP3, PM2, BA1	The filtering allele frequency of the p.Leu79CysfsX3 variant in the GJB2 gene is 0.55% (121/ 18870) of East Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). The ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs the high allele frequency of the variant in population databases. Therefore, the BS1 code will not contribute to the overall classification. The p.Leu79CysfsX3 variant in GJB2 is predicted to cause a premature stop codon in the only exon of the gene, leading to absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 10983956, 10633133). A dye transfer assay, a functional study, has shown that the variant impacts protein function (PS3_M; PMID: 12352684). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_VS, PS3_M, BS1.	10633133, 10983956, 12352684	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-14	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA127025/MONDO:0019497/005	eda5030c-9ccf-4b14-bada-077b25b2562c
NM_004700.3(KCNQ4):c.825G>C (p.Trp275Cys)	505302	CA21112664	NM_004700.3:c.825G>C, NC_000001.11:g.40819463G>C, CM000663.2:g.40819463G>C, NC_000001.10:g.41285135G>C, CM000663.1:g.41285135G>C, NC_000001.9:g.41057722G>C, NG_008139.1:g.40452G>C, NG_008139.2:g.40452G>C, NG_008139.3:g.40677G>C, ENST00000347132.10:c.825G>C, ENST00000347132.9:c.825G>C, ENST00000443478.3:c.511G>C, ENST00000506017.1:n.144G>C, ENST00000509682.6:c.825G>C, NM_172163.2:c.825G>C, XM_011542417.1:c.825G>C, XM_011542418.1:c.825G>C, XM_011542419.1:c.825G>C, XM_011542420.1:c.825G>C, XR_946798.1:n.831G>C, XR_946799.1:n.831G>C, XR_946800.1:n.831G>C, XM_017002792.1:c.-193G>C, NM_004700.4:c.825G>C, NM_172163.3:c.825G>C, NM_004700.3(KCNQ4):c.825G>C (p.Trp275Cys)	KCNQ4	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Likely Pathogenic	PP3, PM5, PM1, PM2_Supporting	BS1, BS3, BS4, BP5, BP7, BS2, PP1, PP4, PP2, PM3, PM4, PM6, PVS1, BA1, BP4, BP1, BP2, BP3, PS4, PS3, PS2, PS1	The c.825G>C variant in KCNQ4 is a missense variant predicted to cause substitution of tryptophan by cysteine at amino acid 275 (p.Trp275Cys). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.928, which is above the threshold of 0.7, evidence that correlates with impact to KCNQ4 function (PP3). This variant has been reported in one individual with hearing loss and segregated in an affected first degree relative (SCV000712456.1). This variant is located within the pore-forming intramembrane region (amino acids 271-292) where many variants that cause autosomal dominant hearing loss are located and is defined as a critical functional domain by the ClinGen Hearing Loss VCEP (PM1; PMID: 23717403). A different missense variant at the same codon (p.Trp275Arg) has been classified as Pathogenic by the ClinGen Hearing Loss VCEP (PM5; ClinVar Variation ID 204597, PMID: 25116015). In summary, this variant is classified as Likely Pathogenic for autosomal dominant sensorineural hearing loss based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: PM2_Supporting, PP3, PM1, PM5. (VCEP specifications version 2; 10.18.2023).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-10-18	2024-07-02	false	https://erepo.genome.network/evrepo/ui/classification/CA21112664/MONDO:0019497/005	3e8e4973-8620-4a94-8c71-3bdec36a8281
NM_004004.5(GJB2):c.35delG (p.Gly12Valfs)	17004	CA127023	NM_004004.5:c.35del, NM_004004.5:c.35delG, NC_000013.11:g.20189552del, CM000675.2:g.20189552del, NC_000013.10:g.20763691del, CM000675.1:g.20763691del, NC_000013.9:g.19661691del, NG_008358.1:g.8429del, XM_011535049.1:c.35del, XM_011535049.2:c.35del, NM_004004.6:c.35del, ENST00000382844.1:c.35del, ENST00000382848.4:c.35del, NM_004004.5(GJB2):c.35delG (p.Gly12Valfs)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PM3_Very Strong, PVS1, BA1, PS4	BP7, BP5, BS1, BS4, BS2, PP3, PP1, PP4, PM5, PM4, PM1, PM2, PM6, BP2, BP4, BP3, PS1, PS3, PS2	The c.35delG variant in GJB2 is predicted to cause a premature stop codon in biologically-relevant-exon 2/2 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 26445815). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMID: 26969326, 25999548). The filtering allele frequency of the c.35delG variant in the GJB2 gene is 0.9% for European (Non-Finnish) chromosomes in the Genome Aggregation Database (1207/124552 with 95% CI), which is  a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). The ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for hearing loss outweighs the high allele frequency of the variant in population databases. Therefore, the BA1 code will not contribute to the overall classification. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive non-syndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_VS, PS4, BA1.	26969326, 25999548	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-20	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA127023/MONDO:0019497/005	58892872-8c79-4342-854b-6878c83611db
NM_004004.6(GJB2):c.34G>T (p.Gly12Cys)	44740	CA172224	NM_004004.6:c.34G>T, NC_000013.11:g.20189548C>A, CM000675.2:g.20189548C>A, NC_000013.10:g.20763687C>A, CM000675.1:g.20763687C>A, NC_000013.9:g.19661687C>A, NG_008358.1:g.8428G>T, ENST00000382844.2:c.34G>T, ENST00000382848.5:c.34G>T, ENST00000382844.1:c.34G>T, ENST00000382848.4:c.34G>T, NM_004004.5:c.34G>T, XM_011535049.1:c.34G>T, XM_011535049.2:c.34G>T, NM_004004.6(GJB2):c.34G>T (p.Gly12Cys)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Likely Pathogenic	BS1, PP3, PM3_Very Strong, PM5	BP7, BP5, BS4, BS3, PP2, PP4, PP1, BS2, PM4, PM1, PM2, PM6, PVS1, BA1, BP4, BP1, BP3, BP2, PS1, PS2, PS4, PS3	The c.34G>T (NM_004004.6) in GJB2 is a missense variant predicted to cause the substitution of glycine by cysteine at amino acid 12 (p.Gly12Cys). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0036 (128/35104 alleles) in the Latino/Admixed American population, which is higher than the ClinGen Hearing Loss VCEP threshold (>0.003) for BS1, and therefore meets this criterion (BS1). This is a high enough frequency that, in absence of conflicting data, might warrant a likely benign classification based on the thresholds defined by the ClinGen Hearing Loss VCEP for autosomal recessive hearing loss variants. However, based on the evidence outlined below, the ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs its high allele frequency in population databases. Therefore, the BS1 code will not contribute to the overall classification. This variant has been detected in at least 10 patients with hearing loss. Of those individuals, at least 4 were compound heterozygous or the variant and a pathogenic or likely pathogenic variant was observed in trans and one proband was homozygous for the variant (c.35delG, p.V37I, p.Val198fs, p.Lys122Ile, PMID: 15365987, 17041943, 17666888, 25288386, 26969326, 31035178, SCV000061501.5) (PM3_Very Strong). A different pathogenic missense variant (p.Gly12Val) (ClinVar Variation ID 21387) in the same codon of GJB2 has been classified as likely pathogenic and pathogenic for hearing loss by 7 labs who are in concordance that this variant is LP/P (PM5). The computational predictor REVEL gives a score of 0.838, and the nucleotide is heavily conserved in UCSC, which is above the threshold of 0.7, evidence that correlates with impact to GJB2 function (PP3). In summary, this variant meets the criteria to be classified as likely pathogenic for autosomal recessive nonsyndromic genetic hearing loss based on the ACMG/AMP criteria applied as specified by the Hearing Loss VCEP: PM3_Very Strong, PM5, PP3, BS1 (ClinGen Hearing Loss VCEP specifications version 2; 10/19/2022)	25288386, 15365987, 17041943, 17666888, 26969326	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2022-10-19	2023-02-02	false	https://erepo.genome.network/evrepo/ui/classification/CA172224/MONDO:0019497/005	060eab50-f9a8-40d2-b449-2edd2f54e4f3
NM_206933.2(USH2A):c.12295-?_14133+?del	177859	-	NM_206933.2:c.12295-?_14133+?del, NM_206933.3(USH2A):c.12295-?_14133+?del, NM_206933.2(USH2A):c.12295-?_14133+?del	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Likely Pathogenic	PVS1_Strong, PP4, PM3, PM2_Supporting		The variant NM_206933.3:c.12295-?_14133+?del in USH2A is an in-frame multi-exon deletion that leads to a truncation of a functionally important region in a gene where loss-of-function is an established disease mechanism (PVS1_Strong). The variant is absent from gnomAD v2.1.1 (PM2_Supporting). It has been detected as homozygous in one proband with Usher syndrome, as compound heterozygous with p.Arg334Gly in one proband with hearing loss and light sensitivity, and as compound heterozygous with p.Tyr3747Ter in one proband with hearing loss (PM3; Partners LMM internal data SCV000204167.4). At least one patient with a variant in this gene displayed features of moderate to severe hearing loss and retinitis pigmentosa (PP4; Partners LMM internal data SCV000204167.4). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1_Strong, PM2_Supporting, PM3, PP4 (ClinGen Hearing Loss VCEP specifications version 2; 9/26/2023).	26969326	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-09-26	2023-10-05	false	https://erepo.genome.network/evrepo/ui/classification/CV177859/MONDO:0019501/005	3e2a9116-5417-4772-b792-45d0463dc138
NM_000260.3(MYO7A):c.3503+12_3503+33delGAGGCGGGGACACCAGGGCCTG	43207	CA132294	NM_000260.3:c.3503+12_3503+33del, NM_000260.3:c.3503+12_3503+33del22, NM_000260.3:c.3503+12_3503+33delGAGGCGGGGACACCAGGGCCTG, NM_000260.3:c.3503+11_3503+32delGGAGGCGGGGACACCAGGGCCT, NM_001127179.2:c.3515_3536del, NM_001127180.1:c.3503+12_3503+33del, XM_005274012.2:c.3503+12_3503+33del, XM_006718558.2:c.3503+12_3503+33del, XM_006718559.2:c.3503+12_3503+33del, XM_006718560.2:c.3503+12_3503+33del, XM_006718561.2:c.3503+12_3503+33del, XM_011545044.1:c.3503+12_3503+33del, XM_011545045.1:c.3503+12_3503+33del, XM_011545046.1:c.3470+12_3470+33del, XM_011545047.1:c.3413+12_3413+33del, XM_011545048.1:c.3284+12_3284+33del, XM_011545049.1:c.3272+12_3272+33del, XM_011545050.1:c.3245+12_3245+33del, XM_011545051.1:c.3503+12_3503+33del, XM_011545052.1:c.3503+12_3503+33del, XR_949938.1:n.3823+12_3823+33del, XR_949941.1:n.3823+12_3823+33del, XR_949942.1:n.3825+12_3825+33del, XR_949943.1:n.3825+12_3825+33del, XM_011545044.2:c.3503+12_3503+33del, XM_011545046.2:c.3593+12_3593+33del, XM_011545050.2:c.3245+12_3245+33del, XM_017017778.1:c.3593+12_3593+33del, XM_017017779.1:c.3593+12_3593+33del, XM_017017780.1:c.3593+12_3593+33del, XM_017017781.1:c.3503+12_3503+33del, XM_017017782.1:c.3593+12_3593+33del, XM_017017783.1:c.3593+12_3593+33del, XM_017017784.1:c.3593+12_3593+33del, XM_017017785.1:c.3362+12_3362+33del, XM_017017786.1:c.3593+12_3593+33del, XM_017017787.1:c.3593+12_3593+33del, XM_017017788.1:c.3593+12_3593+33del, XR_001747885.1:n.3608+12_3608+33del, XR_001747886.1:n.3608+12_3608+33del, XR_001747887.1:n.3608+12_3608+33del, XR_001747888.1:n.3608+12_3608+33del, XR_001747889.1:n.3608+12_3608+33del, NM_000260.4:c.3503+12_3503+33del, ENST00000409619.6:c.3470+12_3470+33del, ENST00000409709.7:c.3503+12_3503+33del, ENST00000409893.5:c.3515_3536del, ENST00000458169.2:n.1046+12_1046+33del, ENST00000458637.6:c.3503+12_3503+33del, ENST00000467137.1:n.30+12_30+33del, ENST00000481328.7:n.1046+12_1046+33del, ENST00000620575.4:c.3501-8_3514del, NC_000011.10:g.77184727_77184748del, CM000673.2:g.77184727_77184748del, NC_000011.9:g.76895772_76895793del, CM000673.1:g.76895772_76895793del, NC_000011.8:g.76573420_76573441del, NG_009086.1:g.61463_61484del, NM_000260.3(MYO7A):c.3503+12_3503+33delGAGGCGGGGACACCAGGGCCTG	MYO7A	nonsyndromic genetic deafness	MONDO:0019497		Benign	BA1	BS4, BP5, BP7, PP4, PP1, PP3, BS2, PM4, PM5, PM3, PM1, PVS1, PM6, BP3, BP2, BP4, PS1, PS2, PS4, PS3	The filtering allele frequency of the c.3503+12_3503+33del (p.Gly1172GlufsX34) variant in the MYO7A gene is 50.8% (11084/21494) of European (Finnish) chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-28	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA132294/MONDO:0019497/005	458d2d78-e20e-4916-a70b-7ea43611edcf
NM_004999.4(MYO6):c.2836C>T (p.Arg946Cys)	164639	CA177354	NM_004999.4:c.2836C>T, NC_000006.12:g.75890234C>T, CM000668.2:g.75890234C>T, NC_000006.11:g.76599951C>T, CM000668.1:g.76599951C>T, NC_000006.10:g.76656671C>T, NG_009934.1:g.146043C>T, NG_009934.2:g.146042C>T, ENST00000369975.6:c.2836C>T, ENST00000369977.8:c.2836C>T, ENST00000369985.9:c.2836C>T, ENST00000627432.3:c.2845C>T, ENST00000664640.1:c.2836C>T, ENST00000671923.1:c.*943C>T, ENST00000672093.1:c.2836C>T, ENST00000369975.5:c.2836C>T, ENST00000369977.7:c.2836C>T, ENST00000369981.7:c.2836C>T, ENST00000369985.8:c.2836C>T, ENST00000430435.1:c.25C>T, ENST00000615563.4:c.2836C>T, ENST00000627432.2:c.2836C>T, NM_001300899.1:c.2836C>T, NM_004999.3:c.2836C>T, XM_005248719.2:c.2836C>T, XM_005248720.2:c.2836C>T, XM_005248721.2:c.2836C>T, XM_005248722.2:c.2836C>T, XM_005248724.2:c.2836C>T, XM_005248726.2:c.2836C>T, XM_005248719.4:c.2836C>T, XM_005248720.4:c.2836C>T, XM_005248721.4:c.2836C>T, XM_005248722.4:c.2836C>T, XM_005248724.4:c.2836C>T, XM_005248726.4:c.2836C>T, XM_017010899.2:c.2836C>T, XM_024446447.1:c.2836C>T, XM_024446448.1:c.2836C>T, NM_001300899.2:c.2836C>T, NM_001368136.1:c.2836C>T, NM_001368137.1:c.2836C>T, NM_001368138.1:c.2821C>T, NM_001368865.1:c.2836C>T, NM_001368866.1:c.2836C>T, NR_160538.1:n.3161C>T, NM_004999.4(MYO6):c.2836C>T (p.Arg946Cys)	MYO6	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Benign	BA1	BP7, BP5, BS1, BS3, BS4, PP3, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, PM2, PVS1, PM6, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.2836C>T(NM_004999.4) variant in MYO6 is a missense variant predicted to cause substitution of arginine by cysteine at amino acid 946 (p.Arg946Cys).â€‹ The filtering allele frequency of the c.2836C>T variant in the MYO6 gene is 0.12% for South Asian chromosomes by the Genome Aggregation Database v4 (94/63976 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).  (ClinGen Hearing Loss VCEP specifications version 2; 12.18.2024)		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2024-12-18	2025-03-28	false	https://erepo.genome.network/evrepo/ui/classification/CA177354/MONDO:0019497/005	fe2fd572-a746-4126-b1ab-8f0f90eabde2
NM_004999.3(MYO6):c.475G>A (p.Glu159Lys)	45163	CA135641	NM_004999.3:c.475G>A, NC_000006.12:g.75832925G>A, CM000668.2:g.75832925G>A, NC_000006.11:g.76542642G>A, CM000668.1:g.76542642G>A, NC_000006.10:g.76599362G>A, NG_009934.1:g.88734G>A, NG_009934.2:g.88733G>A, ENST00000369975.6:c.475G>A, ENST00000369977.8:c.475G>A, ENST00000369985.9:c.475G>A, ENST00000462633.3:c.475G>A, ENST00000627432.3:c.475G>A, ENST00000653423.1:c.475G>A, ENST00000653917.1:c.475G>A, ENST00000660420.1:c.*431G>A, ENST00000662184.1:c.475G>A, ENST00000662603.1:c.475G>A, ENST00000663400.1:c.475G>A, ENST00000664209.1:c.475G>A, ENST00000664640.1:c.475G>A, ENST00000671923.1:c.475G>A, ENST00000672093.1:c.475G>A, ENST00000369975.5:c.475G>A, ENST00000369977.7:c.475G>A, ENST00000369981.7:c.475G>A, ENST00000369985.8:c.475G>A, ENST00000615563.4:c.475G>A, ENST00000627432.2:c.475G>A, NM_001300899.1:c.475G>A, XM_005248719.2:c.475G>A, XM_005248720.2:c.475G>A, XM_005248721.2:c.475G>A, XM_005248722.2:c.475G>A, XM_005248724.2:c.475G>A, XM_005248726.2:c.475G>A, XM_005248719.4:c.475G>A, XM_005248720.4:c.475G>A, XM_005248721.4:c.475G>A, XM_005248722.4:c.475G>A, XM_005248724.4:c.475G>A, XM_005248726.4:c.475G>A, XM_017010899.2:c.475G>A, XM_024446447.1:c.475G>A, XM_024446448.1:c.475G>A, NM_004999.4:c.475G>A, NM_001300899.2:c.475G>A, NM_001368136.1:c.475G>A, NM_001368137.1:c.475G>A, NM_001368138.1:c.475G>A, NM_001368139.1:c.475G>A, NM_001368140.1:c.475G>A, NM_001368865.1:c.475G>A, NM_001368866.1:c.475G>A, NR_160538.1:n.707G>A, NR_160539.1:n.807G>A, NM_004999.3(MYO6):c.475G>A (p.Glu159Lys)	MYO6	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Benign	BA1	BP7, BP5, BS1, BS3, BS4, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, BP1, BP3, BP2, PS1, PS3, PS2, PS4	The c.475G>A variant in MYO6 is a missense variant predicted to cause substitution of glutamic acid by lysine at amino acid 159 (p.Glu159Lys).â€‹ The filtering allele frequency of this variant is 0.013% for South Asian chromosomes by the Genome Aggregation Database v4 (18/91064 with 95% CI), which meets no population allele frequency criteria (PM2_Supporting, BS1, and BA1 are not met). However, this variant is also present in 0.8% (257/29596) of Ashkenazi Jewish chromosomes, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1). This variant has not been reported in the literature in individuals affected with hearing loss. Therefore, given the lack of contradictory evidence, this variant is classified as benign based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BA1. (ClinGen Hearing Loss VCEP specifications version 2; 01.15.2025).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2025-01-15	2025-03-28	false	https://erepo.genome.network/evrepo/ui/classification/CA135641/MONDO:0019497/005	5cc1b9df-7aa4-471a-b98b-ffb43f4fe7c0
NM_206933.2(USH2A):c.11241C>A (p.Tyr3747Ter)	506273	CA1393780	NM_206933.2:c.11241C>A, NC_000001.11:g.215758743G>T, CM000663.2:g.215758743G>T, NC_000001.10:g.215932085G>T, CM000663.1:g.215932085G>T, NC_000001.9:g.213998708G>T, NG_009497.1:g.669654C>A, NM_206933.3:c.11241C>A, ENST00000307340.7:c.11241C>A, NM_206933.2(USH2A):c.11241C>A (p.Tyr3747Ter)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PM3_Supporting, PM2_Supporting, PVS1	BP5, BP7, BS4, BS1, PP4, PP1, PP3, BS2, PM1, PM4, PM5, PM6, BP2, BP3, BP4, BA1, PS2, PS4, PS3, PS1	The p.Tyr3747X variant in USH2A is predicted to cause a premature stop codon in biologically-relevant-exon 58/72 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). The allele frequency of the p.Tyr3747X variant in the Ush2A gene is 0.017% (4/24020) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss ( PM2_Supporting). This variant has been detected in 1 patient with hearing loss in trans with a suspected pathogenic variant (PM3_Supporting, Partners LMM internal data SCV000713838.1). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied: PVS1,  PM2_Supporting, PM3_Supporting.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-17	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA1393780/MONDO:0019501/005	b7a55bd1-1f82-499f-acdf-a7a6884c636c
NM_206933.2(USH2A):c.5039A>G (p.Lys1680Arg)	166499	CA179559	NM_206933.2:c.5039A>G, NC_000001.11:g.216084826T>C, CM000663.2:g.216084826T>C, NC_000001.10:g.216258168T>C, CM000663.1:g.216258168T>C, NC_000001.9:g.214324791T>C, NG_009497.1:g.343571A>G, NG_009497.2:g.343623A>G, ENST00000307340.8:c.5039A>G, ENST00000674083.1:c.5039A>G, ENST00000307340.7:c.5039A>G, ENST00000463147.1:n.283A>G, ENST00000481786.1:n.281A>G, NR_125992.1:n.266-1896T>C, NR_125993.1:n.137-1896T>C, NM_206933.3:c.5039A>G, NM_206933.4:c.5039A>G, NM_206933.2(USH2A):c.5039A>G (p.Lys1680Arg)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	PM3_Supporting, PP4	BP7, BP5, BS1, BS3, BS4, BS2, PP3, PP2, PP1, PM5, PM4, PM1, PVS1, PM2, PM6, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The c.5039A>G (p.Lys1680Arg) variant in USH2A is a missense variant that replaces lysine with arginine at codon 1680. (Add gnomad information) The REVEL score for this variant is 0.252, which does not meet the threshold for PP3. This variant has been observed in the homozygous state in one individual with a clinical diagnosis of Usher syndrome (PMID: 36909829), meeting PM3_Supporting. The phenotype observed is highly specific for Usher syndrome, meeting PP4. In summary, this variant meets criteria to be classified as uncertain significance for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: PM3_Supporting, PP4. (ClinGen Hearing Loss VCEP specifications version 2; 5/21/2025)		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2025-05-21	2025-06-30	false	https://erepo.genome.network/evrepo/ui/classification/CA179559/MONDO:0019501/005	201650f0-4a5b-446d-98e4-65dbae845631
NM_206933.4(USH2A):c.14419G>A (p.Ala4807Thr)	198366	CA246980	NM_206933.4:c.14419G>A, NC_000001.11:g.215648691C>T, CM000663.2:g.215648691C>T, NC_000001.10:g.215822033C>T, CM000663.1:g.215822033C>T, NC_000001.9:g.213888656C>T, NG_009497.1:g.779706G>A, NG_009497.2:g.779758G>A, ENST00000307340.8:c.14419G>A, ENST00000674083.1:c.14419G>A, ENST00000307340.7:c.14419G>A, NM_206933.2:c.14419G>A, NM_206933.3:c.14419G>A, NM_206933.4(USH2A):c.14419G>A (p.Ala4807Thr)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	PM2_Supporting	BP7, BP5, BS1, BS3, BS4, BS2, PP3, PP2, PP1, PP4, PM5, PM4, PM1, PM3, PVS1, PM6, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The variant NM_206933.4:c.14419G>A in USH2A is a missense variant predicted to cause substitution of alanine by threonine at amino acid 4807 (p.Ala4807Thr). The filtering allele frequency (the upper threshold of the 95% CI of 5/30782) of the c.14419G>A variant in USH2A is 0.00006365 for South Asian chromosomes by gnomAD v2.1.1, which is lower than the ClinGen Hearing Loss VCEP threshold (<0.00007) for PM2_Supporting, and therefore meets this criterion (PM2_Supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting (ClinGen Hearing Loss VCEP specifications version 2; 2/21/2024).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2024-02-21	2024-04-01	false	https://erepo.genome.network/evrepo/ui/classification/CA246980/MONDO:0019501/005	c1d605e5-67f2-43d5-8643-a70536da96b7
NM_004700.3(KCNQ4):c.720C>G (p.Thr240=)	227469	CA10576423	NM_004700.3:c.720C>G, NC_000001.11:g.40819358C>G, CM000663.2:g.40819358C>G, NC_000001.10:g.41285030C>G, CM000663.1:g.41285030C>G, NC_000001.9:g.41057617C>G, NG_008139.1:g.40347C>G, NG_008139.2:g.40347C>G, NM_172163.2:c.720C>G, XM_011542417.1:c.720C>G, XM_011542418.1:c.720C>G, XM_011542419.1:c.720C>G, XM_011542420.1:c.720C>G, XR_946798.1:n.726C>G, XR_946799.1:n.726C>G, XR_946800.1:n.726C>G, XM_017002792.1:c.-298C>G, NM_004700.4:c.720C>G, ENST00000347132.9:c.720C>G, ENST00000443478.3:n.406C>G, ENST00000506017.1:n.39C>G, ENST00000509682.6:n.720C>G, NM_004700.3(KCNQ4):c.720C>G (p.Thr240=)	KCNQ4	hearing loss	MONDO:0005365	Autosomal dominant inheritance	Likely Benign	BP7, BP4	BP5, BS4, BS1, PP4, PP1, PP3, BS2, PM3, PM1, PM4, PM5, PVS1, PM6, BP2, BP3, BA1, PS2, PS4, PS3, PS1	The silent p.Thr240= variant in KCNQ4 is not predicted by computational tools to impact splicing (BP7. BP4). The variant is absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org), however this is not considered evidence against a likely benign classification. In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied: BP7, BP4.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-28	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA10576423/MONDO:0005365/005	8cd85444-a428-437c-a5b7-582156401d13
NM_005422.2(TECTA):c.1436C>T (p.Pro479Leu)	178638	CA182711	NM_005422.2:c.1436C>T, NM_005422.2:n.1436C>T, ENST00000264037.2:n.1436C>T, ENST00000392793.5:c.1436C>T, NC_000011.10:g.121125534C>T, CM000673.2:g.121125534C>T, NC_000011.9:g.120996243C>T, CM000673.1:g.120996243C>T, NC_000011.8:g.120501453C>T, NG_011633.1:g.27869C>T, NM_005422.2(TECTA):c.1436C>T (p.Pro479Leu)	TECTA	nonsyndromic genetic deafness	MONDO:0019497		Benign	BA1		The filtering allele frequency of the c.1436C>T (p.Pro479Leu) variant in the TECTA gene is 0.63% (219/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-17	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA182711/MONDO:0019497/005	34755092-11b9-490e-b4c1-2e5fc4db8edd
NM_000441.1(SLC26A4):c.2291C>T (p.Thr764Met)	43546	CA132713	NM_000441.1:c.2291C>T, NC_000007.14:g.107712594C>T, CM000669.2:g.107712594C>T, NC_000007.13:g.107353039C>T, CM000669.1:g.107353039C>T, NC_000007.12:g.107140275C>T, NG_008489.1:g.56960C>T, ENST00000644269.2:c.2291C>T, ENST00000644846.1:c.947C>T, ENST00000265715.7:c.2291C>T, ENST00000492030.2:n.477C>T, XM_005250425.1:c.2291C>T, XM_005250425.2:c.2291C>T, XM_017012318.1:c.2213C>T, NM_000441.2:c.2291C>T, NM_000441.1(SLC26A4):c.2291C>T (p.Thr764Met)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Uncertain Significance		BP7, BP5, BS1, BS3, BS4, PP3, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The c.2291C>T (NM_000441.2(SLC26A4):c.2291C>T (p.Thr764Met)) variant is a missense variant predicted to cause substitution of threonine by methionine at amino acid 764. The highest MAF in gnomAD v4.0.0 is 0.03221 % (2/6022 alleles) in the Middle Eastern population. The next highest MAF in gnomAD is 0.0175 % (13/74302 alleles) in the African/African American population (no population codes met by either frequency). In-silico predictons are conflicting (ie. damaging, neutral, and tolerated). Also, the nucleotide is very poorly conserved among 1000 vertebrates. In summary, this variant meets the criteria to be classified as uncertain significance for autosomal recessive Pendred Syndrome (no codes met; ClinGen Hearing Loss VCEP Specifications Version 2; 02/19/2025).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2025-02-19	2025-03-18	false	https://erepo.genome.network/evrepo/ui/classification/CA132713/MONDO:0010134/005	edaf7951-7b12-42e2-855d-4a2dc61b69c8
NM_206933.2(USH2A):c.8177G>A (p.Gly2726Glu)	179542	CA184631	NM_206933.2:c.8177G>A, NC_000001.11:g.215888472C>T, CM000663.2:g.215888472C>T, NC_000001.10:g.216061814C>T, CM000663.1:g.216061814C>T, NC_000001.9:g.214128437C>T, NG_009497.1:g.539925G>A, NG_009497.2:g.539977G>A, ENST00000307340.8:c.8177G>A, ENST00000674083.1:c.8177G>A, ENST00000307340.7:c.8177G>A, NM_206933.3:c.8177G>A, NM_206933.4:c.8177G>A, NM_206933.4(USH2A):c.8177G>A (p.Gly2726Glu), NM_206933.2(USH2A):c.8177G>A (p.Gly2726Glu)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PP3, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, PM6, PVS1, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.8177G>A variant in USH2A is a missense variant predicted to cause substitution of glycine to glutamic acid at amino acid 2726. The highest population minor allele frequency in gnomAD v2.1.1 is 0.003% (3/111282 alleles) in the European population, which is lower than the ClinGen Hearing Loss VCEP threshold (<0.007) for PM2_Supporting, meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.406, which is neither above nor below the thresholds predicting a damaging or benign impact on USH2A function. The variant has been detected in heterozygosity without a second variant in one female proband from the Laboratory of Molecular Medicine with mild to moderate sensorineural hearing loss and other syndromic features (SCV000206052.5). In summary, this variant meets the criteria to be classified as uncertain significance for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: PM2_Supporting. (ClinGen Hearing Loss VCEP specifications version 2; 9/26/2023)		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-09-26	2023-10-05	false	https://erepo.genome.network/evrepo/ui/classification/CA184631/MONDO:0019501/005	187c6fa0-0a45-4c79-8ee9-d31d1ce8ec97
NM_206933.4(USH2A):c.15494C>G (p.Ala5165Gly)	282144	CA1392668	NM_206933.4:c.15494C>G, NC_000001.11:g.215628839G>C, CM000663.2:g.215628839G>C, NC_000001.10:g.215802181G>C, CM000663.1:g.215802181G>C, NC_000001.9:g.213868804G>C, NG_009497.1:g.799558C>G, NG_009497.2:g.799610C>G, ENST00000307340.8:c.15494C>G, ENST00000674083.1:c.15566C>G, ENST00000307340.7:c.15494C>G, NM_206933.2:c.15494C>G, NM_206933.3:c.15494C>G, NM_206933.4(USH2A):c.15494C>G (p.Ala5165Gly)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Likely Benign	BS1, BP4	BP7, BP5, BS3, BS4, PP3, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, BA1, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The variant NM_206933.4: c.15494C>G in USH2A is a missense variant predicted to cause substitution of alanine by glycine at amino acid 5165 (p.Ala5165Gly). The highest MAF in gnomAD v4.1 is 0.3091% (256/75052) in the African/African American population which is a higher frequency than would be expected for an autosomal recessive pathogenic variant based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (BS1). The computational predictor REVEL gives a score of 0.03 which is below the threshold of 0.15, evidence that does not predict a damaging effect on USH2A function (BP4). In summary, this variant meets criteria to be classified as likely benign based on the ACMG/AMP criteria applied:BS1, BP4 (ClinGen Hearing Loss VCEP specifications version 2; 3/12/2025).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2025-03-12	2025-03-28	false	https://erepo.genome.network/evrepo/ui/classification/CA1392668/MONDO:0019501/005	cf7ad82e-6e16-449c-9f9a-d3d9573505ea
NM_000260.3(MYO7A):c.324C>T (p.Tyr108=)	43201	CA132282	NM_000260.3:c.324C>T, NC_000011.10:g.77155945C>T, CM000673.2:g.77155945C>T, NC_000011.9:g.76866991C>T, CM000673.1:g.76866991C>T, NC_000011.8:g.76544639C>T, NG_009086.1:g.32682C>T, NM_001127179.2:c.324C>T, NM_001127180.1:c.324C>T, XM_005274012.2:c.324C>T, XM_006718558.2:c.324C>T, XM_006718559.2:c.324C>T, XM_006718560.2:c.324C>T, XM_006718561.2:c.324C>T, XM_011545044.1:c.324C>T, XM_011545045.1:c.324C>T, XM_011545046.1:c.291C>T, XM_011545047.1:c.324C>T, XM_011545048.1:c.324C>T, XM_011545049.1:c.324C>T, XM_011545050.1:c.66C>T, XM_011545051.1:c.324C>T, XM_011545052.1:c.324C>T, XR_949938.1:n.644C>T, XR_949941.1:n.644C>T, XR_949942.1:n.646C>T, XR_949943.1:n.646C>T, XM_011545044.2:c.324C>T, XM_011545046.2:c.414C>T, XM_011545050.2:c.66C>T, XM_017017778.1:c.414C>T, XM_017017779.1:c.414C>T, XM_017017780.1:c.414C>T, XM_017017781.1:c.414C>T, XM_017017782.1:c.414C>T, XM_017017783.1:c.414C>T, XM_017017784.1:c.414C>T, XM_017017785.1:c.414C>T, XM_017017786.1:c.414C>T, XM_017017787.1:c.414C>T, XM_017017788.1:c.414C>T, XR_001747885.1:n.429C>T, XR_001747886.1:n.429C>T, XR_001747887.1:n.429C>T, XR_001747888.1:n.429C>T, XR_001747889.1:n.429C>T, NM_000260.4:c.324C>T, ENST00000409619.6:c.291C>T, ENST00000409709.7:c.324C>T, ENST00000409893.5:c.324C>T, ENST00000458637.6:c.324C>T, ENST00000620575.4:c.324C>T, NM_000260.3(MYO7A):c.324C>T (p.Tyr108=)	MYO7A	nonsyndromic genetic deafness	MONDO:0019497		Benign	BA1	BS1, BS4, BP5, PP3, PP1, PP4, BS2, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, BP4, BP3, BP2, PS1, PS3, PS4, PS2	The filtering allele frequency of the p.Tyr108= variant in the MYO7A gene is 1.45% (300/18658) of East Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-28	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA132282/MONDO:0019497/005	8f1b935c-2f47-463c-987b-93081430a581
NM_000260.4(MYO7A):c.1817G>A (p.Arg606His)	517357	CA6197622	NM_000260.4:c.1817G>A, NC_000011.10:g.77172767G>A, CM000673.2:g.77172767G>A, NC_000011.9:g.76883813G>A, CM000673.1:g.76883813G>A, NC_000011.8:g.76561461G>A, NG_009086.1:g.49504G>A, NG_009086.2:g.49522G>A, ENST00000409709.9:c.1817G>A, ENST00000669443.1:c.181G>A, ENST00000409619.6:c.1784G>A, ENST00000409709.7:c.1817G>A, ENST00000409893.5:c.1817G>A, ENST00000458637.6:c.1817G>A, ENST00000620575.4:c.1817G>A, NM_000260.3:c.1817G>A, NM_001127179.2:c.1817G>A, NM_001127180.1:c.1817G>A, XM_005274012.2:c.1817G>A, XM_006718558.2:c.1817G>A, XM_006718559.2:c.1817G>A, XM_006718560.2:c.1817G>A, XM_006718561.2:c.1817G>A, XM_011545044.1:c.1817G>A, XM_011545045.1:c.1817G>A, XM_011545046.1:c.1784G>A, XM_011545047.1:c.1817G>A, XM_011545048.1:c.1817G>A, XM_011545049.1:c.1586G>A, XM_011545050.1:c.1559G>A, XM_011545051.1:c.1817G>A, XM_011545052.1:c.1817G>A, XR_949938.1:n.2137G>A, XR_949941.1:n.2137G>A, XR_949942.1:n.2139G>A, XR_949943.1:n.2139G>A, XM_011545044.2:c.1817G>A, XM_011545046.2:c.1907G>A, XM_011545050.2:c.1559G>A, XM_017017778.1:c.1907G>A, XM_017017779.1:c.1907G>A, XM_017017780.1:c.1907G>A, XM_017017781.1:c.1907G>A, XM_017017782.1:c.1907G>A, XM_017017783.1:c.1907G>A, XM_017017784.1:c.1907G>A, XM_017017785.1:c.1676G>A, XM_017017786.1:c.1907G>A, XM_017017787.1:c.1907G>A, XM_017017788.1:c.1907G>A, XR_001747885.1:n.1922G>A, XR_001747886.1:n.1922G>A, XR_001747887.1:n.1922G>A, XR_001747888.1:n.1922G>A, XR_001747889.1:n.1922G>A, NM_001127180.2:c.1817G>A, NM_001369365.1:c.1784G>A, NM_000260.4(MYO7A):c.1817G>A (p.Arg606His)	MYO7A	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PP3, PM3	BP7, BP5, BS1, BS3, BS4, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM2, PM6, PVS1, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.1817 G>A (NM_000260.4(MYO7A):c.1817G>A (p.Arg606His)) variant in MYO7A is a missense variant predicted to cause substitution of Arginine by Histidine at amino acid 606. The highest major allele frequency in gnomAD v2.1.1 is 0.00035 (0.035 % or 8/23092 alleles) in the South Asian population (PM2_supporting, BS1, and BA1 not met). The computational predictor REVEL gives a score of 0.832, (which is above the threshold of 0.7), evidence that correlates with impact to MYO7A function (PP3). This variant has been detected in at least one individual with autosomal recessive nonsyndromic genetic hearing loss. This proband was compound heterozygous for the variant and a pathogenic variant, confirmed in trans by parental testing (PM3; 1.0 point; LMM Internal Data). The patient with this variant displayed moderate to severe sensorineural hearing loss, although no vision anomalies or difficulty seeing at night were noted (PP4 not met; LMM Internal Data). In summary, this variant meets the criteria to be classified as uncertain significance for autosomal recessive nonsyndromic genetic deafness, based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: (PP3, PM3; Version 2, 7.19.2023).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-07-19	2023-10-05	false	https://erepo.genome.network/evrepo/ui/classification/CA6197622/MONDO:0019497/005	afa3b665-0c01-40e2-9432-4938ce1c8bff
NM_004999.3(MYO6):c.238C>T (p.Arg80Ter)	178957	CA183381	NM_004999.3:c.238C>T, NC_000006.12:g.75828590C>T, CM000668.2:g.75828590C>T, NC_000006.11:g.76538307C>T, CM000668.1:g.76538307C>T, NC_000006.10:g.76595027C>T, NG_009934.1:g.84399C>T, NG_009934.2:g.84398C>T, ENST00000369975.6:c.238C>T, ENST00000369977.8:c.238C>T, ENST00000369985.9:c.238C>T, ENST00000462633.3:c.238C>T, ENST00000627432.3:c.238C>T, ENST00000653423.1:c.238C>T, ENST00000653917.1:c.238C>T, ENST00000660420.1:c.*194C>T, ENST00000662184.1:c.238C>T, ENST00000662603.1:c.238C>T, ENST00000663400.1:c.238C>T, ENST00000664209.1:c.238C>T, ENST00000664640.1:c.238C>T, ENST00000671923.1:c.238C>T, ENST00000672093.1:n.238C>T, ENST00000369975.5:c.238C>T, ENST00000369977.7:c.238C>T, ENST00000369981.7:c.238C>T, ENST00000369985.8:c.238C>T, ENST00000615563.4:c.238C>T, ENST00000627432.2:c.238C>T, NM_001300899.1:c.238C>T, XM_005248719.2:c.238C>T, XM_005248720.2:c.238C>T, XM_005248721.2:c.238C>T, XM_005248722.2:c.238C>T, XM_005248724.2:c.238C>T, XM_005248726.2:c.238C>T, XM_005248719.4:c.238C>T, XM_005248720.4:c.238C>T, XM_005248721.4:c.238C>T, XM_005248722.4:c.238C>T, XM_005248724.4:c.238C>T, XM_005248726.4:c.238C>T, XM_017010899.2:c.238C>T, XM_024446447.1:c.238C>T, XM_024446448.1:c.238C>T, NM_004999.4:c.238C>T, NM_001300899.2:c.238C>T, NM_001368136.1:c.238C>T, NM_001368137.1:c.238C>T, NM_001368138.1:c.238C>T, NM_001368139.1:c.238C>T, NM_001368140.1:c.238C>T, NM_001368865.1:c.238C>T, NM_001368866.1:c.238C>T, NR_160538.1:n.470C>T, NR_160539.1:n.570C>T, NM_004999.4(MYO6):c.238C>T (p.Arg80Ter), NM_004999.3(MYO6):c.238C>T (p.Arg80Ter)	MYO6	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Pathogenic	PP1, PM2_Supporting, PS4_Supporting, PVS1	BP5, BP7, BS1, BS4, BS3, BS2, PP4, PP3, PP2, PM3, PM1, PM5, PM4, PM6, BP2, BP4, BP1, BP3, BA1, PS2, PS3, PS1	The NM_004999.4:c.238C>T (p.Arg80Ter) variant in MYO6 is a nonsense variant predicted to cause a premature stop codon in biologically-relevant-exon 4 and is predicted to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0008% (1/113330 alleles) in the European (non-Finnish) population, which is lower than the ClinGen Hearing Loss VCEP threshold (â‰¤0.002%) for PM2_Supporting. This variant has been reported in 2 families with teenage onset progressive sensorineural hearing loss, both displaying an autosomal dominant pattern of inheritance (PS4_Supporting; PMID: 32143290, 33111345). The variant has been reported to segregate with hearing loss in 2 affected family members from 1 family (PP1; PMID:33111345). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal dominant hearing loss, based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss Variant Curation Expert Panel: (PVS1, PM2_Supporting, PS4_Supporting, PP1). (VCEP specifications version 2.0.0; December 21, 2022)		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-01-24	2023-02-06	false	https://erepo.genome.network/evrepo/ui/classification/CA183381/MONDO:0019497/005	55e341ba-860e-45fd-b865-3fe4a6086732
NM_022124.6(CDH23):c.380A>G (p.Asp127Gly)	228491	CA10576804	NM_022124.6:c.380A>G, NC_000010.11:g.71511163A>G, CM000672.2:g.71511163A>G, NC_000010.10:g.73270920A>G, CM000672.1:g.73270920A>G, NC_000010.9:g.72940926A>G, NG_008835.1:g.119217A>G, ENST00000224721.12:c.380A>G, ENST00000398809.9:c.380A>G, ENST00000442677.4:n.380A>G, ENST00000646131.1:n.44A>G, ENST00000224721.10:c.380A>G, ENST00000299366.11:c.380A>G, ENST00000398809.8:c.380A>G, ENST00000398842.7:c.203A>G, ENST00000461841.7:c.380A>G, ENST00000616684.4:c.380A>G, ENST00000622827.4:c.380A>G, NM_001171930.1:c.380A>G, NM_001171931.1:c.380A>G, NM_001171932.1:c.380A>G, NM_022124.5:c.380A>G, NM_052836.3:c.380A>G, NR_120672.1:n.143+615T>C, XM_006717940.2:c.515A>G, XM_006717942.2:c.515A>G, XM_011540039.1:c.515A>G, XM_011540040.1:c.515A>G, XM_011540041.1:c.515A>G, XM_011540042.1:c.515A>G, XM_011540043.1:c.515A>G, XM_011540044.1:c.380A>G, XM_011540045.1:c.515A>G, XM_011540048.1:c.515A>G, XM_011540049.1:c.515A>G, XM_011540050.1:c.515A>G, XM_011540051.1:c.515A>G, XM_011540053.1:c.515A>G, XM_011540054.1:c.515A>G, XR_945796.1:n.758A>G, NM_001171930.2:c.380A>G, NM_001171931.2:c.380A>G, NM_052836.4:c.380A>G, NM_001171932.2:c.380A>G, NM_022124.6(CDH23):c.380A>G (p.Asp127Gly)	CDH23	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Likely Pathogenic	PP3, PP4, PM2_Supporting, PM3	BS1, BS3, BS4, BP7, BP5, PP2, PP1, BS2, PM5, PM4, PM1, PVS1, PM6, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.380A>G (NM_022124.6(CDH23):c.380A>G (p.Asp127Gly)) variant in CDH23 is a missense variant predicted to cause substitution of aspartate by glycine at amino acid 127. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.796 which is above the threshold of 0.7, evidence that correlates with impact to CDH23 function (PP3). This variant has been detected in one individual with autosomal recessive Usher syndrome. For this individual, they were compound heterozygous for the variant and a pathogenic variant (NM_022124.6(CDH23):c.1949dup (p.Leu651fs) (SCV000271345.2) ) and this individual was confirmed in trans by family testing (1.0 point, PM3; LMM internal data). The patient with the variant had congenital severe-profound hearing loss with vestibular complications and ophthalmology-related issues, features highly specific to Usher syndrome (LMM Internal Data; PP4). This variant was re-reviewed on 1.18.2023 and because no additional evidence is available, professional judgment was used to retain this variant as likely pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP. In summary, this variant is classified as likely pathogenic for autosomal recessive Usher Syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: PM2_supporting, PP3, PM3, PP4 (ClinGen Hearing Loss VCEP Specifications Version 2; 6/27/2022).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-06-27	2023-06-30	false	https://erepo.genome.network/evrepo/ui/classification/CA10576804/MONDO:0019501/005	637bd8ea-a91f-4012-9a60-43d0bfce68ad
NM_005422.2(TECTA):c.1111A>G (p.Arg371Gly)	45314	CA136018	NM_005422.2:c.1111A>G, NM_005422.2:n.1111A>G, ENST00000264037.2:n.1111A>G, ENST00000392793.5:c.1111A>G, NC_000011.10:g.121118626A>G, CM000673.2:g.121118626A>G, NC_000011.9:g.120989335A>G, CM000673.1:g.120989335A>G, NC_000011.8:g.120494545A>G, NG_011633.1:g.20961A>G, NM_005422.2(TECTA):c.1111A>G (p.Arg371Gly)	TECTA	nonsyndromic genetic deafness	MONDO:0019497		Benign	BA1	PP3, BP4	The filtering allele frequency of the p.Arg317Gly variant in the TECTA gene is 67.5% (16434/24006) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant and autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-28	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA136018/MONDO:0019497/005	35d6c7e2-dfb8-46a4-9f4f-7727ac602098
NM_000441.1(SLC26A4):c.1363A>T (p.Ile455Phe)	43507	CA132664	NM_000441.1:c.1363A>T, NC_000007.14:g.107694642A>T, CM000669.2:g.107694642A>T, NC_000007.13:g.107335087A>T, CM000669.1:g.107335087A>T, NC_000007.12:g.107122323A>T, NG_008489.1:g.39008A>T, XM_005250425.1:c.1363A>T, XM_005250425.2:c.1363A>T, XM_017012318.1:c.1285A>T, ENST00000265715.7:c.1363A>T, ENST00000460748.1:n.466A>T, ENST00000477350.5:n.210A>T, ENST00000480841.5:n.212A>T, ENST00000497446.5:n.378A>T, NM_000441.1(SLC26A4):c.1363A>T (p.Ile455Phe)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Benign	PP3, BA1	PM1, PM5, PS1	The filtering allele frequency of the p.Ile455Phe variant in the SLC26A4 gene is 3% (981/30778) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high frequency that is consistent with benign classification based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-28	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA132664/MONDO:0010134/005	2b9fd19d-de91-41b2-a416-dc26fa5062e4
NM_005422.2(TECTA):c.701A>G (p.Gln234Arg)	178532	CA182505	NM_005422.2:c.701A>G, NM_005422.2:n.701A>G, ENST00000264037.2:n.701A>G, ENST00000392793.5:c.701A>G, NC_000011.10:g.121113629A>G, CM000673.2:g.121113629A>G, NC_000011.9:g.120984338A>G, CM000673.1:g.120984338A>G, NC_000011.8:g.120489548A>G, NG_011633.1:g.15964A>G, NM_005422.2(TECTA):c.701A>G (p.Gln234Arg)	TECTA	nonsyndromic genetic deafness	MONDO:0019497		Likely Benign	BS1	PP3, PM4, PM2, PVS1, BP2, BP3, BP4	The filtering allele frequency of the c.701A>G (p.Gln234Arg) variant in the TECTA gene is 0.37% (104/23994) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-28	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA182505/MONDO:0019497/005	af708230-b36c-499d-911b-dea7837335d0
NM_000441.1(SLC26A4):c.565G>T (p.Ala189Ser)	43560	CA132732	NM_000441.1:c.565G>T, NC_000007.14:g.107674313G>T, CM000669.2:g.107674313G>T, NC_000007.13:g.107314758G>T, CM000669.1:g.107314758G>T, NC_000007.12:g.107101994G>T, NG_008489.1:g.18679G>T, XM_005250425.1:c.565G>T, XM_006716025.2:c.565G>T, XM_005250425.2:c.565G>T, XM_006716025.3:c.565G>T, XM_017012318.1:c.565G>T, ENST00000265715.7:c.565G>T, NM_000441.1(SLC26A4):c.565G>T (p.Ala189Ser)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Benign	BA1		The filtering allele frequency of the p.Ala1898Ser variant in the SLC26A4 gene is 1.2%  (324/24040) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-28	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA132732/MONDO:0010134/005	b905ae85-8973-4ed6-b603-52b3b342f2e0
NM_000257.4(MYH7):c.2608C>T (p.Arg870Cys)	161326	CA012732	NM_000257.4:c.2608C>T, NC_000014.9:g.23424840G>A, CM000676.2:g.23424840G>A, NC_000014.8:g.23894049G>A, CM000676.1:g.23894049G>A, NC_000014.7:g.22963889G>A, NG_007884.1:g.15822C>T, LRG_384:g.15822C>T, ENST00000355349.4:c.2608C>T, ENST00000355349.3:c.2608C>T, NM_000257.3:c.2608C>T, XR_245686.3:n.2714C>T, XM_017021340.1:c.2608C>T, NM_000257.4(MYH7):c.2608C>T (p.Arg870Cys)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Pathogenic	PM2, PM5, PP3, PS4	PS3, PM1, PM6, PP1, BS3, BP4, PS1, PS2	The NM_000257.4(MYH7):c.2608C>T (p.Arg870Cys) variant has been reported in >15 individuals with HCM (PS4; Anan 2000 PMID:10862102; Woo 2003 PMID:12975413; Uchiyama 2009 PMID:19149795; Funada 2010 PMID:20975235; Otsuka 2012 PMID:22112859; Fujita 2013 PMID: 24621997; Wang 2014 PMID:25132132; Mademont-Soler 2017 PMID:28771489; Hayashi 2018 PMID:29907873; Mak 2018 PMID:30022097; Inagaki 2018 PMID:30206291; GeneDx pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant segregated with disease in 2 affected individual with HCM from 2 families (Otsuka 2011 PMID 22112859; LMM pers. comm.); however, this data is currently insufficient to establish co-segregation with disease and apply PP1. This variant was identified in 0.0007% (FAF 95% CI; 3/113730) of European chromosomes in gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org/). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be associated with HCM (Walsh 2017 PMID:27532257). Additionally, a different pathogenic missense variant has been previously identified at this codon which indicates that this residue may be critical to the function of the protein (PM5; NM_000257.4(MYH7):c.2609G>A (p.Arg870His) - Variation ID 14120). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4, PM2, PM5, PP3.		Cardiomyopathy VCEP		2021-11-30	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA012732/MONDO:0005045/002	59bad543-333c-4d6f-b5d0-21a40136c576
NM_000257.3(MYH7):c.5726G>C (p.Arg1909Pro)	43085	CA016422	NM_000257.3:c.5726G>C, ENST00000355349.4:c.5726G>C, ENST00000355349.3:c.5726G>C, XM_017021340.1:c.5726G>C, NM_000257.4:c.5726G>C, NC_000014.9:g.23413823C>G, CM000676.2:g.23413823C>G, NC_000014.8:g.23883032C>G, CM000676.1:g.23883032C>G, NC_000014.7:g.22952872C>G, NG_007884.1:g.26839G>C, LRG_384:g.26839G>C, NM_000257.3(MYH7):c.5726G>C (p.Arg1909Pro)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Likely Pathogenic	PM2, PM6, PP3	PP1, BA1, PS3, BS1, BS4, BS3, PS2, PS1, PS4, BP4	The c.5726G>C (p.Arg1909Pro) variant in MYH7 has been reported as a de novo occurrence in 1 individual with dilated cardiomyopathy and myopathy features (PM6; Partners LMM ClinVar SCV000059632.5). Additionally, this variant reportedly segregated with DCM and in 2 affected relatives (Partners LMM ClinVar SCV000059632.5); however this data is currently insufficient to establish co-segregation and apply PP1. This variant was absent from large population studies (PM2; https://gnomad.broadinstitute.org, v2.1.1). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). This variant was previously classified as likely pathogenic for DCM by this expert panel (EP) based on clinical judgement; however, upon re-evaluation, the EP has deemed that uncertain significance was more appropriate based on the available evidence. In summary, this variant is classified as uncertain significance for dilated cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PM6, PM2, PP3.		Cardiomyopathy VCEP		2021-03-22	2021-10-13	false	https://erepo.genome.network/evrepo/ui/classification/CA016422/MONDO:0005021/002	e0f90a49-fd56-4a6e-97a3-d0cc9611d193
NM_000257.3(MYH7):c.4588C>T (p.Arg1530Ter)	43029	CA015132	NM_000257.3:c.4588C>T, NC_000014.9:g.23416924G>A, CM000676.2:g.23416924G>A, NC_000014.8:g.23886133G>A, CM000676.1:g.23886133G>A, NC_000014.7:g.22955973G>A, NG_007884.1:g.23738C>T, LRG_384:g.23738C>T, ENST00000355349.4:c.4588C>T, ENST00000355349.3:c.4588C>T, NR_126491.1:n.567G>A, XM_017021340.1:c.4588C>T, NM_000257.4:c.4588C>T, NM_000257.3(MYH7):c.4588C>T (p.Arg1530Ter)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Uncertain Significance	PM2	PVS1	The c.4588C>T (p.Arg1530Ter) variant in MYH7 has been identified in 1 individual with DCM who also carried another MYH7 missense variant, and both variants were also identified in the individual's affected sibling (DCM). This nonsense variant was inherited from their unaffected father and the p.Arg143Trp variant was inherited from their unaffected mother (Hershkovitz 2019 PMID:30588760; Partners LMM ClinVar SCV000059574.5). This variant has also been identified in 2 individuals with myopathy (Invitae ClinVar SCV000749836.2; pers. comm.) and 1 adolescent with RCM, who inherited the MYH7 variant from his unaffected father, and was also found to have a de novo truncating TNNI3 variant (Ambry Genetics ClinVar SCV000318079.4; pers. comm.). PS4_Supporting was not applied due to the variability in proband phenotypes and occurrence of additional variants. This variant has been identified in 0.0003% (FAF 95% CI, 2/113694) of European chromosomes in gnomAD v2.1.1 (PM2; http://gnomad.broadinstitute.org). This nonsense variant leads to a premature termination codon at position 1530 leading to a truncated or absent protein. The contribution of LOF variants in MYH7 to autosomal dominant inherited cardiomyopathy is incompletely understood. In summary, due to insufficient evidence, this variant is classified as uncertain significance for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PM2.		Cardiomyopathy VCEP		2021-03-22	2021-08-25	false	https://erepo.genome.network/evrepo/ui/classification/CA015132/MONDO:0004994/002	6fe13380-41f6-4b69-a87b-3c8ac1372bc1
NM_000257.3(MYH7):c.4377G>T (p.Lys1459Asn)	43012	CA014901	NM_000257.3:c.4377G>T, NC_000014.9:g.23417295C>A, CM000676.2:g.23417295C>A, NC_000014.8:g.23886504C>A, CM000676.1:g.23886504C>A, NC_000014.7:g.22956344C>A, NG_007884.1:g.23367G>T, LRG_384:g.23367G>T, NR_126491.1:n.735C>A, XM_017021340.1:c.4377G>T, NM_000257.4:c.4377G>T, ENST00000355349.3:c.4377G>T, NM_000257.3(MYH7):c.4377G>T (p.Lys1459Asn)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Likely Benign	PP3, BS1		The filtering allele frequency of the c.4377G>T (p.Lys1459Asn) variant in the MYH7 gene is 0.0375% (34/66566) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BS1; PMID:29300372). Additionally, while computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3), this pathogenic evidence code (PP3) was not considered to be in conflict with a likely benign conclusion given the accuracy of computation prediction tools. In summary, this variant meets criteria to be classified as likely benign for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PP3; BS1		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA014901/MONDO:0004994/002	dfd5170f-2105-4cc6-870a-2f7511d716cd
NM_000257.4(MYH7):c.3578G>A (p.Arg1193His)	42965	CA013815	NM_000257.4:c.3578G>A, NC_000014.9:g.23419993C>T, CM000676.2:g.23419993C>T, NC_000014.8:g.23889202C>T, CM000676.1:g.23889202C>T, NC_000014.7:g.22959042C>T, NG_007884.1:g.20669G>A, LRG_384:g.20669G>A, ENST00000355349.4:c.3578G>A, ENST00000355349.3:c.3578G>A, NM_000257.3:c.3578G>A, XM_017021340.1:c.3578G>A, NM_000257.4(MYH7):c.3578G>A (p.Arg1193His)	MYH7	hypertrophic cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Likely Pathogenic	PM2, PP3, PS4_Moderate, PP1_Moderate	BS2, PP2, PP4, PM6, PM5, PM4, PM1, BA1, PS3, BP1, BP3, BS1, BS4, BS3, PS2, PS1, BP4, BP2, BP5, BP7, PVS1	The NM_000257.4(MYH7):c.3578G>A (p.Arg1193His) variant has been identified in at least 9 individuals with DCM, including 1 individual with an additional variant in another gene that may contribute to their disease and 1 individual with DCM and a bicuspid aortic valve (PS4_Moderate; GeneDx pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant also segregated in 5 affected relatives with DCM from 4 families (PP1_Moderate; LMM pers. comm.; OMGL pers. comm.). Additionally, this variant has also been reported in 1 individual with LVNC, 1 individual with non-ischemic cardiomyopathy and 1 individual with biventricular dilation with ventricular tachycardia (GeneDx pers. comm., Invitae pers. comm., LMM pers. comm.). This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for dilated cardiomyopathy in an autosomal dominant manner. ACMG/AMP Criteria applied: PS4_Moderate, PP1_Moderate, PM2, PP3.		Cardiomyopathy VCEP		2021-12-22	2021-12-22	false	https://erepo.genome.network/evrepo/ui/classification/CA013815/MONDO:0005021/002	da44d8c5-f133-4882-8a5a-1a6c85b2e7b3
NM_000257.3(MYH7):c.3382G>A (p.Ala1128Thr)	42959	CA013661	NM_000257.3:c.3382G>A, ENST00000355349.4:c.3382G>A, ENST00000355349.3:c.3382G>A, XR_245686.3:n.3490G>A, XM_017021340.1:c.3382G>A, NM_000257.4:c.3382G>A, NC_000014.9:g.23420189C>T, CM000676.2:g.23420189C>T, NC_000014.8:g.23889398C>T, CM000676.1:g.23889398C>T, NC_000014.7:g.22959238C>T, NG_007884.1:g.20473G>A, LRG_384:g.20473G>A, NM_000257.3(MYH7):c.3382G>A (p.Ala1128Thr)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Likely Benign	BS1	PM2, PP3, PS4	The c.3382G>A (p.Ala1128Thr) variant in MYH7 has been identified in 0.02% (FAF 95% CI; 10/34232) of Latino chromosomes in gnomAD v2.1.1 (https://gnomad.broadinstitute.org), which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BS1; Kelly 2018 PMID:29300372). Allowing a variant to reach a likely benign classification based on BS1 alone represents a revision of the original ACMG/AMP framework by ClinGenâ€™s Sequence Variant Interpretation Working Group (Tavtigian 2018 PMID: 29300386). In summary, this variant meets criteria to be classified as likely benign for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): BS1		Cardiomyopathy VCEP		2021-03-22	2021-08-25	false	https://erepo.genome.network/evrepo/ui/classification/CA013661/MONDO:0004994/002	dc6a24be-6cd7-45ac-a097-1d5031608aa7
NM_000257.3(MYH7):c.4354-7C>T	43011	CA014888	NM_000257.3:c.4354-7C>T, NC_000014.9:g.23417325G>A, CM000676.2:g.23417325G>A, NC_000014.8:g.23886534G>A, CM000676.1:g.23886534G>A, NC_000014.7:g.22956374G>A, NG_007884.1:g.23337C>T, LRG_384:g.23337C>T, ENST00000355349.4:c.4354-7C>T, ENST00000355349.3:c.4354-7C>T, NR_126491.1:n.765G>A, XM_017021340.1:c.4354-7C>T, NM_000257.4:c.4354-7C>T, NM_000257.4(MYH7):c.4354-7C>T, NM_000257.3(MYH7):c.4354-7C>T	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Uncertain Significance	BP4	BA1, PM2, PM6, PP3, PP1, BS1, BS4, BP7, PS4, PS2	The NM_000257.4(MYH7):c.4354-7C>T variant has been reported in 3 individuals with HCM (Invitae pers. comm; LMM pers. comm.). This variant has also been identified in 0.004% (FAF 95% CI; 4/34362) of Latino/Admixed American chromosomes by gnomAD v2.1.1 (https://gnomad.broadinstitute.org). Since the MYH7 specifications state that PS4 is only applicable if the variant is absent or rare in large population studies, the PS4 criterion was not applied (Kelly 2018 PMID:29300372). This variant is located in the 3' splice region and computational tools do not predict an impact on splicing, though this information is not predictive enough to rule out pathogenicity (BP4). In summary, due to insufficient evidence, this variant is classified as uncertain significance for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): BP4.		Cardiomyopathy VCEP		2021-06-23	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA014888/MONDO:0005045/002	f7c40884-cfcd-4962-978e-647248238679
NM_000257.4(MYH7):c.4276G>A (p.Glu1426Lys)	43005	CA014743	NM_000257.4:c.4276G>A, ENST00000355349.4:c.4276G>A, ENST00000355349.3:c.4276G>A, NM_000257.3:c.4276G>A, NR_126491.1:n.861C>T, XM_017021340.1:c.4276G>A, NC_000014.9:g.23417580C>T, CM000676.2:g.23417580C>T, NC_000014.8:g.23886789C>T, CM000676.1:g.23886789C>T, NC_000014.7:g.22956629C>T, NG_007884.1:g.23082G>A, LRG_384:g.23082G>A, NM_000257.4(MYH7):c.4276G>A (p.Glu1426Lys)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Uncertain Significance	PM2, PP3, PS4_Supporting	PM5, PM1, PM6, PP1, BA1, PS3, BS1, BS3, PS1	The NM_000257.4 (MYH7): c.4276G>A (p.Glu1426Lys) variant has been identified in 5 individuals with DCM (PS4_Supporting; Villard 2005 PMID: 1576978; Shipman 2011 PMID: 21482996; Vikhorev 2017 PMID: 29093449; GeneDx pers. comm.; LMM pers. comm.), including as a de novo occurrence in 1 infant with an additional variant in a cardiomyopathy-associated gene (GeneDx pers. comm.) and in 1 individual with HCM (Walsh 2017 PMID: 27532257;  OMGL pers. comm.). Because of the additional variant observed in the individual with the de novo occurrence, the PM6 criterion was not applied. This variant has also been reported in 1 individual with LVNC and reduced ejection fraction and in 1 individual with familial nondilated cardiomyopathy and their child with LVNC (Ambry pers. comm.; Invitae pers. comm). This variant segregated with disease in 2 affected relatives with DCM from 1 family (Villard 2005 PMID: 1576978); however, this data is currently insufficient to establish co-segregation with disease and apply PP1. This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, due to insufficient evidence, this variant is classified as uncertain significance for dilated cardiomyopathy in an autosomal dominant manner.  MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_Supporting, PM2, PP3.		Cardiomyopathy VCEP		2021-09-22	2021-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA014743/MONDO:0005021/002	cb5ea8fa-74c0-4d48-9e7b-f510d2a84046
NM_000257.4(MYH7):c.4258C>T (p.Arg1420Trp)	43003	CA014718	NM_000257.4:c.4258C>T, NC_000014.9:g.23417598G>A, CM000676.2:g.23417598G>A, NC_000014.8:g.23886807G>A, CM000676.1:g.23886807G>A, NC_000014.7:g.22956647G>A, NG_007884.1:g.23064C>T, LRG_384:g.23064C>T, ENST00000355349.4:c.4258C>T, ENST00000355349.3:c.4258C>T, NM_000257.3:c.4258C>T, XM_017021340.1:c.4258C>T, NM_000257.4(MYH7):c.4258C>T (p.Arg1420Trp)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Pathogenic	PM2, PP3, PS4	PM5, PM1, PM6, PP1, PS3, BA1, BS1, BS3, BS4, PS1, PS2, BP4, BP5	The NM_000257.4(MYH7):c.4258C>T (p.Arg1420Trp) variant has been reported in >15 individuals with HCM, including 1 individual with an additional variant in another gene that may contribute to their disease (PS4_Strong; Van Driest 2004 PMID: 15358028; Millat 2010 PMID: 20624503; Millat 2010 PMID: 20800588; Teirlinck 2012 PMID:23140321; Zou 2013 PMID:23283745; Berge 2014 PMID: 24111713; Ntusi 2016 PMID: 27841901; Homburger 2016 PMID: 27247418; Walsh 2017 PMID:27532257; Ho 2018 PMID: 30297972; Gene Dx pers. comm.; Invitae pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant has also been identified in 0.0003% (FAF 95% CI; 2/113756) of European chromosomes by gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4, PM2, PP3.		Cardiomyopathy VCEP		2021-12-09	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA014718/MONDO:0005045/002	6099dd89-541a-406f-bef7-323e5330bf7a
NM_000257.4(MYH7):c.4130C>T (p.Thr1377Met)	42992	CA014494	NM_000257.4:c.4130C>T, NC_000014.9:g.23418249G>A, CM000676.2:g.23418249G>A, NC_000014.8:g.23887458G>A, CM000676.1:g.23887458G>A, NC_000014.7:g.22957298G>A, NG_007884.1:g.22413C>T, LRG_384:g.22413C>T, ENST00000355349.4:c.4130C>T, ENST00000355349.3:c.4130C>T, NM_000257.3:c.4130C>T, XM_017021340.1:c.4130C>T, NM_000257.4(MYH7):c.4130C>T (p.Thr1377Met)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PP1_Strong, PS4	PS3, BA1, PM1, PM6, PM3, PM4, PM5, BS2, BS1, BS3, BS4, BP3, BP4, BP2, BP7, PS2, PS1	The NM_000257.4(MYH7):c.4130C>T (p.Thr1377Met) variant in MYH7 has been reported in >30 individuals with HCM (PS4; Richard 2003 PMID: 12707239; Van Driest 2004 PMID: 15358028; Girolami 2006 PMID: 16858239; Millat 2010 PMID: 20624503; Witjas-Paalberends 2013 PMID: 23674513; Berge 2014 PMID: 24111713; Helms 2014 PMID: 25031304; Adler 2016 PMID: 26743238; Montag 2017 PMID: 29101517; PÃ©rez-SÃ¡nchez 2018 PMID: 28687478; Wang 2018 PMID: 29343710; Ambry pers. comm.; CHEO pers. comm.; GeneDx pers. comm., Invitae pers. comm.; LMM pers. comm.; Mayo pers. comm.; OMGL pers. comm.). This variant segregated with disease in >10 affected relatives with HCM in at least 4 families (PP1_strong; PÃ©rez-SÃ¡nchez 2018 PMID: 28687478; Wang 2018 PMID: 29343710; LMM pers. comm.). This variant was identified in 0.0009% (1/113754) of European chromosomes by gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_Strong; PM2; PP3.		Cardiomyopathy VCEP		2021-11-23	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA014494/MONDO:0005045/002	f4dea66d-87b3-467f-862c-c239472e6930
NM_000257.4(MYH7):c.4066G>A (p.Glu1356Lys)	164294	CA014400	NM_000257.4:c.4066G>A, NC_000014.9:g.23418313C>T, CM000676.2:g.23418313C>T, NC_000014.8:g.23887522C>T, CM000676.1:g.23887522C>T, NC_000014.7:g.22957362C>T, NG_007884.1:g.22349G>A, LRG_384:g.22349G>A, ENST00000355349.4:c.4066G>A, ENST00000355349.3:c.4066G>A, NM_000257.3:c.4066G>A, XM_017021340.1:c.4066G>A, NM_000257.4(MYH7):c.4066G>A (p.Glu1356Lys)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PP1_Strong, PS4	PS3, PM5, PM1, PM6, BS3, PS1, PS2	The NM_000257.4(MYH7):c.4066G>A (p.Glu1356Lys) variant has been identified in at least 40 individuals with HCM, including 1 with features of RCM (PS4; Brito 2005 PMID: 16335287; Van Driest 2004 PMID: 15358028; Perrot 2005 PMID: 15856146; Theis 2009 PMID: 19808356; Brito 2012 PMID: 22857948; Zou 2013 PMID: 23283745; Lopes 2013 PMID: 23396983; NÃºÃ±ez 2013 PMID: 23782526; Captur 2014 PMID: 24704860; Homburger 2016 PMID: 27247418; Walsh 2017 PMID: 27532257; Mademont-Soler 2017 PMID: 28771489; Lu 2018 PMID: 30165862; Ambry pers. comm.; GeneDx pers. comm.; Invitae pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant segregates with HCM in at least 10 relatives from 5 families (PP1_Strong; LMM pers. comm.; OMGL pers. comm.; Stanford Inherited Heart Center pers. comm.). This variant was also reported to segregate with disease in a family with HCM, although details were not provided (Brito 2012 PMID: 22857948). This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that this variant alters protein function; however, this data is currently insufficient to establish functional impact and apply PS3 (Armel 2010 PMID: 19913502; Wolny 2013 PMID: 24047955). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4, PP1_Strong, PM2, PP3.		Cardiomyopathy VCEP		2021-11-30	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA014400/MONDO:0005045/002	8112b9be-baa4-485d-a686-c223e112af4e
NM_000257.4(MYH7):c.5740G>A (p.Glu1914Lys)	43088	CA016441	NM_000257.4:c.5740G>A, ENST00000355349.4:c.5740G>A, ENST00000355349.3:c.5740G>A, NM_000257.3:c.5740G>A, XM_017021340.1:c.5740G>A, NC_000014.9:g.23413809C>T, CM000676.2:g.23413809C>T, NC_000014.8:g.23883018C>T, CM000676.1:g.23883018C>T, NC_000014.7:g.22952858C>T, NG_007884.1:g.26853G>A, LRG_384:g.26853G>A, NM_000257.4(MYH7):c.5740G>A (p.Glu1914Lys)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Likely Pathogenic	PM2, PP3, PS4_Moderate, PS2	PM6, PM1, PP1, BA1, PS3, BS1, BS3, BS4, PS1, BP4	The c.5740G>A (p.Glu1914Lys) variant in MYH7 has been reported in at least 6 individuals with complex cardiomyopathy presentations, including predominantly dilated cardiomyopathy, features of LVNC, and restrictive physiology with early-onset in multiple instances (Lakdawala 2012 PMID: 22464770; Pugh 2014 PMID: 24503780; Lamont 2015 PMID: 20301606; Walsh 2017 PMID: 27532257; Wang 2017 PMID: 28855170; Miura 2019 PMID: 30996762). This variant segregated with disease in 2 affected siblings from 1 family (Miura 2019 PMID: 30996762); however this data is currently insufficient to apply PP1. This variant has been confirmed de novo occurrence in 2 of the above reported individuals with additional features of myopathy (PS2; Lamont 2014 PMID24664454). This variant was absent from large population studies (PM2; http://gnomad.broadinstitute.org, v2.1.1). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for dilated cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_Moderate; PS2; PM2; PP3	24664454, 24664454, 27532257, 24664454	Cardiomyopathy VCEP		2021-03-22	2021-08-25	false	https://erepo.genome.network/evrepo/ui/classification/CA016441/MONDO:0005021/002	4d2aa3fa-3052-415e-9f35-66031cc8266c
NM_000257.3(MYH7):c.3658_3660delGAG (p.Glu1220del)	42968	CA013921	NM_000257.3:c.3658_3660delGAG, NC_000014.9:g.23419913_23419915del, CM000676.2:g.23419913_23419915del, NC_000014.8:g.23889122_23889124del, CM000676.1:g.23889122_23889124del, NC_000014.7:g.22958962_22958964del, NG_007884.1:g.20749_20751del, LRG_384:g.20749_20751del, ENST00000355349.4:c.3658_3660del, ENST00000355349.3:c.3658_3660del, NM_000257.3:c.3658_3660del, XM_017021340.1:c.3658_3660del, NM_000257.4:c.3658_3660del, NM_000257.3(MYH7):c.3658_3660delGAG (p.Glu1220del)	MYH7	Ebstein anomaly	MONDO:0009144	Autosomal dominant inheritance	Uncertain Significance	PM2, PM4_Supporting, PS4_Supporting	PP1	The c.3658_3660del (p.Glu1220del) variant in MYH7 has been reported in 2 individuals with Ebstein anomaly (PS4_Supporting; Postma 2010 PMID:21127202; Bettinelli 2013 PMID 23956225; Partners LMM ClinVar SCV000059512.5). This variant segregated with Ebstein anomaly in 3 affected individuals from one family (Partners LMM ClinVar SCV000059512.5). While the expert panel waived the ACMG/AMP recommendation for demonstrating segregation in more than one family given that MYH7 is a well-established cardiomyopathy gene, its role in Ebstein anomaly is less established. Therefore, the expert panel felt that the PP1 pathogenic code should not be applied in this case given that all segregations came from one family. This variant was absent from large population studies (PM2; http://gnomad.broadinstitute.org). This variant is a deletion of 1 amino acid at position 1220 and is not predicted to alter the protein reading-frame. Given that only 1 amino acid has been deleted, the expert panel felt that adjusting to supporting evidence would be more appropriate in this case (PM4_Supporting). In summary, this variant is classified as uncertain significance for Ebstein anomaly in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PM2; PM4_Supporting; PS4_ Supporting.	21127202	Cardiomyopathy VCEP		2021-03-22	2021-08-25	false	https://erepo.genome.network/evrepo/ui/classification/CA013921/MONDO:0009144/002	e8215039-95f4-4f85-a85e-1cc2d33278f0
NM_000257.3(MYH7):c.3286G>T (p.Asp1096Tyr)	42953	CA013546	NM_000257.3:c.3286G>T, NC_000014.9:g.23421008C>A, CM000676.2:g.23421008C>A, NC_000014.8:g.23890217C>A, CM000676.1:g.23890217C>A, NC_000014.7:g.22960057C>A, NG_007884.1:g.19654G>T, LRG_384:g.19654G>T, ENST00000355349.4:c.3286G>T, ENST00000355349.3:c.3286G>T, XR_245686.3:n.3394G>T, XM_017021340.1:c.3286G>T, NM_000257.4:c.3286G>T, NM_000257.3(MYH7):c.3286G>T (p.Asp1096Tyr)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Likely Benign	PP3, BS1	PM2, PS4	The c.3286G>T (p.Asp1096Tyr) variant in MYH7 has been identified in 0.023% (FAF 95% CI; 40/129162) of European chromosomes in gnomAD v2.1.1 (https://gnomad.broadinstitute.org), which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BS1; Kelly 2018 PMID:29300372). Allowing a variant to reach a likely benign classification based on BS1 alone represents a revision of the original ACMG/AMP framework by ClinGenâ€™s Sequence Variant Interpretation Working Group (Tavtigian 2018 PMID: 29300386). Additionally, while computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3), this pathogenic evidence code (PP3) was not considered to be in conflict with a likely benign conclusion given the accuracy of computation prediction tools. In summary, this variant meets criteria to be classified as likely benign for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PP3, BS1	27532257, 25031304	Cardiomyopathy VCEP		2021-03-22	2021-08-25	false	https://erepo.genome.network/evrepo/ui/classification/CA013546/MONDO:0004994/002	8b156efb-afd3-4dd9-9602-39a13d32a5b6
NM_000257.4(MYH7):c.3169G>A (p.Gly1057Ser)	42950	CA013436	NM_000257.4:c.3169G>A, NC_000014.9:g.23422256C>T, CM000676.2:g.23422256C>T, NC_000014.8:g.23891465C>T, CM000676.1:g.23891465C>T, NC_000014.7:g.22961305C>T, NG_007884.1:g.18406G>A, LRG_384:g.18406G>A, ENST00000355349.4:c.3169G>A, ENST00000355349.3:c.3169G>A, NM_000257.3:c.3169G>A, XR_245686.3:n.3275G>A, XM_017021340.1:c.3169G>A, NM_000257.4(MYH7):c.3169G>A (p.Gly1057Ser)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Pathogenic	PM2, PP3, PS4	PM5, PM4, PM1, PM6, PP1, PS3, BA1, BS1, BS3, BS4, PS1, PS2, BP4, BP7, BP2, BP5, PVS1	The NM_000257.4(MYH7):c.3169G>A (p.Gly1057Ser) variant has been identified in >20 individuals with HCM, including 1 individual with an additional variant in another gene that may contribute to their disease and 2 individuals with DCM (PS4; Van Driest 2004 PMID 15358028; Kapplinger 2014 PMID:24510615, Walsh 2017 PMID:27532257; Hazebroek 2018 PMID:24510615; Ho 2018 PMID: 30297972; van Lint 2019 PMID: 30847666; Robyns 2020 PMID: 31513939; Verdonschot 2020 PMID: 32880476; Ambry pers. comm; ARUP pers. comm; GeneDx pers. comm.; Invitae pers. comm; LMM pers. comm.). Additionally, this variant has also been reported in 1 individual with RCM and AFib, 4 individuals with unspecified heart disease or cardiomyopathy and 1 individual with LVH, CHD and trisomy 21 (Ambry pers. comm.; GeneDx pers. comm., Invitae pers. comm.). This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. ACMG/AMP Criteria applied: PS4, PM2, PP3.		Cardiomyopathy VCEP		2021-12-09	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA013436/MONDO:0005045/002	6a9cd1dc-183f-4897-91e7-0bfc92a4ce1b
NM_000257.4(MYH7):c.3158G>A (p.Arg1053Gln)	155814	CA013417	NM_000257.4:c.3158G>A, NC_000014.9:g.23422267C>T, CM000676.2:g.23422267C>T, NC_000014.8:g.23891476C>T, CM000676.1:g.23891476C>T, NC_000014.7:g.22961316C>T, NG_007884.1:g.18395G>A, LRG_384:g.18395G>A, ENST00000355349.4:c.3158G>A, ENST00000355349.3:c.3158G>A, NM_000257.3:c.3158G>A, XR_245686.3:n.3264G>A, XM_017021340.1:c.3158G>A, NM_000257.4(MYH7):c.3158G>A (p.Arg1053Gln)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PM2, PP3, PS4	PM5, PM1, PM6, BA1, PS3, BS1, BS3, PS1, PS2, BP4	The NM_000257.4(MYH7):c.3158G>A (p.Arg1053Gln) variant in MYH7 has been reported in >35 individuals with hypertrophic cardiomyopathy (HCM), a large proportion of which are of Finnish ancestry (PS4; KÃ¤rkkÃ¤inen 2004 PMID:15556047; JÃ¤Ã¤skelÃ¤inen 2014 PMID:24888384; Walsh 2017 PMID:27532257; Ambry pers. comm.; GeneDx pers. comm., Invitae pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant segregated with disease in >15 affected individuals with HCM in 9 families (PP1_Moderate; KÃ¤rkkÃ¤inen 2004 PMID:15556047; GeneDx pers. comm.; OMGL pers. comm.). This variant was identified in 0.040% (FAF 95% CI; 16/25124) of Finnish chromosomes in gnomAD v2.1.1 (http://gnomad.broadinstitute.org), but was absent from other populations and is an established Finnish founder variant. Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4; PP1_Strong; PM2; PP3.	15556047, 24888384, 27532257, 15556047	Cardiomyopathy VCEP		2021-11-30	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA013417/MONDO:0005045/002	da96f339-d77d-4caf-afe3-768754b0efca
NM_000257.4(MYH7):c.3133C>T (p.Arg1045Cys)	177753	CA013367	NM_000257.4:c.3133C>T, ENST00000355349.4:c.3133C>T, ENST00000355349.3:c.3133C>T, NM_000257.3:c.3133C>T, XR_245686.3:n.3239C>T, XM_017021340.1:c.3133C>T, NC_000014.9:g.23422292G>A, CM000676.2:g.23422292G>A, NC_000014.8:g.23891501G>A, CM000676.1:g.23891501G>A, NC_000014.7:g.22961341G>A, NG_007884.1:g.18370C>T, LRG_384:g.18370C>T, NM_000257.4(MYH7):c.3133C>T (p.Arg1045Cys)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Uncertain Significance	PM2, PP3, PS4_Moderate	PM5, PM1, PM6, PP1, BS4, PS1, PS2	The NM_000257.4(MYH7):c.3133C>T (p.Arg1045Cys) variant has been identified in at least 12 individuals with HCM (PS4_Moderate; Olivotto 2008 PMID:18533079; Bos 2014 PMID:24793961; Homburger 2016 PMID:27247418; Rubattu 2016 PMID:27483260; Cecconi 2016 PMID:27600940; Walsh 2017 PMID: 27532257; Michels 2017 PMID:28005231) and in an additional individual with early-onset DCM that also carried a de novo TNNC1 variant (Hershberger 2008 PMID:19412328; Hershberger 2010 PMID:20215591; Rampersaud 2011 PMID:21483645; Pinto 2011; PMID:21832052). This variant was identified in 0.00152% (FAF 95% CI; 5/129168) of European chromosomes by gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, due to insufficient evidence, this variant is classified as uncertain significance for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_Moderate, PM2, PP3.		Cardiomyopathy VCEP		2021-08-25	2021-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA013367/MONDO:0005045/002	c69683b9-ae34-4aea-98be-84cd024b37cf
NM_000257.3(MYH7):c.3036C>T (p.Ala1012=)	42945	CA013313	NM_000257.3:c.3036C>T, XR_245686.3:n.3142C>T, XM_017021340.1:c.3036C>T, NM_000257.4:c.3036C>T, ENST00000355349.3:c.3036C>T, NC_000014.9:g.23423610G>A, CM000676.2:g.23423610G>A, NC_000014.8:g.23892819G>A, CM000676.1:g.23892819G>A, NC_000014.7:g.22962659G>A, NG_007884.1:g.17052C>T, LRG_384:g.17052C>T, NM_000257.3(MYH7):c.3036C>T (p.Ala1012=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1, BP7		The filtering allele frequency of the c.3036C>T (p.Ala1012=) silent variant in the MYH7 gene is 0.7% (137/16512) of South Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1, BP7; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013313/MONDO:0004994/002	642005b8-321a-4b2e-9a08-c3cc99d24a7e
NM_000257.4(MYH7):c.2785_2787GAG[2] (p.Glu931del)	42934	-	NM_000257.4:c.2785_2787GAG[2], NM_000257.4(MYH7):c.2785GAG[2] (p.Glu931del), NM_000257.4(MYH7):c.2785_2787GAG[2] (p.Glu931del)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Pathogenic	PM2, PS4_Moderate, PM4_Supporting, PP1_Moderate	PM5, PM1, PM6, PP3, PS3, BA1, BS1, BS4, BS3, PS1, PS2, BP4, BP7, BP2, BP5, PVS1	The NM_000257.3(MYH7):c.2791_2793delGAG (p.Glu931del) variant has been reported in at least 8 individuals with HCM (PS4_Moderate; Tesson 1998 PMID:9829907; Richard 2013 PMID:12707239; Walsh 2017 PMID:27532257; Norrish 2019 PMID:31006259; GeneDx pers. comm., Invitae pers. comm., LMM pers. comm., OMGL pers.comm.) and segregated with disease in 5 affected individuals with HCM in 1 family (PP1_Moderate; Tesson 1998 PMID:9829907). This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). This variant is a deletion of 1 amino acid at position 931 and is not predicted to alter the protein reading-frame. Given that only 1 amino acid has been deleted, the expert panel felt that adjusting to supporting evidence would be more appropriate in this case (PM4_Supporting). In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_ Moderate; PP1_Moderate; PM2; PM4_Supporting.		Cardiomyopathy VCEP		2021-11-23	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CV42934/MONDO:0005045/002	5fe5fef0-e52a-4616-8e14-0b7ae7e8da51
NM_000257.3(MYH7):c.2722C>G (p.Leu908Val)	14097	CA012953	NM_000257.3:c.2722C>G, NC_000014.9:g.23424107G>C, CM000676.2:g.23424107G>C, NC_000014.8:g.23893316G>C, CM000676.1:g.23893316G>C, NC_000014.7:g.22963156G>C, NG_007884.1:g.16555C>G, LRG_384:g.16555C>G, XR_245686.3:n.2828C>G, XM_017021340.1:c.2722C>G, NM_000257.4:c.2722C>G, ENST00000355349.3:c.2722C>G, NM_000257.3(MYH7):c.2722C>G (p.Leu908Val)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP3, PM1, PM2, PP1_Strong, PS4		The c.2722C>G (p.Leu908Val) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:1638703; PMID:8483915 PMID:12473556; PMID:12975413; PMID:27532257; Partners LMM ClinVar SCV000059471.5; AGCMC Sydney ClinVar SCV000692499.1; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >20 affected individuals (PP1_Strong; PMID:1638703; PMID:8483915; Partners LMM ClinVar SCV000059471.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PP3	27532257, 8483915, 1638703, 27532257, 12473556, 8483915, 1638703, 12975413	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012953/MONDO:0005045/002	bd7ac89f-9ef0-4c1b-9884-893fd733703d
NM_000257.3(MYH7):c.2717A>G (p.Asp906Gly)	14125	CA012936	NM_000257.3:c.2717A>G, XR_245686.3:n.2823A>G, XM_017021340.1:c.2717A>G, NM_000257.4:c.2717A>G, ENST00000355349.3:c.2717A>G, NC_000014.9:g.23424112T>C, CM000676.2:g.23424112T>C, NC_000014.8:g.23893321T>C, CM000676.1:g.23893321T>C, NC_000014.7:g.22963161T>C, NG_007884.1:g.16550A>G, LRG_384:g.16550A>G, NM_000257.3(MYH7):c.2717A>G (p.Asp906Gly)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PM1, PM2, PS4		The c.2717A>G (p.Asp906Gly) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:27532257; PMID:12081993; PMID:15528230; PMID:16267253; PMID:24510615; Partners LMM ClinVar SCV000059468.5). This variant segregated with disease in 10 affected individuals (PP1_Strong; PMID:12081993; PMID:15528230). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2	15528230, 12081993, 27532257, 16267253, 15528230, 24510615, 12081993, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012936/MONDO:0005045/002	6a11c78d-e05e-417f-8453-1e66356e09e9
NM_000257.3(MYH7):c.2681A>G (p.Glu894Gly)	42922	CA012832	NM_000257.3:c.2681A>G, NC_000014.9:g.23424148T>C, CM000676.2:g.23424148T>C, NC_000014.8:g.23893357T>C, CM000676.1:g.23893357T>C, NC_000014.7:g.22963197T>C, NG_007884.1:g.16514A>G, LRG_384:g.16514A>G, XR_245686.3:n.2787A>G, XM_017021340.1:c.2681A>G, NM_000257.4:c.2681A>G, ENST00000355349.3:c.2681A>G, NM_000257.3(MYH7):c.2681A>G (p.Glu894Gly)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP3, PM1, PM2, PP1_Moderate, PS4		The c.2681A>G (p.Glu894Gly) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4: PMID:PMID:27532257; PMID:15358028; PMID:15858117; PMID:21511876; PMID:23396983; PMID:24510615; SHaRe consortium, PMID: 30297972, Partners LMM ClinVar SCV000059463.5; AGCMC Sydney ClinVar SCV000212641.2; Invitae ClinVar SCV000253683.5). This variant segregated with disease in 6 affected individuals (PP1_Moderate: AGCMC Sydney ClinVar SCV000212641.2; Partners LMM ClinVar SCV000059463.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PP1_Moderate; PP3	27532257, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012832/MONDO:0005045/002	f89b58e9-fd2b-41c7-9ca3-dd7cedfdd3ee
NM_000257.3(MYH7):c.5704G>C (p.Glu1902Gln)	43082	CA016398	NM_000257.3:c.5704G>C, ENST00000355349.4:c.5704G>C, ENST00000355349.3:c.5704G>C, XM_017021340.1:c.5704G>C, NM_000257.4:c.5704G>C, NC_000014.9:g.23413845C>G, CM000676.2:g.23413845C>G, NC_000014.8:g.23883054C>G, CM000676.1:g.23883054C>G, NC_000014.7:g.22952894C>G, NG_007884.1:g.26817G>C, LRG_384:g.26817G>C, NM_000257.3(MYH7):c.5704G>C (p.Glu1902Gln)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Likely Benign	BS1	BA1, PM2, PM5, PM1, PS3, PM6, PP3, PP1, BS3, BS4, PS4, PS1, PS2, BP4	The c.5704G>C (p.Glu1902Gln) variant in MYH7 has been identified in 0.096% (FAF 95% CI; 27/19954) of East Asian chromosomes in gnomAD v2.1.1 (https://gnomad.broadinstitute.org), which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BS1; Kelly 2018 PMID:29300372). Allowing a variant to reach a likely benign classification based on BS1 alone represents a revision of the original ACMG/AMP framework by ClinGenâ€™s Sequence Variant Interpretation Working Group (Tavtigian 2018 PMID: 29300386). In summary, this variant meets criteria to be classified as likely benign for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): BS1	27532257, 25086479	Cardiomyopathy VCEP		2021-03-22	2021-08-25	false	https://erepo.genome.network/evrepo/ui/classification/CA016398/MONDO:0004994/002	4d5712d1-cc9f-4b7f-a73c-73dcffcd7849
NM_000257.3(MYH7):c.2609G>A (p.Arg870His)	14120	CA012740	NM_000257.3:c.2609G>A, NC_000014.9:g.23424839C>T, CM000676.2:g.23424839C>T, NC_000014.8:g.23894048C>T, CM000676.1:g.23894048C>T, NC_000014.7:g.22963888C>T, NG_007884.1:g.15823G>A, LRG_384:g.15823G>A, XR_245686.3:n.2715G>A, XM_017021340.1:c.2609G>A, NM_000257.4:c.2609G>A, ENST00000355349.3:c.2609G>A, NM_000257.3(MYH7):c.2609G>A (p.Arg870His)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PM1, PM2, PP1_Strong, PS4		The c.2609G>A (p.Arg870His) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:7796500; PMID:12974739; PMID:17703256; PMID:27532257; Partners LMM ClinVar SCV000059458.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >10 affected individuals (PP1_Strong; PMID:7796500; PMID:12974739; PMID:17703256). This variant was identified in 1/66732 European chromosomes (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2	27532257, 7796500, 17703256, 12974739, 27532257, 7796500, 17703256, 12974739	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012740/MONDO:0005045/002	2d09f591-2d8e-40af-a273-07a3ec1e0fc5
NM_000257.3(MYH7):c.2539A>G (p.Lys847Glu)	177757	CA012578	NM_000257.3:c.2539A>G, NC_000014.9:g.23424909T>C, CM000676.2:g.23424909T>C, NC_000014.8:g.23894118T>C, CM000676.1:g.23894118T>C, NC_000014.7:g.22963958T>C, NG_007884.1:g.15753A>G, LRG_384:g.15753A>G, ENST00000355349.4:c.2539A>G, ENST00000355349.3:c.2539A>G, XR_245686.3:n.2645A>G, XM_017021340.1:c.2539A>G, NM_000257.4:c.2539A>G, NM_000257.4(MYH7):c.2539A>G (p.Lys847Glu), NM_000257.3(MYH7):c.2539A>G (p.Lys847Glu)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PM2, PM1, PP1_Strong, PS4	PS3, BA1, PM6, PM3, PM5, PP3, BS1, BP4, BP2, BP5, PS2, PS1	The NM_000257.4(MYH7):c.2539A>G (p.Lys847Glu) variant has been identified in >50 individuals with HCM (PS4; Atiga 2000 PMID:10725281; Kaski 2009 PMID:20031618; Aletras 2011 PMID:21576279; Leung 2013 PMID:23271734; Nunez 2013 PMID:23782526; Homburger 2016 PMID:27247418; Walsh 2017 PMID:27532257; Ross 2017 PMID:28615295; Ambry pers. comm.; CHEO pers. comm.; GeneDx pers. comm.; Invitae pers. comm.; LMM pers. comm.; OMGL pers. comm.; Agnes Ginges Centre for Molecular Cardiology, Centenary Institute pers. comm.). This variant segregated with disease in 7 affected individuals with HCM in 5 families (PP1_Strong; Ross 2017 PMID:28615295; Invitae pers. comm.; OMGL pers. comm.). This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be associated with HCM (PM1; Walsh 2017 PMID:27532257). Computational prediction tools and conservation analysis do not provide evidence for or against an impact to the protein. In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4, PP1_Strong, PM2, PM1.		Cardiomyopathy VCEP		2021-11-30	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA012578/MONDO:0005045/002	5dd3f0f6-7736-4320-bd76-d07ae2cd679c
NM_000257.3(MYH7):c.2539_2541delAAG (p.Lys847del)	42913	CA012568	NC_000014.9:g.23424909_23424911del, CM000676.2:g.23424909_23424911del, NC_000014.8:g.23894118_23894120del, CM000676.1:g.23894118_23894120del, NC_000014.7:g.22963958_22963960del, NG_007884.1:g.15753_15755del, LRG_384:g.15753_15755del, ENST00000355349.4:c.2539_2541del, ENST00000355349.3:c.2539_2541del, NM_000257.3:c.2539_2541del, XR_245686.3:n.2645_2647del, XM_017021340.1:c.2539_2541del, NM_000257.4:c.2539_2541del, NM_000257.3(MYH7):c.2539_2541delAAG (p.Lys847del)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Pathogenic	PM2, PP1, PM4_Supporting, PS4	PM6, BA1, PS3, BP3, BS1, BS3, PS2, BP2, BP5	The NM_000257.4: c.2539_2541del (p.Lys847del) variant in MYH7 has been reported in >15 individuals with HCM (PS4; Van Driest 2004 PMID:15358028; Santos 2012 PMID:22429680; Kassem 2013 PMID:23233322; Marsiglia 2013 PMID:24093860; Waldmuller 2008 PMID:18258667; Walsh 2017 PMID: 27532257; Ho 2018 PMID: 30297972; Jaaskelainen 2019 PMID: 30775854; LMM pers. comm.; Invitae pers. comm.). This variant segregated with disease in 3 affected individuals with HCM from 2 families(PP1; LMM pers. comm.). This variant was absent from large population studies (PM2; gnomAD v.2.1.1, http://exac.broadinstitute.org,). This variant is a deletion of 1 amino acid at position 847 and is not predicted to alter the protein reading-frame. Given that only 1 amino acid has been deleted, the expert panel felt that adjusting to supporting evidence would be more appropriate in this case (PM4_Supporting). In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4; PP1; PM2; PM4_Supporting.		Cardiomyopathy VCEP		2021-10-05	2021-10-05	false	https://erepo.genome.network/evrepo/ui/classification/CA012568/MONDO:0005045/002	58966d39-7dea-41df-be75-5371df18e99e
NM_000257.3(MYH7):c.2513C>T (p.Pro838Leu)	42910	CA012515	NM_000257.3:c.2513C>T, XR_245686.3:n.2619C>T, XM_017021340.1:c.2513C>T, NM_000257.4:c.2513C>T, ENST00000355349.3:c.2513C>T, NC_000014.9:g.23424935G>A, CM000676.2:g.23424935G>A, NC_000014.8:g.23894144G>A, CM000676.1:g.23894144G>A, NC_000014.7:g.22963984G>A, NG_007884.1:g.15727C>T, LRG_384:g.15727C>T, NM_000257.3(MYH7):c.2513C>T (p.Pro838Leu)	MYH7	restrictive cardiomyopathy	MONDO:0005201	Autosomal dominant inheritance	Pathogenic	PP3, PM1, PM2, PS4_Supporting, PS2		The c.2513C>T (p.Pro838Leu) variant in MYH7 has been reported as a de novo occurrence in two individuals with restrictive cardiomyopathy (PS4_Supporting and PS2: PMID:18380764; Partners LMM ClinVar SCV000059450.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for restrictive cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS2; PM1; PM2; PP3; PS4_ Supporting	27532257, 18380764, 18380764	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012515/MONDO:0005201/002	f43eef48-e44b-4436-b419-aee39de7c831
NM_000257.3(MYH7):c.2360G>A (p.Arg787His)	42900	CA012239	NM_000257.3:c.2360G>A, ENST00000355349.4:c.2360G>A, ENST00000355349.3:c.2360G>A, XR_245686.3:n.2466G>A, XM_017021340.1:c.2360G>A, NM_000257.4:c.2360G>A, NC_000014.9:g.23425345C>T, CM000676.2:g.23425345C>T, NC_000014.8:g.23894554C>T, CM000676.1:g.23894554C>T, NC_000014.7:g.22964394C>T, NG_007884.1:g.15317G>A, LRG_384:g.15317G>A, NM_000257.3(MYH7):c.2360G>A (p.Arg787His)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Benign	PM1, BS1, BP2	PM2, PM5, BA1, PP3, PS4, BP4	The c.2360G>A (p.Arg787His) variant in MYH7 has been identified in 0.10% (FAF 95% CI; 41/30616) of South Asian chromosomes in gnomAD v2.1.1 (https://gnomad.broadinstitute.org), which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BS1; Kelly 2018 PMID:29300372). Allowing a variant to reach a likely benign classification based on BS1 alone represents a revision of the original ACMG/AMP framework by ClinGenâ€™s Sequence Variant Interpretation Working Group (Tavtigian 2018 PMID: 29300386). Additionally, while this variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; Walsh 2017 PMID:27532257), this pathogenic evidence code (PM1) was not considered to be in conflict with a likely benign conclusion. In summary, this variant meets criteria to be classified as likely benign for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): BS1, PM1.	27532257, 21959974	Cardiomyopathy VCEP		2021-04-27	2021-06-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012239/MONDO:0005045/002	de961e5a-a5f1-47f5-abee-524b09b41cc0
NM_000257.3(MYH7):c.2221G>T (p.Gly741Trp)	177665	CA012022	NM_000257.3:c.2221G>T, XR_245686.3:n.2327G>T, XM_017021340.1:c.2221G>T, NM_000257.4:c.2221G>T, ENST00000355349.3:c.2221G>T, NC_000014.9:g.23425760C>A, CM000676.2:g.23425760C>A, NC_000014.8:g.23894969C>A, CM000676.1:g.23894969C>A, NC_000014.7:g.22964809C>A, NG_007884.1:g.14902G>T, LRG_384:g.14902G>T, NM_000257.3(MYH7):c.2221G>T (p.Gly741Trp)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP3, PM1, PM5, PM2, PP1_Moderate, PS4		The c.2221G>T (p.Gly741Trp) variant in MYH7 has been reported in >15 individuals with hypertrophic cardiomyopathy (PS4; PMID: 8533830; PMID:15856146; PMID:27532257; Partners LMM ClinVar SCV000203910.4; AGCMC Sydney ClinVar SCV000212638.1). This variant segregated with disease in 5 affected individuals (PP1_Moderate; PMID:15856146; AGCMC Sydney ClinVar SCV000212638.1). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2221G>C p.Gly741Arg - Variation ID 14098). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PM5; PP1_Moderate; PP3	27532257, 15856146, 8533830, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012022/MONDO:0005045/002	6c7676cc-a729-42ee-bc9c-580feb015c57
NM_000257.3(MYH7):c.2221G>C (p.Gly741Arg)	14098	CA012013	NM_000257.3:c.2221G>C, XR_245686.3:n.2327G>C, XM_017021340.1:c.2221G>C, NM_000257.4:c.2221G>C, ENST00000355349.3:c.2221G>C, NC_000014.9:g.23425760C>G, CM000676.2:g.23425760C>G, NC_000014.8:g.23894969C>G, CM000676.1:g.23894969C>G, NC_000014.7:g.22964809C>G, NG_007884.1:g.14902G>C, LRG_384:g.14902G>C, NM_000257.3(MYH7):c.2221G>C (p.Gly741Arg)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1, PP3, PM6, PM5, PM1, PM2, PS4		The c.2221G>C (p.Gly741Arg) variant in MYH7 has been reported in >12 individuals with hypertrophic cardiomyopathy (PS4; PMID:8483915; PMID:15563892; PMID:20031618; PMID:15358028; Partners LMM ClinVar SCV000059430.5; SHaRe consortium, PMID: 30297972). This variant has been identified as a de novo occurrence in 1 proband with hypertrophic cardiomyopathy (PM6; PMID:15563892). This variant segregated with disease in 3 affected individuals (PP1; PMID:8483915; Partners LMM ClinVar SCV000059430.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2221G>T p.Gly741Trp - Variation ID 177665). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PM5; PM6; PP1; PP3	8483915, 15563892, 27532257, 15358028, 20031618, 8483915, 15563892	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012013/MONDO:0005045/002	380d3ce8-4982-4df6-9bc5-6f4f7f75301c
NM_000257.3(MYH7):c.2207T>C (p.Ile736Thr)	164342	CA011970	NM_000257.3:c.2207T>C, XR_245686.3:n.2313T>C, XM_017021340.1:c.2207T>C, NM_000257.4:c.2207T>C, ENST00000355349.3:c.2207T>C, NC_000014.9:g.23425774A>G, CM000676.2:g.23425774A>G, NC_000014.8:g.23894983A>G, CM000676.1:g.23894983A>G, NC_000014.7:g.22964823A>G, NG_007884.1:g.14888T>C, LRG_384:g.14888T>C, NM_000257.3(MYH7):c.2207T>C (p.Ile736Thr)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PM1, PM2, PP1_Moderate, PS4		The c.2207T>C (p.Ile736Thr) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:16630449; PMID:12974739; PMID:16199542; PMID:15856146; PMID:17125710; PMID:20738943; SHaRe consortium, PMID: 30297972; Partners LMM ClinVar SCV000199207.4; AGCMC Sydney ClinVar SCV000212631.2). This variant segregated with disease in 5 affected individuals (PP1_Moderate; PMID:15856146; PMID:17125710; Partners LMM ClinVar SCV000199207.4). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PP1_Moderate	27532257, 15856146, 17125710, 20738943, 15856146, 17125710, 12974739, 16630449, 16199542, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011970/MONDO:0005045/002	e08a8c4f-f972-4f81-80b1-528cd4e6ca91
NM_000257.3(MYH7):c.2167C>T (p.Arg723Cys)	14095	CA011851	NM_000257.3:c.2167C>T, XR_245686.3:n.2273C>T, XM_017021340.1:c.2167C>T, NM_000257.4:c.2167C>T, ENST00000355349.3:c.2167C>T, NC_000014.9:g.23425814G>A, CM000676.2:g.23425814G>A, NC_000014.8:g.23895023G>A, CM000676.1:g.23895023G>A, NC_000014.7:g.22964863G>A, NG_007884.1:g.14848C>T, LRG_384:g.14848C>T, NM_000257.3(MYH7):c.2167C>T (p.Arg723Cys)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PP3, PM6, PM1, PM5, PM2, BP2, PS4		The c.2167C>T (p.Arg723Cys) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:1430197; PMID:27532257; PMID:9829907; PMID:16199542; PMID:20359594; PMID:12707239; Partners LMM ClinVar SCV000059423.5; AGCMC Sydney ClinVar SCV000212630.1). Five of these probands carried additional variants in sarcomere genes (BP2; PMID:20359594; PMID:12707239; Partners LMM ClinVar SCV000059423.5). This variant has been identified as a de novo occurrence in 1 proband with hypertrophic cardiomyopathy (PM6; PMID:1430197). This variant segregated with disease in 7 affected individuals (PP1_Strong; PMID:9829907; Partners LMM ClinVar SCV000059423.5; AGCMC Sydney ClinVar SCV000212630.1). This variant was identified in 2/66738 European chromosomes (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2167C>G p.Arg723Gly - ClinVar Variation ID 42885). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. The benign evidence code BP2 was not considered to be in conflict with this conclusion given that presence of a second variant can be seen in individuals with cardiomyopathy and may contribute to the severity of disease. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PM5; PM6; PP3; BP2	9829907, 27532257, 20359594, 20359594, 1430197, 9829907, 12707239, 16199542, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011851/MONDO:0005045/002	7cad6d45-ed00-44b9-a31d-225ff15a0c10
NM_000257.3(MYH7):c.2167C>G (p.Arg723Gly)	42885	CA011843	NM_000257.3:c.2167C>G, NC_000014.9:g.23425814G>C, CM000676.2:g.23425814G>C, NC_000014.8:g.23895023G>C, CM000676.1:g.23895023G>C, NC_000014.7:g.22964863G>C, NG_007884.1:g.14848C>G, LRG_384:g.14848C>G, XR_245686.3:n.2273C>G, XM_017021340.1:c.2167C>G, NM_000257.4:c.2167C>G, ENST00000355349.3:c.2167C>G, NM_000257.3(MYH7):c.2167C>G (p.Arg723Gly)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PM1, PM5, PM2, PP3, PS4		The c.2167C>G (p.Arg723Gly) variant in MYH7 has been reported in 12 individuals with hypertrophic cardiomyopathy (PS4; PMID:11113006; PMID:19150014; PMID:17097032; Partners LMM ClinVar SCV000059422.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >20 affected individuals (PP1_Strong; PMID:11113006). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2167C>T p.Arg723Cys - ClinVar Variation ID 14095). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PM5; PP3	16630450, 27532257, 19150014, 27532257, 17097032, 11113006	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011843/MONDO:0005045/002	6c2b587c-45cc-4fbc-bc0b-059a87ea6349
NM_000257.3(MYH7):c.5588G>A (p.Arg1863Gln)	43076	CA016295	NM_000257.3:c.5588G>A, ENST00000355349.4:c.5588G>A, ENST00000355349.3:c.5588G>A, XM_017021340.1:c.5588G>A, NM_000257.4:c.5588G>A, NC_000014.9:g.23414074C>T, CM000676.2:g.23414074C>T, NC_000014.8:g.23883283C>T, CM000676.1:g.23883283C>T, NC_000014.7:g.22953123C>T, NG_007884.1:g.26588G>A, LRG_384:g.26588G>A, NM_000257.3(MYH7):c.5588G>A (p.Arg1863Gln)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Uncertain Significance	PM2, PP3, PS4_Moderate	PM5, PM1, PM6, PP1, BA1, PS3, PP2, BS1, BS4, BS3, PS1, PS2, BP4	The c.5588G>A (p.Arg1863Gln) variant in MYH7 has been identified in 1 individual with familial DCM  (Hershberger 2008 PMID:19412328) and 7 individuals with DCM from clinical testing laboratories (PS4_Moderate; PMID:19412328; Partners LMM ClinVar SCV000059623.5; Invitae ClinVar SCV000818269.1, pers. comm.; Ambry pers. comm.; CHEO ClinVar SCV000901909.1, pers. comm.; GeneDx ClinVar SCV000208646.4, pers. comm.). This variant was also identified in 0.00027% (FAF 95% CI; 2/129158) of European chromosomes in gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org).  Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3).  In summary, this variant meets criteria to be classified as uncertain significance for dilated cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_Moderate, PM2; PP3	19412328	Cardiomyopathy VCEP		2021-03-22	2021-08-25	false	https://erepo.genome.network/evrepo/ui/classification/CA016295/MONDO:0005021/002	d896763f-e05b-46ff-a7a2-fc8cdd418c75
NM_000257.3(MYH7):c.2162+4G>A	42884	CA011799	NM_000257.3:c.2162+4G>A, NC_000014.9:g.23425960C>T, CM000676.2:g.23425960C>T, NC_000014.8:g.23895169C>T, CM000676.1:g.23895169C>T, NC_000014.7:g.22965009C>T, NG_007884.1:g.14702G>A, LRG_384:g.14702G>A, XR_245686.3:n.2268+4G>A, XM_017021340.1:c.2162+4G>A, NM_000257.4:c.2162+4G>A, ENST00000355349.3:c.2162+4G>A, NM_000257.3(MYH7):c.2162+4G>A	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1, BP4		The filtering allele frequency of the c.2162+4G>A variant in the MYH7 gene is 0.75% (93/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372). Additionally, computational prediction tools and conservation analysis suggest that this variant may not impact the protein (BP4).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011799/MONDO:0004994/002	90ddeb4d-091c-4378-ad61-ca1d9551ce4e
NM_000257.3(MYH7):c.3770A>G (p.Asn1257Ser)	188628	CA014062	NM_000257.3:c.3770A>G, XM_017021340.1:c.3770A>G, NM_000257.4:c.3770A>G, ENST00000355349.3:c.3770A>G, NC_000014.9:g.23419566T>C, CM000676.2:g.23419566T>C, NC_000014.8:g.23888775T>C, CM000676.1:g.23888775T>C, NC_000014.7:g.22958615T>C, NG_007884.1:g.21096A>G, LRG_384:g.21096A>G, NM_000257.3(MYH7):c.3770A>G (p.Asn1257Ser)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3770A>G (p.Asn1257Ser) variant in the MYH7 gene is 0.17% (37/16512) of South Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-16	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA014062/MONDO:0004994/002	e2762d05-f514-4fde-90de-7e6983a078a7
NM_000257.3(MYH7):c.2358G>T (p.Thr786=)	164334	CA012222	NM_000257.3:c.2358G>T, XR_245686.3:n.2464G>T, XM_017021340.1:c.2358G>T, NM_000257.4:c.2358G>T, ENST00000355349.3:c.2358G>T, NC_000014.9:g.23425347C>A, CM000676.2:g.23425347C>A, NC_000014.8:g.23894556C>A, CM000676.1:g.23894556C>A, NC_000014.7:g.22964396C>A, NG_007884.1:g.15315G>T, LRG_384:g.15315G>T, NM_000257.3(MYH7):c.2358G>T (p.Thr786=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2358G>T (p.Thr786=) variant in the MYH7 gene is 0.15% (33/16512) of South Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).	29300372	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012222/MONDO:0004994/002	830be9c3-5066-4862-ae1d-b5d73bc2a6b3
NM_000257.3(MYH7):c.5736C>T (p.Ile1912=)	43086	CA016427	NM_000257.3:c.5736C>T, XM_017021340.1:c.5736C>T, NM_000257.4:c.5736C>T, ENST00000355349.3:c.5736C>T, NC_000014.9:g.23413813G>A, CM000676.2:g.23413813G>A, NC_000014.8:g.23883022G>A, CM000676.1:g.23883022G>A, NC_000014.7:g.22952862G>A, NG_007884.1:g.26849C>T, LRG_384:g.26849C>T, NM_000257.3(MYH7):c.5736C>T (p.Ile1912=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.5736C>T (p.Ile1912=) variant in the MYH7 gene is 0.36% (72/16512) of South Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA016427/MONDO:0004994/002	ec05bf26-370c-4ac5-bb04-d08996c99723
NM_000257.3(MYH7):c.4671G>A (p.Lys1557=)	43031	CA015216	NM_000257.3:c.4671G>A, NR_126491.1:n.547C>T, XM_017021340.1:c.4671G>A, NM_000257.4:c.4671G>A, ENST00000355349.3:c.4671G>A, NC_000014.9:g.23416286C>T, CM000676.2:g.23416286C>T, NC_000014.8:g.23885495C>T, CM000676.1:g.23885495C>T, NC_000014.7:g.22955335C>T, NG_007884.1:g.24376G>A, LRG_384:g.24376G>A, NM_000257.3(MYH7):c.4671G>A (p.Lys1557=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.4671G>A (p.Lys1557=) variant in the MYH7 gene is 0.16% (34/15896) of South Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA015216/MONDO:0004994/002	6c279822-a998-4501-a37c-1768c4769158
NM_000257.3(MYH7):c.2769C>T (p.Asn923=)	42931	CA013030	NM_000257.3:c.2769C>T, XR_245686.3:n.2875C>T, XM_017021340.1:c.2769C>T, NM_000257.4:c.2769C>T, ENST00000355349.3:c.2769C>T, NC_000014.9:g.23424060G>A, CM000676.2:g.23424060G>A, NC_000014.8:g.23893269G>A, CM000676.1:g.23893269G>A, NC_000014.7:g.22963109G>A, NG_007884.1:g.16602C>T, LRG_384:g.16602C>T, NM_000257.3(MYH7):c.2769C>T (p.Asn923=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2769C>T (p.Asn923=) variant in the MYH7 gene is 0.22% (47/16512) of South Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013030/MONDO:0004994/002	ff8aa757-72b9-4c6d-983e-e31097e01139
NM_000257.3(MYH7):c.1062C>T (p.Gly354=)	42819	CA010125	NM_000257.3:c.1062C>T, NC_000014.9:g.23429851G>A, CM000676.2:g.23429851G>A, NC_000014.8:g.23899060G>A, CM000676.1:g.23899060G>A, NC_000014.7:g.22968900G>A, NG_007884.1:g.10811C>T, LRG_384:g.10811C>T, XR_245686.3:n.1168C>T, XM_017021340.1:c.1062C>T, NM_000257.4:c.1062C>T, ENST00000355349.3:c.1062C>T, NM_000257.3(MYH7):c.1062C>T (p.Gly354=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1062C>T (p.Gly354=) variant in the MYH7 gene is 9.56% (1644/16510) of South Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA010125/MONDO:0004994/002	10979ad9-6d55-41ac-b094-a5afdc161970
NM_000257.3(MYH7):c.975C>T (p.Asp325=)	43116	CA017055	NM_000257.3:c.975C>T, XR_245686.3:n.1081C>T, XM_017021340.1:c.975C>T, NM_000257.4:c.975C>T, ENST00000355349.3:c.975C>T, NC_000014.9:g.23430584G>A, CM000676.2:g.23430584G>A, NC_000014.8:g.23899793G>A, CM000676.1:g.23899793G>A, NC_000014.7:g.22969633G>A, NG_007884.1:g.10078C>T, LRG_384:g.10078C>T, NM_000257.3(MYH7):c.975C>T (p.Asp325=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.975C>T (p.Asp325=) variant in the MYH7 gene is 2.82% (1920/65662) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA017055/MONDO:0004994/002	ae56c58a-f230-4cdd-ae97-4a8854aed98b
NM_000257.3(MYH7):c.597A>G (p.Ala199=)	43092	CA016520	NM_000257.3:c.597A>G, XR_245686.3:n.703A>G, XM_017021340.1:c.597A>G, NM_000257.4:c.597A>G, ENST00000355349.3:c.597A>G, NC_000014.9:g.23431803T>C, CM000676.2:g.23431803T>C, NC_000014.8:g.23901012T>C, CM000676.1:g.23901012T>C, NC_000014.7:g.22970852T>C, NG_007884.1:g.8859A>G, LRG_384:g.8859A>G, NM_000257.3(MYH7):c.597A>G (p.Ala199=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.597A>G (p.Ala199=) variant in the MYH7 gene is 1.44% (1013/66740) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA016520/MONDO:0004994/002	2c987756-3504-454e-b234-61113cfe99e8
NM_000257.3(MYH7):c.4472C>G (p.Ser1491Cys)	43020	CA015008	NM_000257.3:c.4472C>G, NC_000014.9:g.23417200G>C, CM000676.2:g.23417200G>C, NC_000014.8:g.23886409G>C, CM000676.1:g.23886409G>C, NC_000014.7:g.22956249G>C, NG_007884.1:g.23462C>G, LRG_384:g.23462C>G, NR_126491.1:n.652-12G>C, XM_017021340.1:c.4472C>G, NM_000257.4:c.4472C>G, ENST00000355349.3:c.4472C>G, NM_000257.3(MYH7):c.4472C>G (p.Ser1491Cys)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.4472C>G (p.Ser1491Cys) variant in the MYH7 gene is 0.98% (698/66740) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA015008/MONDO:0004994/002	ccf7c102-ea2b-405d-80ab-65ce87901806
NM_000257.3(MYH7):c.5401G>A (p.Glu1801Lys)	43069	CA016087	NM_000257.3:c.5401G>A, NC_000014.9:g.23415153C>T, CM000676.2:g.23415153C>T, NC_000014.8:g.23884362C>T, CM000676.1:g.23884362C>T, NC_000014.7:g.22954202C>T, NG_007884.1:g.25509G>A, LRG_384:g.25509G>A, XM_017021340.1:c.5401G>A, NM_000257.4:c.5401G>A, ENST00000355349.3:c.5401G>A, NM_000257.3(MYH7):c.5401G>A (p.Glu1801Lys)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Likely Pathogenic	PM6, PM2, PP3, PS4_Supporting		The c.5401G>A (p.Glu1801Lys) variant in MYH7 has been reported in 4 individuals with dilated cardiomyopathy, one of whom had additional myopathy features (PS4_Supporting; PMID:19477645; Partners LMM ClinVar SCV000059616.5). Additionally, in two of the probands with dilated cardiomyopathy, the variant occurred de novo (PM6; Partners LMM ClinVar SCV000059616.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for dilated cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PM2; PM6; PP3; PS4_ Supporting	19477645	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA016087/MONDO:0005021/002	7c729fe3-84ef-4174-a0d8-c152b6dc76d7
NM_000257.3(MYH7):c.4005G>A (p.Ser1335=)	42988	CA014353	NM_000257.3:c.4005G>A, NC_000014.9:g.23418374C>T, CM000676.2:g.23418374C>T, NC_000014.8:g.23887583C>T, CM000676.1:g.23887583C>T, NC_000014.7:g.22957423C>T, NG_007884.1:g.22288G>A, LRG_384:g.22288G>A, XM_017021340.1:c.4005G>A, NM_000257.4:c.4005G>A, ENST00000355349.3:c.4005G>A, NM_000257.3(MYH7):c.4005G>A (p.Ser1335=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.4005G>A (p.Ser1335=) variant in the MYH7 gene is 0.19% (140/64766) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA014353/MONDO:0004994/002	0676e72c-311f-400d-af6e-a0c693fbd33a
NM_000257.3(MYH7):c.3853+7C>T	42977	CA014162	NM_000257.3:c.3853+7C>T, XM_017021340.1:c.3853+7C>T, NM_000257.4:c.3853+7C>T, ENST00000355349.3:c.3853+7C>T, NC_000014.9:g.23419476G>A, CM000676.2:g.23419476G>A, NC_000014.8:g.23888685G>A, CM000676.1:g.23888685G>A, NC_000014.7:g.22958525G>A, NG_007884.1:g.21186C>T, LRG_384:g.21186C>T, NM_000257.3(MYH7):c.3853+7C>T	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3853+7C>T  variant in the MYH7 gene is 0.32% (239/66734) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA014162/MONDO:0004994/002	740d3a8f-5dd0-4b55-8045-2571c2606486
NM_000257.3(MYH7):c.3351G>A (p.Glu1117=)	42957	CA013640	NM_000257.3:c.3351G>A, NC_000014.9:g.23420220C>T, CM000676.2:g.23420220C>T, NC_000014.8:g.23889429C>T, CM000676.1:g.23889429C>T, NC_000014.7:g.22959269C>T, NG_007884.1:g.20442G>A, LRG_384:g.20442G>A, XR_245686.3:n.3459G>A, XM_017021340.1:c.3351G>A, NM_000257.4:c.3351G>A, ENST00000355349.3:c.3351G>A, NM_000257.3(MYH7):c.3351G>A (p.Glu1117=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3351G>A (p.Glu1117=) variant in the MYH7 gene is 0.34% (212/55890) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013640/MONDO:0004994/002	5e699e3c-5574-4272-a29d-28f2b1354654
NM_000257.3(MYH7):c.3337-3dupC	42956	CA013590	NM_000257.3:c.3337-3dupC, NM_000257.3:c.3337-3_3337-2insC, NC_000014.9:g.23420238dup, CM000676.2:g.23420238dup, NC_000014.8:g.23889447dup, CM000676.1:g.23889447dup, NC_000014.7:g.22959287dup, NG_007884.1:g.20425dup, LRG_384:g.20425dup, NM_000257.3:c.3337-3dup, XR_245686.3:n.3445-3dup, XM_017021340.1:c.3337-3dup, NM_000257.4:c.3337-3dup, ENST00000355349.3:c.3337-3dup, NM_000257.3(MYH7):c.3337-3dupC	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3337-3dupC  variant in the MYH7 gene is 0.23% (146/54400) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013590/MONDO:0004994/002	ad81c356-fbf8-4c6d-903e-c43fb05f8288
NM_000257.3(MYH7):c.3153G>A (p.Ala1051=)	42946	CA013398	NM_000257.3:c.3153G>A, XR_245686.3:n.3259G>A, XM_017021340.1:c.3153G>A, NM_000257.4:c.3153G>A, ENST00000355349.3:c.3153G>A, NC_000014.9:g.23422272C>T, CM000676.2:g.23422272C>T, NC_000014.8:g.23891481C>T, CM000676.1:g.23891481C>T, NC_000014.7:g.22961321C>T, NG_007884.1:g.18390G>A, LRG_384:g.18390G>A, NM_000257.3(MYH7):c.3153G>A (p.Ala1051=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3153G>A (p.Ala1051=) variant in the MYH7 gene is 0.68% (490/66740) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013398/MONDO:0004994/002	3ac90aed-00ed-4225-a768-90003b4e581b
NM_000257.3(MYH7):c.2945T>C (p.Met982Thr)	42941	CA013227	NM_000257.3:c.2945T>C, NC_000014.9:g.23423701A>G, CM000676.2:g.23423701A>G, NC_000014.8:g.23892910A>G, CM000676.1:g.23892910A>G, NC_000014.7:g.22962750A>G, NG_007884.1:g.16961T>C, LRG_384:g.16961T>C, XR_245686.3:n.3051T>C, XM_017021340.1:c.2945T>C, NM_000257.4:c.2945T>C, ENST00000355349.3:c.2945T>C, NM_000257.3(MYH7):c.2945T>C (p.Met982Thr)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2945T>C (p.Met982Thr) variant in the MYH7 gene is 0.11% (88/66740) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013227/MONDO:0004994/002	391d3665-b29c-4627-bf93-ca50435b06b4
NM_000257.3(MYH7):c.1095G>A (p.Lys365=)	42821	CA010173	NM_000257.3:c.1095G>A, NC_000014.9:g.23429818C>T, CM000676.2:g.23429818C>T, NC_000014.8:g.23899027C>T, CM000676.1:g.23899027C>T, NC_000014.7:g.22968867C>T, NG_007884.1:g.10844G>A, LRG_384:g.10844G>A, XR_245686.3:n.1201G>A, XM_017021340.1:c.1095G>A, NM_000257.4:c.1095G>A, ENST00000355349.3:c.1095G>A, NM_000257.3(MYH7):c.1095G>A (p.Lys365=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1095G>A (p.Lys365=) variant in the MYH7 gene is 15.42% (10459/66736) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA010173/MONDO:0004994/002	57cd51f7-3891-4b22-9d96-d564c65aabdb
NM_000257.3(MYH7):c.3918C>T (p.Leu1306=)	42980	CA014235	NM_000257.3:c.3918C>T, NC_000014.9:g.23419231G>A, CM000676.2:g.23419231G>A, NC_000014.8:g.23888440G>A, CM000676.1:g.23888440G>A, NC_000014.7:g.22958280G>A, NG_007884.1:g.21431C>T, LRG_384:g.21431C>T, XM_017021340.1:c.3918C>T, NM_000257.4:c.3918C>T, ENST00000355349.3:c.3918C>T, NM_000257.3(MYH7):c.3918C>T (p.Leu1306=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3918C>T (p.Leu1306=) variant in the MYH7 gene is 0.55% (60/8654) of East Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA014235/MONDO:0004994/002	85f7499a-f2f0-476e-bcfb-f66f78058cc2
NM_000257.3(MYH7):c.77C>T (p.Ala26Val)	37375	CA016817	NM_000257.3:c.77C>T, XR_245686.3:n.183C>T, XM_017021340.1:c.77C>T, NM_000257.4:c.77C>T, ENST00000355349.3:c.77C>T, NC_000014.9:g.23433656G>A, CM000676.2:g.23433656G>A, NC_000014.8:g.23902865G>A, CM000676.1:g.23902865G>A, NC_000014.7:g.22972705G>A, NG_007884.1:g.7006C>T, LRG_384:g.7006C>T, NM_000257.3(MYH7):c.77C>T (p.Ala26Val)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.77C>T (p.Ala26Val) variant in the MYH7 gene is 0.55% (60/8646) of East Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA016817/MONDO:0004994/002	e26a6375-f03a-4542-9924-d09781723678
NM_000257.3(MYH7):c.1119G>A (p.Ala373=)	138391	CA010221	NM_000257.3:c.1119G>A, NC_000014.9:g.23429794C>T, CM000676.2:g.23429794C>T, NC_000014.8:g.23899003C>T, CM000676.1:g.23899003C>T, NC_000014.7:g.22968843C>T, NG_007884.1:g.10868G>A, LRG_384:g.10868G>A, XR_245686.3:n.1225G>A, XM_017021340.1:c.1119G>A, NM_000257.4:c.1119G>A, ENST00000355349.3:c.1119G>A, NM_000257.3(MYH7):c.1119G>A (p.Ala373=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1119G>A (p.Ala373=) variant in the MYH7 gene is 0.12% (21/11578) of Latino chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA010221/MONDO:0004994/002	57a05647-6a92-4bb6-a94e-b4fb29af2e0f
NM_000257.3(MYH7):c.5329G>A (p.Ala1777Thr)	177697	CA015952	NM_000257.3:c.5329G>A, NC_000014.9:g.23415225C>T, CM000676.2:g.23415225C>T, NC_000014.8:g.23884434C>T, CM000676.1:g.23884434C>T, NC_000014.7:g.22954274C>T, NG_007884.1:g.25437G>A, LRG_384:g.25437G>A, ENST00000355349.4:c.5329G>A, ENST00000355349.3:c.5329G>A, XM_017021340.1:c.5329G>A, NM_000257.4:c.5329G>A, NM_000257.4(MYH7):c.5329G>A (p.Ala1777Thr), NM_000257.3(MYH7):c.5329G>A (p.Ala1777Thr)	MYH7	cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Uncertain Significance		BS2, PP2, PS3, BA1, PM2, PM5, PM1, PM6, PM3, PM4, PP3, PP1, BP1, BP3, BS1, BS4, BS3, BP4, BP2, BP5, BP7, PS4, PS1, PS2, PVS1	The NM_000257.4(MYH7):c.5329G>A (p.Ala1777Thr) variant has been identified in at least 14 individuals with HCM, 2 of whom had an additional variant in another gene that may contribute to their disease, 1 individual with RCM with another pathogenic MYH7 variant, and 5 individuals with DCM including 2 that also had disease-causing variants (Richard 2003 PMID:12707239; Bos 2014 PMID:24793961; Homburger 2016 PMID:27247418; Walsh 2017 PMID: 27532257; Ho 2018 PMID:30297972; Ambry pers. comm.; GeneDx pers. comm.; LMM pers. comm.; OMGL pers. comm). This variant has also been identified in 1 individual with LVNC requiring transplant who also had 2 pathogenic MYBPC3 variants, 1 individual with Brugada syndrome, and 2 individuals with myopathy - 1 with myofibrillar myopathy and 1 with distal and axial myopathy (Hertz 2014 PMID:25467552; EvilÃ¤ 2016 PMID:26627873; Chanson 2016 PMID:26969127; Liu 2020 PMID:31918855). This variant has been observed to segregate with DCM in 1 relative of a proband with DCM as well as not segregate with HCM in an affected sibling of a proband with HCM (OMGL per. comm.). Because of the variability in phenotypes observed in individuals with this variant and because PS4 is only applicable when the variant is absent or rare in large population studies, the PS4 criterion was not applied (Kelly 2018 PMID:29300372). Additionally, the segregation data is currently insufficient to establish segregation or non-segregation with disease and therefore neither PP1 nor BS4 were applied. This variant has been identified in 0.008% (FAF 95% CI; 17/129,190) of European chromosomes in gnomAD v.2.1.1 (http://gnomad.broadinstitute.org) and is above the threshold of 0.004%, therefore PM2 cannot be applied. Computational prediction tools and conservation do not provide evidence for or against an impact to the protein. In summary, due to conflicting evidence, this variant is classified as uncertain significance for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): None.		Cardiomyopathy VCEP		2021-11-30	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA015952/MONDO:0005045/002	a16a1f02-844a-4b61-bd74-71c8230a85de
NM_000257.3(MYH7):c.4974C>T (p.Asp1658=)	43048	CA015510	NM_000257.3:c.4974C>T, NR_126491.1:n.244G>A, XM_017021340.1:c.4974C>T, NM_000257.4:c.4974C>T, ENST00000355349.3:c.4974C>T, NC_000014.9:g.23415812G>A, CM000676.2:g.23415812G>A, NC_000014.8:g.23885021G>A, CM000676.1:g.23885021G>A, NC_000014.7:g.22954861G>A, NG_007884.1:g.24850C>T, LRG_384:g.24850C>T, NM_000257.3(MYH7):c.4974C>T (p.Asp1658=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.4974C>T (p.Asp1658=) variant in the MYH7 gene is 0.36% (53/11558) of Latino chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA015510/MONDO:0004994/002	9d15308c-24d6-4612-83db-e16129e10e7f
NM_000257.3(MYH7):c.4566T>C (p.Thr1522=)	43027	CA015116	NM_000257.3:c.4566T>C, NR_126491.1:n.589A>G, XM_017021340.1:c.4566T>C, NM_000257.4:c.4566T>C, ENST00000355349.3:c.4566T>C, NC_000014.9:g.23416946A>G, CM000676.2:g.23416946A>G, NC_000014.8:g.23886155A>G, CM000676.1:g.23886155A>G, NC_000014.7:g.22955995A>G, NG_007884.1:g.23716T>C, LRG_384:g.23716T>C, NM_000257.3(MYH7):c.4566T>C (p.Thr1522=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.4566T>C (p.Thr1522=) variant in the MYH7 gene is 2.98% (376/11574) of Latino chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA015116/MONDO:0004994/002	7073dd08-2236-46cf-af05-bb7efc08dfc9
NM_000257.3(MYH7):c.930T>C (p.Tyr310=)	177865	CA016969	NM_000257.3:c.930T>C, NC_000014.9:g.23430629A>G, CM000676.2:g.23430629A>G, NC_000014.8:g.23899838A>G, CM000676.1:g.23899838A>G, NC_000014.7:g.22969678A>G, NG_007884.1:g.10033T>C, LRG_384:g.10033T>C, XR_245686.3:n.1036T>C, XM_017021340.1:c.930T>C, NM_000257.4:c.930T>C, ENST00000355349.3:c.930T>C, NM_000257.3(MYH7):c.930T>C (p.Tyr310=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.930T>C (p.Tyr310=) variant in the MYH7 gene is 0.23% (33/10334) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA016969/MONDO:0004994/002	b4ae1402-0ded-4822-9b3a-6f0947d8c41e
NM_000257.3(MYH7):c.732C>T (p.Phe244=)	43103	CA016723	NM_000257.3:c.732C>T, NC_000014.9:g.23431585G>A, CM000676.2:g.23431585G>A, NC_000014.8:g.23900794G>A, CM000676.1:g.23900794G>A, NC_000014.7:g.22970634G>A, NG_007884.1:g.9077C>T, LRG_384:g.9077C>T, XR_245686.3:n.838C>T, XM_017021340.1:c.732C>T, NM_000257.4:c.732C>T, ENST00000355349.3:c.732C>T, NM_000257.3(MYH7):c.732C>T (p.Phe244=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.732C>T (p.Phe244=) variant in the MYH7 gene is 53.63% (5704/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA016723/MONDO:0004994/002	792e7ac9-c650-4b6c-a394-400730a6f471
NM_000257.3(MYH7):c.5106G>A (p.Ala1702=)	43056	CA015682	NM_000257.3:c.5106G>A, NR_126491.1:n.112C>T, XM_017021340.1:c.5106G>A, NM_000257.4:c.5106G>A, ENST00000355349.3:c.5106G>A, NC_000014.9:g.23415680C>T, CM000676.2:g.23415680C>T, NC_000014.8:g.23884889C>T, CM000676.1:g.23884889C>T, NC_000014.7:g.22954729C>T, NG_007884.1:g.24982G>A, LRG_384:g.24982G>A, NM_000257.3(MYH7):c.5106G>A (p.Ala1702=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.5106G>A (p.Ala1702=) variant in the MYH7 gene is 22.43% (2414/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA015682/MONDO:0004994/002	9bfa9ec7-0398-4a25-878d-233b01eafc0a
NM_000257.3(MYH7):c.480C>T (p.Asn160=)	43038	CA015335	NM_000257.3:c.480C>T, XR_245686.3:n.586C>T, XM_017021340.1:c.480C>T, NM_000257.4:c.480C>T, ENST00000355349.3:c.480C>T, NC_000014.9:g.23432661G>A, CM000676.2:g.23432661G>A, NC_000014.8:g.23901870G>A, CM000676.1:g.23901870G>A, NC_000014.7:g.22971710G>A, NG_007884.1:g.8001C>T, LRG_384:g.8001C>T, NM_000257.3(MYH7):c.480C>T (p.Asn160=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.480C>T (p.Asn160=) variant in the MYH7 gene is 0.37% (49/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA015335/MONDO:0004994/002	f7b4f50c-5b5d-4707-acc8-162fb6bfcd17
NM_000257.3(MYH7):c.4788G>A (p.Ser1596=)	43035	CA015299	NM_000257.3:c.4788G>A, NC_000014.9:g.23416169C>T, CM000676.2:g.23416169C>T, NC_000014.8:g.23885378C>T, CM000676.1:g.23885378C>T, NC_000014.7:g.22955218C>T, NG_007884.1:g.24493G>A, LRG_384:g.24493G>A, NR_126491.1:n.430C>T, XM_017021340.1:c.4788G>A, NM_000257.4:c.4788G>A, ENST00000355349.3:c.4788G>A, NM_000257.3(MYH7):c.4788G>A (p.Ser1596=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.4788G>A (p.Ser1596=) variant in the MYH7 gene is 0.74% (92/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA015299/MONDO:0004994/002	63e9b736-1773-4cb2-9e7a-d167b107045e
NM_000257.3(MYH7):c.4716C>T (p.Ile1572=)	43032	CA015251	NM_000257.3:c.4716C>T, NC_000014.9:g.23416241G>A, CM000676.2:g.23416241G>A, NC_000014.8:g.23885450G>A, CM000676.1:g.23885450G>A, NC_000014.7:g.22955290G>A, NG_007884.1:g.24421C>T, LRG_384:g.24421C>T, NR_126491.1:n.502G>A, XM_017021340.1:c.4716C>T, NM_000257.4:c.4716C>T, ENST00000355349.3:c.4716C>T, NM_000257.3(MYH7):c.4716C>T (p.Ile1572=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.4716C>T (p.Ile1572=) variant in the MYH7 gene is 4.59% (514/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA015251/MONDO:0004994/002	ae72e610-e63b-4c45-9b58-993f04531448
NM_000257.3(MYH7):c.4452C>T (p.Leu1484=)	43019	CA014994	NM_000257.3:c.4452C>T, NR_126491.1:n.660G>A, XM_017021340.1:c.4452C>T, NM_000257.4:c.4452C>T, ENST00000355349.3:c.4452C>T, NC_000014.9:g.23417220G>A, CM000676.2:g.23417220G>A, NC_000014.8:g.23886429G>A, CM000676.1:g.23886429G>A, NC_000014.7:g.22956269G>A, NG_007884.1:g.23442C>T, LRG_384:g.23442C>T, NM_000257.3(MYH7):c.4452C>T (p.Leu1484=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.4452C>T (p.Leu1484=) variant in the MYH7 gene is 0.74% (92/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA014994/MONDO:0004994/002	80f1bf99-45f8-4b70-8fdb-a5e3980b862c
NM_000257.3(MYH7):c.3864C>G (p.Ser1288=)	42979	CA014192	NM_000257.3:c.3864C>G, XM_017021340.1:c.3864C>G, NM_000257.4:c.3864C>G, ENST00000355349.3:c.3864C>G, NC_000014.9:g.23419285G>C, CM000676.2:g.23419285G>C, NC_000014.8:g.23888494G>C, CM000676.1:g.23888494G>C, NC_000014.7:g.22958334G>C, NG_007884.1:g.21377C>G, LRG_384:g.21377C>G, NM_000257.3(MYH7):c.3864C>G (p.Ser1288=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3864C>G (p.Ser1288=) variant in the MYH7 gene is 1.33% (159/10404) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA014192/MONDO:0004994/002	8ff577cd-158b-45ba-b21b-c387c3c850e6
NM_000257.3(MYH7):c.5326A>G (p.Ser1776Gly)	177629	CA015944	NM_000257.3:c.5326A>G, XM_017021340.1:c.5326A>G, NM_000257.4:c.5326A>G, ENST00000355349.3:c.5326A>G, NC_000014.9:g.23415228T>C, CM000676.2:g.23415228T>C, NC_000014.8:g.23884437T>C, CM000676.1:g.23884437T>C, NC_000014.7:g.22954277T>C, NG_007884.1:g.25434A>G, LRG_384:g.25434A>G, NM_000257.3(MYH7):c.5326A>G (p.Ser1776Gly)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Uncertain Significance	PP3	PM2, PS4	The c.5326A>G (p.Ser1776Gly) variant in MYH7 has been reported in 12 individuals with hypertrophic cardiomyopathy (PMID:27532257; PMID:11861413; PMID:21239446; Partners LMM ClinVar SCV000203861.4; SHaRe consortium, PMID: 30297972) but has also been identified in 0.02% (2/8654) of East Asian chromosomes by ExAC (http://exac.broadinstitute.org). Since the MYH7 specifications state that PS4 is only applicable if the variant is absent or rare in large population studies, PS4 criterion was not applied (PMID:29300372). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as uncertain significance for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PP3	11861413, 27532257, 21239446	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA015944/MONDO:0005045/002	5d9a840f-4e17-4378-a41d-341cf6eab7b8
NM_000257.3(MYH7):c.3777C>T (p.His1259=)	42974	CA014078	NM_000257.3:c.3777C>T, NC_000014.9:g.23419559G>A, CM000676.2:g.23419559G>A, NC_000014.8:g.23888768G>A, CM000676.1:g.23888768G>A, NC_000014.7:g.22958608G>A, NG_007884.1:g.21103C>T, LRG_384:g.21103C>T, XM_017021340.1:c.3777C>T, NM_000257.4:c.3777C>T, ENST00000355349.3:c.3777C>T, NM_000257.3(MYH7):c.3777C>T (p.His1259=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3777C>T (p.His1259=) variant in the MYH7 gene is 0.14% (22/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA014078/MONDO:0004994/002	36226bd6-2753-49e6-8a0d-cd43e12120c1
NM_000257.3(MYH7):c.3156G>A (p.Lys1052=)	42949	CA013406	NM_000257.3:c.3156G>A, NC_000014.9:g.23422269C>T, CM000676.2:g.23422269C>T, NC_000014.8:g.23891478C>T, CM000676.1:g.23891478C>T, NC_000014.7:g.22961318C>T, NG_007884.1:g.18393G>A, LRG_384:g.18393G>A, XR_245686.3:n.3262G>A, XM_017021340.1:c.3156G>A, NM_000257.4:c.3156G>A, ENST00000355349.3:c.3156G>A, NM_000257.3(MYH7):c.3156G>A (p.Lys1052=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3156G>A (p.Lys1052=) variant in the MYH7 gene is 0.14% (21/10404) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013406/MONDO:0004994/002	3b724301-b55e-4124-bc08-1c7922195671
NM_000257.3(MYH7):c.297C>T (p.Pro99=)	42944	CA013276	NM_000257.3:c.297C>T, XR_245686.3:n.403C>T, XM_017021340.1:c.297C>T, NM_000257.4:c.297C>T, ENST00000355349.3:c.297C>T, NC_000014.9:g.23433132G>A, CM000676.2:g.23433132G>A, NC_000014.8:g.23902341G>A, CM000676.1:g.23902341G>A, NC_000014.7:g.22972181G>A, NG_007884.1:g.7530C>T, LRG_384:g.7530C>T, NM_000257.3(MYH7):c.297C>T (p.Pro99=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.297C>T (p.Pro99=) variant in the MYH7 gene is 0.54% (69/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013276/MONDO:0004994/002	d259092e-4ec8-4e34-9b36-8d548c8e4f7e
NM_000257.3(MYH7):c.2967T>C (p.Ile989=)	42942	CA013242	NM_000257.3:c.2967T>C, NC_000014.9:g.23423679A>G, CM000676.2:g.23423679A>G, NC_000014.8:g.23892888A>G, CM000676.1:g.23892888A>G, NC_000014.7:g.22962728A>G, NG_007884.1:g.16983T>C, LRG_384:g.16983T>C, XR_245686.3:n.3073T>C, XM_017021340.1:c.2967T>C, NM_000257.4:c.2967T>C, ENST00000355349.3:c.2967T>C, NM_000257.3(MYH7):c.2967T>C (p.Ile989=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2967T>C (p.Ile989=) variant in the MYH7 gene is 70.48% (7476/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013242/MONDO:0004994/002	06dd2a85-f0e8-445d-8f25-bcd5a7153a12
NM_000257.3(MYH7):c.2907C>T (p.His969=)	42939	CA013197	NM_000257.3:c.2907C>T, NC_000014.9:g.23423922G>A, CM000676.2:g.23423922G>A, NC_000014.8:g.23893131G>A, CM000676.1:g.23893131G>A, NC_000014.7:g.22962971G>A, NG_007884.1:g.16740C>T, LRG_384:g.16740C>T, XR_245686.3:n.3013C>T, XM_017021340.1:c.2907C>T, NM_000257.4:c.2907C>T, ENST00000355349.3:c.2907C>T, NM_000257.3(MYH7):c.2907C>T (p.His969=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2907C>T (p.His969=) variant in the MYH7 gene is 0.15% (23/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013197/MONDO:0004994/002	8ebacc93-8fcf-4e97-9078-77ffec49ee40
NM_000257.3(MYH7):c.261C>T (p.Ile87=)	42918	CA012747	NM_000257.3:c.261C>T, XR_245686.3:n.367C>T, XM_017021340.1:c.261C>T, NM_000257.4:c.261C>T, ENST00000355349.3:c.261C>T, NC_000014.9:g.23433168G>A, CM000676.2:g.23433168G>A, NC_000014.8:g.23902377G>A, CM000676.1:g.23902377G>A, NC_000014.7:g.22972217G>A, NG_007884.1:g.7494C>T, LRG_384:g.7494C>T, NM_000257.3(MYH7):c.261C>T (p.Ile87=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.261C>T (p.Ile87=) variant in the MYH7 gene is 0.18% (26/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012747/MONDO:0004994/002	558edff6-7f85-4b3c-9436-15e222922594
NM_000257.3(MYH7):c.2553C>A (p.Ser851=)	42915	CA012605	NM_000257.3:c.2553C>A, NC_000014.9:g.23424895G>T, CM000676.2:g.23424895G>T, NC_000014.8:g.23894104G>T, CM000676.1:g.23894104G>T, NC_000014.7:g.22963944G>T, NG_007884.1:g.15767C>A, LRG_384:g.15767C>A, XR_245686.3:n.2659C>A, XM_017021340.1:c.2553C>A, NM_000257.4:c.2553C>A, ENST00000355349.3:c.2553C>A, NM_000257.3(MYH7):c.2553C>A (p.Ser851=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2553C>A (p.Ser851=) variant in the MYH7 gene is 0.18% (27/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012605/MONDO:0004994/002	7ce6fd16-411b-442d-9cee-289cdd327c9c
NM_000257.3(MYH7):c.2514G>A (p.Pro838=)	42911	CA012524	NM_000257.3:c.2514G>A, NC_000014.9:g.23424934C>T, CM000676.2:g.23424934C>T, NC_000014.8:g.23894143C>T, CM000676.1:g.23894143C>T, NC_000014.7:g.22963983C>T, NG_007884.1:g.15728G>A, LRG_384:g.15728G>A, XR_245686.3:n.2620G>A, XM_017021340.1:c.2514G>A, NM_000257.4:c.2514G>A, ENST00000355349.3:c.2514G>A, NM_000257.3(MYH7):c.2514G>A (p.Pro838=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2514G>A (p.Pro838=) variant in the MYH7 gene is 0.18% (27/10404) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA012524/MONDO:0004994/002	d7d969ca-f2e3-4c49-ac31-63f351852a54
NM_000257.3(MYH7):c.189C>T (p.Thr63=)	42869	CA011440	NM_000257.3:c.189C>T, XR_245686.3:n.295C>T, XM_017021340.1:c.189C>T, NM_000257.4:c.189C>T, ENST00000355349.3:c.189C>T, NC_000014.9:g.23433544G>A, CM000676.2:g.23433544G>A, NC_000014.8:g.23902753G>A, CM000676.1:g.23902753G>A, NC_000014.7:g.22972593G>A, NG_007884.1:g.7118C>T, LRG_384:g.7118C>T, NM_000257.3(MYH7):c.189C>T (p.Thr63=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.189C>T (p.Thr63=) variant in the MYH7 gene is 61.57% (6532/10394) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011440/MONDO:0004994/002	869f715e-ecb7-42f4-aad4-123ebe5d3b2d
NM_000257.3(MYH7):c.1767C>T (p.Asn589=)	42864	CA011229	NM_000257.3:c.1767C>T, XR_245686.3:n.1873C>T, XM_017021340.1:c.1767C>T, NM_000257.4:c.1767C>T, ENST00000355349.3:c.1767C>T, NC_000014.9:g.23427706G>A, CM000676.2:g.23427706G>A, NC_000014.8:g.23896915G>A, CM000676.1:g.23896915G>A, NC_000014.7:g.22966755G>A, NG_007884.1:g.12956C>T, LRG_384:g.12956C>T, NM_000257.3(MYH7):c.1767C>T (p.Asn589=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1767C>T (p.Asn589=) variant in the MYH7 gene is 3.71% (419/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011229/MONDO:0004994/002	47b30ecd-c4eb-470e-bd81-0bba893f6f40
NM_000257.3(MYH7):c.5302G>A (p.Glu1768Lys)	43059	CA015893	NM_000257.3:c.5302G>A, NC_000014.9:g.23415252C>T, CM000676.2:g.23415252C>T, NC_000014.8:g.23884461C>T, CM000676.1:g.23884461C>T, NC_000014.7:g.22954301C>T, NG_007884.1:g.25410G>A, LRG_384:g.25410G>A, ENST00000355349.4:c.5302G>A, ENST00000355349.3:c.5302G>A, XM_017021340.1:c.5302G>A, NM_000257.4:c.5302G>A, NM_000257.3(MYH7):c.5302G>A (p.Glu1768Lys)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Uncertain Significance	PM2, PP3, PS4_Moderate	PM5, PM1, BA1, PS3, BS1, BS3, PS1, BP4	The c.5302G>A (p.Glu1768Lys) variant in MYH7 has been identified in at least 7 individuals with HCM (PS4_Moderate; Van Driest 2004 PMID:15358028; Bos 2014 PMID:24793961; Murphy 2016 PMID:26914223; Berge 2014 PMID:24111713; Homburger 2016 PMID:27247418; Cecconi 2016 PMID:27600940; LMM SCV000059606.5). In vitro studies showed this variant had a slight effect on protein structure, but no effect on the ability to incorporate into muscle sarcomeres in an experimental system (Wolny 2013 PMID:24047955); however, this evidence is insufficient to apply PS3. Additionally this variant was absent from large population studies (PM2; http://gnomad.broadinstitute.org, v.2.1.1). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, due to insufficient evidence, this variant is classified as uncertain significance for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_Moderate; PM2; PP3	24047955, 15358028, 24047955	Cardiomyopathy VCEP		2021-03-22	2021-08-25	false	https://erepo.genome.network/evrepo/ui/classification/CA015893/MONDO:0005045/002	1f7adfd4-301c-4b88-bb44-5784d44ef5ce
NM_000257.3(MYH7):c.1605A>G (p.Glu535=)	42853	CA011032	NM_000257.3:c.1605A>G, NC_000014.9:g.23427868T>C, CM000676.2:g.23427868T>C, NC_000014.8:g.23897077T>C, CM000676.1:g.23897077T>C, NC_000014.7:g.22966917T>C, NG_007884.1:g.12794A>G, LRG_384:g.12794A>G, XR_245686.3:n.1711A>G, XM_017021340.1:c.1605A>G, NM_000257.4:c.1605A>G, ENST00000355349.3:c.1605A>G, NM_000257.3(MYH7):c.1605A>G (p.Glu535=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1605A>G (p.Glu535=) variant in the MYH7 gene is 10.63% (1162/10406) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011032/MONDO:0004994/002	db768ec3-6235-4499-8d5a-f18d2dfa3ee7
NM_000257.3(MYH7):c.1395C>T (p.Phe465=)	42843	CA010677	NM_000257.3:c.1395C>T, NC_000014.9:g.23428967G>A, CM000676.2:g.23428967G>A, NC_000014.8:g.23898176G>A, CM000676.1:g.23898176G>A, NC_000014.7:g.22968016G>A, NG_007884.1:g.11695C>T, LRG_384:g.11695C>T, XR_245686.3:n.1501C>T, XM_017021340.1:c.1395C>T, NM_000257.4:c.1395C>T, ENST00000355349.3:c.1395C>T, NM_000257.3(MYH7):c.1395C>T (p.Phe465=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1395C>T (p.Phe465=) variant in the MYH7 gene is 0.18% (27/10402) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA010677/MONDO:0004994/002	84390a12-c383-4dd9-87a4-6900e444fe1b
NM_000257.3(MYH7):c.1128C>T (p.Asp376=)	42823	CA010240	NM_000257.3:c.1128C>T, XR_245686.3:n.1234C>T, XM_017021340.1:c.1128C>T, NM_000257.4:c.1128C>T, ENST00000355349.3:c.1128C>T, NC_000014.9:g.23429785G>A, CM000676.2:g.23429785G>A, NC_000014.8:g.23898994G>A, CM000676.1:g.23898994G>A, NC_000014.7:g.22968834G>A, NG_007884.1:g.10877C>T, LRG_384:g.10877C>T, NM_000257.3(MYH7):c.1128C>T (p.Asp376=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1128C>T (p.Asp376=) variant in the MYH7 gene is 37.6% (4016/10404) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA010240/MONDO:0004994/002	286bd75a-06b0-4040-81ce-6e1c12bf3fc7
NM_000257.3(MYH7):c.2156G>A (p.Arg719Gln)	14107	CA011785	NM_000257.3:c.2156G>A, XR_245686.3:n.2262G>A, XM_017021340.1:c.2156G>A, NM_000257.4:c.2156G>A, ENST00000355349.3:c.2156G>A, NC_000014.9:g.23425970C>T, CM000676.2:g.23425970C>T, NC_000014.8:g.23895179C>T, CM000676.1:g.23895179C>T, NC_000014.7:g.22965019C>T, NG_007884.1:g.14692G>A, LRG_384:g.14692G>A, NM_000257.3(MYH7):c.2156G>A (p.Arg719Gln)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP3, PM1, PM5, PM2, PP1_Strong, PS4		The c.2156G>A (p.Arg719Gln) variant in MYH7 has been reported in >30 individuals with hypertrophic cardiomyopathy (PS4; PMID:7848441; PMID:16199542; PMID:15358028; PMID:18411228; Partners LMM ClinVar SCV000059421.5; AGCMC Sydney ClinVar SCV000212634.1; SHaRe consortium, PMID: 30297972). This variant segregated with disease in 7 affected individuals (PP1_Strong; PMID:7848441; Partners LMM ClinVar SCV000059421.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2155C>T p.Arg719Trp ClinVar Variation ID 14104). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PM5; PP3	27532257, 7848441, 18411228, 16199542, 15358028, 7848441, 15858117	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011785/MONDO:0005045/002	3a4b002a-d683-41f1-9f5f-3211c2a7f950
NM_000257.3(MYH7):c.2155C>T (p.Arg719Trp)	14104	CA011779	NM_000257.3:c.2155C>T, NC_000014.9:g.23425971G>A, CM000676.2:g.23425971G>A, NC_000014.8:g.23895180G>A, CM000676.1:g.23895180G>A, NC_000014.7:g.22965020G>A, NG_007884.1:g.14691C>T, LRG_384:g.14691C>T, XR_245686.3:n.2261C>T, XM_017021340.1:c.2155C>T, NM_000257.4:c.2155C>T, ENST00000355349.3:c.2155C>T, NM_000257.3(MYH7):c.2155C>T (p.Arg719Trp)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP3, PS3, PM1, PM5, PM2, PP1_Strong, PS2, PS4		The c.2155C>T (p.Arg719Trp) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:9829907; PMID:8282798; PMID:9822100; PMID:12974739; PMID:22429680; PMID:23816408; PMID:12707239; PMID:19645038; PMID:27532257; SHaRe consortium, PMID: 30297972; Partners LMM ClinVar SCV000059419.5 ), including 1 de novo occurrence (PS2; 10957787). This variant was found to segregate with disease in 8 affected family members (PP1_Strong; PMID:9829907; PMID:8282798; PMID:9822100; PMID:12974739; SHaRe consortium, PMID: 30297972). A mouse model indicates that this variant disrupts the function of MYH7 and leads to a phenotype consistent with HCM (PS3: PMID:24829265). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2156G>A p.Arg719Gln - Variation ID 14107). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS2; PS3; PS4; PP1_ Strong; PM1; PM2; PM5; PP3	24829265, 27532257, 8282798, 9829907, 12974739, 9822100, 10957787, 23816408, 19645038, 27532257, 12707239, 8282798, 22429680, 10957787, 12974739, 9822100	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011779/MONDO:0005045/002	7b17a8bd-b169-46a1-8efa-b7388c4ecdef
NM_000257.3(MYH7):c.1002C>T (p.Asn334=)	42817	CA010043	NM_000257.3:c.1002C>T, NC_000014.9:g.23429911G>A, CM000676.2:g.23429911G>A, NC_000014.8:g.23899120G>A, CM000676.1:g.23899120G>A, NC_000014.7:g.22968960G>A, NG_007884.1:g.10751C>T, LRG_384:g.10751C>T, XR_245686.3:n.1108C>T, XM_017021340.1:c.1002C>T, NM_000257.4:c.1002C>T, ENST00000355349.3:c.1002C>T, NM_000257.3(MYH7):c.1002C>T (p.Asn334=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1002C>T (p.Asn334=) variant in the MYH7 gene is 4.12% (463/10398) of African chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA010043/MONDO:0004994/002	77abc0d4-5227-44f9-85da-0724f1c0f752
NM_000257.3(MYH7):c.2146G>A (p.Gly716Arg)	14105	CA011770	NM_000257.3:c.2146G>A, XR_245686.3:n.2252G>A, XM_017021340.1:c.2146G>A, NM_000257.4:c.2146G>A, ENST00000355349.3:c.2146G>A, NC_000014.9:g.23425980C>T, CM000676.2:g.23425980C>T, NC_000014.8:g.23895189C>T, CM000676.1:g.23895189C>T, NC_000014.7:g.22965029C>T, NG_007884.1:g.14682G>A, LRG_384:g.14682G>A, NM_000257.3(MYH7):c.2146G>A (p.Gly716Arg)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PP3, PM6, PM1, PM2, PS4		The c.2146G>A (p.Gly716Arg) variant in MYH7 has been reported in >30 individuals with hypertrophic cardiomyopathy (PS4; PMID:23074333; PMID:20641121; PMID:12084606; PMID:8282798; PMID:18953637; PMID:12707239; PMID:15358028; PMID:12975413; Partners LMM ClinVar SCV000059418.5; SHaRe consortium, PMID: 30297972). This variant has been identified as a de novo occurrence in 2 probands with hypertrophic cardiomyopathy (PM6; PMID:18953637; Partners LMM ClinVar SCV000059418.5). This variant segregated with disease in 11 affected individuals (PP1_Strong; PMID:8282798; PMID:20641121; Partners LMM ClinVar SCV000059418.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PM6; PP3	20641121, 8282798, 18953637, 27532257, 12084606, 23074333, 12975413, 20641121, 15358028, 12707239, 18953637, 8282798	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011770/MONDO:0005045/002	768afef8-4fb0-47f1-980f-d95c2ab71447
NM_000257.3(MYH7):c.1988G>A (p.Arg663His)	42875	CA011552	NM_000257.3:c.1988G>A, XR_245686.3:n.2094G>A, XM_017021340.1:c.1988G>A, NM_000257.4:c.1988G>A, ENST00000355349.3:c.1988G>A, NC_000014.9:g.23426833C>T, CM000676.2:g.23426833C>T, NC_000014.8:g.23896042C>T, CM000676.1:g.23896042C>T, NC_000014.7:g.22965882C>T, NG_007884.1:g.13829G>A, LRG_384:g.13829G>A, NM_000257.3(MYH7):c.1988G>A (p.Arg663His)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PM1, PM2, PP1_Strong, PS4		The c.1988G>A (p.Arg663His) variant in MYH7 has been reported in >30 individuals with hypertrophic cardiomyopathy (PS4; PMID:27532257; PMID:10750581; PMID:11133230; PMID:12707239; PMID:15563892; PMID:16199542; PMID:15358028; AGCMC Sydney ClinVar SCV000212629.1; Invitae ClinVar SCV000219103.7; Partners LMM ClinVar SCV000059409.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >15 affected individuals (PP1_Strong; PMID:10750581; Partners LMM ClinVar SCV000059409.5; SHaRe consortium, PMID: 30297972). This variant was identified in 2/66718 European chromosomes (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2	27532257, 10750581, 27532257, 16199542, 15358028, 11133230, 10750581, 12707239, 15563892	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011552/MONDO:0005045/002	b27a29bf-ad68-4066-b07a-e5dcac3e6944
NM_000257.3(MYH7):c.1750G>C (p.Gly584Arg)	14090	CA011186	NM_000257.3:c.1750G>C, NC_000014.9:g.23427723C>G, CM000676.2:g.23427723C>G, NC_000014.8:g.23896932C>G, CM000676.1:g.23896932C>G, NC_000014.7:g.22966772C>G, NG_007884.1:g.12939G>C, LRG_384:g.12939G>C, XR_245686.3:n.1856G>C, XM_017021340.1:c.1750G>C, NM_000257.4:c.1750G>C, ENST00000355349.3:c.1750G>C, NM_000257.3(MYH7):c.1750G>C (p.Gly584Arg)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP3, PM1, PM2, PP1_Moderate, PS4		The c.1750G>C (p.Gly584Arg) variant in MYH7 has been reported in >25 individuals with hypertrophic cardiomyopathy (PS4; PMID:1552912; PMID:10567705; PMID:24093860; Partners LMM ClinVar SCV000059395.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >5 affected individuals (PP1_Moderate; PMID:1552912; Partners LMM ClinVar SCV000059395.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PP1_Moderate; PP3	27532257, 1552912, 10567705, 1552912, 24093860	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011186/MONDO:0005045/002	ad28d5b5-6c74-4aa4-a755-d1b21486fd81
NM_000257.3(MYH7):c.1594T>C (p.Ser532Pro)	14108	CA011011	NM_000257.3:c.1594T>C, NC_000014.9:g.23427879A>G, CM000676.2:g.23427879A>G, NC_000014.8:g.23897088A>G, CM000676.1:g.23897088A>G, NC_000014.7:g.22966928A>G, NG_007884.1:g.12783T>C, LRG_384:g.12783T>C, XR_245686.3:n.1700T>C, XM_017021340.1:c.1594T>C, NM_000257.4:c.1594T>C, ENST00000355349.3:c.1594T>C, NM_000257.3(MYH7):c.1594T>C (p.Ser532Pro)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PM1, PM2, PS3, PP3, PS4_Supporting		The c.1594T>C (p.Ser532Pro) variant in MYH7 has been reported in 2 individuals with dilated cardiomyopathy (PS4_Supporting; PMID:11106718; PMID:22949430; Partners LMM ClinVar SCV000199219.4). This variant segregated with disease in >10 affected individuals (PP1_Strong; PMID:11106718; PMID:22949430). Mouse model indicates that this variant disrupts the function of MYH7 and leads to a phenotype consistent with DCM (PS3; PMID:16983074; PMID:23313350; PMID:17351073 ). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for dilated cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS3; PP1_ Strong; PM1; PM2; PP3; PS4_Supporting	11106718, 22949430, 2753225, 16983074, 17351073, 23313350, 11106718, 22949430	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA011011/MONDO:0005021/002	9486153c-4de2-4686-927c-cbe960ccbc06
NM_000257.4(MYH7):c.5135G>A (p.Arg1712Gln)	36642	CA015727	NM_000257.4:c.5135G>A, NC_000014.9:g.23415651C>T, CM000676.2:g.23415651C>T, NC_000014.8:g.23884860C>T, CM000676.1:g.23884860C>T, NC_000014.7:g.22954700C>T, NG_007884.1:g.25011G>A, LRG_384:g.25011G>A, ENST00000355349.4:c.5135G>A, ENST00000355349.3:c.5135G>A, NM_000257.3:c.5135G>A, NR_126491.1:n.83C>T, XM_017021340.1:c.5135G>A, NM_000257.4(MYH7):c.5135G>A (p.Arg1712Gln)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PM2, PS4	PM1, PM4, PM6, PM5, PP3, BA1, PS3, BS1, BS4, BS3, BP3, BP4, BP7, BP2, BP5, PS2, PS1, PVS1	The NM_000257.4(MYH7):c.5135G>A (p.Arg1712Gln) variant has been reported in >30 individuals with HCM (PS4; Miller 2013 PMID: 23054336; Mook 2013 PMID: 23785128; Glotov 2015 PMID: 25892673; Lopes 2015 PMID: 25351510; Helms 2016 PMID: 27688314; Mademont-Soler 2017 PMID: 28771489; Weissler-Snir 2017 PMID: 28193612; van Velzen 2017 PMID: 2879411; van Lint 2019 PMID: 30847666; Tran Vu 2019 PMID: 31308319; Ambry pers. comm.; CHEO pers. comm.; GeneDx pers. comm.; LMM pers. comm.; Mayo pers. comm.; OMGL pers. comm.). This variant segregated with disease in >15 affected relatives with HCM in at least 9  families (PP1_strong; GeneDx pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant has also been identified in 0.002% (FAF 95% CI; 6/128842) of European chromosomes by gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, this variant meets criteria to be classified as  pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4, PP1_strong, PM2.		Cardiomyopathy VCEP		2021-12-09	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA015727/MONDO:0005045/002	96f084ee-5a31-4783-b4d4-aa2ffe4b4e45
NM_000257.3(MYH7):c.1477_1478delAT (p.Met493Valfs)	177817	CA010796	NM_000257.3:c.1477_1478delAT, NC_000014.9:g.23428600_23428601del, CM000676.2:g.23428600_23428601del, NC_000014.8:g.23897809_23897810del, CM000676.1:g.23897809_23897810del, NC_000014.7:g.22967649_22967650del, NG_007884.1:g.12061_12062del, LRG_384:g.12061_12062del, ENST00000355349.4:c.1477_1478del, ENST00000355349.3:c.1477_1478del, NM_000257.3:c.1477_1478del, XR_245686.3:n.1583_1584del, XM_017021340.1:c.1477_1478del, NM_000257.4:c.1477_1478del, NM_000257.4(MYH7):c.1477_1478del (p.Met493fs), NM_000257.3(MYH7):c.1477_1478delAT (p.Met493Valfs)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Uncertain Significance	PM2	PM5, PM4, PM1, PM6, BA1, PP1, PS3, BS2, BS1, BS3, BS4, BP3, PS4, PS1, PS2, BP7, BP5, PVS1	The NM_000257.3(MYH7):c.1477_1478delAT (p.Met493Valfs) variant has been identified in 1 individual with features of both HCM and DCM (Zimmerman 2010 PMID:20474083; Walsh 2017 PMID: 27532257, LMM pers. comm.) however, this is insufficient to apply the PS4 criterion. This variant was absent from large population studies (PM2; http:// gnomad.broadinstitute.org, v.2.1.1). This variant is predicted to cause a frameshift leading to a truncated or absent protein. The contribution of loss of function (LOF) variants in MYH7 to autosomal dominant inherited cardiomyopathy is incompletely understood therefore PVS1 was not applied. In summary, due to insufficient evidence, this variant meets criteria to be classified as uncertain significance for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PM2.		Cardiomyopathy VCEP		2021-11-30	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA010796/MONDO:0004994/002	8d697e74-5cec-4ffa-a116-f83b4f8fb2b8
NM_000257.3(MYH7):c.1208G>A (p.Arg403Gln)	14087	CA010365	NM_000257.3:c.1208G>A, NC_000014.9:g.23429278C>T, CM000676.2:g.23429278C>T, NC_000014.8:g.23898487C>T, CM000676.1:g.23898487C>T, NC_000014.7:g.22968327C>T, NG_007884.1:g.11384G>A, LRG_384:g.11384G>A, XR_245686.3:n.1314G>A, XM_017021340.1:c.1208G>A, NM_000257.4:c.1208G>A, ENST00000355349.3:c.1208G>A, NM_000257.3(MYH7):c.1208G>A (p.Arg403Gln)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP3, PS3, PM1, PM5, PM2, PP1_Strong, PS4		The c.1208G>A (p.Arg403Gln) variant in MYH7 has been reported in >30 individuals with hypertrophic cardiomyopathy and segregated with disease in >30 affected family members (PS4 and PP1_Strong; PMID:1638703; PMID:1975517; PMID:7789380; PMID:12975413; PMID:24268868; PMID:10725281; PMID:20800588; PMID:12707239; PMID:27532257; AGCMC Sydney ClinVar SCV000692503.1; Invitae ClinVar SCV000253815.4; Partners LMM ClinVar SCV000059359.5; SHaRe consortium, PMID: 30297972). Mouse model indicates that this variant disrupts the function of MYH7 and leads to a phenotype consistent with HCM (PS3: PMID:8614836). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.1207C>T (p.Arg403Trp) - Variation ID 14102). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS3; PS4; PP1_ Strong; PM1; PM2; PM5; PP3	8614836, 27532257, 1975517, 1638703, 12975413, 27532257, 1975517, 12707239, 20800588, 7789380, 10725281, 24268868, 1638703, 12975413	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA010365/MONDO:0005045/002	ae1c8298-2afe-4242-9a38-eea990986d41
NM_000257.3(MYH7):c.1207C>T (p.Arg403Trp)	14102	CA010360	NM_000257.3:c.1207C>T, NC_000014.9:g.23429279G>A, CM000676.2:g.23429279G>A, NC_000014.8:g.23898488G>A, CM000676.1:g.23898488G>A, NC_000014.7:g.22968328G>A, NG_007884.1:g.11383C>T, LRG_384:g.11383C>T, XR_245686.3:n.1313C>T, XM_017021340.1:c.1207C>T, NM_000257.4:c.1207C>T, ENST00000355349.3:c.1207C>T, NM_000257.3(MYH7):c.1207C>T (p.Arg403Trp)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PM1, PM5, PM2, PP3, PS4		The c.1207C>T (p.Arg403Trp) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy and segregated with disease in >20 affected family members (PS4 and PP1_Strong; PMID:1052196; PMID:7662452; PMID:7848420; PMID:8254035; PMID:8268932; PMID:12707239; PMID:12974739; PMID:15010274; PMID:15856146; PMID:17612745; PMID:20428263; PMID:21239446; PMID:26383716; Partners LMM ClinVar SCV000059358.5; AGCMC Sydney ClinVar SCV000212643.1; SHaRe consortium, PMID: 30297972). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.1208G>A p.Arg403Gln - Variation ID 14087). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_Strong; PM1; PM2; PM5; PP3	7662452, 17612745, 8254035, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA010360/MONDO:0005045/002	d065fb29-95bd-49a8-951e-f52b10fac57c
NM_000257.3(MYH7):c.1358G>A (p.Arg453His)	42838	CA010639	NM_000257.3:c.1358G>A, XR_245686.3:n.1464G>A, XM_017021340.1:c.1358G>A, NM_000257.4:c.1358G>A, ENST00000355349.3:c.1358G>A, NC_000014.9:g.23429004C>T, CM000676.2:g.23429004C>T, NC_000014.8:g.23898213C>T, CM000676.1:g.23898213C>T, NC_000014.7:g.22968053C>T, NG_007884.1:g.11658G>A, LRG_384:g.11658G>A, NM_000257.3(MYH7):c.1358G>A (p.Arg453His)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP3, PM6, PM5, PM1, PM2, PS4		The c.1358G>A (p.Arg453His) variant in MYH7 has been reported in >12 individuals with hypertrophic cardiomyopathy (PS4; PMID:27532257; PMID:20428263; PMID:15858117; PMID:20800588; PMID:21835320; PMID:22429680; Partners LMM ClinVar SCV000059369.5; Invitae ClinVar SCV000253816.4; SHaRe consortium, PMID: 30297972). This variant was been identified as a de novo occurrence in 1 proband with hypertrophic cardiomyopathy (PM6; PMID:20428263). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.1357C>T p.Arg453Cys; ClinVar Variation ID 14089). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PM5; PM6; PP3	20428263, 27532257, 22429680, 21835320, 15858117, 20800588, 20428263	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA010639/MONDO:0005045/002	0be32c2f-1227-4089-b5fe-a3fd165b61d5
NM_000257.3(MYH7):c.1157A>G (p.Tyr386Cys)	164378	CA010299	NM_000257.3:c.1157A>G, NC_000014.9:g.23429329T>C, CM000676.2:g.23429329T>C, NC_000014.8:g.23898538T>C, CM000676.1:g.23898538T>C, NC_000014.7:g.22968378T>C, NG_007884.1:g.11333A>G, LRG_384:g.11333A>G, ENST00000355349.4:c.1157A>G, ENST00000355349.3:c.1157A>G, XR_245686.3:n.1263A>G, XM_017021340.1:c.1157A>G, NM_000257.4:c.1157A>G, NM_000257.4(MYH7):c.1157A>G (p.Tyr386Cys), NM_000257.3(MYH7):c.1157A>G (p.Tyr386Cys)	MYH7	cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Pathogenic	PM2, PM1, PM6, PP3, PS4_Supporting	PM5, PS1, BP4	The NM_000257.4(MYH7):c.1157A>G (p.Tyr386Cys) variant has been reported as a de novo occurence in 2 infants with early-onset/severe cardiomyopathy that presented with variable features (1 with features of HCM and RCM, and 1 with features of HCM and LVNC that progressed to DCM; Lakdawala 2012 PMID:22464770; Greenway 2012 PMID:23170025; Alfares 2015 PMID:25611685; LMM pers. comm.) and in an additional case with RCM (age unknown; GeneDx pers. comm.). Collectively, this data meets criteria for PS4_Supporting and PM6. This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be associated with HCM (PM1; Walsh 2017 PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for complex cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_Supporting, PM6, PM2, PM1, PP3.		Cardiomyopathy VCEP		2021-11-30	2021-12-09	false	https://erepo.genome.network/evrepo/ui/classification/CA010299/MONDO:0005045/002	821dbd1d-4ca7-4f58-8a42-0ec982d8eb66
NM_000257.4(MYH7):c.1106G>A (p.Arg369Gln)	42822	CA010192	NM_000257.4:c.1106G>A, NC_000014.9:g.23429807C>T, CM000676.2:g.23429807C>T, NC_000014.8:g.23899016C>T, CM000676.1:g.23899016C>T, NC_000014.7:g.22968856C>T, NG_007884.1:g.10855G>A, LRG_384:g.10855G>A, ENST00000355349.4:c.1106G>A, ENST00000355349.3:c.1106G>A, NM_000257.3:c.1106G>A, XR_245686.3:n.1212G>A, XM_017021340.1:c.1106G>A, NM_000257.4(MYH7):c.1106G>A (p.Arg369Gln)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Likely Pathogenic	PM2, PM6, PP1, PS4	PM1, PM5, PM4, BA1, PP3, PS3, BP3, BS1, BS4, BS3, PS2, PS1, BP4, BP5, BP7, PVS1	The NM_000257.4(MYH7):c.1106G>A (p.Arg369Gln) variant has been identified in >20 individuals with DCM, including 1 individual who also had LVNC (PS4; Lakdawala 2012 PMID: 22464770; Pugh 2014 PMID:24503780; Klauke 2017 PMID: 29253866; Walsh 2017 PMID: 27532257; Horvat 2019 PMID: 29892087; Quiat 2020 PMID: 32458740; Ambry pers. comm.; Centenary Institute Sydney pers. comm.; CHEO pers. comm.; GeneDx pers. comm.; Invitae pers. comm.; LMM pers. comm.; Mayo clinic pers. comm.; OMGL pers comm.) and at least 2 individuals with assumed de novo occurrences (PM6; Lakdawala 2012 PMID: 22464770; Quiat 2020 PMID: 32458740; Klauke 2017 PMID: 29253866; LMM pers. comm.). This variant was also identified in >10 individuals with isolated LVNC, including 1 with an assumed de novo occurrence (Dellefave 2009 PMID: 20031619; Hoedemaekers 2010 PMID: 20530761; Tian 2015 PMID: 24691700; Li 2018 PMID: 30371277; Centenary Institute Sydney pers. comm.; GeneDx pers. comm.; Invitae pers. comm.; LMM pers. comm.; OMGL pers comm). This variant segregated with DCM in at least 3 affected individuals from 3 families (PP1; van der Zwaag 2011 PMID:20573160; GeneDx pers. comm.; LMM pers. comm.; OMGL pers. comm.), and with LVNC in at least 5 individuals from 4 families (Centenary Institute Sydney pers. comm.; LMM pers. comm.; OMGL pers. comm.) . This variant was absent from large population studies (PM2; http://gnomad.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and while missense variants in this region are statistically more likely to be associated with HCM (Walsh 2017 PMID:27532257), location in this region cannot be used to support pathogenicity for other phenotypes; therefore, PM1 is not applicable. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, this variant meets criteria to be classified as likely pathogenic for dilated cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4, PP1, PM6, PM2.		Cardiomyopathy VCEP		2021-12-22	2021-12-22	false	https://erepo.genome.network/evrepo/ui/classification/CA010192/MONDO:0005021/002	64ce5020-8967-4a9e-b432-5a60988016d9
NM_000257.3(MYH7):c.788T>C (p.Ile263Thr)	43106	CA016824	NM_000257.3:c.788T>C, NC_000014.9:g.23431426A>G, CM000676.2:g.23431426A>G, NC_000014.8:g.23900635A>G, CM000676.1:g.23900635A>G, NC_000014.7:g.22970475A>G, NG_007884.1:g.9236T>C, LRG_384:g.9236T>C, XR_245686.3:n.894T>C, XM_017021340.1:c.788T>C, NM_000257.4:c.788T>C, ENST00000355349.3:c.788T>C, NM_000257.3(MYH7):c.788T>C (p.Ile263Thr)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP3, PM1, PM2, PP1_Strong, PS4		The c.788T>C (p.Ile263Thr) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4: PMID:15008060; PMID:9829907; PMID:12707239; PMID:22429680; PMID:20624503; Partners LMM ClinVar SCV000059656.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in 10 affected individuals (PP1_Strong: PMID:15008060; PMID:9829907). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4, PP1_Strong, PM1, PM2, PP3	15008060, 9829907	Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA016824/MONDO:0005045/002	da0ede45-78bd-43e3-8f1f-9ac160621dc4
NM_000257.3(MYH7):c.327C>T (p.Tyr109=)	42952	CA013536	NM_000257.3:c.327C>T, XR_245686.3:n.433C>T, XM_017021340.1:c.327C>T, NM_000257.4:c.327C>T, ENST00000355349.3:c.327C>T, NC_000014.9:g.23433102G>A, CM000676.2:g.23433102G>A, NC_000014.8:g.23902311G>A, CM000676.1:g.23902311G>A, NC_000014.7:g.22972151G>A, NG_007884.1:g.7560C>T, LRG_384:g.7560C>T, NM_000257.3(MYH7):c.327C>T (p.Tyr109=)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1, BP7		The filtering allele frequency of the c.327C>T (p.Tyr109=) silent variant in the MYH7 gene is 0.13% (31/16512) of South Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1, BP7; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA013536/MONDO:0004994/002	0569b019-28db-4569-b243-bcc906486bd5
NM_000257.3(MYH7):c.428G>A (p.Arg143Gln)	43006	CA014774	NM_000257.3:c.428G>A, NC_000014.9:g.23432713C>T, CM000676.2:g.23432713C>T, NC_000014.8:g.23901922C>T, CM000676.1:g.23901922C>T, NC_000014.7:g.22971762C>T, NG_007884.1:g.7949G>A, LRG_384:g.7949G>A, XR_245686.3:n.534G>A, XM_017021340.1:c.428G>A, NM_000257.4:c.428G>A, ENST00000355349.3:c.428G>A, NM_000257.3(MYH7):c.428G>A (p.Arg143Gln)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Pathogenic	PM2, PP1, PS4		The c.428G>A (p.Arg143Gln) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:15563892; PMID:15358028; PMID:21252143; PMID:20075948; PMID:21239446; PMID:22765922; PMID:24093860; Partners LMM ClinVar SCV000059551.5). This variant segregated with disease in 4 affected individuals (PP1; Partners LMM ClinVar SCV000059551.5). This variant has been identified in 1/66732 European chromosomes (PM2; http://exac.broadinstitute.org). In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM2; PP1	22765922, 24093860, 20075948, 21239446, 15358028, 21252143, 15563892	Cardiomyopathy VCEP		2015-12-16	2018-11-16	false	https://erepo.genome.network/evrepo/ui/classification/CA014774/MONDO:0005045/002	0c17fdbf-8ecb-44db-9b84-c261d47f1dff
NM_000257.3(MYH7):c.4909G>A (p.Ala1637Thr)	43044	CA015454	NM_000257.3:c.4909G>A, ENST00000355349.4:c.4909G>A, ENST00000355349.3:c.4909G>A, NR_126491.1:n.309C>T, XM_017021340.1:c.4909G>A, NM_000257.4:c.4909G>A, NC_000014.9:g.23416048C>T, CM000676.2:g.23416048C>T, NC_000014.8:g.23885257C>T, CM000676.1:g.23885257C>T, NC_000014.7:g.22955097C>T, NG_007884.1:g.24614G>A, LRG_384:g.24614G>A, NM_000257.3(MYH7):c.4909G>A (p.Ala1637Thr)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Likely Benign	BS1, BP4	PM2, PS4	The c.4909G>A (p.Ala1637Thr) variant in MYH7 has been observed in 0.060% (FAF 95% CI; 22/24960) of African chromosomes in gnomAD v2.1.1 (http://gnomad.broadinstitute.org), which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BS1; Kelly 2018 PMID:29300372). Additionally, computational prediction tools and conservation analysis suggest that this variant may not impact the protein (BP4). In summary, this variant meets criteria to be classified as likely benign for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): BS1, BP4		Cardiomyopathy VCEP		2021-03-22	2021-08-25	false	https://erepo.genome.network/evrepo/ui/classification/CA015454/MONDO:0004994/002	ccdf0002-db7d-4fd8-989a-73c765052ee9
NM_002834.4(PTPN11):c.1221A>G (p.Gly407=)	436446	CA6798737	NM_002834.4:c.1221A>G, NM_002834.3:c.1221A>G, LRG_614t1:c.1221A>G, NM_080601.1:c.1221A>G, XM_006719526.1:c.1221A>G, XM_006719527.1:c.1107A>G, XM_011538613.1:c.1218A>G, NM_001330437.1:c.1221A>G, NM_080601.2:c.1221A>G, XM_011538613.2:c.1218A>G, XM_017019722.1:c.1218A>G, ENST00000351677.6:c.1221A>G, ENST00000392597.5:c.1221A>G, ENST00000635625.1:n.1221A>G, ENST00000635652.1:n.213A>G, NC_000012.12:g.112482202A>G, CM000674.2:g.112482202A>G, NC_000012.11:g.112920006A>G, CM000674.1:g.112920006A>G, NC_000012.10:g.111404389A>G, NG_007459.1:g.68471A>G, LRG_614:g.68471A>G, NM_002834.4(PTPN11):c.1221A>G (p.Gly407=)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1221A>G (p.Gly407=) variant in the PTPN11 gene is 0.115% (27/16510) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA6798737/MONDO:0021060/004	12ed454d-c461-49c9-bc0c-2cef4abf6af1
NM_005343.3(HRAS):c.520C>T (p.Pro174Ser)	40448	CA135994	NM_005343.3:c.520C>T, NM_001130442.1:c.520C>T, NM_005343.2:c.520C>T, NM_176795.3:c.*89C>T, XM_011519875.1:c.-425+4349G>A, XM_011519877.1:c.-162+4349G>A, XR_242795.1:n.801C>T, NM_001130442.2:c.520C>T, NM_001318054.1:c.283C>T, NM_176795.4:c.*89C>T, XM_011519875.2:c.-425+4349G>A, XM_011519877.2:c.-162+4349G>A, XM_017017167.1:c.-500+4349G>A, XM_017017168.1:c.-500+4349G>A, NM_005343.4:c.520C>T, ENST00000311189.7:c.520C>T, ENST00000397594.5:c.*89C>T, ENST00000397596.6:c.520C>T, ENST00000417302.5:c.*89C>T, ENST00000451590.5:c.520C>T, ENST00000462734.1:n.295C>T, ENST00000478324.5:n.243-56C>T, ENST00000479482.1:n.441C>T, ENST00000493230.5:c.*89C>T, NC_000011.10:g.532686G>A, CM000673.2:g.532686G>A, NC_000011.9:g.532686G>A, CM000673.1:g.532686G>A, NC_000011.8:g.522686G>A, NG_007666.1:g.7865C>T, NM_005343.3(HRAS):c.520C>T (p.Pro174Ser)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.520C>T (p.Pro174Ser) variant in the HRAS gene is 0.115% (20/11482) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135994/MONDO:0021060/004	d37c8250-6a81-4f7a-b0df-8e5eb3216e8a
NM_004333.4(BRAF):c.1068A>G (p.Gln356=)	44788	CA135028	NM_004333.4:c.1068A>G, NC_000007.14:g.140794380T>C, CM000669.2:g.140794380T>C, NC_000007.13:g.140494180T>C, CM000669.1:g.140494180T>C, NC_000007.12:g.140140649T>C, NG_007873.3:g.135385A>G, LRG_299:g.135385A>G, LRG_299t1:c.1068A>G, XM_005250045.1:c.1068A>G, XM_005250046.1:c.1068A>G, XM_011516529.1:c.1068A>G, XM_011516530.1:c.1068A>G, XR_242190.1:n.1076A>G, XR_927520.1:n.1076A>G, XR_927521.1:n.1076A>G, XR_927522.1:n.1076A>G, XR_927523.1:n.1076A>G, NM_001354609.1:c.1068A>G, NM_004333.5:c.1068A>G, NR_148928.1:n.1373A>G, XM_017012558.1:c.1068A>G, XM_017012559.1:c.1068A>G, XR_001744857.1:n.1076A>G, XR_001744858.1:n.1076A>G, ENST00000288602.10:c.1068A>G, ENST00000497784.1:n.1103A>G, NM_004333.4(BRAF):c.1068A>G (p.Gln356=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1068A>G (p.Gln356=) variant in the BRAF gene is 0.115% (27/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135028/MONDO:0021060/004	701249a7-0946-42fa-a856-c7089a0251c6
NM_002880.3(RAF1):c.1830A>G (p.Gln610=)	40627	CA134712	NM_002880.3:c.1830A>G, NC_000003.12:g.12584631T>C, CM000665.2:g.12584631T>C, NC_000003.11:g.12626130T>C, CM000665.1:g.12626130T>C, NC_000003.10:g.12601130T>C, NG_007467.1:g.84549A>G, LRG_413:g.84549A>G, LRG_413t1:c.1830A>G, XM_005265355.1:c.1830A>G, XM_005265357.1:c.1731A>G, XM_005265358.3:c.1587A>G, XM_005265359.3:c.1488A>G, XM_011533974.1:c.1830A>G, XM_011533975.1:c.1587A>G, NM_001354689.1:c.1890A>G, NM_001354690.1:c.1830A>G, NM_001354691.1:c.1587A>G, NM_001354692.1:c.1587A>G, NM_001354693.1:c.1731A>G, NM_001354694.1:c.1647A>G, NM_001354695.1:c.1488A>G, NR_148940.1:n.2358A>G, NR_148941.1:n.2304A>G, NR_148942.1:n.2243A>G, XM_011533974.3:c.1830A>G, XM_017006966.1:c.1731A>G, ENST00000251849.8:c.1830A>G, ENST00000423275.5:c.*1507A>G, ENST00000432427.2:n.1467A>G, ENST00000442415.6:c.1890A>G, ENST00000471449.1:n.519A>G, NM_002880.3(RAF1):c.1830A>G (p.Gln610=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1830A>G (p.Gln610=) variant in the RAF1 gene is 0.11% (88/66740) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134712/MONDO:0021060/004	04430f0e-93d8-4407-9ac9-c6268cb1dbba
NM_005633.3(SOS1):c.2760G>A (p.Arg920=)	40708	CA136108	NM_005633.3:c.2760G>A, LRG_754t1:c.2760G>A, XM_005264515.3:c.2760G>A, XM_011533060.1:c.2853G>A, XM_011533061.1:c.2853G>A, XM_011533062.1:c.2739G>A, XM_011533063.1:c.2736G>A, XM_011533064.1:c.2589G>A, XM_011533065.1:c.2853G>A, XM_011533066.1:c.1695G>A, XM_005264515.4:c.2760G>A, XM_011533062.2:c.2739G>A, XM_011533064.2:c.2589G>A, ENST00000395038.6:c.2760G>A, ENST00000402219.6:c.2760G>A, ENST00000426016.5:c.2760G>A, ENST00000474390.1:n.556G>A, NC_000002.12:g.39006443C>T, CM000664.2:g.39006443C>T, NC_000002.11:g.39233584C>T, CM000664.1:g.39233584C>T, NC_000002.10:g.39087088C>T, NG_007530.1:g.119021G>A, LRG_754:g.119021G>A, NM_005633.3(SOS1):c.2760G>A (p.Arg920=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2760G>A (p.Arg920=) variant in the SOS1 gene is 0.098% (79/66592) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136108/MONDO:0021060/004	9b51411c-83ed-490f-93e5-bc8292c26b66
NM_005343.3(HRAS):c.378A>G (p.Glu126=)	40442	CA135984	NM_005343.3:c.378A>G, NM_001130442.1:c.378A>G, NM_005343.2:c.378A>G, NM_176795.3:c.378A>G, XM_011519875.1:c.-424-5073T>C, XM_011519877.1:c.-162+5188T>C, XR_242795.1:n.577A>G, NM_001130442.2:c.378A>G, NM_001318054.1:c.59A>G, NM_176795.4:c.378A>G, XM_011519875.2:c.-424-5073T>C, XM_011519877.2:c.-162+5188T>C, XM_017017167.1:c.-499-4998T>C, XM_017017168.1:c.-499-4998T>C, NM_005343.4:c.378A>G, ENST00000311189.7:c.378A>G, ENST00000397594.5:c.378A>G, ENST00000397596.6:c.378A>G, ENST00000417302.5:c.378A>G, ENST00000451590.5:c.378A>G, ENST00000462734.1:n.71A>G, ENST00000478324.5:n.88A>G, ENST00000479482.1:n.299A>G, ENST00000493230.5:c.378A>G, NC_000011.10:g.533525T>C, CM000673.2:g.533525T>C, NC_000011.9:g.533525T>C, CM000673.1:g.533525T>C, NC_000011.8:g.523525T>C, NG_007666.1:g.7026A>G, NM_005343.3(HRAS):c.378A>G (p.Glu126=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.378A>G (p.Glu126=) variant in the HRAS gene is 0.095% (23/16510) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135984/MONDO:0021060/004	33df4a63-9662-4572-ab6f-22dc7b693309
NM_005343.3(HRAS):c.369C>T (p.Arg123=)	259747	CA5779327	NM_005343.3:c.369C>T, NM_001130442.1:c.369C>T, NM_005343.2:c.369C>T, NM_176795.3:c.369C>T, XM_011519875.1:c.-424-5064G>A, XM_011519877.1:c.-162+5197G>A, XR_242795.1:n.568C>T, NM_001130442.2:c.369C>T, NM_001318054.1:c.50C>T, NM_176795.4:c.369C>T, XM_011519875.2:c.-424-5064G>A, XM_011519877.2:c.-162+5197G>A, XM_017017167.1:c.-499-4989G>A, XM_017017168.1:c.-499-4989G>A, NM_005343.4:c.369C>T, ENST00000311189.7:c.369C>T, ENST00000397594.5:c.369C>T, ENST00000397596.6:c.369C>T, ENST00000417302.5:c.369C>T, ENST00000451590.5:c.369C>T, ENST00000462734.1:n.62C>T, ENST00000478324.5:n.79C>T, ENST00000479482.1:n.290C>T, ENST00000493230.5:c.369C>T, NC_000011.10:g.533534G>A, CM000673.2:g.533534G>A, NC_000011.9:g.533534G>A, CM000673.1:g.533534G>A, NC_000011.8:g.523534G>A, NG_007666.1:g.7017C>T, NM_005343.3(HRAS):c.369C>T (p.Arg123=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.369C>T (p.Arg123=) variant in the HRAS gene is 0.089% (13/8638) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5779327/MONDO:0021060/004	9e4a0dd5-6d53-4e7d-99ad-b4372dc64dd9
NM_005633.3(SOS1):c.553A>G (p.Ile185Val)	45374	CA136168	NM_005633.3:c.553A>G, LRG_754t1:c.553A>G, XM_005264515.3:c.553A>G, XM_011533060.1:c.646A>G, XM_011533061.1:c.646A>G, XM_011533062.1:c.532A>G, XM_011533063.1:c.529A>G, XM_011533064.1:c.382A>G, XM_011533065.1:c.646A>G, XM_005264515.4:c.553A>G, XM_011533062.2:c.532A>G, XM_011533064.2:c.382A>G, ENST00000395038.6:c.553A>G, ENST00000402219.6:c.553A>G, ENST00000426016.5:c.553A>G, NC_000002.12:g.39054781T>C, CM000664.2:g.39054781T>C, NC_000002.11:g.39281922T>C, CM000664.1:g.39281922T>C, NC_000002.10:g.39135426T>C, NG_007530.1:g.70683A>G, LRG_754:g.70683A>G, NM_005633.3(SOS1):c.553A>G (p.Ile185Val)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.553A>G (p.Ile185Val) variant in the SOS1 gene is 0.087% (16/11574) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136168/MONDO:0021060/004	739972d5-a90d-4c3b-95f9-cf39b58d349c
NM_030662.3(MAP2K2):c.546G>A (p.Ala182=)	138158	CA291993	NM_030662.3:c.546G>A, LRG_750t1:c.546G>A, XM_006722799.2:c.546G>A, XM_011528133.1:c.-25G>A, XM_017026989.1:c.546G>A, XM_017026990.1:c.546G>A, XM_017026991.1:c.546G>A, ENST00000262948.9:c.546G>A, ENST00000394867.8:c.255G>A, ENST00000593364.5:n.493G>A, ENST00000597008.5:n.147G>A, ENST00000597263.5:n.10G>A, ENST00000599345.1:n.816G>A, ENST00000601786.5:n.847G>A, ENST00000602167.5:n.266G>A, NC_000019.10:g.4101263C>T, CM000681.2:g.4101263C>T, NC_000019.9:g.4101261C>T, CM000681.1:g.4101261C>T, NC_000019.8:g.4052261C>T, NG_007996.1:g.27866G>A, LRG_750:g.27866G>A, NM_030662.3(MAP2K2):c.546G>A (p.Ala182=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.546G>A (p.Ala182=) variant in the MAP2K2 gene is 0.083% (7/3952) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA291993/MONDO:0021060/004	fe93cde5-6835-4a9c-b892-408f4f18d37c
NM_030662.3(MAP2K2):c.498C>T (p.Pro166=)	40802	CA137946	NM_030662.3:c.498C>T, NC_000019.10:g.4102406G>A, CM000681.2:g.4102406G>A, NC_000019.9:g.4102404G>A, CM000681.1:g.4102404G>A, NC_000019.8:g.4053404G>A, NG_007996.1:g.26723C>T, LRG_750:g.26723C>T, LRG_750t1:c.498C>T, XM_006722799.2:c.498C>T, XM_011528133.1:c.-73C>T, XM_017026989.1:c.498C>T, XM_017026990.1:c.498C>T, XM_017026991.1:c.498C>T, ENST00000262948.9:c.498C>T, ENST00000394867.8:c.207C>T, ENST00000593364.5:n.445C>T, ENST00000597008.5:n.99C>T, ENST00000599345.1:n.768C>T, ENST00000601786.5:n.799C>T, ENST00000602167.5:n.218C>T, NM_030662.3(MAP2K2):c.498C>T (p.Pro166=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.498C>T (p.Pro166=) variant in the MAP2K2 gene is 0.081% (37/33932) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137946/MONDO:0021060/004	ab66208c-6c46-46b0-9c92-4872421693de
NM_005633.3(SOS1):c.2156G>C (p.Gly719Ala)	40698	CA297202	NM_005633.3:c.2156G>C, NC_000002.12:g.39013471C>G, CM000664.2:g.39013471C>G, NC_000002.11:g.39240612C>G, CM000664.1:g.39240612C>G, NC_000002.10:g.39094116C>G, NG_007530.1:g.111993G>C, LRG_754:g.111993G>C, LRG_754t1:c.2156G>C, XM_005264515.3:c.2156G>C, XM_011533060.1:c.2249G>C, XM_011533061.1:c.2249G>C, XM_011533062.1:c.2135G>C, XM_011533063.1:c.2132G>C, XM_011533064.1:c.1985G>C, XM_011533065.1:c.2249G>C, XM_011533066.1:c.1091G>C, XM_005264515.4:c.2156G>C, XM_011533062.2:c.2135G>C, XM_011533064.2:c.1985G>C, ENST00000395038.6:c.2156G>C, ENST00000402219.6:c.2156G>C, ENST00000426016.5:c.2156G>C, NM_005633.3(SOS1):c.2156G>C (p.Gly719Ala)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.2156G>C (p.Gly719Ala) variant in the SOS1 gene is 0.0414% (37/66598) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA297202/MONDO:0021060/004	2fa3237d-09e4-4fb5-84b2-9a8bfdc4e2bc
NM_030662.3(MAP2K2):c.225C>T (p.Ile75=)	448952	CA9091075	NM_030662.3:c.225C>T, LRG_750t1:c.225C>T, XM_006722799.2:c.225C>T, XM_017026989.1:c.225C>T, XM_017026990.1:c.225C>T, XM_017026991.1:c.225C>T, ENST00000262948.9:c.225C>T, ENST00000394867.8:c.-67C>T, ENST00000599345.1:n.422C>T, NC_000019.10:g.4117497G>A, CM000681.2:g.4117497G>A, NC_000019.9:g.4117495G>A, CM000681.1:g.4117495G>A, NC_000019.8:g.4068495G>A, NG_007996.1:g.11632C>T, LRG_750:g.11632C>T, NM_030662.3(MAP2K2):c.225C>T (p.Ile75=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.225C>T (p.Ile75=) variant in the MAP2K2 gene is 0.08% (20/16508) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA9091075/MONDO:0021060/004	191bbcd7-df10-4543-9569-ef96cf4c255f
NM_007373.3(SHOC2):c.886C>T (p.Leu296=)	448934	CA5689679	NM_007373.3:c.886C>T, NC_000010.11:g.111000459C>T, CM000672.2:g.111000459C>T, NC_000010.10:g.112760217C>T, CM000672.1:g.112760217C>T, NC_000010.9:g.112750207C>T, NG_028922.1:g.85917C>T, LRG_753:g.85917C>T, NM_001269039.1:c.748C>T, LRG_753t1:c.886C>T, XM_011540216.1:c.-198C>T, NM_001269039.2:c.748C>T, NM_001324336.1:c.886C>T, NM_001324337.1:c.886C>T, NR_136749.1:n.298C>T, ENST00000265277.9:c.748C>T, ENST00000369452.8:c.886C>T, ENST00000451838.1:n.256C>T, ENST00000489390.1:n.100C>T, NM_007373.3(SHOC2):c.886C>T (p.Leu296=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.886C>T (p.Leu296=) variant in the SHOC2 gene is 0.08% (15/11572) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5689679/MONDO:0021060/004	b9bd11c9-4ef4-497e-a366-486d58683e19
NM_002834.4(PTPN11):c.526-8C>A	36709	CA134672	NM_002834.4:c.526-8C>A, NC_000012.12:g.112454556C>A, CM000674.2:g.112454556C>A, NC_000012.11:g.112892360C>A, CM000674.1:g.112892360C>A, NC_000012.10:g.111376743C>A, NG_007459.1:g.40825C>A, LRG_614:g.40825C>A, NM_002834.3:c.526-8C>A, LRG_614t1:c.526-8C>A, NM_080601.1:c.526-8C>A, XM_006719526.1:c.526-8C>A, XM_006719527.1:c.526-8C>A, XM_011538613.1:c.523-8C>A, NM_001330437.1:c.526-8C>A, NM_080601.2:c.526-8C>A, XM_011538613.2:c.523-8C>A, XM_017019722.1:c.523-8C>A, ENST00000351677.6:c.526-8C>A, ENST00000392597.5:c.526-8C>A, ENST00000530818.1:n.60-8C>A, ENST00000635625.1:n.526-8C>A, NM_002834.4(PTPN11):c.526-8C>A	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.526-8C>A variant in the PTPN11 gene is 0.079% (65/66646) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134672/MONDO:0021060/004	060519d6-25cd-463c-9fa2-709f2939aebc
NM_004333.4(BRAF):c.1332G>A (p.Arg444=)	40362	CA135067	NM_004333.4:c.1332G>A, LRG_299t1:c.1332G>A, XM_005250045.1:c.1332G>A, XM_005250046.1:c.1332G>A, XM_011516529.1:c.1332G>A, XM_011516530.1:c.1332G>A, XR_242190.1:n.1340G>A, XR_927520.1:n.1340G>A, XR_927521.1:n.1340G>A, XR_927522.1:n.1340G>A, XR_927523.1:n.1340G>A, NM_001354609.1:c.1332G>A, NM_004333.5:c.1332G>A, NR_148928.1:n.1637G>A, XM_017012558.1:c.1452G>A, XM_017012559.1:c.1452G>A, XR_001744857.1:n.1460G>A, XR_001744858.1:n.1460G>A, ENST00000288602.10:c.1332G>A, ENST00000496384.6:n.155G>A, ENST00000497784.1:n.1367G>A, NC_000007.14:g.140781676C>T, CM000669.2:g.140781676C>T, NC_000007.13:g.140481476C>T, CM000669.1:g.140481476C>T, NC_000007.12:g.140127945C>T, NG_007873.3:g.148089G>A, LRG_299:g.148089G>A, NM_004333.4(BRAF):c.1332G>A (p.Arg444=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1332G>A (p.Arg444=) variant in the BRAF gene is 0.077% (64/66708) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135067/MONDO:0021060/004	ffcded9c-7ba2-44bb-9809-17cef8005944
NM_005633.3(SOS1):c.3072C>T (p.Leu1024=)	448941	CA1624273	NM_005633.3:c.3072C>T, LRG_754t1:c.3072C>T, XM_005264515.3:c.3072C>T, XM_011533060.1:c.3165C>T, XM_011533061.1:c.3165C>T, XM_011533062.1:c.3051C>T, XM_011533063.1:c.3048C>T, XM_011533064.1:c.2901C>T, XM_011533065.1:c.3165C>T, XM_011533066.1:c.2007C>T, XM_005264515.4:c.3072C>T, XM_011533062.2:c.3051C>T, XM_011533064.2:c.2901C>T, ENST00000395038.6:c.3072C>T, ENST00000402219.6:c.3072C>T, ENST00000426016.5:c.3072C>T, NC_000002.12:g.38996931G>A, CM000664.2:g.38996931G>A, NC_000002.11:g.39224072G>A, CM000664.1:g.39224072G>A, NC_000002.10:g.39077576G>A, NG_007530.1:g.128533C>T, LRG_754:g.128533C>T, NM_005633.3(SOS1):c.3072C>T (p.Leu1024=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3072C>T (p.Leu1024=) variant in the SOS1 gene is 0.075% (19/16510) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624273/MONDO:0021060/004	8323e22b-23e0-47b4-905a-611c06a49ece
NM_002880.3(RAF1):c.1629G>A (p.Thr543=)	448927	CA2259460	NM_002880.3:c.1629G>A, LRG_413t1:c.1629G>A, XM_005265355.1:c.1629G>A, XM_005265357.1:c.1530G>A, XM_005265358.3:c.1386G>A, XM_005265359.3:c.1287G>A, XM_011533974.1:c.1629G>A, XM_011533975.1:c.1386G>A, NM_001354689.1:c.1689G>A, NM_001354690.1:c.1629G>A, NM_001354691.1:c.1386G>A, NM_001354692.1:c.1386G>A, NM_001354693.1:c.1530G>A, NM_001354694.1:c.1446G>A, NM_001354695.1:c.1287G>A, NR_148940.1:n.2157G>A, NR_148941.1:n.2103G>A, NR_148942.1:n.2042G>A, XM_011533974.3:c.1629G>A, XM_017006966.1:c.1530G>A, ENST00000251849.8:c.1629G>A, ENST00000423275.5:c.*1306G>A, ENST00000432427.2:n.1266G>A, ENST00000442415.6:c.1689G>A, ENST00000471449.1:n.318G>A, NC_000003.12:g.12585161C>T, CM000665.2:g.12585161C>T, NC_000003.11:g.12626660C>T, CM000665.1:g.12626660C>T, NC_000003.10:g.12601660C>T, NG_007467.1:g.84019G>A, LRG_413:g.84019G>A, NM_002880.3(RAF1):c.1629G>A (p.Thr543=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.438+8A>T variant in the MAP2K1 gene is 0.075% (19/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2018-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA2259460/MONDO:0021060/004	4eded74f-437b-40aa-9c2d-bfc1eb61cddc
NM_002755.3(MAP2K1):c.438+8A>T	389759	CA7623922	NM_002755.3:c.438+8A>T, LRG_725t1:c.438+8A>T, XM_011521783.1:c.372+8A>T, XM_011521783.3:c.372+8A>T, XM_017022411.2:c.438+8A>T, XM_017022412.1:c.372+8A>T, ENST00000307102.9:c.438+8A>T, ENST00000425818.2:n.949+8A>T, NC_000015.10:g.66436900A>T, CM000677.2:g.66436900A>T, NC_000015.9:g.66729238A>T, CM000677.1:g.66729238A>T, NC_000015.8:g.64516292A>T, NG_008305.1:g.55028A>T, LRG_725:g.55028A>T, NM_002755.3(MAP2K1):c.438+8A>T	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.438+8A>T variant in the MAP2K1 gene is 0.075% (19/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA7623922/MONDO:0021060/004	942afb93-4139-4b07-851a-75b2358c8128
NM_002834.4(PTPN11):c.1650G>A (p.Ala550=)	138843	CA292973	NM_002834.4:c.1650G>A, NC_000012.12:g.112502194G>A, CM000674.2:g.112502194G>A, NC_000012.11:g.112939998G>A, CM000674.1:g.112939998G>A, NC_000012.10:g.111424381G>A, NG_007459.1:g.88463G>A, LRG_614:g.88463G>A, NM_002834.3:c.1650G>A, LRG_614t1:c.1650G>A, XM_006719526.1:c.1662G>A, XM_006719527.1:c.1548G>A, XM_011538613.1:c.1659G>A, NM_001330437.1:c.1662G>A, XM_011538613.2:c.1659G>A, XM_017019722.1:c.1647G>A, ENST00000351677.6:c.1650G>A, ENST00000635625.1:n.1662G>A, NM_002834.4(PTPN11):c.1650G>A (p.Ala550=)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1650G>A (p.Ala550=) variant in the PTPN11 gene is 0.067% (13/11548) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA292973/MONDO:0021060/004	44e8200c-0983-497e-bcb9-d1d61782e537
NM_005343.3(HRAS):c.309G>A (p.Val103=)	40440	CA5779334	NM_005343.3:c.309G>A, NC_000011.10:g.533594C>T, CM000673.2:g.533594C>T, NC_000011.9:g.533594C>T, CM000673.1:g.533594C>T, NC_000011.8:g.523594C>T, NG_007666.1:g.6957G>A, NM_001130442.1:c.309G>A, NM_005343.2:c.309G>A, NM_176795.3:c.309G>A, XM_011519875.1:c.-424-5004C>T, XM_011519877.1:c.-162+5257C>T, XR_242795.1:n.508G>A, NM_001130442.2:c.309G>A, NM_001318054.1:c.-11G>A, NM_176795.4:c.309G>A, XM_011519875.2:c.-424-5004C>T, XM_011519877.2:c.-162+5257C>T, XM_017017167.1:c.-499-4929C>T, XM_017017168.1:c.-499-4929C>T, NM_005343.4:c.309G>A, ENST00000311189.7:c.309G>A, ENST00000397594.5:c.309G>A, ENST00000397596.6:c.309G>A, ENST00000417302.5:c.309G>A, ENST00000451590.5:c.309G>A, ENST00000462734.1:n.2G>A, ENST00000478324.5:n.19G>A, ENST00000479482.1:n.230G>A, ENST00000493230.5:c.309G>A, NM_005343.3(HRAS):c.309G>A (p.Val103=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.309G>A (p.Val103=) variant in the HRAS gene is 0.063% (10/8640) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5779334/MONDO:0021060/004	b7f7a482-5a60-4da9-8e99-433b8dea636b
NM_005633.3(SOS1):c.2010G>C (p.Leu670Phe)	448942	CA1624490	NM_005633.3:c.2010G>C, LRG_754t1:c.2010G>C, XM_005264515.3:c.2010G>C, XM_011533060.1:c.2103G>C, XM_011533061.1:c.2103G>C, XM_011533062.1:c.1989G>C, XM_011533063.1:c.1986G>C, XM_011533064.1:c.1839G>C, XM_011533065.1:c.2103G>C, XM_011533066.1:c.945G>C, XM_005264515.4:c.2010G>C, XM_011533062.2:c.1989G>C, XM_011533064.2:c.1839G>C, ENST00000395038.6:c.2010G>C, ENST00000402219.6:c.2010G>C, ENST00000426016.5:c.2010G>C, NC_000002.12:g.39013920C>G, CM000664.2:g.39013920C>G, NC_000002.11:g.39241061C>G, CM000664.1:g.39241061C>G, NC_000002.10:g.39094565C>G, NG_007530.1:g.111544G>C, LRG_754:g.111544G>C, NM_005633.3(SOS1):c.2010G>C (p.Leu670Phe)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2010G>C (p.Leu670Phe) variant in the SOS1 gene is 0.055% (9/8572) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624490/MONDO:0021060/004	42ea487d-ec44-44f7-a90a-ac98312de0f1
NM_005633.3(SOS1):c.698A>G (p.Asn233Ser)	197778	CA246107	NM_005633.3:c.698A>G, NC_000002.12:g.39054636T>C, CM000664.2:g.39054636T>C, NC_000002.11:g.39281777T>C, CM000664.1:g.39281777T>C, NC_000002.10:g.39135281T>C, NG_007530.1:g.70828A>G, LRG_754:g.70828A>G, LRG_754t1:c.698A>G, XM_005264515.3:c.698A>G, XM_011533060.1:c.791A>G, XM_011533061.1:c.791A>G, XM_011533062.1:c.677A>G, XM_011533063.1:c.674A>G, XM_011533064.1:c.527A>G, XM_011533065.1:c.791A>G, XM_005264515.4:c.698A>G, XM_011533062.2:c.677A>G, XM_011533064.2:c.527A>G, ENST00000395038.6:c.698A>G, ENST00000402219.6:c.698A>G, ENST00000426016.5:c.698A>G, NM_005633.3(SOS1):c.698A>G (p.Asn233Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.698A>G (p.Asn233Ser) variant in the SOS1 gene is 0.0393% (8/10108) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA246107/MONDO:0021060/004	997bfe08-d211-4276-b0cc-f38b734d1427
NM_030662.3(MAP2K2):c.141C>T (p.Asp47=)	448953	CA9091086	NM_030662.3:c.141C>T, NC_000019.10:g.4117581G>A, CM000681.2:g.4117581G>A, NC_000019.9:g.4117579G>A, CM000681.1:g.4117579G>A, NC_000019.8:g.4068579G>A, NG_007996.1:g.11548C>T, LRG_750:g.11548C>T, LRG_750t1:c.141C>T, XM_006722799.2:c.141C>T, XM_017026989.1:c.141C>T, XM_017026990.1:c.141C>T, XM_017026991.1:c.141C>T, ENST00000262948.9:c.141C>T, ENST00000394867.8:c.-151C>T, ENST00000599345.1:n.338C>T, NM_030662.3(MAP2K2):c.141C>T (p.Asp47=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.141C>T (p.Asp47=) variant in the MAP2K2 gene is 0.054% (9/8646) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA9091086/MONDO:0021060/004	39270fbb-deac-4d6c-b2ab-d39741932713
NM_004333.4(BRAF):c.375T>G (p.Ser125=)	44825	CA135125	NM_004333.4:c.375T>G, NC_000007.14:g.140834738A>C, CM000669.2:g.140834738A>C, NC_000007.13:g.140534538A>C, CM000669.1:g.140534538A>C, NC_000007.12:g.140181007A>C, NG_007873.3:g.95027T>G, LRG_299:g.95027T>G, LRG_299t1:c.375T>G, XM_005250045.1:c.375T>G, XM_005250046.1:c.375T>G, XM_011516529.1:c.375T>G, XM_011516530.1:c.375T>G, XR_242190.1:n.383T>G, XR_927520.1:n.383T>G, XR_927521.1:n.383T>G, XR_927522.1:n.383T>G, XR_927523.1:n.383T>G, NM_001354609.1:c.375T>G, NM_004333.5:c.375T>G, NR_148928.1:n.600T>G, XM_017012558.1:c.375T>G, XM_017012559.1:c.375T>G, XR_001744857.1:n.383T>G, XR_001744858.1:n.383T>G, ENST00000288602.10:c.375T>G, ENST00000469930.1:n.381T>G, ENST00000497784.1:n.330T>G, NM_004333.4(BRAF):c.375T>G (p.Ser125=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.375T>G (p.Ser125=) variant in the BRAF gene is 0.054% (9/8644) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135125/MONDO:0021060/004	0fdcd6c2-d132-4727-b944-17e200706a31
NM_007373.3(SHOC2):c.894A>C (p.Ala298=)	448935	CA5689680	NM_007373.3:c.894A>C, NC_000010.11:g.111000467A>C, CM000672.2:g.111000467A>C, NC_000010.10:g.112760225A>C, CM000672.1:g.112760225A>C, NC_000010.9:g.112750215A>C, NG_028922.1:g.85925A>C, LRG_753:g.85925A>C, NM_001269039.1:c.756A>C, LRG_753t1:c.894A>C, XM_011540216.1:c.-190A>C, NM_001269039.2:c.756A>C, NM_001324336.1:c.894A>C, NM_001324337.1:c.894A>C, NR_136749.1:n.306A>C, ENST00000265277.9:c.756A>C, ENST00000369452.8:c.894A>C, ENST00000451838.1:n.264A>C, ENST00000489390.1:n.108A>C, NM_007373.3(SHOC2):c.894A>C (p.Ala298=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.894A>C (p.Ala298=) variant in the SHOC2 gene is 0.054% (9/8648) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5689680/MONDO:0021060/004	427ef48f-bd18-4b28-9163-b6b6a922ccc8
NM_002880.3(RAF1):c.1629G>C (p.Thr543=)	40621	CA235376	NM_002880.3:c.1629G>C, LRG_413t1:c.1629G>C, XM_005265355.1:c.1629G>C, XM_005265357.1:c.1530G>C, XM_005265358.3:c.1386G>C, XM_005265359.3:c.1287G>C, XM_011533974.1:c.1629G>C, XM_011533975.1:c.1386G>C, NM_001354689.1:c.1689G>C, NM_001354690.1:c.1629G>C, NM_001354691.1:c.1386G>C, NM_001354692.1:c.1386G>C, NM_001354693.1:c.1530G>C, NM_001354694.1:c.1446G>C, NM_001354695.1:c.1287G>C, NR_148940.1:n.2157G>C, NR_148941.1:n.2103G>C, NR_148942.1:n.2042G>C, XM_011533974.3:c.1629G>C, XM_017006966.1:c.1530G>C, ENST00000251849.8:c.1629G>C, ENST00000423275.5:c.*1306G>C, ENST00000432427.2:n.1266G>C, ENST00000442415.6:c.1689G>C, ENST00000471449.1:n.318G>C, NC_000003.12:g.12585161C>G, CM000665.2:g.12585161C>G, NC_000003.11:g.12626660C>G, CM000665.1:g.12626660C>G, NC_000003.10:g.12601660C>G, NG_007467.1:g.84019G>C, LRG_413:g.84019G>C, NM_002880.3(RAF1):c.1629G>C (p.Thr543=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1629G>C (p.Thr543=) variant in the RAF1 gene is 0.054% (9/8654) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA235376/MONDO:0021060/004	72d45c95-18bf-47fe-a2fa-b6ca719e877f
NM_004333.4(BRAF):c.976A>G (p.Ile326Val)	417225	CA4516861	NM_004333.4:c.976A>G, LRG_299t1:c.976A>G, XM_005250045.1:c.976A>G, XM_005250046.1:c.976A>G, XM_011516529.1:c.976A>G, XM_011516530.1:c.976A>G, XR_242190.1:n.984A>G, XR_927520.1:n.984A>G, XR_927521.1:n.984A>G, XR_927522.1:n.984A>G, XR_927523.1:n.984A>G, NM_001354609.1:c.976A>G, NM_004333.5:c.976A>G, NR_148928.1:n.1281A>G, XM_017012558.1:c.976A>G, XM_017012559.1:c.976A>G, XR_001744857.1:n.984A>G, XR_001744858.1:n.984A>G, ENST00000288602.10:c.976A>G, ENST00000497784.1:n.1011A>G, NC_000007.14:g.140800366T>C, CM000669.2:g.140800366T>C, NC_000007.13:g.140500166T>C, CM000669.1:g.140500166T>C, NC_000007.12:g.140146635T>C, NG_007873.3:g.129399A>G, LRG_299:g.129399A>G, NM_004333.4(BRAF):c.976A>G (p.Ile326Val)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1772A>G (p.Asn591Ser) variant in the SOS1 gene is 0.054% (11/11524) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA4516861/MONDO:0021060/004	e46ee061-0859-4581-9333-f113c0784ab0
NM_005633.3(SOS1):c.1772A>G (p.Asn591Ser)	448943	CA1624554	NM_005633.3:c.1772A>G, LRG_754t1:c.1772A>G, XM_005264515.3:c.1772A>G, XM_011533060.1:c.1865A>G, XM_011533061.1:c.1865A>G, XM_011533062.1:c.1751A>G, XM_011533063.1:c.1748A>G, XM_011533064.1:c.1601A>G, XM_011533065.1:c.1865A>G, XM_011533066.1:c.707A>G, XM_005264515.4:c.1772A>G, XM_011533062.2:c.1751A>G, XM_011533064.2:c.1601A>G, ENST00000395038.6:c.1772A>G, ENST00000402219.6:c.1772A>G, ENST00000426016.5:c.1772A>G, NC_000002.12:g.39022656T>C, CM000664.2:g.39022656T>C, NC_000002.11:g.39249797T>C, CM000664.1:g.39249797T>C, NC_000002.10:g.39103301T>C, NG_007530.1:g.102808A>G, LRG_754:g.102808A>G, NM_005633.3(SOS1):c.1772A>G (p.Asn591Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1772A>G (p.Asn591Ser) variant in the SOS1 gene is 0.054% (11/11524) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624554/MONDO:0021060/004	43130945-2556-414b-8804-afafb2608a11
NM_002880.3(RAF1):c.1668+4A>G	285438	CA2259454	NM_002880.3:c.1668+4A>G, NC_000003.12:g.12585118T>C, CM000665.2:g.12585118T>C, NC_000003.11:g.12626617T>C, CM000665.1:g.12626617T>C, NC_000003.10:g.12601617T>C, NG_007467.1:g.84062A>G, LRG_413:g.84062A>G, LRG_413t1:c.1668+4A>G, XM_005265355.1:c.1668+4A>G, XM_005265357.1:c.1569+4A>G, XM_005265358.3:c.1425+4A>G, XM_005265359.3:c.1326+4A>G, XM_011533974.1:c.1668+4A>G, XM_011533975.1:c.1425+4A>G, NM_001354689.1:c.1728+4A>G, NM_001354690.1:c.1668+4A>G, NM_001354691.1:c.1425+4A>G, NM_001354692.1:c.1425+4A>G, NM_001354693.1:c.1569+4A>G, NM_001354694.1:c.1485+4A>G, NM_001354695.1:c.1326+4A>G, NR_148940.1:n.2196+4A>G, NR_148941.1:n.2142+4A>G, NR_148942.1:n.2081+4A>G, XM_011533974.3:c.1668+4A>G, XM_017006966.1:c.1569+4A>G, ENST00000251849.8:c.1668+4A>G, ENST00000423275.5:c.*1345+4A>G, ENST00000432427.2:n.1305+4A>G, ENST00000442415.6:c.1728+4A>G, ENST00000471449.1:n.357+4A>G, NM_002880.3(RAF1):c.1668+4A>G	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1668+4A>G variant in the RAF1 gene is 0.053% (11/11576) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA2259454/MONDO:0021060/004	b36ca919-43d1-4147-a163-d7613a3b1d81
NM_002880.3(RAF1):c.1587G>A (p.Ser529=)	40620	CA2259466	NM_002880.3:c.1587G>A, LRG_413t1:c.1587G>A, XM_005265355.1:c.1587G>A, XM_005265357.1:c.1488G>A, XM_005265358.3:c.1344G>A, XM_005265359.3:c.1245G>A, XM_011533974.1:c.1587G>A, XM_011533975.1:c.1344G>A, NM_001354689.1:c.1647G>A, NM_001354690.1:c.1587G>A, NM_001354691.1:c.1344G>A, NM_001354692.1:c.1344G>A, NM_001354693.1:c.1488G>A, NM_001354694.1:c.1404G>A, NM_001354695.1:c.1245G>A, NR_148940.1:n.2115G>A, NR_148941.1:n.2061G>A, NR_148942.1:n.2000G>A, XM_011533974.3:c.1587G>A, XM_017006966.1:c.1488G>A, ENST00000251849.8:c.1587G>A, ENST00000423275.5:c.*1264G>A, ENST00000432427.2:n.1224G>A, ENST00000442415.6:c.1647G>A, ENST00000471449.1:n.276G>A, NC_000003.12:g.12585203C>T, CM000665.2:g.12585203C>T, NC_000003.11:g.12626702C>T, CM000665.1:g.12626702C>T, NC_000003.10:g.12601702C>T, NG_007467.1:g.83977G>A, LRG_413:g.83977G>A, NM_002880.3(RAF1):c.1587G>A (p.Ser529=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1587G>A (p.Ser529=) variant in the RAF1 gene is 0.052% (10/10402) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA2259466/MONDO:0021060/004	ba266709-c2b5-4699-8ada-c3904f1b43ce
NM_005343.3(HRAS):c.291-6T>G	448926	CA5779338	NM_005343.3:c.291-6T>G, NC_000011.10:g.533618A>C, CM000673.2:g.533618A>C, NC_000011.9:g.533618A>C, CM000673.1:g.533618A>C, NC_000011.8:g.523618A>C, NG_007666.1:g.6933T>G, NM_001130442.1:c.291-6T>G, NM_005343.2:c.291-6T>G, NM_176795.3:c.291-6T>G, XM_011519875.1:c.-424-4980A>C, XM_011519877.1:c.-162+5281A>C, XR_242795.1:n.490-6T>G, NM_001130442.2:c.291-6T>G, NM_001318054.1:c.-29-6T>G, NM_176795.4:c.291-6T>G, XM_011519875.2:c.-424-4980A>C, XM_011519877.2:c.-162+5281A>C, XM_017017167.1:c.-499-4905A>C, XM_017017168.1:c.-499-4905A>C, NM_005343.4:c.291-6T>G, ENST00000311189.7:c.291-6T>G, ENST00000397594.5:c.291-6T>G, ENST00000397596.6:c.291-6T>G, ENST00000417302.5:c.291-6T>G, ENST00000451590.5:c.291-6T>G, ENST00000479482.1:n.212-6T>G, ENST00000493230.5:c.291-6T>G, NM_005343.3(HRAS):c.291-6T>G	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.291-6T>G variant in the HRAS gene is 0.051% (14/16510) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5779338/MONDO:0021060/004	24881ada-4882-44bc-80b5-48408f7b3e0f
NM_005633.3(SOS1):c.109A>G (p.Thr37Ala)	40641	CA136074	NM_005633.3:c.109A>G, LRG_754t1:c.109A>G, XM_005264515.3:c.109A>G, XM_011533060.1:c.202A>G, XM_011533061.1:c.202A>G, XM_011533062.1:c.88A>G, XM_011533063.1:c.85A>G, XM_011533064.1:c.-63A>G, XM_011533065.1:c.202A>G, XM_005264515.4:c.109A>G, XM_011533062.2:c.88A>G, XM_011533064.2:c.-63A>G, ENST00000395038.6:c.109A>G, ENST00000402219.6:c.109A>G, ENST00000426016.5:c.109A>G, ENST00000451331.1:c.-63A>G, NC_000002.12:g.39067732T>C, CM000664.2:g.39067732T>C, NC_000002.11:g.39294873T>C, CM000664.1:g.39294873T>C, NC_000002.10:g.39148377T>C, NG_007530.1:g.57732A>G, LRG_754:g.57732A>G, NM_005633.3(SOS1):c.109A>G (p.Thr37Ala)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP5, BS4, BP4		The c.109A>G (p.Thr37Ala) variant did not segregate with disease in affected family members (BS4; Partners LMM internal data; GTR Lab ID: 21766; ClinVar SCV000062187.5). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; Partners LMM internal data; GTR Lab ID: 21766; ClinVar SCV000062187.5). Computational prediction tools and conservation analysis suggest that the p.Thr37Ala variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS4, BP5, BP4.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136074/MONDO:0021060/004	b6f58a98-fd4f-42ec-a406-4b49d996c1dd
NM_007373.3(SHOC2):c.377C>T (p.Thr126Ile)	448932	CA5689584	NM_007373.3:c.377C>T, NC_000010.11:g.110964735C>T, CM000672.2:g.110964735C>T, NC_000010.10:g.112724493C>T, CM000672.1:g.112724493C>T, NC_000010.9:g.112714483C>T, NG_028922.1:g.50193C>T, LRG_753:g.50193C>T, NM_001269039.1:c.377C>T, LRG_753t1:c.377C>T, XM_011540216.1:c.-380-20893C>T, NM_001269039.2:c.377C>T, NM_001324336.1:c.377C>T, NM_001324337.1:c.377C>T, NR_136749.1:n.116-20893C>T, ENST00000265277.9:c.377C>T, ENST00000369452.8:c.377C>T, ENST00000489390.1:n.56-35680C>T, NM_007373.3(SHOC2):c.377C>T (p.Thr126Ile)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.377C>T (p.Thr126Ile) variant in the SHOC2 gene is 0.0384% (8/10346) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5689584/MONDO:0021060/004	d94b82b8-4e72-4968-9e10-08d187667aa6
NM_005633.3(SOS1):c.3032A>G (p.Asn1011Ser)	40716	CA136129	NM_005633.3:c.3032A>G, LRG_754t1:c.3032A>G, XM_005264515.3:c.3032A>G, XM_011533060.1:c.3125A>G, XM_011533061.1:c.3125A>G, XM_011533062.1:c.3011A>G, XM_011533063.1:c.3008A>G, XM_011533064.1:c.2861A>G, XM_011533065.1:c.3125A>G, XM_011533066.1:c.1967A>G, XM_005264515.4:c.3032A>G, XM_011533062.2:c.3011A>G, XM_011533064.2:c.2861A>G, ENST00000395038.6:c.3032A>G, ENST00000402219.6:c.3032A>G, ENST00000426016.5:c.3032A>G, NC_000002.12:g.38996971T>C, CM000664.2:g.38996971T>C, NC_000002.11:g.39224112T>C, CM000664.1:g.39224112T>C, NC_000002.10:g.39077616T>C, NG_007530.1:g.128493A>G, LRG_754:g.128493A>G, NM_005633.3(SOS1):c.3032A>G (p.Asn1011Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3032A>G (p.Asn1011Ser) variant in the SOS1 gene is 0.26% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (197/66620 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136129/MONDO:0021060/004	8c759015-333c-4286-a49f-d6ca9f266789
NM_005633.3(SOS1):c.1230G>A (p.Gln410=)	40665	CA136077	NM_005633.3:c.1230G>A, NC_000002.12:g.39023198C>T, CM000664.2:g.39023198C>T, NC_000002.11:g.39250339C>T, CM000664.1:g.39250339C>T, NC_000002.10:g.39103843C>T, NG_007530.1:g.102266G>A, LRG_754:g.102266G>A, ENST00000472480.2:n.1110G>A, ENST00000685279.1:c.-4G>A, ENST00000688043.1:n.1451G>A, ENST00000689668.1:n.1237G>A, ENST00000690679.1:c.1417G>A, ENST00000690876.1:c.1119G>A, ENST00000691229.1:c.1119G>A, ENST00000692089.1:c.1119G>A, ENST00000692620.1:c.-4G>A, ENST00000402219.8:c.1230G>A, ENST00000395038.6:c.1230G>A, ENST00000402219.6:c.1230G>A, ENST00000426016.5:c.1230G>A, ENST00000472480.1:n.74G>A, LRG_754t1:c.1230G>A, XM_005264515.3:c.1230G>A, XM_011533060.1:c.1323G>A, XM_011533061.1:c.1323G>A, XM_011533062.1:c.1209G>A, XM_011533063.1:c.1206G>A, XM_011533064.1:c.1059G>A, XM_011533065.1:c.1323G>A, XM_011533066.1:c.165G>A, XM_005264515.4:c.1230G>A, XM_011533062.2:c.1209G>A, XM_011533064.2:c.1059G>A, NM_001382394.1:c.1209G>A, NM_001382395.1:c.1230G>A, NM_005633.4:c.1230G>A, NM_005633.3(SOS1):c.1230G>A (p.Gln410=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP4, BP7, BP5	BS1, PM2, PP3	The c.1230G>A variant in the SOS1 gene is a synonymous (silent) variant (p.Gln410=) at a nucleotide that is not highly conserved and not predicted by SpliceAI to impact splicing (BP4, BP7). The filtering allele frequency in gnomAD v4.1.0 is 4.078% (2165/59926 alleles, 47 homozygotes) in the Admixed American population and therefore meets BA1. This variant has been identified in patients with an alternate molecular basis for disease (BP5; Partners LMM internal data GTR Lab ID: 21766, ClinVar SCV000062189.6). In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BP4, BP5, BP7 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA136077/MONDO:0021060/041	dcfb56fe-0b80-4c22-b9fc-d5d834b1bf38
NM_005633.3(SOS1):c.73C>T (p.Pro25Ser)	40640	CA181527	NM_005633.3:c.73C>T, LRG_754t1:c.73C>T, XM_005264515.3:c.73C>T, XM_011533062.1:c.66+4314C>T, XM_005264515.4:c.73C>T, XM_011533062.2:c.66+4314C>T, ENST00000395038.6:c.73C>T, ENST00000402219.6:c.73C>T, ENST00000426016.5:c.73C>T, ENST00000451331.1:c.-85+3809C>T, NC_000002.12:g.39120350G>A, CM000664.2:g.39120350G>A, NC_000002.11:g.39347491G>A, CM000664.1:g.39347491G>A, NC_000002.10:g.39200995G>A, NG_007530.1:g.5114C>T, LRG_754:g.5114C>T, NM_005633.3(SOS1):c.73C>T (p.Pro25Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.73C>T (p.Pro25Ser) variant in the SOS1 gene is 0.23% for African chromosomes by the Exome Aggregation Consortium (21/6116 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA181527/MONDO:0021060/004	64e8b1a2-45eb-49be-932c-fc67eb53aae9
NM_005633.3(SOS1):c.350T>G (p.Val117Gly)	45364	CA136140	NM_005633.3:c.350T>G, NC_000002.12:g.39056862A>C, CM000664.2:g.39056862A>C, NC_000002.11:g.39284003A>C, CM000664.1:g.39284003A>C, NC_000002.10:g.39137507A>C, NG_007530.1:g.68602T>G, LRG_754:g.68602T>G, LRG_754t1:c.350T>G, XM_005264515.3:c.350T>G, XM_011533060.1:c.443T>G, XM_011533061.1:c.443T>G, XM_011533062.1:c.329T>G, XM_011533063.1:c.326T>G, XM_011533064.1:c.179T>G, XM_011533065.1:c.443T>G, XM_005264515.4:c.350T>G, XM_011533062.2:c.329T>G, XM_011533064.2:c.179T>G, ENST00000395038.6:c.350T>G, ENST00000402219.6:c.350T>G, ENST00000426016.5:c.350T>G, ENST00000451331.1:c.179T>G, NM_005633.3(SOS1):c.350T>G (p.Val117Gly)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP5, BS2, PP3		The c.350T>G (p.Val117Gly) variant has been identified in a patient with clinical features of a RASopathy with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM GTR Lab ID: 26957, 21766; ClinVar SCV000062230.5, SCV000209093.5). This variant was observed in a healthy adult individual who did not have clinical features of a RASopathy (BS2; GeneDx, Partners LMM; GTR ID's: 26957, 21766; ClinVar SCV000062230.5, SCV000209093.5). Computational prediction tools and conservation analysis suggest that the p.Val117Gly variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BP5, BS2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136140/MONDO:0021060/004	35b65877-4f4e-4afc-b8ac-5e10c6c2f474
NM_005633.3(SOS1):c.2122G>A (p.Ala708Thr)	40697	CA136094	NM_005633.3:c.2122G>A, LRG_754t1:c.2122G>A, XM_005264515.3:c.2122G>A, XM_011533060.1:c.2215G>A, XM_011533061.1:c.2215G>A, XM_011533062.1:c.2101G>A, XM_011533063.1:c.2098G>A, XM_011533064.1:c.1951G>A, XM_011533065.1:c.2215G>A, XM_011533066.1:c.1057G>A, XM_005264515.4:c.2122G>A, XM_011533062.2:c.2101G>A, XM_011533064.2:c.1951G>A, ENST00000395038.6:c.2122G>A, ENST00000402219.6:c.2122G>A, ENST00000426016.5:c.2122G>A, NC_000002.12:g.39013505C>T, CM000664.2:g.39013505C>T, NC_000002.11:g.39240646C>T, CM000664.1:g.39240646C>T, NC_000002.10:g.39094150C>T, NG_007530.1:g.111959G>A, LRG_754:g.111959G>A, NM_005633.3(SOS1):c.2122G>A (p.Ala708Thr)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2122G>A (p.Ala708Thr) variant in the SOS1 gene is 5.13% for Latino chromosomes by the Exome Aggregation Consortium (633/11554 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136094/MONDO:0021060/004	0fc9c039-08e1-4b28-8161-1cb12bd63b04
NM_005633.3(SOS1):c.2371C>A (p.Leu791Ile)	40702	CA136098	NM_005633.3:c.2371C>A, NC_000002.12:g.39012145G>T, CM000664.2:g.39012145G>T, NC_000002.11:g.39239286G>T, CM000664.1:g.39239286G>T, NC_000002.10:g.39092790G>T, NG_007530.1:g.113319C>A, LRG_754:g.113319C>A, LRG_754t1:c.2371C>A, XM_005264515.3:c.2371C>A, XM_011533060.1:c.2464C>A, XM_011533061.1:c.2464C>A, XM_011533062.1:c.2350C>A, XM_011533063.1:c.2347C>A, XM_011533064.1:c.2200C>A, XM_011533065.1:c.2464C>A, XM_011533066.1:c.1306C>A, XM_005264515.4:c.2371C>A, XM_011533062.2:c.2350C>A, XM_011533064.2:c.2200C>A, ENST00000395038.6:c.2371C>A, ENST00000402219.6:c.2371C>A, ENST00000426016.5:c.2371C>A, NM_005633.3(SOS1):c.2371C>A (p.Leu791Ile)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2371C>A (p.Leu791Ile) variant in the SOS1 gene is 0.081% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (67/66688 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136098/MONDO:0021060/004	5cdf91d2-4341-4b5c-9657-3a3132543f1a
NM_005633.3(SOS1):c.749T>C (p.Val250Ala)	40660	CA136183	NM_005633.3:c.749T>C, LRG_754t1:c.749T>C, XM_005264515.3:c.749T>C, XM_011533060.1:c.842T>C, XM_011533061.1:c.842T>C, XM_011533062.1:c.728T>C, XM_011533063.1:c.725T>C, XM_011533064.1:c.578T>C, XM_011533065.1:c.842T>C, XM_005264515.4:c.749T>C, XM_011533062.2:c.728T>C, XM_011533064.2:c.578T>C, ENST00000395038.6:c.749T>C, ENST00000402219.6:c.749T>C, ENST00000426016.5:c.749T>C, ENST00000461545.1:n.99T>C, NC_000002.12:g.39051259A>G, CM000664.2:g.39051259A>G, NC_000002.11:g.39278400A>G, CM000664.1:g.39278400A>G, NC_000002.10:g.39131904A>G, NG_007530.1:g.74205T>C, LRG_754:g.74205T>C, NM_005633.3(SOS1):c.749T>C (p.Val250Ala)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.749T>C (p.Val250Ala) variant in the SOS1 gene is 0.089% for African chromosomes by the Exome Aggregation Consortium (15/10392 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136183/MONDO:0021060/004	b29f4adc-7b22-4d66-89e7-1538798f3f2a
NM_005633.3(SOS1):c.322G>A (p.Glu108Lys)	40649	CA261739	NM_005633.3:c.322G>A, LRG_754t1:c.322G>A, XM_005264515.3:c.322G>A, XM_011533060.1:c.415G>A, XM_011533061.1:c.415G>A, XM_011533062.1:c.301G>A, XM_011533063.1:c.298G>A, XM_011533064.1:c.151G>A, XM_011533065.1:c.415G>A, XM_005264515.4:c.322G>A, XM_011533062.2:c.301G>A, XM_011533064.2:c.151G>A, ENST00000395038.6:c.322G>A, ENST00000402219.6:c.322G>A, ENST00000426016.5:c.322G>A, ENST00000451331.1:c.151G>A, NC_000002.12:g.39058696C>T, CM000664.2:g.39058696C>T, NC_000002.11:g.39285837C>T, CM000664.1:g.39285837C>T, NC_000002.10:g.39139341C>T, NG_007530.1:g.66768G>A, LRG_754:g.66768G>A, NM_005633.3(SOS1):c.322G>A (p.Glu108Lys)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PS2, PS4_Moderate, PM2, PM6, PP2		The c.322G>A (p.Glu108Lys) variant in SOS1 has been reported as confirmed and unconfirmed occurrences in patients with clinical features of a RASopathy (PM6 and PS2; GeneDx, Partners LMM, APHP-Robert DebrÃ© Hospital internal data GTR Lab ID: 26957, 21766, 28338; ClinVar SCV000209088.9, SCV000062224.5, SCV000659144.2). The p.Glu108Lys variant has been identified in several independent occurrences in patients with clinical features of a RASopathy (PS4_Moderate; GeneDx, Partners LMM, APHP-Robert DebrÃ© Hospital internal data GTR Lab ID: 26957, 21766, 28338; ClinVar SCV000209088.9, SCV000062224.5, SCV000659144.2; PMID: 17143282; 23487764). In vitro functional studies provide some evidence that the p.Glu108Lys variant may impact protein function (PS3; PMID: 17143282, 23487764). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS3, PM6, PS4_Moderate, PM2, PP2.	17143282, 23487764, 17143282, 23487764	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA261739/MONDO:0018997/004	31e0095f-919b-4660-81cd-4f5bf83b5bcb
NM_007373.3(SHOC2):c.519G>A (p.Met173Ile)	181528	CA199174	NM_007373.3:c.519G>A, NC_000010.11:g.110964877G>A, CM000672.2:g.110964877G>A, NC_000010.10:g.112724635G>A, CM000672.1:g.112724635G>A, NC_000010.9:g.112714625G>A, NG_028922.1:g.50335G>A, LRG_753:g.50335G>A, ENST00000265277.10:c.519G>A, ENST00000451838.2:c.-242-35538G>A, ENST00000480155.2:n.755G>A, ENST00000685059.1:c.519G>A, ENST00000685613.1:c.519G>A, ENST00000687592.1:n.818G>A, ENST00000688928.1:c.519G>A, ENST00000689118.1:c.519G>A, ENST00000689300.1:c.519G>A, ENST00000689997.1:c.-380-20751G>A, ENST00000691151.1:n.811G>A, ENST00000691369.1:c.519G>A, ENST00000691441.1:c.519G>A, ENST00000691903.1:c.519G>A, ENST00000692776.1:c.519G>A, ENST00000369452.9:c.519G>A, ENST00000265277.9:c.519G>A, ENST00000369452.8:c.519G>A, ENST00000451838.1:c.27G>A, ENST00000489390.1:n.56-35538G>A, NM_001269039.1:c.519G>A, LRG_753t1:c.519G>A, XM_011540216.1:c.-380-20751G>A, NM_001269039.2:c.519G>A, NM_001324336.1:c.519G>A, NM_001324337.1:c.519G>A, NR_136749.1:n.116-20751G>A, NM_007373.4:c.519G>A, NM_001269039.3:c.519G>A, NM_001324336.2:c.519G>A, NM_001324337.2:c.519G>A, NR_136749.2:n.55-20751G>A, NM_007373.3(SHOC2):c.519G>A (p.Met173Ile)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PP3, PM2_Supporting, PS4	BS1, BP4, BA1, PS3	The c.519G>A variant in the SHOC2 gene is a missense variant predicted to cause substitution of methionine by isoleucine at amino acid 173 (p.Met173Ile). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives a score of 0.768 (PP3). This variant has been identified as a de novo occurrence with confirmed parental relationships in 3 individuals and  with unconfirmed parental relationships in 1 individual with RASopathy (PS2_VeryStrong; Invitae, GeneDx, Ambry, Genomic Medicine Lab; ClinVar SCV001573982.4, SCV000209055.14, SCV002641556.1, SCV001573024.1). This variant has been reported in more than 5 probands diagnosed with RASopathy (PS4; PMIDs: 25137548, 29907801; Invitae, GeneDx, UCSF Genomic Medicine Lab, LabCorp, Ambry; ClinVar SCV001573982.4, SCV000209055.14, SCV001573024.1, SCV000699327.2, SCV002641556.1). ERK phosphorylation assays showed that this variant decreases the ability of SHOC2 to accelerate ERK1/2 phosphorylation (PS3 not met, PMID: 25137548). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2_VeryStrong, PS4, PM2_Supporting, PP3 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA199174/MONDO:0021060/038	6b6330b2-05be-48be-a7e9-3e8e77d8e63b
NM_007373.3(SHOC2):c.10A>C (p.Ser4Arg)	40635	CA136657	NM_007373.3:c.10A>C, NC_000010.11:g.110964368A>C, CM000672.2:g.110964368A>C, NC_000010.10:g.112724126A>C, CM000672.1:g.112724126A>C, NC_000010.9:g.112714116A>C, NG_028922.1:g.49826A>C, LRG_753:g.49826A>C, ENST00000265277.10:c.10A>C, ENST00000451838.2:c.-242-36047A>C, ENST00000480155.2:n.246A>C, ENST00000685059.1:c.10A>C, ENST00000685613.1:c.10A>C, ENST00000687592.1:n.309A>C, ENST00000688928.1:c.10A>C, ENST00000689118.1:c.10A>C, ENST00000689300.1:c.10A>C, ENST00000689997.1:c.-380-21260A>C, ENST00000691151.1:n.302A>C, ENST00000691369.1:c.10A>C, ENST00000691441.1:c.10A>C, ENST00000691903.1:c.10A>C, ENST00000692776.1:c.10A>C, ENST00000369452.9:c.10A>C, ENST00000265277.9:c.10A>C, ENST00000369452.8:c.10A>C, ENST00000480155.1:n.494A>C, ENST00000489390.1:n.56-36047A>C, ENST00000489783.1:n.388A>C, NM_001269039.1:c.10A>C, LRG_753t1:c.10A>C, XM_011540216.1:c.-380-21260A>C, NM_001269039.2:c.10A>C, NM_001324336.1:c.10A>C, NM_001324337.1:c.10A>C, NR_136749.1:n.116-21260A>C, NM_007373.4:c.10A>C, NM_001269039.3:c.10A>C, NM_001324336.2:c.10A>C, NM_001324337.2:c.10A>C, NR_136749.2:n.55-21260A>C, NM_007373.3(SHOC2):c.10A>C (p.Ser4Arg)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP5, BA1, BP4	BS1, PM2, PP3, BP2	The c.10A>C variant in the SHOC2 gene is a missense variant predicted to cause substitution of serine by arginine at amino acid 4 (p.Ser4Arg). The highest filtering allele frequency in gnomAD v4.1.0 is 0.2286% (124/59742 alleles) in the Admixed American population and therefore meets this criterion (BA1). The computational predictor tool REVEL gives a score of 0.113 and does not predict a damaging effect on SHOC2 function (BP4). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM GTR Lab ID: 26957, 21766 internal data; ClinVar SCV000209046.7, SCV000062455.5). In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BP4, BP5 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA136657/MONDO:0021060/038	f8ec95a4-b09f-4a17-984e-06b4098449c2
NM_007373.3(SHOC2):c.363G>A (p.Glu121=)	448931	CA5689580	NM_007373.3:c.363G>A, NC_000010.11:g.110964721G>A, CM000672.2:g.110964721G>A, NC_000010.10:g.112724479G>A, CM000672.1:g.112724479G>A, NC_000010.9:g.112714469G>A, NG_028922.1:g.50179G>A, LRG_753:g.50179G>A, NM_001269039.1:c.363G>A, LRG_753t1:c.363G>A, XM_011540216.1:c.-380-20907G>A, NM_001269039.2:c.363G>A, NM_001324336.1:c.363G>A, NM_001324337.1:c.363G>A, NR_136749.1:n.116-20907G>A, ENST00000265277.9:c.363G>A, ENST00000369452.8:c.363G>A, ENST00000489390.1:n.56-35694G>A, ENST00000489783.1:n.741G>A, NM_007373.3(SHOC2):c.363G>A (p.Glu121=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.363G>A (p.Glu121=) variant in the SHOC2 gene is 0.0384% (8/10350) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5689580/MONDO:0021060/004	868dd09f-5604-4c92-83c0-bf8fa7edd5f2
NM_007373.3(SHOC2):c.1302C>T (p.Asn434=)	139108	CA293482	NM_007373.3:c.1302C>T, NC_000010.11:g.111009265C>T, CM000672.2:g.111009265C>T, NC_000010.10:g.112769023C>T, CM000672.1:g.112769023C>T, NC_000010.9:g.112759013C>T, NG_028922.1:g.94723C>T, LRG_753:g.94723C>T, NM_001269039.1:c.1164C>T, LRG_753t1:c.1302C>T, XM_011540216.1:c.219C>T, NM_001269039.2:c.1164C>T, NM_001324336.1:c.1302C>T, NM_001324337.1:c.1302C>T, NR_136749.1:n.714C>T, ENST00000265277.9:c.1164C>T, ENST00000369452.8:c.1302C>T, ENST00000451838.1:n.672C>T, ENST00000489390.1:n.516C>T, NM_007373.3(SHOC2):c.1302C>T (p.Asn434=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP5, BP7, BP4, BA1	BP2	The c.1302C>T (p.Asn434=) variant in the SHOC2 gene has been identified in a patient with an alternate molecular basis for disease (BP5; ClinVar SCV000171633.12). The silent p.Asn434= variant is not predicted by MaxEntScan to impact splicing (BP7, BP4).The filtering allele frequency of the c.1302C>T (p.Asn434=) variant is 0.74% for African chromosomes by the Exome Aggregation Consortium (87/9772 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BP5, BP4, BP7.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA293482/MONDO:0021060/004	ba4e5908-3b34-42d0-8df7-f0b029ff11e2
NM_007373.3(SHOC2):c.38A>C (p.Glu13Ala)	181526	CA297169	NM_007373.3:c.38A>C, NC_000010.11:g.110964396A>C, CM000672.2:g.110964396A>C, NC_000010.10:g.112724154A>C, CM000672.1:g.112724154A>C, NC_000010.9:g.112714144A>C, NG_028922.1:g.49854A>C, LRG_753:g.49854A>C, NM_001269039.1:c.38A>C, LRG_753t1:c.38A>C, XM_011540216.1:c.-380-21232A>C, NM_001269039.2:c.38A>C, NM_001324336.1:c.38A>C, NM_001324337.1:c.38A>C, NR_136749.1:n.116-21232A>C, ENST00000265277.9:c.38A>C, ENST00000369452.8:c.38A>C, ENST00000480155.1:n.522A>C, ENST00000489390.1:n.56-36019A>C, ENST00000489783.1:n.416A>C, NM_007373.3(SHOC2):c.38A>C (p.Glu13Ala)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1	BA1	The filtering allele frequency of the c.38A>C (p.Glu13Ala) variant in the SHOC2 gene is 0.0484% (10/11206) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA297169/MONDO:0021060/004	f83b1020-86c7-4755-94be-9a1eabb874c4
NM_007373.3(SHOC2):c.-1C>T	40634	CA223027	NM_007373.3:c.-1C>T, NC_000010.11:g.110964358C>T, CM000672.2:g.110964358C>T, NC_000010.10:g.112724116C>T, CM000672.1:g.112724116C>T, NC_000010.9:g.112714106C>T, NG_028922.1:g.49816C>T, LRG_753:g.49816C>T, ENST00000265277.10:c.-1C>T, ENST00000451838.2:c.-242-36057C>T, ENST00000480155.2:n.236C>T, ENST00000685059.1:c.-1C>T, ENST00000685613.1:c.-1C>T, ENST00000687592.1:n.299C>T, ENST00000688928.1:c.-1C>T, ENST00000689118.1:c.-1C>T, ENST00000689300.1:c.-1C>T, ENST00000689997.1:c.-380-21270C>T, ENST00000691151.1:n.292C>T, ENST00000691369.1:c.-1C>T, ENST00000691441.1:c.-1C>T, ENST00000691903.1:c.-1C>T, ENST00000692776.1:c.-1C>T, ENST00000369452.9:c.-1C>T, ENST00000265277.9:c.-1C>T, ENST00000369452.8:c.-1C>T, ENST00000480155.1:n.484C>T, ENST00000489390.1:n.56-36057C>T, ENST00000489783.1:n.378C>T, NM_001269039.1:c.-1C>T, LRG_753t1:c.-1C>T, XM_011540216.1:c.-380-21270C>T, NM_001269039.2:c.-1C>T, NM_001324336.1:c.-1C>T, NM_001324337.1:c.-1C>T, NR_136749.1:n.116-21270C>T, NM_007373.4:c.-1C>T, NM_001269039.3:c.-1C>T, NM_001324336.2:c.-1C>T, NM_001324337.2:c.-1C>T, NR_136749.2:n.55-21270C>T, NM_007373.3(SHOC2):c.-1C>T	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance		BS1, PM2, PP2, PP3, BP4, BA1, PS4	The c.-1C>T variant in the SHOC2 gene is an intronic variant located in the 5' UTR, 1 base upstream from the first translated codon. The highest population minor allele frequency in gnomAD v4.1.0 is 0.01172% (7/59740 alleles) in the Latino/Admixed American population. (PM2_Supporting/BS1/BA1 are not met). This variant has been identified in 2 independent occurrences in patients with a clinical features of a RASopathy (PS4 not met; GeneDx, EGL internal data GTR Lab ID's: 26957, 500060; ClinVar SCV000209050.9, SCV000113449.7). In summary, this variant meets criteria to be classified as variant of uncertain significance for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: None (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA223027/MONDO:0021060/038	7390e608-04b8-42c9-b7d9-27c20be71622
NM_007373.3(SHOC2):c.4A>G (p.Ser2Gly)	6821	CA118524	NM_007373.3:c.4A>G, NC_000010.11:g.110964362A>G, CM000672.2:g.110964362A>G, NC_000010.10:g.112724120A>G, CM000672.1:g.112724120A>G, NC_000010.9:g.112714110A>G, NG_028922.1:g.49820A>G, LRG_753:g.49820A>G, NM_001269039.1:c.4A>G, LRG_753t1:c.4A>G, XM_011540216.1:c.-380-21266A>G, NM_001269039.2:c.4A>G, NM_001324336.1:c.4A>G, NM_001324337.1:c.4A>G, NR_136749.1:n.116-21266A>G, ENST00000265277.9:c.4A>G, ENST00000369452.8:c.4A>G, ENST00000480155.1:n.488A>G, ENST00000489390.1:n.56-36053A>G, ENST00000489783.1:n.382A>G, NM_007373.3(SHOC2):c.4A>G (p.Ser2Gly)	SHOC2	Noonan syndrome-like disorder with loose anagen hair 1	MONDO:0054637	Autosomal dominant inheritance	Pathogenic	PS4, PS3, PM2, PS2_Very Strong, PP2		The c.4A>G (p.Ser2Gly) variant in SHOC2 has been reported as a confirmed de novo occurrence in multiple patients with clinical features of a RASopathy (PS2_VeryStrong; Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg, APHP-Robert DebrÃ© Hospital internal data; GTR ID's: 21766, 506381, 28338; ClinVar SCV000062456.5, SCV000209051.10, SCV000263045.1 PMID 19684605, 21548061, 23918763, 22528146). The p.Ser2Gly variant has been identified in at least 5 independent occurrences in patients with clinical features of a RASopathy (PS4; Institute of Human Genetics, Otto von Guericke University Magdeburg, APHP-Robert DebrÃ© Hospital internal data GTR ID's: 506381, 28338; PMID: 25563136, 24458587). In vitro functional studies provide some evidence that the p.Ser2Gly variant may impact protein function (PS3; PMID: 19684605). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SHOC2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS3, PS4, PM2, PP2.	25563136, 24458587, 19684605, 22528146, 23918763, 19684605, 21548061	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA118524/MONDO:0054637/004	39b0e509-abdb-415d-87bd-98b7310bb1c0
NM_002880.4(RAF1):c.1108+9_1108+21del	178666	CA182757	NM_002880.4:c.1108+9_1108+21del, NC_000003.12:g.12599673_12599685del, CM000665.2:g.12599673_12599685del, NC_000003.11:g.12641172_12641184del, CM000665.1:g.12641172_12641184del, NC_000003.10:g.12616172_12616184del, NG_007467.1:g.69498_69510del, LRG_413:g.69498_69510del, ENST00000423275.6:c.*773+9_*773+21del, ENST00000432427.3:c.428+9_428+21del, ENST00000465826.6:n.699+9_699+21del, ENST00000491290.2:n.1485+9_1485+21del, ENST00000684903.1:c.*785+9_*785+21del, ENST00000685348.1:c.*785+9_*785+21del, ENST00000685437.1:c.1009+9_1009+21del, ENST00000685653.1:c.1108+9_1108+21del, ENST00000685738.1:c.1108+9_1108+21del, ENST00000686409.1:n.2159+9_2159+21del, ENST00000686455.1:n.1471+9_1471+21del, ENST00000686479.1:n.1488_1500del, ENST00000686762.1:c.1108+9_1108+21del, ENST00000687257.1:n.1344+9_1344+21del, ENST00000687326.1:c.1108+9_1108+21del, ENST00000687486.1:c.300+9_300+21del, ENST00000687505.1:n.1226+9_1226+21del, ENST00000687923.1:c.997+21_997+33del, ENST00000687940.1:n.1485+9_1485+21del, ENST00000688269.1:n.1704+9_1704+21del, ENST00000688326.1:c.428+9_428+21del, ENST00000688444.1:n.1434+9_1434+21del, ENST00000688543.1:c.1009+9_1009+21del, ENST00000688625.1:c.*686+9_*686+21del, ENST00000688803.1:n.1339+9_1339+21del, ENST00000688914.1:n.94+9_94+21del, ENST00000689097.1:c.*785+9_*785+21del, ENST00000689389.1:c.1108+9_1108+21del, ENST00000689418.1:c.*785+9_*785+21del, ENST00000689481.1:c.*785+9_*785+21del, ENST00000689540.1:n.1258+9_1258+21del, ENST00000689876.1:c.1108+9_1108+21del, ENST00000689914.1:c.1108+9_1108+21del, ENST00000690397.1:c.997+9_997+21del, ENST00000690460.1:c.1096+9_1096+21del, ENST00000690625.1:n.1411+9_1411+21del, ENST00000691396.1:c.*901+9_*901+21del, ENST00000691724.1:c.*65+9_*65+21del, ENST00000691779.1:c.*686+9_*686+21del, ENST00000691899.1:c.1108+9_1108+21del, ENST00000692069.1:n.1674+9_1674+21del, ENST00000692093.1:c.1009+9_1009+21del, ENST00000692311.1:n.1932+9_1932+21del, ENST00000692558.1:n.1473+9_1473+21del, ENST00000692773.1:c.*845+9_*845+21del, ENST00000692830.1:c.*853+9_*853+21del, ENST00000693069.1:c.1009+9_1009+21del, ENST00000693312.1:c.883+9_883+21del, ENST00000693664.1:c.1108+9_1108+21del, ENST00000693705.1:c.*785+9_*785+21del, ENST00000251849.9:c.1108+9_1108+21del, ENST00000442415.7:c.1168+9_1168+21del, ENST00000251849.8:c.1108+9_1108+21del, ENST00000423275.5:c.*785+9_*785+21del, ENST00000432427.2:c.745+9_745+21del, ENST00000442415.6:c.1168+9_1168+21del, ENST00000460610.1:n.65+9_65+21del, ENST00000465826.5:n.352+9_352+21del, NM_002880.3:c.1108+9_1108+21del, LRG_413t1:c.1108+9_1108+21del, XM_005265355.1:c.1108+9_1108+21del, XM_005265357.1:c.1009+9_1009+21del, XM_005265358.3:c.865+9_865+21del, XM_005265359.3:c.766+9_766+21del, XM_005265360.1:c.1108+9_1108+21del, XM_011533974.1:c.1108+9_1108+21del, XM_011533975.1:c.865+9_865+21del, NM_001354689.1:c.1168+9_1168+21del, NM_001354690.1:c.1108+9_1108+21del, NM_001354691.1:c.865+9_865+21del, NM_001354692.1:c.865+9_865+21del, NM_001354693.1:c.1009+9_1009+21del, NM_001354694.1:c.925+9_925+21del, NM_001354695.1:c.766+9_766+21del, NR_148940.1:n.1523+9_1523+21del, NR_148941.1:n.1523+9_1523+21del, NR_148942.1:n.1521+9_1521+21del, XM_011533974.3:c.1108+9_1108+21del, XM_017006966.1:c.1009+9_1009+21del, XR_001740227.1:n.1340+9_1340+21del, NM_001354689.3:c.1168+9_1168+21del, NM_001354690.2:c.1108+9_1108+21del, NM_001354691.2:c.865+9_865+21del, NM_001354692.2:c.865+9_865+21del, NM_001354693.2:c.1009+9_1009+21del, NM_001354694.2:c.925+9_925+21del, NM_001354695.2:c.766+9_766+21del, NR_148940.2:n.1439+9_1439+21del, NR_148941.2:n.1439+9_1439+21del, NR_148942.2:n.1437+9_1437+21del, NM_001354690.3:c.1108+9_1108+21del, NM_001354691.3:c.865+9_865+21del, NM_001354692.3:c.865+9_865+21del, NM_001354693.3:c.1009+9_1009+21del, NM_001354694.3:c.925+9_925+21del, NM_001354695.3:c.766+9_766+21del, NR_148940.3:n.1439+9_1439+21del, NR_148941.3:n.1439+9_1439+21del, NR_148942.3:n.1437+9_1437+21del, NM_002880.4(RAF1):c.1108+9_1108+21del	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP7, BP5		The c.1108+9_1108+21del variant is located in intron 10 of the RAF1 gene. This variant has a filtering allele frequency of 0.05951% in the European (non-Finnish) population in gnomAD v2, which is higher than the ClinGen RASopathy VCEP threshold (>0.0005) for BA1 and therefore meets this criterion (BA1). The variant is a synonymous (silent) variant at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP7). Additionally, this variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM internal data; GTR Lab ID's: 26957, 21766; ClinVar SCV000205113.4, SCV000209007.2).  In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BP5, BP7. (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-25	false	https://erepo.genome.network/evrepo/ui/classification/CA182757/MONDO:0021060/040	e3caac03-d88a-45f8-bcde-e41975fe8745
NM_002880.4(RAF1):c.775T>A (p.Ser259Thr)	40601	CA261617	NM_002880.4:c.775T>A, NC_000003.12:g.12604195A>T, CM000665.2:g.12604195A>T, NC_000003.11:g.12645694A>T, CM000665.1:g.12645694A>T, NC_000003.10:g.12620694A>T, NG_007467.1:g.64985T>A, LRG_413:g.64985T>A, ENST00000416093.2:c.*452T>A, ENST00000423275.6:c.*452T>A, ENST00000432427.3:c.95T>A, ENST00000465826.6:n.366T>A, ENST00000491290.2:n.1152T>A, ENST00000684903.1:c.*452T>A, ENST00000685348.1:c.*452T>A, ENST00000685437.1:c.676T>A, ENST00000685653.1:c.775T>A, ENST00000685738.1:c.775T>A, ENST00000685959.1:c.775T>A, ENST00000686409.1:n.1375T>A, ENST00000686455.1:n.1138T>A, ENST00000686479.1:n.1146T>A, ENST00000686762.1:c.775T>A, ENST00000687257.1:n.1011T>A, ENST00000687326.1:c.775T>A, ENST00000687486.1:c.95T>A, ENST00000687505.1:n.893T>A, ENST00000687923.1:c.676T>A, ENST00000687940.1:n.1152T>A, ENST00000688269.1:n.1383T>A, ENST00000688326.1:c.95T>A, ENST00000688444.1:n.1101T>A, ENST00000688543.1:c.676T>A, ENST00000688625.1:c.*353T>A, ENST00000688803.1:n.1006T>A, ENST00000689033.1:c.775T>A, ENST00000689097.1:c.*452T>A, ENST00000689389.1:c.775T>A, ENST00000689418.1:c.*452T>A, ENST00000689481.1:c.*452T>A, ENST00000689540.1:n.925T>A, ENST00000689876.1:c.775T>A, ENST00000689914.1:c.775T>A, ENST00000690397.1:c.676T>A, ENST00000690460.1:c.775T>A, ENST00000690625.1:n.1078T>A, ENST00000691268.1:c.262-3780T>A, ENST00000691396.1:c.*568T>A, ENST00000691724.1:c.775T>A, ENST00000691779.1:c.*353T>A, ENST00000691899.1:c.775T>A, ENST00000692093.1:c.676T>A, ENST00000692311.1:n.1148T>A, ENST00000692558.1:n.1140T>A, ENST00000692773.1:c.*452T>A, ENST00000692830.1:c.*520T>A, ENST00000693069.1:c.676T>A, ENST00000693312.1:c.550T>A, ENST00000693664.1:c.775T>A, ENST00000693705.1:c.*452T>A, ENST00000251849.9:c.775T>A, ENST00000442415.7:c.775T>A, ENST00000251849.8:c.775T>A, ENST00000416093.1:c.*353T>A, ENST00000423275.5:c.*452T>A, ENST00000432427.2:c.412T>A, ENST00000442415.6:c.775T>A, ENST00000465826.5:n.19T>A, ENST00000491290.1:n.296T>A, NM_002880.3:c.775T>A, LRG_413t1:c.775T>A, XM_005265355.1:c.775T>A, XM_005265357.1:c.676T>A, XM_005265358.3:c.532T>A, XM_005265359.3:c.433T>A, XM_005265360.1:c.775T>A, XM_011533974.1:c.775T>A, XM_011533975.1:c.532T>A, NM_001354689.1:c.775T>A, NM_001354690.1:c.775T>A, NM_001354691.1:c.532T>A, NM_001354692.1:c.532T>A, NM_001354693.1:c.676T>A, NM_001354694.1:c.532T>A, NM_001354695.1:c.433T>A, NR_148940.1:n.1190T>A, NR_148941.1:n.1190T>A, NR_148942.1:n.1190T>A, XM_011533974.3:c.775T>A, XM_017006966.1:c.676T>A, XR_001740227.1:n.1007T>A, NM_001354689.3:c.775T>A, NM_001354690.2:c.775T>A, NM_001354691.2:c.532T>A, NM_001354692.2:c.532T>A, NM_001354693.2:c.676T>A, NM_001354694.2:c.532T>A, NM_001354695.2:c.433T>A, NR_148940.2:n.1106T>A, NR_148941.2:n.1106T>A, NR_148942.2:n.1106T>A, NM_001354690.3:c.775T>A, NM_001354691.3:c.532T>A, NM_001354692.3:c.532T>A, NM_001354693.3:c.676T>A, NM_001354694.3:c.532T>A, NM_001354695.3:c.433T>A, NR_148940.3:n.1106T>A, NR_148941.3:n.1106T>A, NR_148942.3:n.1106T>A, NM_002880.4(RAF1):c.775T>A (p.Ser259Thr)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM1, PP1, PP3, PP2, PM2_Supporting, PM6_Strong, PS4, PM5_Strong, PS3_Supporting		The c.775T>A (p.Ser259Thr) variant in the RAF1 gene is a missense variant predicted to cause substitution of serine by threonine at amino acid 259. This variant is absent from gnomAD v2 (PM2_Supporting). The computational predictor REVEL gives a score of 0.753, which is above the threshold of 0.7 and is evidence that correlates with impact to RAF1 function (PP3). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). The variant is also in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). The p.Ser259Thr variant has been identified in at least 8 independent occurrences in patients with a RASopathy (PS4; GeneDx, Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; GTR ID's: 26957, 21766, 506381 PMID: 21784453; ClinVar SCV000061360.5; SCV000209017.10). The variant has also been reported to segregate with clinical features of a RASopathy in at least 3 family members (PP1; GeneDx, Zenker et al. internal data; ClinVar SCV000209017.9). Additionally, it has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; APHP-Robert DebrÃ© Hospital internal data; GTR ID's: 28338). At least 2 other pathogenic missense variants have been previously identified at this codon of RAF1 which may indicate that this residue is critical to the function of the protein (PM5_Strong; ClinVar 40603, 40602, 228288). In vitro functional studies also provide some evidence that the p.Ser259Thr variant may impact protein function (PS3_Supporting; PMID: 21784453, 20052757). In summary, this variant meets the criteria to be classified as  pathogenic for autosomal dominant RASopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy VCEP: PM5_Strong, PM6_Strong, PS4, PM1, PP1, PP2, PP3, PM2_Supporting, PS3_Supporting.  (RASopathy VCEP specifications version 2.3; 12/3/2024)	29493581	RASopathy VCEP		2024-12-03	2025-03-25	false	https://erepo.genome.network/evrepo/ui/classification/CA261617/MONDO:0021060/040	70e55828-a26c-447c-863d-156419f819e2
NM_002880.3(RAF1):c.788T>G (p.Val263Gly)	40607	CA273745	NM_002880.3:c.788T>G, LRG_413t1:c.788T>G, XM_005265355.1:c.788T>G, XM_005265357.1:c.689T>G, XM_005265358.3:c.545T>G, XM_005265359.3:c.446T>G, XM_005265360.1:c.788T>G, XM_011533974.1:c.788T>G, XM_011533975.1:c.545T>G, NM_001354689.1:c.788T>G, NM_001354690.1:c.788T>G, NM_001354691.1:c.545T>G, NM_001354692.1:c.545T>G, NM_001354693.1:c.689T>G, NM_001354694.1:c.545T>G, NM_001354695.1:c.446T>G, NR_148940.1:n.1203T>G, NR_148941.1:n.1203T>G, NR_148942.1:n.1203T>G, XM_011533974.3:c.788T>G, XM_017006966.1:c.689T>G, XR_001740227.1:n.1020T>G, NM_001354689.3:c.788T>G, NM_001354690.2:c.788T>G, NM_001354691.2:c.545T>G, NM_001354692.2:c.545T>G, NM_001354693.2:c.689T>G, NM_001354694.2:c.545T>G, NM_001354695.2:c.446T>G, NR_148940.2:n.1119T>G, NR_148941.2:n.1119T>G, NR_148942.2:n.1119T>G, ENST00000251849.8:c.788T>G, ENST00000416093.1:c.*366T>G, ENST00000423275.5:c.*465T>G, ENST00000432427.2:n.425T>G, ENST00000442415.6:c.788T>G, ENST00000465826.5:n.32T>G, ENST00000491290.1:n.309T>G, NC_000003.12:g.12604182A>C, CM000665.2:g.12604182A>C, NC_000003.11:g.12645681A>C, CM000665.1:g.12645681A>C, NC_000003.10:g.12620681A>C, NG_007467.1:g.64998T>G, LRG_413:g.64998T>G, NM_002880.3(RAF1):c.788T>G (p.Val263Gly)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PM2, PP2, PP3, PM6_Strong	PM5	The c.788T>G (p.Val263Gly) variant in RAF1 has been reported as a de novo occurrence in at least two patients with clinical features of a RASopathy (PM6_Strong; PMID: 30732632; GeneDx internal data, ClinVar SCV000209021.10). The p.Val263Gly variant has been identified in at least 5 other independent occurrences in patients with a RASopathy (PS4; PMID: 30732632, 31560489, 31145547; Partners Laboratory for Molecular Medicine, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; ClinVar SCV000061370.6). This variant was absent from large population studies (PM2; gnomad.broadinstitute.org). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). Different pathogenic missense variants have been previously identified at this codon of RAF1, which may indicate that this residue is critical to the function of the protein (PM5 not applied; ClinVar ID: 496189, 40608). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Val263Gly variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4, PM6_Strong, PM1, PM2, PP2, PP3.	29493581	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-07-01	false	https://erepo.genome.network/evrepo/ui/classification/CA273745/MONDO:0021060/004	fb3934fe-b004-493d-ac6a-987127cebac3
NM_002880.3(RAF1):c.769T>C (p.Ser257Pro)	40600	CA184835	NM_002880.3:c.769T>C, LRG_413t1:c.769T>C, XM_005265355.1:c.769T>C, XM_005265357.1:c.670T>C, XM_005265358.3:c.526T>C, XM_005265359.3:c.427T>C, XM_005265360.1:c.769T>C, XM_011533974.1:c.769T>C, XM_011533975.1:c.526T>C, NM_001354689.1:c.769T>C, NM_001354690.1:c.769T>C, NM_001354691.1:c.526T>C, NM_001354692.1:c.526T>C, NM_001354693.1:c.670T>C, NM_001354694.1:c.526T>C, NM_001354695.1:c.427T>C, NR_148940.1:n.1184T>C, NR_148941.1:n.1184T>C, NR_148942.1:n.1184T>C, XM_011533974.3:c.769T>C, XM_017006966.1:c.670T>C, XR_001740227.1:n.1001T>C, NM_001354689.3:c.769T>C, NM_001354690.2:c.769T>C, NM_001354691.2:c.526T>C, NM_001354692.2:c.526T>C, NM_001354693.2:c.670T>C, NM_001354694.2:c.526T>C, NM_001354695.2:c.427T>C, NR_148940.2:n.1100T>C, NR_148941.2:n.1100T>C, NR_148942.2:n.1100T>C, ENST00000251849.8:c.769T>C, ENST00000416093.1:c.*347T>C, ENST00000423275.5:c.*446T>C, ENST00000432427.2:n.406T>C, ENST00000442415.6:c.769T>C, ENST00000465826.5:n.13T>C, ENST00000491290.1:n.290T>C, NC_000003.12:g.12604201A>G, CM000665.2:g.12604201A>G, NC_000003.11:g.12645700A>G, CM000665.1:g.12645700A>G, NC_000003.10:g.12620700A>G, NG_007467.1:g.64979T>C, LRG_413:g.64979T>C, NM_002880.3(RAF1):c.769T>C (p.Ser257Pro)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PS4_Moderate, PM2, PM6, PP2	PM5	The c.769T>C (p.Ser257Pro) variant in RAF1 was absent from large population studies (PM2; gnomAD.broadinstitute.org). It has been identified in 3 patients with clinical features of a RASopathy (PS4_Moderate, SCV000206160.5; SCV000209015.10; PMID 23321623). In one proband the variant occurred de novo without parental confirmation (PM6). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 13957) Furthermore, the p.Ser257Pro variant is located in RAF1, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Moderate, PM1, PM2, PM6, PP2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-07-23	2020-07-28	false	https://erepo.genome.network/evrepo/ui/classification/CA184835/MONDO:0021060/004	a0bdf58d-d601-4924-95a5-27039f763685
NM_002880.3(RAF1):c.212A>G (p.Asn71Ser)	40588	CA134721	NM_002880.3:c.212A>G, LRG_413t1:c.212A>G, XM_005265355.1:c.212A>G, XM_005265357.1:c.212A>G, XM_005265358.3:c.78-2723A>G, XM_005265359.3:c.78-2723A>G, XM_005265360.1:c.212A>G, XM_011533974.1:c.212A>G, XM_011533975.1:c.78-2723A>G, NM_001354689.1:c.212A>G, NM_001354690.1:c.212A>G, NM_001354691.1:c.78-2723A>G, NM_001354692.1:c.78-2723A>G, NM_001354693.1:c.212A>G, NM_001354694.1:c.78-2723A>G, NM_001354695.1:c.78-2723A>G, NR_148940.1:n.627A>G, NR_148941.1:n.627A>G, NR_148942.1:n.627A>G, XM_011533974.3:c.212A>G, XM_017006966.1:c.212A>G, XR_001740227.1:n.543A>G, ENST00000251849.8:c.212A>G, ENST00000416093.1:c.208-2723A>G, ENST00000423275.5:c.208-2723A>G, ENST00000442415.6:c.212A>G, NC_000003.12:g.12612058T>C, CM000665.2:g.12612058T>C, NC_000003.11:g.12653557T>C, CM000665.1:g.12653557T>C, NC_000003.10:g.12628557T>C, NG_007467.1:g.57122A>G, LRG_413:g.57122A>G, NM_002880.3(RAF1):c.212A>G (p.Asn71Ser)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.212A>G (p.Asn71Ser) variant in the RAF1 gene is 0.14% for Latino chromosomes by the Exome Aggregation Consortium (24/11578 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134721/MONDO:0021060/004	bf556c8c-6cec-4e49-b9c7-2d92535a28ae
NM_002880.4(RAF1):c.935T>C (p.Val312Ala)	40612	CA177679	NM_002880.4:c.935T>C, NC_000003.12:g.12600207A>G, CM000665.2:g.12600207A>G, NC_000003.11:g.12641706A>G, CM000665.1:g.12641706A>G, NC_000003.10:g.12616706A>G, NG_007467.1:g.68973T>C, LRG_413:g.68973T>C, ENST00000423275.6:c.*600T>C, ENST00000432427.3:c.255T>C, ENST00000465826.6:n.526T>C, ENST00000491290.2:n.1312T>C, ENST00000684903.1:c.*612T>C, ENST00000685348.1:c.*612T>C, ENST00000685437.1:c.836T>C, ENST00000685438.1:n.699T>C, ENST00000685653.1:c.935T>C, ENST00000685738.1:c.935T>C, ENST00000686409.1:n.1643T>C, ENST00000686455.1:n.1298T>C, ENST00000686479.1:n.1306T>C, ENST00000686762.1:c.935T>C, ENST00000687257.1:n.1171T>C, ENST00000687326.1:c.935T>C, ENST00000687486.1:c.182+181T>C, ENST00000687505.1:n.1053T>C, ENST00000687923.1:c.836T>C, ENST00000687940.1:n.1312T>C, ENST00000688269.1:n.1531T>C, ENST00000688326.1:c.255T>C, ENST00000688444.1:n.1261T>C, ENST00000688543.1:c.836T>C, ENST00000688625.1:c.*513T>C, ENST00000688803.1:n.1166T>C, ENST00000689097.1:c.*612T>C, ENST00000689389.1:c.935T>C, ENST00000689418.1:c.*612T>C, ENST00000689481.1:c.*612T>C, ENST00000689540.1:n.1085T>C, ENST00000689876.1:c.935T>C, ENST00000689914.1:c.935T>C, ENST00000690397.1:c.824T>C, ENST00000690460.1:c.923T>C, ENST00000690625.1:n.1238T>C, ENST00000691268.1:c.362T>C, ENST00000691396.1:c.*728T>C, ENST00000691724.1:c.935T>C, ENST00000691779.1:c.*513T>C, ENST00000691899.1:c.935T>C, ENST00000692069.1:n.1158T>C, ENST00000692093.1:c.836T>C, ENST00000692311.1:n.1416T>C, ENST00000692558.1:n.1300T>C, ENST00000692773.1:c.*672T>C, ENST00000692830.1:c.*680T>C, ENST00000693069.1:c.836T>C, ENST00000693312.1:c.710T>C, ENST00000693664.1:c.935T>C, ENST00000693705.1:c.*612T>C, ENST00000251849.9:c.935T>C, ENST00000442415.7:c.995T>C, ENST00000251849.8:c.935T>C, ENST00000423275.5:c.*612T>C, ENST00000432427.2:c.572T>C, ENST00000442415.6:c.995T>C, ENST00000465826.5:n.179T>C, ENST00000491290.1:n.564T>C, NM_002880.3:c.935T>C, LRG_413t1:c.935T>C, XM_005265355.1:c.935T>C, XM_005265357.1:c.836T>C, XM_005265358.3:c.692T>C, XM_005265359.3:c.593T>C, XM_005265360.1:c.935T>C, XM_011533974.1:c.935T>C, XM_011533975.1:c.692T>C, NM_001354689.1:c.995T>C, NM_001354690.1:c.935T>C, NM_001354691.1:c.692T>C, NM_001354692.1:c.692T>C, NM_001354693.1:c.836T>C, NM_001354694.1:c.752T>C, NM_001354695.1:c.593T>C, NR_148940.1:n.1350T>C, NR_148941.1:n.1350T>C, NR_148942.1:n.1350T>C, XM_011533974.3:c.935T>C, XM_017006966.1:c.836T>C, XR_001740227.1:n.1167T>C, NM_001354689.3:c.995T>C, NM_001354690.2:c.935T>C, NM_001354691.2:c.692T>C, NM_001354692.2:c.692T>C, NM_001354693.2:c.836T>C, NM_001354694.2:c.752T>C, NM_001354695.2:c.593T>C, NR_148940.2:n.1266T>C, NR_148941.2:n.1266T>C, NR_148942.2:n.1266T>C, NM_001354690.3:c.935T>C, NM_001354691.3:c.692T>C, NM_001354692.3:c.692T>C, NM_001354693.3:c.836T>C, NM_001354694.3:c.752T>C, NM_001354695.3:c.593T>C, NR_148940.3:n.1266T>C, NR_148941.3:n.1266T>C, NR_148942.3:n.1266T>C, NM_002880.4(RAF1):c.935T>C (p.Val312Ala)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP4, BP5		The c.935T>C (p.Val312Ala) variant in the RAF1 gene is a missense variant predicted to cause substitution of valine by alanine at amino acid 312. The computational predictor REVEL gives a score of 0.174, which is below the threshold of 0.3 and does not predict a damaging effect on RAF1 function (BP4). Additionally, this variant was identified in a case with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM internal data; GTR ID's: 26957, 21766; ClinVar SCV000200036.4; SCV000209006.12). In summary, this variant meets criteria to be classified as likely benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BP4, BP5. (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-25	false	https://erepo.genome.network/evrepo/ui/classification/CA177679/MONDO:0021060/040	5dd4045c-aa85-4341-8238-7a7b67f85d3f
NM_005633.3(SOS1):c.3330G>C (p.Ser1110=)	448940	CA1624221	NM_005633.3:c.3330G>C, LRG_754t1:c.3330G>C, XM_005264515.3:c.3330G>C, XM_011533060.1:c.3423G>C, XM_011533061.1:c.3423G>C, XM_011533062.1:c.3309G>C, XM_011533063.1:c.3306G>C, XM_011533064.1:c.3159G>C, XM_011533065.1:c.3423G>C, XM_011533066.1:c.2265G>C, XM_005264515.4:c.3330G>C, XM_011533062.2:c.3309G>C, XM_011533064.2:c.3159G>C, ENST00000395038.6:c.3330G>C, ENST00000402219.6:c.3330G>C, ENST00000426016.5:c.3330G>C, NC_000002.12:g.38995139C>G, CM000664.2:g.38995139C>G, NC_000002.11:g.39222280C>G, CM000664.1:g.39222280C>G, NC_000002.10:g.39075784C>G, NG_007530.1:g.130325G>C, LRG_754:g.130325G>C, NM_005633.3(SOS1):c.3330G>C (p.Ser1110=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.3330G>C (p.Ser1110=) variant in the SOS1 gene is 0.0382% (8/10406) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624221/MONDO:0021060/004	ffbc3b95-48ea-412c-a45b-92033d327cb7
NM_002880.3(RAF1):c.1082G>C (p.Gly361Ala)	40613	CA134687	NM_002880.3:c.1082G>C, NC_000003.12:g.12599717C>G, CM000665.2:g.12599717C>G, NC_000003.11:g.12641216C>G, CM000665.1:g.12641216C>G, NC_000003.10:g.12616216C>G, NG_007467.1:g.69463G>C, LRG_413:g.69463G>C, LRG_413t1:c.1082G>C, XM_005265355.1:c.1082G>C, XM_005265357.1:c.983G>C, XM_005265358.3:c.839G>C, XM_005265359.3:c.740G>C, XM_005265360.1:c.1082G>C, XM_011533974.1:c.1082G>C, XM_011533975.1:c.839G>C, NM_001354689.1:c.1142G>C, NM_001354690.1:c.1082G>C, NM_001354691.1:c.839G>C, NM_001354692.1:c.839G>C, NM_001354693.1:c.983G>C, NM_001354694.1:c.899G>C, NM_001354695.1:c.740G>C, NR_148940.1:n.1497G>C, NR_148941.1:n.1497G>C, NR_148942.1:n.1495G>C, XM_011533974.3:c.1082G>C, XM_017006966.1:c.983G>C, XR_001740227.1:n.1314G>C, ENST00000251849.8:c.1082G>C, ENST00000423275.5:c.*759G>C, ENST00000432427.2:n.719G>C, ENST00000442415.6:c.1142G>C, ENST00000460610.1:n.39G>C, ENST00000465826.5:n.326G>C, NM_002880.3(RAF1):c.1082G>C (p.Gly361Ala)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM2, PP2, PP3, PM6_Strong		The c.1082G>C (p.Gly361Ala) variant in RAF1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; GeneDx, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; GTR ID's: 26957, 506381 ClinVar SCV000209024.9). The p.Gly361Ala variant has been identified in at least 4 independent occurrences in patients with a RASopathy (PS4_Moderate; GeneDx, Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; GTR ID's: 26957, 21766, 506381;  SCV000209024.9, SCV000061333.5). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly361Ala variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6_Strong, PS4_Moderate, PM2, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134687/MONDO:0021060/004	04812bc6-1939-486b-9212-b10aa1e3260e
NM_002880.4(RAF1):c.1193G>T (p.Arg398Leu)	40614	CA235336	NM_002880.4:c.1193G>T, NC_000003.12:g.12591708C>A, CM000665.2:g.12591708C>A, NC_000003.11:g.12633207C>A, CM000665.1:g.12633207C>A, NC_000003.10:g.12608207C>A, NG_007467.1:g.77472G>T, LRG_413:g.77472G>T, ENST00000423275.6:c.*858G>T, ENST00000432427.3:c.510G>T, ENST00000465826.6:n.784G>T, ENST00000475353.2:n.1115G>T, ENST00000491290.2:n.1553G>T, ENST00000494557.2:n.1004G>T, ENST00000684903.1:c.*870G>T, ENST00000685348.1:c.*870G>T, ENST00000685437.1:c.1094G>T, ENST00000685653.1:c.1193G>T, ENST00000685738.1:c.*157G>T, ENST00000686409.1:n.2244G>T, ENST00000686455.1:n.1556G>T, ENST00000686762.1:c.1193G>T, ENST00000687257.1:n.1429G>T, ENST00000687326.1:c.*127G>T, ENST00000687486.1:c.385G>T, ENST00000687505.1:n.1311G>T, ENST00000687923.1:c.1082G>T, ENST00000687940.1:n.1570G>T, ENST00000688269.1:n.1789G>T, ENST00000688326.1:c.626G>T, ENST00000688444.1:n.1519G>T, ENST00000688543.1:c.1094G>T, ENST00000688625.1:c.*771G>T, ENST00000688803.1:n.1424G>T, ENST00000688914.1:n.179G>T, ENST00000689097.1:c.*870G>T, ENST00000689389.1:c.1193G>T, ENST00000689418.1:c.*870G>T, ENST00000689481.1:c.*870G>T, ENST00000689540.1:n.1343G>T, ENST00000689876.1:c.1193G>T, ENST00000689914.1:c.*127G>T, ENST00000690397.1:c.1082G>T, ENST00000690460.1:c.1181G>T, ENST00000690585.1:c.85G>T, ENST00000690625.1:n.1496G>T, ENST00000691396.1:c.*1045G>T, ENST00000691724.1:c.*150G>T, ENST00000691779.1:c.*771G>T, ENST00000691888.1:c.85G>T, ENST00000691899.1:c.1193G>T, ENST00000692069.1:n.1759G>T, ENST00000692093.1:c.1094G>T, ENST00000692311.1:n.2017G>T, ENST00000692558.1:n.1558G>T, ENST00000692773.1:c.*930G>T, ENST00000692830.1:c.*938G>T, ENST00000693069.1:c.*127G>T, ENST00000693312.1:c.968G>T, ENST00000693664.1:c.1193G>T, ENST00000693705.1:c.*870G>T, ENST00000251849.9:c.1193G>T, ENST00000442415.7:c.1253G>T, ENST00000251849.8:c.1193G>T, ENST00000423275.5:c.*870G>T, ENST00000432427.2:c.830G>T, ENST00000442415.6:c.1253G>T, ENST00000460610.1:n.150G>T, ENST00000465826.5:n.550G>T, ENST00000475353.1:n.361G>T, ENST00000494557.1:n.209G>T, NM_002880.3:c.1193G>T, LRG_413t1:c.1193G>T, XM_005265355.1:c.1193G>T, XM_005265357.1:c.1094G>T, XM_005265358.3:c.950G>T, XM_005265359.3:c.851G>T, XM_005265360.1:c.1193G>T, XM_011533974.1:c.1193G>T, XM_011533975.1:c.950G>T, NM_001354689.1:c.1253G>T, NM_001354690.1:c.1193G>T, NM_001354691.1:c.950G>T, NM_001354692.1:c.950G>T, NM_001354693.1:c.1094G>T, NM_001354694.1:c.1010G>T, NM_001354695.1:c.851G>T, NR_148940.1:n.1721G>T, NR_148941.1:n.1667G>T, NR_148942.1:n.1606G>T, XM_011533974.3:c.1193G>T, XM_017006966.1:c.1094G>T, XR_001740227.1:n.1484G>T, NM_001354689.3:c.1253G>T, NM_001354690.2:c.1193G>T, NM_001354691.2:c.950G>T, NM_001354692.2:c.950G>T, NM_001354693.2:c.1094G>T, NM_001354694.2:c.1010G>T, NM_001354695.2:c.851G>T, NR_148940.2:n.1637G>T, NR_148941.2:n.1583G>T, NR_148942.2:n.1522G>T, NM_001354690.3:c.1193G>T, NM_001354691.3:c.950G>T, NM_001354692.3:c.950G>T, NM_001354693.3:c.1094G>T, NM_001354694.3:c.1010G>T, NM_001354695.3:c.851G>T, NR_148940.3:n.1637G>T, NR_148941.3:n.1583G>T, NR_148942.3:n.1522G>T, NM_002880.4(RAF1):c.1193G>T (p.Arg398Leu)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PP3, PM2_Supporting	PS4	The c.1193G>T variant in the RAF1 gene is a missense variant predicted to cause substitution of arginine by leucine at amino acid 398 (p.Arg398Leu). This variant is absent from gnomAD v2 (PM2_Supporting). The computational predictor REVEL gives a score of 0.861, which is above the threshold of 0.7 and is evidence that correlates with impact to RAF1 function. The variant is also entirely conserved in the UCSC database, and Alamut does not predict an impact to splicing (PP3). This variant has been identified in at least 5 probands with variable phenotypic features, with two of them having a clinical suspicion of Noonan syndrome (PS4 not met; Rady Children's Institute for Genomic Medicine internal communications, Invitae; SCV000209025.5; SCV000207671.1; SCV000552095.2, SCV000552095.6). In summary, this variant meets criteria to be classified as a variant of uncertain significance for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PM2_Supporting, PP3. (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-25	false	https://erepo.genome.network/evrepo/ui/classification/CA235336/MONDO:0021060/040	54e513e4-3d82-4530-8f42-82522d750073
NM_002880.4(RAF1):c.119G>A (p.Arg40His)	40585	CA201617	NM_002880.4:c.119G>A, NC_000003.12:g.12618603C>T, CM000665.2:g.12618603C>T, NC_000003.11:g.12660102C>T, CM000665.1:g.12660102C>T, NC_000003.10:g.12635102C>T, NG_007467.1:g.50577G>A, LRG_413:g.50577G>A, ENST00000416093.2:c.119G>A, ENST00000423275.6:c.119G>A, ENST00000491290.2:n.496G>A, ENST00000684903.1:c.119G>A, ENST00000685348.1:c.119G>A, ENST00000685437.1:c.119G>A, ENST00000685653.1:c.119G>A, ENST00000685738.1:c.119G>A, ENST00000685740.1:c.119G>A, ENST00000685959.1:c.119G>A, ENST00000686409.1:n.410G>A, ENST00000686455.1:n.482G>A, ENST00000686479.1:n.490G>A, ENST00000686762.1:c.119G>A, ENST00000687257.1:n.454G>A, ENST00000687326.1:c.119G>A, ENST00000687348.1:c.119G>A, ENST00000687923.1:c.119G>A, ENST00000687940.1:n.496G>A, ENST00000688269.1:n.418G>A, ENST00000688444.1:n.445G>A, ENST00000688543.1:c.119G>A, ENST00000688625.1:c.119G>A, ENST00000688753.1:c.119G>A, ENST00000688779.1:n.450G>A, ENST00000688803.1:n.449G>A, ENST00000689033.1:c.119G>A, ENST00000689097.1:c.119G>A, ENST00000689226.1:c.119G>A, ENST00000689389.1:c.119G>A, ENST00000689418.1:c.119G>A, ENST00000689481.1:c.119G>A, ENST00000689540.1:n.269G>A, ENST00000689876.1:c.119G>A, ENST00000689914.1:c.119G>A, ENST00000690397.1:c.119G>A, ENST00000690460.1:c.119G>A, ENST00000690625.1:n.422G>A, ENST00000691396.1:c.119G>A, ENST00000691718.1:c.119G>A, ENST00000691724.1:c.119G>A, ENST00000691779.1:c.119G>A, ENST00000691899.1:c.119G>A, ENST00000692093.1:c.119G>A, ENST00000692311.1:n.492G>A, ENST00000692558.1:n.484G>A, ENST00000692773.1:c.119G>A, ENST00000692777.1:n.447G>A, ENST00000692830.1:c.119G>A, ENST00000692959.1:c.119G>A, ENST00000693069.1:c.119G>A, ENST00000693312.1:c.-18-6541G>A, ENST00000693664.1:c.119G>A, ENST00000693705.1:c.119G>A, ENST00000251849.9:c.119G>A, ENST00000442415.7:c.119G>A, ENST00000251849.8:c.119G>A, ENST00000416093.1:c.119G>A, ENST00000423275.5:c.119G>A, ENST00000442415.6:c.119G>A, NM_002880.3:c.119G>A, LRG_413t1:c.119G>A, XM_005265355.1:c.119G>A, XM_005265357.1:c.119G>A, XM_005265358.3:c.-12G>A, XM_005265359.3:c.-12G>A, XM_005265360.1:c.119G>A, XM_011533974.1:c.119G>A, XM_011533975.1:c.-12G>A, NM_001354689.1:c.119G>A, NM_001354690.1:c.119G>A, NM_001354691.1:c.-12G>A, NM_001354692.1:c.-12G>A, NM_001354693.1:c.119G>A, NM_001354694.1:c.-12G>A, NM_001354695.1:c.-12G>A, NR_148940.1:n.534G>A, NR_148941.1:n.534G>A, NR_148942.1:n.534G>A, XM_011533974.3:c.119G>A, XM_017006966.1:c.119G>A, XR_001740227.1:n.450G>A, NM_001354689.3:c.119G>A, NM_001354690.2:c.119G>A, NM_001354691.2:c.-12G>A, NM_001354692.2:c.-12G>A, NM_001354693.2:c.119G>A, NM_001354694.2:c.-12G>A, NM_001354695.2:c.-12G>A, NR_148940.2:n.450G>A, NR_148941.2:n.450G>A, NR_148942.2:n.450G>A, NM_001354690.3:c.119G>A, NM_001354691.3:c.-12G>A, NM_001354692.3:c.-12G>A, NM_001354693.3:c.119G>A, NM_001354694.3:c.-12G>A, NM_001354695.3:c.-12G>A, NR_148940.3:n.450G>A, NR_148941.3:n.450G>A, NR_148942.3:n.450G>A, NM_002880.4(RAF1):c.119G>A (p.Arg40His)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP4, BS2_Supporting, BP5, BS4		The c.119G>A variant in the RAF1 gene is a missense variant predicted to cause substitution of arginine by histidine at amino acid 40 (p.Arg40His). The filtering allele frequency of this variant is 0.5265% for Admixed American chromosomes in gnomAD v4, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). The computational predictor REVEL gives a score of 0.281, which is below the threshold of 0.3 and does not predict a damaging effect on RAF1 function (BP4). This variant has been identified in a patient with an alternate molecular basis for disease and did not segregate with disease in affected family members (BP5, BS4; GeneDx internal data; GTR ID: 26957; SCV000171283.11). Additionally this variant was identified in multiple healthy individuals (BS2_P, Eurofins, SCV000227278.5; Illumina, SCV000440638.3; Ambry Genetics, SCV000736788.4). In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BS4, BS2_supporting, BP4, BP5 (Specification Version 2.1, 9/17/2024)		RASopathy VCEP		2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA201617/MONDO:0021060/040	e3a025b8-32a2-4d0f-92e0-d44516304ddc
NM_002880.3(RAF1):c.66T>G (p.Phe22Leu)	40583	CA134746	NM_002880.3:c.66T>G, NC_000003.12:g.12618656A>C, CM000665.2:g.12618656A>C, NC_000003.11:g.12660155A>C, CM000665.1:g.12660155A>C, NC_000003.10:g.12635155A>C, NG_007467.1:g.50524T>G, LRG_413:g.50524T>G, LRG_413t1:c.66T>G, XM_005265355.1:c.66T>G, XM_005265357.1:c.66T>G, XM_005265358.3:c.-65T>G, XM_005265359.3:c.-65T>G, XM_005265360.1:c.66T>G, XM_011533974.1:c.66T>G, XM_011533975.1:c.-65T>G, NM_001354689.1:c.66T>G, NM_001354690.1:c.66T>G, NM_001354691.1:c.-65T>G, NM_001354692.1:c.-65T>G, NM_001354693.1:c.66T>G, NM_001354694.1:c.-65T>G, NM_001354695.1:c.-65T>G, NR_148940.1:n.481T>G, NR_148941.1:n.481T>G, NR_148942.1:n.481T>G, XM_011533974.3:c.66T>G, XM_017006966.1:c.66T>G, XR_001740227.1:n.397T>G, ENST00000251849.8:c.66T>G, ENST00000416093.1:c.66T>G, ENST00000423275.5:c.66T>G, ENST00000442415.6:c.66T>G, NM_002880.3(RAF1):c.66T>G (p.Phe22Leu)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP5, BS4		The c.66T>G (p.Phe22Leu) variant has been identified in patients with clinical features of a RASopathy, however the variant did not segregate with disease in affected family members (BS4; GeneDx, Partners LMM, Invitae internal data GTR ID's: 26957, 21766, 500031; ClinVar SCV000218672.4; SCV000061358.5). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; LMM internal data; SCV000061358.5). In summary, this variant meets criteria to be classified as likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581):  BS4, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134746/MONDO:0021060/004	f0461c83-c8eb-4af2-abbc-482d7a9b30f5
NM_002834.4(PTPN11):c.525+12G>C	40516	CA134671	NM_002834.4:c.525+12G>C, NC_000012.12:g.112453399G>C, CM000674.2:g.112453399G>C, NC_000012.11:g.112891203G>C, CM000674.1:g.112891203G>C, NC_000012.10:g.111375586G>C, NG_007459.1:g.39668G>C, LRG_614:g.39668G>C, NM_002834.3:c.525+12G>C, LRG_614t1:c.525+12G>C, NM_080601.1:c.525+12G>C, XM_006719526.1:c.525+12G>C, XM_006719527.1:c.525+12G>C, XM_011538613.1:c.522+12G>C, NM_001330437.1:c.525+12G>C, NM_080601.2:c.525+12G>C, XM_011538613.2:c.522+12G>C, XM_017019722.1:c.522+12G>C, ENST00000351677.6:c.525+12G>C, ENST00000392597.5:c.525+12G>C, ENST00000530818.1:n.59+12G>C, ENST00000635625.1:n.525+12G>C, NM_002834.4(PTPN11):c.525+12G>C	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.525+12G>C variant in the PTPN11 gene is 1.4% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (969/66644 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Additional case level data available: SCV000057399.8; SCV000061311.5; SCV000248623.2; SCV000206755.1; SCV000207666.1.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134671/MONDO:0021060/004	e349cc49-74ea-4be5-b0ec-3257498743d6
NM_002834.4(PTPN11):c.781C>T (p.Leu261Phe)	40520	CA235373	NM_002834.4:c.781C>T, NM_002834.3:c.781C>T, LRG_614t1:c.781C>T, NM_080601.1:c.781C>T, XM_006719526.1:c.781C>T, XM_006719527.1:c.667C>T, XM_011538613.1:c.778C>T, NM_001330437.1:c.781C>T, NM_080601.2:c.781C>T, XM_011538613.2:c.778C>T, XM_017019722.1:c.778C>T, ENST00000351677.6:c.781C>T, ENST00000392597.5:c.781C>T, ENST00000635625.1:n.781C>T, NC_000012.12:g.112472968C>T, CM000674.2:g.112472968C>T, NC_000012.11:g.112910772C>T, CM000674.1:g.112910772C>T, NC_000012.10:g.111395155C>T, NG_007459.1:g.59237C>T, LRG_614:g.59237C>T, NM_002834.4(PTPN11):c.781C>T (p.Leu261Phe)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1, PM2, PP2, PM6_Strong		The c.781C>T (p.Leu261Phe) variant in PTPN11 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 22465605; GeneDx, Cave lab internal data ClinVar SCV000057404.12). The p.Leu261Phe variant has also been identified in at least 4 independent occurrences in patients with a RASopathy (PS4_Moderate; Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg,  APHP-Robert DebrÃ© Hospital internal data; GTR ID's: 21766, 506381, 28338; SCV000061319.5, SCV000207687.1 PMID: 22465605). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTPN11 (PM1; PMID 29493581). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6_Strong, PS4_Moderate, PM2, PM1, PP2.	22465605, 29493581	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA235373/MONDO:0021060/004	90bd1343-a396-445b-985c-d23c393118d4
NM_002834.4(PTPN11):c.1658C>T (p.Thr553Met)	40570	CA134644	NM_002834.4:c.1658C>T, NC_000012.12:g.112502202C>T, CM000674.2:g.112502202C>T, NC_000012.11:g.112940006C>T, CM000674.1:g.112940006C>T, NC_000012.10:g.111424389C>T, NG_007459.1:g.88471C>T, LRG_614:g.88471C>T, ENST00000639857.2:c.1658C>T, ENST00000685487.1:c.*860C>T, ENST00000687120.1:n.1041C>T, ENST00000687906.1:c.1544C>T, ENST00000688597.1:c.1283C>T, ENST00000688701.1:n.902C>T, ENST00000690210.1:c.1658C>T, ENST00000690472.1:n.867C>T, ENST00000692624.1:c.*204C>T, ENST00000351677.7:c.1658C>T, ENST00000351677.6:c.1658C>T, ENST00000635625.1:c.1670C>T, NM_002834.3:c.1658C>T, LRG_614t1:c.1658C>T, XM_006719526.1:c.1670C>T, XM_006719527.1:c.1556C>T, XM_011538613.1:c.1667C>T, NM_001330437.1:c.1670C>T, XM_011538613.2:c.1667C>T, XM_017019722.1:c.1655C>T, NM_001330437.2:c.1670C>T, NM_001374625.1:c.1655C>T, NM_002834.5:c.1658C>T, NM_002834.4(PTPN11):c.1658C>T (p.Thr553Met)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP4		The filtering allele frequency of the c.1658C>T (p.Thr553Met) variant in the PTPN11 gene (NM_002834.5(PTPN11):c.1658C>T (p.Thr553Met)) is 0.048% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (49/66556 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Computational prediction tools and conservation analysis suggest that the p.Thr553Met variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied: BA1, BP4 (Version 2.1; 09/17/2024).		RASopathy VCEP		2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA134644/MONDO:0021060/043	8b509a72-e8ae-4215-92db-567fba446b08
NM_002834.4(PTPN11):c.1530G>C (p.Gln510His)	40567	CA220143	NM_002834.4:c.1530G>C, NC_000012.12:g.112489106G>C, CM000674.2:g.112489106G>C, NC_000012.11:g.112926910G>C, CM000674.1:g.112926910G>C, NC_000012.10:g.111411293G>C, NG_007459.1:g.75375G>C, LRG_614:g.75375G>C, NM_002834.3:c.1530G>C, LRG_614t1:c.1530G>C, XM_006719526.1:c.1542G>C, XM_006719527.1:c.1428G>C, XM_011538613.1:c.1539G>C, NM_001330437.1:c.1542G>C, XM_011538613.2:c.1539G>C, XM_017019722.1:c.1527G>C, ENST00000351677.6:c.1530G>C, ENST00000635625.1:n.1542G>C, ENST00000635652.1:n.543G>C, NM_002834.4(PTPN11):c.1530G>C (p.Gln510His)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM5_Strong, PM2, PP2, PP3, PM6_Strong		The c.1530G>C (p.Gln510His) variant in PTPN11 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; GeneDx, EGL, APHP-Robert DebrÃ© Hospital internal data; GTR ID's: 26957, 500060, 28338 ClinVar SCV000057460.11; SCV000331072.3). At least 2 other pathogenic missense variants have been previously identified at this codon of PTPN11 which may indicate that this residue is critical to the function of the protein (PM5_Strong; ClinVar 40566, 13345, 13344). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Gln510His variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PM6_Strong, PM5_Strong, PM2, PP3, PP2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA220143/MONDO:0021060/004	c1682ae1-ce46-41b9-b916-5efef827298a
NM_002834.4(PTPN11):c.925A>G (p.Ile309Val)	40536	CA177674	NM_002834.4:c.925A>G, NM_002834.3:c.925A>G, LRG_614t1:c.925A>G, NM_080601.1:c.925A>G, XM_006719526.1:c.925A>G, XM_006719527.1:c.811A>G, XM_011538613.1:c.922A>G, NM_001330437.1:c.925A>G, NM_080601.2:c.925A>G, XM_011538613.2:c.922A>G, XM_017019722.1:c.922A>G, ENST00000351677.6:c.925A>G, ENST00000392597.5:c.925A>G, ENST00000635625.1:n.925A>G, NC_000012.12:g.112477722A>G, CM000674.2:g.112477722A>G, NC_000012.11:g.112915526A>G, CM000674.1:g.112915526A>G, NC_000012.10:g.111399909A>G, NG_007459.1:g.63991A>G, LRG_614:g.63991A>G, NM_002834.4(PTPN11):c.925A>G (p.Ile309Val)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.925A>G (p.Ile309Val) variant in the PTPN11 gene is 0.04% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (46/66736 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA177674/MONDO:0021060/004	4cec7b98-aaab-4623-a50c-b195372c6afa
NM_002834.4(PTPN11):c.854-32A>C	40530	CA215447	NM_002834.4:c.854-32A>C, NM_002834.3:c.854-32A>C, LRG_614t1:c.854-32A>C, NM_080601.1:c.854-32A>C, XM_006719526.1:c.854-32A>C, XM_006719527.1:c.740-32A>C, XM_011538613.1:c.851-32A>C, NM_001330437.1:c.854-32A>C, NM_080601.2:c.854-32A>C, XM_011538613.2:c.851-32A>C, XM_017019722.1:c.851-32A>C, ENST00000351677.6:c.854-32A>C, ENST00000392597.5:c.854-32A>C, ENST00000635625.1:n.854-32A>C, NC_000012.12:g.112477619A>C, CM000674.2:g.112477619A>C, NC_000012.11:g.112915423A>C, CM000674.1:g.112915423A>C, NC_000012.10:g.111399806A>C, NG_007459.1:g.63888A>C, LRG_614:g.63888A>C, NM_002834.4(PTPN11):c.854-32A>C	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.854-32A>C  variant in the PTPN11 gene is 15.2% for Latino chromosomes by the Exome Aggregation Consortium (1824/11514 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA215447/MONDO:0021060/004	d075d2b2-41cf-44a5-be84-8bdd1d974908
NM_002880.3(RAF1):c.581+4A>G	448929	CA2259744	NM_002880.3:c.581+4A>G, NC_000003.12:g.12608762T>C, CM000665.2:g.12608762T>C, NC_000003.11:g.12650261T>C, CM000665.1:g.12650261T>C, NC_000003.10:g.12625261T>C, NG_007467.1:g.60418A>G, LRG_413:g.60418A>G, LRG_413t1:c.581+4A>G, XM_005265355.1:c.581+4A>G, XM_005265357.1:c.581+4A>G, XM_005265358.3:c.338+4A>G, XM_005265359.3:c.338+4A>G, XM_005265360.1:c.581+4A>G, XM_011533974.1:c.581+4A>G, XM_011533975.1:c.338+4A>G, NM_001354689.1:c.581+4A>G, NM_001354690.1:c.581+4A>G, NM_001354691.1:c.338+4A>G, NM_001354692.1:c.338+4A>G, NM_001354693.1:c.581+4A>G, NM_001354694.1:c.338+4A>G, NM_001354695.1:c.338+4A>G, NR_148940.1:n.996+4A>G, NR_148941.1:n.996+4A>G, NR_148942.1:n.996+4A>G, XM_011533974.3:c.581+4A>G, XM_017006966.1:c.581+4A>G, XR_001740227.1:n.912+4A>G, ENST00000251849.8:c.581+4A>G, ENST00000416093.1:c.*258+4A>G, ENST00000423275.5:c.*258+4A>G, ENST00000432427.2:n.317+4A>G, ENST00000442415.6:c.581+4A>G, ENST00000491290.1:n.102+4A>G, ENST00000492690.1:n.317A>G, NM_002880.3(RAF1):c.581+4A>G	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.581+4A>G variant in the RAF1 gene is 0.0375% (34/66642) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA2259744/MONDO:0021060/004	e521ccdb-9cc3-4dbc-8325-1408912d06a0
NM_002834.5(PTPN11):c.794G>A (p.Arg265Gln)	40522	CA234739	NM_002834.5:c.794G>A, NC_000012.12:g.112472981G>A, CM000674.2:g.112472981G>A, NC_000012.11:g.112910785G>A, CM000674.1:g.112910785G>A, NC_000012.10:g.111395168G>A, NG_007459.1:g.59250G>A, LRG_614:g.59250G>A, ENST00000639857.2:c.794G>A, ENST00000685487.1:c.794G>A, ENST00000687906.1:c.680G>A, ENST00000688597.1:c.794G>A, ENST00000690210.1:c.794G>A, ENST00000692624.1:c.794G>A, ENST00000351677.7:c.794G>A, ENST00000351677.6:c.794G>A, ENST00000392597.5:c.794G>A, ENST00000635625.1:c.794G>A, NM_002834.3:c.794G>A, LRG_614t1:c.794G>A, NM_080601.1:c.794G>A, XM_006719526.1:c.794G>A, XM_006719527.1:c.680G>A, XM_011538613.1:c.791G>A, NM_001330437.1:c.794G>A, NM_002834.4:c.794G>A, NM_080601.2:c.794G>A, XM_011538613.2:c.791G>A, XM_017019722.1:c.791G>A, NM_001330437.2:c.794G>A, NM_001374625.1:c.791G>A, NM_080601.3:c.794G>A, NM_002834.5(PTPN11):c.794G>A (p.Arg265Gln)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS3_Moderate, PP1, PP3, PP2, PM1, PS4, PS2_Very Strong	PM2	The c.794G>A (NM_002834.5(PTPN11):c.794G>A (p.Arg265Gln)) variant in PTPN11 is a missense variant predicted to cause substitution of arginine by glutamine at amino acid 265 (p.Arg265Gln). The highest MAF for this variant in gnomAD v2.1.1 is 0.00006349 (7/110252 alleles) in the European (non-Finnish) population (no homozygotes) (no population codes met). The computational predictor REVEL gives a score of 0.814, which is above the RASopathy VCEP threshold of 0.7, evidence that correlates with impact to PTPN11 function (PP3). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common. The Z-score for missense variants in PTPN11 in gnomAD v4.1.0 is 4.95 (PP2; PMID: 29493581). This variant resides at a residue (amino acid 265) of PTPN11 that is defined as a mutational hotspot and/or critical functional domain by the ClinGen RASopathy VCEP (PM1; PMID 29493581). The p.Arg265Gln variant has been identified in 7 probands with clinical features of Noonan Syndrome included in this curation (PS4, 6.5 points.; PMIDs: 28074573, 32233106, Ann and Robert H. Lurie Children's Hospital of Chicago (Center for Genomics; SCV003920365) and GeneDx (SCV000057406) internal data). The c.794G>A p.Arg265Gln variant in PTPN11 has been reported as an unconfirmed de novo occurrence in 1 patient with clinical features of a RASopathy, and as a confirmed de novo case in 2 patients included in this curation (5.0 PS2 points; PMID: 28074573, Ann and Robert H. Lurie Children's Hospital of Chicago (Center for Genomics; SCV003920365) and GeneDx (SCV000057406) internal data). Additional case level-data is available, but enough evidence to apply PS4 and PS2_VeryStrong, the maximum strengths of these codes, have already been met. Two studies, an analysis in HEK293 cells and an in-vitro phosphatase assay, both showed significantly increased phosphatase activity for the p.Arg265Gln mutant compared to the wild-type (PS3_moderate; PMID 28074573). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant RASopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy VCEP: PP3, PP2, PM1, PS4, PS2_VeryStrong, PS3_moderate (VCEP specifications version 2.3.0; 9/9/2025).		RASopathy VCEP		2025-09-09	2025-09-25	false	https://erepo.genome.network/evrepo/ui/classification/CA234739/MONDO:0021060/043	0478380b-41bf-443f-bb02-184b55a7aba8
NM_002834.4(PTPN11):c.1529A>C (p.Gln510Pro)	13344	CA256758	NM_002834.4:c.1529A>C, NM_002834.3:c.1529A>C, LRG_614t1:c.1529A>C, XM_006719526.1:c.1541A>C, XM_006719527.1:c.1427A>C, XM_011538613.1:c.1538A>C, NM_001330437.1:c.1541A>C, XM_011538613.2:c.1538A>C, XM_017019722.1:c.1526A>C, ENST00000351677.6:c.1529A>C, ENST00000635625.1:n.1541A>C, ENST00000635652.1:n.542A>C, NC_000012.12:g.112489105A>C, CM000674.2:g.112489105A>C, NC_000012.11:g.112926909A>C, CM000674.1:g.112926909A>C, NC_000012.10:g.111411292A>C, NG_007459.1:g.75374A>C, LRG_614:g.75374A>C, NM_002834.4(PTPN11):c.1529A>C (p.Gln510Pro)	PTPN11	Noonan syndrome with multiple lentigines	MONDO:0007893	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS2_Very Strong, PM2, PP2, PP3, PS4_Supporting		The c.1529A>C (p.Gln510Pro) variant in PTPN11 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; Partners LMM, GeneDx, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data, APHP-Robert DebrÃ© Hospital; SCV000057459.14; SCV000200027.4; SCV000265844.1;. PMID 15520399, 20578946).  The p.Gln510Pro variant in PTPN11 has been reported in the literature to segregate with clinical features of a RASopathy in at least 4 family members (PP1_Moderate; APHP-Robert DebrÃ© Hospital: GTR Lab ID: 28338). The variant has also been identified in at least 2 independent occurrences in patients with clinical features of a RASopathy (PS4_Supporting; Partners LMM, GeneDx, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data, APHP-Robert DebrÃ© Hospital; SCV000057459.14; SCV000200027.4; SCV000265844.1;. PMID 15520399, 20578946). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is in PTPN11, which has been defined by the ClinGen RASopathy Expert Panel as a gene with low rate of benign missense with missense variants commonly being pathogenic (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Gln510Pro variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PS2_VeryStrong, PP1_Moderate, PM2, PP2, PP3, PS4_Supporting.	20578946, 15520399	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA256758/MONDO:0007893/004	74aa9bfb-79b2-4d78-8440-29866a548c82
NM_002834.4(PTPN11):c.244A>G (p.Met82Val)	40504	CA243279	NM_002834.4:c.244A>G, NC_000012.12:g.112450424A>G, CM000674.2:g.112450424A>G, NC_000012.11:g.112888228A>G, CM000674.1:g.112888228A>G, NC_000012.10:g.111372611A>G, NG_007459.1:g.36693A>G, LRG_614:g.36693A>G, NM_002834.3:c.244A>G, LRG_614t1:c.244A>G, NM_080601.1:c.244A>G, XM_006719526.1:c.244A>G, XM_006719527.1:c.244A>G, XM_011538613.1:c.241A>G, NM_001330437.1:c.244A>G, NM_080601.2:c.244A>G, XM_011538613.2:c.241A>G, XM_017019722.1:c.241A>G, NM_001330437.2:c.244A>G, NM_001374625.1:c.241A>G, NM_002834.5:c.244A>G, NM_080601.3:c.244A>G, ENST00000351677.6:c.244A>G, ENST00000392597.5:c.244A>G, ENST00000635625.1:n.244A>G, NM_002834.4(PTPN11):c.244A>G (p.Met82Val)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	BP5, PM6, PP2	PM2, PP3	The c.244A>G (p.Met82Val) variant in PTPN11 was present in 0.006152% (1/16256) of African alleles in gnomAD (gnomad.broadinstitute.org). It was identified as a de novo occurrence in 1 proband (PM6; PMID: 30577886). It was also observed in a proband with features of Noonan syndrome with an alternate molecular mechanism of disease (BP5; GeneDx internal data, SCV000057386.12). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.Met82Val variant in PTPN11 is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PP2, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-05-28	2020-07-01	false	https://erepo.genome.network/evrepo/ui/classification/CA243279/MONDO:0021060/004	9a9c6639-bd78-4169-b494-17e19c0101cc
NM_002834.4(PTPN11):c.1678C>T (p.Leu560Phe)	44599	CA134647	NM_002834.4:c.1678C>T, NC_000012.12:g.112502222C>T, CM000674.2:g.112502222C>T, NC_000012.11:g.112940026C>T, CM000674.1:g.112940026C>T, NC_000012.10:g.111424409C>T, NG_007459.1:g.88491C>T, LRG_614:g.88491C>T, ENST00000639857.2:c.1678C>T, ENST00000685487.1:c.*880C>T, ENST00000687120.1:n.1061C>T, ENST00000687906.1:c.1564C>T, ENST00000688597.1:c.1303C>T, ENST00000688701.1:n.922C>T, ENST00000690210.1:c.1678C>T, ENST00000690472.1:n.887C>T, ENST00000692624.1:c.*224C>T, ENST00000351677.7:c.1678C>T, ENST00000351677.6:c.1678C>T, ENST00000635625.1:c.1690C>T, NM_002834.3:c.1678C>T, LRG_614t1:c.1678C>T, XM_006719526.1:c.1690C>T, XM_006719527.1:c.1576C>T, XM_011538613.1:c.1687C>T, NM_001330437.1:c.1690C>T, XM_011538613.2:c.1687C>T, XM_017019722.1:c.1675C>T, NM_001330437.2:c.1690C>T, NM_001374625.1:c.1675C>T, NM_002834.5:c.1678C>T, NM_002834.4(PTPN11):c.1678C>T (p.Leu560Phe)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP5, BS3		The c.1678C>T (p.Leu560Phe) variant in PTPN11 (NM_002834.5(PTPN11):c.1678C>T (p.Leu560Phe)) has been identified in individuals with some features of a RASopathy but none were diagnosed with a RASopathy (PS4 not met; GeneDx, Partners LMM, APHP-Robert DebrÃ© Hospital internal data; GTR ID's: 28338, 26957, 21766; SCV000061285.5; SCV000208999.2; SCV000207690.1). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx internal data: GTR ID: 26957; SCV000208999.2). In vitro functional studies provide some evidence that the p.Leu560Phe variant does not impact protein function (BS3; PMID: 15987685). In summary, this variant meets criteria to be classified as likely benign. RASopathy-specific ACMG/AMP criteria applied: BS3, BP5 (Version 2.1; 09/17/2024).	15987685	RASopathy VCEP		2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA134647/MONDO:0021060/043	1de1c18c-c026-4034-afda-2b4516c6cdae
NM_002834.5(PTPN11):c.155C>T (p.Thr52Ile)	40484	CA261555	NM_002834.5:c.155C>T, NC_000012.12:g.112450335C>T, CM000674.2:g.112450335C>T, NC_000012.11:g.112888139C>T, CM000674.1:g.112888139C>T, NC_000012.10:g.111372522C>T, NG_007459.1:g.36604C>T, LRG_614:g.36604C>T, ENST00000639857.2:c.155C>T, ENST00000685487.1:c.155C>T, ENST00000687906.1:c.155C>T, ENST00000688597.1:c.155C>T, ENST00000690210.1:c.155C>T, ENST00000692624.1:c.155C>T, ENST00000351677.7:c.155C>T, ENST00000639857.1:c.155C>T, ENST00000351677.6:c.155C>T, ENST00000392597.5:c.155C>T, ENST00000635625.1:c.155C>T, NM_002834.3:c.155C>T, LRG_614t1:c.155C>T, NM_080601.1:c.155C>T, XM_006719526.1:c.155C>T, XM_006719527.1:c.155C>T, XM_011538613.1:c.152C>T, NM_001330437.1:c.155C>T, NM_002834.4:c.155C>T, NM_080601.2:c.155C>T, XM_011538613.2:c.152C>T, XM_017019722.1:c.152C>T, NM_001330437.2:c.155C>T, NM_001374625.1:c.152C>T, NM_080601.3:c.155C>T, NM_002834.5(PTPN11):c.155C>T (p.Thr52Ile)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PP3, PP2, PS4, PS2		The c.155C>T (NM_002834.5(PTPN11):c.155C>T (p.Thr52Ile)) variant in PTPN11 is a missense variant predicted to cause substitution of threonine byisoleucine at amino acid 52 (p.Thr52Ile). This variant is absent from gnomAD v2.1.1 (PM2_supporting). The computational predictor REVEL gives a score of 0.912, which is above the threshold of 0.7, evidence that correlates with impact to PTPN11 function (PP3). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are a common mechanism of disease (PP2; PMID: 29493581). This variant has been reported in 11 probands from 9 families with features of Noonan Syndrome (PS4, 8.0 pts.; PMIDs: 22465605, 25804457, 32059087; GeneDx, Partners Laboratory for Molecular Medicine, & Service de GÃ©nÃ©tique MolÃ©culaire (HÃ©lÃ¨ne Cave) internal data: ClinVar SCV000057357, SCV000061283, & SCV001438499). This variant has been identified as a de novo occurrence with confirmed parental relationships in 1 individual with Noonan Syndrome (PS2, 2.0 pts.; Service de GÃ©nÃ©tique MolÃ©culaire (HÃ©lÃ¨ne Cave) internal data: SCV001438499). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant RASopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy VCEP: (PM2_supporting, PP3, PP2, PS4, PS2. (Specification Version 2.3.0, 07/08/25).		RASopathy VCEP		2025-07-08	2025-09-25	false	https://erepo.genome.network/evrepo/ui/classification/CA261555/MONDO:0021060/043	c650daaa-d00c-411a-9439-fe0b0570e53e
NM_030662.3(MAP2K2):c.1162C>T (p.Arg388Trp)	40843	CA180895	NM_030662.3:c.1162C>T, NC_000019.10:g.4090639G>A, CM000681.2:g.4090639G>A, NC_000019.9:g.4090637G>A, CM000681.1:g.4090637G>A, NC_000019.8:g.4041637G>A, NG_007996.1:g.38490C>T, LRG_750:g.38490C>T, LRG_750t1:c.1162C>T, XM_006722799.2:c.883C>T, XM_011528133.1:c.592C>T, ENST00000262948.9:c.1162C>T, ENST00000394867.8:c.871C>T, ENST00000597263.5:n.347C>T, ENST00000599021.1:n.272C>T, ENST00000600584.5:n.2611C>T, ENST00000601786.5:n.1463C>T, NM_030662.3(MAP2K2):c.1162C>T (p.Arg388Trp)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1162C>T (p.Arg388Trp) variant in the MAP2K2 gene is 0.125% for African chromosomes by the Exome Aggregation Consortium (25/2788 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Additional case-level data available: SCV000204180.4; SCV000252871.4.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA180895/MONDO:0021060/004	a8067cbf-1dd7-4aab-bdb7-dfb3edfdaedf
NM_030662.3(MAP2K2):c.*8C>T	46223	CA137903	NM_030662.3:c.*8C>T, NC_000019.10:g.4090590G>A, CM000681.2:g.4090590G>A, NC_000019.9:g.4090588G>A, CM000681.1:g.4090588G>A, NC_000019.8:g.4041588G>A, NG_007996.1:g.38539C>T, LRG_750:g.38539C>T, ENST00000394867.9:n.1650C>T, ENST00000688002.1:n.3362C>T, ENST00000688751.1:n.347C>T, ENST00000689792.1:n.1115C>T, ENST00000262948.10:c.*8C>T, ENST00000262948.9:c.*8C>T, ENST00000394867.8:c.*8C>T, ENST00000597263.5:n.396C>T, ENST00000600584.5:n.2660C>T, ENST00000601786.5:n.1512C>T, LRG_750t1:c.*8C>T, XM_006722799.2:c.*8C>T, XM_011528133.1:c.*8C>T, NM_030662.4:c.*8C>T, NM_030662.3(MAP2K2):c.*8C>T	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP7, BP5	BA1, PS4, BS1, PM2	The c.*8C>T variant in the MAP2K2 gene is located in the untranslated mRNA region downstream of the termination codon. The filtering allele frequency in gnomAD v4.1.0 is 0.01257%(172/1145270 alleles) in non-Finnish European population (PM2_Supporting/BS1/BA1 are not met). This variant is at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP7). The c.*8C>T variant has been observed in at least 6 individuals who underwent testing for RASopathies (PS4 not met; GeneDx, LMM internal data; GTR ID's: 26957, 21766; SCV000063150.4, SCV000170190.9). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx internal data, SCV000170190.9). In summary, this variant meets criteria to be classified as likely benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BP5, BP7 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA137903/MONDO:0021060/048	ccf6cba7-1870-484b-aeae-e6fcd0cace13
NM_030662.4(MAP2K2):c.784G>A (p.Val262Ile)	46242	CA137966	NM_030662.4:c.784G>A, NC_000019.10:g.4099336C>T, CM000681.2:g.4099336C>T, NC_000019.9:g.4099334C>T, CM000681.1:g.4099334C>T, NC_000019.8:g.4050334C>T, NG_007996.1:g.29793G>A, LRG_750:g.29793G>A, ENST00000394867.9:n.1223G>A, ENST00000687128.1:n.1223G>A, ENST00000688002.1:n.1078G>A, ENST00000689792.1:n.688G>A, ENST00000262948.10:c.784G>A, ENST00000262948.9:c.784G>A, ENST00000394867.8:c.493G>A, ENST00000593364.5:n.731G>A, ENST00000595715.1:n.599G>A, ENST00000597263.5:n.169+1683G>A, ENST00000599021.1:c.29+1683G>A, ENST00000600584.5:n.1344G>A, ENST00000601786.5:n.1085G>A, NM_030662.3:c.784G>A, LRG_750t1:c.784G>A, XM_006722799.2:c.705+1683G>A, XM_011528133.1:c.214G>A, XM_017026989.1:c.784G>A, XM_017026990.1:c.705+1683G>A, NM_030662.4(MAP2K2):c.784G>A (p.Val262Ile)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	BP4	PP3, BA1, PS4, BS1, PM2	The c.784G>A variant in the MAP2K2 gene is a missense variant predicted to cause substitution of valine by isoleucine at amino acid 262 (p.Val262Ile). The filtering allele frequency in gnomAD v4.1.0 is 0.01543% (201/1178752 alleles) in the European (non-Finnish) population (PM2_Supporting/BS1/BA1 are not met). The computational predictor REVEL gives a score of 0.219, which predicts no impact on protein function (BP4). This variant has been identified in 4 independent occurrences in patients with disparate phenotypes of RASopathy (PS4 not met; GeneDx, LMM internal data; GTR ID's 26957, 21766; SCV000207950.9, SCV000063182.5). In summary, this variant meets criteria to be classified as variant of uncertain significance for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BP4 (Specification Version 2.1, 9/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA137966/MONDO:0021060/048	89d53e74-33f3-465b-abde-d4f656802fed
NM_030662.3(MAP2K2):c.281C>T (p.Ser94Leu)	40786	CA180967	NM_030662.3:c.281C>T, NC_000019.10:g.4117441G>A, CM000681.2:g.4117441G>A, NC_000019.9:g.4117439G>A, CM000681.1:g.4117439G>A, NC_000019.8:g.4068439G>A, NG_007996.1:g.11688C>T, LRG_750:g.11688C>T, LRG_750t1:c.281C>T, XM_006722799.2:c.281C>T, XM_017026989.1:c.281C>T, XM_017026990.1:c.281C>T, XM_017026991.1:c.281C>T, NM_030662.4:c.281C>T, ENST00000262948.9:c.281C>T, ENST00000394867.8:c.-11C>T, ENST00000599345.1:n.478C>T, NM_030662.3(MAP2K2):c.281C>T (p.Ser94Leu)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PP2, PP3	BS1, BS2	The c.281C>T (p.Ser94Leu) variant in MAP2K2 has been identified in 2 independent occurrences in patients with a RASopathy; however, in both cases it was inherited from an apparently unaffected parent (BS2 not met; GeneDx, LMM internal data; ClinVar SCV000204231.4; SCV000207977.8). The p.Ser94Leu variant was present in 0.012% (3/24906) of African alleles in gnomAD (PM2 not met, gnomad.broadinstitute.org). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that this variant may impact protein function (PP3). In summary, the clinical significance of the p.Ser94Leu variant is uncertain. ACMG/AMP criteria applied: PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-05-18	2020-07-01	false	https://erepo.genome.network/evrepo/ui/classification/CA180967/MONDO:0021060/004	2ae26f96-8b07-456f-9375-37c36e0c6d97
NM_030662.4(MAP2K2):c.844C>T (p.Pro282Ser)	40826	CA137972	NM_030662.4:c.844C>T, NC_000019.10:g.4099276G>A, CM000681.2:g.4099276G>A, NC_000019.9:g.4099274G>A, CM000681.1:g.4099274G>A, NC_000019.8:g.4050274G>A, NG_007996.1:g.29853C>T, LRG_750:g.29853C>T, ENST00000394867.9:n.1283C>T, ENST00000687128.1:n.1283C>T, ENST00000688002.1:n.1138C>T, ENST00000689792.1:n.748C>T, ENST00000262948.10:c.844C>T, ENST00000262948.9:c.844C>T, ENST00000394867.8:c.553C>T, ENST00000593364.5:n.791C>T, ENST00000595715.1:n.659C>T, ENST00000597263.5:n.169+1743C>T, ENST00000599021.1:c.29+1743C>T, ENST00000600584.5:n.1404C>T, ENST00000601786.5:n.1145C>T, NM_030662.3:c.844C>T, LRG_750t1:c.844C>T, XM_006722799.2:c.705+1743C>T, XM_011528133.1:c.274C>T, XM_017026989.1:c.844C>T, XM_017026990.1:c.705+1743C>T, NM_030662.4(MAP2K2):c.844C>T (p.Pro282Ser)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP4, BP5	PP3, BS1, PM2	The c.844C>T variant in the MAP2K2 gene is a missense variant predicted to cause substitution of proline by serine at amino acid 282 (p.Pro282Ser). The filtering allele frequency in gnomAD v2.1.1 is 0.001415 (42/22756 alleles) in the African/African American population, meeting the criterion for BA1. The computational predictor REVEL gives a score of 0.072, which predicts no impact on protein function (BP4). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx internal data; GTR ID's 26957; SCV000207963.8). In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BP4, BP5 (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA137972/MONDO:0021060/048	413325d3-6867-4b66-a6a6-655f337675bc
NM_007373.3(SHOC2):c.1540+8C>T	448936	CA5689792	NM_007373.3:c.1540+8C>T, NM_001269039.1:c.1402+8C>T, LRG_753t1:c.1540+8C>T, XM_011540216.1:c.457+8C>T, NM_001269039.2:c.1402+8C>T, NM_001324336.1:c.1540+8C>T, NM_001324337.1:c.1540+8C>T, NR_136749.1:n.952+8C>T, ENST00000265277.9:c.1402+8C>T, ENST00000369452.8:c.1540+8C>T, ENST00000451838.1:n.910+8C>T, ENST00000489390.1:n.754+8C>T, NC_000010.11:g.111009838C>T, CM000672.2:g.111009838C>T, NC_000010.10:g.112769596C>T, CM000672.1:g.112769596C>T, NC_000010.9:g.112759586C>T, NG_028922.1:g.95296C>T, LRG_753:g.95296C>T, NM_007373.3(SHOC2):c.1540+8C>T	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.1540+8C>T variant in the SHOC2 gene is 0.0374% (34/66702) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5689792/MONDO:0021060/004	f1d3c01f-a03b-43fe-9292-f016ee2c4a44
NM_030662.3(MAP2K2):c.619G>A (p.Glu207Lys)	40813	CA180944	NM_030662.3:c.619G>A, LRG_750t1:c.619G>A, XM_006722799.2:c.619G>A, XM_011528133.1:c.49G>A, XM_017026989.1:c.619G>A, XM_017026990.1:c.619G>A, XM_017026991.1:c.619G>A, NM_030662.4:c.619G>A, ENST00000262948.9:c.619G>A, ENST00000394867.8:c.328G>A, ENST00000593364.5:n.566G>A, ENST00000597008.5:n.220G>A, ENST00000597263.5:n.83G>A, ENST00000599345.1:n.889G>A, ENST00000601786.5:n.920G>A, ENST00000602167.5:n.339G>A, NC_000019.10:g.4101105C>T, CM000681.2:g.4101105C>T, NC_000019.9:g.4101103C>T, CM000681.1:g.4101103C>T, NC_000019.8:g.4052103C>T, NG_007996.1:g.28024G>A, LRG_750:g.28024G>A, NM_030662.3(MAP2K2):c.619G>A (p.Glu207Lys)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS4, PS2, PM2, PM6, PP2		The c.619G>A (p.Glu207Lys) variant in MAP2K2 was absent from large population studies (PM2; gnomAD.broadinstitute.org). It has been identified in 6 individuals with clinical features of a RASopathy (PS4; SCV000204213.4, SCV000207959.10, SCV000815593.1, Otto von Guericke University Magdeburg internal data). One of these cases was a confirmed de novo occurrence and another was an unconfirmed de novo occurrence (PS2; PM6; SCV000815593.1, Otto von Guericke University Magdeburg internal data). Additionally, the c.619G>A (p.Glu207Lys) is located in MAP2K2, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4, PS2, PM6, PM2, PP2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-06-25	false	https://erepo.genome.network/evrepo/ui/classification/CA180944/MONDO:0015280/004	93491eab-4df5-480a-a62b-7022611f18ee
NM_002755.4(MAP2K1):c.169A>C (p.Lys57Gln)	40779	CA134595	NM_002755.4:c.169A>C, NC_000015.10:g.66435115A>C, CM000677.2:g.66435115A>C, NC_000015.9:g.66727453A>C, CM000677.1:g.66727453A>C, NC_000015.8:g.64514507A>C, NG_008305.1:g.53243A>C, LRG_725:g.53243A>C, ENST00000684779.1:c.103A>C, ENST00000685172.1:c.169A>C, ENST00000685763.1:c.169A>C, ENST00000686347.1:c.169A>C, ENST00000687191.1:n.605A>C, ENST00000689951.1:c.169A>C, ENST00000691077.1:c.169A>C, ENST00000691576.1:c.169A>C, ENST00000691937.1:c.169A>C, ENST00000692487.1:c.169A>C, ENST00000692683.1:c.103A>C, ENST00000693150.1:c.103A>C, ENST00000307102.10:c.169A>C, ENST00000307102.9:c.169A>C, ENST00000425818.2:n.680A>C, NM_002755.3:c.169A>C, LRG_725t1:c.169A>C, XM_011521783.1:c.103A>C, XM_011521783.3:c.103A>C, XM_017022411.2:c.169A>C, XM_017022412.1:c.103A>C, NM_002755.4(MAP2K1):c.169A>C (p.Lys57Gln)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PP3, PP2, PM6, PM2, PM1, PS2, PS4		The c.169A>C variant in the MAP2K1 gene is a missense variant predicted to cause substitution of lysine by glutamine at amino acid 57 (p.Lys57Gln). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.726, evidence that the p.Lys57Gln variant may impact the protein function (PP3). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). The variant is located in a specific region supporting pathogenicity (PM1, aa 43-61). This variant has been reported in at least 6 independent patients with clinical feature of a RASopathy, 1 as a confirmed de novo occurrence and 1 as an unconfirmed de novo occurrence (PS2, PS4; Partners LMM, GeneDx, Invitae, Baylor, Otto von Guericke University Magdeburg internal data; ClinVar SCV000061249.5, SCV000207949.3, SCV001568953.4, PMID: 35524774). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2, PS4, PM1, PM2_Supporting, PP2, PP3 (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-27	false	https://erepo.genome.network/evrepo/ui/classification/CA134595/MONDO:0021060/045	5fa3b275-1dad-4c57-bed5-dd904a8b11bb
NM_002755.3(MAP2K1):c.694-8_694-7dupTC	94082	CA147595	NM_002755.3:c.694-7_694-6insTC, NM_002755.3:c.694-8_694-7dupTC, NC_000015.10:g.66484982_66484983dup, CM000677.2:g.66484982_66484983dup, NC_000015.9:g.66777320_66777321dup, CM000677.1:g.66777320_66777321dup, NC_000015.8:g.64564374_64564375dup, NG_008305.1:g.103110_103111dup, LRG_725:g.103110_103111dup, ENST00000684779.1:c.628-2246_628-2245dup, ENST00000685172.1:c.694-8_694-7dup, ENST00000685763.1:c.547-8_547-7dup, ENST00000686347.1:c.569-2246_569-2245dup, ENST00000687191.1:n.1052-8_1052-7dup, ENST00000687481.1:n.101_102dup, ENST00000689951.1:c.745-8_745-7dup, ENST00000691077.1:c.694-12_694-11dup, ENST00000691576.1:c.569-12_569-11dup, ENST00000691937.1:c.694-8_694-7dup, ENST00000692487.1:c.694-12_694-11dup, ENST00000692683.1:c.628-8_628-7dup, ENST00000693150.1:c.550-8_550-7dup, ENST00000307102.10:c.694-8_694-7dup, ENST00000307102.9:c.694-8_694-7dup, ENST00000566326.1:c.166-8_166-7dup, NM_002755.3:c.694-8_694-7dup, LRG_725t1:c.694-8_694-7dup, XM_011521783.1:c.628-8_628-7dup, XM_011521783.3:c.628-8_628-7dup, XM_017022411.2:c.616-8_616-7dup, XM_017022412.1:c.550-8_550-7dup, XM_017022413.1:c.166-8_166-7dup, NM_002755.4:c.694-8_694-7dup, NM_002755.3(MAP2K1):c.694-8_694-7dupTC	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP5, BP7	PP3, PM2, BS1	The c.694-8_694-7dupTC variant is an intronic variant located in intron 6 of the MAP2K1 gene. The filtering allele frequency in gnomAD v4.1.0 is 4.669% (3488/74934 alleles) in the African/African American population, which meets the threshold to apply BA1.  The computational predictor SpliceAI predicts no impact on splicing (BP7). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM, EGL genetics internal data 26957, 21766, 500060; ClinVar SCV000111925.5; SCV000204171.4; SCV000207934.6). In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BP5, BP7 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA147595/MONDO:0021060/045	683b32d2-f588-4a79-be69-e8717aa258d0
NM_004985.5(KRAS):c.451-14T>C	138060	CA176485	NM_004985.5:c.451-14T>C, NC_000012.12:g.25209925A>G, CM000674.2:g.25209925A>G, NC_000012.11:g.25362859A>G, CM000674.1:g.25362859A>G, NC_000012.10:g.25254126A>G, NG_007524.1:g.45996T>C, NG_007524.2:g.46079T>C, ENST00000557334.6:c.112-14T>C, ENST00000685328.1:c.451-14T>C, ENST00000686877.1:c.*422-14T>C, ENST00000687356.1:c.*149-14T>C, ENST00000688228.1:n.925-14T>C, ENST00000688940.1:c.451-14T>C, ENST00000690406.1:c.254-14T>C, ENST00000690804.1:c.*412-14T>C, ENST00000692768.1:c.253-14T>C, ENST00000693229.1:c.376-14T>C, ENST00000256078.10:c.*5-14T>C, ENST00000311936.8:c.451-14T>C, ENST00000256078.8:c.*5-14T>C, ENST00000311936.7:c.451-14T>C, ENST00000557334.5:c.112-14T>C, NM_004985.4:c.451-14T>C, NM_033360.3:c.*5-14T>C, XM_006719069.2:c.*5-14T>C, XM_011520653.1:c.451-14T>C, XM_006719069.4:c.*5-14T>C, XM_011520653.3:c.451-14T>C, NM_001369786.1:c.*5-14T>C, NM_001369787.1:c.451-14T>C, NM_033360.4:c.*5-14T>C, NM_004985.5(KRAS):c.451-14T>C	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP4, BP7	PP3, BA1, BS1, PM2	The c.451-14T>C variant in the KRAS gene is an intronic variant located in intron 6. The filtering allele frequency in gnomAD v4.1.0 is 0.01135% (10/73838 alleles) in the African/African American population (PM2_Supporting/ BS1/ BA1 are not met).This variant is located at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP4, BP7). In summary, this variant meets criteria to be classified as likely benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BP4, BP7 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA176485/MONDO:0021060/044	8ec28790-8df3-4c37-9e77-84dddf694f7a
NM_004985.5(KRAS):c.65A>G (p.Gln22Arg)	40452	CA235299	NM_004985.5:c.65A>G, NC_000012.12:g.25245320T>C, CM000674.2:g.25245320T>C, NC_000012.11:g.25398254T>C, CM000674.1:g.25398254T>C, NC_000012.10:g.25289521T>C, NG_007524.1:g.10601A>G, NG_007524.2:g.10684A>G, ENST00000556131.2:c.65A>G, ENST00000557334.6:c.65A>G, ENST00000685328.1:c.65A>G, ENST00000686877.1:c.65A>G, ENST00000686969.1:c.65A>G, ENST00000687356.1:c.65A>G, ENST00000688940.1:c.65A>G, ENST00000690804.1:c.65A>G, ENST00000692768.1:c.-88+5431A>G, ENST00000693229.1:c.65A>G, ENST00000256078.10:c.65A>G, ENST00000311936.8:c.65A>G, ENST00000256078.8:c.65A>G, ENST00000311936.7:c.65A>G, ENST00000556131.1:c.65A>G, ENST00000557334.5:c.65A>G, NM_004985.4:c.65A>G, NM_033360.3:c.65A>G, XM_006719069.2:c.65A>G, XM_011520653.1:c.65A>G, XM_006719069.4:c.65A>G, XM_011520653.3:c.65A>G, NM_001369786.1:c.65A>G, NM_001369787.1:c.65A>G, NM_033360.4:c.65A>G, NM_004985.5(KRAS):c.65A>G (p.Gln22Arg)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PP3, PP2, PM2_Supporting, PS4, PS3_Supporting, PM6_Very Strong	BA1, BP4, BP1, BS1, BS3	The c.65A>G variant in the KRAS gene is a missense variant predicted to cause substitution of glutamine by arginine at amino acid 22 (p.Glln22Arg). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.749 supporting a deleterious impact to KRAS function (PP3). The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). This variant has been reported in several individuals with clinical features of a RASopathy, with 2 unconfirmed de novo occurrences (PS4, PM6_VeryStrong; GeneDx, Partners LMM, HudsonAlpha Institute for Biotechnology, Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago, ARUP Laboratories, Molecular Genetics and Genomics; ClinVar: SCV000207881.10; SCV000198473.4; SCV001870321.1; SCV000678231.1; SCV000604082.1). In vitro functional studies showed that this variant enhanced ERK activation (PS3_Supporting; PMID: 20949621). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PM6_VeryStrong, PS4, PS3_Supporting, PM2_Supporting, PP2, PP3 (Specification Version 2.3, 12/3/2024)	20949621	RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA235299/MONDO:0021060/044	f148a4b1-945e-4dc1-8d90-77bc00006052
NM_033360.4(KRAS):c.15A>T (p.Lys5Asn)	12594	CA234191	NM_033360.4:c.15A>T, NC_000012.12:g.25245370T>A, CM000674.2:g.25245370T>A, NC_000012.11:g.25398304T>A, CM000674.1:g.25398304T>A, NC_000012.10:g.25289571T>A, NG_007524.1:g.10551A>T, NG_007524.2:g.10634A>T, ENST00000556131.2:c.15A>T, ENST00000557334.6:c.15A>T, ENST00000685328.1:c.15A>T, ENST00000686877.1:c.15A>T, ENST00000686969.1:c.15A>T, ENST00000687356.1:c.15A>T, ENST00000688940.1:c.15A>T, ENST00000690804.1:c.15A>T, ENST00000692768.1:c.-88+5381A>T, ENST00000693229.1:c.15A>T, ENST00000256078.10:c.15A>T, ENST00000311936.8:c.15A>T, ENST00000256078.8:c.15A>T, ENST00000311936.7:c.15A>T, ENST00000556131.1:c.15A>T, ENST00000557334.5:c.15A>T, NM_004985.4:c.15A>T, NM_033360.3:c.15A>T, XM_006719069.2:c.15A>T, XM_011520653.1:c.15A>T, XM_006719069.4:c.15A>T, XM_011520653.3:c.15A>T, NM_001369786.1:c.15A>T, NM_001369787.1:c.15A>T, NM_004985.5:c.15A>T, NM_033360.4(KRAS):c.15A>T (p.Lys5Asn)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PP3, PP2, PM2_Supporting, PS4, PS3_Supporting, PS2_Very Strong	BP4, BA1, BS1	The c.15A>T variant in the KRAS gene is a missense variant predicted to cause substitution of lysine by asparagine at amino acid 5 (p.Lys5Asn). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.764 supporting a deleterious impact to KRAS function (PP3). The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). This variant has been reported in at least 5 individuals with clinical features of a RASopathy, in 2 confirmed de novo occurrences (PS4, PS2_VeryStrong; PMID: 17056636; Ambry, EGL Genetics, Invitae internal data, ClinVar SCV000742406.3, SCV000202928.7). In vitro functional studies showed that the p.Val14Ile variant enhanced MEK activation (PS3_Supporting; PMID: 20949621). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2_VeryStrong, PS4, PS3_Supporting, PM2_Supporting, PP2, PP3 (Specification Version 2.3, 12/3/2024).	20949621	RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA234191/MONDO:0021060/044	15c2f120-e3bd-4bf0-8ecb-86290c93de7c
NM_004985.5(KRAS):c.528GAA[1] (p.Lys180del)	45129	CA135584	NM_004985.5:c.528GAA[1], NC_000012.12:g.25209834_25209836del, CM000674.2:g.25209834_25209836del, NC_000012.11:g.25362768_25362770del, CM000674.1:g.25362768_25362770del, NC_000012.10:g.25254035_25254037del, NG_007524.1:g.46090_46092del, NG_007524.2:g.46173_46175del, ENST00000557334.6:c.192_194del, ENST00000685328.1:c.531_533del, ENST00000686877.1:c.*502_*504del, ENST00000687356.1:c.*229_*231del, ENST00000688228.1:n.1005_1007del, ENST00000688940.1:c.531_533del, ENST00000690406.1:c.334_336del, ENST00000690804.1:c.*492_*494del, ENST00000692768.1:c.333_335del, ENST00000693229.1:c.456_458del, ENST00000256078.10:c.*85_*87del, ENST00000311936.8:c.531_533del, ENST00000256078.8:c.*85_*87del, ENST00000311936.7:c.531_533del, ENST00000557334.5:c.192_194del, NM_004985.4:c.531_533del, NM_033360.3:c.*85_*87del, XM_006719069.2:c.*85_*87del, XM_011520653.1:c.531_533del, XM_006719069.4:c.*85_*87del, XM_011520653.3:c.531_533del, NM_001369786.1:c.*85_*87del, NM_001369787.1:c.531_533del, NM_004985.5:c.531_533del, NM_033360.4:c.*85_*87del, NM_004985.5(KRAS):c.528GAA[1] (p.Lys180del)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP5	BS1, PM2	The c.531_533delGAA variant in the KRAS gene is an in-frame deletion of the amino acid lysine (Lys) at position 180 (p.Lys180del). The gnomAD v.4.1.0 filtering allele frequency of this variant is 0.1339% for European (non-Finnish) chromosomes (1637/1177578 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM internal data; GTR ID's: 21766, 26957; ClinVar SCV000061947, SCV000207865). In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BP5 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA135584/MONDO:0021060/044	54ddcd15-893f-4be1-9525-18126097d55a
NM_004985.5(KRAS):c.519T>C (p.Asp173=)	41449	CA135582	NM_004985.5:c.519T>C, NC_000012.12:g.25209843A>G, CM000674.2:g.25209843A>G, NC_000012.11:g.25362777A>G, CM000674.1:g.25362777A>G, NC_000012.10:g.25254044A>G, NG_007524.1:g.46078T>C, NG_007524.2:g.46161T>C, ENST00000557334.6:c.180T>C, ENST00000685328.1:c.519T>C, ENST00000686877.1:c.*490T>C, ENST00000687356.1:c.*217T>C, ENST00000688228.1:n.993T>C, ENST00000688940.1:c.519T>C, ENST00000690406.1:c.322T>C, ENST00000690804.1:c.*480T>C, ENST00000692768.1:c.321T>C, ENST00000693229.1:c.444T>C, ENST00000256078.10:c.*73T>C, ENST00000311936.8:c.519T>C, ENST00000256078.8:c.*73T>C, ENST00000311936.7:c.519T>C, ENST00000557334.5:c.180T>C, NM_004985.4:c.519T>C, NM_033360.3:c.*73T>C, XM_006719069.2:c.*73T>C, XM_011520653.1:c.519T>C, XM_006719069.4:c.*73T>C, XM_011520653.3:c.519T>C, NM_001369786.1:c.*73T>C, NM_001369787.1:c.519T>C, NM_033360.4:c.*73T>C, NM_004985.5(KRAS):c.519T>C (p.Asp173=)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP4, BP7	PP3, BS1, PM2	The c.519T>C variant in the KRAS gene is a synonymous (silent) variant (p.Asp173=) at a nucleotide that is not conserved as shown by UCSC browser, and not predicted by SpliceAI to impact splicing (BP4, BP7). The filtering allele frequency in gnomAD v2.1.1 is 0.2201 (28382/128282 alleles with 3073 homozygotes) in the European (non-Finnish) population, which is higher than the ClinGen RASopathy VCEP threshold (>0.0005) for BA1, and therefore meets this criterion (BA1). In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BP4, BP7 (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA135582/MONDO:0021060/044	ecd3287d-e567-4c6a-ad88-0fcb872a517d
NM_005343.3(HRAS):c.510G>A (p.Lys170=)	45305	CA135992	NM_005343.3:c.510G>A, NC_000011.10:g.532696C>T, CM000673.2:g.532696C>T, NC_000011.9:g.532696C>T, CM000673.1:g.532696C>T, NC_000011.8:g.522696C>T, NG_007666.1:g.7855G>A, ENST00000397594.7:c.*20-66G>A, ENST00000417302.7:c.*79G>A, ENST00000397594.6:c.251-66G>A, ENST00000417302.6:c.*79G>A, ENST00000462734.2:c.*122G>A, ENST00000311189.8:c.510G>A, ENST00000311189.7:c.510G>A, ENST00000397594.5:c.*79G>A, ENST00000397596.6:c.510G>A, ENST00000417302.5:c.*79G>A, ENST00000451590.5:c.510G>A, ENST00000462734.1:n.285G>A, ENST00000478324.5:n.243-66G>A, ENST00000479482.1:n.431G>A, ENST00000493230.5:c.*79G>A, NM_001130442.1:c.510G>A, NM_005343.2:c.510G>A, NM_176795.3:c.*79G>A, XM_011519875.1:c.-425+4359C>T, XM_011519877.1:c.-162+4359C>T, XR_242795.1:n.791G>A, NM_001130442.2:c.510G>A, NM_001318054.1:c.273G>A, NM_176795.4:c.*79G>A, XM_011519875.2:c.-425+4359C>T, XM_011519877.2:c.-162+4359C>T, XM_017017167.1:c.-500+4359C>T, XM_017017168.1:c.-500+4359C>T, NM_005343.4:c.510G>A, NM_001318054.2:c.273G>A, NM_001130442.3:c.510G>A, NM_176795.5:c.*79G>A, NM_005343.3(HRAS):c.510G>A (p.Lys170=)	HRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP5, BP7, BS1, BP4	PM2, PP3, BA1	The c.510G>A variant in the HRAS gene is a synonymous (silent) variant (p.Lys170=) at a nucleotide that is not predicted by SpliceAI to impact splicing (BP4, BP7). The filtering allele frequency in gnomAD v4.1.0 is 0.02525% (17/44900 alleles) in the East Asian population meeting BS1. This variant has been identified in patients with an alternate molecular basis for disease (BP5; LMM and GeneDx internal data; GTR ID's: 21766, 26957; ClinVar SCV000062144.5; SCV000168832.9). In summary, this variant meets criteria to be classified as likely benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BS1, BP4, BP5, BP7 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA135992/MONDO:0021060/046	9a40f720-b52f-4f73-b00a-f4480714a568
NM_005343.3(HRAS):c.175G>A (p.Ala59Thr)	40435	CA176353	NM_005343.3:c.175G>A, NC_000011.10:g.533881C>T, CM000673.2:g.533881C>T, NC_000011.9:g.533881C>T, CM000673.1:g.533881C>T, NC_000011.8:g.523881C>T, NG_007666.1:g.6670G>A, ENST00000397594.7:c.175G>A, ENST00000417302.7:c.175G>A, ENST00000417302.6:c.175G>A, ENST00000462734.2:c.175G>A, ENST00000311189.8:c.175G>A, ENST00000311189.7:c.175G>A, ENST00000397594.5:c.175G>A, ENST00000397596.6:c.175G>A, ENST00000417302.5:c.175G>A, ENST00000451590.5:c.175G>A, ENST00000468682.2:n.663G>A, ENST00000479482.1:n.96G>A, ENST00000493230.5:c.175G>A, NM_001130442.1:c.175G>A, NM_005343.2:c.175G>A, NM_176795.3:c.175G>A, XM_011519875.1:c.-424-4717C>T, XM_011519877.1:c.-162+5544C>T, XR_242795.1:n.374G>A, NM_001130442.2:c.175G>A, NM_001318054.1:c.-145G>A, NM_176795.4:c.175G>A, XM_011519875.2:c.-424-4717C>T, XM_011519877.2:c.-162+5544C>T, XM_017017167.1:c.-499-4642C>T, XM_017017168.1:c.-499-4642C>T, NM_005343.4:c.175G>A, NM_001318054.2:c.-145G>A, NM_001130442.3:c.175G>A, NM_176795.5:c.175G>A, NM_005343.3(HRAS):c.175G>A (p.Ala59Thr)	HRAS	RASopathy	MONDO:0009026	Autosomal dominant inheritance	Likely Pathogenic	PS4_Moderate, PM1, PP1, PP3, PM2_Supporting	BS1, PP2, BA1, BP4	The c.175G>A variant in the HRAS gene is a missense variant predicted to cause substitution of alanine by threonine at amino acid 59 (p.Ala59Thr). This variant was absent from gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives a score of 0.755 supporting deleterious impact to HRAS function (PP3). This variant resides within a region (amino acids 57 â€“ 64), of HRAS that is defined as a critical functional domain by the ClinGen RASopathy VCEP (PM1). The c.175G>A (p.Ala59Thr) variant has been identified in at least 3 independent occurrences in patients with a RASopathy (PS4_Moderate; GeneDx, Partners Laboratory for Molecular Medicine, Invitae internal data, ClinVar SCV000198374.4, SCV000950586.1). Moreover, this variant has been reported to segregate with clinical features of a RASopathy in at least 3 family members (PP1; Partners Laboratory for Molecular Medicine internal data, ClinVar SCV000198374.4). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS4_Moderate, PM1, PM2_Supporting, PP1, PP3 (Specification Version 2.1, 09/17/2024)	29493581	RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA176353/MONDO:0009026/046	2bb21939-344a-41a8-be46-3787926538b9
NM_005633.3(SOS1):c.3709C>A (p.Pro1237Thr)	45367	CA136149	NM_005633.3:c.3709C>A, LRG_754t1:c.3709C>A, XM_005264515.3:c.3664C>A, XM_011533060.1:c.3802C>A, XM_011533061.1:c.3757C>A, XM_011533062.1:c.3688C>A, XM_011533063.1:c.3685C>A, XM_011533064.1:c.3538C>A, XM_011533065.1:c.3604-754C>A, XM_011533066.1:c.2644C>A, XM_005264515.4:c.3664C>A, XM_011533062.2:c.3688C>A, XM_011533064.2:c.3538C>A, ENST00000395038.6:c.3664C>A, ENST00000402219.6:c.3709C>A, ENST00000426016.5:c.3709C>A, ENST00000469581.1:n.452C>A, NC_000002.12:g.38986117G>T, CM000664.2:g.38986117G>T, NC_000002.11:g.39213258G>T, CM000664.1:g.39213258G>T, NC_000002.10:g.39066762G>T, NG_007530.1:g.139347C>A, LRG_754:g.139347C>A, NM_005633.3(SOS1):c.3709C>A (p.Pro1237Thr)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.3709C>A (p.Pro1237Thr) variant in the SOS1 gene is 0.0373% (11/16510) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136149/MONDO:0021060/004	95b1a6fb-b4b5-4f40-b593-6235a54a0739
NM_176795.4(HRAS):c.277A>G (p.Ile93Val)	40439	CA296061	NM_176795.4:c.277A>G, NC_000011.10:g.533779T>C, CM000673.2:g.533779T>C, NC_000011.9:g.533779T>C, CM000673.1:g.533779T>C, NC_000011.8:g.523779T>C, NG_007666.1:g.6772A>G, ENST00000397594.7:c.277A>G, ENST00000417302.7:c.277A>G, ENST00000417302.6:c.277A>G, ENST00000462734.2:c.277A>G, ENST00000311189.8:c.277A>G, ENST00000311189.7:c.277A>G, ENST00000397594.5:c.277A>G, ENST00000397596.6:c.277A>G, ENST00000417302.5:c.277A>G, ENST00000451590.5:c.277A>G, ENST00000479482.1:n.198A>G, ENST00000493230.5:c.277A>G, NM_001130442.1:c.277A>G, NM_005343.2:c.277A>G, NM_176795.3:c.277A>G, XM_011519875.1:c.-424-4819T>C, XM_011519877.1:c.-162+5442T>C, XR_242795.1:n.476A>G, NM_001130442.2:c.277A>G, NM_001318054.1:c.-43A>G, NM_005343.3:c.277A>G, XM_011519875.2:c.-424-4819T>C, XM_011519877.2:c.-162+5442T>C, XM_017017167.1:c.-499-4744T>C, XM_017017168.1:c.-499-4744T>C, NM_005343.4:c.277A>G, NM_001318054.2:c.-43A>G, NM_001130442.3:c.277A>G, NM_176795.5:c.277A>G, NM_176795.4(HRAS):c.277A>G (p.Ile93Val)	HRAS	RASopathy	MONDO:0009026	Autosomal dominant inheritance	Uncertain Significance	BP4	PS4, BS1, PM2, PP2, PP3, BS2, BA1	The c.277A>G variant in the HRAS gene is a missense variant predicted to cause substitution of isoleucine by valine at amino acid 93 (p.Ile93Val). The highest population minor allele frequency in gnomAD v4.1.0 is 0.0002053% (2/63238 alleles) in the European (Finnish) population (PM2_Supporting/BS1/BA1 are not met). The computational predictor REVEL gives a score of 0.141 and does not predict a damaging effect on HRAS function (BP4). The c.277A>G (p.Ile93Val) variant has been identified in 1 patient with a features of a RASopathy, however an additional proband inherited this variant from an asymptomatic parent (PS4_Supporting not met, BS2 not met; GeneDx internal data, Blueprint Genetics internal data; GTR ID's: 26957, 500188; ClinVar SCV000207855.10, SCV000188770.2). In summary, this variant meets criteria to be classified as variant of uncertain significance for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BP4 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA296061/MONDO:0009026/046	f12837d2-3463-4374-982c-98e2b63c406a
NM_005343.3(HRAS):c.81T>C (p.His27=)	40431	CA135996	NM_005343.3:c.81T>C, NC_000011.10:g.534242A>G, CM000673.2:g.534242A>G, NC_000011.9:g.534242A>G, CM000673.1:g.534242A>G, NC_000011.8:g.524242A>G, NG_007666.1:g.6309T>C, NM_001130442.1:c.81T>C, NM_005343.2:c.81T>C, NM_176795.3:c.81T>C, XM_011519875.1:c.-424-4356A>G, XM_011519877.1:c.-161-5338A>G, XR_242795.1:n.280T>C, NM_001130442.2:c.81T>C, NM_001318054.1:c.-239T>C, NM_176795.4:c.81T>C, XM_011519875.2:c.-424-4356A>G, XM_011519877.2:c.-161-5338A>G, XM_017017167.1:c.-499-4281A>G, XM_017017168.1:c.-499-4281A>G, NM_005343.4:c.81T>C, ENST00000311189.7:c.81T>C, ENST00000397594.5:c.81T>C, ENST00000397596.6:c.81T>C, ENST00000417302.5:c.81T>C, ENST00000451590.5:c.81T>C, ENST00000468682.2:n.569T>C, ENST00000493230.5:c.81T>C, NM_005343.3(HRAS):c.81T>C (p.His27=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.81T>C (p.His27=) variant in the HRAS gene is 36.7% for African chromosomes by the Exome Aggregation Consortium (3874/10274 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Additional case-level data provided by: SCV000058315; SCV000062146; SCV000196686.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135996/MONDO:0021060/004	c23db7a4-fb09-4dd7-9ab1-e7f4dfc7dbe9
NM_005343.4(HRAS):c.257A>C (p.Asn86Thr)	40437	CA180888	NM_005343.4:c.257A>C, NC_000011.10:g.533799T>G, CM000673.2:g.533799T>G, NC_000011.9:g.533799T>G, CM000673.1:g.533799T>G, NC_000011.8:g.523799T>G, NG_007666.1:g.6752A>C, ENST00000397594.7:c.257A>C, ENST00000417302.7:c.257A>C, ENST00000417302.6:c.257A>C, ENST00000462734.2:c.257A>C, ENST00000311189.8:c.257A>C, ENST00000311189.7:c.257A>C, ENST00000397594.5:c.257A>C, ENST00000397596.6:c.257A>C, ENST00000417302.5:c.257A>C, ENST00000451590.5:c.257A>C, ENST00000468682.2:n.745A>C, ENST00000479482.1:n.178A>C, ENST00000493230.5:c.257A>C, NM_001130442.1:c.257A>C, NM_005343.2:c.257A>C, NM_176795.3:c.257A>C, XM_011519875.1:c.-424-4799T>G, XM_011519877.1:c.-162+5462T>G, XR_242795.1:n.456A>C, NM_001130442.2:c.257A>C, NM_001318054.1:c.-63A>C, NM_005343.3:c.257A>C, NM_176795.4:c.257A>C, XM_011519875.2:c.-424-4799T>G, XM_011519877.2:c.-162+5462T>G, XM_017017167.1:c.-499-4724T>G, XM_017017168.1:c.-499-4724T>G, NM_001318054.2:c.-63A>C, NM_001130442.3:c.257A>C, NM_176795.5:c.257A>C, NM_005343.4(HRAS):c.257A>C (p.Asn86Thr)	HRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP5, BA1	BS1, PM2, PP3, BP4	The c.257A>C variant in the HRAS gene is a missense variant predicted to cause substitution of asparagine by threonine at amino acid 86 (p.Asn86Thr). The filtering allele frequency in gnomAD v2.1.1 is 0.0006669 (22/24924 alleles) in the Latino/Admixed American population, which is higher than the ClinGen RASopathy VCEP threshold (>0.0005) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.367, which is neither above nor below the thresholds predicting a damaging or benign impact on HRAS function. This variant has been identified in a patient with an alternate molecular basis for disease (BP5; Partners LMM, GeneDx internal data GTR ID: 21766, 26957, ClinVar SCV000204177.4, SCV000207861.7). In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BP5 (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA180888/MONDO:0021060/046	7a67f8eb-da68-4c6b-9d98-ee169176af3c
NM_004333.4(BRAF):c.1785T>G (p.Phe595Leu)	177672	CA280058	NM_004333.4:c.1785T>G, NC_000007.14:g.140753350A>C, CM000669.2:g.140753350A>C, NC_000007.13:g.140453150A>C, CM000669.1:g.140453150A>C, NC_000007.12:g.140099619A>C, NG_007873.3:g.176415T>G, LRG_299:g.176415T>G, LRG_299t1:c.1785T>G, XM_005250045.1:c.1785T>G, XM_005250046.1:c.1785T>G, XM_011516529.1:c.1785T>G, XM_011516530.1:c.1695-3932T>G, XR_242190.1:n.1793T>G, XR_927520.1:n.1793T>G, XR_927521.1:n.1793T>G, XR_927522.1:n.1703-3932T>G, XR_927523.1:n.1703-3932T>G, NM_001354609.1:c.1785T>G, NM_004333.5:c.1785T>G, NR_148928.1:n.2883T>G, XM_017012558.1:c.1905T>G, XM_017012559.1:c.1905T>G, XR_001744857.1:n.1913T>G, XR_001744858.1:n.1823-3932T>G, ENST00000288602.10:c.1785T>G, ENST00000479537.5:n.69T>G, ENST00000496384.6:n.608T>G, ENST00000497784.1:n.1820T>G, NM_004333.4(BRAF):c.1785T>G (p.Phe595Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM1, PM2, PP2, PP3, PS4_Supporting, PM6_Strong		The c.1785T>G (p.Phe595Leu) variant in BRAF has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 19206169, 18042262; GTR ID's: 26957, 21766; ClinVar SCV000203922.4, SCV000207755.12). The variant has also been identified in at least 2 independent occurences in patients with clinical features of a RASopathy (PS4_Supporting; APHP-Robert DebrÃ© internal data; GTR ID 28338). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581, 16439621). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe595Leu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PM6_Strong, PM2, PM1, PP2, PP3, PS4_Supporting.	29493581, 16439621, 19206169, 8042262	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA280058/MONDO:0021060/004	020e6a22-3189-484a-8ca8-77cd1a08adba
NM_004333.4(BRAF):c.111G>A (p.Ser37=)	162804	CA175346	NM_004333.4:c.111G>A, NC_000007.14:g.140924593C>T, CM000669.2:g.140924593C>T, NC_000007.13:g.140624393C>T, CM000669.1:g.140624393C>T, NC_000007.12:g.140270862C>T, NG_007873.3:g.5172G>A, LRG_299:g.5172G>A, LRG_299t1:c.111G>A, XM_005250045.1:c.111G>A, XM_005250046.1:c.111G>A, XM_011516529.1:c.111G>A, XM_011516530.1:c.111G>A, XR_242190.1:n.119G>A, XR_927520.1:n.119G>A, XR_927521.1:n.119G>A, XR_927522.1:n.119G>A, XR_927523.1:n.119G>A, NM_001354609.1:c.111G>A, NM_004333.5:c.111G>A, NR_148928.1:n.336G>A, XM_017012558.1:c.111G>A, XM_017012559.1:c.111G>A, XR_001744857.1:n.119G>A, XR_001744858.1:n.119G>A, ENST00000288602.10:c.111G>A, ENST00000469930.1:n.117G>A, ENST00000497784.1:n.66G>A, NM_004333.4(BRAF):c.111G>A (p.Ser37=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP7, BP5		The c.111G>A (p.Ser37=) variant in BRAF is a synonymous (silent) variant at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP7). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; Partners LMM, GeneDx internal data, GTR ID's: SCV000197179.4, SCV000512270.5). In summary, this variant meets criteria to be classified as likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BP7, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA175346/MONDO:0021060/004	7e872ce6-f7c9-4c3d-a39e-8a174058fd77
NM_004333.6(BRAF):c.1433-19A>G	136532	CA232434	NM_004333.6:c.1433-19A>G, NC_000007.14:g.140778094T>C, CM000669.2:g.140778094T>C, NC_000007.13:g.140477894T>C, CM000669.1:g.140477894T>C, NC_000007.12:g.140124363T>C, NG_007873.3:g.151671A>G, LRG_299:g.151671A>G, ENST00000646891.2:c.1433-19A>G, ENST00000288602.11:c.1553-19A>G, ENST00000479537.6:c.103-19A>G, ENST00000496384.7:c.1433-19A>G, ENST00000497784.2:c.*883-19A>G, ENST00000642228.1:c.*511-19A>G, ENST00000642875.1:n.997-19A>G, ENST00000644120.1:n.1823-19A>G, ENST00000644650.1:c.529-19A>G, ENST00000644905.1:n.1522-19A>G, ENST00000644969.2:c.1553-19A>G, ENST00000646730.1:c.1433-19A>G, ENST00000646891.1:c.1433-19A>G, ENST00000647434.1:c.476-19A>G, ENST00000288602.10:c.1433-19A>G, ENST00000496384.6:c.256-19A>G, ENST00000497784.1:c.1468-19A>G, NM_004333.4:c.1433-19A>G, LRG_299t1:c.1433-19A>G, XM_005250045.1:c.1433-19A>G, XM_005250046.1:c.1433-19A>G, XM_011516529.1:c.1433-19A>G, XM_011516530.1:c.1433-19A>G, XR_242190.1:n.1441-19A>G, XR_927520.1:n.1441-19A>G, XR_927521.1:n.1441-19A>G, XR_927522.1:n.1441-19A>G, XR_927523.1:n.1441-19A>G, NM_001354609.1:c.1433-19A>G, NM_004333.5:c.1433-19A>G, NR_148928.1:n.1738-19A>G, XM_017012558.1:c.1553-19A>G, XM_017012559.1:c.1553-19A>G, XR_001744857.1:n.1561-19A>G, XR_001744858.1:n.1561-19A>G, NM_001354609.2:c.1433-19A>G, NM_001374244.1:c.1553-19A>G, NM_001374258.1:c.1553-19A>G, NM_001378467.1:c.1442-19A>G, NM_001378468.1:c.1433-19A>G, NM_001378469.1:c.1367-19A>G, NM_001378470.1:c.1331-19A>G, NM_001378471.1:c.1322-19A>G, NM_001378472.1:c.1277-19A>G, NM_001378473.1:c.1277-19A>G, NM_001378474.1:c.1433-19A>G, NM_001378475.1:c.1169-19A>G, NM_004333.6(BRAF):c.1433-19A>G	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP4, BP5, BP7		The c.1433-19A>G in BRAF is an intronic variant located in intron 11. The minor allele frequency of this variant in gnomAD v4 is 0.2572% (3030/1178128) in the European (non-Finnish) population, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). This variant is not predicted by SpliceAI to impact splicing. In addition, it occurs at a nucleotide that is not conserved (BP4, BP7). This variant has been identified in at least 2 patients with clinical features of a RASopathy (PS4_Supporting not met; GeneDx, Greenwood Genetics, Otto von Guericke University Magdeburg, internal data, GTR ID's: 26957, 1019; ClinVar SCV000207632.1, SCV000167210.14). However, this variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx internal data, GTR ID's: 26957; ClinVar SCV000167210.14). In summary, this variant meets criteria to be classified as benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BA1, BP4, BP5, BP7 (Specification Version 2.1, 9/17/2024)		RASopathy VCEP		2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA232434/MONDO:0021060/049	32508ced-9033-4f01-b4c7-f8b4db5a4307
NM_004333.4(BRAF):c.1595G>A (p.Cys532Tyr)	40380	CA175337	NM_004333.4:c.1595G>A, NC_000007.14:g.140777011C>T, CM000669.2:g.140777011C>T, NC_000007.13:g.140476811C>T, CM000669.1:g.140476811C>T, NC_000007.12:g.140123280C>T, NG_007873.3:g.152754G>A, LRG_299:g.152754G>A, LRG_299t1:c.1595G>A, XM_005250045.1:c.1595G>A, XM_005250046.1:c.1595G>A, XM_011516529.1:c.1595G>A, XM_011516530.1:c.1595G>A, XR_242190.1:n.1603G>A, XR_927520.1:n.1603G>A, XR_927521.1:n.1603G>A, XR_927522.1:n.1603G>A, XR_927523.1:n.1603G>A, NM_001354609.1:c.1595G>A, NM_004333.5:c.1595G>A, NR_148928.1:n.1900G>A, XM_017012558.1:c.1715G>A, XM_017012559.1:c.1715G>A, XR_001744857.1:n.1723G>A, XR_001744858.1:n.1723G>A, NM_001354609.2:c.1595G>A, NM_001374244.1:c.1715G>A, NM_001374258.1:c.1715G>A, NM_004333.6:c.1595G>A, ENST00000288602.10:c.1595G>A, ENST00000496384.6:n.418G>A, ENST00000497784.1:n.1630G>A, NM_004333.4(BRAF):c.1595G>A (p.Cys532Tyr)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PS4_Moderate, PM2, PM6, PP2, PP3		The c.1595G>A (p.Cys532Tyr) variant in BRAF has been observed in three probands with RASopathies (PS4_Moderate; Laboratory for Molecular Medicine, Hopital Universitaire Robert Debre internal data, ClinVar SCV000197143.4) It has also been seen as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; EGL internal data, ClinVar SCV000112809.8). This variant was absent from large population studies (PM2; gnomad.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Cys532Tyr variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Moderate, PM2, PM6, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-05-18	2020-07-01	false	https://erepo.genome.network/evrepo/ui/classification/CA175337/MONDO:0021060/004	d9ad9287-b52a-479a-8ff9-9ba17dc649ae
NM_004333.4(BRAF):c.1227A>G (p.Ser409=)	40360	CA135058	NM_004333.4:c.1227A>G, NC_000007.14:g.140783108T>C, CM000669.2:g.140783108T>C, NC_000007.13:g.140482908T>C, CM000669.1:g.140482908T>C, NC_000007.12:g.140129377T>C, NG_007873.3:g.146657A>G, LRG_299:g.146657A>G, LRG_299t1:c.1227A>G, XM_005250045.1:c.1227A>G, XM_005250046.1:c.1227A>G, XM_011516529.1:c.1227A>G, XM_011516530.1:c.1227A>G, XR_242190.1:n.1235A>G, XR_927520.1:n.1235A>G, XR_927521.1:n.1235A>G, XR_927522.1:n.1235A>G, XR_927523.1:n.1235A>G, NM_001354609.1:c.1227A>G, NM_004333.5:c.1227A>G, NR_148928.1:n.1532A>G, XM_017012558.1:c.1347A>G, XM_017012559.1:c.1347A>G, XR_001744857.1:n.1355A>G, XR_001744858.1:n.1355A>G, ENST00000288602.10:c.1227A>G, ENST00000496384.6:n.50A>G, ENST00000497784.1:n.1262A>G, NM_004333.4(BRAF):c.1227A>G (p.Ser409=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP7, BP5, BA1, BP4		The filtering allele frequency of the c.1227A>G (p.Ser409=) variant in the BRAF gene is 0.313% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (233/66620 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Additionally, this variant is a synonymous (silent) variant at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP7). The p.Ser409= variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM, EGL Genetics internal data; GTR ID's: 21766, 26957, 500060; SCV000057203.8; SCV000061570.5; SCV000112807.7). Computational prediction tools and conservation analysis suggest that the p.Ser409= variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied: BA1, BP7, BP5, BP4.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135058/MONDO:0021060/004	dd0b96ec-49ad-4f28-801a-b7b31c5fe734
NM_004333.6(BRAF):c.92C>G (p.Ala31Gly)	44833	CA135146	NM_004333.6:c.92C>G, NC_000007.14:g.140924612G>C, CM000669.2:g.140924612G>C, NC_000007.13:g.140624412G>C, CM000669.1:g.140624412G>C, NC_000007.12:g.140270881G>C, NG_007873.3:g.5153C>G, LRG_299:g.5153C>G, ENST00000646891.2:c.92C>G, ENST00000288602.11:c.92C>G, ENST00000469930.2:c.92C>G, ENST00000496384.7:c.92C>G, ENST00000497784.2:c.92C>G, ENST00000642228.1:c.92C>G, ENST00000642272.1:n.115C>G, ENST00000642808.1:n.92C>G, ENST00000643790.1:n.95C>G, ENST00000644905.1:n.101C>G, ENST00000644969.2:c.92C>G, ENST00000646730.1:c.92C>G, ENST00000646891.1:c.92C>G, ENST00000288602.10:c.92C>G, ENST00000469930.1:n.98C>G, ENST00000497784.1:c.47C>G, NM_004333.4:c.92C>G, LRG_299t1:c.92C>G, XM_005250045.1:c.92C>G, XM_005250046.1:c.92C>G, XM_011516529.1:c.92C>G, XM_011516530.1:c.92C>G, XR_242190.1:n.100C>G, XR_927520.1:n.100C>G, XR_927521.1:n.100C>G, XR_927522.1:n.100C>G, XR_927523.1:n.100C>G, NM_001354609.1:c.92C>G, NM_004333.5:c.92C>G, NR_148928.1:n.317C>G, XM_017012558.1:c.92C>G, XM_017012559.1:c.92C>G, XR_001744857.1:n.100C>G, XR_001744858.1:n.100C>G, NM_001354609.2:c.92C>G, NM_001374244.1:c.92C>G, NM_001374258.1:c.92C>G, NM_001378467.1:c.92C>G, NM_001378468.1:c.92C>G, NM_001378469.1:c.92C>G, NM_001378470.1:c.92C>G, NM_001378471.1:c.92C>G, NM_001378474.1:c.92C>G, NM_001378475.1:c.92C>G, NM_004333.6(BRAF):c.92C>G (p.Ala31Gly)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS2, BP4		The c.92C>G variant in the BRAF gene is a missense variant predicted to cause substitution of alanine by glycine at amino acid 31 (p.Ala31Gly). The minor allele frequency in gnomAD v4 of this variant is 0.01119% (128/1143560 alleles) for the European (non-Finnish) population (PM2_Supporting/BS1/BA1 are not met). The REVEL computational prediction analysis tool produced a score of 0.207, which meets the threshold for BP4 application. This variant has been identified in at least 1 individual with clinical features of a RASopathy (PS4 not met; Partners LMM internal data; GTR ID's 21766; SCV000061629.5). However, the p.Ala31Gly variant was observed in at least one healthy adult individual who did not have clinical features of a RASopathy (BS2; Partners LMM and GeneDx internal data; GTR ID's 21766, 26957; SCV000061629.5, SCV000207745.9). In summary, this variant meets criteria to be classified as likely benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BS2, BP4 (Specification Version 2.1, 9/17/2024)		RASopathy VCEP		2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA135146/MONDO:0021060/049	2c995b09-a4bb-4aac-a4ff-9717ea5fe648
NM_030662.3(MAP2K2):c.818A>G (p.Lys273Arg)	40824	CA296139	NM_030662.3:c.818A>G, LRG_750t1:c.818A>G, XM_006722799.2:c.705+1717A>G, XM_011528133.1:c.248A>G, XM_017026989.1:c.818A>G, XM_017026990.1:c.705+1717A>G, ENST00000262948.9:c.818A>G, ENST00000394867.8:c.527A>G, ENST00000593364.5:n.765A>G, ENST00000595715.1:n.633A>G, ENST00000597263.5:n.169+1717A>G, ENST00000599021.1:n.29+1717A>G, ENST00000600584.5:n.1378A>G, ENST00000601786.5:n.1119A>G, NC_000019.10:g.4099302T>C, CM000681.2:g.4099302T>C, NC_000019.9:g.4099300T>C, CM000681.1:g.4099300T>C, NC_000019.8:g.4050300T>C, NG_007996.1:g.29827A>G, LRG_750:g.29827A>G, NM_030662.3(MAP2K2):c.818A>G (p.Lys273Arg)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.818A>G (p.Lys273Arg) variant in the MAP2K2 gene is 0.0368% (6/7088) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA296139/MONDO:0021060/004	905a415a-6df7-4dab-b492-c7ae4a886f9f
NM_004333.4(BRAF):c.968C>T (p.Ser323Leu)	44834	CA135149	NM_004333.4:c.968C>T, NC_000007.14:g.140800374G>A, CM000669.2:g.140800374G>A, NC_000007.13:g.140500174G>A, CM000669.1:g.140500174G>A, NC_000007.12:g.140146643G>A, NG_007873.3:g.129391C>T, LRG_299:g.129391C>T, LRG_299t1:c.968C>T, XM_005250045.1:c.968C>T, XM_005250046.1:c.968C>T, XM_011516529.1:c.968C>T, XM_011516530.1:c.968C>T, XR_242190.1:n.976C>T, XR_927520.1:n.976C>T, XR_927521.1:n.976C>T, XR_927522.1:n.976C>T, XR_927523.1:n.976C>T, NM_001354609.1:c.968C>T, NM_004333.5:c.968C>T, NR_148928.1:n.1273C>T, XM_017012558.1:c.968C>T, XM_017012559.1:c.968C>T, XR_001744857.1:n.976C>T, XR_001744858.1:n.976C>T, ENST00000288602.10:c.968C>T, ENST00000497784.1:n.1003C>T, NM_004333.4(BRAF):c.968C>T (p.Ser323Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.968C>T (p.Ser323Leu) variant in the BRAF gene is 0.06% for South Asian chromosomes by the Exome Aggregation Consortium (17/16512 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135149/MONDO:0021060/004	991935c6-c179-4715-b017-4dacb3dfd3ac
NM_004333.4(BRAF):c.1787G>T (p.Gly596Val)	40387	CA220161	NM_004333.4:c.1787G>T, NC_000007.14:g.140753348C>A, CM000669.2:g.140753348C>A, NC_000007.13:g.140453148C>A, CM000669.1:g.140453148C>A, NC_000007.12:g.140099617C>A, NG_007873.3:g.176417G>T, LRG_299:g.176417G>T, LRG_299t1:c.1787G>T, XM_005250045.1:c.1787G>T, XM_005250046.1:c.1787G>T, XM_011516529.1:c.1787G>T, XM_011516530.1:c.1695-3930G>T, XR_242190.1:n.1795G>T, XR_927520.1:n.1795G>T, XR_927521.1:n.1795G>T, XR_927522.1:n.1703-3930G>T, XR_927523.1:n.1703-3930G>T, NM_001354609.1:c.1787G>T, NM_004333.5:c.1787G>T, NR_148928.1:n.2885G>T, XM_017012558.1:c.1907G>T, XM_017012559.1:c.1907G>T, XR_001744857.1:n.1915G>T, XR_001744858.1:n.1823-3930G>T, ENST00000288602.10:c.1787G>T, ENST00000479537.5:n.71G>T, ENST00000496384.6:n.610G>T, ENST00000497784.1:n.1822G>T, NM_004333.4(BRAF):c.1787G>T (p.Gly596Val)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PP2, PP3, PM6_Strong		The c.1787G>T (p.Gly596Val) variant in BRAF has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 16439621, 25463315, Partners LMM and GeneDx internal data; GTR ID's: 21766, 26957; ClinVar SCV000197137, SCV000057237). In vitro functional studies provide some evidence that the p.Gly596Val variant may impact protein function (PS3; PMID 18413255). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly596Val variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581):  PM6_Strong, PS3, PM2, PP2, PP3, PM1.	18413255, 16439621, 25463315	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2020-01-23	false	https://erepo.genome.network/evrepo/ui/classification/CA220161/MONDO:0021060/004	5fbeb559-b94f-4487-833a-8ea50dea3862
NM_004985.4(KRAS):c.178G>C (p.Gly60Arg)	12586	CA273416	NM_004985.4:c.178G>C, NC_000012.12:g.25227346C>G, CM000674.2:g.25227346C>G, NC_000012.11:g.25380280C>G, CM000674.1:g.25380280C>G, NC_000012.10:g.25271547C>G, NG_007524.1:g.28575G>C, NM_033360.3:c.178G>C, XM_006719069.2:c.178G>C, XM_011520653.1:c.178G>C, XM_006719069.4:c.178G>C, XM_011520653.3:c.178G>C, ENST00000256078.8:c.178G>C, ENST00000311936.7:c.178G>C, ENST00000557334.5:c.112-17435G>C, NM_004985.4(KRAS):c.178G>C (p.Gly60Arg)	KRAS	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PP2, PP3, PM6_Strong		The c.178G>C (p.Gly60Arg) variant in KRAS has been reported in the literature as a de novo occurrence in 2 patients with clinical features of a RASopathy (PM6_Strong; PMID 16474404, 20949621). In vitro functional studies provide some evidence that the p.Gly60Arg variant may impact protein function (PS3; PMID 20949621). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is in KRAS, which has been defined by the ClinGen RASopathy Expert Panel as a gene with low rate of benign missense with missense variants commonly being pathogenic (PP2; PMID 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of KRAS (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly60Arg variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PM6_Strong, PS3, PM2, PM1, PP3, PP2.	20949621, 20949621, 16474404	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA273416/MONDO:0015280/004	a8c6153e-d737-4b86-8d68-caf8ddd418fd
NM_004985.4(KRAS):c.101C>T (p.Pro34Leu)	40454	CA235301	NM_004985.4:c.101C>T, NC_000012.12:g.25245284G>A, CM000674.2:g.25245284G>A, NC_000012.11:g.25398218G>A, CM000674.1:g.25398218G>A, NC_000012.10:g.25289485G>A, NG_007524.1:g.10637C>T, NG_007524.2:g.10720C>T, ENST00000556131.2:c.101C>T, ENST00000557334.6:c.101C>T, ENST00000685328.1:c.101C>T, ENST00000686877.1:c.101C>T, ENST00000686969.1:c.101C>T, ENST00000687356.1:c.101C>T, ENST00000688940.1:c.101C>T, ENST00000690804.1:c.101C>T, ENST00000692768.1:c.-88+5467C>T, ENST00000693229.1:c.101C>T, ENST00000256078.10:c.101C>T, ENST00000311936.8:c.101C>T, ENST00000256078.8:c.101C>T, ENST00000311936.7:c.101C>T, ENST00000556131.1:c.101C>T, ENST00000557334.5:c.101C>T, NM_033360.3:c.101C>T, XM_006719069.2:c.101C>T, XM_011520653.1:c.101C>T, XM_006719069.4:c.101C>T, XM_011520653.3:c.101C>T, NM_001369786.1:c.101C>T, NM_001369787.1:c.101C>T, NM_004985.5:c.101C>T, NM_033360.4:c.101C>T, NM_004985.4(KRAS):c.101C>T (p.Pro34Leu)	KRAS	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM5, PS3_Supporting, PS2_Very Strong, PP3, PP2, PM2_Supporting	BS1, BP4, BA1	The c.101C>T variant in the KRAS gene is a missense variant predicted to cause substitution of proline by leucine at amino acid 34 (p.Pro34Leu). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives a score of 0.867 supporting a deleterious impact to KRAS function (PP3). The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). A different pathogenic missense variant has been previously identified at this codon of KRAS (c.101C>G (p.Pro34Arg)) which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 12590). This variant has been reported in 3 individuals as two confirmed de novo occurrences and one unconfirmed de novo occurrence with clinical features of a RASopathy (PS4_Moderate, PS2_VeryStrong; PMIDs: 17056636, 30732632, ClinVar SCV: SCV000207884.10, Internal lab contributors: GeneDx). A RAS activation assay showed that this variant led to increased RAS activation (PS3_Supporting; PMID: 20949621). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2_VeryStrong, PS4_Moderate, PM5, PS3_Supporting, PM2_Supporting, PP2, PP3 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA235301/MONDO:0018997/004	bf62d2f1-6047-4d6b-9cb9-dfdab291cdfb
NM_004985.5(KRAS):c.458A>T (p.Asp153Val)	12587	CA256478	NM_004985.5:c.458A>T, NC_000012.12:g.25209904T>A, CM000674.2:g.25209904T>A, NC_000012.11:g.25362838T>A, CM000674.1:g.25362838T>A, NC_000012.10:g.25254105T>A, NG_007524.1:g.46017A>T, NG_007524.2:g.46100A>T, ENST00000557334.6:c.119A>T, ENST00000685328.1:c.458A>T, ENST00000686877.1:c.*429A>T, ENST00000687356.1:c.*156A>T, ENST00000688228.1:n.932A>T, ENST00000688940.1:c.458A>T, ENST00000690406.1:c.261A>T, ENST00000690804.1:c.*419A>T, ENST00000692768.1:c.260A>T, ENST00000693229.1:c.383A>T, ENST00000256078.10:c.*12A>T, ENST00000311936.8:c.458A>T, ENST00000256078.8:c.*12A>T, ENST00000311936.7:c.458A>T, ENST00000557334.5:c.119A>T, NM_004985.4:c.458A>T, NM_033360.3:c.*12A>T, XM_006719069.2:c.*12A>T, XM_011520653.1:c.458A>T, XM_006719069.4:c.*12A>T, XM_011520653.3:c.458A>T, NM_001369786.1:c.*12A>T, NM_001369787.1:c.458A>T, NM_033360.4:c.*12A>T, NM_004985.5(KRAS):c.458A>T (p.Asp153Val)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PP3, PP2, PM2_Supporting, PS3_Moderate, PS4, PS2_Very Strong	BA1, BP4, BS1, BS3	The c.458A>T variant in the KRAS gene is a missense variant predicted to cause substitution of asparagine by valine at amino acid 153 (p.Asp153Val). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.791 supporting a deleterious impact to KRAS function (PP3). The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). This variant has been reported in at least 6 individuals with four confirmed de novo occurrences with clinical features of a RASopathy (PS4, PS2_VeryStrong; PMIDs: 16474405, 16474404, 21062266, 21871821, 24703799, 16773572). In vitro functional studies showed that this variant enhanced RAS/MEK/ERK activation (PS3_Moderate; PMID: 17875937, 20949621). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2_VeryStrong, PS4, PS3_Moderate, PM2_Supporting, PP2, PP3 (Specification Version 2.3, 12/3/2024)	17875937	RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA256478/MONDO:0021060/044	583866a1-1915-4ccd-bc75-8672ca18c8e4
NM_004985.4(KRAS):c.173C>T (p.Thr58Ile)	12588	CA256480	NM_004985.4:c.173C>T, NM_033360.3:c.173C>T, XM_006719069.2:c.173C>T, XM_011520653.1:c.173C>T, XM_006719069.4:c.173C>T, XM_011520653.3:c.173C>T, ENST00000256078.8:c.173C>T, ENST00000311936.7:c.173C>T, ENST00000557334.5:c.112-17440C>T, NC_000012.12:g.25227351G>A, CM000674.2:g.25227351G>A, NC_000012.11:g.25380285G>A, CM000674.1:g.25380285G>A, NC_000012.10:g.25271552G>A, NG_007524.1:g.28570C>T, NM_004985.4(KRAS):c.173C>T (p.Thr58Ile)	KRAS	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PP2, PP3, PM6_Strong	PS1	The c.173C>T (p.Thr58Ile) variant in KRAS has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6_Strong; PMID 23321623, 20112233, 16921267, 16474405, 22488832, 18247425, 20949621). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). In vitro functional studies provide some evidence that the p.Thr58Ile variant may impact protein function (PS3; PMID: 23321623, 20949621, 16921267). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of KRAS (PM1; PMID 29493581). The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Thr58Ile variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6_Strong, PS3, PM2, PM1, PP2, PP3.	16921267, 20112233, 23321623, 16474405	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA256480/MONDO:0018997/004	be68e302-48f4-4cb4-80a8-915ac3fff981
NM_004985.5(KRAS):c.40G>A (p.Val14Ile)	12589	CA156358	NM_004985.5:c.40G>A, NC_000012.12:g.25245345C>T, CM000674.2:g.25245345C>T, NC_000012.11:g.25398279C>T, CM000674.1:g.25398279C>T, NC_000012.10:g.25289546C>T, NG_007524.1:g.10576G>A, NG_007524.2:g.10659G>A, ENST00000556131.2:c.40G>A, ENST00000557334.6:c.40G>A, ENST00000685328.1:c.40G>A, ENST00000686877.1:c.40G>A, ENST00000686969.1:c.40G>A, ENST00000687356.1:c.40G>A, ENST00000688940.1:c.40G>A, ENST00000690804.1:c.40G>A, ENST00000692768.1:c.-88+5406G>A, ENST00000693229.1:c.40G>A, ENST00000256078.10:c.40G>A, ENST00000311936.8:c.40G>A, ENST00000256078.8:c.40G>A, ENST00000311936.7:c.40G>A, ENST00000556131.1:c.40G>A, ENST00000557334.5:c.40G>A, NM_004985.4:c.40G>A, NM_033360.3:c.40G>A, XM_006719069.2:c.40G>A, XM_011520653.1:c.40G>A, XM_006719069.4:c.40G>A, XM_011520653.3:c.40G>A, NM_001369786.1:c.40G>A, NM_001369787.1:c.40G>A, NM_033360.4:c.40G>A, NM_004985.5(KRAS):c.40G>A (p.Val14Ile)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PP3, PP2, PM2_Supporting, PS3_Moderate, PS4, PM1, PS2_Very Strong	BA1, BP4, BP1, BS3, BS1	The c.40G>A variant in the KRAS gene is a missense variant predicted to cause substitution of valine by isoleucine at amino acid 14 (p.Val14Ile). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.803 supporting a deleterious impact to KRAS function (PP3). The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). This variant resides within a region (amino acids 10-17) of KRAS that is defined as a critical functional domain by the ClinGen RASopathy VCEP (PM1). This variant has been reported in 6 individuals with two confirmed de novo occurrences with clinical features of a RASopathy (PS4, PS2_VeryStrong; PMIDs: 16474405, 17704260, 18958496, 19020799, 20949621). In vitro functional studies showed that the p.Val14Ile variant enhanced RAS/MEK/ERK activation (PS3_Moderate; PMID: 20949621). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2_VeryStrong, PS4, PS3_Moderate, PM1, PM2_Supporting, PP2, PP3 (Specification Version 2.3, 12/3/2024)	20949621, 17704260, 18958496, 19020799, 20949621, 16474405	RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA156358/MONDO:0021060/044	e103be05-5fbf-42b0-b4a8-809da2f2181d
NM_005343.4(HRAS):c.173C>T (p.Thr58Ile)	12610	CA341206	NM_005343.4:c.173C>T, NC_000011.10:g.533883G>A, CM000673.2:g.533883G>A, NC_000011.9:g.533883G>A, CM000673.1:g.533883G>A, NC_000011.8:g.523883G>A, NG_007666.1:g.6668C>T, ENST00000397594.7:c.173C>T, ENST00000417302.7:c.173C>T, ENST00000417302.6:c.173C>T, ENST00000462734.2:c.173C>T, ENST00000311189.8:c.173C>T, ENST00000311189.7:c.173C>T, ENST00000397594.5:c.173C>T, ENST00000397596.6:c.173C>T, ENST00000417302.5:c.173C>T, ENST00000451590.5:c.173C>T, ENST00000468682.2:n.661C>T, ENST00000479482.1:n.94C>T, ENST00000493230.5:c.173C>T, NM_001130442.1:c.173C>T, NM_005343.2:c.173C>T, NM_176795.3:c.173C>T, XM_011519875.1:c.-424-4715G>A, XM_011519877.1:c.-162+5546G>A, XR_242795.1:n.372C>T, NM_001130442.2:c.173C>T, NM_001318054.1:c.-147C>T, NM_005343.3:c.173C>T, NM_176795.4:c.173C>T, XM_011519875.2:c.-424-4715G>A, XM_011519877.2:c.-162+5546G>A, XM_017017167.1:c.-499-4640G>A, XM_017017168.1:c.-499-4640G>A, NM_001318054.2:c.-147C>T, NM_001130442.3:c.173C>T, NM_176795.5:c.173C>T, NM_005343.4(HRAS):c.173C>T (p.Thr58Ile)	HRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2, PS1, PS4_Moderate, PM1, PP3, PP2, PM2_Supporting	BS1, BA1, BP4, BP1	The c.173C>T variant in the HRAS gene is a missense variant predicted to cause substitution of threonine by isoleucine at amino acid 58 (p.Thr58Ile). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.777, which is above the threshold of 0.7, evidence that correlates with impact to HRAS function (PP3). This variant resides within a region (amino acids 57 â€“ 64), of HRAS that is defined as a critical functional domain by the ClinGen RASopathy VCEP (PM1). The p.Thr58Ile variant in HRAS is analogous to the same previously established amino acid change in the KRAS gene and the ClinGen RASopathy Expert Panel has defined that the pathogenicity of analogous variants in the HRAS and KRAS genes are correlated based on the assumption that a known functional residue in one gene is equivalent to other functions within that subgroup (PS1). At least 4 independent occurrences of this variant have been detected in patients with a RASopathy, of which 1 was reported as a de novo occurrence (PS2, PS4_Moderate; CeGaT Center for Human Genetics, ClinVar SCV003916655.13; PMIDs: 22488832, 18247425, 23321623, 26888048). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS1, PS2, PS4_Moderate, PM1, PM2_Supporting, PP3 (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA341206/MONDO:0021060/046	4fa14d9d-3bce-4dd8-affa-771b6298c4fc
NM_005343.3(HRAS):c.34G>A (p.Gly12Ser)	12602	CA122549	NM_005343.3:c.34G>A, NC_000011.10:g.534289C>T, CM000673.2:g.534289C>T, NC_000011.9:g.534289C>T, CM000673.1:g.534289C>T, NC_000011.8:g.524289C>T, NG_007666.1:g.6262G>A, NM_001130442.1:c.34G>A, NM_005343.2:c.34G>A, NM_176795.3:c.34G>A, XM_011519875.1:c.-424-4309C>T, XM_011519877.1:c.-161-5291C>T, XR_242795.1:n.233G>A, NM_001130442.2:c.34G>A, NM_001318054.1:c.-286G>A, NM_176795.4:c.34G>A, XM_011519875.2:c.-424-4309C>T, XM_011519877.2:c.-161-5291C>T, XM_017017167.1:c.-499-4234C>T, XM_017017168.1:c.-499-4234C>T, NM_005343.4:c.34G>A, ENST00000311189.7:c.34G>A, ENST00000397594.5:c.34G>A, ENST00000397596.6:c.34G>A, ENST00000417302.5:c.34G>A, ENST00000451590.5:c.34G>A, ENST00000468682.2:n.522G>A, ENST00000482021.1:n.157G>A, ENST00000493230.5:c.34G>A, NM_005343.3(HRAS):c.34G>A (p.Gly12Ser)	LRRC56	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Pathogenic	PS3, PS4, PM1, PM2, PS2_Very Strong, PP2, PP3		The c.34G>A (p.Gly12Ser) variant in HRAS has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 16170316, 16835863, 16443854, 16835863, 16881968, 17054105, 19669404). The p.Gly12Ser variant has been identified in >5 independent occurrences in patients with clinical features of a RASopathy (PS4; PMID: 20660566, 16372351, 16329078, 16969868, 18039947, 19371735, 19206176, 16835863). In vitro functional studies provide some evidence that the p.Gly12Ser variant may impact protein function (PS3; PMID: 17412879). Computational prediction tools and conservation analysis suggest that the p.Gly12Ser variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the HRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4, PS3, PM1, PM2,  PP2, PP3.	17412879, 19206176, 19371735, 16329078, 16372351, 16969868, 16835863, 20660566, 18039947, 29493581, 17054105, 16443854, 19669404, 16170316, 16881968, 16835863	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA122549/MONDO:0009026/004	51947641-2e77-498f-93d6-ca73b8e343de
NM_005343.4(HRAS):c.350A>G (p.Lys117Arg)	12605	CA256490	NM_005343.4:c.350A>G, NC_000011.10:g.533553T>C, CM000673.2:g.533553T>C, NC_000011.9:g.533553T>C, CM000673.1:g.533553T>C, NC_000011.8:g.523553T>C, NG_007666.1:g.6998A>G, ENST00000397594.7:c.350A>G, ENST00000417302.7:c.350A>G, ENST00000397594.6:c.68A>G, ENST00000417302.6:c.350A>G, ENST00000462734.2:c.350A>G, ENST00000311189.8:c.350A>G, ENST00000311189.7:c.350A>G, ENST00000397594.5:c.350A>G, ENST00000397596.6:c.350A>G, ENST00000417302.5:c.350A>G, ENST00000451590.5:c.350A>G, ENST00000462734.1:n.43A>G, ENST00000478324.5:n.60A>G, ENST00000479482.1:n.271A>G, ENST00000493230.5:c.350A>G, NM_001130442.1:c.350A>G, NM_005343.2:c.350A>G, NM_176795.3:c.350A>G, XM_011519875.1:c.-424-5045T>C, XM_011519877.1:c.-162+5216T>C, XR_242795.1:n.549A>G, NM_001130442.2:c.350A>G, NM_001318054.1:c.31A>G, NM_005343.3:c.350A>G, NM_176795.4:c.350A>G, XM_011519875.2:c.-424-5045T>C, XM_011519877.2:c.-162+5216T>C, XM_017017167.1:c.-499-4970T>C, XM_017017168.1:c.-499-4970T>C, NM_001318054.2:c.31A>G, NM_001130442.3:c.350A>G, NM_176795.5:c.350A>G, NM_005343.4(HRAS):c.350A>G (p.Lys117Arg)	HRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PS2_Very Strong, PP3, PM2_Supporting, PS3_Moderate	BS3, BS1, BA1, BP4	The c.350A>G variant in the HRAS gene is a missense variant predicted to cause substitution of lysine by arginine at amino acid 117 (p.Lys117Arg). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.916, which is above the threshold of 0.7, evidence that correlates with impact to HRAS function (PP3). At least 4 independent occurrences of this variant have been detected in patients with a RASopathy, of which 3 were reported as confirmed de novo cases while 1 was an unconfirmed de novo occurrence (PS2_VeryStrong, PS4_Moderate; PMID: 16443854, 17979197, 35595280, 32313153). In vitro functional assays showed that the variant increased RAS/MEK/ERK activation compared to wildtype (PS3_Moderate; PMID: 17979197, 21850009). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2_VeryStrong, PS4_Moderate, PS3_Modertae, PM2_Supporting, PP3 (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA256490/MONDO:0021060/046	42e841f0-7121-4d9d-a2ae-ebc27adacd88
NM_030662.3(MAP2K2):c.535C>T (p.Arg179Trp)	180905	CA296130	NM_030662.3:c.535C>T, LRG_750t1:c.535C>T, XM_006722799.2:c.535C>T, XM_011528133.1:c.-36C>T, XM_017026989.1:c.535C>T, XM_017026990.1:c.535C>T, XM_017026991.1:c.535C>T, ENST00000262948.9:c.535C>T, ENST00000394867.8:c.244C>T, ENST00000593364.5:n.482C>T, ENST00000597008.5:n.136C>T, ENST00000599345.1:n.805C>T, ENST00000601786.5:n.836C>T, ENST00000602167.5:n.255C>T, NC_000019.10:g.4101274G>A, CM000681.2:g.4101274G>A, NC_000019.9:g.4101272G>A, CM000681.1:g.4101272G>A, NC_000019.8:g.4052272G>A, NG_007996.1:g.27855C>T, LRG_750:g.27855C>T, NM_030662.3(MAP2K2):c.535C>T (p.Arg179Trp)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.535C>T (p.Arg179Trp) variant in the MAP2K2 gene is 0.0362% (3/2258) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA296130/MONDO:0021060/004	87032436-5de0-42c5-bbd4-68bd737592cc
NM_002834.4(PTPN11):c.643-6dup	448922	CA6798615	NM_002834.4:c.643-6dup, NM_002834.3:c.643-6dup, LRG_614t1:c.643-6dup, NM_080601.1:c.643-6dup, XM_006719526.1:c.643-6dup, XM_006719527.1:c.642+1264dup, XM_011538613.1:c.640-6dup, NM_001330437.1:c.643-6dup, NM_080601.2:c.643-6dup, XM_011538613.2:c.640-6dup, XM_017019722.1:c.640-6dup, ENST00000351677.6:c.643-6dup, ENST00000392597.5:c.643-6dup, ENST00000530818.1:n.177-6dup, ENST00000635625.1:n.643-6dup, NC_000012.12:g.112455944dup, CM000674.2:g.112455944dup, NC_000012.11:g.112893748dup, CM000674.1:g.112893748dup, NC_000012.10:g.111378131dup, NG_007459.1:g.42213dup, LRG_614:g.42213dup, NM_002834.4(PTPN11):c.643-6dup	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.643-6dupG variant in the PTPN11 gene is 0.0461% (9/10166) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA6798615/MONDO:0021060/004	809e2362-8dff-4288-a90f-cef41c788bd2
NM_005343.3(HRAS):c.37G>T (p.Gly13Cys)	12606	CA295247	NM_005343.3:c.37G>T, NM_001130442.1:c.37G>T, NM_005343.2:c.37G>T, NM_176795.3:c.37G>T, XM_011519875.1:c.-424-4312C>A, XM_011519877.1:c.-161-5294C>A, XR_242795.1:n.236G>T, NM_001130442.2:c.37G>T, NM_001318054.1:c.-283G>T, NM_176795.4:c.37G>T, XM_011519875.2:c.-424-4312C>A, XM_011519877.2:c.-161-5294C>A, XM_017017167.1:c.-499-4237C>A, XM_017017168.1:c.-499-4237C>A, NM_005343.4:c.37G>T, ENST00000311189.7:c.37G>T, ENST00000397594.5:c.37G>T, ENST00000397596.6:c.37G>T, ENST00000417302.5:c.37G>T, ENST00000451590.5:c.37G>T, ENST00000468682.2:n.525G>T, ENST00000482021.1:n.160G>T, ENST00000493230.5:c.37G>T, NC_000011.10:g.534286C>A, CM000673.2:g.534286C>A, NC_000011.9:g.534286C>A, CM000673.1:g.534286C>A, NC_000011.8:g.524286C>A, NG_007666.1:g.6265G>T, NM_005343.3(HRAS):c.37G>T (p.Gly13Cys)	LRRC56	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1, PM2, PS2_Very Strong, PP2, PP3		The c.37G>T (p.Gly13Cys) variant in HRAS has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 21438134, 16329078). The p.Gly13Cys variant has been identified in at least 3 other independent occurrence in patients with clinical features of a RASopathy (PS4_Moderate; PMID: 16372351). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the HRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly13Cys variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PP2, PP3, PM1, PM2, PS4_Moderate, PS2_VeryStrong.	29493581, 16329078, 21438134	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA295247/MONDO:0018997/004	77fd6395-3146-46f0-86ca-08fb626eb660
NM_005633.3(SOS1):c.1654A>G (p.Arg552Gly)	12871	CA235350	NM_005633.3:c.1654A>G, LRG_754t1:c.1654A>G, XM_005264515.3:c.1654A>G, XM_011533060.1:c.1747A>G, XM_011533061.1:c.1747A>G, XM_011533062.1:c.1633A>G, XM_011533063.1:c.1630A>G, XM_011533064.1:c.1483A>G, XM_011533065.1:c.1747A>G, XM_011533066.1:c.589A>G, XM_005264515.4:c.1654A>G, XM_011533062.2:c.1633A>G, XM_011533064.2:c.1483A>G, ENST00000395038.6:c.1654A>G, ENST00000402219.6:c.1654A>G, ENST00000426016.5:c.1654A>G, NC_000002.12:g.39022774T>C, CM000664.2:g.39022774T>C, NC_000002.11:g.39249915T>C, CM000664.1:g.39249915T>C, NC_000002.10:g.39103419T>C, NG_007530.1:g.102690A>G, LRG_754:g.102690A>G, NM_005633.3(SOS1):c.1654A>G (p.Arg552Gly)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PS2_Very Strong, PM2, PP2, PP3		The c.1654A>G (p.Arg552Gly) variant in SOS1 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 17143282). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). In vitro functional studies provide some evidence that the p.Arg552Gly variant may impact protein function (PS3; PMID: 17143282). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of SOS1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg552Gly variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PS3, PS2_VeryStrong.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA235350/MONDO:0018997/004	b5a21ed5-8cbc-465c-8a14-9be1d1d54011
NM_005633.3(SOS1):c.1642A>C (p.Ser548Arg)	40678	CA234977	NM_005633.3:c.1642A>C, LRG_754t1:c.1642A>C, XM_005264515.3:c.1642A>C, XM_011533060.1:c.1735A>C, XM_011533061.1:c.1735A>C, XM_011533062.1:c.1621A>C, XM_011533063.1:c.1618A>C, XM_011533064.1:c.1471A>C, XM_011533065.1:c.1735A>C, XM_011533066.1:c.577A>C, XM_005264515.4:c.1642A>C, XM_011533062.2:c.1621A>C, XM_011533064.2:c.1471A>C, ENST00000395038.6:c.1642A>C, ENST00000402219.6:c.1642A>C, ENST00000426016.5:c.1642A>C, NC_000002.12:g.39022786T>G, CM000664.2:g.39022786T>G, NC_000002.11:g.39249927T>G, CM000664.1:g.39249927T>G, NC_000002.10:g.39103431T>G, NG_007530.1:g.102678A>C, LRG_754:g.102678A>C, NM_005633.3(SOS1):c.1642A>C (p.Ser548Arg)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PS2_Very Strong, PP2, PP3		The c.1642A>C (p.Ser548Arg) variant in SOS1 has been reported as a confirmed de novo occurrence in a patient with clinical features of a RASopathy (PS2_VeryStrong; PMID 17143282). In vitro functional studies provide some evidence that the p.Ser548Arg variant may impact protein function (PS3; PMID 23487764). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of SOS1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Ser548Arg variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PP2, PP3, PM1, PM2, PS3 PS2_VeryStrong.	17143285, 29493581, 17143282	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA234977/MONDO:0018997/004	940ad8e1-71b4-424b-b085-ae78bed7e9d7
NM_005633.3(SOS1):c.806T>C (p.Met269Thr)	40662	CA235344	NM_005633.3:c.806T>C, NC_000002.12:g.39051202A>G, CM000664.2:g.39051202A>G, NC_000002.11:g.39278343A>G, CM000664.1:g.39278343A>G, NC_000002.10:g.39131847A>G, NG_007530.1:g.74262T>C, LRG_754:g.74262T>C, LRG_754t1:c.806T>C, XM_005264515.3:c.806T>C, XM_011533060.1:c.899T>C, XM_011533061.1:c.899T>C, XM_011533062.1:c.785T>C, XM_011533063.1:c.782T>C, XM_011533064.1:c.635T>C, XM_011533065.1:c.899T>C, XM_005264515.4:c.806T>C, XM_011533062.2:c.785T>C, XM_011533064.2:c.635T>C, ENST00000395038.6:c.806T>C, ENST00000402219.6:c.806T>C, ENST00000426016.5:c.806T>C, ENST00000461545.1:n.156T>C, NM_005633.3(SOS1):c.806T>C (p.Met269Thr)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM1, PM2, PS2_Very Strong, PP2, PP3		The c.806T>C (p.Met269Thr) variant in SOS1 has been reported in the literature in at least 2 unconfirmed and 1 confirmed de novo occurrences in patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 17586837; 19953625, 20683980). It has also been reported as a confirmed de novo occurrence in a patient with clinical features of a RASoapthy (PMID: 20683980). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is in SOS1, which has been defined by the ClinGen RASopathy Expert Panel as a gene with low rate of benign missense with missense variants commonly being pathogenic (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Met269Thr variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of SOS1 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PP2, PP3, PM1, PM2, PS2_VeryStrong.	17586837, 19953625, 20683980	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA235344/MONDO:0018997/004	4536a40e-a4fc-474b-b83d-f63fa7e74a4a
NM_005633.3(SOS1):c.2536G>A (p.Glu846Lys)	40706	CA261734	NM_005633.3:c.2536G>A, LRG_754t1:c.2536G>A, XM_005264515.3:c.2536G>A, XM_011533060.1:c.2629G>A, XM_011533061.1:c.2629G>A, XM_011533062.1:c.2515G>A, XM_011533063.1:c.2512G>A, XM_011533064.1:c.2365G>A, XM_011533065.1:c.2629G>A, XM_011533066.1:c.1471G>A, XM_005264515.4:c.2536G>A, XM_011533062.2:c.2515G>A, XM_011533064.2:c.2365G>A, ENST00000395038.6:c.2536G>A, ENST00000402219.6:c.2536G>A, ENST00000426016.5:c.2536G>A, ENST00000474390.1:n.332G>A, NC_000002.12:g.39007168C>T, CM000664.2:g.39007168C>T, NC_000002.11:g.39234309C>T, CM000664.1:g.39234309C>T, NC_000002.10:g.39087813C>T, NG_007530.1:g.118296G>A, LRG_754:g.118296G>A, NM_005633.3(SOS1):c.2536G>A (p.Glu846Lys)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PM6, PP2, PP3	PS4	The c.2536G>A (p.Glu846Lys) variant in SOS1 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 23673306). It has also been reported in a patient diagnosed with HCM (PMID 22555271). In vitro functional studies provide some evidence that the p.Glu846Lys variant may impact protein function (PS3; PMID 17143285). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Glu846Lys variant may impact the protein (PP3). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined to be a mutational hotspot or domain of SOS1 (PM1; PMID 21387466). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PM6, PS3.	17143285, 22555271, 23673306	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA261734/MONDO:0018997/004	f2a2e5e9-f8ba-43a4-9776-40b192ce87cf
NM_005633.3(SOS1):c.508A>G (p.Lys170Glu)	40651	CA235342	NM_005633.3:c.508A>G, NC_000002.12:g.39056704T>C, CM000664.2:g.39056704T>C, NC_000002.11:g.39283845T>C, CM000664.1:g.39283845T>C, NC_000002.10:g.39137349T>C, NG_007530.1:g.68760A>G, LRG_754:g.68760A>G, LRG_754t1:c.508A>G, XM_005264515.3:c.508A>G, XM_011533060.1:c.601A>G, XM_011533061.1:c.601A>G, XM_011533062.1:c.487A>G, XM_011533063.1:c.484A>G, XM_011533064.1:c.337A>G, XM_011533065.1:c.601A>G, XM_005264515.4:c.508A>G, XM_011533062.2:c.487A>G, XM_011533064.2:c.337A>G, ENST00000395038.6:c.508A>G, ENST00000402219.6:c.508A>G, ENST00000426016.5:c.508A>G, NM_005633.3(SOS1):c.508A>G (p.Lys170Glu)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PM6, PP2, PP3		The c.508A>G (p.Lys170Glu) variant in SOS1 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 19020799, 21387466). In vitro functional studies provide some evidence that the p.Lys170Glu variant may impact protein function (PS3; PMID 21784453, 23487764). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of SOS1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Lys170Glu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581):  PP2, PP3, PM1, PM2, PM6, PS3.	21784453, 23487764, 29493581, 21387466, 19020799	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA235342/MONDO:0018997/004	07b0e3e7-5c67-41c3-a988-3c438dfba738
NM_002880.3(RAF1):c.770C>T (p.Ser257Leu)	13957	CA235334	NM_002880.3:c.770C>T, LRG_413t1:c.770C>T, XM_005265355.1:c.770C>T, XM_005265357.1:c.671C>T, XM_005265358.3:c.527C>T, XM_005265359.3:c.428C>T, XM_005265360.1:c.770C>T, XM_011533974.1:c.770C>T, XM_011533975.1:c.527C>T, NM_001354689.1:c.770C>T, NM_001354690.1:c.770C>T, NM_001354691.1:c.527C>T, NM_001354692.1:c.527C>T, NM_001354693.1:c.671C>T, NM_001354694.1:c.527C>T, NM_001354695.1:c.428C>T, NR_148940.1:n.1185C>T, NR_148941.1:n.1185C>T, NR_148942.1:n.1185C>T, XM_011533974.3:c.770C>T, XM_017006966.1:c.671C>T, XR_001740227.1:n.1002C>T, ENST00000251849.8:c.770C>T, ENST00000416093.1:c.*348C>T, ENST00000423275.5:c.*447C>T, ENST00000432427.2:n.407C>T, ENST00000442415.6:c.770C>T, ENST00000465826.5:n.14C>T, ENST00000491290.1:n.291C>T, NC_000003.12:g.12604200G>A, CM000665.2:g.12604200G>A, NC_000003.11:g.12645699G>A, CM000665.1:g.12645699G>A, NC_000003.10:g.12620699G>A, NG_007467.1:g.64980C>T, LRG_413:g.64980C>T, NM_002880.3(RAF1):c.770C>T (p.Ser257Leu)	RAF1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PP2, PM6_Strong		The c.770C>T (p.Ser257Leu) variant in RAF1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 17603482,22389993, 23877478, 23312806, 25706034). In vitro functional studies provide some evidence that the p.Ser257Leu variant may impact protein function (PS3; PMID 17603482). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PP2, PM1, PM2, PS3, PM6_Strong.	17603482, 29493581, 25706034, 17603482, 22389993, 23877478	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA235334/MONDO:0018997/004	6eb64962-8efe-49ca-a5e1-499e4cddd80f
NM_002880.3(RAF1):c.781C>T (p.Pro261Ser)	13958	CA257062	NM_002880.3:c.781C>T, NC_000003.12:g.12604189G>A, CM000665.2:g.12604189G>A, NC_000003.11:g.12645688G>A, CM000665.1:g.12645688G>A, NC_000003.10:g.12620688G>A, NG_007467.1:g.64991C>T, LRG_413:g.64991C>T, LRG_413t1:c.781C>T, XM_005265355.1:c.781C>T, XM_005265357.1:c.682C>T, XM_005265358.3:c.538C>T, XM_005265359.3:c.439C>T, XM_005265360.1:c.781C>T, XM_011533974.1:c.781C>T, XM_011533975.1:c.538C>T, NM_001354689.1:c.781C>T, NM_001354690.1:c.781C>T, NM_001354691.1:c.538C>T, NM_001354692.1:c.538C>T, NM_001354693.1:c.682C>T, NM_001354694.1:c.538C>T, NM_001354695.1:c.439C>T, NR_148940.1:n.1196C>T, NR_148941.1:n.1196C>T, NR_148942.1:n.1196C>T, XM_011533974.3:c.781C>T, XM_017006966.1:c.682C>T, XR_001740227.1:n.1013C>T, ENST00000251849.8:c.781C>T, ENST00000416093.1:c.*359C>T, ENST00000423275.5:c.*458C>T, ENST00000432427.2:n.418C>T, ENST00000442415.6:c.781C>T, ENST00000465826.5:n.25C>T, ENST00000491290.1:n.302C>T, NM_002880.3(RAF1):c.781C>T (p.Pro261Ser)	RAF1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PP2, PM6_Strong		The c.781C>T (p.Pro261Ser) variant in RAF1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 17603482, 20683980). In vitro functional studies provide some evidence that the p.Pro261Leu variant may impact protein function (PS3; PMID 17603483, 17603482). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PP2, PM1, PM2, PS3, PM6_Strong.	17603482, 20683980, 17603482	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA257062/MONDO:0018997/004	563677cb-406b-41f7-9c7d-7fc9d73cbbe2
NM_002880.4(RAF1):c.1837C>G (p.Leu613Val)	13960	CA257066	NM_002880.4:c.1837C>G, NC_000003.12:g.12584624G>C, CM000665.2:g.12584624G>C, NC_000003.11:g.12626123G>C, CM000665.1:g.12626123G>C, NC_000003.10:g.12601123G>C, NG_007467.1:g.84556C>G, LRG_413:g.84556C>G, ENST00000423275.6:c.*1502C>G, ENST00000432427.3:c.1154C>G, ENST00000460610.2:n.6149C>G, ENST00000471449.2:n.647C>G, ENST00000475353.2:n.4117C>G, ENST00000684903.1:c.*1514C>G, ENST00000685348.1:c.*1548C>G, ENST00000685437.1:c.1738C>G, ENST00000685653.1:c.1837C>G, ENST00000685697.1:n.2572C>G, ENST00000685738.1:c.*801C>G, ENST00000686409.1:n.5246C>G, ENST00000686455.1:n.4558C>G, ENST00000686762.1:c.*396C>G, ENST00000687257.1:n.4291C>G, ENST00000687326.1:c.*3129C>G, ENST00000687505.1:n.1955C>G, ENST00000687923.1:c.1726C>G, ENST00000688269.1:n.2433C>G, ENST00000688444.1:n.3954C>G, ENST00000688543.1:c.1738C>G, ENST00000688625.1:c.*3206C>G, ENST00000688803.1:n.3265C>G, ENST00000689097.1:c.*1514C>G, ENST00000689389.1:c.1660C>G, ENST00000689418.1:c.*3732C>G, ENST00000689540.1:n.4205C>G, ENST00000689876.1:c.*386C>G, ENST00000689914.1:c.*771C>G, ENST00000690397.1:c.1726C>G, ENST00000690460.1:c.1825C>G, ENST00000690585.1:c.563C>G, ENST00000690625.1:n.2873C>G, ENST00000691396.1:c.*1709C>G, ENST00000691643.1:n.2890C>G, ENST00000691724.1:c.*794C>G, ENST00000691779.1:c.*1415C>G, ENST00000691888.1:c.711C>G, ENST00000691899.1:c.1837C>G, ENST00000692069.1:n.4761C>G, ENST00000692093.1:c.1738C>G, ENST00000692311.1:n.2661C>G, ENST00000692558.1:n.4420C>G, ENST00000692773.1:c.*1574C>G, ENST00000692830.1:c.*1582C>G, ENST00000693312.1:c.1612C>G, ENST00000693664.1:c.*288C>G, ENST00000693705.1:c.*1216C>G, ENST00000251849.9:c.1837C>G, ENST00000442415.7:c.1897C>G, ENST00000676541.1:c.*2371G>C, ENST00000677142.1:c.*2371G>C, ENST00000677816.1:c.*926G>C, ENST00000677941.1:n.2434G>C, ENST00000251849.8:c.1837C>G, ENST00000423275.5:c.*1514C>G, ENST00000432427.2:c.1474C>G, ENST00000442415.6:c.1897C>G, ENST00000471449.1:n.526C>G, NM_002880.3:c.1837C>G, LRG_413t1:c.1837C>G, XM_005265355.1:c.1837C>G, XM_005265357.1:c.1738C>G, XM_005265358.3:c.1594C>G, XM_005265359.3:c.1495C>G, XM_011533974.1:c.1837C>G, XM_011533975.1:c.1594C>G, NM_001354689.1:c.1897C>G, NM_001354690.1:c.1837C>G, NM_001354691.1:c.1594C>G, NM_001354692.1:c.1594C>G, NM_001354693.1:c.1738C>G, NM_001354694.1:c.1654C>G, NM_001354695.1:c.1495C>G, NR_148940.1:n.2365C>G, NR_148941.1:n.2311C>G, NR_148942.1:n.2250C>G, XM_011533974.3:c.1837C>G, XM_017006966.1:c.1738C>G, NM_001354689.3:c.1897C>G, NM_001354690.2:c.1837C>G, NM_001354691.2:c.1594C>G, NM_001354692.2:c.1594C>G, NM_001354693.2:c.1738C>G, NM_001354694.2:c.1654C>G, NM_001354695.2:c.1495C>G, NR_148940.2:n.2281C>G, NR_148941.2:n.2227C>G, NR_148942.2:n.2166C>G, NM_001354690.3:c.1837C>G, NM_001354691.3:c.1594C>G, NM_001354692.3:c.1594C>G, NM_001354693.3:c.1738C>G, NM_001354694.3:c.1654C>G, NM_001354695.3:c.1495C>G, NR_148940.3:n.2281C>G, NR_148941.3:n.2227C>G, NR_148942.3:n.2166C>G, NM_002880.4(RAF1):c.1837C>G (p.Leu613Val)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS3_Moderate, PS2_Very Strong, PS4		The c.1837C>G (p.Leu613Val) variant in the RAF1 gene is a missense variant predicted to cause substitution of leucine by valine at amino acid 613. This variant is absent from gnomAD v2 (PM2_Supporting). The variant has been reported in at least one confirmed de novo case in an individual with clinical features of a RASopathy (PS2_VeryStrong; PMID:17603483), and its prevalence in affecteds is statistically increased over controls (PS4). In vitro functional studies also provide some evidence that the p.Leu613Val variant may impact protein function (PS3; PMID: 7603482, 17603483, 22826437). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2_VeryStrong, PS4, PS3_Moderate, PM2_Supporting. (Specification Version 2.3, 12/3/2024)	17603483, 17603482, 22826437	RASopathy VCEP		2024-12-03	2025-03-25	false	https://erepo.genome.network/evrepo/ui/classification/CA257066/MONDO:0021060/040	f8f03fe0-c539-40c8-ad23-64451f155a8c
NM_002880.4(RAF1):c.1472C>T (p.Thr491Ile)	21342	CA261612	NM_002880.4:c.1472C>T, NC_000003.12:g.12585745G>A, CM000665.2:g.12585745G>A, NC_000003.11:g.12627244G>A, CM000665.1:g.12627244G>A, NC_000003.10:g.12602244G>A, NG_007467.1:g.83435C>T, LRG_413:g.83435C>T, ENST00000423275.6:c.*1137C>T, ENST00000432427.3:c.789C>T, ENST00000460610.2:n.5217C>T, ENST00000471449.2:n.282C>T, ENST00000475353.2:n.3185C>T, ENST00000684903.1:c.*1149C>T, ENST00000685348.1:c.*1095-339C>T, ENST00000685437.1:c.1373C>T, ENST00000685653.1:c.1472C>T, ENST00000685697.1:n.2207C>T, ENST00000685738.1:c.*436C>T, ENST00000686409.1:n.4314C>T, ENST00000686455.1:n.3626C>T, ENST00000686762.1:c.*31C>T, ENST00000687257.1:n.3499C>T, ENST00000687326.1:c.*2197C>T, ENST00000687505.1:n.1590C>T, ENST00000687923.1:c.1361C>T, ENST00000688269.1:n.2068C>T, ENST00000688444.1:n.3589C>T, ENST00000688543.1:c.1373C>T, ENST00000688625.1:c.*2841C>T, ENST00000688803.1:n.2965-492C>T, ENST00000688914.1:n.458C>T, ENST00000689097.1:c.*1149C>T, ENST00000689389.1:c.1295C>T, ENST00000689418.1:c.*2940C>T, ENST00000689540.1:n.3413C>T, ENST00000689876.1:c.1418-339C>T, ENST00000689914.1:c.*406C>T, ENST00000690397.1:c.1361C>T, ENST00000690460.1:c.1460C>T, ENST00000690585.1:c.263-492C>T, ENST00000690625.1:n.2508C>T, ENST00000691396.1:c.*1344C>T, ENST00000691643.1:n.2098C>T, ENST00000691724.1:c.*429C>T, ENST00000691779.1:c.*1050C>T, ENST00000691888.1:c.346C>T, ENST00000691899.1:c.1472C>T, ENST00000692069.1:n.3829C>T, ENST00000692093.1:c.1373C>T, ENST00000692311.1:n.2296C>T, ENST00000692558.1:n.3628C>T, ENST00000692773.1:c.*1209C>T, ENST00000692830.1:c.*1217C>T, ENST00000693312.1:c.1247C>T, ENST00000693664.1:c.1488-492C>T, ENST00000693705.1:c.*1048-764C>T, ENST00000251849.9:c.1472C>T, ENST00000442415.7:c.1532C>T, ENST00000676541.1:c.*3492G>A, ENST00000677142.1:c.*3492G>A, ENST00000677816.1:c.*2047G>A, ENST00000677941.1:n.3555G>A, ENST00000251849.8:c.1472C>T, ENST00000423275.5:c.*1149C>T, ENST00000432427.2:c.1109C>T, ENST00000442415.6:c.1532C>T, ENST00000471449.1:n.161C>T, NM_002880.3:c.1472C>T, LRG_413t1:c.1472C>T, XM_005265355.1:c.1472C>T, XM_005265357.1:c.1373C>T, XM_005265358.3:c.1229C>T, XM_005265359.3:c.1130C>T, XM_005265360.1:c.1418-339C>T, XM_011533974.1:c.1472C>T, XM_011533975.1:c.1229C>T, NM_001354689.1:c.1532C>T, NM_001354690.1:c.1472C>T, NM_001354691.1:c.1229C>T, NM_001354692.1:c.1229C>T, NM_001354693.1:c.1373C>T, NM_001354694.1:c.1289C>T, NM_001354695.1:c.1130C>T, NR_148940.1:n.2000C>T, NR_148941.1:n.1946C>T, NR_148942.1:n.1885C>T, XM_011533974.3:c.1472C>T, XM_017006966.1:c.1373C>T, NM_001354689.3:c.1532C>T, NM_001354690.2:c.1472C>T, NM_001354691.2:c.1229C>T, NM_001354692.2:c.1229C>T, NM_001354693.2:c.1373C>T, NM_001354694.2:c.1289C>T, NM_001354695.2:c.1130C>T, NR_148940.2:n.1916C>T, NR_148941.2:n.1862C>T, NR_148942.2:n.1801C>T, NM_001354690.3:c.1472C>T, NM_001354691.3:c.1229C>T, NM_001354692.3:c.1229C>T, NM_001354693.3:c.1373C>T, NM_001354694.3:c.1289C>T, NM_001354695.3:c.1130C>T, NR_148940.3:n.1916C>T, NR_148941.3:n.1862C>T, NR_148942.3:n.1801C>T, NM_002880.4(RAF1):c.1472C>T (p.Thr491Ile)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM1, PP3, PM2_Supporting, PS3_Moderate, PS2, PS4		The c.1472C>T (p.Thr491Ile variant in the RAF1 gene is a missense variant predicted to cause substitution of threonine by isoleucine at amino acid 491. This variant is absent from gnomAD v2 (PM2_Supporting). Computational prediction tools and conservation analysis suggest that the p.Thr491Ile variant may impact the RAF1 protein (PP3). In vitro functional studies provide some evidence that the p.Thr491Ile variant may impact protein function (PS3_Moderate; PMID:20679480). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). The variant has also been identified as a de novo occurrence with confirmed parental relationships in an individual with features of RASopathy (PS2), and the prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2, PS4, PM1, PS3_Moderate, PP3, PM2_Supporting. (Specification Version 2.3, 12/3/2024)	29493581, 20679480	RASopathy VCEP		2024-12-03	2025-03-25	false	https://erepo.genome.network/evrepo/ui/classification/CA261612/MONDO:0021060/040	3d3d7a51-6ba9-4434-a6d9-ebf5e4b84ae4
NM_005633.3(SOS1):c.1705C>G (p.Leu569Val)	40686	CA1624560	NM_005633.3:c.1705C>G, NC_000002.12:g.39022723G>C, CM000664.2:g.39022723G>C, NC_000002.11:g.39249864G>C, CM000664.1:g.39249864G>C, NC_000002.10:g.39103368G>C, NG_007530.1:g.102741C>G, LRG_754:g.102741C>G, LRG_754t1:c.1705C>G, XM_005264515.3:c.1705C>G, XM_011533060.1:c.1798C>G, XM_011533061.1:c.1798C>G, XM_011533062.1:c.1684C>G, XM_011533063.1:c.1681C>G, XM_011533064.1:c.1534C>G, XM_011533065.1:c.1798C>G, XM_011533066.1:c.640C>G, XM_005264515.4:c.1705C>G, XM_011533062.2:c.1684C>G, XM_011533064.2:c.1534C>G, ENST00000395038.6:c.1705C>G, ENST00000402219.6:c.1705C>G, ENST00000426016.5:c.1705C>G, NM_005633.3(SOS1):c.1705C>G (p.Leu569Val)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.1705C>G (p.Leu569Val) variant in the SOS1 gene is 0.0336% (31/66714) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624560/MONDO:0021060/004	c7313ee6-151e-4480-8724-8201a7355956
NM_002880.4(RAF1):c.768G>T (p.Arg256Ser)	40599	CA261625	NM_002880.4:c.768G>T, NC_000003.12:g.12604202C>A, CM000665.2:g.12604202C>A, NC_000003.11:g.12645701C>A, CM000665.1:g.12645701C>A, NC_000003.10:g.12620701C>A, NG_007467.1:g.64978G>T, LRG_413:g.64978G>T, ENST00000416093.2:c.*445G>T, ENST00000423275.6:c.*445G>T, ENST00000432427.3:c.88G>T, ENST00000465826.6:n.359G>T, ENST00000491290.2:n.1145G>T, ENST00000684903.1:c.*445G>T, ENST00000685348.1:c.*445G>T, ENST00000685437.1:c.669G>T, ENST00000685653.1:c.768G>T, ENST00000685738.1:c.768G>T, ENST00000685959.1:c.768G>T, ENST00000686409.1:n.1368G>T, ENST00000686455.1:n.1131G>T, ENST00000686479.1:n.1139G>T, ENST00000686762.1:c.768G>T, ENST00000687257.1:n.1004G>T, ENST00000687326.1:c.768G>T, ENST00000687486.1:c.88G>T, ENST00000687505.1:n.886G>T, ENST00000687923.1:c.669G>T, ENST00000687940.1:n.1145G>T, ENST00000688269.1:n.1376G>T, ENST00000688326.1:c.88G>T, ENST00000688444.1:n.1094G>T, ENST00000688543.1:c.669G>T, ENST00000688625.1:c.*346G>T, ENST00000688803.1:n.999G>T, ENST00000689033.1:c.768G>T, ENST00000689097.1:c.*445G>T, ENST00000689389.1:c.768G>T, ENST00000689418.1:c.*445G>T, ENST00000689481.1:c.*445G>T, ENST00000689540.1:n.918G>T, ENST00000689876.1:c.768G>T, ENST00000689914.1:c.768G>T, ENST00000690397.1:c.669G>T, ENST00000690460.1:c.768G>T, ENST00000690625.1:n.1071G>T, ENST00000691268.1:c.262-3787G>T, ENST00000691396.1:c.*561G>T, ENST00000691724.1:c.768G>T, ENST00000691779.1:c.*346G>T, ENST00000691899.1:c.768G>T, ENST00000692093.1:c.669G>T, ENST00000692311.1:n.1141G>T, ENST00000692558.1:n.1133G>T, ENST00000692773.1:c.*445G>T, ENST00000692830.1:c.*513G>T, ENST00000693069.1:c.669G>T, ENST00000693312.1:c.543G>T, ENST00000693664.1:c.768G>T, ENST00000693705.1:c.*445G>T, ENST00000251849.9:c.768G>T, ENST00000442415.7:c.768G>T, ENST00000251849.8:c.768G>T, ENST00000416093.1:c.*346G>T, ENST00000423275.5:c.*445G>T, ENST00000432427.2:c.405G>T, ENST00000442415.6:c.768G>T, ENST00000465826.5:n.12G>T, ENST00000491290.1:n.289G>T, NM_002880.3:c.768G>T, LRG_413t1:c.768G>T, XM_005265355.1:c.768G>T, XM_005265357.1:c.669G>T, XM_005265358.3:c.525G>T, XM_005265359.3:c.426G>T, XM_005265360.1:c.768G>T, XM_011533974.1:c.768G>T, XM_011533975.1:c.525G>T, NM_001354689.1:c.768G>T, NM_001354690.1:c.768G>T, NM_001354691.1:c.525G>T, NM_001354692.1:c.525G>T, NM_001354693.1:c.669G>T, NM_001354694.1:c.525G>T, NM_001354695.1:c.426G>T, NR_148940.1:n.1183G>T, NR_148941.1:n.1183G>T, NR_148942.1:n.1183G>T, XM_011533974.3:c.768G>T, XM_017006966.1:c.669G>T, XR_001740227.1:n.1000G>T, NM_001354689.3:c.768G>T, NM_001354690.2:c.768G>T, NM_001354691.2:c.525G>T, NM_001354692.2:c.525G>T, NM_001354693.2:c.669G>T, NM_001354694.2:c.525G>T, NM_001354695.2:c.426G>T, NR_148940.2:n.1099G>T, NR_148941.2:n.1099G>T, NR_148942.2:n.1099G>T, NM_001354690.3:c.768G>T, NM_001354691.3:c.525G>T, NM_001354692.3:c.525G>T, NM_001354693.3:c.669G>T, NM_001354694.3:c.525G>T, NM_001354695.3:c.426G>T, NR_148940.3:n.1099G>T, NR_148941.3:n.1099G>T, NR_148942.3:n.1099G>T, NM_002880.4(RAF1):c.768G>T (p.Arg256Ser)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PM1, PM2_Supporting, PS4_Moderate, PS3_Supporting	PP3, BP4	The c.768G>T variant in the RAF1 gene is a missense variant predicted to cause substitution of arginine by serine at amino acid 256 (p.Arg256Ser). This variant is absent from gnomAD v2 (PM2_Supporting). The computational predictor REVEL gives a score of 0.665, which does not meet PP3 or BP4. This variant is located in the CR2 critical functional domain as defined by the ClinGen RASopathy Expert Panel (PM1). This variant has been reported in 3 individuals with clinical features of Noonan syndrome (PS4_Moderate, PMIDs: 17603483, 22190897, 31292302). In vitro functional studies provide some evidence that the p.Arg256Ser variant may impact protein function (PMID: 20679480). ERK phosphorylation assay showed that the p.Arg256Ser variant led to significantly increased phosphorylation compared to wild-type (PS3_Supporting; PMID:20679480). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal dominant RASopathies based on ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS4_Moderate, PM1, PS3_Supporting, PM2_Supporting (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-25	false	https://erepo.genome.network/evrepo/ui/classification/CA261625/MONDO:0021060/040	4f1ea3bf-fe0e-4be0-bb44-c2fbf8522598
NM_002834.4(PTPN11):c.922A>G (p.Asn308Asp)	13326	CA220158	NM_002834.4:c.922A>G, NC_000012.12:g.112477719A>G, CM000674.2:g.112477719A>G, NC_000012.11:g.112915523A>G, CM000674.1:g.112915523A>G, NC_000012.10:g.111399906A>G, NG_007459.1:g.63988A>G, LRG_614:g.63988A>G, NM_002834.3:c.922A>G, LRG_614t1:c.922A>G, NM_080601.1:c.922A>G, XM_006719526.1:c.922A>G, XM_006719527.1:c.808A>G, XM_011538613.1:c.919A>G, NM_001330437.1:c.922A>G, NM_080601.2:c.922A>G, XM_011538613.2:c.919A>G, XM_017019722.1:c.919A>G, ENST00000351677.6:c.922A>G, ENST00000392597.5:c.922A>G, ENST00000635625.1:n.922A>G, NM_002834.4(PTPN11):c.922A>G (p.Asn308Asp)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PP1_Strong, PM2, PS2_Very Strong, PP2, PP3	PM6	The c.922A>G (p.Asn308Asp) variant in PTPN11 has been reported in the literature as a confirmed and unconfirmed de novo occurrence in 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 20979190, and 11704759, 22465605). The variant has co-segregated with disease in more than 7 family members (PP1_Strong; PMID: 11992261). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Asn308Asp variant may impact the protein (PP3). Additionally, at least 2  functional studies have been concordant in showing that this variant may be deleterious to the protein (PS3; PMID 14974085, 15987685, 19509418, 20308328). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM2, PP1_Strong, PS2_VeryStrong, PS3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA220158/MONDO:0018997/004	6525f07c-2ebf-4229-9447-62d126ad46cd
NM_030662.4(MAP2K2):c.401A>G (p.Tyr134Cys)	177868	CA180890	NM_030662.4:c.401A>G, NC_000019.10:g.4110558T>C, CM000681.2:g.4110558T>C, NC_000019.9:g.4110556T>C, CM000681.1:g.4110556T>C, NC_000019.8:g.4061556T>C, NG_007996.1:g.18571A>G, LRG_750:g.18571A>G, ENST00000394867.9:n.840A>G, ENST00000687128.1:n.840A>G, ENST00000262948.10:c.401A>G, ENST00000262948.9:c.401A>G, ENST00000394867.8:c.110A>G, ENST00000599345.1:n.598A>G, NM_030662.3:c.401A>G, LRG_750t1:c.401A>G, XM_006722799.2:c.401A>G, XM_017026989.1:c.401A>G, XM_017026990.1:c.401A>G, XM_017026991.1:c.401A>G, NM_030662.4(MAP2K2):c.401A>G (p.Tyr134Cys)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PP3, PM2_Supporting, PS4_Moderate, PM1, PS3_Supporting	BA1, BP4, BS3, BS1	The c.401A>G variant in the MAP2K2 gene is a missense variant predicted to cause substitution of tyrosine by cysteine at amino acid 134 (p.Tyr134Cys). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.966, predicting a damaging impact on protein function (PP3). This variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a critical functional domain of MAP2K2 (PM1, AA 128-138). This variant has been identified in at least 4 patients with RASopathy (PS4_Moderate; PMID: 18413255, 18039235, 21062266, 23885229). ERK phosphorylation assays showed that this variant led to increased phosphorylation compared to wild-type (PS3_Supporting; PMID: 17981815, 18413255). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS4_Moderate, PM1, PS3_Supporting, PM2_Supporting, PP3 (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA180890/MONDO:0021060/048	06d3c00a-69eb-4612-b456-062e6ac0a274
NM_030662.4(MAP2K2):c.400T>C (p.Tyr134His)	8274	CA119417	NM_030662.4:c.400T>C, NC_000019.10:g.4110559A>G, CM000681.2:g.4110559A>G, NC_000019.9:g.4110557A>G, CM000681.1:g.4110557A>G, NC_000019.8:g.4061557A>G, NG_007996.1:g.18570T>C, LRG_750:g.18570T>C, ENST00000394867.9:n.839T>C, ENST00000687128.1:n.839T>C, ENST00000262948.10:c.400T>C, ENST00000262948.9:c.400T>C, ENST00000394867.8:c.109T>C, ENST00000599345.1:n.597T>C, NM_030662.3:c.400T>C, LRG_750t1:c.400T>C, XM_006722799.2:c.400T>C, XM_017026989.1:c.400T>C, XM_017026990.1:c.400T>C, XM_017026991.1:c.400T>C, NM_030662.4(MAP2K2):c.400T>C (p.Tyr134His)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PM6_Strong, PS4, PM1, PS3_Supporting	BA1, BP4, PM5, BS1	The c.400T>C variant in the MAP2K2 gene is a missense variant predicted to cause substitution of tyrosine by histidine at amino acid 134 (p.Tyr134His). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.917, predicting a damaging impact on protein function (PP3). This variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a critical functional domain of MAP2K2 (PM1, AA 128-138). Furthermore, a different pathogenic variant at this residue (Tyr134Cys) has been identified in several patients with RASopathies (PM5). This variant has been identified in at least 6 patients with a RASopathy, of which 2 were unconfirmed de novo cases (PS4, PM6_Strong; Partners LMM, Labcorp internal data, ClinVar: SCV000063166.5, SCV002210187.3; PMID: 18042262, 18456719, 27763634). Western blot assay in Ba/F3 cells showed that the variant activated ERK signaling while the wildtype did not (PS3_Supporting, PMID: 30867592). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS4, PM6_Strong, PM1, PM5, PS3_Supprting, PM2_Supporting, PP3 (Specification Version 2.3, 12/3/2024)		RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA119417/MONDO:0021060/048	b513b1fc-147c-4877-bb0a-38f55e252576
NM_030662.4(MAP2K2):c.170T>G (p.Phe57Cys)	8272	CA279958	NM_030662.4:c.170T>G, NC_000019.10:g.4117552A>C, CM000681.2:g.4117552A>C, NC_000019.9:g.4117550A>C, CM000681.1:g.4117550A>C, NC_000019.8:g.4068550A>C, NG_007996.1:g.11577T>G, LRG_750:g.11577T>G, ENST00000394867.9:n.609T>G, ENST00000687128.1:n.609T>G, ENST00000262948.10:c.170T>G, ENST00000262948.9:c.170T>G, ENST00000394867.8:c.-122T>G, ENST00000599345.1:n.367T>G, NM_030662.3:c.170T>G, LRG_750t1:c.170T>G, XM_006722799.2:c.170T>G, XM_017026989.1:c.170T>G, XM_017026990.1:c.170T>G, XM_017026991.1:c.170T>G, NM_030662.4(MAP2K2):c.170T>G (p.Phe57Cys)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS4_Moderate, PM5, PM1, PS3_Supporting, PM6	BA1, BP4, BS3, BS1	The c.170T>G variant in the MAP2K2 gene is a missense variant predicted to cause substitution of phenylalanine by cysteine at amino acid 57 (p.Phe57Cys). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.959, predicting a damaging impact on protein function (PP3). This variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a critical functional domain of MAP2K2 (PM1, AA 47-65). Furthermore, other pathogenic missense variants has been previously identified at this codon of MAP2K2 (Phe57Val, Phe57Ile, Phe57Leu) and in nearby residues in association with CFC syndrome, which may indicate that this residue is critical to the function of the protein (PM5). This variant has been identified in at least 4 patients with RASopathy, of which 1 was an unconfirmed de novo occurrence (PS4_Moderate, PM6; GenomeConnect, ClinVar: SCV002047662.1; PMID: 16439621, 18039235, 21062266). ERK phosphorylation assays showed that this variant led to increased phosphorylation compared to wild-type (PS3_Supporting; PMID: 16439621, 17981815). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS4_Moderate, PM1, PM5, PM6, PS3_Supporting, PM2_Supporting, PP3 (Specification Version 2.3, 12/3/2024)	17981815, 16439621	RASopathy VCEP		2024-12-03	2025-03-31	false	https://erepo.genome.network/evrepo/ui/classification/CA279958/MONDO:0021060/048	07aecf91-9cf2-48c7-b101-b21e809f57a4
NM_030662.4(MAP2K2):c.383C>A (p.Pro128Gln)	8275	CA279962	NM_030662.4:c.383C>A, NC_000019.10:g.4110576G>T, CM000681.2:g.4110576G>T, NC_000019.9:g.4110574G>T, CM000681.1:g.4110574G>T, NC_000019.8:g.4061574G>T, NG_007996.1:g.18553C>A, LRG_750:g.18553C>A, ENST00000394867.9:n.822C>A, ENST00000687128.1:n.822C>A, ENST00000262948.10:c.383C>A, ENST00000262948.9:c.383C>A, ENST00000394867.8:c.92C>A, ENST00000599345.1:n.580C>A, NM_030662.3:c.383C>A, LRG_750t1:c.383C>A, XM_006722799.2:c.383C>A, XM_017026989.1:c.383C>A, XM_017026990.1:c.383C>A, XM_017026991.1:c.383C>A, NM_030662.4(MAP2K2):c.383C>A (p.Pro128Gln)	MAP2K2	RASopathy	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PP3, PS4_Supporting, PM2_Supporting, PP1_Strong, PM1, PS3_Supporting	BA1, PM5, BS1	The c.383C>A variant in the MAP2K2 gene is a missense variant predicted to cause substitution of proline by glutamine at amino acid 128 (p.Pro128Gln). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives a score of 0.928 (PP3). This variant is located in a functional domain supporting pathogenicity (PM1). This variant has been reported to segregate with clinical features of a RASopathy in at least 7 family members of the proband (PS4_Supporting, PP1_Strong; 20358587). ERK phosphorylation assay showed that this variant led to increased ERK phosphorylation compared to wild-type (PS3_P; PMID 20358587). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PP1_Strong, PM1, PS3_Supporting, PS4_Supporting, PM2_Supporting, PP3 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-02	false	https://erepo.genome.network/evrepo/ui/classification/CA279962/MONDO:0015280/048	307f4b6c-ef49-48bd-98e2-5cf382642800
NM_002755.4(MAP2K1):c.158T>C (p.Phe53Ser)	13350	CA279966	NM_002755.4:c.158T>C, NC_000015.10:g.66435104T>C, CM000677.2:g.66435104T>C, NC_000015.9:g.66727442T>C, CM000677.1:g.66727442T>C, NC_000015.8:g.64514496T>C, NG_008305.1:g.53232T>C, LRG_725:g.53232T>C, ENST00000684779.1:c.92T>C, ENST00000685172.1:c.158T>C, ENST00000685763.1:c.158T>C, ENST00000686347.1:c.158T>C, ENST00000687191.1:n.594T>C, ENST00000689951.1:c.158T>C, ENST00000691077.1:c.158T>C, ENST00000691576.1:c.158T>C, ENST00000691937.1:c.158T>C, ENST00000692487.1:c.158T>C, ENST00000692683.1:c.92T>C, ENST00000693150.1:c.92T>C, ENST00000307102.10:c.158T>C, ENST00000307102.9:c.158T>C, ENST00000425818.2:n.669T>C, NM_002755.3:c.158T>C, LRG_725t1:c.158T>C, XM_011521783.1:c.92T>C, XM_011521783.3:c.92T>C, XM_017022411.2:c.158T>C, XM_017022412.1:c.92T>C, NM_002755.4(MAP2K1):c.158T>C (p.Phe53Ser)	MAP2K1	RASopathy	MONDO:0015280	Autosomal dominant inheritance	Likely Pathogenic	PP3, PP2, PM2_Supporting, PS3_Moderate, PM1, PS4_Moderate, PM6_Supporting	BP4, BA1, BS1	The c.158T>C variant in the MAP2K1 gene is a missense variant predicted to cause substitution of phenylalanine by serine at amino acid 53 (p.Phe53Ser). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives a score of 0.938 (PP3). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). Furthermore, the variant is in a location, analogous to MEK2 F57 residue, that has been defined by the ClinGen RASopathy Expert Panel functional domain of MAP2K1 (PM1). This variant has been reported in the literature in 4 individuals with clinical features of RASopathy with 1 unconfirmed de novo occurrence (PS4_Moderate, PM6_Supporting; PMIDs: 16439621, 18039235, 21062266, 30141192). ERK/MAPK phosphorylation assays showed that this variant led to significantly increased phosphorylation compared to wildtype (PS3_Moderate; PMID: 16439621, 17981815). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal dominant RASopathies based on ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS3_Moderate, PS4_Moderate, PM1, PM2_Supporting, PM6_Supporting, PP2, PP3 (Specification Version 2.1, 9/17/2024)		RASopathy VCEP		2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA279966/MONDO:0015280/045	b78d797f-9630-4e8f-a1e3-8bf3ece401f5
NM_002755.3(MAP2K1):c.199G>A (p.Asp67Asn)	40781	CA180743	NM_002755.3:c.199G>A, NC_000015.10:g.66435145G>A, CM000677.2:g.66435145G>A, NC_000015.9:g.66727483G>A, CM000677.1:g.66727483G>A, NC_000015.8:g.64514537G>A, NG_008305.1:g.53273G>A, LRG_725:g.53273G>A, LRG_725t1:c.199G>A, XM_011521783.1:c.133G>A, XM_011521783.3:c.133G>A, XM_017022411.2:c.199G>A, XM_017022412.1:c.133G>A, ENST00000307102.9:c.199G>A, ENST00000425818.2:n.710G>A, NM_002755.3(MAP2K1):c.199G>A (p.Asp67Asn)	MAP2K1	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS3, PM2, PP2, PP3, PM6_Strong		The c.199G>A (p.Asp67Asn) variant in MAP2K1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 17704260). In vitro functional studies provide some evidence that the p.Asp67Asn variant may impact protein function (PS3; PMID 25049390). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Asp67Asn variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581):  PM6_Strong, PS3, PM2, PP2, PP3.	25049390, 17704260	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2020-01-23	false	https://erepo.genome.network/evrepo/ui/classification/CA180743/MONDO:0015280/004	8197dee3-bc2e-49dc-88bc-d31b5fd7286f
NM_002755.3(MAP2K1):c.388T>C (p.Tyr130His)	40747	CA279999	NM_002755.3:c.388T>C, LRG_725t1:c.388T>C, XM_011521783.1:c.322T>C, XM_011521783.3:c.322T>C, XM_017022411.2:c.388T>C, XM_017022412.1:c.322T>C, NM_002755.4:c.388T>C, ENST00000307102.9:c.388T>C, ENST00000425818.2:n.899T>C, NC_000015.10:g.66436842T>C, CM000677.2:g.66436842T>C, NC_000015.9:g.66729180T>C, CM000677.1:g.66729180T>C, NC_000015.8:g.64516234T>C, NG_008305.1:g.54970T>C, LRG_725:g.54970T>C, NM_002755.3(MAP2K1):c.388T>C (p.Tyr130His)	MAP2K1	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM5, PM2, PP2, PP3, PM6_Strong, PS4_Supporting		The c.388T>C (p.Tyr130His) variant in MAP2K1 has been reported as an unconfirmed de novo occurrence in two probands with clinical features of a RASopathy (PM6_Strong; PMID: 1915617, Ambry Genetics internal data, ClinVar SCV000740998.1). One of these patients had a clinical diagnosis of cardiofaciocutaneous syndrome (PS4_Supporting). This variant was absent from large population studies (PM2; gnomad.broadinstitute.org). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). The variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K1 (PM1 not applied; PMID 29493581). Moreover, a different pathogenic missense variant has been previously identified at this codon of MAP2K1 which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 13351). Computational prediction tools and conservation analysis suggest that the p.Tyr130His variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PM6_Strong, PM5, PM2, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-05-18	2020-07-01	false	https://erepo.genome.network/evrepo/ui/classification/CA279999/MONDO:0015280/004	9f86afbc-b31d-472c-ac5d-ee0799f21c9c
NM_002755.3(MAP2K1):c.389A>G (p.Tyr130Cys)	13351	CA280036	NM_002755.3:c.389A>G, LRG_725t1:c.389A>G, XM_011521783.1:c.323A>G, XM_011521783.3:c.323A>G, XM_017022411.2:c.389A>G, XM_017022412.1:c.323A>G, ENST00000307102.9:c.389A>G, ENST00000425818.2:n.900A>G, NC_000015.10:g.66436843A>G, CM000677.2:g.66436843A>G, NC_000015.9:g.66729181A>G, CM000677.1:g.66729181A>G, NC_000015.8:g.64516235A>G, NG_008305.1:g.54971A>G, LRG_725:g.54971A>G, NM_002755.3(MAP2K1):c.389A>G (p.Tyr130Cys)	MAP2K1	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PS2_Very Strong, PM2, PP2, PP3		The c.389A>G (p.Tyr130Cys) variant in MAP2K1 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStong; PMID 16439621, 17551924, 18042262). In vitro functional studies provide some evidence that the p.Tyr130Cys variant may impact protein function (PS3; PMID 18413255, 23093928, 17981815). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Tyr130Cys variant may impact the protein (PP3).  In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PP3, PS3, PM2, PP2, PM1.	18413255, 17981815, 23093928, 16439621, 18042262, 17551924	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA280036/MONDO:0015280/004	1eaf4dad-ab0c-49ae-8548-22bad4210249
NM_005633.3(SOS1):c.3658G>A (p.Val1220Met)	448938	CA1624132	NM_005633.3:c.3658G>A, LRG_754t1:c.3658G>A, XM_005264515.3:c.3613G>A, XM_011533060.1:c.3751G>A, XM_011533061.1:c.3706G>A, XM_011533062.1:c.3637G>A, XM_011533063.1:c.3634G>A, XM_011533064.1:c.3487G>A, XM_011533065.1:c.3604-805G>A, XM_011533066.1:c.2593G>A, XM_005264515.4:c.3613G>A, XM_011533062.2:c.3637G>A, XM_011533064.2:c.3487G>A, ENST00000395038.6:c.3613G>A, ENST00000402219.6:c.3658G>A, ENST00000426016.5:c.3658G>A, ENST00000469581.1:n.401G>A, NC_000002.12:g.38986168C>T, CM000664.2:g.38986168C>T, NC_000002.11:g.39213309C>T, CM000664.1:g.39213309C>T, NC_000002.10:g.39066813C>T, NG_007530.1:g.139296G>A, LRG_754:g.139296G>A, NM_005633.3(SOS1):c.3658G>A (p.Val1220Met)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.3658G>A (p.Val1220Met) variant in the SOS1 gene is 0.0328% (10/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624132/MONDO:0021060/004	6ff7d21d-3c34-4d7d-b6e4-fc68a890a4b0
NM_004333.4(BRAF):c.1741A>G (p.Asn581Asp)	13979	CA279976	NM_004333.4:c.1741A>G, LRG_299t1:c.1741A>G, XM_005250045.1:c.1741A>G, XM_005250046.1:c.1741A>G, XM_011516529.1:c.1741A>G, XM_011516530.1:c.1695-4769A>G, XR_242190.1:n.1749A>G, XR_927520.1:n.1749A>G, XR_927521.1:n.1749A>G, XR_927522.1:n.1703-4769A>G, XR_927523.1:n.1703-4769A>G, NM_001354609.1:c.1741A>G, NM_004333.5:c.1741A>G, NR_148928.1:n.2046A>G, XM_017012558.1:c.1861A>G, XM_017012559.1:c.1861A>G, XR_001744857.1:n.1869A>G, XR_001744858.1:n.1823-4769A>G, ENST00000288602.10:c.1741A>G, ENST00000479537.5:n.25A>G, ENST00000496384.6:n.564A>G, ENST00000497784.1:n.1776A>G, NC_000007.14:g.140754187T>C, CM000669.2:g.140754187T>C, NC_000007.13:g.140453987T>C, CM000669.1:g.140453987T>C, NC_000007.12:g.140100456T>C, NG_007873.3:g.175578A>G, LRG_299:g.175578A>G, NM_004333.4(BRAF):c.1741A>G (p.Asn581Asp)	BRAF	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PP2, PP3, PM6_Strong		The c.1741A>G (p.Asn581Asp) variant in BRAF has been reported in the literature as a non-maternity/paternity confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PM6_Strong; PMID 25463315). In vitro functional studies provide some evidence that the p.Asn581Asp variant may impact protein function (PS3; 19376813, 16474404).  This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Furthermore, this variant is located in the catalytic loop of BRAF (PM1; 16474404, 29493581).  Computational prediction tools and conservation analysis suggest that the p.Asn581Asp variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PM6_Strong, PS3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA279976/MONDO:0015280/004	f2cf40e6-1706-4a5e-b2f8-b7b396ddbde2
NM_004333.4(BRAF):c.736G>C (p.Ala246Pro)	13965	CA279968	NM_004333.4:c.736G>C, NC_000007.14:g.140801536C>G, CM000669.2:g.140801536C>G, NC_000007.13:g.140501336C>G, CM000669.1:g.140501336C>G, NC_000007.12:g.140147805C>G, NG_007873.3:g.128229G>C, LRG_299:g.128229G>C, LRG_299t1:c.736G>C, XM_005250045.1:c.736G>C, XM_005250046.1:c.736G>C, XM_011516529.1:c.736G>C, XM_011516530.1:c.736G>C, XR_242190.1:n.744G>C, XR_927520.1:n.744G>C, XR_927521.1:n.744G>C, XR_927522.1:n.744G>C, XR_927523.1:n.744G>C, NM_001354609.1:c.736G>C, NM_004333.5:c.736G>C, NR_148928.1:n.1041G>C, XM_017012558.1:c.736G>C, XM_017012559.1:c.736G>C, XR_001744857.1:n.744G>C, XR_001744858.1:n.744G>C, ENST00000288602.10:c.736G>C, ENST00000497784.1:n.771G>C, NM_004333.4(BRAF):c.736G>C (p.Ala246Pro)	BRAF	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS3, PS2, PM1, PM6, PM2, PP2, PP3		The c.736G>C (p.Ala246Pro) variant in BRAF has been reported in the literature as a de novo occurrence in at least 2 patients with clinical features of a RASopathy (PM6 and PS2; PMID 16474404 and 18042262). In vitro functional studies provide some evidence that the p.Ala246Pro variant may impact protein function (PS3; 16474404, 19376813).  This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). This variant is in a location which has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Ala246Pro variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PM6, PS2, PS3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA279968/MONDO:0015280/004	2eac9953-9576-4ab4-8bd3-c9d0c1d40f0c
NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu)	13974	CA279970	NM_004333.6:c.1406G>A, NC_000007.14:g.140781602C>T, CM000669.2:g.140781602C>T, NC_000007.13:g.140481402C>T, CM000669.1:g.140481402C>T, NC_000007.12:g.140127871C>T, NG_007873.3:g.148163G>A, LRG_299:g.148163G>A, ENST00000646891.2:c.1406G>A, ENST00000288602.11:c.1526G>A, ENST00000479537.6:c.76G>A, ENST00000496384.7:c.1406G>A, ENST00000497784.2:c.*856G>A, ENST00000642228.1:c.*484G>A, ENST00000642875.1:n.848G>A, ENST00000644120.1:n.1796G>A, ENST00000644650.1:c.502G>A, ENST00000644905.1:n.1495G>A, ENST00000644969.2:c.1526G>A, ENST00000646334.1:n.536G>A, ENST00000646730.1:c.1406G>A, ENST00000646891.1:c.1406G>A, ENST00000647434.1:c.449G>A, ENST00000288602.10:c.1406G>A, ENST00000496384.6:c.229G>A, ENST00000497784.1:c.1441G>A, NM_004333.4:c.1406G>A, LRG_299t1:c.1406G>A, XM_005250045.1:c.1406G>A, XM_005250046.1:c.1406G>A, XM_011516529.1:c.1406G>A, XM_011516530.1:c.1406G>A, XR_242190.1:n.1414G>A, XR_927520.1:n.1414G>A, XR_927521.1:n.1414G>A, XR_927522.1:n.1414G>A, XR_927523.1:n.1414G>A, NM_001354609.1:c.1406G>A, NM_004333.5:c.1406G>A, NR_148928.1:n.1711G>A, XM_017012558.1:c.1526G>A, XM_017012559.1:c.1526G>A, XR_001744857.1:n.1534G>A, XR_001744858.1:n.1534G>A, NM_001354609.2:c.1406G>A, NM_001374244.1:c.1526G>A, NM_001374258.1:c.1526G>A, NM_001378467.1:c.1415G>A, NM_001378468.1:c.1406G>A, NM_001378469.1:c.1340G>A, NM_001378470.1:c.1304G>A, NM_001378471.1:c.1295G>A, NM_001378472.1:c.1250G>A, NM_001378473.1:c.1250G>A, NM_001378474.1:c.1406G>A, NM_001378475.1:c.1142G>A, NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu)	BRAF	RASopathy	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS3_Supporting, PS2_Very Strong, PM1, PP3, PP2, PM2_Supporting, PS4		The c.1406G>A variant in BRAF is a missense variant predicted to cause substitution of glycine by glutamic acid at amino acid 469 (p.Gly469Glu). This variant is absent from gnomAD v4 (PM2_Supporting). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). The REVEL computational prediction analysis tool produced a score of 0.921, which is above the threshold necessary to apply PP3 (PP3). Furthermore, this variant is in a location which has been defined by the ClinGen RASopathy Expert Panel functional domain of BRAF (PM1). This variant has been reported in the literature in at least 12 patients with clinical features of RASopathy (PS4, PMIDs: 18042262, 16474404, 30141192, 29907801, 35418823), out of which 3 patients were reported as a confirmed de novo occurrence (PS2_VeryStrong; PMIDs: 18042262, 16474404). Luciferase assays showed that p.Gly469Glu did not enhance ELK-dependent transcription indicating that this variant impacts protein function (PS3_Supporting; 16474404). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2_VeryStrong, PS4, PM1, PS3_Supporting, PM2_Supporting, PP2, PP3 (Specification Version 2.1, 9/17/2024)		RASopathy VCEP		2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA279970/MONDO:0015280/049	f75f3f8b-6c9c-41a1-9cee-4716d67229dd
NM_004333.4(BRAF):c.730A>C (p.Thr244Pro)	40346	CA280025	NM_004333.4:c.730A>C, NC_000007.14:g.140801542T>G, CM000669.2:g.140801542T>G, NC_000007.13:g.140501342T>G, CM000669.1:g.140501342T>G, NC_000007.12:g.140147811T>G, NG_007873.3:g.128223A>C, LRG_299:g.128223A>C, LRG_299t1:c.730A>C, XM_005250045.1:c.730A>C, XM_005250046.1:c.730A>C, XM_011516529.1:c.730A>C, XM_011516530.1:c.730A>C, XR_242190.1:n.738A>C, XR_927520.1:n.738A>C, XR_927521.1:n.738A>C, XR_927522.1:n.738A>C, XR_927523.1:n.738A>C, NM_001354609.1:c.730A>C, NM_004333.5:c.730A>C, NR_148928.1:n.1035A>C, XM_017012558.1:c.730A>C, XM_017012559.1:c.730A>C, XR_001744857.1:n.738A>C, XR_001744858.1:n.738A>C, ENST00000288602.10:c.730A>C, ENST00000497784.1:n.765A>C, NM_004333.4(BRAF):c.730A>C (p.Thr244Pro)	BRAF	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS2, PM1, PM6, PM2, PP2, PP3	PS3	The c.730A>C (p.Thr244Pro) variant in BRAF has been reported in the literature as a de novo occurrence in at least 2 patients with clinical features of a RASopathy (PM6 and PS2; PMID 17551924 and 18042262). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). This variant is in a location which has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Thr244Pro variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581):  PP2, PP3, PM1, PM2, PM6, PS2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA280025/MONDO:0015280/004	4581b48f-d077-4114-baf4-9c4b42fd49c4
NM_002755.3(MAP2K1):c.848C>T (p.Ala283Val)	40756	CA134622	NM_002755.3:c.848C>T, NC_000015.10:g.66485144C>T, CM000677.2:g.66485144C>T, NC_000015.9:g.66777482C>T, CM000677.1:g.66777482C>T, NC_000015.8:g.64564536C>T, NG_008305.1:g.103272C>T, LRG_725:g.103272C>T, LRG_725t1:c.848C>T, XM_011521783.1:c.782C>T, XM_011521783.3:c.782C>T, XM_017022411.2:c.770C>T, XM_017022412.1:c.704C>T, XM_017022413.1:c.320C>T, ENST00000307102.9:c.848C>T, ENST00000566326.1:c.320C>T, NM_002755.3(MAP2K1):c.848C>T (p.Ala283Val)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP5, BA1		The filtering allele frequency of the c.848C>T (p.Ala283Val) variant in the MAP2K1 gene is 0.052% for African chromosomes by the Exome Aggregation Consortium (10/10366 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; Partners LMM, GeneDx internal data; GTR ID: 21766, 26957; ClinVar SCV000207935.12; SCV000061262.5). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134622/MONDO:0021060/004	d798c554-02fa-4c7b-96d8-4fda7463f9de
NM_002755.4(MAP2K1):c.275T>G (p.Leu92Arg)	44588	CA134601	NM_002755.4:c.275T>G, NC_000015.10:g.66435221T>G, CM000677.2:g.66435221T>G, NC_000015.9:g.66727559T>G, CM000677.1:g.66727559T>G, NC_000015.8:g.64514613T>G, NG_008305.1:g.53349T>G, LRG_725:g.53349T>G, ENST00000684779.1:c.209T>G, ENST00000685172.1:c.275T>G, ENST00000685763.1:c.275T>G, ENST00000686347.1:c.275T>G, ENST00000687191.1:n.711T>G, ENST00000689951.1:c.275T>G, ENST00000691077.1:c.275T>G, ENST00000691576.1:c.275T>G, ENST00000691937.1:c.275T>G, ENST00000692487.1:c.275T>G, ENST00000692683.1:c.209T>G, ENST00000693150.1:c.209T>G, ENST00000307102.10:c.275T>G, ENST00000307102.9:c.275T>G, ENST00000425818.2:n.786T>G, NM_002755.3:c.275T>G, LRG_725t1:c.275T>G, XM_011521783.1:c.209T>G, XM_011521783.3:c.209T>G, XM_017022411.2:c.275T>G, XM_017022412.1:c.209T>G, NM_002755.4(MAP2K1):c.275T>G (p.Leu92Arg)	MAP2K1	RASopathy	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PP3, PP2, PM6_Very Strong, PM2_Supporting, PS4_Moderate	BA1, BP4, BS1	The c.275T>G variant in the MAP2K1 gene is a missense variant predicted to cause substitution of leucine by arginine at amino acid 92 (p.Leu92Arg). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives a score of 0.793 (PP3). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). This variant has been reported in 4 independent patients with clinical feature of a RASopathy, 1 as a confirmed de novo occurrence and 2 as unconfirmed de novo occurrences (PS4_Moderate, PM6_VeryStrong; GeneDx, APHP-Robert DebrÃ© hospital, Laboratory for Molecular Medicine internal data; ClinVar SCV000207940.11, SCV000965969.1, SCV000061251.5, PMID: 35524774). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PM6_VeryStrong, PS4_Moderate, PM2_Supporting, PP2, PP3 (Specification Version 2.1, 09/17/2024)		RASopathy VCEP		2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA134601/MONDO:0015280/045	2986f8eb-3ee8-416d-a279-f72ff1c134a1
NM_004333.4(BRAF):c.770A>G (p.Gln257Arg)	13973	CA222583	NM_004333.4:c.770A>G, LRG_299t1:c.770A>G, XM_005250045.1:c.770A>G, XM_005250046.1:c.770A>G, XM_011516529.1:c.770A>G, XM_011516530.1:c.770A>G, XR_242190.1:n.778A>G, XR_927520.1:n.778A>G, XR_927521.1:n.778A>G, XR_927522.1:n.778A>G, XR_927523.1:n.778A>G, NM_001354609.1:c.770A>G, NM_004333.5:c.770A>G, NR_148928.1:n.1075A>G, XM_017012558.1:c.770A>G, XM_017012559.1:c.770A>G, XR_001744857.1:n.778A>G, XR_001744858.1:n.778A>G, ENST00000288602.10:c.770A>G, ENST00000497784.1:n.805A>G, NC_000007.14:g.140801502T>C, CM000669.2:g.140801502T>C, NC_000007.13:g.140501302T>C, CM000669.1:g.140501302T>C, NC_000007.12:g.140147771T>C, NG_007873.3:g.128263A>G, LRG_299:g.128263A>G, NM_004333.4(BRAF):c.770A>G (p.Gln257Arg)	BRAF	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS3, PM1, PM2, PS2_Very Strong, PP2, PP3		The c.770A>G (p.Gln257Arg) variant in BRAF has been reported in the literature as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID:18042262, PMID:17551924, PMID:16474404). In vitro functional studies provide some evidence that the p.Q257R variant may impact protein function (PS3; PMID:18413255; PMID:19376813).  This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID:29493581). Furthermore, this variant is located in exon 6, which has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID:29493581).  Computational prediction tools and conservation analysis suggest that the p.Q257R variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for cardio-facio-cutaneous syndrome in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PS3, PS2_VeryStrong.	19376813, 18413255, 18042262, 16474404, 17551924	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA222583/MONDO:0015280/004	5f9417cc-43e4-41be-b920-ae6db397bdaa
NM_007373.3(SHOC2):c.613A>G (p.Thr205Ala)	448933	CA5689601	NM_007373.3:c.613A>G, NC_000010.11:g.110964971A>G, CM000672.2:g.110964971A>G, NC_000010.10:g.112724729A>G, CM000672.1:g.112724729A>G, NC_000010.9:g.112714719A>G, NG_028922.1:g.50429A>G, LRG_753:g.50429A>G, NM_001269039.1:c.613A>G, LRG_753t1:c.613A>G, XM_011540216.1:c.-380-20657A>G, NM_001269039.2:c.613A>G, NM_001324336.1:c.613A>G, NM_001324337.1:c.613A>G, NR_136749.1:n.116-20657A>G, ENST00000265277.9:c.613A>G, ENST00000369452.8:c.613A>G, ENST00000451838.1:n.121A>G, ENST00000489390.1:n.56-35444A>G, NM_007373.3(SHOC2):c.613A>G (p.Thr205Ala)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.613A>G (p.Thr205Ala) variant in the SHOC2 gene is 0.0328% (10/16502) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5689601/MONDO:0021060/004	795ea8ea-3f7d-49cf-b7e6-d4efa4eb47e5
NM_002755.3(MAP2K1):c.896-5T>C	448948	CA7624046	NM_002755.3:c.896-5T>C, LRG_725t1:c.896-5T>C, XM_011521783.1:c.830-5T>C, XM_011521783.3:c.830-5T>C, XM_017022411.2:c.818-5T>C, XM_017022412.1:c.752-5T>C, XM_017022413.1:c.368-5T>C, ENST00000307102.9:c.896-5T>C, ENST00000566326.1:c.368-5T>C, NC_000015.10:g.66487223T>C, CM000677.2:g.66487223T>C, NC_000015.9:g.66779561T>C, CM000677.1:g.66779561T>C, NC_000015.8:g.64566615T>C, NG_008305.1:g.105351T>C, LRG_725:g.105351T>C, NM_002755.3(MAP2K1):c.896-5T>C	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.896-5T>C variant in the MAP2K1 gene is 0.0328% (10/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA7624046/MONDO:0021060/004	977fc918-e24e-4858-8b4f-f63a40068950
NM_004333.4(BRAF):c.483G>C (p.Leu161=)	44826	CA135128	NM_004333.4:c.483G>C, NC_000007.14:g.140834630C>G, CM000669.2:g.140834630C>G, NC_000007.13:g.140534430C>G, CM000669.1:g.140534430C>G, NC_000007.12:g.140180899C>G, NG_007873.3:g.95135G>C, LRG_299:g.95135G>C, LRG_299t1:c.483G>C, XM_005250045.1:c.483G>C, XM_005250046.1:c.483G>C, XM_011516529.1:c.483G>C, XM_011516530.1:c.483G>C, XR_242190.1:n.491G>C, XR_927520.1:n.491G>C, XR_927521.1:n.491G>C, XR_927522.1:n.491G>C, XR_927523.1:n.491G>C, NM_001354609.1:c.483G>C, NM_004333.5:c.483G>C, NR_148928.1:n.708G>C, XM_017012558.1:c.483G>C, XM_017012559.1:c.483G>C, XR_001744857.1:n.491G>C, XR_001744858.1:n.491G>C, ENST00000288602.10:c.483G>C, ENST00000469930.1:n.489G>C, ENST00000497784.1:n.438G>C, NM_004333.4(BRAF):c.483G>C (p.Leu161=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.483G>C (p.Leu161=) variant in the BRAF gene is 0.0315% (7/10404) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135128/MONDO:0021060/004	4fcbc6a6-a933-4864-9c77-53427914f590
NM_030662.3(MAP2K2):c.45C>T (p.Asn15=)	448954	CA9091108	NM_030662.3:c.45C>T, LRG_750t1:c.45C>T, XM_006722799.2:c.45C>T, XM_017026989.1:c.45C>T, XM_017026990.1:c.45C>T, XM_017026991.1:c.45C>T, ENST00000262948.9:c.45C>T, ENST00000394867.8:c.-231-16C>T, ENST00000599345.1:n.242C>T, NC_000019.10:g.4123831G>A, CM000681.2:g.4123831G>A, NC_000019.9:g.4123828G>A, CM000681.1:g.4123828G>A, NC_000019.8:g.4074828G>A, NG_007996.1:g.5299C>T, LRG_750:g.5299C>T, NM_030662.3(MAP2K2):c.45C>T (p.Asn15=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.45C>T (p.Asn15=) variant in the MAP2K2 gene is 0.0295% (6/8856) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA9091108/MONDO:0021060/004	b38274d0-0a58-4c74-896c-135e9c481ac6
NM_004985.4(KRAS):c.90C>T (p.Asp30=)	138061	CA291858	NM_004985.4:c.90C>T, NM_033360.3:c.90C>T, XM_006719069.2:c.90C>T, XM_011520653.1:c.90C>T, XM_006719069.4:c.90C>T, XM_011520653.3:c.90C>T, ENST00000256078.8:c.90C>T, ENST00000311936.7:c.90C>T, ENST00000556131.1:c.90C>T, ENST00000557334.5:c.90C>T, NC_000012.12:g.25245295G>A, CM000674.2:g.25245295G>A, NC_000012.11:g.25398229G>A, CM000674.1:g.25398229G>A, NC_000012.10:g.25289496G>A, NG_007524.1:g.10626C>T, NM_004985.4(KRAS):c.90C>T (p.Asp30=)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.90C>T (p.Asp30=) variant in the KRAS gene is 0.0292% (5/6746) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA291858/MONDO:0021060/004	68557210-74f7-4a1b-90d6-38f877f1a54a
NM_002880.3(RAF1):c.909A>C (p.Thr303=)	40609	CA134759	NM_002880.3:c.909A>C, NC_000003.12:g.12600233T>G, CM000665.2:g.12600233T>G, NC_000003.11:g.12641732T>G, CM000665.1:g.12641732T>G, NC_000003.10:g.12616732T>G, NG_007467.1:g.68947A>C, LRG_413:g.68947A>C, LRG_413t1:c.909A>C, XM_005265355.1:c.909A>C, XM_005265357.1:c.810A>C, XM_005265358.3:c.666A>C, XM_005265359.3:c.567A>C, XM_005265360.1:c.909A>C, XM_011533974.1:c.909A>C, XM_011533975.1:c.666A>C, NM_001354689.1:c.969A>C, NM_001354690.1:c.909A>C, NM_001354691.1:c.666A>C, NM_001354692.1:c.666A>C, NM_001354693.1:c.810A>C, NM_001354694.1:c.726A>C, NM_001354695.1:c.567A>C, NR_148940.1:n.1324A>C, NR_148941.1:n.1324A>C, NR_148942.1:n.1324A>C, XM_011533974.3:c.909A>C, XM_017006966.1:c.810A>C, XR_001740227.1:n.1141A>C, ENST00000251849.8:c.909A>C, ENST00000423275.5:c.*586A>C, ENST00000432427.2:n.546A>C, ENST00000442415.6:c.969A>C, ENST00000465826.5:n.153A>C, ENST00000491290.1:n.538A>C, NM_002880.3(RAF1):c.909A>C (p.Thr303=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.909A>C (p.Thr303=) variant in the RAF1 gene is 0.0285% (27/66658) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134759/MONDO:0021060/004	2692fba7-430e-447b-bb66-828d255d1af1
NM_005633.3(SOS1):c.294G>A (p.Lys98=)	448944	CA1624823	NM_005633.3:c.294G>A, NC_000002.12:g.39058724C>T, CM000664.2:g.39058724C>T, NC_000002.11:g.39285865C>T, CM000664.1:g.39285865C>T, NC_000002.10:g.39139369C>T, NG_007530.1:g.66740G>A, LRG_754:g.66740G>A, LRG_754t1:c.294G>A, XM_005264515.3:c.294G>A, XM_011533060.1:c.387G>A, XM_011533061.1:c.387G>A, XM_011533062.1:c.273G>A, XM_011533063.1:c.270G>A, XM_011533064.1:c.123G>A, XM_011533065.1:c.387G>A, XM_005264515.4:c.294G>A, XM_011533062.2:c.273G>A, XM_011533064.2:c.123G>A, ENST00000395038.6:c.294G>A, ENST00000402219.6:c.294G>A, ENST00000426016.5:c.294G>A, ENST00000451331.1:c.123G>A, NM_005633.3(SOS1):c.294G>A (p.Lys98=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.294G>A (p.Lys98=) variant in the SOS1 gene is 0.0284% (9/16504) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624823/MONDO:0021060/004	941717e7-7c04-404f-8bba-f9f7c73a7a6b
NM_002880.3(RAF1):c.907A>G (p.Thr303Ala)	448928	CA2259632	NM_002880.3:c.907A>G, LRG_413t1:c.907A>G, XM_005265355.1:c.907A>G, XM_005265357.1:c.808A>G, XM_005265358.3:c.664A>G, XM_005265359.3:c.565A>G, XM_005265360.1:c.907A>G, XM_011533974.1:c.907A>G, XM_011533975.1:c.664A>G, NM_001354689.1:c.967A>G, NM_001354690.1:c.907A>G, NM_001354691.1:c.664A>G, NM_001354692.1:c.664A>G, NM_001354693.1:c.808A>G, NM_001354694.1:c.724A>G, NM_001354695.1:c.565A>G, NR_148940.1:n.1322A>G, NR_148941.1:n.1322A>G, NR_148942.1:n.1322A>G, XM_011533974.3:c.907A>G, XM_017006966.1:c.808A>G, XR_001740227.1:n.1139A>G, ENST00000251849.8:c.907A>G, ENST00000423275.5:c.*584A>G, ENST00000432427.2:n.544A>G, ENST00000442415.6:c.967A>G, ENST00000465826.5:n.151A>G, ENST00000491290.1:n.536A>G, NC_000003.12:g.12600235T>C, CM000665.2:g.12600235T>C, NC_000003.11:g.12641734T>C, CM000665.1:g.12641734T>C, NC_000003.10:g.12616734T>C, NG_007467.1:g.68945A>G, LRG_413:g.68945A>G, NM_002880.3(RAF1):c.907A>G (p.Thr303Ala)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.907A>G (p.Thr303Ala) variant in the RAF1 gene is 0.0284% (7/11568) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA2259632/MONDO:0021060/004	92a20fc0-2bb5-4c16-b8cb-13af84a65a97
NM_002834.4(PTPN11):c.48A>G (p.Ala16=)	44608	CA134668	NM_002834.4:c.48A>G, NM_002834.3:c.48A>G, LRG_614t1:c.48A>G, NM_080601.1:c.48A>G, XM_006719526.1:c.48A>G, XM_006719527.1:c.48A>G, XM_011538613.1:c.48A>G, NM_001330437.1:c.48A>G, NM_080601.2:c.48A>G, XM_011538613.2:c.48A>G, XM_017019722.1:c.48A>G, ENST00000351677.6:c.48A>G, ENST00000392597.5:c.48A>G, ENST00000635625.1:n.48A>G, NC_000012.12:g.112446309A>G, CM000674.2:g.112446309A>G, NC_000012.11:g.112884113A>G, CM000674.1:g.112884113A>G, NC_000012.10:g.111368496A>G, NG_007459.1:g.32578A>G, LRG_614:g.32578A>G, NM_002834.4(PTPN11):c.48A>G (p.Ala16=)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.48A>G (p.Ala16=) variant in the PTPN11 gene is 0.0284% (9/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134668/MONDO:0021060/004	44c75d04-cfb3-4a52-840e-30d2eb641915
NM_030662.3(MAP2K2):c.240G>A (p.Ala80=)	378913	CA9091070	NM_030662.3:c.240G>A, NC_000019.10:g.4117482C>T, CM000681.2:g.4117482C>T, NC_000019.9:g.4117480C>T, CM000681.1:g.4117480C>T, NC_000019.8:g.4068480C>T, NG_007996.1:g.11647G>A, LRG_750:g.11647G>A, LRG_750t1:c.240G>A, XM_006722799.2:c.240G>A, XM_017026989.1:c.240G>A, XM_017026990.1:c.240G>A, XM_017026991.1:c.240G>A, ENST00000262948.9:c.240G>A, ENST00000394867.8:c.-52G>A, ENST00000599345.1:n.437G>A, NM_030662.3(MAP2K2):c.240G>A (p.Ala80=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.240G>A (p.Ala80=) variant in the MAP2K2 gene is 0.0284% (9/16506) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA9091070/MONDO:0021060/004	63dda72c-31c5-4e8f-b694-d44b4e9c8d51
NM_002834.4(PTPN11):c.333-3T>C	40511	CA282088	NM_002834.4:c.333-3T>C, NM_002834.3:c.333-3T>C, LRG_614t1:c.333-3T>C, NM_080601.1:c.333-3T>C, XM_006719526.1:c.333-3T>C, XM_006719527.1:c.333-3T>C, XM_011538613.1:c.330-3T>C, NM_001330437.1:c.333-3T>C, NM_080601.2:c.333-3T>C, XM_011538613.2:c.330-3T>C, XM_017019722.1:c.330-3T>C, ENST00000351677.6:c.333-3T>C, ENST00000392597.5:c.333-3T>C, ENST00000635625.1:n.333-3T>C, NC_000012.12:g.112453192T>C, CM000674.2:g.112453192T>C, NC_000012.11:g.112890996T>C, CM000674.1:g.112890996T>C, NC_000012.10:g.111375379T>C, NG_007459.1:g.39461T>C, LRG_614:g.39461T>C, NM_002834.4(PTPN11):c.333-3T>C	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.333-3T>C variant in the PTPN11 gene is 0.0276% (6/9456) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA282088/MONDO:0021060/004	9a983768-4bb6-4ea5-a081-ded31831d374
NM_002880.3(RAF1):c.124G>A (p.Ala42Thr)	448930	CA2259833	NM_002880.3:c.124G>A, NC_000003.12:g.12618598C>T, CM000665.2:g.12618598C>T, NC_000003.11:g.12660097C>T, CM000665.1:g.12660097C>T, NC_000003.10:g.12635097C>T, NG_007467.1:g.50582G>A, LRG_413:g.50582G>A, LRG_413t1:c.124G>A, XM_005265355.1:c.124G>A, XM_005265357.1:c.124G>A, XM_005265358.3:c.-7G>A, XM_005265359.3:c.-7G>A, XM_005265360.1:c.124G>A, XM_011533974.1:c.124G>A, XM_011533975.1:c.-7G>A, NM_001354689.1:c.124G>A, NM_001354690.1:c.124G>A, NM_001354691.1:c.-7G>A, NM_001354692.1:c.-7G>A, NM_001354693.1:c.124G>A, NM_001354694.1:c.-7G>A, NM_001354695.1:c.-7G>A, NR_148940.1:n.539G>A, NR_148941.1:n.539G>A, NR_148942.1:n.539G>A, XM_011533974.3:c.124G>A, XM_017006966.1:c.124G>A, XR_001740227.1:n.455G>A, ENST00000251849.8:c.124G>A, ENST00000416093.1:c.124G>A, ENST00000423275.5:c.124G>A, ENST00000442415.6:c.124G>A, NM_002880.3(RAF1):c.124G>A (p.Ala42Thr)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.124G>A (p.Ala42Thr) variant in the RAF1 gene is 0.026% (25/66738) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA2259833/MONDO:0021060/004	751d9970-bb11-4fb7-b5b2-153cc27ddc68
NM_002880.3(RAF1):c.125C>T (p.Ala42Val)	343103	CA2259832	NM_002880.3:c.125C>T, LRG_413t1:c.125C>T, XM_005265355.1:c.125C>T, XM_005265357.1:c.125C>T, XM_005265358.3:c.-6C>T, XM_005265359.3:c.-6C>T, XM_005265360.1:c.125C>T, XM_011533974.1:c.125C>T, XM_011533975.1:c.-6C>T, NM_001354689.1:c.125C>T, NM_001354690.1:c.125C>T, NM_001354691.1:c.-6C>T, NM_001354692.1:c.-6C>T, NM_001354693.1:c.125C>T, NM_001354694.1:c.-6C>T, NM_001354695.1:c.-6C>T, NR_148940.1:n.540C>T, NR_148941.1:n.540C>T, NR_148942.1:n.540C>T, XM_011533974.3:c.125C>T, XM_017006966.1:c.125C>T, XR_001740227.1:n.456C>T, ENST00000251849.8:c.125C>T, ENST00000416093.1:c.125C>T, ENST00000423275.5:c.125C>T, ENST00000442415.6:c.125C>T, NC_000003.12:g.12618597G>A, CM000665.2:g.12618597G>A, NC_000003.11:g.12660096G>A, CM000665.1:g.12660096G>A, NC_000003.10:g.12635096G>A, NG_007467.1:g.50583C>T, LRG_413:g.50583C>T, NM_002880.3(RAF1):c.125C>T (p.Ala42Val)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.125C>T (p.Ala42Val) variant in the RAF1 gene is 0.026% (25/66738) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA2259832/MONDO:0021060/004	da2fd72c-d28d-424b-92b6-eb26ccf60d9f
NM_005633.3(SOS1):c.280A>G (p.Ile94Val)	448945	CA1624825	NM_005633.3:c.280A>G, LRG_754t1:c.280A>G, XM_005264515.3:c.280A>G, XM_011533060.1:c.373A>G, XM_011533061.1:c.373A>G, XM_011533062.1:c.259A>G, XM_011533063.1:c.256A>G, XM_011533064.1:c.109A>G, XM_011533065.1:c.373A>G, XM_005264515.4:c.280A>G, XM_011533062.2:c.259A>G, XM_011533064.2:c.109A>G, ENST00000395038.6:c.280A>G, ENST00000402219.6:c.280A>G, ENST00000426016.5:c.280A>G, ENST00000451331.1:c.109A>G, NC_000002.12:g.39058738T>C, CM000664.2:g.39058738T>C, NC_000002.11:g.39285879T>C, CM000664.1:g.39285879T>C, NC_000002.10:g.39139383T>C, NG_007530.1:g.66726A>G, LRG_754:g.66726A>G, NM_005633.3(SOS1):c.280A>G (p.Ile94Val)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.280A>G (p.Ile94Val) variant in the SOS1 gene is 0.0253% (6/10300) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624825/MONDO:0021060/004	906b02c4-507d-4053-a5bb-59b403751a0d
NM_005633.3(SOS1):c.1647A>G (p.Thr549=)	139236	CA293658	NM_005633.3:c.1647A>G, NC_000002.12:g.39022781T>C, CM000664.2:g.39022781T>C, NC_000002.11:g.39249922T>C, CM000664.1:g.39249922T>C, NC_000002.10:g.39103426T>C, NG_007530.1:g.102683A>G, LRG_754:g.102683A>G, LRG_754t1:c.1647A>G, XM_005264515.3:c.1647A>G, XM_011533060.1:c.1740A>G, XM_011533061.1:c.1740A>G, XM_011533062.1:c.1626A>G, XM_011533063.1:c.1623A>G, XM_011533064.1:c.1476A>G, XM_011533065.1:c.1740A>G, XM_011533066.1:c.582A>G, XM_005264515.4:c.1647A>G, XM_011533062.2:c.1626A>G, XM_011533064.2:c.1476A>G, ENST00000395038.6:c.1647A>G, ENST00000402219.6:c.1647A>G, ENST00000426016.5:c.1647A>G, NM_005633.3(SOS1):c.1647A>G (p.Thr549=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.1647A>G (p.Thr549=) variant in the SOS1 gene is 0.0251% (6/10398) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA293658/MONDO:0021060/004	145cda70-23c6-4a63-a935-0a89d4d2b4cd
NM_030662.3(MAP2K2):c.813C>T (p.Asp271=)	378108	CA9090826	NM_030662.3:c.813C>T, LRG_750t1:c.813C>T, XM_006722799.2:c.705+1712C>T, XM_011528133.1:c.243C>T, XM_017026989.1:c.813C>T, XM_017026990.1:c.705+1712C>T, ENST00000262948.9:c.813C>T, ENST00000394867.8:c.522C>T, ENST00000593364.5:n.760C>T, ENST00000595715.1:n.628C>T, ENST00000597263.5:n.169+1712C>T, ENST00000599021.1:n.29+1712C>T, ENST00000600584.5:n.1373C>T, ENST00000601786.5:n.1114C>T, NC_000019.10:g.4099307G>A, CM000681.2:g.4099307G>A, NC_000019.9:g.4099305G>A, CM000681.1:g.4099305G>A, NC_000019.8:g.4050305G>A, NG_007996.1:g.29822C>T, LRG_750:g.29822C>T, NM_030662.3(MAP2K2):c.813C>T (p.Asp271=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.813C>T (p.Asp271=) variant in the MAP2K2 gene is 0.0045% (1/7096) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA9090826/MONDO:0021060/004	241fca61-876f-4b2a-bc64-30fd49bd7ee2
NM_030662.3(MAP2K2):c.1140C>T (p.Ala380=)	50938	CA143886	NM_030662.3:c.1140C>T, LRG_750t1:c.1140C>T, XM_006722799.2:c.861C>T, XM_011528133.1:c.570C>T, ENST00000262948.9:c.1140C>T, ENST00000394867.8:c.849C>T, ENST00000597263.5:n.325C>T, ENST00000599021.1:n.250C>T, ENST00000600584.5:n.2589C>T, ENST00000601786.5:n.1441C>T, NC_000019.10:g.4090661G>A, CM000681.2:g.4090661G>A, NC_000019.9:g.4090659G>A, CM000681.1:g.4090659G>A, NC_000019.8:g.4041659G>A, NG_007996.1:g.38468C>T, LRG_750:g.38468C>T, NM_030662.3(MAP2K2):c.1140C>T (p.Ala380=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.1140C>T (p.Ala380=) variant in the MAP2K2 gene is 0.003% (2/796) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA143886/MONDO:0021060/004	b23e5835-5f83-4a46-b686-0e354d53e944
NM_004333.4(BRAF):c.1929A>G (p.Gly643=)	40391	CA135110	NM_004333.4:c.1929A>G, NC_000007.14:g.140749350T>C, CM000669.2:g.140749350T>C, NC_000007.13:g.140449150T>C, CM000669.1:g.140449150T>C, NC_000007.12:g.140095619T>C, NG_007873.3:g.180415A>G, LRG_299:g.180415A>G, LRG_299t1:c.1929A>G, XM_005250045.1:c.1929A>G, XM_005250046.1:c.1929A>G, XM_011516529.1:c.1929A>G, XM_011516530.1:c.1763A>G, XR_242190.1:n.1937A>G, XR_927520.1:n.1937A>G, XR_927521.1:n.1937A>G, XR_927522.1:n.1771A>G, XR_927523.1:n.1771A>G, NM_001354609.1:c.1929A>G, NM_004333.5:c.1929A>G, NR_148928.1:n.3027A>G, XM_017012558.1:c.2049A>G, XM_017012559.1:c.2049A>G, XR_001744857.1:n.2057A>G, XR_001744858.1:n.1891A>G, ENST00000288602.10:c.1929A>G, ENST00000479537.5:n.213A>G, ENST00000496384.6:n.752A>G, ENST00000497784.1:n.1964A>G, NM_004333.4(BRAF):c.1929A>G (p.Gly643=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1929A>G (p.Gly643=) variant in the BRAF gene is 66.117% (6984/10356) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135110/MONDO:0021060/004	043632b0-38d9-48f7-b0b4-993f0aa553b4
NM_004985.4(KRAS):c.24A>G (p.Val8=)	45119	CA135558	NM_004985.4:c.24A>G, NM_033360.3:c.24A>G, XM_006719069.2:c.24A>G, XM_011520653.1:c.24A>G, XM_006719069.4:c.24A>G, XM_011520653.3:c.24A>G, ENST00000256078.8:c.24A>G, ENST00000311936.7:c.24A>G, ENST00000556131.1:c.24A>G, ENST00000557334.5:c.24A>G, NC_000012.12:g.25245361T>C, CM000674.2:g.25245361T>C, NC_000012.11:g.25398295T>C, CM000674.1:g.25398295T>C, NC_000012.10:g.25289562T>C, NG_007524.1:g.10560A>G, NM_004985.4(KRAS):c.24A>G (p.Val8=)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.24A>G (p.Val8=) variant in the KRAS gene is 0.0499% (35/51828) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135558/MONDO:0021060/004	56c9c209-4dc1-4b23-8b13-5e4465526b77
NM_030662.3(MAP2K2):c.660C>A (p.Ile220=)	40816	CA137959	NM_030662.3:c.660C>A, NC_000019.10:g.4101064G>T, CM000681.2:g.4101064G>T, NC_000019.9:g.4101062G>T, CM000681.1:g.4101062G>T, NC_000019.8:g.4052062G>T, NG_007996.1:g.28065C>A, LRG_750:g.28065C>A, LRG_750t1:c.660C>A, XM_006722799.2:c.660C>A, XM_011528133.1:c.90C>A, XM_017026989.1:c.660C>A, XM_017026990.1:c.660C>A, XM_017026991.1:c.660C>A, ENST00000262948.9:c.660C>A, ENST00000394867.8:c.369C>A, ENST00000593364.5:n.607C>A, ENST00000597008.5:n.261C>A, ENST00000597263.5:n.124C>A, ENST00000601786.5:n.961C>A, ENST00000602167.5:n.380C>A, NM_030662.3(MAP2K2):c.660C>A (p.Ile220=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.660C>A (p.Ile220=) variant in the MAP2K2 gene is 65.271% (3631/5412) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137959/MONDO:0021060/004	f9d2ab1b-971b-4536-826d-99d4f2dd7426
NM_030662.3(MAP2K2):c.453C>T (p.Asp151=)	46237	CA137943	NM_030662.3:c.453C>T, NC_000019.10:g.4102451G>A, CM000681.2:g.4102451G>A, NC_000019.9:g.4102449G>A, CM000681.1:g.4102449G>A, NC_000019.8:g.4053449G>A, NG_007996.1:g.26678C>T, LRG_750:g.26678C>T, LRG_750t1:c.453C>T, XM_006722799.2:c.453C>T, XM_011528133.1:c.-118C>T, XM_017026989.1:c.453C>T, XM_017026990.1:c.453C>T, XM_017026991.1:c.453C>T, ENST00000262948.9:c.453C>T, ENST00000394867.8:c.162C>T, ENST00000593364.5:n.400C>T, ENST00000597008.5:n.54C>T, ENST00000599345.1:n.723C>T, ENST00000601786.5:n.754C>T, ENST00000602167.5:n.173C>T, NM_030662.3(MAP2K2):c.453C>T (p.Asp151=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.453C>T (p.Asp151=) variant in the MAP2K2 gene is 27.128% (10569/38338) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137943/MONDO:0021060/004	b79aa141-9bf2-4854-99cb-72cca42926e8
NM_030662.3(MAP2K2):c.405G>C (p.Gly135=)	40793	CA137935	NM_030662.3:c.405G>C, NC_000019.10:g.4110554C>G, CM000681.2:g.4110554C>G, NC_000019.9:g.4110552C>G, CM000681.1:g.4110552C>G, NC_000019.8:g.4061552C>G, NG_007996.1:g.18575G>C, LRG_750:g.18575G>C, LRG_750t1:c.405G>C, XM_006722799.2:c.405G>C, XM_017026989.1:c.405G>C, XM_017026990.1:c.405G>C, XM_017026991.1:c.405G>C, ENST00000262948.9:c.405G>C, ENST00000394867.8:c.114G>C, ENST00000599345.1:n.602G>C, NM_030662.3(MAP2K2):c.405G>C (p.Gly135=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.405G>C (p.Gly135=) variant in the MAP2K2 gene is 14.69% (1588/10368) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137935/MONDO:0021060/004	bd530659-0ddb-40c4-bec5-738830eaca7f
NM_005633.3(SOS1):c.195A>C (p.Arg65=)	40643	CA136085	NM_005633.3:c.195A>C, LRG_754t1:c.195A>C, XM_005264515.3:c.195A>C, XM_011533060.1:c.288A>C, XM_011533061.1:c.288A>C, XM_011533062.1:c.174A>C, XM_011533063.1:c.171A>C, XM_011533064.1:c.24A>C, XM_011533065.1:c.288A>C, XM_005264515.4:c.195A>C, XM_011533062.2:c.174A>C, XM_011533064.2:c.24A>C, ENST00000395038.6:c.195A>C, ENST00000402219.6:c.195A>C, ENST00000426016.5:c.195A>C, ENST00000451331.1:c.24A>C, NC_000002.12:g.39067646T>G, CM000664.2:g.39067646T>G, NC_000002.11:g.39294787T>G, CM000664.1:g.39294787T>G, NC_000002.10:g.39148291T>G, NG_007530.1:g.57818A>C, LRG_754:g.57818A>C, NM_005633.3(SOS1):c.195A>C (p.Arg65=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.195A>C (p.Arg65=) variant in the SOS1 gene is 10.978% (1192/10346) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136085/MONDO:0021060/004	7c7c5faa-dff9-4352-b563-fea9d0af98a6
NM_002755.3(MAP2K1):c.1023-8C>T	40760	CA134590	NM_002755.3:c.1023-8C>T, NC_000015.10:g.66489710C>T, CM000677.2:g.66489710C>T, NC_000015.9:g.66782048C>T, CM000677.1:g.66782048C>T, NC_000015.8:g.64569102C>T, NG_008305.1:g.107838C>T, LRG_725:g.107838C>T, NG_051234.1:g.13106G>A, LRG_725t1:c.1023-8C>T, XM_011521783.1:c.957-8C>T, XM_011521783.3:c.957-8C>T, XM_017022411.2:c.945-8C>T, XM_017022412.1:c.879-8C>T, XM_017022413.1:c.495-8C>T, ENST00000307102.9:c.1023-8C>T, ENST00000566326.1:c.495-8C>T, NM_002755.3(MAP2K1):c.1023-8C>T	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1023-8C>T variant in the MAP2K1 gene is 10.315% (1128/10406) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134590/MONDO:0021060/004	eb76d7fe-96e9-4113-aa3b-de76d46d565d
NM_002834.4(PTPN11):c.255C>T (p.His85=)	36708	CA134659	NM_002834.4:c.255C>T, NM_002834.3:c.255C>T, LRG_614t1:c.255C>T, NM_080601.1:c.255C>T, XM_006719526.1:c.255C>T, XM_006719527.1:c.255C>T, XM_011538613.1:c.252C>T, NM_001330437.1:c.255C>T, NM_080601.2:c.255C>T, XM_011538613.2:c.252C>T, XM_017019722.1:c.252C>T, ENST00000351677.6:c.255C>T, ENST00000392597.5:c.255C>T, ENST00000635625.1:n.255C>T, NC_000012.12:g.112450435C>T, CM000674.2:g.112450435C>T, NC_000012.11:g.112888239C>T, CM000674.1:g.112888239C>T, NC_000012.10:g.111372622C>T, NG_007459.1:g.36704C>T, LRG_614:g.36704C>T, NM_002834.4(PTPN11):c.255C>T (p.His85=)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.255C>T (p.His85=) variant in the PTPN11 gene is 7.417% (818/10402) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134659/MONDO:0021060/004	cc78505d-9b7f-4e98-be44-54c0653cc0f0
NM_030662.3(MAP2K2):c.192C>T (p.Val64=)	40770	CA137916	NM_030662.3:c.192C>T, NC_000019.10:g.4117530G>A, CM000681.2:g.4117530G>A, NC_000019.9:g.4117528G>A, CM000681.1:g.4117528G>A, NC_000019.8:g.4068528G>A, NG_007996.1:g.11599C>T, LRG_750:g.11599C>T, LRG_750t1:c.192C>T, XM_006722799.2:c.192C>T, XM_017026989.1:c.192C>T, XM_017026990.1:c.192C>T, XM_017026991.1:c.192C>T, ENST00000262948.9:c.192C>T, ENST00000394867.8:c.-100C>T, ENST00000599345.1:n.389C>T, NM_030662.3(MAP2K2):c.192C>T (p.Val64=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.192C>T (p.Val64=) variant in the MAP2K2 gene is 7.417% (1283/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137916/MONDO:0021060/004	cf89340c-b64c-46a6-aef4-094850f57f25
NM_002880.3(RAF1):c.1755A>G (p.Val585=)	40626	CA134709	NM_002880.3:c.1755A>G, LRG_413t1:c.1755A>G, XM_005265355.1:c.1755A>G, XM_005265357.1:c.1656A>G, XM_005265358.3:c.1512A>G, XM_005265359.3:c.1413A>G, XM_011533974.1:c.1755A>G, XM_011533975.1:c.1512A>G, NM_001354689.1:c.1815A>G, NM_001354690.1:c.1755A>G, NM_001354691.1:c.1512A>G, NM_001354692.1:c.1512A>G, NM_001354693.1:c.1656A>G, NM_001354694.1:c.1572A>G, NM_001354695.1:c.1413A>G, NR_148940.1:n.2283A>G, NR_148941.1:n.2229A>G, NR_148942.1:n.2168A>G, XM_011533974.3:c.1755A>G, XM_017006966.1:c.1656A>G, ENST00000251849.8:c.1755A>G, ENST00000423275.5:c.*1432A>G, ENST00000432427.2:n.1392A>G, ENST00000442415.6:c.1815A>G, ENST00000471449.1:n.444A>G, NC_000003.12:g.12584895T>C, CM000665.2:g.12584895T>C, NC_000003.11:g.12626394T>C, CM000665.1:g.12626394T>C, NC_000003.10:g.12601394T>C, NG_007467.1:g.84285A>G, LRG_413:g.84285A>G, NM_002880.3(RAF1):c.1755A>G (p.Val585=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1755A>G (p.Val585=) variant in the RAF1 gene is 6.222% (690/10404) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134709/MONDO:0021060/004	d1aca5e8-fdc6-4f63-acc4-05595b97c993
NM_007373.3(SHOC2):c.1423-7C>T	139109	CA293485	NM_007373.3:c.1423-7C>T, NC_000010.11:g.111009706C>T, CM000672.2:g.111009706C>T, NC_000010.10:g.112769464C>T, CM000672.1:g.112769464C>T, NC_000010.9:g.112759454C>T, NG_028922.1:g.95164C>T, LRG_753:g.95164C>T, NM_001269039.1:c.1285-7C>T, LRG_753t1:c.1423-7C>T, XM_011540216.1:c.340-7C>T, NM_001269039.2:c.1285-7C>T, NM_001324336.1:c.1423-7C>T, NM_001324337.1:c.1423-7C>T, NR_136749.1:n.835-7C>T, ENST00000265277.9:c.1285-7C>T, ENST00000369452.8:c.1423-7C>T, ENST00000451838.1:n.793-7C>T, ENST00000489390.1:n.637-7C>T, NM_007373.3(SHOC2):c.1423-7C>T	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1423-7C>T variant in the SHOC2 gene is 1.826% (183/8836) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA293485/MONDO:0021060/004	20c12a82-b03f-42bd-b0e7-cded270a1ecd
NM_002755.3(MAP2K1):c.711G>A (p.Gly237=)	40754	CA134613	NM_002755.3:c.711G>A, LRG_725t1:c.711G>A, XM_011521783.1:c.645G>A, XM_011521783.3:c.645G>A, XM_017022411.2:c.633G>A, XM_017022412.1:c.567G>A, XM_017022413.1:c.183G>A, ENST00000307102.9:c.711G>A, ENST00000566326.1:c.183G>A, NC_000015.10:g.66485007G>A, CM000677.2:g.66485007G>A, NC_000015.9:g.66777345G>A, CM000677.1:g.66777345G>A, NC_000015.8:g.64564399G>A, NG_008305.1:g.103135G>A, LRG_725:g.103135G>A, NM_002755.3(MAP2K1):c.711G>A (p.Gly237=)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.711G>A (p.Gly237=) variant in the MAP2K1 gene is 1.612% (1130/66724) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134613/MONDO:0021060/004	73aeb3b9-cf0f-441d-8fde-7baab940b780
NM_002755.3(MAP2K1):c.69C>T (p.Thr23=)	138155	CA181309	NM_002755.3:c.69C>T, LRG_725t1:c.69C>T, XM_017022411.2:c.69C>T, ENST00000307102.9:c.69C>T, ENST00000425818.2:n.580C>T, NC_000015.10:g.66387416C>T, CM000677.2:g.66387416C>T, NC_000015.9:g.66679754C>T, CM000677.1:g.66679754C>T, NC_000015.8:g.64466808C>T, NG_008305.1:g.5544C>T, LRG_725:g.5544C>T, NM_002755.3(MAP2K1):c.69C>T (p.Thr23=)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.69C>T (p.Thr23=) variant in the MAP2K1 gene is 0.0484% (4/2820) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA181309/MONDO:0021060/004	3eacc550-bf0c-432b-b902-eee2cb07e8c4
NM_007373.3(SHOC2):c.457C>T (p.Leu153=)	139104	CA333154	NM_007373.3:c.457C>T, NC_000010.11:g.110964815C>T, CM000672.2:g.110964815C>T, NC_000010.10:g.112724573C>T, CM000672.1:g.112724573C>T, NC_000010.9:g.112714563C>T, NG_028922.1:g.50273C>T, LRG_753:g.50273C>T, NM_001269039.1:c.457C>T, LRG_753t1:c.457C>T, XM_011540216.1:c.-380-20813C>T, NM_001269039.2:c.457C>T, NM_001324336.1:c.457C>T, NM_001324337.1:c.457C>T, NR_136749.1:n.116-20813C>T, ENST00000265277.9:c.457C>T, ENST00000369452.8:c.457C>T, ENST00000489390.1:n.56-35600C>T, NM_007373.3(SHOC2):c.457C>T (p.Leu153=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.457C>T (p.Leu153=) variant in the SHOC2 gene is 1.574% (1104/66696) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA333154/MONDO:0021060/004	8e46fe32-f801-413d-8145-c24fea550548
NM_005633.3(SOS1):c.1074+5G>C	45343	CA136073	NM_005633.3:c.1074+5G>C, LRG_754t1:c.1074+5G>C, XM_005264515.3:c.1074+5G>C, XM_011533060.1:c.1167+5G>C, XM_011533061.1:c.1167+5G>C, XM_011533062.1:c.1053+5G>C, XM_011533063.1:c.1050+5G>C, XM_011533064.1:c.903+5G>C, XM_011533065.1:c.1167+5G>C, XM_005264515.4:c.1074+5G>C, XM_011533062.2:c.1053+5G>C, XM_011533064.2:c.903+5G>C, ENST00000395038.6:c.1074+5G>C, ENST00000402219.6:c.1074+5G>C, ENST00000426016.5:c.1074+5G>C, ENST00000461545.1:n.424+5G>C, NC_000002.12:g.39035207C>G, CM000664.2:g.39035207C>G, NC_000002.11:g.39262348C>G, CM000664.1:g.39262348C>G, NC_000002.10:g.39115852C>G, NG_007530.1:g.90257G>C, LRG_754:g.90257G>C, NM_005633.3(SOS1):c.1074+5G>C	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1074+5G>C variant in the SOS1 gene is 1.551% (837/50942) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136073/MONDO:0021060/004	bffcd141-eb92-4fd7-a50d-07a51fe63f32
NM_002880.3(RAF1):c.923C>T (p.Pro308Leu)	40611	CA134762	NM_002880.3:c.923C>T, NC_000003.12:g.12600219G>A, CM000665.2:g.12600219G>A, NC_000003.11:g.12641718G>A, CM000665.1:g.12641718G>A, NC_000003.10:g.12616718G>A, NG_007467.1:g.68961C>T, LRG_413:g.68961C>T, LRG_413t1:c.923C>T, XM_005265355.1:c.923C>T, XM_005265357.1:c.824C>T, XM_005265358.3:c.680C>T, XM_005265359.3:c.581C>T, XM_005265360.1:c.923C>T, XM_011533974.1:c.923C>T, XM_011533975.1:c.680C>T, NM_001354689.1:c.983C>T, NM_001354690.1:c.923C>T, NM_001354691.1:c.680C>T, NM_001354692.1:c.680C>T, NM_001354693.1:c.824C>T, NM_001354694.1:c.740C>T, NM_001354695.1:c.581C>T, NR_148940.1:n.1338C>T, NR_148941.1:n.1338C>T, NR_148942.1:n.1338C>T, XM_011533974.3:c.923C>T, XM_017006966.1:c.824C>T, XR_001740227.1:n.1155C>T, ENST00000251849.8:c.923C>T, ENST00000423275.5:c.*600C>T, ENST00000432427.2:n.560C>T, ENST00000442415.6:c.983C>T, ENST00000465826.5:n.167C>T, ENST00000491290.1:n.552C>T, NM_002880.3(RAF1):c.923C>T (p.Pro308Leu)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.923C>T (p.Pro308Leu) variant in the RAF1 gene is 1.516% (179/10394) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134762/MONDO:0021060/004	ed484574-9b2a-4dda-bd46-ea935a45f83c
NM_005633.3(SOS1):c.2167+6T>G	45350	CA136097	NM_005633.3:c.2167+6T>G, LRG_754t1:c.2167+6T>G, XM_005264515.3:c.2167+6T>G, XM_011533060.1:c.2260+6T>G, XM_011533061.1:c.2260+6T>G, XM_011533062.1:c.2146+6T>G, XM_011533063.1:c.2143+6T>G, XM_011533064.1:c.1996+6T>G, XM_011533065.1:c.2260+6T>G, XM_011533066.1:c.1102+6T>G, XM_005264515.4:c.2167+6T>G, XM_011533062.2:c.2146+6T>G, XM_011533064.2:c.1996+6T>G, ENST00000395038.6:c.2167+6T>G, ENST00000402219.6:c.2167+6T>G, ENST00000426016.5:c.2167+6T>G, NC_000002.12:g.39013454A>C, CM000664.2:g.39013454A>C, NC_000002.11:g.39240595A>C, CM000664.1:g.39240595A>C, NC_000002.10:g.39094099A>C, NG_007530.1:g.112010T>G, LRG_754:g.112010T>G, NM_005633.3(SOS1):c.2167+6T>G	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2167+6T>G variant in the SOS1 gene is 1.442% (169/10278) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136097/MONDO:0021060/004	5b21bf7e-ed81-44bc-8bb2-e27420a0d015
NM_002755.3(MAP2K1):c.927A>T (p.Ala309=)	40758	CA180933	NM_002755.3:c.927A>T, LRG_725t1:c.927A>T, XM_011521783.1:c.861A>T, XM_011521783.3:c.861A>T, XM_017022411.2:c.849A>T, XM_017022412.1:c.783A>T, XM_017022413.1:c.399A>T, ENST00000307102.9:c.927A>T, ENST00000566326.1:c.399A>T, NC_000015.10:g.66487259A>T, CM000677.2:g.66487259A>T, NC_000015.9:g.66779597A>T, CM000677.1:g.66779597A>T, NC_000015.8:g.64566651A>T, NG_008305.1:g.105387A>T, LRG_725:g.105387A>T, NM_002755.3(MAP2K1):c.927A>T (p.Ala309=)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.927A>T (p.Ala309=) variant in the MAP2K1 gene is 1.307% (156/10406) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA180933/MONDO:0021060/004	a895f2eb-4350-485d-b678-a8f94a4cc002
NM_002755.3(MAP2K1):c.804C>G (p.Ala268=)	44592	CA134619	NM_002755.3:c.804C>G, LRG_725t1:c.804C>G, XM_011521783.1:c.738C>G, XM_011521783.3:c.738C>G, XM_017022411.2:c.726C>G, XM_017022412.1:c.660C>G, XM_017022413.1:c.276C>G, ENST00000307102.9:c.804C>G, ENST00000566326.1:c.276C>G, NC_000015.10:g.66485100C>G, CM000677.2:g.66485100C>G, NC_000015.9:g.66777438C>G, CM000677.1:g.66777438C>G, NC_000015.8:g.64564492C>G, NG_008305.1:g.103228C>G, LRG_725:g.103228C>G, NM_002755.3(MAP2K1):c.804C>G (p.Ala268=)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.804C>G (p.Ala268=) variant in the MAP2K1 gene is 1.234% (228/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134619/MONDO:0021060/004	240b9c1e-16ca-4644-9dfa-ec5011367f68
NM_005633.3(SOS1):c.1964C>T (p.Pro655Leu)	40692	CA136088	NM_005633.3:c.1964C>T, NC_000002.12:g.39013966G>A, CM000664.2:g.39013966G>A, NC_000002.11:g.39241107G>A, CM000664.1:g.39241107G>A, NC_000002.10:g.39094611G>A, NG_007530.1:g.111498C>T, LRG_754:g.111498C>T, LRG_754t1:c.1964C>T, XM_005264515.3:c.1964C>T, XM_011533060.1:c.2057C>T, XM_011533061.1:c.2057C>T, XM_011533062.1:c.1943C>T, XM_011533063.1:c.1940C>T, XM_011533064.1:c.1793C>T, XM_011533065.1:c.2057C>T, XM_011533066.1:c.899C>T, XM_005264515.4:c.1964C>T, XM_011533062.2:c.1943C>T, XM_011533064.2:c.1793C>T, ENST00000395038.6:c.1964C>T, ENST00000402219.6:c.1964C>T, ENST00000426016.5:c.1964C>T, NM_005633.3(SOS1):c.1964C>T (p.Pro655Leu)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1964C>T (p.Pro655Leu) variant in the SOS1 gene is 1.153% (803/65674) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136088/MONDO:0021060/004	6a6d042c-678f-4246-a5be-507e028cd2fc
NM_007373.3(SHOC2):c.1594A>G (p.Ser532Gly)	139110	CA293486	NM_007373.3:c.1594A>G, NM_001269039.1:c.1456A>G, LRG_753t1:c.1594A>G, XM_011540216.1:c.511A>G, NM_001269039.2:c.1456A>G, NM_001324336.1:c.1594A>G, NM_001324337.1:c.1594A>G, NR_136749.1:n.1006A>G, ENST00000265277.9:c.1456A>G, ENST00000369452.8:c.1594A>G, ENST00000451838.1:n.964A>G, ENST00000489390.1:n.808A>G, NC_000010.11:g.111011663A>G, CM000672.2:g.111011663A>G, NC_000010.10:g.112771421A>G, CM000672.1:g.112771421A>G, NC_000010.9:g.112761411A>G, NG_028922.1:g.97121A>G, LRG_753:g.97121A>G, NM_007373.3(SHOC2):c.1594A>G (p.Ser532Gly)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1594A>G (p.Ser532Gly) variant in the SHOC2 gene is 1.147% (138/10402) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA293486/MONDO:0021060/004	1bcfceba-23f2-4e97-8281-791f9602856c
NM_004333.4(BRAF):c.2235A>G (p.Leu745=)	40399	CA135122	NM_004333.4:c.2235A>G, NC_000007.14:g.140734663T>C, CM000669.2:g.140734663T>C, NC_000007.13:g.140434463T>C, CM000669.1:g.140434463T>C, NC_000007.12:g.140080932T>C, NG_007873.3:g.195102A>G, LRG_299:g.195102A>G, LRG_299t1:c.2235A>G, XM_005250045.1:c.2235A>G, XM_005250046.1:c.2127+5149A>G, XM_011516529.1:c.2127+5149A>G, XR_242190.1:n.2325A>G, XR_927520.1:n.2364A>G, XR_927521.1:n.2446A>G, XR_927522.1:n.2077A>G, XR_927523.1:n.2159A>G, NM_001354609.1:c.2235A>G, NM_004333.5:c.2235A>G, NR_148928.1:n.3333A>G, XM_017012558.1:c.2355A>G, XM_017012559.1:c.2247+5149A>G, XR_001744857.1:n.2445A>G, XR_001744858.1:n.2197A>G, ENST00000288602.10:c.2235A>G, ENST00000479537.5:n.601A>G, ENST00000496384.6:n.1058A>G, ENST00000497784.1:n.2270A>G, NM_004333.4(BRAF):c.2235A>G (p.Leu745=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2235A>G (p.Leu745=) variant in the BRAF gene is 1.11% (113/8654) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135122/MONDO:0021060/004	22cacbf8-01e0-4363-90a4-3a3c3fb5804d
NM_002880.3(RAF1):c.1941C>T (p.Val647=)	44623	CA134718	NM_002880.3:c.1941C>T, NC_000003.12:g.12584520G>A, CM000665.2:g.12584520G>A, NC_000003.11:g.12626019G>A, CM000665.1:g.12626019G>A, NC_000003.10:g.12601019G>A, NG_007467.1:g.84660C>T, LRG_413:g.84660C>T, LRG_413t1:c.1941C>T, XM_005265355.1:c.1941C>T, XM_005265357.1:c.1842C>T, XM_005265358.3:c.1698C>T, XM_005265359.3:c.1599C>T, XM_011533974.1:c.1941C>T, XM_011533975.1:c.1698C>T, NM_001354689.1:c.2001C>T, NM_001354690.1:c.1941C>T, NM_001354691.1:c.1698C>T, NM_001354692.1:c.1698C>T, NM_001354693.1:c.1842C>T, NM_001354694.1:c.1758C>T, NM_001354695.1:c.1599C>T, NR_148940.1:n.2469C>T, NR_148941.1:n.2415C>T, NR_148942.1:n.2354C>T, XM_011533974.3:c.1941C>T, XM_017006966.1:c.1842C>T, ENST00000251849.8:c.1941C>T, ENST00000423275.5:c.*1618C>T, ENST00000432427.2:n.1578C>T, ENST00000442415.6:c.2001C>T, ENST00000471449.1:n.630C>T, NM_002880.3(RAF1):c.1941C>T (p.Val647=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1941C>T (p.Val647=) variant in the RAF1 gene is 1.04% (738/66732) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134718/MONDO:0021060/004	62438d26-e85a-41a6-ae0f-89550c868512
NM_005343.3(HRAS):c.36C>T (p.Gly12=)	222076	CA356960	NM_005343.3:c.36C>T, NC_000011.10:g.534287G>A, CM000673.2:g.534287G>A, NC_000011.9:g.534287G>A, CM000673.1:g.534287G>A, NC_000011.8:g.524287G>A, NG_007666.1:g.6264C>T, NM_001130442.1:c.36C>T, NM_005343.2:c.36C>T, NM_176795.3:c.36C>T, XM_011519875.1:c.-424-4311G>A, XM_011519877.1:c.-161-5293G>A, XR_242795.1:n.235C>T, NM_001130442.2:c.36C>T, NM_001318054.1:c.-284C>T, NM_176795.4:c.36C>T, XM_011519875.2:c.-424-4311G>A, XM_011519877.2:c.-161-5293G>A, XM_017017167.1:c.-499-4236G>A, XM_017017168.1:c.-499-4236G>A, NM_005343.4:c.36C>T, ENST00000311189.7:c.36C>T, ENST00000397594.5:c.36C>T, ENST00000397596.6:c.36C>T, ENST00000417302.5:c.36C>T, ENST00000451590.5:c.36C>T, ENST00000468682.2:n.524C>T, ENST00000482021.1:n.159C>T, ENST00000493230.5:c.36C>T, NM_005343.3(HRAS):c.36C>T (p.Gly12=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.36C>T (p.Gly12=) variant in the HRAS gene is 0.0461% (8/8626) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA356960/MONDO:0021060/004	983c5b9a-3d66-4c13-b328-8b9ab7c22543
NM_005633.3(SOS1):c.2997T>C (p.Asn999=)	40714	CA136126	NM_005633.3:c.2997T>C, LRG_754t1:c.2997T>C, XM_005264515.3:c.2997T>C, XM_011533060.1:c.3090T>C, XM_011533061.1:c.3090T>C, XM_011533062.1:c.2976T>C, XM_011533063.1:c.2973T>C, XM_011533064.1:c.2826T>C, XM_011533065.1:c.3090T>C, XM_011533066.1:c.1932T>C, XM_005264515.4:c.2997T>C, XM_011533062.2:c.2976T>C, XM_011533064.2:c.2826T>C, ENST00000395038.6:c.2997T>C, ENST00000402219.6:c.2997T>C, ENST00000426016.5:c.2997T>C, NC_000002.12:g.38997006A>G, CM000664.2:g.38997006A>G, NC_000002.11:g.39224147A>G, CM000664.1:g.39224147A>G, NC_000002.10:g.39077651A>G, NG_007530.1:g.128458T>C, LRG_754:g.128458T>C, NM_005633.3(SOS1):c.2997T>C (p.Asn999=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2997T>C (p.Asn999=) variant in the SOS1 gene is 1.009% (120/10162) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136126/MONDO:0021060/004	1ff6e201-6947-4593-9413-423a33954701
NM_004333.4(BRAF):c.1383A>G (p.Gln461=)	40363	CA135073	NM_004333.4:c.1383A>G, LRG_299t1:c.1383A>G, XM_005250045.1:c.1383A>G, XM_005250046.1:c.1383A>G, XM_011516529.1:c.1383A>G, XM_011516530.1:c.1383A>G, XR_242190.1:n.1391A>G, XR_927520.1:n.1391A>G, XR_927521.1:n.1391A>G, XR_927522.1:n.1391A>G, XR_927523.1:n.1391A>G, NM_001354609.1:c.1383A>G, NM_004333.5:c.1383A>G, NR_148928.1:n.1688A>G, XM_017012558.1:c.1503A>G, XM_017012559.1:c.1503A>G, XR_001744857.1:n.1511A>G, XR_001744858.1:n.1511A>G, ENST00000288602.10:c.1383A>G, ENST00000496384.6:n.206A>G, ENST00000497784.1:n.1418A>G, NC_000007.14:g.140781625T>C, CM000669.2:g.140781625T>C, NC_000007.13:g.140481425T>C, CM000669.1:g.140481425T>C, NC_000007.12:g.140127894T>C, NG_007873.3:g.148140A>G, LRG_299:g.148140A>G, NM_004333.4(BRAF):c.1383A>G (p.Gln461=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1383A>G (p.Gln461=) variant in the BRAF gene is 0.986% (120/10404) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135073/MONDO:0021060/004	ab868908-3f55-4346-8bad-adcda350acb4
NM_030662.3(MAP2K2):c.893C>T (p.Pro298Leu)	40832	CA180870	NM_030662.3:c.893C>T, LRG_750t1:c.893C>T, XM_006722799.2:c.705+1792C>T, XM_011528133.1:c.323C>T, XM_017026989.1:c.893C>T, XM_017026990.1:c.705+1792C>T, ENST00000262948.9:c.893C>T, ENST00000394867.8:c.602C>T, ENST00000593364.5:n.840C>T, ENST00000595715.1:n.708C>T, ENST00000597263.5:n.169+1792C>T, ENST00000599021.1:n.29+1792C>T, ENST00000600584.5:n.1453C>T, ENST00000601786.5:n.1194C>T, NC_000019.10:g.4099227G>A, CM000681.2:g.4099227G>A, NC_000019.9:g.4099225G>A, CM000681.1:g.4099225G>A, NC_000019.8:g.4050225G>A, NG_007996.1:g.29902C>T, LRG_750:g.29902C>T, NM_030662.3(MAP2K2):c.893C>T (p.Pro298Leu)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.893C>T (p.Pro298Leu) variant in the MAP2K2 gene is 0.953% (68/5776) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA180870/MONDO:0021060/004	40ceccb2-5456-4905-8d02-1878c6fe945f
NM_002880.3(RAF1):c.1914G>A (p.Thr638=)	40628	CA134715	NM_002880.3:c.1914G>A, LRG_413t1:c.1914G>A, XM_005265355.1:c.1914G>A, XM_005265357.1:c.1815G>A, XM_005265358.3:c.1671G>A, XM_005265359.3:c.1572G>A, XM_011533974.1:c.1914G>A, XM_011533975.1:c.1671G>A, NM_001354689.1:c.1974G>A, NM_001354690.1:c.1914G>A, NM_001354691.1:c.1671G>A, NM_001354692.1:c.1671G>A, NM_001354693.1:c.1815G>A, NM_001354694.1:c.1731G>A, NM_001354695.1:c.1572G>A, NR_148940.1:n.2442G>A, NR_148941.1:n.2388G>A, NR_148942.1:n.2327G>A, XM_011533974.3:c.1914G>A, XM_017006966.1:c.1815G>A, ENST00000251849.8:c.1914G>A, ENST00000423275.5:c.*1591G>A, ENST00000432427.2:n.1551G>A, ENST00000442415.6:c.1974G>A, ENST00000471449.1:n.603G>A, NC_000003.12:g.12584547C>T, CM000665.2:g.12584547C>T, NC_000003.11:g.12626046C>T, CM000665.1:g.12626046C>T, NC_000003.10:g.12601046C>T, NG_007467.1:g.84633G>A, LRG_413:g.84633G>A, NM_002880.3(RAF1):c.1914G>A (p.Thr638=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1914G>A (p.Thr638=) variant in the RAF1 gene is 0.926% (174/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134715/MONDO:0021060/004	5dd1c397-b2a2-4954-bbbb-583d4a4576dc
NM_030662.3(MAP2K2):c.846C>T (p.Pro282=)	40827	CA137975	NM_030662.3:c.846C>T, NC_000019.10:g.4099274G>A, CM000681.2:g.4099274G>A, NC_000019.9:g.4099272G>A, CM000681.1:g.4099272G>A, NC_000019.8:g.4050272G>A, NG_007996.1:g.29855C>T, LRG_750:g.29855C>T, LRG_750t1:c.846C>T, XM_006722799.2:c.705+1745C>T, XM_011528133.1:c.276C>T, XM_017026989.1:c.846C>T, XM_017026990.1:c.705+1745C>T, ENST00000262948.9:c.846C>T, ENST00000394867.8:c.555C>T, ENST00000593364.5:n.793C>T, ENST00000595715.1:n.661C>T, ENST00000597263.5:n.169+1745C>T, ENST00000599021.1:n.29+1745C>T, ENST00000600584.5:n.1406C>T, ENST00000601786.5:n.1147C>T, NM_030662.3(MAP2K2):c.846C>T (p.Pro282=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.846C>T (p.Pro282=) variant in the MAP2K2 gene is 0.515% (46/6886) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137975/MONDO:0021060/004	3a3c6e6a-a7bb-47bf-afb2-aacf5127c6fd
NM_005633.3(SOS1):c.2988G>A (p.Pro996=)	40713	CA136123	NM_005633.3:c.2988G>A, NC_000002.12:g.38997015C>T, CM000664.2:g.38997015C>T, NC_000002.11:g.39224156C>T, CM000664.1:g.39224156C>T, NC_000002.10:g.39077660C>T, NG_007530.1:g.128449G>A, LRG_754:g.128449G>A, LRG_754t1:c.2988G>A, XM_005264515.3:c.2988G>A, XM_011533060.1:c.3081G>A, XM_011533061.1:c.3081G>A, XM_011533062.1:c.2967G>A, XM_011533063.1:c.2964G>A, XM_011533064.1:c.2817G>A, XM_011533065.1:c.3081G>A, XM_011533066.1:c.1923G>A, XM_005264515.4:c.2988G>A, XM_011533062.2:c.2967G>A, XM_011533064.2:c.2817G>A, ENST00000395038.6:c.2988G>A, ENST00000402219.6:c.2988G>A, ENST00000426016.5:c.2988G>A, NM_005633.3(SOS1):c.2988G>A (p.Pro996=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2988G>A (p.Pro996=) variant in the SOS1 gene is 0.396% (51/10072) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136123/MONDO:0021060/004	47edbaff-50ac-42ee-838b-2ac0c4a4054c
NM_005633.3(SOS1):c.570C>T (p.Asp190=)	40655	CA136171	NM_005633.3:c.570C>T, LRG_754t1:c.570C>T, XM_005264515.3:c.570C>T, XM_011533060.1:c.663C>T, XM_011533061.1:c.663C>T, XM_011533062.1:c.549C>T, XM_011533063.1:c.546C>T, XM_011533064.1:c.399C>T, XM_011533065.1:c.663C>T, XM_005264515.4:c.570C>T, XM_011533062.2:c.549C>T, XM_011533064.2:c.399C>T, ENST00000395038.6:c.570C>T, ENST00000402219.6:c.570C>T, ENST00000426016.5:c.570C>T, NC_000002.12:g.39054764G>A, CM000664.2:g.39054764G>A, NC_000002.11:g.39281905G>A, CM000664.1:g.39281905G>A, NC_000002.10:g.39135409G>A, NG_007530.1:g.70700C>T, LRG_754:g.70700C>T, NM_005633.3(SOS1):c.570C>T (p.Asp190=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.570C>T (p.Asp190=) variant in the SOS1 gene is 0.314% (234/66628) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136171/MONDO:0021060/004	b4afa727-6000-4b36-b685-4bcd8c3df504
NM_030662.3(MAP2K2):c.580+6G>A	40808	CA137955	NM_030662.3:c.580+6G>A, NC_000019.10:g.4101223C>T, CM000681.2:g.4101223C>T, NC_000019.9:g.4101221C>T, CM000681.1:g.4101221C>T, NC_000019.8:g.4052221C>T, NG_007996.1:g.27906G>A, LRG_750:g.27906G>A, LRG_750t1:c.580+6G>A, XM_006722799.2:c.580+6G>A, XM_011528133.1:c.10+6G>A, XM_017026989.1:c.580+6G>A, XM_017026990.1:c.580+6G>A, XM_017026991.1:c.580+6G>A, ENST00000262948.9:c.580+6G>A, ENST00000394867.8:c.289+6G>A, ENST00000593364.5:n.527+6G>A, ENST00000597008.5:n.181+6G>A, ENST00000597263.5:n.44+6G>A, ENST00000599345.1:n.850+6G>A, ENST00000601786.5:n.881+6G>A, ENST00000602167.5:n.300+6G>A, NM_030662.3(MAP2K2):c.580+6G>A	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.580+6G>A variant in the MAP2K2 gene is 0.311% (91/24374) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137955/MONDO:0021060/004	882d53d6-99d2-4e81-810c-f4daf709b813
NM_005633.3(SOS1):c.1770G>A (p.Glu590=)	40687	CA1624555	NM_005633.3:c.1770G>A, LRG_754t1:c.1770G>A, XM_005264515.3:c.1770G>A, XM_011533060.1:c.1863G>A, XM_011533061.1:c.1863G>A, XM_011533062.1:c.1749G>A, XM_011533063.1:c.1746G>A, XM_011533064.1:c.1599G>A, XM_011533065.1:c.1863G>A, XM_011533066.1:c.705G>A, XM_005264515.4:c.1770G>A, XM_011533062.2:c.1749G>A, XM_011533064.2:c.1599G>A, ENST00000395038.6:c.1770G>A, ENST00000402219.6:c.1770G>A, ENST00000426016.5:c.1770G>A, NC_000002.12:g.39022658C>T, CM000664.2:g.39022658C>T, NC_000002.11:g.39249799C>T, CM000664.1:g.39249799C>T, NC_000002.10:g.39103303C>T, NG_007530.1:g.102806G>A, LRG_754:g.102806G>A, NM_005633.3(SOS1):c.1770G>A (p.Glu590=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1770G>A (p.Glu590=) variant in the SOS1 gene is 0.29% (34/8634) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624555/MONDO:0021060/004	8284a0ef-b684-4d8c-81b6-a0be0727a5ca
NM_002755.3(MAP2K1):c.1068+12_1068+15delTATT	44586	CA134591	NM_002755.3:c.1068+8_1068+11delTATT, NM_002755.3:c.1068+12_1068+15delTATT, NC_000015.10:g.66489775_66489778del, CM000677.2:g.66489775_66489778del, NC_000015.9:g.66782113_66782116del, CM000677.1:g.66782113_66782116del, NC_000015.8:g.64569167_64569170del, NG_008305.1:g.107903_107906del, LRG_725:g.107903_107906del, NG_051234.1:g.13042_13045del, NM_002755.3:c.1068+12_1068+15del, LRG_725t1:c.1068+12_1068+15del, XM_011521783.1:c.1002+12_1002+15del, NM_006049.3:c.*965_*968del, NR_138061.1:n.1484_1487del, XM_011521783.3:c.1002+12_1002+15del, XM_017022411.2:c.990+12_990+15del, XM_017022412.1:c.924+12_924+15del, XM_017022413.1:c.540+12_540+15del, ENST00000307102.9:c.1068+12_1068+15del, ENST00000566326.1:c.540+12_540+15del, NM_002755.3(MAP2K1):c.1068+12_1068+15delTATT	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1068+12_1068+15delTATT variant in the MAP2K1 gene is 0.285% (214/66740) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134591/MONDO:0021060/004	a8e91870-1b3e-43d5-b3b5-f0559a0e3599
NM_007373.3(SHOC2):c.1540+8C>A	448937	CA5689793	NM_007373.3:c.1540+8C>A, NC_000010.11:g.111009838C>A, CM000672.2:g.111009838C>A, NC_000010.10:g.112769596C>A, CM000672.1:g.112769596C>A, NC_000010.9:g.112759586C>A, NG_028922.1:g.95296C>A, LRG_753:g.95296C>A, NM_001269039.1:c.1402+8C>A, LRG_753t1:c.1540+8C>A, XM_011540216.1:c.457+8C>A, NM_001269039.2:c.1402+8C>A, NM_001324336.1:c.1540+8C>A, NM_001324337.1:c.1540+8C>A, NR_136749.1:n.952+8C>A, ENST00000265277.9:c.1402+8C>A, ENST00000369452.8:c.1540+8C>A, ENST00000451838.1:n.910+8C>A, ENST00000489390.1:n.754+8C>A, NM_007373.3(SHOC2):c.1540+8C>A	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.1540+8C>A variant in the SHOC2 gene is 0.0459% (8/8654) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA5689793/MONDO:0021060/004	2f985b45-4b2f-4cf7-9c5f-216b9c6f4426
NM_002755.3(MAP2K1):c.648C>T (p.Ile216=)	44590	CA134607	NM_002755.3:c.648C>T, LRG_725t1:c.648C>T, XM_011521783.1:c.582C>T, XM_011521783.3:c.582C>T, XM_017022411.2:c.570C>T, XM_017022412.1:c.504C>T, XM_017022413.1:c.120C>T, ENST00000307102.9:c.648C>T, ENST00000566326.1:c.120C>T, NC_000015.10:g.66481834C>T, CM000677.2:g.66481834C>T, NC_000015.9:g.66774172C>T, CM000677.1:g.66774172C>T, NC_000015.8:g.64561226C>T, NG_008305.1:g.99962C>T, LRG_725:g.99962C>T, NM_002755.3(MAP2K1):c.648C>T (p.Ile216=)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.648C>T (p.Ile216=) variant in the MAP2K1 gene is 0.274% (38/10402) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134607/MONDO:0021060/004	4e4166b8-f343-4e54-a3e5-aab6290a5355
NM_030662.3(MAP2K2):c.420C>T (p.Asp140=)	46235	CA137938	NM_030662.3:c.420C>T, NC_000019.10:g.4110539G>A, CM000681.2:g.4110539G>A, NC_000019.9:g.4110537G>A, CM000681.1:g.4110537G>A, NC_000019.8:g.4061537G>A, NG_007996.1:g.18590C>T, LRG_750:g.18590C>T, LRG_750t1:c.420C>T, XM_006722799.2:c.420C>T, XM_017026989.1:c.420C>T, XM_017026990.1:c.420C>T, XM_017026991.1:c.420C>T, ENST00000262948.9:c.420C>T, ENST00000394867.8:c.129C>T, ENST00000599345.1:n.617C>T, NM_030662.3(MAP2K2):c.420C>T (p.Asp140=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.420C>T (p.Asp140=) variant in the MAP2K2 gene is 0.271% (32/8604) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137938/MONDO:0021060/004	dc9fdbbf-4e28-41d1-96de-532d635a2b43
NM_002834.4(PTPN11):c.1052G>A (p.Arg351Gln)	40541	CA282114	NM_002834.4:c.1052G>A, NC_000012.12:g.112477975G>A, CM000674.2:g.112477975G>A, NC_000012.11:g.112915779G>A, CM000674.1:g.112915779G>A, NC_000012.10:g.111400162G>A, NG_007459.1:g.64244G>A, LRG_614:g.64244G>A, NM_002834.3:c.1052G>A, LRG_614t1:c.1052G>A, NM_080601.1:c.1052G>A, XM_006719526.1:c.1052G>A, XM_006719527.1:c.938G>A, XM_011538613.1:c.1049G>A, NM_001330437.1:c.1052G>A, NM_080601.2:c.1052G>A, XM_011538613.2:c.1049G>A, XM_017019722.1:c.1049G>A, ENST00000351677.6:c.1052G>A, ENST00000392597.5:c.1052G>A, ENST00000635625.1:n.1052G>A, ENST00000635652.1:n.44G>A, NM_002834.4(PTPN11):c.1052G>A (p.Arg351Gln)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1052G>A (p.Arg351Gln) variant in the PTPN11 gene is 0.263% (55/16488) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA282114/MONDO:0021060/004	d67ff0bd-70c2-44c7-a7af-94d111f387e6
NM_030662.3(MAP2K2):c.1020C>T (p.Pro340=)	46226	CA137906	NM_030662.3:c.1020C>T, LRG_750t1:c.1020C>T, XM_006722799.2:c.741C>T, XM_011528133.1:c.450C>T, XM_017026989.1:c.1020C>T, XM_017026990.1:c.741C>T, ENST00000262948.9:c.1020C>T, ENST00000394867.8:c.729C>T, ENST00000595715.1:n.835C>T, ENST00000597263.5:n.205C>T, ENST00000599021.1:n.130C>T, ENST00000600584.5:n.1580C>T, ENST00000601786.5:n.1321C>T, NC_000019.10:g.4095414G>A, CM000681.2:g.4095414G>A, NC_000019.9:g.4095412G>A, CM000681.1:g.4095412G>A, NC_000019.8:g.4046412G>A, NG_007996.1:g.33715C>T, LRG_750:g.33715C>T, NM_030662.3(MAP2K2):c.1020C>T (p.Pro340=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1020C>T (p.Pro340=) variant in the MAP2K2 gene is 0.262% (29/7910) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137906/MONDO:0021060/004	ce8d4a0e-fe41-460b-91e2-0b5c99377b0a
NM_030662.3(MAP2K2):c.525C>T (p.Ile175=)	46239	CA137952	NM_030662.3:c.525C>T, NC_000019.10:g.4102379G>A, CM000681.2:g.4102379G>A, NC_000019.9:g.4102377G>A, CM000681.1:g.4102377G>A, NC_000019.8:g.4053377G>A, NG_007996.1:g.26750C>T, LRG_750:g.26750C>T, LRG_750t1:c.525C>T, XM_006722799.2:c.525C>T, XM_011528133.1:c.-46C>T, XM_017026989.1:c.525C>T, XM_017026990.1:c.525C>T, XM_017026991.1:c.525C>T, ENST00000262948.9:c.525C>T, ENST00000394867.8:c.234C>T, ENST00000593364.5:n.472C>T, ENST00000597008.5:n.126C>T, ENST00000599345.1:n.795C>T, ENST00000601786.5:n.826C>T, ENST00000602167.5:n.245C>T, NM_030662.3(MAP2K2):c.525C>T (p.Ile175=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.525C>T (p.Ile175=) variant in the MAP2K2 gene is 0.255% (11/2418) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137952/MONDO:0021060/004	5a6be788-3cc6-4e54-b10f-96366d0767d5
NM_005633.3(SOS1):c.2238T>C (p.Asn746=)	139228	CA178021	NM_005633.3:c.2238T>C, NC_000002.12:g.39012278A>G, CM000664.2:g.39012278A>G, NC_000002.11:g.39239419A>G, CM000664.1:g.39239419A>G, NC_000002.10:g.39092923A>G, NG_007530.1:g.113186T>C, LRG_754:g.113186T>C, LRG_754t1:c.2238T>C, XM_005264515.3:c.2238T>C, XM_011533060.1:c.2331T>C, XM_011533061.1:c.2331T>C, XM_011533062.1:c.2217T>C, XM_011533063.1:c.2214T>C, XM_011533064.1:c.2067T>C, XM_011533065.1:c.2331T>C, XM_011533066.1:c.1173T>C, XM_005264515.4:c.2238T>C, XM_011533062.2:c.2217T>C, XM_011533064.2:c.2067T>C, ENST00000395038.6:c.2238T>C, ENST00000402219.6:c.2238T>C, ENST00000426016.5:c.2238T>C, NM_005633.3(SOS1):c.2238T>C (p.Asn746=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2238T>C (p.Asn746=) variant in the SOS1 gene is 0.232% (33/10404) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA178021/MONDO:0021060/004	e46916ef-098f-4c2a-b597-52e1ae6ba641
NM_002834.4(PTPN11):c.951G>A (p.Lys317=)	307226	CA6798691	NM_002834.4:c.951G>A, NM_002834.3:c.951G>A, LRG_614t1:c.951G>A, NM_080601.1:c.951G>A, XM_006719526.1:c.951G>A, XM_006719527.1:c.837G>A, XM_011538613.1:c.948G>A, NM_001330437.1:c.951G>A, NM_080601.2:c.951G>A, XM_011538613.2:c.948G>A, XM_017019722.1:c.948G>A, ENST00000351677.6:c.951G>A, ENST00000392597.5:c.951G>A, ENST00000635625.1:n.951G>A, NC_000012.12:g.112477874G>A, CM000674.2:g.112477874G>A, NC_000012.11:g.112915678G>A, CM000674.1:g.112915678G>A, NC_000012.10:g.111400061G>A, NG_007459.1:g.64143G>A, LRG_614:g.64143G>A, NM_002834.4(PTPN11):c.951G>A (p.Lys317=)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.951G>A (p.Lys317=) variant in the PTPN11 gene is 0.231% (49/16480) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA6798691/MONDO:0021060/004	4b23453d-9e67-4633-aab5-49c2f6fe967e
NM_002834.4(PTPN11):c.558G>T (p.Arg186=)	178109	CA181422	NM_002834.4:c.558G>T, NC_000012.12:g.112454596G>T, CM000674.2:g.112454596G>T, NC_000012.11:g.112892400G>T, CM000674.1:g.112892400G>T, NC_000012.10:g.111376783G>T, NG_007459.1:g.40865G>T, LRG_614:g.40865G>T, NM_002834.3:c.558G>T, LRG_614t1:c.558G>T, NM_080601.1:c.558G>T, XM_006719526.1:c.558G>T, XM_006719527.1:c.558G>T, XM_011538613.1:c.555G>T, NM_001330437.1:c.558G>T, NM_080601.2:c.558G>T, XM_011538613.2:c.555G>T, XM_017019722.1:c.555G>T, ENST00000351677.6:c.558G>T, ENST00000392597.5:c.558G>T, ENST00000530818.1:n.92G>T, ENST00000635625.1:n.558G>T, NM_002834.4(PTPN11):c.558G>T (p.Arg186=)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.558G>T (p.Arg186=) variant in the PTPN11 gene is 0.231% (49/16504) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA181422/MONDO:0021060/004	ff743f9f-7a04-4e11-8654-6e63c340e74f
NM_030662.3(MAP2K2):c.823C>T (p.Leu275=)	40825	CA137969	NM_030662.3:c.823C>T, NC_000019.10:g.4099297G>A, CM000681.2:g.4099297G>A, NC_000019.9:g.4099295G>A, CM000681.1:g.4099295G>A, NC_000019.8:g.4050295G>A, NG_007996.1:g.29832C>T, LRG_750:g.29832C>T, LRG_750t1:c.823C>T, XM_006722799.2:c.705+1722C>T, XM_011528133.1:c.253C>T, XM_017026989.1:c.823C>T, XM_017026990.1:c.705+1722C>T, ENST00000262948.9:c.823C>T, ENST00000394867.8:c.532C>T, ENST00000593364.5:n.770C>T, ENST00000595715.1:n.638C>T, ENST00000597263.5:n.169+1722C>T, ENST00000599021.1:n.29+1722C>T, ENST00000600584.5:n.1383C>T, ENST00000601786.5:n.1124C>T, NM_030662.3(MAP2K2):c.823C>T (p.Leu275=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.823C>T (p.Leu275=) variant in the MAP2K2 gene is 0.2% (19/6224) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137969/MONDO:0021060/004	83c490e2-5683-4fc1-b3be-2fa89e92f868
NM_005633.3(SOS1):c.3391+7A>G	45362	CA136138	NM_005633.3:c.3391+7A>G, LRG_754t1:c.3391+7A>G, XM_005264515.3:c.3347-1672A>G, XM_011533060.1:c.3484+7A>G, XM_011533061.1:c.3440-1672A>G, XM_011533062.1:c.3370+7A>G, XM_011533063.1:c.3367+7A>G, XM_011533064.1:c.3220+7A>G, XM_011533065.1:c.3484+7A>G, XM_011533066.1:c.2326+7A>G, XM_005264515.4:c.3347-1672A>G, XM_011533062.2:c.3370+7A>G, XM_011533064.2:c.3220+7A>G, ENST00000395038.6:c.3347-1672A>G, ENST00000402219.6:c.3391+7A>G, ENST00000426016.5:c.3391+7A>G, NC_000002.12:g.38989263T>C, CM000664.2:g.38989263T>C, NC_000002.11:g.39216404T>C, CM000664.1:g.39216404T>C, NC_000002.10:g.39069908T>C, NG_007530.1:g.136201A>G, LRG_754:g.136201A>G, NM_005633.3(SOS1):c.3391+7A>G	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3391+7A>G variant in the SOS1 gene is 0.193% (41/16108) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA136138/MONDO:0021060/004	0c2a6fb5-1765-45ef-bae8-c71d38cebdbb
NM_002755.3(MAP2K1):c.1098T>C (p.Ala366=)	448949	CA7624163	NM_002755.3:c.1098T>C, NC_000015.10:g.66490531T>C, CM000677.2:g.66490531T>C, NC_000015.9:g.66782869T>C, CM000677.1:g.66782869T>C, NC_000015.8:g.64569923T>C, NG_008305.1:g.108659T>C, LRG_725:g.108659T>C, NG_051234.1:g.12285A>G, LRG_725t1:c.1098T>C, NM_006049.2:c.*208A>G, XM_011521783.1:c.1032T>C, NM_006049.3:c.*208A>G, NR_138061.1:n.727A>G, XM_011521783.3:c.1032T>C, XM_017022411.2:c.1020T>C, XM_017022412.1:c.954T>C, XM_017022413.1:c.570T>C, ENST00000307102.9:c.1098T>C, ENST00000395589.6:c.*208A>G, ENST00000563480.6:c.*208A>G, ENST00000566326.1:c.570T>C, NM_002755.3(MAP2K1):c.1098T>C (p.Ala366=)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.1098T>C (p.Ala366=) variant in the MAP2K1 gene is 0.0459% (8/8654) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA7624163/MONDO:0021060/004	9581cc43-8005-4a02-8e31-2c7cb18c67df
NM_030662.3(MAP2K2):c.603C>T (p.Leu201=)	40811	CA137956	NM_030662.3:c.603C>T, NC_000019.10:g.4101121G>A, CM000681.2:g.4101121G>A, NC_000019.9:g.4101119G>A, CM000681.1:g.4101119G>A, NC_000019.8:g.4052119G>A, NG_007996.1:g.28008C>T, LRG_750:g.28008C>T, LRG_750t1:c.603C>T, XM_006722799.2:c.603C>T, XM_011528133.1:c.33C>T, XM_017026989.1:c.603C>T, XM_017026990.1:c.603C>T, XM_017026991.1:c.603C>T, ENST00000262948.9:c.603C>T, ENST00000394867.8:c.312C>T, ENST00000593364.5:n.550C>T, ENST00000597008.5:n.204C>T, ENST00000597263.5:n.67C>T, ENST00000599345.1:n.873C>T, ENST00000601786.5:n.904C>T, ENST00000602167.5:n.323C>T, NM_030662.3(MAP2K2):c.603C>T (p.Leu201=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.603C>T (p.Leu201=) variant in the MAP2K2 gene is 0.191% (18/6102) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137956/MONDO:0021060/004	a290ee11-587b-4c61-861c-80b328f3af80
NM_005343.3(HRAS):c.477G>A (p.Leu159=)	40446	CA135990	NM_005343.3:c.477G>A, NC_000011.10:g.532729C>T, CM000673.2:g.532729C>T, NC_000011.9:g.532729C>T, CM000673.1:g.532729C>T, NC_000011.8:g.522729C>T, NG_007666.1:g.7822G>A, NM_001130442.1:c.477G>A, NM_005343.2:c.477G>A, NM_176795.3:c.*46G>A, XM_011519875.1:c.-425+4392C>T, XM_011519877.1:c.-162+4392C>T, XR_242795.1:n.758G>A, NM_001130442.2:c.477G>A, NM_001318054.1:c.240G>A, NM_176795.4:c.*46G>A, XM_011519875.2:c.-425+4392C>T, XM_011519877.2:c.-162+4392C>T, XM_017017167.1:c.-500+4392C>T, XM_017017168.1:c.-500+4392C>T, NM_005343.4:c.477G>A, ENST00000311189.7:c.477G>A, ENST00000397594.5:c.*46G>A, ENST00000397596.6:c.477G>A, ENST00000417302.5:c.*46G>A, ENST00000451590.5:c.477G>A, ENST00000462734.1:n.252G>A, ENST00000478324.5:n.243-99G>A, ENST00000479482.1:n.398G>A, ENST00000493230.5:c.*46G>A, NM_005343.3(HRAS):c.477G>A (p.Leu159=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.477G>A (p.Leu159=) variant in the HRAS gene is 0.185% (140/65296) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135990/MONDO:0021060/004	e93d3e64-ccf6-4e9a-814f-910533bb7473
NM_030662.3(MAP2K2):c.291C>A (p.Ile97=)	40787	CA9091060	NM_030662.3:c.291C>A, NC_000019.10:g.4117431G>T, CM000681.2:g.4117431G>T, NC_000019.9:g.4117429G>T, CM000681.1:g.4117429G>T, NC_000019.8:g.4068429G>T, NG_007996.1:g.11698C>A, LRG_750:g.11698C>A, LRG_750t1:c.291C>A, XM_006722799.2:c.291C>A, XM_017026989.1:c.291C>A, XM_017026990.1:c.291C>A, XM_017026991.1:c.291C>A, ENST00000262948.9:c.291C>A, ENST00000394867.8:c.-1C>A, ENST00000599345.1:n.488C>A, NM_030662.3(MAP2K2):c.291C>A (p.Ile97=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.291C>A (p.Ile97=) variant in the MAP2K2 gene is 0.182% (23/8614) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA9091060/MONDO:0021060/004	e1e02e53-1c53-4e7b-bc2f-0007f57eb7ef
NM_002755.3(MAP2K1):c.1137C>T (p.Ile379=)	40762	CA134592	NM_002755.3:c.1137C>T, LRG_725t1:c.1137C>T, NM_006049.2:c.*169G>A, XM_011521783.1:c.1071C>T, NM_006049.3:c.*169G>A, NR_138061.1:n.688G>A, XM_011521783.3:c.1071C>T, XM_017022411.2:c.1059C>T, XM_017022412.1:c.993C>T, XM_017022413.1:c.609C>T, ENST00000307102.9:c.1137C>T, ENST00000395589.6:c.*169G>A, ENST00000563480.6:c.*169G>A, ENST00000566326.1:c.609C>T, NC_000015.10:g.66490570C>T, CM000677.2:g.66490570C>T, NC_000015.9:g.66782908C>T, CM000677.1:g.66782908C>T, NC_000015.8:g.64569962C>T, NG_008305.1:g.108698C>T, LRG_725:g.108698C>T, NG_051234.1:g.12246G>A, NM_002755.3(MAP2K1):c.1137C>T (p.Ile379=)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1137C>T (p.Ile379=) variant in the MAP2K1 gene is 0.175% (26/10406) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134592/MONDO:0021060/004	bb9af7db-7756-46f9-88be-f7ca17304539
NM_030662.3(MAP2K2):c.1074G>A (p.Ala358=)	261928	CA9090706	NM_030662.3:c.1074G>A, NC_000019.10:g.4094471C>T, CM000681.2:g.4094471C>T, NC_000019.9:g.4094469C>T, CM000681.1:g.4094469C>T, NC_000019.8:g.4045469C>T, NG_007996.1:g.34658G>A, LRG_750:g.34658G>A, LRG_750t1:c.1074G>A, XM_006722799.2:c.795G>A, XM_011528133.1:c.504G>A, ENST00000262948.9:c.1074G>A, ENST00000394867.8:c.783G>A, ENST00000597263.5:n.259G>A, ENST00000599021.1:n.184G>A, ENST00000600584.5:n.2523G>A, ENST00000601786.5:n.1375G>A, NM_030662.3(MAP2K2):c.1074G>A (p.Ala358=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1074G>A (p.Ala358=) variant in the MAP2K2 gene is 0.174% (10/3124) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA9090706/MONDO:0021060/004	6ce143a5-0894-4639-94d0-072a2ffe2774
NM_030662.3(MAP2K2):c.1093-6T>C	46228	CA137912	NM_030662.3:c.1093-6T>C, NC_000019.10:g.4090714A>G, CM000681.2:g.4090714A>G, NC_000019.9:g.4090712A>G, CM000681.1:g.4090712A>G, NC_000019.8:g.4041712A>G, NG_007996.1:g.38415T>C, LRG_750:g.38415T>C, LRG_750t1:c.1093-6T>C, XM_006722799.2:c.814-6T>C, XM_011528133.1:c.523-6T>C, ENST00000262948.9:c.1093-6T>C, ENST00000394867.8:c.802-6T>C, ENST00000597263.5:n.278-6T>C, ENST00000599021.1:n.203-6T>C, ENST00000600584.5:n.2542-6T>C, ENST00000601786.5:n.1394-6T>C, NM_030662.3(MAP2K2):c.1093-6T>C	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1093-6T>C variant in the MAP2K2 gene is 0.166% (9/2834) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137912/MONDO:0021060/004	02ac4895-4755-4b08-a354-b128d2bb4e61
NM_002880.3(RAF1):c.1141G>A (p.Asp381Asn)	181509	CA297118	NM_002880.3:c.1141G>A, LRG_413t1:c.1141G>A, XM_005265355.1:c.1141G>A, XM_005265357.1:c.1042G>A, XM_005265358.3:c.898G>A, XM_005265359.3:c.799G>A, XM_005265360.1:c.1141G>A, XM_011533974.1:c.1141G>A, XM_011533975.1:c.898G>A, NM_001354689.1:c.1201G>A, NM_001354690.1:c.1141G>A, NM_001354691.1:c.898G>A, NM_001354692.1:c.898G>A, NM_001354693.1:c.1042G>A, NM_001354694.1:c.958G>A, NM_001354695.1:c.799G>A, NR_148940.1:n.1669G>A, NR_148941.1:n.1615G>A, NR_148942.1:n.1554G>A, XM_011533974.3:c.1141G>A, XM_017006966.1:c.1042G>A, XR_001740227.1:n.1432G>A, ENST00000251849.8:c.1141G>A, ENST00000423275.5:c.*818G>A, ENST00000432427.2:n.778G>A, ENST00000442415.6:c.1201G>A, ENST00000460610.1:n.98G>A, ENST00000465826.5:n.498G>A, ENST00000475353.1:n.309G>A, ENST00000494557.1:n.157G>A, NC_000003.12:g.12591760C>T, CM000665.2:g.12591760C>T, NC_000003.11:g.12633259C>T, CM000665.1:g.12633259C>T, NC_000003.10:g.12608259C>T, NG_007467.1:g.77420G>A, LRG_413:g.77420G>A, NM_002880.3(RAF1):c.1141G>A (p.Asp381Asn)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1141G>A (p.Asp381Asn) variant in the RAF1 gene is 0.162% (36/16508) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA297118/MONDO:0021060/004	f46177ab-5c80-48cf-bd17-6acc5668f182
NM_030662.3(MAP2K2):c.1194C>T (p.Thr398=)	40846	CA137913	NM_030662.3:c.1194C>T, NC_000019.10:g.4090607G>A, CM000681.2:g.4090607G>A, NC_000019.9:g.4090605G>A, CM000681.1:g.4090605G>A, NC_000019.8:g.4041605G>A, NG_007996.1:g.38522C>T, LRG_750:g.38522C>T, LRG_750t1:c.1194C>T, XM_006722799.2:c.915C>T, XM_011528133.1:c.624C>T, ENST00000262948.9:c.1194C>T, ENST00000394867.8:c.903C>T, ENST00000597263.5:n.379C>T, ENST00000599021.1:n.304C>T, ENST00000600584.5:n.2643C>T, ENST00000601786.5:n.1495C>T, NM_030662.3(MAP2K2):c.1194C>T (p.Thr398=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1194C>T (p.Thr398=) variant in the MAP2K2 gene is 0.159% (19/7836) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137913/MONDO:0021060/004	4dda494b-f286-41e8-b20f-481268ec7d54
NM_030662.3(MAP2K2):c.303+8C>G	177969	CA181090	NM_030662.3:c.303+8C>G, NC_000019.10:g.4117411G>C, CM000681.2:g.4117411G>C, NC_000019.9:g.4117409G>C, CM000681.1:g.4117409G>C, NC_000019.8:g.4068409G>C, NG_007996.1:g.11718C>G, LRG_750:g.11718C>G, LRG_750t1:c.303+8C>G, XM_006722799.2:c.303+8C>G, XM_017026989.1:c.303+8C>G, XM_017026990.1:c.303+8C>G, XM_017026991.1:c.303+8C>G, ENST00000262948.9:c.303+8C>G, ENST00000394867.8:c.12+8C>G, ENST00000599345.1:n.500+8C>G, NM_030662.3(MAP2K2):c.303+8C>G	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.303+8C>G variant in the MAP2K2 gene is 0.154% (22/9636) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA181090/MONDO:0021060/004	df47805e-3c96-49ac-ab9d-045364018616
NM_002834.4(PTPN11):c.53A>G (p.Asn18Ser)	135112	CA161776	NM_002834.4:c.53A>G, NC_000012.12:g.112446314A>G, CM000674.2:g.112446314A>G, NC_000012.11:g.112884118A>G, CM000674.1:g.112884118A>G, NC_000012.10:g.111368501A>G, NG_007459.1:g.32583A>G, LRG_614:g.32583A>G, NM_002834.3:c.53A>G, LRG_614t1:c.53A>G, NM_080601.1:c.53A>G, XM_006719526.1:c.53A>G, XM_006719527.1:c.53A>G, XM_011538613.1:c.53A>G, NM_001330437.1:c.53A>G, NM_080601.2:c.53A>G, XM_011538613.2:c.53A>G, XM_017019722.1:c.53A>G, ENST00000351677.6:c.53A>G, ENST00000392597.5:c.53A>G, ENST00000635625.1:n.53A>G, NM_002834.4(PTPN11):c.53A>G (p.Asn18Ser)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.53A>G (p.Asn18Ser) variant in the PTPN11 gene is 0.056% (15/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA161776/MONDO:0021060/004	b05eb983-c118-4f08-88a9-d168d803a9d0
NM_030662.3(MAP2K2):c.847G>T (p.Val283Leu)	448950	CA9090817	NM_030662.3:c.847G>T, LRG_750t1:c.847G>T, XM_006722799.2:c.705+1746G>T, XM_011528133.1:c.277G>T, XM_017026989.1:c.847G>T, XM_017026990.1:c.705+1746G>T, ENST00000262948.9:c.847G>T, ENST00000394867.8:c.556G>T, ENST00000593364.5:n.794G>T, ENST00000595715.1:n.662G>T, ENST00000597263.5:n.169+1746G>T, ENST00000599021.1:n.29+1746G>T, ENST00000600584.5:n.1407G>T, ENST00000601786.5:n.1148G>T, NC_000019.10:g.4099273C>A, CM000681.2:g.4099273C>A, NC_000019.9:g.4099271C>A, CM000681.1:g.4099271C>A, NC_000019.8:g.4050271C>A, NG_007996.1:g.29856G>T, LRG_750:g.29856G>T, NM_030662.3(MAP2K2):c.847G>T (p.Val283Leu)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.847G>T (p.Val283Leu) variant in the MAP2K2 gene is 0.0448% (6/5824) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA9090817/MONDO:0021060/004	76be5ede-4c76-4fed-a94a-188c6bcea2f1
NM_002755.3(MAP2K1):c.315C>T (p.Pro105=)	44589	CA134604	NM_002755.3:c.315C>T, LRG_725t1:c.315C>T, XM_011521783.1:c.249C>T, XM_011521783.3:c.249C>T, XM_017022411.2:c.315C>T, XM_017022412.1:c.249C>T, ENST00000307102.9:c.315C>T, ENST00000425818.2:n.826C>T, NC_000015.10:g.66436769C>T, CM000677.2:g.66436769C>T, NC_000015.9:g.66729107C>T, CM000677.1:g.66729107C>T, NC_000015.8:g.64516161C>T, NG_008305.1:g.54897C>T, LRG_725:g.54897C>T, NM_002755.3(MAP2K1):c.315C>T (p.Pro105=)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.315C>T (p.Pro105=) variant in the MAP2K1 gene is 0.01% (64/66728) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA134604/MONDO:0021060/004	f18e6c0b-7a6f-4a7e-82d7-5de48e915d3c
NM_004333.5(BRAF):c.2127+3A>G	41447	CA130842	NM_004333.5:c.2127+3A>G, NM_004333.4:c.2127+3A>G, LRG_299t1:c.2127+3A>G, XM_005250045.1:c.2127+3A>G, XM_005250046.1:c.2127+3A>G, XM_011516529.1:c.2127+3A>G, XR_242190.1:n.2217+3A>G, XR_927520.1:n.2256+3A>G, XR_927521.1:n.2338+3A>G, XR_927522.1:n.1969+3A>G, XR_927523.1:n.2051+3A>G, NM_001354609.1:c.2127+3A>G, NR_148928.1:n.3225+3A>G, XM_017012558.1:c.2247+3A>G, XM_017012559.1:c.2247+3A>G, XR_001744857.1:n.2337+3A>G, XR_001744858.1:n.2089+3A>G, ENST00000288602.10:c.2127+3A>G, ENST00000479537.5:n.493+3A>G, ENST00000496384.6:n.950+3A>G, ENST00000497784.1:n.2162+3A>G, NC_000007.14:g.140739809T>C, CM000669.2:g.140739809T>C, NC_000007.13:g.140439609T>C, CM000669.1:g.140439609T>C, NC_000007.12:g.140086078T>C, NG_007873.3:g.189956A>G, LRG_299:g.189956A>G, NM_004333.5(BRAF):c.2127+3A>G	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2127+3A>G variant in the BRAF gene is 0.151% (23/10398) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA130842/MONDO:0021060/004	e87a2198-4bd7-4ee1-a9fb-db8ca97151a8
NM_030662.3(MAP2K2):c.825G>A (p.Leu275=)	138161	CA291999	NM_030662.3:c.825G>A, NC_000019.10:g.4099295C>T, CM000681.2:g.4099295C>T, NC_000019.9:g.4099293C>T, CM000681.1:g.4099293C>T, NC_000019.8:g.4050293C>T, NG_007996.1:g.29834G>A, LRG_750:g.29834G>A, LRG_750t1:c.825G>A, XM_006722799.2:c.705+1724G>A, XM_011528133.1:c.255G>A, XM_017026989.1:c.825G>A, XM_017026990.1:c.705+1724G>A, ENST00000262948.9:c.825G>A, ENST00000394867.8:c.534G>A, ENST00000593364.5:n.772G>A, ENST00000595715.1:n.640G>A, ENST00000597263.5:n.169+1724G>A, ENST00000599021.1:n.29+1724G>A, ENST00000600584.5:n.1385G>A, ENST00000601786.5:n.1126G>A, NM_030662.3(MAP2K2):c.825G>A (p.Leu275=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.825G>A (p.Leu275=) variant in the MAP2K2 gene is 0.142% (14/5968) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA291999/MONDO:0021060/004	13f158e3-3e4e-42f5-8828-d2509a51af7d
NM_005343.3(HRAS):c.357C>T (p.Asp119=)	40441	CA135978	NM_005343.3:c.357C>T, NM_001130442.1:c.357C>T, NM_005343.2:c.357C>T, NM_176795.3:c.357C>T, XM_011519875.1:c.-424-5052G>A, XM_011519877.1:c.-162+5209G>A, XR_242795.1:n.556C>T, NM_001130442.2:c.357C>T, NM_001318054.1:c.38C>T, NM_176795.4:c.357C>T, XM_011519875.2:c.-424-5052G>A, XM_011519877.2:c.-162+5209G>A, XM_017017167.1:c.-499-4977G>A, XM_017017168.1:c.-499-4977G>A, NM_005343.4:c.357C>T, ENST00000311189.7:c.357C>T, ENST00000397594.5:c.357C>T, ENST00000397596.6:c.357C>T, ENST00000417302.5:c.357C>T, ENST00000451590.5:c.357C>T, ENST00000462734.1:n.50C>T, ENST00000478324.5:n.67C>T, ENST00000479482.1:n.278C>T, ENST00000493230.5:c.357C>T, NC_000011.10:g.533546G>A, CM000673.2:g.533546G>A, NC_000011.9:g.533546G>A, CM000673.1:g.533546G>A, NC_000011.8:g.523546G>A, NG_007666.1:g.7005C>T, NM_005343.3(HRAS):c.357C>T (p.Asp119=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.357C>T (p.Asp119=) variant in the HRAS gene is 0.129% (102/66416) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135978/MONDO:0021060/004	4da936bb-53cd-4fad-8d47-40c90dc60a73
NM_005633.3(SOS1):c.3552T>G (p.Pro1184=)	448939	CA1624148	NM_005633.3:c.3552T>G, LRG_754t1:c.3552T>G, XM_005264515.3:c.3507T>G, XM_011533060.1:c.3645T>G, XM_011533061.1:c.3600T>G, XM_011533062.1:c.3531T>G, XM_011533063.1:c.3528T>G, XM_011533064.1:c.3381T>G, XM_011533065.1:c.3604-911T>G, XM_011533066.1:c.2487T>G, XM_005264515.4:c.3507T>G, XM_011533062.2:c.3531T>G, XM_011533064.2:c.3381T>G, ENST00000395038.6:c.3507T>G, ENST00000402219.6:c.3552T>G, ENST00000426016.5:c.3552T>G, ENST00000469581.1:n.295T>G, NC_000002.12:g.38986274A>C, CM000664.2:g.38986274A>C, NC_000002.11:g.39213415A>C, CM000664.1:g.39213415A>C, NC_000002.10:g.39066919A>C, NG_007530.1:g.139190T>G, LRG_754:g.139190T>G, NM_005633.3(SOS1):c.3552T>G (p.Pro1184=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3552T>G (p.Pro1184=) variant in the SOS1 gene is 0.126% (17/8594) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624148/MONDO:0021060/004	b0d402e5-8499-4446-84bb-97ef592e9ba7
NM_004333.4(BRAF):c.708C>T (p.Asn236=)	44827	CA135134	NM_004333.4:c.708C>T, LRG_299t1:c.708C>T, XM_005250045.1:c.708C>T, XM_005250046.1:c.708C>T, XM_011516529.1:c.708C>T, XM_011516530.1:c.708C>T, XR_242190.1:n.716C>T, XR_927520.1:n.716C>T, XR_927521.1:n.716C>T, XR_927522.1:n.716C>T, XR_927523.1:n.716C>T, NM_001354609.1:c.708C>T, NM_004333.5:c.708C>T, NR_148928.1:n.1013C>T, XM_017012558.1:c.708C>T, XM_017012559.1:c.708C>T, XR_001744857.1:n.716C>T, XR_001744858.1:n.716C>T, ENST00000288602.10:c.708C>T, ENST00000497784.1:n.743C>T, NC_000007.14:g.140807963G>A, CM000669.2:g.140807963G>A, NC_000007.13:g.140507763G>A, CM000669.1:g.140507763G>A, NC_000007.12:g.140154232G>A, NG_007873.3:g.121802C>T, LRG_299:g.121802C>T, NM_004333.4(BRAF):c.708C>T (p.Asn236=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.708C>T (p.Asn236=) variant in the BRAF gene is 0.116% (27/16412) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA135134/MONDO:0021060/004	a981d131-53cd-457c-9cff-8897fff5e486
NM_004333.4(BRAF):c.36G>A (p.Ala12=)	40333	CA281921	NM_004333.4:c.36G>A, LRG_299t1:c.36G>A, XM_005250045.1:c.36G>A, XM_005250046.1:c.36G>A, XM_011516529.1:c.36G>A, XM_011516530.1:c.36G>A, XR_242190.1:n.44G>A, XR_927520.1:n.44G>A, XR_927521.1:n.44G>A, XR_927522.1:n.44G>A, XR_927523.1:n.44G>A, NM_001354609.1:c.36G>A, NM_004333.5:c.36G>A, NR_148928.1:n.261G>A, XM_017012558.1:c.36G>A, XM_017012559.1:c.36G>A, XR_001744857.1:n.44G>A, XR_001744858.1:n.44G>A, ENST00000288602.10:c.36G>A, ENST00000469930.1:n.42G>A, NC_000007.14:g.140924668C>T, CM000669.2:g.140924668C>T, NC_000007.13:g.140624468C>T, CM000669.1:g.140624468C>T, NC_000007.12:g.140270937C>T, NG_007873.3:g.5097G>A, LRG_299:g.5097G>A, NM_004333.4(BRAF):c.36G>A (p.Ala12=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.36G>A (p.Ala12=) variant in the BRAF gene is 0.116% (14/7290) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA281921/MONDO:0021060/004	37d415c0-90e7-425c-84bc-6361413d50aa
NM_004333.5(BRAF):c.1150A>G (p.Arg384Gly)	448924	CA4516796	NM_004333.5:c.1150A>G, NM_004333.4:c.1150A>G, LRG_299t1:c.1150A>G, XM_005250045.1:c.1150A>G, XM_005250046.1:c.1150A>G, XM_011516529.1:c.1150A>G, XM_011516530.1:c.1150A>G, XR_242190.1:n.1158A>G, XR_927520.1:n.1158A>G, XR_927521.1:n.1158A>G, XR_927522.1:n.1158A>G, XR_927523.1:n.1158A>G, NM_001354609.1:c.1150A>G, NR_148928.1:n.1455A>G, XM_017012558.1:c.1150A>G, XM_017012559.1:c.1150A>G, XR_001744857.1:n.1158A>G, XR_001744858.1:n.1158A>G, ENST00000288602.10:c.1150A>G, ENST00000497784.1:n.1185A>G, NC_000007.14:g.140787575T>C, CM000669.2:g.140787575T>C, NC_000007.13:g.140487375T>C, CM000669.1:g.140487375T>C, NC_000007.12:g.140133844T>C, NG_007873.3:g.142190A>G, LRG_299:g.142190A>G, NM_004333.5(BRAF):c.1150A>G (p.Arg384Gly)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1150A>G (p.Arg384Gly) variant in the BRAF gene is 0.116% (16/8646) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA4516796/MONDO:0021060/004	2153a39b-818c-4cb1-b6e6-db1a736b545f
NM_005633.3(SOS1):c.141T>C (p.Tyr47=)	448947	CA1624855	NM_005633.3:c.141T>C, NC_000002.12:g.39067700A>G, CM000664.2:g.39067700A>G, NC_000002.11:g.39294841A>G, CM000664.1:g.39294841A>G, NC_000002.10:g.39148345A>G, NG_007530.1:g.57764T>C, LRG_754:g.57764T>C, LRG_754t1:c.141T>C, XM_005264515.3:c.141T>C, XM_011533060.1:c.234T>C, XM_011533061.1:c.234T>C, XM_011533062.1:c.120T>C, XM_011533063.1:c.117T>C, XM_011533064.1:c.-31T>C, XM_011533065.1:c.234T>C, XM_005264515.4:c.141T>C, XM_011533062.2:c.120T>C, XM_011533064.2:c.-31T>C, ENST00000395038.6:c.141T>C, ENST00000402219.6:c.141T>C, ENST00000426016.5:c.141T>C, ENST00000451331.1:c.-31T>C, NM_005633.3(SOS1):c.141T>C (p.Tyr47=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.141T>C (p.Tyr47=) variant in the SOS1 gene is 0.116% (16/8654) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624855/MONDO:0021060/004	e56ef21d-72b1-4858-b546-98bab809c78d
NM_002834.4(PTPN11):c.1028G>A (p.Arg343Gln)	181766	CA297648	NM_002834.4:c.1028G>A, NC_000012.12:g.112477951G>A, CM000674.2:g.112477951G>A, NC_000012.11:g.112915755G>A, CM000674.1:g.112915755G>A, NC_000012.10:g.111400138G>A, NG_007459.1:g.64220G>A, LRG_614:g.64220G>A, NM_002834.3:c.1028G>A, LRG_614t1:c.1028G>A, NM_080601.1:c.1028G>A, XM_006719526.1:c.1028G>A, XM_006719527.1:c.914G>A, XM_011538613.1:c.1025G>A, NM_001330437.1:c.1028G>A, NM_080601.2:c.1028G>A, XM_011538613.2:c.1025G>A, XM_017019722.1:c.1025G>A, ENST00000351677.6:c.1028G>A, ENST00000392597.5:c.1028G>A, ENST00000635625.1:n.1028G>A, ENST00000635652.1:n.20G>A, NM_002834.4(PTPN11):c.1028G>A (p.Arg343Gln)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1028G>A (p.Arg343Gln) variant in the PTPN11 gene is 0.116% (27/16494) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA297648/MONDO:0021060/004	8d55f3e7-09d7-4c84-98a4-830352b7611a
NM_005633.3(SOS1):c.225A>G (p.Gln75=)	448946	CA1624827	NM_005633.3:c.225A>G, NC_000002.12:g.39058793T>C, CM000664.2:g.39058793T>C, NC_000002.11:g.39285934T>C, CM000664.1:g.39285934T>C, NC_000002.10:g.39139438T>C, NG_007530.1:g.66671A>G, LRG_754:g.66671A>G, LRG_754t1:c.225A>G, XM_005264515.3:c.225A>G, XM_011533060.1:c.318A>G, XM_011533061.1:c.318A>G, XM_011533062.1:c.204A>G, XM_011533063.1:c.201A>G, XM_011533064.1:c.54A>G, XM_011533065.1:c.318A>G, XM_005264515.4:c.225A>G, XM_011533062.2:c.204A>G, XM_011533064.2:c.54A>G, ENST00000395038.6:c.225A>G, ENST00000402219.6:c.225A>G, ENST00000426016.5:c.225A>G, ENST00000451331.1:c.54A>G, NM_005633.3(SOS1):c.225A>G (p.Gln75=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1		The filtering allele frequency of the c.225A>G (p.Gln75=) variant in the SOS1 gene is 0.042% (12/16448) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA1624827/MONDO:0021060/004	47bd0e22-7b07-4048-9afc-7fad23a874ad
NM_004360.3:c.1137G>T	599655	CA496153150	NM_004360.3:c.1137G>T, NC_000016.10:g.68812263G>T, CM000678.2:g.68812263G>T, NC_000016.9:g.68846166G>T, CM000678.1:g.68846166G>T, NC_000016.8:g.67403667G>T, NG_008021.1:g.79972G>T, LRG_301:g.79972G>T, ENST00000261769.10:c.1137G>T, ENST00000261769.9:c.1137G>T, ENST00000422392.6:c.1137G>T, ENST00000562836.5:n.1208G>T, ENST00000565810.1:n.181G>T, ENST00000566510.5:c.981G>T, ENST00000566612.5:c.1137G>T, ENST00000611625.4:c.1137G>T, ENST00000612417.4:c.1137G>T, ENST00000621016.4:c.1137G>T, LRG_301t1:c.1137G>T, XM_011523488.1:c.402G>T, XM_011523489.1:c.402G>T, NM_001317184.1:c.1137G>T, NM_001317185.1:c.-479G>T, NM_001317186.1:c.-683G>T, NM_004360.4:c.1137G>T, NM_004360.5:c.1137G>T, NM_001317184.2:c.1137G>T, NM_001317185.2:c.-479G>T, NM_001317186.2:c.-683G>T, NM_004360.5(CDH1):c.1137G>T (p.Thr379=)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Pathogenic	PS4_Supporting, PM2_Supporting, PVS1_Moderate, PP3_Moderate	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PM6, PP2, PP1, PP4, BS2, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS2	The c.1137G>T p. (Thr379=) variant results in a G to non-G change at the last nucleotide of an exon (PVS1_Moderate).  The variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant affects the same splice site as a well-characterized splice variant with similar or worse in silico/ RNA predictions (PP3_Moderate). Additionally, this variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; PMID: 26182300). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Moderate, PM2_Supporting, PP3_Moderate, PS4_Supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-30	2023-08-30	false	https://erepo.genome.network/evrepo/ui/classification/CA496153150/MONDO:0007648/007	e4b2700f-9760-4cfc-8513-12d276db2589
NM_004360.4(CDH1):c.2104G>A (p.Glu702Lys)	127921	CA288054	NM_004360.4:c.2104G>A, NC_000016.10:g.68823566G>A, CM000678.2:g.68823566G>A, NC_000016.9:g.68857469G>A, CM000678.1:g.68857469G>A, NC_000016.8:g.67414970G>A, NG_008021.1:g.91275G>A, LRG_301:g.91275G>A, ENST00000261769.10:c.2104G>A, ENST00000261769.9:c.2104G>A, ENST00000422392.6:c.1921G>A, ENST00000562118.1:n.322G>A, ENST00000562836.5:n.2175G>A, ENST00000566510.5:c.*770G>A, ENST00000566612.5:c.*344G>A, ENST00000611625.4:c.2167G>A, ENST00000612417.4:c.1830+1447G>A, ENST00000621016.4:c.1865+1412G>A, NM_004360.3:c.2104G>A, LRG_301t1:c.2104G>A, XM_011523488.1:c.1369G>A, XM_011523489.1:c.1369G>A, NM_001317184.1:c.1921G>A, NM_001317185.1:c.556G>A, NM_001317186.1:c.139G>A, NM_004360.5:c.2104G>A, NM_001317184.2:c.1921G>A, NM_001317185.2:c.556G>A, NM_001317186.2:c.139G>A, NM_004360.5(CDH1):c.2104G>A (p.Glu702Lys), NM_004360.4(CDH1):c.2104G>A (p.Glu702Lys)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, BS2, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.2104G>A (p.GLu702Lys) variant has an allele frequency of 0.001714 (0.2%, 71/41,414 alleles) in the African subpopulation of the gnomAD cohort (BA1). Therefore, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	false	https://erepo.genome.network/evrepo/ui/classification/CA288054/MONDO:0007648/007	89edf24d-5117-4ff9-8e40-1aad098773dd
NM_004360.5(CDH1):c.1118C>T (p.Pro373Leu)	142285	CA167953	NM_004360.5:c.1118C>T, NC_000016.10:g.68812244C>T, CM000678.2:g.68812244C>T, NC_000016.9:g.68846147C>T, CM000678.1:g.68846147C>T, NC_000016.8:g.67403648C>T, NG_008021.1:g.79953C>T, LRG_301:g.79953C>T, ENST00000261769.10:c.1118C>T, ENST00000261769.9:c.1118C>T, ENST00000422392.6:c.1118C>T, ENST00000562836.5:n.1189C>T, ENST00000565810.1:n.162C>T, ENST00000566510.5:c.962C>T, ENST00000566612.5:c.1118C>T, ENST00000611625.4:c.1118C>T, ENST00000612417.4:c.1118C>T, ENST00000621016.4:c.1118C>T, NM_004360.3:c.1118C>T, LRG_301t1:c.1118C>T, XM_011523488.1:c.383C>T, XM_011523489.1:c.383C>T, NM_001317184.1:c.1118C>T, NM_001317185.1:c.-498C>T, NM_001317186.1:c.-702C>T, NM_004360.4:c.1118C>T, NM_001317184.2:c.1118C>T, NM_001317185.2:c.-498C>T, NM_001317186.2:c.-702C>T, NM_004360.5(CDH1):c.1118C>T (p.Pro373Leu)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Benign	BS2	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The c.1118C>T (p.Pro373Leu) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is classified as likely benign based on BS2 alone. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-17	2023-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA167953/MONDO:0007648/007	1aac37aa-cb97-4617-9023-3e7f155f338f
NM_004360.4(CDH1):c.1018A>G (p.Thr340Ala)	12245	CA288016	NM_004360.4:c.1018A>G, NC_000016.10:g.68812144A>G, CM000678.2:g.68812144A>G, NC_000016.9:g.68846047A>G, CM000678.1:g.68846047A>G, NC_000016.8:g.67403548A>G, NG_008021.1:g.79853A>G, LRG_301:g.79853A>G, ENST00000261769.10:c.1018A>G, ENST00000261769.9:c.1018A>G, ENST00000422392.6:c.1018A>G, ENST00000561751.1:c.640A>G, ENST00000562836.5:n.1089A>G, ENST00000565810.1:n.62A>G, ENST00000566510.5:c.862A>G, ENST00000566612.5:c.1018A>G, ENST00000611625.4:c.1018A>G, ENST00000612417.4:c.1018A>G, ENST00000621016.4:c.1018A>G, NM_004360.3:c.1018A>G, LRG_301t1:c.1018A>G, XM_011523488.1:c.283A>G, XM_011523489.1:c.283A>G, NM_001317184.1:c.1018A>G, NM_001317185.1:c.-598A>G, NM_001317186.1:c.-802A>G, NM_004360.5:c.1018A>G, NM_001317184.2:c.1018A>G, NM_001317185.2:c.-598A>G, NM_001317186.2:c.-802A>G, NM_004360.5(CDH1):c.1018A>G (p.Thr340Ala), NM_004360.4(CDH1):c.1018A>G (p.Thr340Ala)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BP7, BP5, BS1, BS3, BS4, PM2, PM6, PVS1, PM5, PM4, PM1, PM3, PP3, PP2, PP1, PP4, BS2, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.1018A>G (p.Thr340Ala) variant has an allele frequency of 0.00360 (0.36%, 68/18,866 alleles) in the East Asian subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	false	https://erepo.genome.network/evrepo/ui/classification/CA288016/MONDO:0007648/007	de5b0e27-fa33-4621-930e-61569417ceff
NM_004360.4(CDH1):c.1225T>C (p.Trp409Arg)	133855	CA157989	NM_004360.4:c.1225T>C, NC_000016.10:g.68813400T>C, CM000678.2:g.68813400T>C, NC_000016.9:g.68847303T>C, CM000678.1:g.68847303T>C, NC_000016.8:g.67404804T>C, NG_008021.1:g.81109T>C, LRG_301:g.81109T>C, ENST00000261769.10:c.1225T>C, ENST00000261769.9:c.1225T>C, ENST00000422392.6:c.1137+1137T>C, ENST00000562836.5:n.1296T>C, ENST00000565810.1:n.269T>C, ENST00000566510.5:c.1069T>C, ENST00000566612.5:c.1225T>C, ENST00000611625.4:c.1225T>C, ENST00000612417.4:c.1225T>C, ENST00000621016.4:c.1225T>C, NM_004360.3:c.1225T>C, LRG_301t1:c.1225T>C, XM_011523488.1:c.490T>C, XM_011523489.1:c.490T>C, NM_001317184.1:c.1137+1137T>C, NM_001317185.1:c.-391T>C, NM_001317186.1:c.-595T>C, NM_004360.5:c.1225T>C, NM_001317184.2:c.1137+1137T>C, NM_001317185.2:c.-391T>C, NM_001317186.2:c.-595T>C, NM_004360.5(CDH1):c.1225T>C (p.Trp409Arg), NM_004360.4(CDH1):c.1225T>C (p.Trp409Arg)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Benign	BS2	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BP2, BA1, PS3, PS1, PS4, PS2	The c.1225T>C (p. Trp409Arg) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is classified as likely benign based on BS2 alone. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-17	2023-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA157989/MONDO:0007648/007	26997937-9088-4611-9ef8-bd80077ed64c
NM_004360.5(CDH1):c.1409C>T (p.Thr470Ile)	127913	CA151518	NM_004360.5:c.1409C>T, NC_000016.10:g.68815603C>T, CM000678.2:g.68815603C>T, NC_000016.9:g.68849506C>T, CM000678.1:g.68849506C>T, NC_000016.8:g.67407007C>T, NG_008021.1:g.83312C>T, LRG_301:g.83312C>T, ENST00000261769.10:c.1409C>T, ENST00000261769.9:c.1409C>T, ENST00000422392.6:c.1226C>T, ENST00000562836.5:n.1480C>T, ENST00000566510.5:c.*75C>T, ENST00000566612.5:c.1409C>T, ENST00000611625.4:c.1472C>T, ENST00000612417.4:c.1409C>T, ENST00000621016.4:c.1409C>T, NM_004360.3:c.1409C>T, LRG_301t1:c.1409C>T, XM_011523488.1:c.674C>T, XM_011523489.1:c.674C>T, NM_001317184.1:c.1226C>T, NM_001317185.1:c.-140C>T, NM_001317186.1:c.-411C>T, NM_004360.4:c.1409C>T, NM_001317184.2:c.1226C>T, NM_001317185.2:c.-140C>T, NM_001317186.2:c.-411C>T, NM_004360.5(CDH1):c.1409C>T (p.Thr470Ile)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2_Strong	BP5, BP7, BS1, BS4, BS3, PM2, PM6, PVS1, PM3, PM5, PM4, PM1, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BA1, PS1, PS3, PS4, PS2	The c.1409C>T (p.Thr470Ile) variant was observed in trans with a known pathogenic CDH1 variant with phase confirmed (BP2_Strong; PMID: 9537325). This variant was also observed in the homozygous state in at least 6 individuals without a personal and/or family history of diffuse gastric cancer, signet ring cell tumor or lobular breast cancer (BP2_Strong; internal laboratory contributors). Additionally, this variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BP2_Strong, BS2.	9537325, 9537325	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	false	https://erepo.genome.network/evrepo/ui/classification/CA151518/MONDO:0007648/007	1149db17-78d8-4b2c-bbd4-e5f6b193a1eb
NM_004360.5(CDH1):c.2245C>T (p.Arg749Trp)	418841	CA8130235	NM_004360.5:c.2245C>T, NC_000016.10:g.68828254C>T, CM000678.2:g.68828254C>T, NC_000016.9:g.68862157C>T, CM000678.1:g.68862157C>T, NC_000016.8:g.67419658C>T, NG_008021.1:g.95963C>T, LRG_301:g.95963C>T, ENST00000261769.10:c.2245C>T, ENST00000261769.9:c.2245C>T, ENST00000422392.6:c.2062C>T, ENST00000562118.1:n.463C>T, ENST00000562836.5:n.2316C>T, ENST00000566510.5:c.*911C>T, ENST00000566612.5:c.*485C>T, ENST00000611625.4:c.2308C>T, ENST00000612417.4:c.1853+1700C>T, ENST00000621016.4:c.1866-5949C>T, NM_004360.3:c.2245C>T, LRG_301t1:c.2245C>T, XM_011523488.1:c.1510C>T, XM_011523489.1:c.1510C>T, NM_001317184.1:c.2062C>T, NM_001317185.1:c.697C>T, NM_001317186.1:c.280C>T, NM_004360.4:c.2245C>T, NM_001317184.2:c.2062C>T, NM_001317185.2:c.697C>T, NM_001317186.2:c.280C>T, NM_004360.5(CDH1):c.2245C>T (p.Arg749Trp)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PVS1, PM6, PP3, PP2, PP4, PP1, BS2, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The NM_004360.5(CDH1):c.2245C>T (p.Arg749Trp) variant is a missense variant in exon 14 and results in the change of an Arginine to a Tryptophan. This variant is present in <1/100,000 alleles in the ExAC and gnomAD cohort (PM2_Supporting). Furthermore, it has been observed in > 10 individuals (34) without DGC, SRC tumours or LBC and whose families do not suggest HDGC. This variant has been reported in four families meeting HDGC clinical criteria, however, this represents only 11% of all families carrying this variant (threshold is 30% to consider applying PS4). Given that multiple families with this variants meet the HDGC criteria, CDH1-VCEP recommended not to apply BS2 code. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-28	2023-09-27	false	https://erepo.genome.network/evrepo/ui/classification/CA8130235/MONDO:0007648/007	c46e3e12-7172-498b-86a7-d9cd9f01bbee
NM_004360.4(CDH1):c.88C>A (p.Pro30Thr)	127933	CA151524	NM_004360.4:c.88C>A, NC_000016.10:g.68738336C>A, CM000678.2:g.68738336C>A, NC_000016.9:g.68772239C>A, CM000678.1:g.68772239C>A, NC_000016.8:g.67329740C>A, NG_008021.1:g.6045C>A, LRG_301:g.6045C>A, ENST00000261769.10:c.88C>A, ENST00000261769.9:c.88C>A, ENST00000422392.6:c.88C>A, ENST00000566510.5:c.88C>A, ENST00000566612.5:c.88C>A, ENST00000611625.4:c.88C>A, ENST00000612417.4:c.88C>A, ENST00000621016.4:c.88C>A, NM_004360.3:c.88C>A, LRG_301t1:c.88C>A, NM_001317184.1:c.88C>A, NM_001317185.1:c.-1528C>A, NM_001317186.1:c.-1732C>A, NM_004360.5:c.88C>A, NM_001317184.2:c.88C>A, NM_001317185.2:c.-1528C>A, NM_001317186.2:c.-1732C>A, NM_004360.5(CDH1):c.88C>A (p.Pro30Thr), NM_004360.4(CDH1):c.88C>A (p.Pro30Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BA1	BP7, BP5, BS1, BS3, BS4, PM5, PM1, PM3, PM4, PM2, PM6, PVS1, PP3, PP2, PP1, PP4, BP4, BP1, BP2, BP3, PS3, PS1, PS4, PS2	The c.88C>A (p.Pro30Thr) variant has an allele frequency of 0.00249 (0.25%, 178/71372 alleles) in the European (non-Finnish) subpopulation of the gnomAD cohort (BA1). In addition to meeting stand along criteria for a benign classification, this variant has also been seen in >900 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors).  In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-17	2023-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA151524/MONDO:0007648/007	d1e6757d-87b2-428c-a699-e2ac2893485c
NM_004360.4(CDH1):c.2396C>G (p.Pro799Arg)	140871	CA163797	NM_004360.4:c.2396C>G, NC_000016.10:g.68829754C>G, CM000678.2:g.68829754C>G, NC_000016.9:g.68863657C>G, CM000678.1:g.68863657C>G, NC_000016.8:g.67421158C>G, NG_008021.1:g.97463C>G, LRG_301:g.97463C>G, ENST00000261769.10:c.2396C>G, ENST00000261769.9:c.2396C>G, ENST00000422392.6:c.2213C>G, ENST00000562118.1:n.614C>G, ENST00000562836.5:n.2467C>G, ENST00000566510.5:c.*1062C>G, ENST00000566612.5:c.*636C>G, ENST00000611625.4:c.2459C>G, ENST00000612417.4:c.1853+3200C>G, ENST00000621016.4:c.1866-4449C>G, NM_004360.3:c.2396C>G, LRG_301t1:c.2396C>G, XM_011523488.1:c.1661C>G, XM_011523489.1:c.1661C>G, NM_001317184.1:c.2213C>G, NM_001317185.1:c.848C>G, NM_001317186.1:c.431C>G, NM_004360.5:c.2396C>G, NM_001317184.2:c.2213C>G, NM_001317185.2:c.848C>G, NM_001317186.2:c.431C>G, NM_004360.5(CDH1):c.2396C>G (p.Pro799Arg), NM_004360.4(CDH1):c.2396C>G (p.Pro799Arg)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PM6, PVS1, PM5, PM4, PM1, PM3, PP3, PP2, PP1, PP4, BS2, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The c.2396C>G (p.Pro799Arg) variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). There is no other supporting data that meet criteria for consideration. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting.	19268661, 22850631, 15173255, 19268661, 22850631, 15173255	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-21	2023-08-21	false	https://erepo.genome.network/evrepo/ui/classification/CA163797/MONDO:0007648/007	adcfd805-c238-4e80-b9ad-f6fa541ab04d
NM_004360.4(CDH1):c.1888C>G (p.Leu630Val)	133846	CA157951	NM_004360.4:c.1888C>G, NC_000016.10:g.68822177C>G, CM000678.2:g.68822177C>G, NC_000016.9:g.68856080C>G, CM000678.1:g.68856080C>G, NC_000016.8:g.67413581C>G, NG_008021.1:g.89886C>G, LRG_301:g.89886C>G, ENST00000261769.10:c.1888C>G, ENST00000261769.9:c.1888C>G, ENST00000422392.6:c.1705C>G, ENST00000562836.5:n.1959C>G, ENST00000566510.5:c.*554C>G, ENST00000566612.5:c.*128C>G, ENST00000611625.4:c.1951C>G, ENST00000612417.4:c.1830+58C>G, ENST00000621016.4:c.1865+23C>G, NM_004360.3:c.1888C>G, LRG_301t1:c.1888C>G, XM_011523488.1:c.1153C>G, XM_011523489.1:c.1153C>G, NM_001317184.1:c.1705C>G, NM_001317185.1:c.340C>G, NM_001317186.1:c.-78C>G, NM_004360.5:c.1888C>G, NM_001317184.2:c.1705C>G, NM_001317185.2:c.340C>G, NM_001317186.2:c.-78C>G, NM_004360.5(CDH1):c.1888C>G (p.Leu630Val), NM_004360.4(CDH1):c.1888C>G (p.Leu630Val)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, PP3, PP2, PP1, PP4, BS2, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.1888C>G (p.Leu630Val) variant has an allele frequency of 0.00519 (0.52%, 98/18,866 alleles) in the East Asian subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	false	https://erepo.genome.network/evrepo/ui/classification/CA157951/MONDO:0007648/007	98319533-e1cd-4555-9251-571e07d52e56
NM_004360.4(CDH1):c.2494G>A (p.Val832Met)	12246	CA157969	NM_004360.4:c.2494G>A, NC_000016.10:g.68833344G>A, CM000678.2:g.68833344G>A, NC_000016.9:g.68867247G>A, CM000678.1:g.68867247G>A, NC_000016.8:g.67424748G>A, NG_008021.1:g.101053G>A, LRG_301:g.101053G>A, ENST00000261769.10:c.2494G>A, ENST00000261769.9:c.2494G>A, ENST00000422392.6:c.2311G>A, ENST00000562118.1:n.712G>A, ENST00000562836.5:n.2565G>A, ENST00000566510.5:c.*1160G>A, ENST00000566612.5:c.*734G>A, ENST00000611625.4:c.2557G>A, ENST00000612417.4:c.1854-847G>A, ENST00000621016.4:c.1866-859G>A, NM_004360.3:c.2494G>A, LRG_301t1:c.2494G>A, XM_011523488.1:c.1759G>A, XM_011523489.1:c.1759G>A, NM_001317184.1:c.2311G>A, NM_001317185.1:c.946G>A, NM_001317186.1:c.529G>A, NM_004360.5:c.2494G>A, NM_001317184.2:c.2311G>A, NM_001317185.2:c.946G>A, NM_001317186.2:c.529G>A, NM_004360.5(CDH1):c.2494G>A (p.Val832Met), NM_004360.4(CDH1):c.2494G>A (p.Val832Met)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS1, BS2	BP5, BP7, BS4, BS3, PM2, PM6, PVS1, PM5, PM4, PM1, PM3, PP3, PP2, PP4, PP1, BP4, BP1, BP3, BP2, BA1, PS3, PS1, PS4, PS2	The c.2494G>A (p.Val832Met) variant has an allele frequency of 0.00175 (0.175%, 33/18,868 alleles) in the East Asian subpopulation of the gnomAD cohort (BS1). This variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.	12216071, 17668349, 22850631, 19017792, 12944922, 20921021, 12216071, 12216071, 17668349, 22850631, 19017792, 12944922	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	false	https://erepo.genome.network/evrepo/ui/classification/CA157969/MONDO:0007648/007	fa3b9647-d4d2-4091-8d83-e4e2f0f16391
NM_004360.3:c.535A>G	496233	CA396457842	NM_004360.3:c.535A>G, NC_000016.10:g.68808696A>G, CM000678.2:g.68808696A>G, NC_000016.9:g.68842599A>G, CM000678.1:g.68842599A>G, NC_000016.8:g.67400100A>G, NG_008021.1:g.76405A>G, LRG_301:g.76405A>G, ENST00000261769.10:c.535A>G, ENST00000261769.9:c.535A>G, ENST00000422392.6:c.535A>G, ENST00000561751.1:n.302A>G, ENST00000562836.5:n.606A>G, ENST00000564676.5:n.817A>G, ENST00000564745.1:n.530A>G, ENST00000566510.5:c.531+129A>G, ENST00000566612.5:c.535A>G, ENST00000567320.1:n.45A>G, ENST00000611625.4:c.535A>G, ENST00000612417.4:c.535A>G, ENST00000621016.4:c.535A>G, LRG_301t1:c.535A>G, XM_011523488.1:c.-201A>G, XM_011523489.1:c.-201A>G, NM_001317184.1:c.535A>G, NM_001317185.1:c.-1081A>G, NM_001317186.1:c.-1285A>G, NM_004360.4:c.535A>G, NM_004360.5:c.535A>G, NM_001317184.2:c.535A>G, NM_001317185.2:c.-1081A>G, NM_001317186.2:c.-1285A>G, NM_004360.5(CDH1):c.535A>G (p.Lys179Glu)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	PP1, PM2_Supporting, PS4_Supporting	BP7, BP5, BS1, BS4, BS3, PM5, PM4, PM1, PM3, PM6, PVS1, PP3, PP2, PP4, BS2, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS2	The c.535A>G (p.Lys179Glu) variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant was found to co-segregate with disease in multiple affected family members, with 4 meioses observed (PP1; internal laboratory contributor). This variant has also been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; internal laboratory contributor). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting, PP1, PS4_Supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-21	2023-08-21	false	https://erepo.genome.network/evrepo/ui/classification/CA396457842/MONDO:0007648/007	c47d2e21-ae8f-4349-b873-bb19817b9e24
NM_004360.3:c.1913G>A	599651	CA396467238	NM_004360.3:c.1913G>A, NC_000016.10:g.68822202G>A, CM000678.2:g.68822202G>A, NC_000016.9:g.68856105G>A, CM000678.1:g.68856105G>A, NC_000016.8:g.67413606G>A, NG_008021.1:g.89911G>A, LRG_301:g.89911G>A, ENST00000261769.10:c.1913G>A, ENST00000261769.9:c.1913G>A, ENST00000422392.6:c.1730G>A, ENST00000562836.5:n.1984G>A, ENST00000566510.5:c.*579G>A, ENST00000566612.5:c.*153G>A, ENST00000611625.4:c.1976G>A, ENST00000612417.4:c.1830+83G>A, ENST00000621016.4:c.1865+48G>A, LRG_301t1:c.1913G>A, XM_011523488.1:c.1178G>A, XM_011523489.1:c.1178G>A, NM_001317184.1:c.1730G>A, NM_001317185.1:c.365G>A, NM_001317186.1:c.-53G>A, NM_004360.4:c.1913G>A, NM_004360.5:c.1913G>A, NM_001317184.2:c.1730G>A, NM_001317185.2:c.365G>A, NM_001317186.2:c.-53G>A, NM_004360.5(CDH1):c.1913G>A (p.Trp638Ter)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PS4_Supporting, PM2_Supporting	BS1, BS3, BS4, BP7, BP5, PM4, PM1, PM3, PM6, BS2, PP4, PP3, PP2, PP1, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS2	The c.1913G>A (p.Trp638*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1, PM5_Supporting). The variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; PMID: 17955726). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1, PM2_Supporting, PS4_Supporting, PM5_Supporting.	17955726, 17955726	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA396467238/MONDO:0007648/007	79f7bb71-1142-4f73-bb7e-59866f3acbfe
NM_004360.4(CDH1):c.1298A>G (p.Asp433Gly)	141810	CA294197	NM_004360.4:c.1298A>G, NC_000016.10:g.68813473A>G, CM000678.2:g.68813473A>G, NC_000016.9:g.68847376A>G, CM000678.1:g.68847376A>G, NC_000016.8:g.67404877A>G, NG_008021.1:g.81182A>G, LRG_301:g.81182A>G, ENST00000261769.10:c.1298A>G, ENST00000261769.9:c.1298A>G, ENST00000422392.6:c.1137+1210A>G, ENST00000562836.5:n.1369A>G, ENST00000566510.5:c.1142A>G, ENST00000566612.5:c.1298A>G, ENST00000611625.4:c.1298A>G, ENST00000612417.4:c.1298A>G, ENST00000621016.4:c.1298A>G, NM_004360.3:c.1298A>G, LRG_301t1:c.1298A>G, XM_011523488.1:c.563A>G, XM_011523489.1:c.563A>G, NM_001317184.1:c.1137+1210A>G, NM_001317185.1:c.-318A>G, NM_001317186.1:c.-522A>G, NM_004360.5:c.1298A>G, NM_001317184.2:c.1137+1210A>G, NM_001317185.2:c.-318A>G, NM_001317186.2:c.-522A>G, NM_004360.5(CDH1):c.1298A>G (p.Asp433Gly), NM_004360.4(CDH1):c.1298A>G (p.Asp433Gly)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2_Strong	BP7, BP5, BS1, BS3, BS4, PM2, PM6, PVS1, PM5, PM3, PM4, PM1, PP3, PP2, PP4, PP1, BP4, BP1, BP3, BA1, PS1, PS3, PS4, PS2	The c.1298A>G (p.Asp433Gly) variant was observed at least twice in the homozygous state in individuals without a personal and/or family history of diffuse gastric cancer, signet ring cell tumor or lobular breast cancer (BP2_Strong; SCV000253407.6). This variant has also been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring cell tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BP2_Strong, BS2.	23435907, 20921021, 23435907, 20921021	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	false	https://erepo.genome.network/evrepo/ui/classification/CA294197/MONDO:0007648/007	13766caf-9ff5-48fb-a208-1ee4d81736e0
NM_004360.4(CDH1):c.1003C>T (p.Arg335Ter)	136055	CA166866	NM_004360.4:c.1003C>T, NC_000016.10:g.68811854C>T, CM000678.2:g.68811854C>T, NC_000016.9:g.68845757C>T, CM000678.1:g.68845757C>T, NC_000016.8:g.67403258C>T, NG_008021.1:g.79563C>T, LRG_301:g.79563C>T, ENST00000261769.10:c.1003C>T, ENST00000261769.9:c.1003C>T, ENST00000422392.6:c.1003C>T, ENST00000561751.1:n.625C>T, ENST00000562836.5:n.1074C>T, ENST00000566510.5:c.847C>T, ENST00000566612.5:c.1003C>T, ENST00000611625.4:c.1003C>T, ENST00000612417.4:c.1003C>T, ENST00000621016.4:c.1003C>T, NM_004360.3:c.1003C>T, LRG_301t1:c.1003C>T, XM_011523488.1:c.268C>T, XM_011523489.1:c.268C>T, NM_001317184.1:c.1003C>T, NM_001317185.1:c.-613C>T, NM_001317186.1:c.-817C>T, NM_004360.5:c.1003C>T, NM_001317184.2:c.1003C>T, NM_001317185.2:c.-613C>T, NM_001317186.2:c.-817C>T, NM_004360.5(CDH1):c.1003C>T (p.Arg335Ter), NM_004360.4(CDH1):c.1003C>T (p.Arg335Ter)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PP1_Strong	BS1, BS4, BS3, BP7, BP5, PM4, PM1, PM3, PM2, PM6, BS2, PP3, PP2, PP4, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.1003C>T (p.Arg335*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1, PM5_Supporting). This variant was found to co-segregate with disease in multiple affected family members, with >7 meioses observed across at least two families (PP1_Strong; PMID: 16061854, 22723466, 17522512). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1, PP1_Strong, PM5_Supporting.	22723466, 17522512, 16061854, 22723466, 17522512, 16061854	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA166866/MONDO:0007648/007	ce612d02-2bbe-433b-a871-e4ddcfeca78d
NM_004360.4(CDH1):c.283C>T (p.Gln95Ter)	463775	-	NM_004360.4:c.283C>T, NM_004360.5(CDH1):c.283C>T (p.Gln95Ter), NM_004360.4(CDH1):c.283C>T (p.Gln95Ter)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PM2_Supporting, PS4_Moderate	BP7, BP5, BS1, BS3, BS4, PM1, PM4, PM3, PM6, PP4, PP1, PP3, PP2, BS2, BP4, BP1, BP3, BP2, BA1, PS3, PS1, PS2	The c.283C>T (p.Gln95*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1, PM5_Supporting). The variant is present in <1/100,000 alleles in the gnomAD cohort. (PM2_Supporting; http://gnomad.broadinstitute.org).  This variant has been reported in at least 2 families meeting HDGC clinical criteria (PS4_Moderate; PMID: 17545690, internal laboratory contributor). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1, PM2_Supporting, PS4_Moderate, PM5_Supporting.	17545690, 17545690	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CV463775/MONDO:0007648/007	b376ba62-95aa-49c6-8b93-54ef1ce4448e
NM_004360.4(CDH1):c.187C>T (p.Arg63Ter)	156496	-	NM_004360.4:c.187C>T, NM_004360.5(CDH1):c.187C>T (p.Arg63Ter), NM_004360.4(CDH1):c.187C>T (p.Arg63Ter)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PM2_Supporting, PS4_Supporting	BP5, BP7, BS1, BS3, BS4, PM1, PM3, PM4, PM6, PP4, PP1, PP3, PP2, BS2, BP2, BP4, BP1, BP3, BA1, PS3, PS2, PS1	The c.187C>T (p.Arg63*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1, PM5_Supporting). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). The variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; PMID: 9751616). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1, PM2_Supporting, PS4_Supporting, PM5_Supporting.	9751616	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CV156496/MONDO:0007648/007	be4384f2-4317-4809-956c-12533c2847e1
NM_004360.3:c.2265T>A	599653	CA396469962	NM_004360.3:c.2265T>A, NC_000016.10:g.68828274T>A, CM000678.2:g.68828274T>A, NC_000016.9:g.68862177T>A, CM000678.1:g.68862177T>A, NC_000016.8:g.67419678T>A, NG_008021.1:g.95983T>A, LRG_301:g.95983T>A, ENST00000261769.10:c.2265T>A, ENST00000261769.9:c.2265T>A, ENST00000422392.6:c.2082T>A, ENST00000562118.1:n.483T>A, ENST00000562836.5:n.2336T>A, ENST00000566510.5:c.*931T>A, ENST00000566612.5:c.*505T>A, ENST00000611625.4:c.2328T>A, ENST00000612417.4:c.1853+1720T>A, ENST00000621016.4:c.1866-5929T>A, LRG_301t1:c.2265T>A, XM_011523488.1:c.1530T>A, XM_011523489.1:c.1530T>A, NM_001317184.1:c.2082T>A, NM_001317185.1:c.717T>A, NM_001317186.1:c.300T>A, NM_004360.4:c.2265T>A, NM_004360.5:c.2265T>A, NM_001317184.2:c.2082T>A, NM_001317185.2:c.717T>A, NM_001317186.2:c.300T>A, NM_004360.5(CDH1):c.2265T>A (p.Tyr755Ter)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PS4_Supporting, PM2_Supporting	BS1, BS3, BS4, BP7, BP5, PM4, PM1, PM3, PM6, BS2, PP4, PP3, PP2, PP1, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS2	The c.2265T>A (p.Tyr755*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1, PM5_Supporting). The variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). Additionally, this variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; PMID: 26182300). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1, PM2_Supporting, PS4_Supporting, PM5_Supporting.	26182300, 26182300	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA396469962/MONDO:0007648/007	2efeb055-c565-494f-8e8d-5ae0dccaa3e7
NM_004360.3:c.760G>C	599656	CA396458612	NM_004360.3:c.760G>C, NC_000016.10:g.68810269G>C, CM000678.2:g.68810269G>C, NC_000016.9:g.68844172G>C, CM000678.1:g.68844172G>C, NC_000016.8:g.67401673G>C, NG_008021.1:g.77978G>C, LRG_301:g.77978G>C, ENST00000261769.10:c.760G>C, ENST00000261769.9:c.760G>C, ENST00000422392.6:c.760G>C, ENST00000561751.1:n.455-1415G>C, ENST00000562836.5:n.831G>C, ENST00000566510.5:c.604G>C, ENST00000566612.5:c.760G>C, ENST00000611625.4:c.760G>C, ENST00000612417.4:c.760G>C, ENST00000621016.4:c.760G>C, LRG_301t1:c.760G>C, XM_011523488.1:c.25G>C, XM_011523489.1:c.25G>C, NM_001317184.1:c.760G>C, NM_001317185.1:c.-856G>C, NM_001317186.1:c.-1060G>C, NM_004360.4:c.760G>C, NM_004360.5:c.760G>C, NM_001317184.2:c.760G>C, NM_001317185.2:c.-856G>C, NM_001317186.2:c.-1060G>C, NM_004360.5(CDH1):c.760G>C (p.Asp254His)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	PM2_Supporting, PS4_Supporting	BP7, BP5, BS1, BS3, BS4, PM3, PM5, PM4, PM1, PM6, PVS1, PP3, PP2, PP1, PP4, BS2, BP4, BP1, BP2, BP3, BA1, PS3, PS1, PS2	The c.760G>C (p.Asp254His) variant is absent in the gnomAD cohort (PM2_Supporting). This variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; internal laboratory contributor). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting, PS4_Supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-21	2023-08-21	false	https://erepo.genome.network/evrepo/ui/classification/CA396458612/MONDO:0007648/007	07c40511-607b-44ff-8565-e682c5ce756f
NM_004360.4(CDH1):c.832+1G>T	239914	-	NM_004360.4:c.832+1G>T, NM_004360.5(CDH1):c.832+1G>T, NM_004360.4(CDH1):c.832+1G>T	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PM2_Supporting, PS4, PVS1_Strong	BS1, BS3, BS4, BP7, BP5, PM4, PM1, PM3, PM6, BS2, PP3, PP2, PP4, PP1, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS2	The c.832+G>T variant is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_Strong, PM5_Supporting). The variant is present in <1/100,000 alleles in the gnomAD cohort. (PM2_Supporting; http://gnomad.broadinstitute.org).  This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID: 23709761, 23124477, 26182300 and SCV000288497.3). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PM2_Supporting, PS4, PM5_Supporting.	26182300, 23709761, 23124477	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CV239914/MONDO:0007648/007	ca8eb295-29b0-45b5-8879-6065cde6d70d
NM_004360.3:c.2161C>G	599652	CA396467967	NM_004360.3:c.2161C>G, NC_000016.10:g.68823623C>G, CM000678.2:g.68823623C>G, NC_000016.9:g.68857526C>G, CM000678.1:g.68857526C>G, NC_000016.8:g.67415027C>G, NG_008021.1:g.91332C>G, LRG_301:g.91332C>G, ENST00000261769.10:c.2161C>G, ENST00000261769.9:c.2161C>G, ENST00000422392.6:c.1978C>G, ENST00000562118.1:n.379C>G, ENST00000562836.5:n.2232C>G, ENST00000566510.5:c.*827C>G, ENST00000566612.5:c.*401C>G, ENST00000611625.4:c.2224C>G, ENST00000612417.4:c.1830+1504C>G, ENST00000621016.4:c.1865+1469C>G, LRG_301t1:c.2161C>G, XM_011523488.1:c.1426C>G, XM_011523489.1:c.1426C>G, NM_001317184.1:c.1978C>G, NM_001317185.1:c.613C>G, NM_001317186.1:c.196C>G, NM_004360.4:c.2161C>G, NM_004360.5:c.2161C>G, NM_001317184.2:c.1978C>G, NM_001317185.2:c.613C>G, NM_001317186.2:c.196C>G, NM_004360.5(CDH1):c.2161C>G (p.Leu721Val)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	PP3, PS4_Supporting, PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PM6, PVS1, PM5, PM4, PM1, PM3, PP2, PP4, PP1, BS2, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS2	The c.2161C>G (p.Leu721Val) variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). There are at least 3 in silico predictors in agreement that this variant affects splicing (PP3). Additionally, this variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; internal laboratory contributor). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting, PP3, PS4_Supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-21	2023-08-21	false	https://erepo.genome.network/evrepo/ui/classification/CA396467967/MONDO:0007648/007	fc7868d5-8f10-4e93-9838-9697956e06a6
NM_004360.4(CDH1):c.2413G>A (p.Asp805Asn)	127925	CA157966	NM_004360.4:c.2413G>A, NC_000016.10:g.68829771G>A, CM000678.2:g.68829771G>A, NC_000016.9:g.68863674G>A, CM000678.1:g.68863674G>A, NC_000016.8:g.67421175G>A, NG_008021.1:g.97480G>A, LRG_301:g.97480G>A, ENST00000261769.10:c.2413G>A, ENST00000261769.9:c.2413G>A, ENST00000422392.6:c.2230G>A, ENST00000562118.1:n.631G>A, ENST00000562836.5:n.2484G>A, ENST00000566510.5:c.*1079G>A, ENST00000566612.5:c.*653G>A, ENST00000611625.4:c.2476G>A, ENST00000612417.4:c.1853+3217G>A, ENST00000621016.4:c.1866-4432G>A, NM_004360.3:c.2413G>A, LRG_301t1:c.2413G>A, XM_011523488.1:c.1678G>A, XM_011523489.1:c.1678G>A, NM_001317184.1:c.2230G>A, NM_001317185.1:c.865G>A, NM_001317186.1:c.448G>A, NM_004360.5:c.2413G>A, NM_001317184.2:c.2230G>A, NM_001317185.2:c.865G>A, NM_001317186.2:c.448G>A, NM_004360.5(CDH1):c.2413G>A (p.Asp805Asn), NM_004360.4(CDH1):c.2413G>A (p.Asp805Asn)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BP5, BP7, BS1, BS3, BS4, PM2, PM6, PVS1, PM5, PM3, PM4, PM1, PP3, PP2, PP4, PP1, BS2, BP4, BP1, BP2, BP3, PS3, PS1, PS4, PS2	The c.2413G>A (p.Asp805Asn) variant has an allele frequency of 0.00207 (0.21%, 21/10,148 alleles) in the Ashkenazi Jewish subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.	23197654, 26182300, 24728327, 25980754, 23197654	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	false	https://erepo.genome.network/evrepo/ui/classification/CA157966/MONDO:0007648/007	8f3f955a-56d1-4528-83ec-f23b19eb3126
NM_004360.4(CDH1):c.892G>A (p.Ala298Thr)	41787	CA211397	NM_004360.4:c.892G>A, NC_000016.10:g.68811743G>A, CM000678.2:g.68811743G>A, NC_000016.9:g.68845646G>A, CM000678.1:g.68845646G>A, NC_000016.8:g.67403147G>A, NG_008021.1:g.79452G>A, LRG_301:g.79452G>A, ENST00000261769.10:c.892G>A, ENST00000261769.9:c.892G>A, ENST00000422392.6:c.892G>A, ENST00000561751.1:n.514G>A, ENST00000562836.5:n.963G>A, ENST00000566510.5:c.736G>A, ENST00000566612.5:c.892G>A, ENST00000611625.4:c.892G>A, ENST00000612417.4:c.892G>A, ENST00000621016.4:c.892G>A, NM_004360.3:c.892G>A, LRG_301t1:c.892G>A, XM_011523488.1:c.157G>A, XM_011523489.1:c.157G>A, NM_001317184.1:c.892G>A, NM_001317185.1:c.-724G>A, NM_001317186.1:c.-928G>A, NM_004360.5:c.892G>A, NM_001317184.2:c.892G>A, NM_001317185.2:c.-724G>A, NM_001317186.2:c.-928G>A, NM_004360.5(CDH1):c.892G>A (p.Ala298Thr), NM_004360.4(CDH1):c.892G>A (p.Ala298Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS1, BS2	BP5, BP7, BS3, BS4, PM3, PM5, PM4, PM1, PVS1, PM2, PM6, PP1, PP3, PP2, PP4, BP2, BP4, BP1, BP3, BA1, PS3, PS1, PS4, PS2	The c.892G>A (p.Ala298Thr) variant has an allele frequency of 0.00133 (0.1%, 41/30,782 alleles) in the South Asian subpopulation of the gnomAD cohort (BS1). This variant has also been observed in >10 without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	false	https://erepo.genome.network/evrepo/ui/classification/CA211397/MONDO:0007648/007	1d1c6414-89d7-42c8-85d3-38f95b02cc08
NM_004360.4(CDH1):c.2398delC (p.Arg800Alafs)	156497	CA281459	NM_004360.4:c.2398delC, NC_000016.10:g.68829756del, CM000678.2:g.68829756del, NC_000016.9:g.68863659del, CM000678.1:g.68863659del, NC_000016.8:g.67421160del, NG_008021.1:g.97465del, LRG_301:g.97465del, ENST00000261769.10:c.2398del, ENST00000261769.9:c.2398del, ENST00000422392.6:c.2215del, ENST00000562118.1:n.616del, ENST00000562836.5:n.2469del, ENST00000566510.5:c.*1064del, ENST00000566612.5:c.*638del, ENST00000611625.4:c.2461del, ENST00000612417.4:c.1853+3202del, ENST00000621016.4:c.1866-4447del, NM_004360.3:c.2398del, LRG_301t1:c.2398del, XM_011523488.1:c.1663del, XM_011523489.1:c.1663del, NM_001317184.1:c.2215del, NM_001317185.1:c.850del, NM_001317186.1:c.433del, NM_004360.4:c.2398del, NM_004360.5:c.2398del, NM_001317184.2:c.2215del, NM_001317185.2:c.850del, NM_001317186.2:c.433del, NM_004360.5(CDH1):c.2398del (p.Arg800fs), NM_004360.4(CDH1):c.2398delC (p.Arg800Alafs)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PP1, PM2_Supporting, PS4, PVS1_Strong	BP7, BP5, BS1, BS4, BS3, PM5, PM4, PM1, PM3, PM6, PP4, PP3, PP2, BS2, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS2	The c.2398delC (p.Arg800Alafs*16) variant is predicted to result in a premature stop codon that leads to a truncated protein. However, it is located within the nonsense mediated decay resistance region upstream of c.2506G>T (p.Glu836*) (PVS1_Strong). The variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID 17545690). This variant was also found to co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed (PP1; PMID: 17545690). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PM2_Supporting, PS4, PP1.	17545690, 17545690, 17545690, 17545690, 18427545	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA281459/MONDO:0007648/007	a4959b72-3cf7-4e15-96c5-b96fd19dd327
NM_004360.4(CDH1):c.1137G>A (p.Thr379=)	156499	CA186229	NM_004360.4:c.1137G>A, NC_000016.10:g.68812263G>A, CM000678.2:g.68812263G>A, NC_000016.9:g.68846166G>A, CM000678.1:g.68846166G>A, NC_000016.8:g.67403667G>A, NG_008021.1:g.79972G>A, LRG_301:g.79972G>A, ENST00000261769.10:c.1137G>A, ENST00000261769.9:c.1137G>A, ENST00000422392.6:c.1137G>A, ENST00000562836.5:n.1208G>A, ENST00000565810.1:n.181G>A, ENST00000566510.5:c.981G>A, ENST00000566612.5:c.1137G>A, ENST00000611625.4:c.1137G>A, ENST00000612417.4:c.1137G>A, ENST00000621016.4:c.1137G>A, NM_004360.3:c.1137G>A, LRG_301t1:c.1137G>A, XM_011523488.1:c.402G>A, XM_011523489.1:c.402G>A, NM_001317184.1:c.1137G>A, NM_001317185.1:c.-479G>A, NM_001317186.1:c.-683G>A, NM_004360.5:c.1137G>A, NM_001317184.2:c.1137G>A, NM_001317185.2:c.-479G>A, NM_001317186.2:c.-683G>A, NM_004360.5(CDH1):c.1137G>A (p.Thr379=), NM_004360.4(CDH1):c.1137G>A (p.Thr379=)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS3, PS4, PVS1_Moderate	BP7, BP5, BS1, BS3, BS4, PM5, PM1, PM4, PM3, PM6, BS2, PP3, PP2, PP4, PP1, BP4, BP1, BP3, BP2, BA1, PS1, PS2	The c.1137G>A p.(Thr379=) variant results in a G to non-G change at the last nucleotide of an exon (PVS1_Moderate).  The variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). There is also an RNA assay demonstrating abnormal out-of-frame transcript (PS3; PMID: 15831593). Additionally, this variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID: 15831593, 17545690, 17221870, 21681551, 27995193). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Moderate, PM2_Supporting, PS3, PS4.	18427545, 15831593, 27995193, 15831593, 17545690, 21681551, 17221870, 18427545, 15831593, 18427545, 15831593, 27995193, 15831593, 17545690, 21681551, 17221870	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA186229/MONDO:0007648/007	3a1d0937-896d-4522-8899-90ddc6945ae1
NM_004360.5(CDH1):c.48+1G>A	449341	CA396451431	NM_004360.5:c.48+1G>A, NC_000016.10:g.68737464G>A, CM000678.2:g.68737464G>A, NC_000016.9:g.68771367G>A, CM000678.1:g.68771367G>A, NC_000016.8:g.67328868G>A, NG_008021.1:g.5173G>A, LRG_301:g.5173G>A, ENST00000261769.10:c.48+1G>A, ENST00000261769.9:c.48+1G>A, ENST00000422392.6:c.48+1G>A, ENST00000566510.5:c.48+1G>A, ENST00000566612.5:c.48+1G>A, ENST00000611625.4:c.48+1G>A, ENST00000612417.4:c.48+1G>A, ENST00000621016.4:c.48+1G>A, NM_004360.3:c.48+1G>A, LRG_301t1:c.48+1G>A, NM_001317184.1:c.48+1G>A, NM_001317185.1:c.-1568+1G>A, NM_001317186.1:c.-1772+1G>A, NM_004360.4:c.48+1G>A, NM_001317184.2:c.48+1G>A, NM_001317185.2:c.-1568+1G>A, NM_001317186.2:c.-1772+1G>A, NM_004360.5(CDH1):c.48+1G>A	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PM5_Supporting, PM2_Supporting, PS4_Moderate, PVS1_Strong	BP5, BP7, BS1, BS4, BS3, PM1, PM3, PM4, PM6, PP3, PP2, PP4, BS2, BP4, BP1, BP2, BP3, BA1, PS3, PS1, PS2	The c.48+1G>A is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_Strong, PM5_Supporting).  This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least two families meeting HDGC clinical criteria (PS4_Moderate; PMID: 20719348, 24366306).  The variant was also found to co-segregate with disease in multiple affected family members, with 5 or 6 meioses observed (PP1_Moderate; SCV000617359.1).  In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PM2_Supporting, PS4_Moderate and PP1_Moderate, PM5_Supporting.	20719348, 24366306, 20719348, 24366306	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA396451431/MONDO:0007648/007	8608d63b-7b00-4c76-a9f7-a0b9a5502446
NM_004360.3:c.614T>C	599654	CA396458013	NM_004360.3:c.614T>C, NC_000016.10:g.68808775T>C, CM000678.2:g.68808775T>C, NC_000016.9:g.68842678T>C, CM000678.1:g.68842678T>C, NC_000016.8:g.67400179T>C, NG_008021.1:g.76484T>C, LRG_301:g.76484T>C, ENST00000261769.10:c.614T>C, ENST00000261769.9:c.614T>C, ENST00000422392.6:c.614T>C, ENST00000561751.1:n.381T>C, ENST00000562836.5:n.685T>C, ENST00000564676.5:n.896T>C, ENST00000566510.5:c.531+208T>C, ENST00000566612.5:c.614T>C, ENST00000567320.1:n.124T>C, ENST00000611625.4:c.614T>C, ENST00000612417.4:c.614T>C, ENST00000621016.4:c.614T>C, LRG_301t1:c.614T>C, XM_011523488.1:c.-122T>C, XM_011523489.1:c.-122T>C, NM_001317184.1:c.614T>C, NM_001317185.1:c.-1002T>C, NM_001317186.1:c.-1206T>C, NM_004360.4:c.614T>C, NM_004360.5:c.614T>C, NM_001317184.2:c.614T>C, NM_001317185.2:c.-1002T>C, NM_001317186.2:c.-1206T>C, NM_004360.5(CDH1):c.614T>C (p.Phe205Ser)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	PM2_Supporting, PS4_Supporting	BP7, BP5, BS1, BS3, BS4, PVS1, PM6, PM5, PM4, PM1, PM3, BS2, PP3, PP2, PP4, PP1, BP4, BP1, BP3, BP2, BA1, PS3, PS1, PS2	The c.614T>C (p. Phe205Ser) variant is absent in the gnomAD cohort (PM2_Supporting). This variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; internal laboratory contributor). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting, PS4_Supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-21	2023-08-21	false	https://erepo.genome.network/evrepo/ui/classification/CA396458013/MONDO:0007648/007	36659513-f448-4457-900a-485812518ebb
NM_004360.4(CDH1):c.382delC (p.His128Ilefs)	486824	CA496152715	NM_004360.4:c.382delC, NC_000016.10:g.68801888del, CM000678.2:g.68801888del, NC_000016.9:g.68835791del, CM000678.1:g.68835791del, NC_000016.8:g.67393292del, NG_008021.1:g.69597del, LRG_301:g.69597del, ENST00000261769.10:c.382del, ENST00000261769.9:c.382del, ENST00000422392.6:c.382del, ENST00000561751.1:n.149del, ENST00000562836.5:n.453del, ENST00000564676.5:n.664del, ENST00000564745.1:n.377del, ENST00000566510.5:c.382del, ENST00000566612.5:c.382del, ENST00000611625.4:c.382del, ENST00000612417.4:c.382del, ENST00000621016.4:c.382del, NM_004360.3:c.382del, LRG_301t1:c.382del, XM_011523488.1:c.-354del, XM_011523489.1:c.-354del, NM_001317184.1:c.382del, NM_001317185.1:c.-1234del, NM_001317186.1:c.-1438del, NM_004360.4:c.382del, NM_004360.5:c.382del, NM_001317184.2:c.382del, NM_001317185.2:c.-1234del, NM_001317186.2:c.-1438del, NM_004360.5(CDH1):c.382del (p.His128fs), NM_004360.4(CDH1):c.382delC (p.His128Ilefs)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PM2_Supporting, PS4_Supporting	BP7, BP5, BS1, BS3, BS4, PM4, PM1, PM3, PM6, PP4, PP3, PP2, PP1, BS2, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS2	The c.382delC (p.His128Ilefs*87) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1, PM5_Supporting). The variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; PMID: 15235021). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1, PM2_Supporting, PS4_Supporting, PM5_Supporting.	19269290, 15235021	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA496152715/MONDO:0007648/007	df80cd71-95e2-4ee3-b0bb-62143042f6c7
NM_004360.4(CDH1):c.79C>T (p.Pro27Ser)	239913	CA10583401	NM_004360.4:c.79C>T, NC_000016.10:g.68738327C>T, CM000678.2:g.68738327C>T, NC_000016.9:g.68772230C>T, CM000678.1:g.68772230C>T, NC_000016.8:g.67329731C>T, NG_008021.1:g.6036C>T, LRG_301:g.6036C>T, ENST00000261769.10:c.79C>T, ENST00000261769.9:c.79C>T, ENST00000422392.6:c.79C>T, ENST00000566510.5:c.79C>T, ENST00000566612.5:c.79C>T, ENST00000611625.4:c.79C>T, ENST00000612417.4:c.79C>T, ENST00000621016.4:c.79C>T, NM_004360.3:c.79C>T, LRG_301t1:c.79C>T, NM_001317184.1:c.79C>T, NM_001317185.1:c.-1537C>T, NM_001317186.1:c.-1741C>T, NM_004360.5:c.79C>T, NM_001317184.2:c.79C>T, NM_001317185.2:c.-1537C>T, NM_001317186.2:c.-1741C>T, NM_004360.5(CDH1):c.79C>T (p.Pro27Ser), NM_004360.4(CDH1):c.79C>T (p.Pro27Ser)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PVS1, PM6, BS2, PP3, PP2, PP4, PP1, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The c.79C>T (p.Pro27Ser) variant has allele frequency <1 out of 100, 000  in the gnomAD cohort (1/156646 in gnomAD v2.1.1; PM2_Supporting). No additional evidence met criteria for consideration. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-21	2023-08-21	false	https://erepo.genome.network/evrepo/ui/classification/CA10583401/MONDO:0007648/007	9a9082a0-343e-4b16-a256-c64b923d37b2
NM_004360.4(CDH1):c.1774G>A (p.Ala592Thr)	41783	CA157954	NM_004360.4:c.1774G>A, NC_000016.10:g.68822063G>A, CM000678.2:g.68822063G>A, NC_000016.9:g.68855966G>A, CM000678.1:g.68855966G>A, NC_000016.8:g.67413467G>A, NG_008021.1:g.89772G>A, LRG_301:g.89772G>A, ENST00000261769.10:c.1774G>A, ENST00000261769.9:c.1774G>A, ENST00000422392.6:c.1591G>A, ENST00000562836.5:n.1845G>A, ENST00000566510.5:c.*440G>A, ENST00000566612.5:c.*14G>A, ENST00000611625.4:c.1837G>A, ENST00000612417.4:c.1774G>A, ENST00000621016.4:c.1774G>A, NM_004360.3:c.1774G>A, LRG_301t1:c.1774G>A, XM_011523488.1:c.1039G>A, XM_011523489.1:c.1039G>A, NM_001317184.1:c.1591G>A, NM_001317185.1:c.226G>A, NM_001317186.1:c.-192G>A, NM_004360.5:c.1774G>A, NM_001317184.2:c.1591G>A, NM_001317185.2:c.226G>A, NM_001317186.2:c.-192G>A, NM_004360.5(CDH1):c.1774G>A (p.Ala592Thr), NM_004360.4(CDH1):c.1774G>A (p.Ala592Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BP7, BP5, BS1, BS3, BS4, PM2, PM6, PVS1, PM5, PM4, PM1, PM3, PP4, PP3, PP2, PP1, BS2, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.1774G>A  (p.Ala592Thr) variant has an allele frequency of 0.00481 (0.48%, 609/126,710 alleles) in the European (non-Finnish) subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	false	https://erepo.genome.network/evrepo/ui/classification/CA157954/MONDO:0007648/007	ba6046f9-9dfa-4961-912e-d1cadcaa922d
NM_004360.4(CDH1):c.2506G>T (p.Glu836Ter)	479504	CA396472215	NM_004360.4:c.2506G>T, NC_000016.10:g.68833356G>T, CM000678.2:g.68833356G>T, NC_000016.9:g.68867259G>T, CM000678.1:g.68867259G>T, NC_000016.8:g.67424760G>T, NG_008021.1:g.101065G>T, LRG_301:g.101065G>T, ENST00000261769.10:c.2506G>T, ENST00000261769.9:c.2506G>T, ENST00000422392.6:c.2323G>T, ENST00000562118.1:n.724G>T, ENST00000562836.5:n.2577G>T, ENST00000566510.5:c.*1172G>T, ENST00000566612.5:c.*746G>T, ENST00000611625.4:c.2569G>T, ENST00000612417.4:c.1854-835G>T, ENST00000621016.4:c.1866-847G>T, NM_004360.3:c.2506G>T, LRG_301t1:c.2506G>T, XM_011523488.1:c.1771G>T, XM_011523489.1:c.1771G>T, NM_001317184.1:c.2323G>T, NM_001317185.1:c.958G>T, NM_001317186.1:c.541G>T, NM_004360.5:c.2506G>T, NM_001317184.2:c.2323G>T, NM_001317185.2:c.958G>T, NM_001317186.2:c.541G>T, NM_004360.5(CDH1):c.2506G>T (p.Glu836Ter), NM_004360.4(CDH1):c.2506G>T (p.Glu836Ter)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS2, PVS1_Strong	BS1, BS3, BS4, BP7, BP5, PM6, PM5, PM4, PM1, PM3, BS2, PP3, PP2, PP1, PP4, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS4	The c.2506G>T (p.Glu836*) variant results in a premature stop codon that leads to a truncated protein. While it is located within the nonsense mediated decay resistance region,it is recognized as the most c-terminal pathogenic variant in CDH1 (PVS1_Strong, PMID: 29798843). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). There is one known de novo observation with parental confirmation in a patient with diffuse gastric cancer and/or lobular breast cancer (PS2; PMID: 29798843). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1_Strong, PM2_Supporting, PS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA396472215/MONDO:0007648/007	1a5e5e0d-db23-4e6c-a7f2-002891504b0f
NM_004360.4(CDH1):c.635G>T (p.Gly212Val)	479488	CA396458057	NM_004360.4:c.635G>T, NC_000016.10:g.68808796G>T, CM000678.2:g.68808796G>T, NC_000016.9:g.68842699G>T, CM000678.1:g.68842699G>T, NC_000016.8:g.67400200G>T, NG_008021.1:g.76505G>T, LRG_301:g.76505G>T, ENST00000261769.10:c.635G>T, ENST00000261769.9:c.635G>T, ENST00000422392.6:c.635G>T, ENST00000561751.1:n.402G>T, ENST00000562836.5:n.706G>T, ENST00000564676.5:n.917G>T, ENST00000566510.5:c.531+229G>T, ENST00000566612.5:c.635G>T, ENST00000567320.1:n.145G>T, ENST00000611625.4:c.635G>T, ENST00000612417.4:c.635G>T, ENST00000621016.4:c.635G>T, NM_004360.3:c.635G>T, LRG_301t1:c.635G>T, XM_011523488.1:c.-101G>T, XM_011523489.1:c.-101G>T, NM_001317184.1:c.635G>T, NM_001317185.1:c.-981G>T, NM_001317186.1:c.-1185G>T, NM_004360.5:c.635G>T, NM_001317184.2:c.635G>T, NM_001317185.2:c.-981G>T, NM_001317186.2:c.-1185G>T, NM_004360.5(CDH1):c.635G>T (p.Gly212Val), NM_004360.4(CDH1):c.635G>T (p.Gly212Val)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	PM2_Supporting, PS4_Supporting	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PVS1, PM6, BS2, PP4, PP3, PP2, PP1, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS2	The c.635G>T (p.Gly212Val) variant is absent in the gnomAD cohort (PM2_Supporting). This variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; SCV000661629.1). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting, PS4_Supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-21	2023-08-21	false	https://erepo.genome.network/evrepo/ui/classification/CA396458057/MONDO:0007648/007	7900d2e0-27b5-45b8-841e-fc65c3aad8ef
NM_004360.4(CDH1):c.2512A>G (p.Ser838Gly)	12233	CA121994	NM_004360.4:c.2512A>G, NC_000016.10:g.68833362A>G, CM000678.2:g.68833362A>G, NC_000016.9:g.68867265A>G, CM000678.1:g.68867265A>G, NC_000016.8:g.67424766A>G, NG_008021.1:g.101071A>G, LRG_301:g.101071A>G, ENST00000261769.10:c.2512A>G, ENST00000261769.9:c.2512A>G, ENST00000422392.6:c.2329A>G, ENST00000562118.1:n.730A>G, ENST00000562836.5:n.2583A>G, ENST00000566510.5:c.*1178A>G, ENST00000566612.5:c.*752A>G, ENST00000611625.4:c.2575A>G, ENST00000612417.4:c.1854-829A>G, ENST00000621016.4:c.1866-841A>G, NM_004360.3:c.2512A>G, LRG_301t1:c.2512A>G, XM_011523488.1:c.1777A>G, XM_011523489.1:c.1777A>G, NM_001317184.1:c.2329A>G, NM_001317185.1:c.964A>G, NM_001317186.1:c.547A>G, NM_004360.5:c.2512A>G, NM_001317184.2:c.2329A>G, NM_001317185.2:c.964A>G, NM_001317186.2:c.547A>G, NM_004360.5(CDH1):c.2512A>G (p.Ser838Gly), NM_004360.4(CDH1):c.2512A>G (p.Ser838Gly)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Benign	BS2	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The c.2512A>G (p.Ser838Gly) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is classified as likely benign based on BS2 alone. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-17	2023-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA121994/MONDO:0007648/007	85364a5d-816a-4c65-a3f3-29c77698b3b9
NM_004360.4(CDH1):c.1297G>A (p.Asp433Asn)	127910	CA288028	NM_004360.4:c.1297G>A, NC_000016.10:g.68813472G>A, CM000678.2:g.68813472G>A, NC_000016.9:g.68847375G>A, CM000678.1:g.68847375G>A, NC_000016.8:g.67404876G>A, NG_008021.1:g.81181G>A, LRG_301:g.81181G>A, ENST00000261769.10:c.1297G>A, ENST00000261769.9:c.1297G>A, ENST00000422392.6:c.1137+1209G>A, ENST00000562836.5:n.1368G>A, ENST00000566510.5:c.1141G>A, ENST00000566612.5:c.1297G>A, ENST00000611625.4:c.1297G>A, ENST00000612417.4:c.1297G>A, ENST00000621016.4:c.1297G>A, NM_004360.3:c.1297G>A, LRG_301t1:c.1297G>A, XM_011523488.1:c.562G>A, XM_011523489.1:c.562G>A, NM_001317184.1:c.1137+1209G>A, NM_001317185.1:c.-319G>A, NM_001317186.1:c.-523G>A, NM_004360.5:c.1297G>A, NM_001317184.2:c.1137+1209G>A, NM_001317185.2:c.-319G>A, NM_001317186.2:c.-523G>A, NM_004360.5(CDH1):c.1297G>A (p.Asp433Asn), NM_004360.4(CDH1):c.1297G>A (p.Asp433Asn)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Benign	BS2	BP5, BP7, BS1, BS3, BS4, PM1, PM3, PM5, PM4, PVS1, PM2, PM6, PP3, PP2, PP4, PP1, BP4, BP1, BP2, BP3, BA1, PS3, PS4, PS2, PS1	The c.1297G>A (p.Asp433Asn) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is classified as likely benign based on BS2 alone. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-17	2023-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA288028/MONDO:0007648/007	f04175e5-9dd2-4137-8102-442c8b07c0d7
NM_004360.4(CDH1):c.188G>A (p.Arg63Gln)	127919	CA288048	NM_004360.4:c.188G>A, NC_000016.10:g.68801694G>A, CM000678.2:g.68801694G>A, NC_000016.9:g.68835597G>A, CM000678.1:g.68835597G>A, NC_000016.8:g.67393098G>A, NG_008021.1:g.69403G>A, LRG_301:g.69403G>A, ENST00000261769.10:c.188G>A, ENST00000261769.9:c.188G>A, ENST00000422392.6:c.188G>A, ENST00000562836.5:n.259G>A, ENST00000564676.5:n.470G>A, ENST00000564745.1:n.183G>A, ENST00000566510.5:c.188G>A, ENST00000566612.5:c.188G>A, ENST00000611625.4:c.188G>A, ENST00000612417.4:c.188G>A, ENST00000621016.4:c.188G>A, NM_004360.3:c.188G>A, LRG_301t1:c.188G>A, XM_011523488.1:c.-548G>A, XM_011523489.1:c.-548G>A, NM_001317184.1:c.188G>A, NM_001317185.1:c.-1428G>A, NM_001317186.1:c.-1632G>A, NM_004360.5:c.188G>A, NM_001317184.2:c.188G>A, NM_001317185.2:c.-1428G>A, NM_001317186.2:c.-1632G>A, NM_004360.5(CDH1):c.188G>A (p.Arg63Gln), NM_004360.4(CDH1):c.188G>A (p.Arg63Gln)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS1, BS2	BP5, BP7, BS3, BS4, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The c.188G>A (p.Arg63Gln) variant has an allele frequency of 0.00109 (0.11%, 6/5486 alleles) in the â€œOtherâ€ subpopulation of the gnomAD cohort (BS1). This variant has also been observed in >10 without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	false	https://erepo.genome.network/evrepo/ui/classification/CA288048/MONDO:0007648/007	4de15575-228f-4350-8bab-2e2dbfd23694
NM_004360.4(CDH1):c.604G>A (p.Val202Ile)	133853	CA163776	NM_004360.4:c.604G>A, NC_000016.10:g.68808765G>A, CM000678.2:g.68808765G>A, NC_000016.9:g.68842668G>A, CM000678.1:g.68842668G>A, NC_000016.8:g.67400169G>A, NG_008021.1:g.76474G>A, LRG_301:g.76474G>A, ENST00000261769.10:c.604G>A, ENST00000261769.9:c.604G>A, ENST00000422392.6:c.604G>A, ENST00000561751.1:c.371G>A, ENST00000562836.5:n.675G>A, ENST00000564676.5:n.886G>A, ENST00000566510.5:c.531+198G>A, ENST00000566612.5:c.604G>A, ENST00000567320.1:n.114G>A, ENST00000611625.4:c.604G>A, ENST00000612417.4:c.604G>A, ENST00000621016.4:c.604G>A, NM_004360.3:c.604G>A, LRG_301t1:c.604G>A, XM_011523488.1:c.-132G>A, XM_011523489.1:c.-132G>A, NM_001317184.1:c.604G>A, NM_001317185.1:c.-1012G>A, NM_001317186.1:c.-1216G>A, NM_004360.5:c.604G>A, NM_001317184.2:c.604G>A, NM_001317185.2:c.-1012G>A, NM_001317186.2:c.-1216G>A, NM_004360.5(CDH1):c.604G>A (p.Val202Ile), NM_004360.4(CDH1):c.604G>A (p.Val202Ile)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, BS2, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.604G>A (p.Val202Ile) variant has an allele frequency of 0.00354 (0.35%, 109/30,772 alleles) in the South Asian subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	false	https://erepo.genome.network/evrepo/ui/classification/CA163776/MONDO:0007648/007	4f56b139-4c6b-4107-aebc-4368f6c6f68b
NM_004360.4(CDH1):c.1679C>G (p.Thr560Arg)	234554	CA10577547	NM_004360.4:c.1679C>G, NC_000016.10:g.68819393C>G, CM000678.2:g.68819393C>G, NC_000016.9:g.68853296C>G, CM000678.1:g.68853296C>G, NC_000016.8:g.67410797C>G, NG_008021.1:g.87102C>G, LRG_301:g.87102C>G, ENST00000261769.10:c.1679C>G, ENST00000261769.9:c.1679C>G, ENST00000422392.6:c.1496C>G, ENST00000562836.5:n.1750C>G, ENST00000566510.5:c.*345C>G, ENST00000566612.5:c.1566-2608C>G, ENST00000611625.4:c.1742C>G, ENST00000612417.4:c.1679C>G, ENST00000621016.4:c.1679C>G, NM_004360.3:c.1679C>G, LRG_301t1:c.1679C>G, XM_011523488.1:c.944C>G, XM_011523489.1:c.944C>G, NM_001317184.1:c.1496C>G, NM_001317185.1:c.131C>G, NM_001317186.1:c.-254-2608C>G, NM_004360.5:c.1679C>G, NM_001317184.2:c.1496C>G, NM_001317185.2:c.131C>G, NM_001317186.2:c.-254-2608C>G, NM_004360.5(CDH1):c.1679C>G (p.Thr560Arg), NM_004360.4(CDH1):c.1679C>G (p.Thr560Arg)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS3, PS4, PP1_Strong	BS1, BS4, BS3, BP7, BP5, PM5, PM1, PM3, PM4, PVS1, PM6, BS2, PP2, PP4, BA1, BP4, BP1, BP2, BP3, PS1, PS2	The c.1679C>G (p.Thr560Arg) variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). There are at least 3 in silico predictors in agreement that this variant affects splicing (PP3). There is also an RNA assay demonstrating abnormal out-of-frame transcript (PS3; PMID: 27880784). Additionally, the variant was found to co-segregation with disease in multiple affected family members, with >7 meioses observed across at least 4 families (PP1_Strong; PMID: 27880784, 29769627). This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID: 27880784, 29769627, 23709761 and SCV000580704.2). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting, PP3, PS3, PP1_Strong, PS4.	29769627, 27880784, 29769627, 23709761, 29769627	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA10577547/MONDO:0007648/007	89320d2b-848b-4794-bcc3-84d990e99660
NM_004360.4(CDH1):c.670C>T (p.Arg224Cys)	127932	CA288074	NM_004360.4:c.670C>T, NC_000016.10:g.68808831C>T, CM000678.2:g.68808831C>T, NC_000016.9:g.68842734C>T, CM000678.1:g.68842734C>T, NC_000016.8:g.67400235C>T, NG_008021.1:g.76540C>T, LRG_301:g.76540C>T, ENST00000261769.10:c.670C>T, ENST00000261769.9:c.670C>T, ENST00000422392.6:c.670C>T, ENST00000561751.1:n.437C>T, ENST00000562836.5:n.741C>T, ENST00000564676.5:n.952C>T, ENST00000566510.5:c.531+264C>T, ENST00000566612.5:c.670C>T, ENST00000567320.1:n.180C>T, ENST00000611625.4:c.670C>T, ENST00000612417.4:c.670C>T, ENST00000621016.4:c.670C>T, NM_004360.3:c.670C>T, LRG_301t1:c.670C>T, XM_011523488.1:c.-66C>T, XM_011523489.1:c.-66C>T, NM_001317184.1:c.670C>T, NM_001317185.1:c.-946C>T, NM_001317186.1:c.-1150C>T, NM_004360.5:c.670C>T, NM_001317184.2:c.670C>T, NM_001317185.2:c.-946C>T, NM_001317186.2:c.-1150C>T, NM_004360.5(CDH1):c.670C>T (p.Arg224Cys), NM_004360.4(CDH1):c.670C>T (p.Arg224Cys)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Benign	BS2	BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, PP3, PP2, PP4, PP1, BP4, BP1, BP3, BP2, BA1, PS3, PS1, PS4, PS2	The c.670C>T (p.Arg224Cys) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is classified as likely benign based on BS2 alone. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2.	27582386, 27582386	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-17	2023-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA288074/MONDO:0007648/007	d4d12c86-59cb-40a8-92ec-13925d97080a
NM_004360.4(CDH1):c.3G>A (p.Met1Ile)	239906	CA10583399	NM_004360.4:c.3G>A, NC_000016.10:g.68737418G>A, CM000678.2:g.68737418G>A, NC_000016.9:g.68771321G>A, CM000678.1:g.68771321G>A, NC_000016.8:g.67328822G>A, NG_008021.1:g.5127G>A, LRG_301:g.5127G>A, ENST00000261769.10:c.3G>A, ENST00000261769.9:c.3G>A, ENST00000422392.6:c.3G>A, ENST00000566510.5:c.3G>A, ENST00000566612.5:c.3G>A, ENST00000611625.4:c.3G>A, ENST00000612417.4:c.3G>A, ENST00000621016.4:c.3G>A, NM_004360.3:c.3G>A, LRG_301t1:c.3G>A, NM_001317184.1:c.3G>A, NM_001317185.1:c.-1613G>A, NM_001317186.1:c.-1817G>A, NM_004360.5:c.3G>A, NM_001317184.2:c.3G>A, NM_001317185.2:c.-1613G>A, NM_001317186.2:c.-1817G>A, NM_004360.5(CDH1):c.3G>A (p.Met1Ile), NM_004360.4(CDH1):c.3G>A (p.Met1Ile)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PVS1, PM2_Supporting, PS4	BP7, BP5, BS1, BS4, BS3, PM5, PM4, PM1, PM6, PM3, PP3, PP2, PP4, BS2, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS2	The c.3G>A (p.Met1Ile) variant causes a truncated or absent protein by altering the start codon of the coding sequence and is predicted to lead to the omission of a critical region of the protein (18726070, 2317870, 20066110) (PVS1). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant was found to co-segregate with disease in multiple affected family members, with 5 or 6 meioses observed (PP1_Moderate; PMID:  28202063, 26182300). This variant has also been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID: 26182300, 20719348, clinical lab internal data). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP Variant Interpretation Guidelines Version 3.1 as specified by the CDH1 Variant Curation Expert Panel: PVS1, PM2_Supporting, PP1_Moderate, PS4.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA10583399/MONDO:0007648/007	d13fa937-98cf-4da0-956f-8d7d5543f0a3
NM_004360.4(CDH1):c.1138-3C>T	184346	CA188674	NM_004360.4:c.1138-3C>T, NC_000016.10:g.68813310C>T, CM000678.2:g.68813310C>T, NC_000016.9:g.68847213C>T, CM000678.1:g.68847213C>T, NC_000016.8:g.67404714C>T, NG_008021.1:g.81019C>T, LRG_301:g.81019C>T, ENST00000261769.10:c.1138-3C>T, ENST00000261769.9:c.1138-3C>T, ENST00000422392.6:c.1137+1047C>T, ENST00000562836.5:n.1209-3C>T, ENST00000565810.1:n.182-3C>T, ENST00000566510.5:c.982-3C>T, ENST00000566612.5:c.1138-3C>T, ENST00000611625.4:c.1138-3C>T, ENST00000612417.4:c.1138-3C>T, ENST00000621016.4:c.1138-3C>T, NM_004360.3:c.1138-3C>T, LRG_301t1:c.1138-3C>T, XM_011523488.1:c.403-3C>T, XM_011523489.1:c.403-3C>T, NM_001317184.1:c.1137+1047C>T, NM_001317185.1:c.-478-3C>T, NM_001317186.1:c.-682-3C>T, NM_004360.5:c.1138-3C>T, NM_001317184.2:c.1137+1047C>T, NM_001317185.2:c.-478-3C>T, NM_001317186.2:c.-682-3C>T, NM_004360.5(CDH1):c.1138-3C>T, NM_004360.4(CDH1):c.1138-3C>T	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Benign	BS1, BP4	BP7, BP5, BS3, BS4, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, PP3, PP2, PP1, PP4, BS2, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	The c.1138-3C>T variant has an allele frequency of 0.00121 (0.121%, 29/24,036 alleles) in the African subpopulation of the gnomAD cohort (BS1). There are at least 3 in silico predictors in agreement that this variant does not affect splicing (BP4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS1, BP4 (Variant Interpretation Guidelines Version 3.1).	15322508	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-24	2023-08-24	false	https://erepo.genome.network/evrepo/ui/classification/CA188674/MONDO:0007648/007	44ff0837-63d3-46af-9fc3-d319e5146005
NM_004360.4(CDH1):c.1085delT (p.Val362Glyfs)	483264	CA658658486	NM_004360.4:c.1085delT, NC_000016.10:g.68812211del, CM000678.2:g.68812211del, NC_000016.9:g.68846114del, CM000678.1:g.68846114del, NC_000016.8:g.67403615del, NG_008021.1:g.79920del, LRG_301:g.79920del, ENST00000261769.10:c.1085del, ENST00000261769.9:c.1085del, ENST00000422392.6:c.1085del, ENST00000561751.1:n.707del, ENST00000562836.5:n.1156del, ENST00000565810.1:n.129del, ENST00000566510.5:c.929del, ENST00000566612.5:c.1085del, ENST00000611625.4:c.1085del, ENST00000612417.4:c.1085del, ENST00000621016.4:c.1085del, NM_004360.3:c.1085del, LRG_301t1:c.1085del, XM_011523488.1:c.350del, XM_011523489.1:c.350del, NM_001317184.1:c.1085del, NM_001317185.1:c.-531del, NM_001317186.1:c.-735del, NM_004360.4:c.1085del, NM_004360.5:c.1085del, NM_001317184.2:c.1085del, NM_001317185.2:c.-531del, NM_001317186.2:c.-735del, NM_004360.5(CDH1):c.1085del (p.Val362fs), NM_004360.4(CDH1):c.1085delT (p.Val362Glyfs)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PM2_Supporting, PS4_Supporting	BP7, BP5, BS4, BS1, BS3, PM4, PM1, PM3, PM6, PP1, PP4, PP3, PP2, BS2, BP3, BP4, BP1, BP2, BA1, PS1, PS3, PS2	The c.1085delT (p.Val362Glyfs*31) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1, PM5_Supporting). The variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; SCV000669065.1). Therefore, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1, PM2_Supporting, PS4_Supporting, PM5_Supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA658658486/MONDO:0007648/007	c5d03db0-c5d6-426b-9059-585ca0cccb44
NM_004360.4(CDH1):c.1792C>T (p.Arg598Ter)	12241	CA281000	NM_004360.4:c.1792C>T, NC_000016.10:g.68822081C>T, CM000678.2:g.68822081C>T, NC_000016.9:g.68855984C>T, CM000678.1:g.68855984C>T, NC_000016.8:g.67413485C>T, NG_008021.1:g.89790C>T, LRG_301:g.89790C>T, ENST00000261769.10:c.1792C>T, ENST00000261769.9:c.1792C>T, ENST00000422392.6:c.1609C>T, ENST00000562836.5:n.1863C>T, ENST00000566510.5:c.*458C>T, ENST00000566612.5:c.*32C>T, ENST00000611625.4:c.1855C>T, ENST00000612417.4:c.1792C>T, ENST00000621016.4:c.1792C>T, NM_004360.3:c.1792C>T, LRG_301t1:c.1792C>T, XM_011523488.1:c.1057C>T, XM_011523489.1:c.1057C>T, NM_001317184.1:c.1609C>T, NM_001317185.1:c.244C>T, NM_001317186.1:c.-174C>T, NM_004360.5:c.1792C>T, NM_001317184.2:c.1609C>T, NM_001317185.2:c.244C>T, NM_001317186.2:c.-174C>T, NM_004360.5(CDH1):c.1792C>T (p.Arg598Ter), NM_004360.4(CDH1):c.1792C>T (p.Arg598Ter)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PM2_Supporting, PS2, PS4, PP1_Strong	BP5, BP7, BS1, BS4, BS3, PM1, PM3, PM4, PM6, PP3, PP2, PP4, BS2, BP4, BP1, BP2, BP3, BA1, PS3, PS1	The c.1792C>T (p.Arg598*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1, PM5_Supporting). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant was found to co-segregate with disease in multiple affected family members, with >7 meioses observed across at least two families (PP1_Strong; PMID: 21696387, 16061854, 11419427 and SCV000275702.5). This variant has also been reported in at least four families meeting HDGC clinical criteria (PS4_Strong; PMID: 9751616, 21696387, 16061854, 11419427). There is one known de novo observation of this variant with parental confirmation in a patient with diffuse gastric cancer and/or lobular breast cancer (PS2; PMID: 21696387). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1, PM2_Supporting, PP1_Strong, PS4, PS2, PM5_Supporting.	16061854, 21696387, 11419427, 16061854, 9751616, 21696387, 16061854, 21696387	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA281000/MONDO:0007648/007	8d966550-3108-4786-8d4d-092988c239d6
NM_004360.4(CDH1):c.1849G>A (p.Ala617Thr)	12232	CA121991	NM_004360.4:c.1849G>A, NC_000016.10:g.68822138G>A, CM000678.2:g.68822138G>A, NC_000016.9:g.68856041G>A, CM000678.1:g.68856041G>A, NC_000016.8:g.67413542G>A, NG_008021.1:g.89847G>A, LRG_301:g.89847G>A, ENST00000261769.10:c.1849G>A, ENST00000261769.9:c.1849G>A, ENST00000422392.6:c.1666G>A, ENST00000562836.5:n.1920G>A, ENST00000566510.5:c.*515G>A, ENST00000566612.5:c.*89G>A, ENST00000611625.4:c.1912G>A, ENST00000612417.4:c.1830+19G>A, ENST00000621016.4:c.1849G>A, NM_004360.3:c.1849G>A, LRG_301t1:c.1849G>A, XM_011523488.1:c.1114G>A, XM_011523489.1:c.1114G>A, NM_001317184.1:c.1666G>A, NM_001317185.1:c.301G>A, NM_001317186.1:c.-117G>A, NM_004360.5:c.1849G>A, NM_001317184.2:c.1666G>A, NM_001317185.2:c.301G>A, NM_001317186.2:c.-117G>A, NM_004360.5(CDH1):c.1849G>A (p.Ala617Thr), NM_004360.4(CDH1):c.1849G>A (p.Ala617Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BP7, BP5, BS1, BS3, BS4, PVS1, PM2, PM6, PM5, PM4, PM1, PM3, BS2, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.1849G>A (p.Ala617Thr) variant has an allele frequency of 0.04479 (4.5%, 1,076/24,022 alleles) in the African subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	false	https://erepo.genome.network/evrepo/ui/classification/CA121991/MONDO:0007648/007	8fe2e0a3-670f-4cdb-bbf8-3836f7fc45e9
NM_004360.5(CDH1):c.1008G>A (p.Glu336=)	231647	CA10580100	NM_004360.5:c.1008G>A, NC_000016.10:g.68811859G>A, CM000678.2:g.68811859G>A, NC_000016.9:g.68845762G>A, CM000678.1:g.68845762G>A, NC_000016.8:g.67403263G>A, NG_008021.1:g.79568G>A, LRG_301:g.79568G>A, ENST00000261769.10:c.1008G>A, ENST00000261769.9:c.1008G>A, ENST00000422392.6:c.1008G>A, ENST00000561751.1:c.630G>A, ENST00000562836.5:n.1079G>A, ENST00000566510.5:c.852G>A, ENST00000566612.5:c.1008G>A, ENST00000611625.4:c.1008G>A, ENST00000612417.4:c.1008G>A, ENST00000621016.4:c.1008G>A, NM_004360.3:c.1008G>A, LRG_301t1:c.1008G>A, XM_011523488.1:c.273G>A, XM_011523489.1:c.273G>A, NM_001317184.1:c.1008G>A, NM_001317185.1:c.-608G>A, NM_001317186.1:c.-812G>A, NM_004360.4:c.1008G>A, NM_001317184.2:c.1008G>A, NM_001317185.2:c.-608G>A, NM_001317186.2:c.-812G>A, NM_004360.5(CDH1):c.1008G>A (p.Glu336=)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS3, PS4, PVS1_Moderate	BP7, BP5, BS1, BS3, BS4, PM6, PM4, PM5, PM1, PM3, BS2, PP2, PP4, PP1, BP4, BP1, BP3, BP2, BA1, PS1, PS2	The c.1008G>A (NM_004360.5) variant in CDH1is a G to non-G variant in the last nucleotide in exon 7. It is predicted to cause a loss of the donor splice site resulting in retention of intron 7 (PVS1_Moderate). This prediction is confirmed by RT-PCR cDNA demonstrating that the variant impacts splicing by producing 4 different alternatively spliced transcripts containing premature termination codons (PTC) caused by the use of cryptic donor splice sites in the intron (PS3, PMID: 8127895). This variant has been reported in 4 probands/families meeting hereditary diffuse gastric cancer genetic testing criteria (PS4; PMIDs 9536098, 27730413, ClinVar SCVs: SCV000275557.6, SCV000760854.3, Internal lab contributors). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). The results from 3 in silico splicing predictors (SpliceAI, MaxEntScan, NNsplice) indicate that this variant may affect splicing by disrupting the donor splice site of intron 7 of CDH1 (PP3). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Moderate, PM2_Supporting, PS3, PS4, PP3.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2024-03-25	2024-03-27	false	https://erepo.genome.network/evrepo/ui/classification/CA10580100/MONDO:0007648/007	03f19343-ea6f-460e-b6f5-a18145f32513
NM_004360.4(CDH1):c.2430delT (p.Phe810Leufs)	187464	CA197715	NM_004360.4:c.2430delT, NC_000016.10:g.68829788del, CM000678.2:g.68829788del, NC_000016.9:g.68863691del, CM000678.1:g.68863691del, NC_000016.8:g.67421192del, NG_008021.1:g.97497del, LRG_301:g.97497del, ENST00000261769.10:c.2430del, ENST00000261769.9:c.2430del, ENST00000422392.6:c.2247del, ENST00000562118.1:n.648del, ENST00000562836.5:n.2501del, ENST00000566510.5:c.*1096del, ENST00000566612.5:c.*670del, ENST00000611625.4:c.2493del, ENST00000612417.4:c.1853+3234del, ENST00000621016.4:c.1866-4415del, NM_004360.3:c.2430del, LRG_301t1:c.2430del, XM_011523488.1:c.1695del, XM_011523489.1:c.1695del, NM_001317184.1:c.2247del, NM_001317185.1:c.882del, NM_001317186.1:c.465del, NM_004360.4:c.2430del, NM_004360.5:c.2430del, NM_001317184.2:c.2247del, NM_001317185.2:c.882del, NM_001317186.2:c.465del, NM_004360.5(CDH1):c.2430del (p.Phe810fs), NM_004360.4(CDH1):c.2430delT (p.Phe810Leufs)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS4, PVS1_Strong	BP5, BP7, BS1, BS4, BS3, PM6, PM3, PM5, PM4, PM1, BS2, PP1, PP4, PP3, PP2, BP2, BP4, BP1, BP3, BA1, PS2, PS1, PS3	The c.2430delT (p.Phe810Leufs*6) variant is predicted to result in a premature stop codon that leads to a truncated protein. However, it is located within the nonsense mediated decay resistance region upstream of c.2506G>T (p.Glu836*) (PVS1_Strong). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID 26182300, SCV000261293.4, SCV000218032.4). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PM2_Supporting, PS4.	26182300, 26182300	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	false	https://erepo.genome.network/evrepo/ui/classification/CA197715/MONDO:0007648/007	9eee2198-3726-4f14-81e7-c8c62c01506a
NM_004360.4(CDH1):c.286A>G (p.Ile96Val)	220611	CA349520	NM_004360.4:c.286A>G, NC_000016.10:g.68801792A>G, CM000678.2:g.68801792A>G, NC_000016.9:g.68835695A>G, CM000678.1:g.68835695A>G, NC_000016.8:g.67393196A>G, NG_008021.1:g.69501A>G, LRG_301:g.69501A>G, ENST00000261769.10:c.286A>G, ENST00000261769.9:c.286A>G, ENST00000422392.6:c.286A>G, ENST00000561751.1:n.53A>G, ENST00000562836.5:n.357A>G, ENST00000564676.5:n.568A>G, ENST00000564745.1:n.281A>G, ENST00000566510.5:c.286A>G, ENST00000566612.5:c.286A>G, ENST00000611625.4:c.286A>G, ENST00000612417.4:c.286A>G, ENST00000621016.4:c.286A>G, NM_004360.3:c.286A>G, LRG_301t1:c.286A>G, XM_011523488.1:c.-450A>G, XM_011523489.1:c.-450A>G, NM_001317184.1:c.286A>G, NM_001317185.1:c.-1330A>G, NM_001317186.1:c.-1534A>G, NM_004360.5:c.286A>G, NM_001317184.2:c.286A>G, NM_001317185.2:c.-1330A>G, NM_001317186.2:c.-1534A>G, NM_004360.5(CDH1):c.286A>G (p.Ile96Val), NM_004360.4(CDH1):c.286A>G (p.Ile96Val)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS1, BS2	BP5, BP7, BS3, BS4, PM2, PM6, PVS1, PM5, PM3, PM1, PM4, PP3, PP2, PP1, PP4, BP4, BP1, BP2, BP3, BA1, PS1, PS3, PS4, PS2	The c.286A>G (p.Ile96Val) variant has an allele frequency of 0.00122 (0.12%, 41/33,578 alleles) in the Latino subpopulation of the gnomAD cohort (BS1). This variant has also been observed in >10 without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.	26182300	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	false	https://erepo.genome.network/evrepo/ui/classification/CA349520/MONDO:0007648/007	d9039763-3145-4298-b468-da3967101df3
NM_004360.4(CDH1):c.1008G>T (p.Glu336Asp)	18453	CA280990	NM_004360.4:c.1008G>T, NC_000016.10:g.68811859G>T, CM000678.2:g.68811859G>T, NC_000016.9:g.68845762G>T, CM000678.1:g.68845762G>T, NC_000016.8:g.67403263G>T, NG_008021.1:g.79568G>T, LRG_301:g.79568G>T, ENST00000261769.10:c.1008G>T, ENST00000261769.9:c.1008G>T, ENST00000422392.6:c.1008G>T, ENST00000561751.1:c.630G>T, ENST00000562836.5:n.1079G>T, ENST00000566510.5:c.852G>T, ENST00000566612.5:c.1008G>T, ENST00000611625.4:c.1008G>T, ENST00000612417.4:c.1008G>T, ENST00000621016.4:c.1008G>T, NM_004360.3:c.1008G>T, LRG_301t1:c.1008G>T, XM_011523488.1:c.273G>T, XM_011523489.1:c.273G>T, NM_001317184.1:c.1008G>T, NM_001317185.1:c.-608G>T, NM_001317186.1:c.-812G>T, NM_004360.5:c.1008G>T, NM_001317184.2:c.1008G>T, NM_001317185.2:c.-608G>T, NM_001317186.2:c.-812G>T, NM_004360.4(CDH1):c.1008G>T (p.Glu336Asp)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0100488	Autosomal dominant inheritance	Likely Pathogenic	PM2_Supporting, PS3, PS4_Moderate, PVS1_Moderate	BP7, BP5, BS1, BS3, BS4, PM1, PM5, PM4, PM3, PM6, BS2, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BP2, BA1, PS1, PS2	The c.1008G>T (p.Glu336Asp) variant results in a G to non-G change at the last nucleotide of an exon (PVS1_Moderate). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). There is an RNA assay demonstrating an abnormal out-of-frame transcript for this variant (PS3; PMID: 9537325). Additionally, the variant has also been reported in at least two families meeting HDGC clinical criteria (PS4_Moderate; PMID: 9537325 and internal laboratory data). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Moderate, PM2_Supporting, PS3, PS4_Moderate.	9537325	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2024-11-25	2024-12-17	false	https://erepo.genome.network/evrepo/ui/classification/CA280990/MONDO:0100488/007	f17d1590-599b-49d7-a1e0-273ed56fef12
NM_004360.4(CDH1):c.1162G>A (p.Glu388Lys)	127906	CA157986	NM_004360.4:c.1162G>A, NC_000016.10:g.68813337G>A, CM000678.2:g.68813337G>A, NC_000016.9:g.68847240G>A, CM000678.1:g.68847240G>A, NC_000016.8:g.67404741G>A, NG_008021.1:g.81046G>A, LRG_301:g.81046G>A, ENST00000261769.10:c.1162G>A, ENST00000261769.9:c.1162G>A, ENST00000422392.6:c.1137+1074G>A, ENST00000562836.5:n.1233G>A, ENST00000565810.1:n.206G>A, ENST00000566510.5:c.1006G>A, ENST00000566612.5:c.1162G>A, ENST00000611625.4:c.1162G>A, ENST00000612417.4:c.1162G>A, ENST00000621016.4:c.1162G>A, NM_004360.3:c.1162G>A, LRG_301t1:c.1162G>A, XM_011523488.1:c.427G>A, XM_011523489.1:c.427G>A, NM_001317184.1:c.1137+1074G>A, NM_001317185.1:c.-454G>A, NM_001317186.1:c.-658G>A, NM_004360.5:c.1162G>A, NM_001317184.2:c.1137+1074G>A, NM_001317185.2:c.-454G>A, NM_001317186.2:c.-658G>A, NM_004360.5(CDH1):c.1162G>A (p.Glu388Lys), NM_004360.4(CDH1):c.1162G>A (p.Glu388Lys)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2_Strong	BP7, BP5, BS1, BS3, BS4, PM2, PM6, PVS1, PM5, PM4, PM1, PM3, PP3, PP2, PP1, PP4, BP4, BP1, BP3, BA1, PS1, PS3, PS4, PS2	The c.1162G>A (p.Glu388Lys) variant was observed in the homozygous state in an individual without a personal and/or family history of diffuse gastric cancer, lobular breast cancer (BP2_Strong; SCV000254804.3). The variant has also been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BP2_Strong, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	false	https://erepo.genome.network/evrepo/ui/classification/CA157986/MONDO:0007648/007	5c24cb6c-a751-4e76-83ab-baccc23c4caa
NM_004360.4(CDH1):c.2635G>A (p.Gly879Ser)	127928	CA288064	NM_004360.4:c.2635G>A, NC_000016.10:g.68833485G>A, CM000678.2:g.68833485G>A, NC_000016.9:g.68867388G>A, CM000678.1:g.68867388G>A, NC_000016.8:g.67424889G>A, NG_008021.1:g.101194G>A, LRG_301:g.101194G>A, ENST00000261769.10:c.2635G>A, ENST00000261769.9:c.2635G>A, ENST00000422392.6:c.2452G>A, ENST00000562118.1:n.853G>A, ENST00000562836.5:n.2706G>A, ENST00000566510.5:c.*1301G>A, ENST00000566612.5:c.*875G>A, ENST00000611625.4:c.2698G>A, ENST00000612417.4:c.1854-706G>A, ENST00000621016.4:c.1866-718G>A, NM_004360.3:c.2635G>A, LRG_301t1:c.2635G>A, XM_011523488.1:c.1900G>A, XM_011523489.1:c.1900G>A, NM_001317184.1:c.2452G>A, NM_001317185.1:c.1087G>A, NM_001317186.1:c.670G>A, NM_004360.5:c.2635G>A, NM_001317184.2:c.2452G>A, NM_001317185.2:c.1087G>A, NM_001317186.2:c.670G>A, NM_004360.5(CDH1):c.2635G>A (p.Gly879Ser), NM_004360.4(CDH1):c.2635G>A (p.Gly879Ser)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Benign	BS2	BP5, BP7, BS1, BS3, BS4, PM5, PM1, PM3, PM4, PM2, PM6, PVS1, PP3, PP2, PP1, PP4, BP4, BP1, BP2, BP3, BA1, PS1, PS3, PS4, PS2	The c.2635G>A (p.Gly879Ser) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is classified as likely benign based on BS2 alone. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-17	2023-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA288064/MONDO:0007648/007	86a85614-4966-4b5e-9e92-5bcb810ab482
NM_004360.4(CDH1):c.2195G>A (p.Arg732Gln)	406663	CA16615410	NM_004360.4:c.2195G>A, NC_000016.10:g.68828204G>A, CM000678.2:g.68828204G>A, NC_000016.9:g.68862107G>A, CM000678.1:g.68862107G>A, NC_000016.8:g.67419608G>A, NG_008021.1:g.95913G>A, LRG_301:g.95913G>A, ENST00000261769.10:c.2195G>A, ENST00000261769.9:c.2195G>A, ENST00000422392.6:c.2012G>A, ENST00000562118.1:n.413G>A, ENST00000562836.5:n.2266G>A, ENST00000566510.5:c.*861G>A, ENST00000566612.5:c.*435G>A, ENST00000611625.4:c.2258G>A, ENST00000612417.4:c.1853+1650G>A, ENST00000621016.4:c.1866-5999G>A, NM_004360.3:c.2195G>A, LRG_301t1:c.2195G>A, XM_011523488.1:c.1460G>A, XM_011523489.1:c.1460G>A, NM_001317184.1:c.2012G>A, NM_001317185.1:c.647G>A, NM_001317186.1:c.230G>A, NM_004360.5:c.2195G>A, NM_001317184.2:c.2012G>A, NM_001317185.2:c.647G>A, NM_001317186.2:c.230G>A, NM_004360.5(CDH1):c.2195G>A (p.Arg732Gln), NM_004360.4(CDH1):c.2195G>A (p.Arg732Gln)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS3, PS4	BP7, BP5, BS1, BS3, BS4, PM5, PM1, PM3, PM4, PVS1, PM6, BS2, PP3, PP2, PP1, PP4, BP4, BP1, BP2, BP3, BA1, PS1, PS2	The c.2195G>A variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). There is an RNA assay demonstrating an abnormal out-of-frame transcript for this variant (PS3; PMID: 17545690 15235021). This variant has also been reported in at least 12 families with HDGC criteria (PS4; PMID: 17545690 15235021 and laboratory internal data). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting, PS3, PS4.	26580448, 17545690, 17545690, 15235021, 17545690, 17545690, 17545690, 15235021, 17545690, 26580448, 15235021, 17545690	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-11-27	2023-12-22	false	https://erepo.genome.network/evrepo/ui/classification/CA16615410/MONDO:0007648/007	0b968ecb-5432-4588-a812-7dd328f2b93d
NM_000257.3(MYH7):c.2678C>T (p.Ala893Val)	177763	CA012811	NM_000257.3:c.2678C>T, ENST00000355349.4:c.2678C>T, ENST00000355349.3:c.2678C>T, XR_245686.3:n.2784C>T, XM_017021340.1:c.2678C>T, NM_000257.4:c.2678C>T, NC_000014.9:g.23424770G>A, CM000676.2:g.23424770G>A, NC_000014.8:g.23893979G>A, CM000676.1:g.23893979G>A, NC_000014.7:g.22963819G>A, NG_007884.1:g.15892C>T, LRG_384:g.15892C>T, NM_000257.3(MYH7):c.2678C>T (p.Ala893Val)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Uncertain Significance	PM2, PS4_Supporting, PP1_Moderate	PM1, PM5, PP3, PS3, BS4, BS3, PS1, BP4	The NM_000257.4(MYH7):c.2678C>T (p.Ala893Val) variant in MYH7 has been reported in 4 individuals with DCM (PS4_Supporting; Lakdawala 2012 PMID:22464770; Miller 2013 PMID:23054336; LMM pers. comm.). This variant segregated with disease in 5 affected individuals with DCM in 2 families (PP1_Moderate; Lakdawala 2012 PMID:22464770; LMM pers. comm.); however, in one of these families the variant was absent from a set of identical twins with mild LV dysfunction prior to testing at 4 months of age and additional clinical data was not available. This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and while missense variants in this region are statistically more likely to be associated with HCM (Walsh 2017 PMID:27532257), location in this region cannot be used to support pathogenicity for other phenotypes; therefore PM1 is not applicable. In addition, computational prediction tools and conservation analysis were mixed about the potential impact of this variant. In summary, due to insufficient and conflicting evidence, this variant is classified as uncertain significance for dilated cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_Supporting; PM5_Moderate, PM2.		Cardiomyopathy VCEP		2021-09-22	2021-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA012811/MONDO:0005021/002	1db3f365-c635-4541-82da-6d48c06d14e6
NM_000314.6(PTEN):c.209T>C (p.Leu70Pro)	7826	CA000350	NM_000314.6:c.209T>C, NC_000010.11:g.87925557T>C, CM000672.2:g.87925557T>C, NC_000010.10:g.89685314T>C, CM000672.1:g.89685314T>C, NC_000010.9:g.89675294T>C, NG_007466.2:g.67119T>C, LRG_311:g.67119T>C, ENST00000686459.1:c.209T>C, ENST00000688158.1:c.*320T>C, ENST00000688308.1:c.209T>C, ENST00000688922.1:n.78T>C, ENST00000693560.1:c.728T>C, ENST00000371953.8:c.209T>C, ENST00000371953.7:c.209T>C, ENST00000498703.1:n.35T>C, ENST00000610634.1:c.107T>C, NM_000314.5:c.209T>C, NM_001304717.2:c.728T>C, NM_001304718.1:c.-541-5489T>C, XM_006717926.2:c.165-5489T>C, XM_011539981.1:c.209T>C, XM_011539982.1:c.113T>C, XR_945789.1:n.921T>C, XR_945790.1:n.921T>C, XR_945791.1:n.921T>C, NM_000314.7:c.209T>C, NM_001304717.5:c.728T>C, NM_001304718.2:c.-541-5489T>C, NM_000314.8:c.209T>C, NM_000314.8(PTEN):c.209T>C (p.Leu70Pro), NM_000314.6(PTEN):c.209T>C (p.Leu70Pro)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2, PP2, PS4_Supporting, PS3	BP7, BP5, BS1, BS3, BS4, PVS1, PM6, PP3, PP4, PP1, BS2, PM5, PM4, PM1, PM3, BA1, BP4, BP1, BP3, BP2, PS1, PS2	PTEN c.209T>C (p.Leu70Pro) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (internal laboratory contributor(s) ClinVar Organization ID: 26957)		PTEN VCEP		2021-06-04	2022-09-30	false	https://erepo.genome.network/evrepo/ui/classification/CA000350/MONDO:0017623/003	12985d15-e1e7-45ab-b3e5-48e082086d4d
NM_000314.6(PTEN):c.170T>G (p.Leu57Trp)	185713	CA000131	NM_000314.6:c.170T>G, NC_000010.11:g.87925518T>G, CM000672.2:g.87925518T>G, NC_000010.10:g.89685275T>G, CM000672.1:g.89685275T>G, NC_000010.9:g.89675255T>G, NG_007466.2:g.67080T>G, LRG_311:g.67080T>G, ENST00000700029.2:c.170T>G, ENST00000710265.1:c.170T>G, ENST00000472832.3:c.170T>G, ENST00000688158.2:n.905T>G, ENST00000688922.2:c.170T>G, ENST00000700021.1:c.165-5528T>G, ENST00000700022.1:c.170T>G, ENST00000700029.1:c.4T>G, ENST00000706954.1:c.170T>G, ENST00000706955.1:c.*205T>G, ENST00000686459.1:c.170T>G, ENST00000688158.1:c.*281T>G, ENST00000688308.1:c.170T>G, ENST00000688922.1:c.39T>G, ENST00000693560.1:c.689T>G, ENST00000371953.8:c.170T>G, ENST00000371953.7:c.170T>G, ENST00000610634.1:c.68T>G, NM_000314.5:c.170T>G, NM_001304717.2:c.689T>G, NM_001304718.1:c.-541-5528T>G, XM_006717926.2:c.165-5528T>G, XM_011539981.1:c.170T>G, XM_011539982.1:c.74T>G, XR_945789.1:n.882T>G, XR_945790.1:n.882T>G, XR_945791.1:n.882T>G, NM_000314.7:c.170T>G, NM_001304717.5:c.689T>G, NM_001304718.2:c.-541-5528T>G, NM_000314.8:c.170T>G, NM_000314.6(PTEN):c.170T>G (p.Leu57Trp)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PP3, PP2, PS3_Moderate, PM2_Supporting	PM6, PVS1, BP7, BP5, BS1, BS3, BS4, BS2, PP1, PP4, PM5, PM4, PM1, PM3, BP4, BP1, BP3, BP2, BA1, PS1, PS4, PS2	PTEN c.170T>G (p.Leu57Trp) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 9256433, 29706350)PM2: Absent in large sequenced populationsPP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	29785012, 29706350	PTEN VCEP		2025-08-01	2025-10-08	false	https://erepo.genome.network/evrepo/ui/classification/CA000131/MONDO:0017623/003	d0edcf69-04fa-4771-afb0-a49f8aab9ead
NM_000314.6(PTEN):c.761_765delAAGTA (p.Lys254Argfs)	7830	CA000566	NM_000314.6:c.761_765delAAGTA, NC_000010.11:g.87957978_87957982del, CM000672.2:g.87957978_87957982del, NC_000010.10:g.89717735_89717739del, CM000672.1:g.89717735_89717739del, NC_000010.9:g.89707715_89707719del, NG_007466.2:g.99540_99544del, LRG_311:g.99540_99544del, ENST00000371953.8:c.760_764del, ENST00000371953.7:c.760_764del, ENST00000472832.2:n.187_191del, NM_000314.5:c.760_764del, NM_000314.6:c.760_764del, NM_001304717.2:c.1279_1283del, NM_001304718.1:c.169_173del, XM_006717926.2:c.715_719del, XM_011539981.1:c.760_764del, XM_011539982.1:c.664_668del, NM_000314.7:c.760_764del, NM_001304717.5:c.1279_1283del, NM_001304718.2:c.169_173del, NM_000314.8:c.760_764del, NM_000314.6(PTEN):c.761_765delAAGTA (p.Lys254Argfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1, PM2	PM6, BP5, BS1, BS3, BS4, PP3, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	PTEN c.761_765delAAGTA (p.K254Rfs) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).		PTEN VCEP		2018-04-06	2021-04-29	true	https://erepo.genome.network/evrepo/ui/classification/CA000566/MONDO:0017623/003	3530100c-d75d-44ae-8775-47e7f7f5978c
NM_000314.8(PTEN):c.564T>A (p.Tyr188Ter)	7831	CA000521	NM_000314.8:c.564T>A, NC_000010.11:g.87952189T>A, CM000672.2:g.87952189T>A, NC_000010.10:g.89711946T>A, CM000672.1:g.89711946T>A, NC_000010.9:g.89701926T>A, NG_007466.2:g.93751T>A, LRG_311:g.93751T>A, ENST00000700029.2:c.564T>A, ENST00000710265.1:c.564T>A, ENST00000472832.3:c.564T>A, ENST00000688158.2:n.1299T>A, ENST00000688922.2:c.*394T>A, ENST00000700021.1:c.519T>A, ENST00000700022.1:c.493-5664T>A, ENST00000700023.1:n.1722T>A, ENST00000700024.1:n.1956T>A, ENST00000700025.1:n.1333T>A, ENST00000700029.1:c.398T>A, ENST00000706954.1:c.564T>A, ENST00000706955.1:c.*599T>A, ENST00000686459.1:c.*150T>A, ENST00000688158.1:c.*675T>A, ENST00000688308.1:c.564T>A, ENST00000688922.1:c.485T>A, ENST00000693560.1:c.1083T>A, ENST00000371953.8:c.564T>A, ENST00000371953.7:c.564T>A, NM_000314.5:c.564T>A, NM_000314.6:c.564T>A, NM_001304717.2:c.1083T>A, NM_001304718.1:c.-28T>A, XM_006717926.2:c.519T>A, XM_011539981.1:c.564T>A, XM_011539982.1:c.468T>A, XR_945791.1:n.1205-5664T>A, NM_000314.7:c.564T>A, NM_001304717.5:c.1083T>A, NM_001304718.2:c.-28T>A, NM_000314.8(PTEN):c.564T>A (p.Tyr188Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1, PM2_Supporting	PM6, BP7, BP5, BS1, BS3, BS4, BS2, PP3, PP2, PP1, PP4, PM4, PM1, PM3, PM5, BP4, BP1, BP3, BP2, BA1, PS3, PS4, PS2, PS1	PTEN c.564T>A (p.Y188X) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria v3 (PMID 30311380). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4). PM2_P: Absent in gnomad v4.		PTEN VCEP		2025-10-03	2025-10-08	false	https://erepo.genome.network/evrepo/ui/classification/CA000521/MONDO:0017623/003	3026a8af-72dd-459e-be90-922c578fc8f6
NM_000314.6(PTEN):c.766G>T (p.Glu256Ter)	7828	CA000569	NM_000314.6:c.766G>T, NM_000314.5:c.766G>T, NM_001304717.2:c.1285G>T, NM_001304718.1:c.175G>T, XM_006717926.2:c.721G>T, XM_011539981.1:c.766G>T, XM_011539982.1:c.670G>T, XR_945791.1:n.1336G>T, NM_000314.7:c.766G>T, NM_001304717.5:c.1285G>T, NM_001304718.2:c.175G>T, ENST00000371953.7:c.766G>T, ENST00000472832.2:n.193G>T, NC_000010.11:g.87957984G>T, CM000672.2:g.87957984G>T, NC_000010.10:g.89717741G>T, CM000672.1:g.89717741G>T, NC_000010.9:g.89707721G>T, NG_007466.2:g.99546G>T, LRG_311:g.99546G>T, NM_000314.6(PTEN):c.766G>T (p.Glu256Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM6, PVS1, PM2, PS4_Supporting	BP5, BP7, BS4, BS3, BS1, PP4, PP1, PP2, PP3, BS2, PM1, PM4, PM5, BP2, BP4, BA1, PS2, PS3, PS1	PTEN c.766G>T (p.E256X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 9832032)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 9832032)	9832032	PTEN VCEP		2018-04-06	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000569/MONDO:0017623/003	4284ff17-816f-4321-a0b3-e3baeb0afc95
NM_000314.6(PTEN):c.586delC (p.His196Thrfs)	7823	CA000526	NM_000314.6:c.586delC, NC_000010.11:g.87952211del, CM000672.2:g.87952211del, NC_000010.10:g.89711968del, CM000672.1:g.89711968del, NC_000010.9:g.89701948del, NG_007466.2:g.93773del, LRG_311:g.93773del, NM_000314.5:c.586del, NM_000314.6:c.586del, NM_001304717.2:c.1105del, NM_001304718.1:c.-6del, XM_006717926.2:c.541del, XM_011539981.1:c.586del, XM_011539982.1:c.490del, XR_945791.1:n.1205-5642del, NM_000314.7:c.586del, NM_001304717.5:c.1105del, NM_001304718.2:c.-6del, ENST00000371953.7:c.586del, ENST00000472832.2:n.13del, NM_000314.6(PTEN):c.586delC (p.His196Thrfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1, PM2, PS4_Supporting	PM6, BP5, BP7, BS4, BS3, BS1, PP4, PP1, PP2, PP3, BS2, PM1, PM4, PM5, BA1, BP2, BP4, PS2, PS3, PS1	PTEN c.586delC (p.H196Tfs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 9832032)	9832032	PTEN VCEP		2018-04-06	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000526/MONDO:0017623/003	47291ab6-b17d-4e14-9acd-faae6fe9ec1e
NM_000314.8(PTEN):c.500C>A (p.Thr167Asn)	39668	CA000487	NM_000314.8:c.500C>A, NC_000010.11:g.87952125C>A, CM000672.2:g.87952125C>A, NC_000010.10:g.89711882C>A, CM000672.1:g.89711882C>A, NC_000010.9:g.89701862C>A, NG_007466.2:g.93687C>A, LRG_311:g.93687C>A, ENST00000686459.1:c.*86C>A, ENST00000688158.1:c.*611C>A, ENST00000688308.1:c.500C>A, ENST00000688922.1:c.421C>A, ENST00000693560.1:c.1019C>A, ENST00000371953.8:c.500C>A, ENST00000371953.7:c.500C>A, NM_000314.5:c.500C>A, NM_000314.6:c.500C>A, NM_001304717.2:c.1019C>A, NM_001304718.1:c.-92C>A, XM_006717926.2:c.455C>A, XM_011539981.1:c.500C>A, XM_011539982.1:c.404C>A, XR_945789.1:n.1371C>A, XR_945790.1:n.1488C>A, XR_945791.1:n.1205-5728C>A, NM_000314.7:c.500C>A, NM_001304717.5:c.1019C>A, NM_001304718.2:c.-92C>A, NM_000314.8(PTEN):c.500C>A (p.Thr167Asn)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM6, PP3, PP2, PM1, PM2_Supporting	PVS1, BP7, BP5, BS1, BS3, BS4, PP1, PP4, BS2, PM5, PM4, PM3, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS2, PS4	PTEN c.500C>A (p.Thr167Asn) variant meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2_Supporting: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID:23160955)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PP3: REVEL score > 0.7 (score=0.751).	23160955, 28250423, 23160955, 28250423, 23160955	PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000487/MONDO:0017623/003	73986d71-3b36-4038-80e9-66da44231b6f
NM_000314.6(PTEN):c.79+20C>G	140807	CA000575	NM_000314.6:c.79+20C>G, NC_000010.11:g.87864568C>G, CM000672.2:g.87864568C>G, NC_000010.10:g.89624325C>G, CM000672.1:g.89624325C>G, NC_000010.9:g.89614305C>G, NG_007466.2:g.6130C>G, LRG_311:g.6130C>G, NG_033079.1:g.3870G>C, ENST00000686459.1:c.79+20C>G, ENST00000688158.1:c.79+20C>G, ENST00000688308.1:c.79+20C>G, ENST00000693560.1:c.598+20C>G, ENST00000371953.8:c.79+20C>G, ENST00000371953.7:c.79+20C>G, ENST00000462694.1:n.81+20C>G, ENST00000487939.1:n.100+20C>G, ENST00000610634.1:c.-24+20C>G, ENST00000618586.1:n.68C>G, NM_000314.5:c.79+20C>G, NM_001304717.2:c.598+20C>G, NM_001304718.1:c.-627+20C>G, XM_006717926.2:c.79+20C>G, XM_011539981.1:c.79+20C>G, XR_945789.1:n.791+20C>G, XR_945790.1:n.791+20C>G, XR_945791.1:n.791+20C>G, NM_000314.7:c.79+20C>G, NM_001304717.5:c.598+20C>G, NM_001304718.2:c.-627+20C>G, NM_000314.8:c.79+20C>G, NM_000314.8(PTEN):c.79+20C>G, NM_000314.6(PTEN):c.79+20C>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	BP7, PM2_Supporting	PVS1, PM6, BP5, BS1, BS3, BS4, PP3, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	PTEN c.79+20C>G (IVS1+20C>G) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2_Supporting: Absent in large sequenced populations (PMID 27535533).BP7: Variant is intronic and at or beyond +7/-21, nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP		2023-08-04	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000575/MONDO:0017623/003	58d4d344-a1e3-409c-b952-bcb231e15d01
NM_000314.6(PTEN):c.331T>C (p.Trp111Arg)	92820	CA000401	NM_000314.6:c.331T>C, NC_000010.11:g.87933090T>C, CM000672.2:g.87933090T>C, NC_000010.10:g.89692847T>C, CM000672.1:g.89692847T>C, NC_000010.9:g.89682827T>C, NG_007466.2:g.74652T>C, LRG_311:g.74652T>C, ENST00000686459.1:c.331T>C, ENST00000688158.1:c.*442T>C, ENST00000688308.1:c.331T>C, ENST00000688922.1:n.252T>C, ENST00000693560.1:c.850T>C, ENST00000371953.8:c.331T>C, ENST00000371953.7:c.331T>C, ENST00000498703.1:n.157T>C, ENST00000610634.1:c.229T>C, NM_000314.5:c.331T>C, NM_001304717.2:c.850T>C, NM_001304718.1:c.-420T>C, XM_006717926.2:c.286T>C, XM_011539981.1:c.331T>C, XM_011539982.1:c.235T>C, XR_945789.1:n.1043T>C, XR_945790.1:n.1043T>C, XR_945791.1:n.1043T>C, NM_000314.7:c.331T>C, NM_001304717.5:c.850T>C, NM_001304718.2:c.-420T>C, NM_000314.8:c.331T>C, NM_000314.8(PTEN):c.331T>C (p.Trp111Arg), NM_000314.6(PTEN):c.331T>C (p.Trp111Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2, PP2, PS3, PS4_Moderate	BP7, BP5, BS1, BS3, BS4, PM6, PVS1, PP3, PP1, PP4, BS2, PM4, PM1, PM3, PM5, BA1, BP4, BP1, BP3, BP2, PS2, PS1	PTEN c.331T>C (p.Trp111Arg) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29785012, 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PS4_M: Probands with phenotype specificity score of 2-3.5. (internal laboratory contributor(s) ClinVar Organization ID: 61756, ClinVar Organization ID: 19864)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	11476841, 29785012, 29706350	PTEN VCEP		2021-06-04	2022-09-30	false	https://erepo.genome.network/evrepo/ui/classification/CA000401/MONDO:0017623/003	59486401-1daa-48dc-813f-bde6605d8cfd
NM_000314.6(PTEN):c.392C>T (p.Thr131Ile)	39669	CA000442	NM_000314.6:c.392C>T, NM_000314.5:c.392C>T, NM_001304717.2:c.911C>T, NM_001304718.1:c.-359C>T, XM_006717926.2:c.347C>T, XM_011539981.1:c.392C>T, XM_011539982.1:c.296C>T, XR_945789.1:n.1104C>T, XR_945790.1:n.1104C>T, XR_945791.1:n.1104C>T, NM_000314.7:c.392C>T, NM_001304717.5:c.911C>T, NM_001304718.2:c.-359C>T, ENST00000371953.7:c.392C>T, ENST00000498703.1:n.218C>T, ENST00000610634.1:c.290C>T, NC_000010.11:g.87933151C>T, CM000672.2:g.87933151C>T, NC_000010.10:g.89692908C>T, CM000672.1:g.89692908C>T, NC_000010.9:g.89682888C>T, NG_007466.2:g.74713C>T, LRG_311:g.74713C>T, NM_000314.6(PTEN):c.392C>T (p.Thr131Ile)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PM6_Strong, PS3, PS4_Moderate	PVS1, BP5, BP7, BS4, BS3, BS1, PP1, PP4, PP3, BS2, PM1, PM4, PM5, BP2, BP4, BA1, PS2, PS1	PTEN c.392C>T (p.Thr131Ile) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 21828076)PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (PMID 23160955, 23335809 author communication)PM2: Absent in large sequenced populations (PMID 27535533).PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 23160955, 23335809)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	23335809, 23160955, 23335809, 28250423, 29785012, 21828076, 29706350, 23160955, 23335809, 28250423, 23160955, 23335809	PTEN VCEP		2018-11-28	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000442/MONDO:0017623/003	78613fd1-ded6-4249-b54d-0894617cf17d
NM_000314.8(PTEN):c.270dup (p.Glu91Ter)	428271	CA645369474	NM_000314.8:c.270dup, NC_000010.11:g.87933029dup, CM000672.2:g.87933029dup, NC_000010.10:g.89692786dup, CM000672.1:g.89692786dup, NC_000010.9:g.89682766dup, NG_007466.2:g.74591dup, LRG_311:g.74591dup, ENST00000686459.1:c.270dup, ENST00000688158.1:c.*381dup, ENST00000688308.1:c.270dup, ENST00000688922.1:c.191dup, ENST00000693560.1:c.789dup, ENST00000371953.8:c.270dup, ENST00000371953.7:c.270dup, ENST00000498703.1:n.96dup, ENST00000610634.1:c.168dup, NM_000314.5:c.270dup, NM_000314.6:c.270dup, NM_001304717.2:c.789dup, NM_001304718.1:c.-481dup, XM_006717926.2:c.225dup, XM_011539981.1:c.270dup, XM_011539982.1:c.174dup, XR_945789.1:n.982dup, XR_945790.1:n.982dup, XR_945791.1:n.982dup, NM_000314.7:c.270dup, NM_001304717.5:c.789dup, NM_001304718.2:c.-481dup, NM_000314.8(PTEN):c.270dup (p.Glu91Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1, PM2_Supporting	PM6, BP7, BP5, BS1, BS3, BS4, PP3, PP2, PP1, PP4, BS2, PM4, PM1, PM3, PM5, BP4, BP1, BP3, BP2, BA1, PS3, PS4, PS2, PS1	NM_000314.8(PTEN):c.270dup (p.Glu91Ter) variant meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.8). PM2_P: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort (PMID:27535533).		PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA645369474/MONDO:0017623/003	a3be49ba-5c93-4f8f-a2a8-e7d30a583ad9
NM_000314.6(PTEN):c.884_900del17insG (p.Leu295Argfs)	428274	CA645369469	NM_000314.6:c.884_900del17insG, NC_000010.11:g.87960976_87960992delinsG, CM000672.2:g.87960976_87960992delinsG, NC_000010.10:g.89720733_89720749delinsG, CM000672.1:g.89720733_89720749delinsG, NC_000010.9:g.89710713_89710729delinsG, NG_007466.2:g.102538_102554delinsG, LRG_311:g.102538_102554delinsG, ENST00000686459.1:c.*470_*486delinsG, ENST00000688158.1:c.*995_*1011delinsG, ENST00000688308.1:c.884_900delinsG, ENST00000688922.1:c.805_821delinsG, ENST00000693560.1:c.1403_1419delinsG, ENST00000371953.8:c.884_900delinsG, ENST00000371953.7:c.884_900delinsG, ENST00000472832.2:c.311_327delinsG, NM_000314.5:c.884_900delinsG, NM_000314.6:c.884_900delinsG, NM_001304717.2:c.1403_1419delinsG, NM_001304718.1:c.293_309delinsG, XM_006717926.2:c.839_855delinsG, XM_011539981.1:c.884_900delinsG, XM_011539982.1:c.788_804delinsG, XR_945791.1:n.1454_1470delinsG, NM_000314.7:c.884_900delinsG, NM_001304717.5:c.1403_1419delinsG, NM_001304718.2:c.293_309delinsG, NM_000314.8:c.884_900delinsG, NM_000314.8(PTEN):c.884_900delinsG (p.Leu295fs), NM_000314.6(PTEN):c.884_900del17insG (p.Leu295Argfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1, PM2_Supporting	PM6, BP7, BS1, BS3, BS4, PP3, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	NM_000314.8(PTEN):c.884_900delinsG (p.Leu295ArgfsTer7) variant meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.8). PM2_P: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort (PMID:27535533).		PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA645369469/MONDO:0017623/003	f8132715-4506-41cb-a82b-d722fa440f3d
NM_000314.6(PTEN):c.-1084C>T	127660	CA151479	NM_000314.6:c.-1084C>T, NC_000010.11:g.87863385C>T, CM000672.2:g.87863385C>T, NC_000010.10:g.89623142C>T, CM000672.1:g.89623142C>T, NC_000010.9:g.89613122C>T, NG_007466.2:g.4948C>T, LRG_311:g.4948C>T, NG_033079.1:g.5053G>A, NM_001126049.1:c.-898G>A, ENST00000371953.7:c.-1085C>T, ENST00000445946.3:c.-898G>A, NM_000314.6(PTEN):c.-1084C>T	KLLN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS2_Supporting, BS1, BP2	PVS1, PM6, PM2, BP5, BP7, BS3, BS4, PP4, PP1, PP2, PP3, PM1, PM4, PM5, BA1, BP4, PS2, PS3, PS4, PS1	PTEN c.-1084C>T (NC_000010.10:g.89623142C>T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0025 (0.25%, 38/14,966 alleles) in the European subpopulation of the gnomAD cohort. (PMID 27535533)BP2: At least three observations in cis and/or phase unknown with different pathogenic/likely pathogenic PTEN variants. (internal laboratory contributor(s) SCV000149464.4)BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (PMID 27884173, internal laboratory contributor(s) SCV000149464.4, SCV000185343.1)	27884173	PTEN VCEP		2018-11-28	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA151479/MONDO:0017623/003	e2f7ef05-08bd-4ef3-ace7-9e1121c35952
NM_000314.8(PTEN):c.1061C>A (p.Pro354Gln)	143020	CA000275	NM_000314.8:c.1061C>A, NC_000010.11:g.87965321C>A, CM000672.2:g.87965321C>A, NC_000010.10:g.89725078C>A, CM000672.1:g.89725078C>A, NC_000010.9:g.89715058C>A, NG_007466.2:g.106883C>A, LRG_311:g.106883C>A, ENST00000686459.1:c.*647C>A, ENST00000688158.1:c.*1172C>A, ENST00000688308.1:c.1061C>A, ENST00000688922.1:c.982C>A, ENST00000693560.1:c.1580C>A, ENST00000371953.8:c.1061C>A, ENST00000371953.7:c.1061C>A, NM_000314.5:c.1061C>A, NM_000314.6:c.1061C>A, NM_001304717.2:c.1580C>A, NM_001304718.1:c.470C>A, XM_006717926.2:c.1016C>A, XM_011539982.1:c.965C>A, XR_945791.1:n.1631C>A, NM_000314.7:c.1061C>A, NM_001304717.5:c.1580C>A, NM_001304718.2:c.470C>A, NM_000314.8(PTEN):c.1061C>A (p.Pro354Gln)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS1, PP2, BS3_Supporting, BP4	PVS1, PM2, PM6, BP7, BP5, BS4, PP3, PP1, PP4, BS2, PM5, PM4, PM1, PM3, BA1, BP1, BP3, BP2, PS1, PS3, PS4, PS2	NM_000314.8(PTEN):c.1061C>A (p.Pro354Gln) variant meets criteria to be classified as likely benign  for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). BS1: To be applied for variants with filtering allele frequency (FAF) of 0.000043 up to 0.00056 (0.0043% up to 0.056%) in gnomAD. Popmax FAF of this variant=0.0001051.BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function. This variant: score of 0.09 (WT-like range) on high throughput phosphatase assay (PMID:29706350).BP4: REVEL score < 0.5 (score=0.497).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.Using the Bayesian point system (PMID: 29300386) for this variant with conflicting evidence: 1 benign strong and 2 benign supporting = -6. 1 pathogenic supporting = 1. Total = â€“ 5 (likely benign).	21343951, 21659347, 26580448, 26898890, 25980754, 29785012, 29706350	PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000275/MONDO:0017623/003	e75a40b0-8e18-418e-b6c7-079646958d18
NM_000314.6(PTEN):c.181C>G (p.His61Asp)	7841	CA000330	NM_000314.6:c.181C>G, NC_000010.11:g.87925529C>G, CM000672.2:g.87925529C>G, NC_000010.10:g.89685286C>G, CM000672.1:g.89685286C>G, NC_000010.9:g.89675266C>G, NG_007466.2:g.67091C>G, LRG_311:g.67091C>G, ENST00000686459.1:c.181C>G, ENST00000688158.1:c.*292C>G, ENST00000688308.1:c.181C>G, ENST00000688922.1:n.50C>G, ENST00000693560.1:c.700C>G, ENST00000371953.8:c.181C>G, ENST00000371953.7:c.181C>G, ENST00000498703.1:n.7C>G, ENST00000610634.1:c.79C>G, NM_000314.5:c.181C>G, NM_001304717.2:c.700C>G, NM_001304718.1:c.-541-5517C>G, XM_006717926.2:c.165-5517C>G, XM_011539981.1:c.181C>G, XM_011539982.1:c.85C>G, XR_945789.1:n.893C>G, XR_945790.1:n.893C>G, XR_945791.1:n.893C>G, NM_000314.7:c.181C>G, NM_001304717.5:c.700C>G, NM_001304718.2:c.-541-5517C>G, NM_000314.8:c.181C>G, NM_000314.8(PTEN):c.181C>G (p.His61Asp), NM_000314.6(PTEN):c.181C>G (p.His61Asp)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2, PM6, PP2, PS3	BP7, BP5, BS1, BS3, BS4, PVS1, PP3, PP1, PP4, BS2, PM4, PM5, PM1, PM3, BA1, BP3, BP4, BP1, BP2, PS1, PS4, PS2	PTEN c.181C>G (p.His61Asp) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29706350, PMID 17942903, PMID 21828076)PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 11748304)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	11748304, 11748304, 21828076, 17942903, 29706350, 11748304	PTEN VCEP		2021-06-04	2022-09-30	false	https://erepo.genome.network/evrepo/ui/classification/CA000330/MONDO:0017623/003	37398c37-6caa-4c1d-a1b1-3881be31e38b
NM_000314.6(PTEN):c.651C>T (p.Val217=)	255814	CA10587096	NM_000314.6:c.651C>T, NC_000010.11:g.87957869C>T, CM000672.2:g.87957869C>T, NC_000010.10:g.89717626C>T, CM000672.1:g.89717626C>T, NC_000010.9:g.89707606C>T, NG_007466.2:g.99431C>T, LRG_311:g.99431C>T, NM_000314.5:c.651C>T, NM_001304717.2:c.1170C>T, NM_001304718.1:c.60C>T, XM_006717926.2:c.606C>T, XM_011539981.1:c.651C>T, XM_011539982.1:c.555C>T, XR_945791.1:n.1221C>T, NM_000314.7:c.651C>T, NM_001304717.5:c.1170C>T, NM_001304718.2:c.60C>T, ENST00000371953.7:c.651C>T, ENST00000472832.2:n.78C>T, NM_000314.6(PTEN):c.651C>T (p.Val217=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	PM2, BP7, BP4	PVS1, PM6, BP5, BS4, BS3, BS1, PP4, PP1, PP2, PP3, BS2, PM1, PM4, PM5, BA1, BP2, PS2, PS4, PS3, PS1	PTEN c.651C>T (p.V217=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP		2018-07-25	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA10587096/MONDO:0017623/003	2f3d636c-4b73-48ee-93dd-243ce38e9778
NM_000314.6(PTEN):c.755A>G (p.Asp252Gly)	7849	CA000564	NM_000314.6:c.755A>G, NC_000010.11:g.87957973A>G, CM000672.2:g.87957973A>G, NC_000010.10:g.89717730A>G, CM000672.1:g.89717730A>G, NC_000010.9:g.89707710A>G, NG_007466.2:g.99535A>G, LRG_311:g.99535A>G, ENST00000686459.1:c.*341A>G, ENST00000688158.1:c.*866A>G, ENST00000688308.1:c.755A>G, ENST00000688922.1:c.676A>G, ENST00000693560.1:c.1274A>G, ENST00000371953.8:c.755A>G, ENST00000371953.7:c.755A>G, ENST00000472832.2:c.182A>G, NM_000314.5:c.755A>G, NM_001304717.2:c.1274A>G, NM_001304718.1:c.164A>G, XM_006717926.2:c.710A>G, XM_011539981.1:c.755A>G, XM_011539982.1:c.659A>G, XR_945791.1:n.1325A>G, NM_000314.7:c.755A>G, NM_001304717.5:c.1274A>G, NM_001304718.2:c.164A>G, NM_000314.8:c.755A>G, NM_000314.8(PTEN):c.755A>G (p.Asp252Gly), NM_000314.6(PTEN):c.755A>G (p.Asp252Gly)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PP3, PP2, PS4_Supporting, PS3_Moderate, PM2_Supporting, PM6_Strong	BP7, BP5, BS1, BS3, BS4, PVS1, PP4, PP1, BS2, PM5, PM4, PM1, PM3, BP4, BP1, BP3, BP2, BA1, PS1, PS2	NM_000314.8(PTEN):c.755A>G (p.Asp252Gly) variant meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PS6_S: One proband with presumed de novo occurrence (maternity/paternity not confirmed) for a patient with highly specific phenotype. (PMID: 23335809).PS3_M: Phosphatase activity â‰¤ -1.11 per Mighell et al. 2018, PMID: 29706350.PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PP3: REVEL score > 0.7 (score=0.971)PM2_P: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID: 23335809).	23335809, 15805158, 21194675, 21659347, 17286265, 21828076, 29373119, 29706350, 29706633, 25527629	PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000564/MONDO:0017623/003	d7efe33c-ab88-4472-ad12-90db0ed372bf
NM_000314.6(PTEN):c.802delG (p.Asp268Thrfs)	7839	CA000595	NM_000314.6:c.802delG, NC_000010.11:g.87960894del, CM000672.2:g.87960894del, NC_000010.10:g.89720651del, CM000672.1:g.89720651del, NC_000010.9:g.89710631del, NG_007466.2:g.102456del, LRG_311:g.102456del, ENST00000686459.1:c.*388del, ENST00000688158.1:c.*913del, ENST00000688308.1:c.802del, ENST00000688922.1:c.723del, ENST00000693560.1:c.1321del, ENST00000371953.8:c.802del, ENST00000371953.7:c.802del, ENST00000472832.2:c.229del, NM_000314.5:c.802del, NM_000314.6:c.802del, NM_001304717.2:c.1321del, NM_001304718.1:c.211del, XM_006717926.2:c.757del, XM_011539981.1:c.802del, XM_011539982.1:c.706del, XR_945791.1:n.1372del, NM_000314.7:c.802del, NM_001304717.5:c.1321del, NM_001304718.2:c.211del, NM_000314.8:c.802del, NM_000314.6(PTEN):c.802delG (p.Asp268Thrfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1, PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PM6, PP3, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS4, PS2	NM_000314.8(PTEN):c.802del (p.Asp268ThrfsTer8) variant meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.8). PM2_Supporting: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort (PMID:27535533).	11238682, 11238682, 11238682, 11238682, 11238682, 11238682	PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000595/MONDO:0017623/003	7fae3512-3b64-4560-8e0f-65a045970149
NM_000314.6(PTEN):c.722T>C (p.Phe241Ser)	7850	CA000555	NM_000314.6:c.722T>C, NC_000010.11:g.87957940T>C, CM000672.2:g.87957940T>C, NC_000010.10:g.89717697T>C, CM000672.1:g.89717697T>C, NC_000010.9:g.89707677T>C, NG_007466.2:g.99502T>C, LRG_311:g.99502T>C, ENST00000686459.1:c.*308T>C, ENST00000688158.1:c.*833T>C, ENST00000688308.1:c.722T>C, ENST00000688922.1:c.643T>C, ENST00000693560.1:c.1241T>C, ENST00000371953.8:c.722T>C, ENST00000371953.7:c.722T>C, ENST00000472832.2:c.149T>C, NM_000314.5:c.722T>C, NM_001304717.2:c.1241T>C, NM_001304718.1:c.131T>C, XM_006717926.2:c.677T>C, XM_011539981.1:c.722T>C, XM_011539982.1:c.626T>C, XR_945791.1:n.1292T>C, NM_000314.7:c.722T>C, NM_001304717.5:c.1241T>C, NM_001304718.2:c.131T>C, NM_000314.8:c.722T>C, NM_000314.8(PTEN):c.722T>C (p.Phe241Ser), NM_000314.6(PTEN):c.722T>C (p.Phe241Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PP3, PP2, PS3_Moderate, PS4_Supporting, PM2_Supporting	BP5, BP7, BS4, BS3, BS1, PM6, PVS1, PP1, PP4, BS2, PM3, PM1, PM4, PM5, BP2, BP4, BP1, BP3, BA1, PS2, PS1	NM_000314.8(PTEN):c.722T>C (p.Phe241Ser) variant meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PS3_M: Functional studies supportive of a damaging effect on the gene or gene product. This variant: score of -2.39943 (â‰¤ -1.11) on a high throughput phosphatase assay (PMID:29706350).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID:15805158).PM2_P: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PP3: REVEL score > 0.7 (score=0.858).	15805158, 21194675, 21828076, 25527629, 29785012, 25937288, 29373119, 29706350, 26579216, 15805158	PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000555/MONDO:0017623/003	5c047758-6fb8-4f71-9a53-077a7bf9a2c2
NM_000314.6(PTEN):c.278A>G (p.His93Arg)	7848	CA000381	NM_000314.6:c.278A>G, NC_000010.11:g.87933037A>G, CM000672.2:g.87933037A>G, NC_000010.10:g.89692794A>G, CM000672.1:g.89692794A>G, NC_000010.9:g.89682774A>G, NG_007466.2:g.74599A>G, LRG_311:g.74599A>G, NM_000314.5:c.278A>G, NM_001304717.2:c.797A>G, NM_001304718.1:c.-473A>G, XM_006717926.2:c.233A>G, XM_011539981.1:c.278A>G, XM_011539982.1:c.182A>G, XR_945789.1:n.990A>G, XR_945790.1:n.990A>G, XR_945791.1:n.990A>G, NM_000314.7:c.278A>G, NM_001304717.5:c.797A>G, NM_001304718.2:c.-473A>G, ENST00000371953.7:c.278A>G, ENST00000498703.1:n.104A>G, ENST00000610634.1:c.176A>G, NM_000314.6(PTEN):c.278A>G (p.His93Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PS3_Supporting, PP2, PS4_Supporting, PM1, PS2	PM6, PVS1, BS4, BS3, BS1, BP5, BP7, BS2, PP4, PP1, PP3, PM4, PM5, BP2, BP4, BA1, PS1	PTEN c.278A>G (p.His93Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (internal laboratory contributor(s) ClinVar Organization ID: 26957)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS3_P: Abnormal in vitro cellular assay or transgenic model with phenotype different from wild type that does not meet PS3. (PMID 26579216, 25647146, 20718038, 21828076, 29373119, 29785012, 29706350)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 15805158, internal laboratory contributor(s) ClinVar Organization ID: 26957)	15805158, 25647146, 21828076, 22505997, 29785012, 20718038, 29373119, 29706350, 26579216, 21194675, 24345843, 15805158, 15805158, 15805158	PTEN VCEP		2018-11-28	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000381/MONDO:0017623/003	902dd050-bb88-4ce6-b98d-dd80cbc3aa5e
NM_000314.6(PTEN):c.79+7A>G	127692	CA000580	NM_000314.6:c.79+7A>G, NC_000010.11:g.87864555A>G, CM000672.2:g.87864555A>G, NC_000010.10:g.89624312A>G, CM000672.1:g.89624312A>G, NC_000010.9:g.89614292A>G, NG_007466.2:g.6117A>G, LRG_311:g.6117A>G, NG_033079.1:g.3883T>C, ENST00000686459.1:c.79+7A>G, ENST00000688158.1:c.79+7A>G, ENST00000688308.1:c.79+7A>G, ENST00000693560.1:c.598+7A>G, ENST00000371953.8:c.79+7A>G, ENST00000371953.7:c.79+7A>G, ENST00000462694.1:n.81+7A>G, ENST00000487939.1:n.100+7A>G, ENST00000610634.1:c.-24+7A>G, ENST00000618586.1:n.55A>G, NM_000314.5:c.79+7A>G, NM_001304717.2:c.598+7A>G, NM_001304718.1:c.-627+7A>G, XM_006717926.2:c.79+7A>G, XM_011539981.1:c.79+7A>G, XR_945789.1:n.791+7A>G, XR_945790.1:n.791+7A>G, XR_945791.1:n.791+7A>G, NM_000314.7:c.79+7A>G, NM_001304717.5:c.598+7A>G, NM_001304718.2:c.-627+7A>G, NM_000314.8:c.79+7A>G, NM_000314.8(PTEN):c.79+7A>G, NM_000314.6(PTEN):c.79+7A>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS3	PM2, PM6, PVS1, BS1, BS4, BP7, BP5, BS2, PP3, PP2, PP4, PP1, PM5, PM4, PM1, PM3, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS2, PS4	NM_000314.8(PTEN):c.79+7A>G variant meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). BS3: Intronic variant with RNA, mini-gene, or other splicing assay demonstrating no splicing impact. (PMID: 28677221)	28677221, 28677221, 25669429, 21659347	PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000580/MONDO:0017623/003	3acf8a70-e306-4b52-9401-648b6e0a3c99
NM_000314.6(PTEN):c.-909T>C	127681	CA000631	NM_000314.6:c.-909T>C, NC_000010.11:g.87863560T>C, CM000672.2:g.87863560T>C, NC_000010.10:g.89623317T>C, CM000672.1:g.89623317T>C, NC_000010.9:g.89613297T>C, NG_007466.2:g.5123T>C, LRG_311:g.5123T>C, NG_033079.1:g.4878A>G, NM_000314.5:c.-909T>C, NM_001304717.2:c.-390T>C, NM_001304718.1:c.-1614T>C, ENST00000371953.7:c.-910T>C, ENST00000610634.1:c.-1012T>C, NM_000314.6(PTEN):c.-909T>C	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP5, BP2	PVS1, PM6, PM2, BP7, BS4, BS3, BS1, PP4, PP1, PP2, PP3, BS2, PM1, PM4, PM5, BA1, BP4, PS2, PS4, PS3, PS1	PTEN c.-909T>C (NC_000010.10:g.87863560T>C) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BP2: Observed in trans with a pathogenic or likely pathogenic PTEN variant. (internal laboratory contributor ClinVar Organization ID 19864)BP5: Variant found in multiple cases with alternate molecular basis for disease. (internal laboratory contributors SCV000185347.1, SCV000149485.5)		PTEN VCEP		2018-07-25	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA000631/MONDO:0017623/003	6645334e-8bca-425f-949d-27eb2959bb70
NM_000277.1:c.1218A>G	552907	CA6748708	NM_000277.1:c.1218A>G, NC_000012.12:g.102840497T>C, CM000674.2:g.102840497T>C, NC_000012.11:g.103234275T>C, CM000674.1:g.103234275T>C, NC_000012.10:g.101758405T>C, NG_008690.1:g.82106A>G, NG_008690.2:g.122914A>G, XM_011538422.1:c.1161A>G, NM_000277.2:c.1218A>G, NM_001354304.1:c.1218A>G, NM_000277.3:c.1218A>G, ENST00000307000.7:c.1203A>G, ENST00000551114.2:n.880A>G, ENST00000553106.5:c.1218A>G, ENST00000635477.1:n.322A>G, ENST00000635528.1:n.733A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM5, PM2, PP4	PP3	The c.1218A>G (p.Ile406Met) variant in PAH is reported in 2 individuals with non-PKU HPA. BH4 assessment was not stated. It was detected with a known pathogenic variant, p.Arg408Trp. (PMID: 23357515) This variant has a low allele frequency in gnomAD and ExAC (MAF=0.00003) and is absent in 1000G. Computational evidence is discordant. Another missense change at this amino acid is interpreted as likely pathogenic by the PAH VCEP (p.I406T). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PM5, PP4.	23357515, 23357515	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA6748708/MONDO:0009861/006	855d18fc-6dd6-4938-9924-d6694afb9079
	619167	CA6748709	NM_000277.1:c.1216A>G, NC_000012.12:g.102840499T>C, CM000674.2:g.102840499T>C, NC_000012.11:g.103234277T>C, CM000674.1:g.103234277T>C, NC_000012.10:g.101758407T>C, NG_008690.1:g.82104A>G, NG_008690.2:g.122912A>G, XM_011538422.1:c.1159A>G, NM_000277.2:c.1216A>G, NM_001354304.1:c.1216A>G, NM_000277.3:c.1216A>G, ENST00000307000.7:c.1201A>G, ENST00000551114.2:n.878A>G, ENST00000553106.5:c.1216A>G, ENST00000635477.1:n.320A>G, ENST00000635528.1:n.731A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM2, PP4_Moderate, PP3		The c.1216A>G (p.Ile406Val) variant in PAH is reported in an individual with PKU. Dihydropteridine reductase activity, urinary biopterin and neopterin ratio, and tetrahydrobiopterin loading were collected. (PMID: 26503515) This variant has a low frequency in ExAC/gnomAD (MAF=0.00016) and is absent from 1000G. A deleterious effect is predicted by SIFT, Polyphen, and MutationTaster. Another missense variant at this amino acid is interpreted as likely pathogenic by our PAH VCEP (p.I406T). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM5, PP4_Moderate, PP3.	26503515	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA6748709/MONDO:0009861/006	99c1aff1-c37d-4471-90f9-86d122e11e34
NM_000277.2(PAH):c.1217T>C (p.Ile406Thr)	102567	CA229398	NM_000277.2:c.1217T>C, NC_000012.12:g.102840498A>G, CM000674.2:g.102840498A>G, NC_000012.11:g.103234276A>G, CM000674.1:g.103234276A>G, NC_000012.10:g.101758406A>G, NG_008690.1:g.82105T>C, NG_008690.2:g.122913T>C, NM_000277.1:c.1217T>C, XM_011538422.1:c.1160T>C, NM_001354304.1:c.1217T>C, NM_000277.3:c.1217T>C, ENST00000307000.7:c.1202T>C, ENST00000551114.2:n.879T>C, ENST00000553106.5:c.1217T>C, ENST00000635477.1:n.321T>C, ENST00000635528.1:n.732T>C, NM_000277.2(PAH):c.1217T>C (p.Ile406Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2, PP4_Moderate, PP3, PM3_Strong		The c.1217T>C (p.Ile406Thr) variant in PAH is reported in 2 unrelated patients with PKU; BH4 cofactor deficiency was ruled out. (PMID: 10234516, 27121329, 28754886) This variant was reported in trans with known pathogenic variants p.I65T (PMID: 10234516) and IVS4-1G>A (PMID: 28754886). It is absent in population databases, and multiple lines of computational evidence support a deleterious effect. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PP4_Moderate, PP3.	27121329, 10234516, 28754886, 10234516	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229398/MONDO:0009861/006	47b1110a-e06d-487d-b096-69829820e761
NM_000277.1:c.1285C>A	551555	CA6748701	NM_000277.1:c.1285C>A, NC_000012.12:g.102840430G>T, CM000674.2:g.102840430G>T, NC_000012.11:g.103234208G>T, CM000674.1:g.103234208G>T, NC_000012.10:g.101758338G>T, NG_008690.1:g.82173C>A, NG_008690.2:g.122981C>A, XM_011538422.1:c.1228C>A, NM_000277.2:c.1285C>A, NM_001354304.1:c.1285C>A, NM_000277.3:c.1285C>A, ENST00000307000.7:c.1270C>A, ENST00000551114.2:n.947C>A, ENST00000553106.5:c.1285C>A, ENST00000635477.1:n.389C>A, ENST00000635528.1:n.800C>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2	PP3	The c.1285C>A (p.Gln429Lys) variant in PAH is reported in a patient with mild PKU (Phe level 720). BH4 cofactor deficiency was excluded. It was detected with a known pathogenic variant, EX6-96A>G (VarID 590). (PMID: 26503515, 28982351) This variant has a low frequency in gnomAD and ExAC (MAF=0.00002), and absent in 1000G. Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PM3.	28982351, 28982351, 26503515	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA6748701/MONDO:0009861/006	7531cb9b-9ac5-43c2-b83a-24078467de09
NM_000277.2(PAH):c.1101G>A (p.Leu367=)	102526	CA229346	NM_000277.2:c.1101G>A, NC_000012.12:g.102843744C>T, CM000674.2:g.102843744C>T, NC_000012.11:g.103237522C>T, CM000674.1:g.103237522C>T, NC_000012.10:g.101761652C>T, NG_008690.1:g.78859G>A, NG_008690.2:g.119667G>A, ENST00000553106.6:c.1101G>A, ENST00000307000.7:c.1086G>A, ENST00000549247.6:n.860G>A, ENST00000551114.2:n.763G>A, ENST00000553106.5:c.1101G>A, ENST00000635477.1:n.205G>A, ENST00000635528.1:n.616G>A, NM_000277.1:c.1101G>A, XM_011538422.1:c.1044G>A, NM_001354304.1:c.1101G>A, NM_000277.3:c.1101G>A, NM_001354304.2:c.1101G>A, NM_000277.3(PAH):c.1101G>A (p.Leu367=), NM_000277.2(PAH):c.1101G>A (p.Leu367=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM3, PP3, PP4, PM2_Supporting		The c.1101G>A (p.Leu367=) variant in PAH is reported in an individual with Classic PKU, in trans with p.R243Q. (PMID: 16256386) This variant is absent in population databases. Two splicing algorthms predict a deleterious effect (Human splicing finder: potential alteration of splicing; MaxEnt scan: +571.94% Variation). In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2_supporting, PM3, PP4, PP3.		Phenylketonuria VCEP		2023-07-23	2023-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA229346/MONDO:0009861/006	7e24b8a9-c6fa-4c49-8a3b-42729f9e6f4f
	619161	CA16020939	NM_000277.1:c.1100T>G, NC_000012.12:g.102843745A>C, CM000674.2:g.102843745A>C, NC_000012.11:g.103237523A>C, CM000674.1:g.103237523A>C, NC_000012.10:g.101761653A>C, NG_008690.1:g.78858T>G, NG_008690.2:g.119666T>G, XM_011538422.1:c.1043T>G, NM_000277.2:c.1100T>G, NM_001354304.1:c.1100T>G, NM_000277.3:c.1100T>G, ENST00000307000.7:c.1085T>G, ENST00000549247.6:n.859T>G, ENST00000551114.2:n.762T>G, ENST00000553106.5:c.1100T>G, ENST00000635477.1:n.204T>G, ENST00000635528.1:n.615T>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4, PP3		The c.1100T>G (p.Leu367Arg) variant in PAH is reported in a Chinese patient with PKU. BH4 deficiencies were not assessed/reported. (PMID: 19915519) This variant is absent in population databases. It is predicted deleterious by PolyPhen-2, MutationTaster, and SIFT. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PP3.	19915519	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020939/MONDO:0009861/006	ac26db6c-ecfb-4389-97ff-f8ad23eedd46
NM_000277.2(PAH):c.1100T>C (p.Leu367Pro)	102525	CA229344	NM_000277.2:c.1100T>C, NC_000012.12:g.102843745A>G, CM000674.2:g.102843745A>G, NC_000012.11:g.103237523A>G, CM000674.1:g.103237523A>G, NC_000012.10:g.101761653A>G, NG_008690.1:g.78858T>C, NG_008690.2:g.119666T>C, NM_000277.1:c.1100T>C, XM_011538422.1:c.1043T>C, NM_001354304.1:c.1100T>C, NM_000277.3:c.1100T>C, ENST00000307000.7:c.1085T>C, ENST00000549247.6:n.859T>C, ENST00000551114.2:n.762T>C, ENST00000553106.5:c.1100T>C, ENST00000635477.1:n.204T>C, ENST00000635528.1:n.615T>C, NM_000277.2(PAH):c.1100T>C (p.Leu367Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4_Moderate, PM2, PP3		The c.1100T>C (p.Leu367Pro) variant in PAH is reported in a Japanese patient with PKU, BH4 deficiency was excluded. (PMID: 21307867) This variant is absent in population databases. It is predicted deleterious by SIFT, Polyphen-2 and MutationTaster. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PP3.	21307867	Phenylketonuria VCEP		2018-12-08	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229344/MONDO:0009861/006	26cea1af-9453-4d25-8531-cb770a0f706d
	619153	CA16020938	NM_000277.1:c.1099C>G, NC_000012.12:g.102843746G>C, CM000674.2:g.102843746G>C, NC_000012.11:g.103237524G>C, CM000674.1:g.103237524G>C, NC_000012.10:g.101761654G>C, NG_008690.1:g.78857C>G, NG_008690.2:g.119665C>G, XM_011538422.1:c.1042C>G, NM_000277.2:c.1099C>G, NM_001354304.1:c.1099C>G, NM_000277.3:c.1099C>G, ENST00000307000.7:c.1084C>G, ENST00000549247.6:n.858C>G, ENST00000551114.2:n.761C>G, ENST00000553106.5:c.1099C>G, ENST00000635477.1:n.203C>G, ENST00000635528.1:n.614C>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4_Moderate, PM2	PM3, PP3	The c.1099C>G (p.Leu367Val) variant in PAH is reported in 2 unrelated patients with PKU (from Italy and China). BH4 deficiencies were assessed in the Chinese patient. (PMID: 10693064, 26503515) It was detected in the Chinese patient with c.1174T>A (p.F392I) (not in ClinVar). This variant is absent in population databases. Computational evidence is conflicting. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2.	26322415, 10693064, 26503515	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020938/MONDO:0009861/006	091220fb-ed36-4e4d-bcd9-aa8cf3d9d1b0
NM_000277.2(PAH):c.529G>A (p.Val177Met)	102726	CA229609	NM_000277.2:c.529G>A, NC_000012.12:g.102855313C>T, CM000674.2:g.102855313C>T, NC_000012.11:g.103249091C>T, CM000674.1:g.103249091C>T, NC_000012.10:g.101773221C>T, NG_008690.1:g.67290G>A, NG_008690.2:g.108098G>A, NM_000277.1:c.529G>A, XM_011538422.1:c.529G>A, NM_001354304.1:c.529G>A, XM_017019370.2:c.529G>A, NM_000277.3:c.529G>A, ENST00000307000.7:c.514G>A, ENST00000549111.5:n.625G>A, ENST00000551988.5:n.550G>A, ENST00000553106.5:c.529G>A, NM_000277.2(PAH):c.529G>A (p.Val177Met)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM5, PM2, PP4_Moderate, PP3, PM3_Strong		The c.529G>A (p.Val177Met) variant in PAH was detected in a patient with Mild hyperphenylalaninemia (BH4 deficiency ruled out). PMID: 12501224 It has been detected with known pathogenic variants R408W (PMID: 12501224), and IVS12+1G>A (PMID: 23764561). It is absent from 1000G, ESP, and gnomAD; and at extremely low frequency in ExAC (MAF=0.00003). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.89. A different pathogenic missense change has been seen at this amino acid (V177L). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PM5, PP4_Moderate, PP3.	12501224, 23764561, 12501224	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229609/MONDO:0009861/006	8e00de6f-21da-48a5-9606-f7afe7fbb6e5
NM_000277.2(PAH):c.293T>C (p.Leu98Ser)	627	CA114368	NM_000277.2:c.293T>C, NC_000012.12:g.102894794A>G, CM000674.2:g.102894794A>G, NC_000012.11:g.103288572A>G, CM000674.1:g.103288572A>G, NC_000012.10:g.101812702A>G, NG_008690.1:g.27809T>C, NG_008690.2:g.68617T>C, ENST00000553106.6:c.293T>C, ENST00000307000.7:c.278T>C, ENST00000546844.1:c.293T>C, ENST00000548928.1:n.215T>C, ENST00000549111.5:n.389T>C, ENST00000550978.6:n.277T>C, ENST00000551337.5:c.293T>C, ENST00000551988.5:n.382T>C, ENST00000553106.5:c.293T>C, NM_000277.1:c.293T>C, XM_011538422.1:c.293T>C, NM_001354304.1:c.293T>C, XM_017019370.2:c.293T>C, NM_000277.3:c.293T>C, NM_001354304.2:c.293T>C, NM_000277.3(PAH):c.293T>C (p.Leu98Ser), NM_000277.2(PAH):c.293T>C (p.Leu98Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PP3, PM3_Supporting	PM5	The c.293T>C (p.Leu98Ser) variant in PAH has been reported as homozygous in a Pakistani patient with mild PKU (BH4 deficiency excluded) (PMID: 8364546, 9634518, 26542770) This variant has an extremely low frequency in gnomAD v2.1.1 (MAF=0.0001307). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.846. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_supporting, PP3.		Phenylketonuria VCEP		2022-01-14	2022-01-14	false	https://erepo.genome.network/evrepo/ui/classification/CA114368/MONDO:0009861/006	fcf34e9b-443b-490c-af8d-a6643cc7dc59
NM_000277.2(PAH):c.242C>A (p.Thr81Asn)	208180	CA275937	NM_000277.2:c.242C>A, NC_000012.12:g.102894845G>T, CM000674.2:g.102894845G>T, NC_000012.11:g.103288623G>T, CM000674.1:g.103288623G>T, NC_000012.10:g.101812753G>T, NG_008690.1:g.27758C>A, NG_008690.2:g.68566C>A, NM_000277.1:c.242C>A, XM_011538422.1:c.242C>A, NM_001354304.1:c.242C>A, XM_017019370.2:c.242C>A, NM_000277.3:c.242C>A, ENST00000307000.7:c.227C>A, ENST00000546844.1:c.242C>A, ENST00000548677.2:n.329C>A, ENST00000548928.1:n.164C>A, ENST00000549111.5:n.338C>A, ENST00000550978.6:n.226C>A, ENST00000551337.5:c.242C>A, ENST00000551988.5:n.331C>A, ENST00000553106.5:c.242C>A, NM_000277.2(PAH):c.242C>A (p.Thr81Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4_Moderate, PP3		The c.242C>A (p.Thr81Asn) variant in PAH is reported in 1 PKU patient. PAH and BH4DH genes were sequenced. It was detected with p.V230I which is interpreted as Pathogenic/Likely Pathogenic in ClinVar. (PMID: 23942198) This variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, MutationTaster, and Polyphen-2. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PM3, PP3.	23942198, 23942198	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA275937/MONDO:0009861/006	50209afd-af57-49df-9248-edd2fd6d5cab
NM_000277.2(PAH):c.110T>C (p.Leu37Pro)	225133	CA357242	NM_000277.2:c.110T>C, NC_000012.12:g.102912849A>G, CM000674.2:g.102912849A>G, NC_000012.11:g.103306627A>G, CM000674.1:g.103306627A>G, NC_000012.10:g.101830757A>G, NG_008690.1:g.9754T>C, NG_008690.2:g.50562T>C, NM_000277.1:c.110T>C, XM_011538422.1:c.110T>C, NM_001354304.1:c.110T>C, XM_017019370.2:c.110T>C, NM_000277.3:c.110T>C, ENST00000307000.7:c.95T>C, ENST00000546844.1:c.110T>C, ENST00000548677.2:n.197T>C, ENST00000548928.1:n.32T>C, ENST00000549111.5:n.206T>C, ENST00000550978.6:n.94T>C, ENST00000551337.5:c.110T>C, ENST00000551988.5:n.199T>C, ENST00000553106.5:c.110T>C, ENST00000635500.1:n.78T>C, NM_000277.2(PAH):c.110T>C (p.Leu37Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4, PP3		The c.110T>C (p.Leu37Pro) variant in PAH is reported in 1 patient with mild PKU. Assessment of BH4 deficiencies not reported. It was detected with a known pathogenic variant, p.R408W. (PMID: 24350308) This variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, Polyphen-2, and MutationTaster. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4, PP3.	24350308, 24350308, 24078561	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA357242/MONDO:0009861/006	42dfc728-4452-4eae-ae00-32fd711ab8ac
NM_000277.2(PAH):c.1065+3A>G	633	CA212751	NM_000277.2:c.1065+3A>G, NC_000012.12:g.102844333T>C, CM000674.2:g.102844333T>C, NC_000012.11:g.103238111T>C, CM000674.1:g.103238111T>C, NC_000012.10:g.101762241T>C, NG_008690.1:g.78270A>G, NG_008690.2:g.119078A>G, NM_000277.1:c.1065+3A>G, XM_011538422.1:c.1008+3A>G, NM_001354304.1:c.1065+3A>G, NM_000277.3:c.1065+3A>G, ENST00000307000.7:c.1050+3A>G, ENST00000549247.6:n.824+3A>G, ENST00000551114.2:n.727+3A>G, ENST00000553106.5:c.1065+3A>G, ENST00000635477.1:n.169+3A>G, ENST00000635528.1:n.580+3A>G, NM_000277.2(PAH):c.1065+3A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP1, PP4, PP3		The c.1065+3A>G variant in PAH was detected in 2 siblings with an increased serum Phenylalanine level of 365 uM. BH4 deficiency was not assessed/reported. (PMID: 8088845) They were compound heterozygous for Y414C. The c.1065+3A>G variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted for this variant in HSF and MaxEnt (Alteration of the WT donor site; activation of an intronic cryptic donor site). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP1, PP3, PP4.	8088845, 8088845, 8088845	Phenylketonuria VCEP		2018-12-10	2019-05-04	false	https://erepo.genome.network/evrepo/ui/classification/CA212751/MONDO:0009861/006	1eaf05e7-3220-43e3-be9a-82f4eb06577c
NM_000277.2(PAH):c.940C>T (p.Pro314Ser)	102905	CA229865	NM_000277.2:c.940C>T, NC_000012.12:g.102846924G>A, CM000674.2:g.102846924G>A, NC_000012.11:g.103240702G>A, CM000674.1:g.103240702G>A, NC_000012.10:g.101764832G>A, NG_008690.1:g.75679C>T, NG_008690.2:g.116487C>T, NM_000277.1:c.940C>T, XM_011538422.1:c.913-2493C>T, NM_001354304.1:c.940C>T, NM_000277.3:c.940C>T, ENST00000307000.7:c.925C>T, ENST00000549247.6:n.699C>T, ENST00000551114.2:n.602C>T, ENST00000553106.5:c.940C>T, ENST00000635477.1:n.74-2493C>T, ENST00000635528.1:n.455C>T, NM_000277.2(PAH):c.940C>T (p.Pro314Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM5, PM3, PP4_Moderate, PM2, PS3	PP3	The c.940C>T (p.Pro314Ser) variant in PAH is absent in population databases, and is in the same codon as two previously described Pathogenic/Likely pathogenic variants (p.Pro314His and p.Pro314Thr).  It has been found in trans with a pathogenic variant (p.R408W) in a patient with PAH deficiency (BH4 defects excluded, PMID: 12501224). Functional studies showed it has 26% enzyme activity compared to wild type controls. PMID: 18590700. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM2, PM3, PM5.		Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229865/MONDO:0009861/006	bd417e52-1ddf-48db-8a18-b1341bfa724a
	619151	CA16020901	NM_000277.1:c.934G>C, NC_000012.12:g.102846930C>G, CM000674.2:g.102846930C>G, NC_000012.11:g.103240708C>G, CM000674.1:g.103240708C>G, NC_000012.10:g.101764838C>G, NG_008690.1:g.75673G>C, NG_008690.2:g.116481G>C, XM_011538422.1:c.913-2499G>C, NM_000277.2:c.934G>C, NM_001354304.1:c.934G>C, NM_000277.3:c.934G>C, ENST00000307000.7:c.919G>C, ENST00000549247.6:n.693G>C, ENST00000551114.2:n.596G>C, ENST00000553106.5:c.934G>C, ENST00000635477.1:n.74-2499G>C, ENST00000635528.1:n.449G>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4, PP3	PM3	The c.934G>C (p.Gly312Arg) variant in PAH is absent from population databases, and predicted damaging by in silico algorithms.  It is identified in a single patient with phenylketonuria, in trans with a VUS (IVS8-7A>G)  Defect in BH4 metabolism was not excluded in this publication (Bashyam, 2014. PMID: 24130151). In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PP3.	24130151, 24130151	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020901/MONDO:0009861/006	a61018fa-1019-4c4e-8bb6-1f469dc6e5de
NM_001354304.1:c.470G>C	619162	CA16020797	NM_001354304.1:c.470G>C, ENST00000553106.6:c.470G>C, ENST00000307000.7:c.455G>C, ENST00000549111.5:n.566G>C, ENST00000551988.5:n.530+10827G>C, ENST00000553106.5:c.470G>C, NM_000277.1:c.470G>C, XM_011538422.1:c.470G>C, NM_000277.2:c.470G>C, XM_017019370.2:c.470G>C, NM_000277.3:c.470G>C, NM_001354304.2:c.470G>C, NC_000012.12:g.102866635C>G, CM000674.2:g.102866635C>G, NC_000012.11:g.103260413C>G, CM000674.1:g.103260413C>G, NC_000012.10:g.101784543C>G, NG_008690.1:g.55968G>C, NG_008690.2:g.96776G>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM5, PM2, PP3	PS3	The c.470G>C (p.Arg157Thr) variant in PAH has not been reported in an affected patient to our knowledge. The reference in BioPKU (Carter KC, 1998) does not include this variant. The p.R157T mutant is listed as having 5% of wt PAH activity in vitro (BioPKU), but this likely corresponds to the p.R157N variant (PMID: 9450897). The p.Arg157Asn variant at the same amino acid is interpreted as pathogenic in ClinVar (VarID 590772). p.Arg157Thr is absent from ExAC, gnomAD, 1000G, and ESP. It is predicted deleterious in SIFT, Polyphen-2, MutationTaster, and REVEL=0.95. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM5, PP3.	9450897	Phenylketonuria VCEP		2021-02-14	2021-05-14	false	https://erepo.genome.network/evrepo/ui/classification/CA16020797/MONDO:0009861/006	a2d92aa7-5fed-4ba2-be23-93c6b25c50cb
	619155	CA16020779	NM_000277.1:c.362T>C, NC_000012.12:g.102877541A>G, CM000674.2:g.102877541A>G, NC_000012.11:g.103271319A>G, CM000674.1:g.103271319A>G, NC_000012.10:g.101795449A>G, NG_008690.1:g.45062T>C, NG_008690.2:g.85870T>C, XM_011538422.1:c.362T>C, NM_000277.2:c.362T>C, NM_001354304.1:c.362T>C, XM_017019370.2:c.362T>C, NM_000277.3:c.362T>C, ENST00000307000.7:c.347T>C, ENST00000549111.5:n.458T>C, ENST00000550978.6:n.346T>C, ENST00000551337.5:c.362T>C, ENST00000551988.5:n.451T>C, ENST00000553106.5:c.362T>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4_Moderate, PM2, PP3	PM5	The c.362T>C (p.Phe121Ser) variant in PAH is reported in 1 patient with hyperphenylalaninemia. A BH4 metabolism defect was excluded. (PMID: 26701937) This variant is absent from ExAC, gnomAD, 1000G, and ESP. It is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.977. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PP3.	26701937	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020779/MONDO:0009861/006	6628a148-458a-49f0-bb4f-f4d481b62a08
	619157	CA16020751	NM_000277.1:c.224A>T, NC_000012.12:g.102894863T>A, CM000674.2:g.102894863T>A, NC_000012.11:g.103288641T>A, CM000674.1:g.103288641T>A, NC_000012.10:g.101812771T>A, NG_008690.1:g.27740A>T, NG_008690.2:g.68548A>T, XM_011538422.1:c.224A>T, NM_000277.2:c.224A>T, NM_001354304.1:c.224A>T, XM_017019370.2:c.224A>T, NM_000277.3:c.224A>T, ENST00000307000.7:c.209A>T, ENST00000546844.1:c.224A>T, ENST00000548677.2:n.311A>T, ENST00000548928.1:n.146A>T, ENST00000549111.5:n.320A>T, ENST00000550978.6:n.208A>T, ENST00000551337.5:c.224A>T, ENST00000551988.5:n.313A>T, ENST00000553106.5:c.224A>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4_Moderate	PM5, PP3	The c.224A>T (p.Asp75Val) variant in PAH is reported in 1 classic PKU patient. BH4 deficiency was excluded. It was detected in trans with a known pathogenic variant, p.R413P. (PMID: 26322415) This variant is absent from ExAC, gnomAD, 1000G, and ESP.Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4_Moderate.	26322415, 26322415	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020751/MONDO:0009861/006	a02baf54-2908-452e-974a-462fb13bcf24
NM_000277.2(PAH):c.865G>C (p.Gly289Arg)	102882	CA229830	NM_000277.2:c.865G>C, NC_000012.12:g.102851734C>G, CM000674.2:g.102851734C>G, NC_000012.11:g.103245512C>G, CM000674.1:g.103245512C>G, NC_000012.10:g.101769642C>G, NG_008690.1:g.70869G>C, NG_008690.2:g.111677G>C, NM_000277.1:c.865G>C, XM_011538422.1:c.865G>C, NM_001354304.1:c.865G>C, NM_000277.3:c.865G>C, ENST00000307000.7:c.850G>C, ENST00000549247.6:n.624G>C, ENST00000551114.2:n.527G>C, ENST00000553106.5:c.865G>C, ENST00000635477.1:n.26G>C, NM_000277.2(PAH):c.865G>C (p.Gly289Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PP3, PS1		The c.865G>C (p.Gly289Arg) variant in PAH is absent from population databases and predicted deleterious with in silico prediction software.  This is the same amnio acid change as a previously established pathogenic variant (c.865G>A; p.Gly289Arg).  It has been identified in trans with a pathogenic variant (R155C, curated by the PAH EP), and a defect in BH4 metabolism was excluded (PMID: 22921945). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS1, PM2, PM3, PP3.	23514811, 22921945	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229830/MONDO:0009861/006	f6f2fb05-fc57-4712-ad91-80732194a1e8
NM_000277.2(PAH):c.864G>C (p.Leu288Phe)	102881	CA229828	NM_000277.2:c.864G>C, NC_000012.12:g.102851735C>G, CM000674.2:g.102851735C>G, NC_000012.11:g.103245513C>G, CM000674.1:g.103245513C>G, NC_000012.10:g.101769643C>G, NG_008690.1:g.70868G>C, NG_008690.2:g.111676G>C, NM_000277.1:c.864G>C, XM_011538422.1:c.864G>C, NM_001354304.1:c.864G>C, NM_000277.3:c.864G>C, ENST00000307000.7:c.849G>C, ENST00000549247.6:n.623G>C, ENST00000551114.2:n.526G>C, ENST00000553106.5:c.864G>C, ENST00000635477.1:n.25G>C, NM_000277.2(PAH):c.864G>C (p.Leu288Phe)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4, PP3		The c.864G>C (p.Leu288Phe) variant in PAH is absent from population databases, and in silico predictors suggest a damaging effect on protein function.  It is listed in hPAHdb 2009 McGill, but there is no clinical information on any patient.  To our current knowledge (December, 2018), this variant has not been previously reported in the literature. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PP3.		Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229828/MONDO:0009861/006	fe639d15-3da2-40b0-ad2f-cf2cb65db78d
	619164	CA6748814	NM_000277.1:c.859C>G, NC_000012.12:g.102851740G>C, CM000674.2:g.102851740G>C, NC_000012.11:g.103245518G>C, CM000674.1:g.103245518G>C, NC_000012.10:g.101769648G>C, NG_008690.1:g.70863C>G, NG_008690.2:g.111671C>G, XM_011538422.1:c.859C>G, NM_000277.2:c.859C>G, NM_001354304.1:c.859C>G, NM_000277.3:c.859C>G, ENST00000307000.7:c.844C>G, ENST00000549247.6:n.618C>G, ENST00000551114.2:n.521C>G, ENST00000553106.5:c.859C>G, ENST00000635477.1:n.20C>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PM3_Strong	PP3	The c.859C>G (p.Leu287Val) variant in PAH is found with low allele frequency in population databases (3.0e-5). It has been identified in trans with pathogenic variants in two individuals in the literature (P281L and A300S, PMID: 12409276), and in one of those patients a defect in BH4 metabolism was excluded as a cause of elevated phenylalanine (PMID: 16198137). . In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3.	16198137, 12409276, 16198137	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA6748814/MONDO:0009861/006	381aa0a0-283a-47df-a1b8-0180f05e3d16
NM_000277.2(PAH):c.856G>A (p.Glu286Lys)	102880	CA229826	NM_000277.2:c.856G>A, NC_000012.12:g.102851743C>T, CM000674.2:g.102851743C>T, NC_000012.11:g.103245521C>T, CM000674.1:g.103245521C>T, NC_000012.10:g.101769651C>T, NG_008690.1:g.70860G>A, NG_008690.2:g.111668G>A, NM_000277.1:c.856G>A, XM_011538422.1:c.856G>A, NM_001354304.1:c.856G>A, NM_000277.3:c.856G>A, ENST00000307000.7:c.841G>A, ENST00000549247.6:n.615G>A, ENST00000551114.2:n.518G>A, ENST00000553106.5:c.856G>A, ENST00000635477.1:n.17G>A, NM_000277.2(PAH):c.856G>A (p.Glu286Lys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PP3, PS3		The c.856G>A (p.Glu286Lys) variant in PAH is present with low frequency in population databases (1.2e-4), and is predicted to be deleterious using in silico algorithms.  It has been identified in trans with pathogenic variants in two independent patients (R243Q, R241C), and has been identified in a patients with Phenylketonuria in which a defect in BH4 metabolism has been excluded (PMID: 14722928, 24401910).  Enzyme activity has been measured as 1% of wild type controls (BioPKU). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4_Moderate, PS3, PP3.	14722928, 14722928, 24401910	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229826/MONDO:0009861/006	4dc6bb14-c14b-4cd7-854f-bb6dab99dc54
NM_000277.2(PAH):c.848T>A (p.Ile283Asn)	102877	CA229821	NM_000277.2:c.848T>A, NC_000012.12:g.102851751A>T, CM000674.2:g.102851751A>T, NC_000012.11:g.103245529A>T, CM000674.1:g.103245529A>T, NC_000012.10:g.101769659A>T, NG_008690.1:g.70852T>A, NG_008690.2:g.111660T>A, NM_000277.1:c.848T>A, XM_011538422.1:c.848T>A, NM_001354304.1:c.848T>A, NM_000277.3:c.848T>A, ENST00000307000.7:c.833T>A, ENST00000549247.6:n.607T>A, ENST00000551114.2:n.510T>A, ENST00000553106.5:c.848T>A, ENST00000635477.1:n.9T>A, NM_000277.2(PAH):c.848T>A (p.Ile283Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM5, PP4_Moderate, PM2, PP3, PM3_Strong		The c.848T>A (p.Ile283Asn) variant in PAH is absent from population databases and predicted damaging with in silico predictors.  It is a novel missense change in a residue where a different pathogenic variant has been identified (c.847A>T (p.Ile283Phe).  It has been identified in multiple affected individuals in trans with known pathogenic variants (PMID: 9521426, 26413448), and was identified in a patient in which a defect in BH4 metabolism had been excluded. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PM5, PP4_Moderate, PP3.	9521426, 26413448	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229821/MONDO:0009861/006	bff8b781-b702-44cc-bf6e-880d367c1a91
	619158	CA16020750	NM_000277.1:c.224A>G, NC_000012.12:g.102894863T>C, CM000674.2:g.102894863T>C, NC_000012.11:g.103288641T>C, CM000674.1:g.103288641T>C, NC_000012.10:g.101812771T>C, NG_008690.1:g.27740A>G, NG_008690.2:g.68548A>G, XM_011538422.1:c.224A>G, NM_000277.2:c.224A>G, NM_001354304.1:c.224A>G, XM_017019370.2:c.224A>G, NM_000277.3:c.224A>G, ENST00000307000.7:c.209A>G, ENST00000546844.1:c.224A>G, ENST00000548677.2:n.311A>G, ENST00000548928.1:n.146A>G, ENST00000549111.5:n.320A>G, ENST00000550978.6:n.208A>G, ENST00000551337.5:c.224A>G, ENST00000551988.5:n.313A>G, ENST00000553106.5:c.224A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM2, PP4_Moderate	PP3	The c.224A>G (p.Asp75Gly) variant in PAH is reported in 1 Chinese PKU patient. BH4 deficiency was assessed. (PMID: 26503515) It is absent from ExAC, gnomAD, 1000G, and ESP. Computational evidence is conflicting. Another missense change at this amino acid is interpreted as likely pathogenic by our PAH VCEP, c.224A>T (p.Asp75Val). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM5, PP4.	26503515, 25456745	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020750/MONDO:0009861/006	ed279f84-6b13-4f46-a481-787bc75a8fc2
	619149	CA16020738	NM_000277.1:c.184C>G, NC_000012.12:g.102894903G>C, CM000674.2:g.102894903G>C, NC_000012.11:g.103288681G>C, CM000674.1:g.103288681G>C, NC_000012.10:g.101812811G>C, NG_008690.1:g.27700C>G, NG_008690.2:g.68508C>G, XM_011538422.1:c.184C>G, NM_000277.2:c.184C>G, NM_001354304.1:c.184C>G, XM_017019370.2:c.184C>G, NM_000277.3:c.184C>G, ENST00000307000.7:c.169C>G, ENST00000546844.1:c.184C>G, ENST00000548677.2:n.271C>G, ENST00000548928.1:n.106C>G, ENST00000549111.5:n.280C>G, ENST00000550978.6:n.168C>G, ENST00000551337.5:c.184C>G, ENST00000551988.5:n.273C>G, ENST00000553106.5:c.184C>G, ENST00000635500.1:n.152C>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4_Moderate	PM5, PP3	The c.184C>G (p.Leu62Val) variant in PAH is reported in a Chinese PAH patient. BH4 deficiency was excluded. (PMID: 23932990) This variant is absent from ExAC, gnomAD, 1000G, and ESP. Computational evidence is conflicting. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4.	23932990	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020738/MONDO:0009861/006	976702ea-6fd3-46bb-b3b3-2624b3ebc581
	619154	CA16020736	NM_000277.1:c.176A>T, NC_000012.12:g.102894911T>A, CM000674.2:g.102894911T>A, NC_000012.11:g.103288689T>A, CM000674.1:g.103288689T>A, NC_000012.10:g.101812819T>A, NG_008690.1:g.27692A>T, NG_008690.2:g.68500A>T, XM_011538422.1:c.176A>T, NM_000277.2:c.176A>T, NM_001354304.1:c.176A>T, XM_017019370.2:c.176A>T, NM_000277.3:c.176A>T, ENST00000307000.7:c.161A>T, ENST00000546844.1:c.176A>T, ENST00000548677.2:n.263A>T, ENST00000548928.1:n.98A>T, ENST00000549111.5:n.272A>T, ENST00000550978.6:n.160A>T, ENST00000551337.5:c.176A>T, ENST00000551988.5:n.265A>T, ENST00000553106.5:c.176A>T, ENST00000635500.1:n.144A>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM3, PM2, PP4	PP3	The c.176A>T (p.Asp59Val) variant in PAH has been reported in an Italian patient with mild PKU (BH4 deficiency not totally excluded) with pathogenic variant p.R261Q (PP4, PM3; PMID: 25003100) This variant is absent from 1000G, ESP, ExAC and gnomAD. computational evidence is conflicting. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PP3.	25003100, 25003100	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020736/MONDO:0009861/006	cfee7c8b-e49c-474a-bebe-719a67c0306e
NM_000277.2(PAH):c.568G>A (p.Val190Met)	120279	CA267660	NM_000277.2:c.568G>A, NC_000012.12:g.102855274C>T, CM000674.2:g.102855274C>T, NC_000012.11:g.103249052C>T, CM000674.1:g.103249052C>T, NC_000012.10:g.101773182C>T, NG_008690.1:g.67329G>A, NG_008690.2:g.108137G>A, NM_000277.1:c.568G>A, XM_011538422.1:c.568G>A, NM_001354304.1:c.568G>A, XM_017019370.2:c.568G>A, NM_000277.3:c.568G>A, ENST00000307000.7:c.553G>A, ENST00000549111.5:n.664G>A, ENST00000553106.5:c.568G>A, NM_000277.2(PAH):c.568G>A (p.Val190Met)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM5, PM2, PP3		The c.568G>A (p.Val190Met) variant in PAH has not been reported in the literature to our knowledge. The reference from BioPKU (Namour B, Jeannesson E, Chery C, Gueant JL, Feillet F, 2013) cannot be located. This variant is absent from ExAC, gnomAD, 1000G, and ESP. It is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.836. Another variant at this amino acid (p.V190G) is interpreted as pathogenic by the PAH VCEP. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM5, PP3.		Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA267660/MONDO:0009861/006	59d6f750-a5a9-42de-89cd-6796d87ed220
NM_000277.2(PAH):c.473G>C (p.Arg158Pro)	102694	CA229571	NM_000277.2:c.473G>C, NC_000012.12:g.102866632C>G, CM000674.2:g.102866632C>G, NC_000012.11:g.103260410C>G, CM000674.1:g.103260410C>G, NC_000012.10:g.101784540C>G, NG_008690.1:g.55971G>C, NG_008690.2:g.96779G>C, NM_000277.1:c.473G>C, XM_011538422.1:c.473G>C, NM_001354304.1:c.473G>C, XM_017019370.2:c.473G>C, NM_000277.3:c.473G>C, NM_001354304.2:c.473G>C, ENST00000307000.7:c.458G>C, ENST00000549111.5:n.569G>C, ENST00000551988.5:n.530+10830G>C, ENST00000553106.5:c.473G>C, NM_000277.2(PAH):c.473G>C (p.Arg158Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM5, PM2, PP3	PM3, PP4	The c.473G>C (p.Arg158Pro) variant in PAH was reported in PMID: 22330942, but was listed as (p.Arg158Gln). Therefore, we are uncertain if the variant is c.473G>C, or p.Arg158Gln. This variant has an extremely low frequency in ExAC and gnomAD (MAF 0.00002). It is predicted deleterious in SIFT, Polyphen2, MutationTaster and REVEL=0.98. Two different pathogenic missense changes at this amino acid have been seen before (R158W, R158Q). In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM5, PP3.	22330942	Phenylketonuria VCEP		2020-02-28	2020-02-28	false	https://erepo.genome.network/evrepo/ui/classification/CA229571/MONDO:0009861/006	4e4301cb-1d43-4b70-9923-1aceceb5a6cf
NM_000277.2(PAH):c.434A>T (p.Asp145Val)	102667	CA229539	NM_000277.2:c.434A>T, NC_000012.12:g.102877469T>A, CM000674.2:g.102877469T>A, NC_000012.11:g.103271247T>A, CM000674.1:g.103271247T>A, NC_000012.10:g.101795377T>A, NG_008690.1:g.45134A>T, NG_008690.2:g.85942A>T, NM_000277.1:c.434A>T, XM_011538422.1:c.434A>T, NM_001354304.1:c.434A>T, XM_017019370.2:c.434A>T, NM_000277.3:c.434A>T, ENST00000307000.7:c.419A>T, ENST00000549111.5:n.530A>T, ENST00000550978.6:n.418A>T, ENST00000551988.5:n.523A>T, ENST00000553106.5:c.434A>T, NM_000277.2(PAH):c.434A>T (p.Asp145Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2, PP4_Moderate, PP3, PM3_Strong	PM5	The c.434A>T (p.Asp145Val) PAH variant has been identified in patients with PAH deficiency from the US, Germany, Italy and Spain. BH4 deficiency was excluded. (PMID: 8659548; 11385716; 12655553; 17096675; 23514811) It was detected with known pathogenic variants: V388M (PMID: 8659548), I65T (PMID: 24368688), and R408W (PMID: 26666653). It is found at extremely low frequency (MAF 0.00012 in gnomAD). A deleterious effect is predicted in SIFT, Polyphen2, MutationTaster, and REVEL=0.987. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PP4_Moderate, PP3	11385716, 17096675, 12655553, 8659548, 23514811, 24368688, 8659548, 26666653	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229539/MONDO:0009861/006	6ebfc9b5-513f-4058-98a8-49294b98dd36
NM_000277.2(PAH):c.368G>T (p.Arg123Ile)	102658	CA286501	NM_000277.2:c.368G>T, NC_000012.12:g.102877535C>A, CM000674.2:g.102877535C>A, NC_000012.11:g.103271313C>A, CM000674.1:g.103271313C>A, NC_000012.10:g.101795443C>A, NG_008690.1:g.45068G>T, NG_008690.2:g.85876G>T, NM_000277.1:c.368G>T, XM_011538422.1:c.368G>T, NM_001354304.1:c.368G>T, XM_017019370.2:c.368G>T, NM_000277.3:c.368G>T, ENST00000307000.7:c.353G>T, ENST00000549111.5:n.464G>T, ENST00000550978.6:n.352G>T, ENST00000551337.5:c.368G>T, ENST00000551988.5:n.457G>T, ENST00000553106.5:c.368G>T, NM_000277.2(PAH):c.368G>T (p.Arg123Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP3	PM5	The c.368G>T (p.Arg123Ile) variant in PAH has not been reported in the literature to our knowledge. A reference listed in BioPKU/PAHdb cannot be located (Carducci, C 2009). This variant is absent from ExAC, gnomAD, 1000G, and ESP. Deleterious effect is predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.864. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP3.		Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA286501/MONDO:0009861/006	39d9d335-9484-430d-ab6e-318f3eef65d4
NM_000277.2(PAH):c.190C>A (p.His64Asn)	102620	CA229475	NM_000277.2:c.190C>A, NC_000012.12:g.102894897G>T, CM000674.2:g.102894897G>T, NC_000012.11:g.103288675G>T, CM000674.1:g.103288675G>T, NC_000012.10:g.101812805G>T, NG_008690.1:g.27706C>A, NG_008690.2:g.68514C>A, NM_000277.1:c.190C>A, XM_011538422.1:c.190C>A, NM_001354304.1:c.190C>A, XM_017019370.2:c.190C>A, NM_000277.3:c.190C>A, ENST00000307000.7:c.175C>A, ENST00000546844.1:c.190C>A, ENST00000548677.2:n.277C>A, ENST00000548928.1:n.112C>A, ENST00000549111.5:n.286C>A, ENST00000550978.6:n.174C>A, ENST00000551337.5:c.190C>A, ENST00000551988.5:n.279C>A, ENST00000553106.5:c.190C>A, ENST00000635500.1:n.158C>A, NM_000277.2(PAH):c.190C>A (p.His64Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4_Moderate, PM2, PP3	PM5	The c.190C>A (p.His64Asn) variant in PAH has been reported in a Danish mild PKU patient. Serum Phe levels exceeded 600 umol/L and other causes of hyperphenylalaninemia had been ruled out. It was In cis with p.T63P. PMID: 8406445. The c.190C>A variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, Polyphen-2, and MutationTaster. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PP3.	8406445	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229475/MONDO:0009861/006	b8b9ffdf-a020-475b-8cc2-5e3e64b25c10
NM_000277.2(PAH):c.187A>C (p.Thr63Pro)	102619	CA229473	NM_000277.2:c.187A>C, NC_000012.12:g.102894900T>G, CM000674.2:g.102894900T>G, NC_000012.11:g.103288678T>G, CM000674.1:g.103288678T>G, NC_000012.10:g.101812808T>G, NG_008690.1:g.27703A>C, NG_008690.2:g.68511A>C, NM_000277.1:c.187A>C, XM_011538422.1:c.187A>C, NM_001354304.1:c.187A>C, XM_017019370.2:c.187A>C, NM_000277.3:c.187A>C, ENST00000307000.7:c.172A>C, ENST00000546844.1:c.187A>C, ENST00000548677.2:n.274A>C, ENST00000548928.1:n.109A>C, ENST00000549111.5:n.283A>C, ENST00000550978.6:n.171A>C, ENST00000551337.5:c.187A>C, ENST00000551988.5:n.276A>C, ENST00000553106.5:c.187A>C, ENST00000635500.1:n.155A>C, NM_000277.2(PAH):c.187A>C (p.Thr63Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4_Moderate, PM2	PM5, PP3	The c.187A>C (p.Thr63Pro) variant in PAH was detected in 1 Danish PKU patient (Phenylalanine > 600 umol/L). Other causes of hyperphenylalaninemia had been ruled out. (PMID: 8406445). It was in cis with a p.H64N variant (No assertion provided, ClinVar). The c.187A>C variant is absent from ExAC, gnomAD, 1000G, and ESP. There are conflicting predictions of pathogenicity: SIFT:T,D; Polyphen2:D,P; MutationTaster:Disease causing; REVEL:0.768. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate.	8406445	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229473/MONDO:0009861/006	cb8e3701-5523-4f65-afc4-045cb61b8851
NM_000277.2(PAH):c.176A>G (p.Asp59Gly)	102616	CA229468	NM_000277.2:c.176A>G, NC_000012.12:g.102894911T>C, CM000674.2:g.102894911T>C, NC_000012.11:g.103288689T>C, CM000674.1:g.103288689T>C, NC_000012.10:g.101812819T>C, NG_008690.1:g.27692A>G, NG_008690.2:g.68500A>G, NM_000277.1:c.176A>G, XM_011538422.1:c.176A>G, NM_001354304.1:c.176A>G, XM_017019370.2:c.176A>G, NM_000277.3:c.176A>G, ENST00000307000.7:c.161A>G, ENST00000546844.1:c.176A>G, ENST00000548677.2:n.263A>G, ENST00000548928.1:n.98A>G, ENST00000549111.5:n.272A>G, ENST00000550978.6:n.160A>G, ENST00000551337.5:c.176A>G, ENST00000551988.5:n.265A>G, ENST00000553106.5:c.176A>G, ENST00000635500.1:n.144A>G, NM_000277.2(PAH):c.176A>G (p.Asp59Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2	PM5, PP3	The c.176A>G (p.Asp59Gly) variant in PAH has not been reported in the literature to our knowledge. A reference from BioPKU/PAHdb is not located (Carducci C, 1999). It is absent from ExAC, gnomAD, 1000G, and ESP.  There are conflicting predictions of pathogenicity: SIFT/Polyphen2: benign; MutationTaster: Damaging; REVEL=0.565. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2.		Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229468/MONDO:0009861/006	67b0c9a7-1a39-4ab6-a4c6-f15a393519b4
NM_000277.2(PAH):c.164T>C (p.Phe55Ser)	120266	CA267639	NM_000277.2:c.164T>C, NC_000012.12:g.102912795A>G, CM000674.2:g.102912795A>G, NC_000012.11:g.103306573A>G, CM000674.1:g.103306573A>G, NC_000012.10:g.101830703A>G, NG_008690.1:g.9808T>C, NG_008690.2:g.50616T>C, NM_000277.1:c.164T>C, XM_011538422.1:c.164T>C, NM_001354304.1:c.164T>C, XM_017019370.2:c.164T>C, NM_000277.3:c.164T>C, ENST00000307000.7:c.149T>C, ENST00000546844.1:c.164T>C, ENST00000548677.2:n.251T>C, ENST00000548928.1:n.86T>C, ENST00000549111.5:n.260T>C, ENST00000550978.6:n.148T>C, ENST00000551337.5:c.164T>C, ENST00000551988.5:n.253T>C, ENST00000553106.5:c.164T>C, ENST00000635500.1:n.132T>C, NM_000277.2(PAH):c.164T>C (p.Phe55Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4, PP3	PM5	The c.164T>C (p.Phe55Ser) variant in PAH is reported in 1 French patient with classic PKU. BH4 deficiency was not assessed. It was detected with a known pathogenic variant c.1066-11G>A (PMID: 26666653). This variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.96. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4, PP3.	26666653, 26666653	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA267639/MONDO:0009861/006	cd7b08c0-d1ff-4dc6-95f5-142a0fb35f8b
	619156	CA16020731	NM_000277.1:c.136G>C, NC_000012.12:g.102912823C>G, CM000674.2:g.102912823C>G, NC_000012.11:g.103306601C>G, CM000674.1:g.103306601C>G, NC_000012.10:g.101830731C>G, NG_008690.1:g.9780G>C, NG_008690.2:g.50588G>C, XM_011538422.1:c.136G>C, NM_000277.2:c.136G>C, NM_001354304.1:c.136G>C, XM_017019370.2:c.136G>C, NM_000277.3:c.136G>C, ENST00000307000.7:c.121G>C, ENST00000546844.1:c.136G>C, ENST00000548677.2:n.223G>C, ENST00000548928.1:n.58G>C, ENST00000549111.5:n.232G>C, ENST00000550978.6:n.120G>C, ENST00000551337.5:c.136G>C, ENST00000551988.5:n.225G>C, ENST00000553106.5:c.136G>C, ENST00000635500.1:n.104G>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM2, PP4, PP3	PM3	The c.136G>C (p.Gly46Arg) variant in PAH has been reported in 1 individual with classic PKU (BH4 deficiency not totally excluded). (PP4; PMID: 25920592). This variant is absent in population databases (PM2). This variant was detected with a novel large deletion of exons 12 and 13: c.1200-?_1359+?del (EX12_13del). Computational evidence support a deleterious effect. A different pathogenic missense change has been seen at p.G46 (p.G46S) In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM5, PP3.	25920592, 25920592	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020731/MONDO:0009861/006	01270d6f-f459-45a9-b9c4-3bb85fc0998f
NM_000277.2(PAH):c.820A>G (p.Lys274Glu)	102851	CA229786	NM_000277.2:c.820A>G, NC_000012.12:g.102852837T>C, CM000674.2:g.102852837T>C, NC_000012.11:g.103246615T>C, CM000674.1:g.103246615T>C, NC_000012.10:g.101770745T>C, NG_008690.1:g.69766A>G, NG_008690.2:g.110574A>G, NM_000277.1:c.820A>G, XM_011538422.1:c.820A>G, NM_001354304.1:c.820A>G, NM_000277.3:c.820A>G, ENST00000307000.7:c.805A>G, ENST00000549247.6:n.579A>G, ENST00000553106.5:c.820A>G, NM_000277.2(PAH):c.820A>G (p.Lys274Glu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Benign	BS3_Supporting, BS1	PM5, PP3	PAH-specific ACMG/AMP criteria applied: BS1: MAF= 0.01815 in 1000G. 2 homozygotes in ExAC, 1 homozygote in 1000G.; BS3_Supporting: Enzyme activity of K274E is indistinguishable from that of the wild-type protein. Detailed kinetic analyses of PAH expressed in E. coli showed that the K274E mutant protein has kinetic properties similar to that of the wild-type protein. (PMID:11461196). In summary this variant meets criteria to be classified as likely benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BS3_Supporting).	11461196	Phenylketonuria VCEP		2018-08-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229786/MONDO:0009861/006	f459ef35-b6d1-4155-b1aa-7bb752fd55a0
	619148	CA16020866	NM_000277.1:c.817T>C, NC_000012.12:g.102852840A>G, CM000674.2:g.102852840A>G, NC_000012.11:g.103246618A>G, CM000674.1:g.103246618A>G, NC_000012.10:g.101770748A>G, NG_008690.1:g.69763T>C, NG_008690.2:g.110571T>C, XM_011538422.1:c.817T>C, NM_000277.2:c.817T>C, NM_001354304.1:c.817T>C, NM_000277.3:c.817T>C, ENST00000307000.7:c.802T>C, ENST00000549247.6:n.576T>C, ENST00000553106.5:c.817T>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4_Moderate, PP3	PM3	The c.817T>C (p.Ser273Pro) variant in PAH has been reported in a Japanese patient with classic PKU.  (Biopterin deficiency excluded. PMID: 1114275, PP4_Moderate) It was detected with c.442-2G>A (not in ClinVar). This variant is absent from ExAC, gnomAD, 1000G and ESP. A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.976. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PP3.	11142755, 11142755	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020866/MONDO:0009861/006	b2e85334-2419-4c6d-a58e-3cf6e83e25c9
	619152	CA16020865	NM_000277.1:c.813T>G, NC_000012.12:g.102852844A>C, CM000674.2:g.102852844A>C, NC_000012.11:g.103246622A>C, CM000674.1:g.103246622A>C, NC_000012.10:g.101770752A>C, NG_008690.1:g.69759T>G, NG_008690.2:g.110567T>G, XM_011538422.1:c.813T>G, NM_000277.2:c.813T>G, NM_001354304.1:c.813T>G, NM_000277.3:c.813T>G, ENST00000307000.7:c.798T>G, ENST00000549247.6:n.572T>G, ENST00000553106.5:c.813T>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3	PM5	The c.813T>G (p.His271Gln) variant in PAH has been reported in 3 individuals with PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 1829436, 18299955, 21307867). This variant is absent in population databases (PM2). This variant was detected with IVS10-11G>A, known pathogenic (PM3; PMID: 18299955). Computational evidence support a deleterious effect. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.	18299955, 18299955, 21307867, 18294361	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020865/MONDO:0009861/006	294f7fa4-2bba-4ea4-9bd0-32859d3e9ee3
NM_000277.2(PAH):c.812A>G (p.His271Arg)	102850	CA286508	NM_000277.2:c.812A>G, NC_000012.12:g.102852845T>C, CM000674.2:g.102852845T>C, NC_000012.11:g.103246623T>C, CM000674.1:g.103246623T>C, NC_000012.10:g.101770753T>C, NG_008690.1:g.69758A>G, NG_008690.2:g.110566A>G, NM_000277.1:c.812A>G, XM_011538422.1:c.812A>G, NM_001354304.1:c.812A>G, NM_000277.3:c.812A>G, ENST00000307000.7:c.797A>G, ENST00000549247.6:n.571A>G, ENST00000553106.5:c.812A>G, NM_000277.2(PAH):c.812A>G (p.His271Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3	PM5	The c.812A>G (p.His271Arg) variant in the PAH gene has been reported in PKU patients in Henan, and France. Dihydropteridine reductase activity, urinary biopterin and neopterin ratio, and tetrahydrobiopterin loading were collected for the Chinese patient. (PMID: 21462123, 26666653, 26503515). This variant was detected with R408W (PMID: 26666653). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.969. It has an extremely low frequency in ExAC and gnomAD (MAF=0.00006). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4_Moderate, PP3.	26666653, 21462123, 26503515, 26666653	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA286508/MONDO:0009861/006	d192c79d-a8eb-4120-9330-b886bf5f592a
NM_000277.2(PAH):c.811C>T (p.His271Tyr)	102849	CA229784	NM_000277.2:c.811C>T, NC_000012.12:g.102852846G>A, CM000674.2:g.102852846G>A, NC_000012.11:g.103246624G>A, CM000674.1:g.103246624G>A, NC_000012.10:g.101770754G>A, NG_008690.1:g.69757C>T, NG_008690.2:g.110565C>T, NM_000277.1:c.811C>T, XM_011538422.1:c.811C>T, NM_001354304.1:c.811C>T, NM_000277.3:c.811C>T, ENST00000307000.7:c.796C>T, ENST00000549247.6:n.570C>T, ENST00000553106.5:c.811C>T, NM_000277.2(PAH):c.811C>T (p.His271Tyr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4, PP3	PM5	The c.811C>T (p.His271Tyr) variant in PAH has been reported in 2 unrelated PKU patients. BH4 deficiencies not assessed. (PMID: 9012412) A deleterious effect is predicted in SIFT, Polyphen2, MutationTaster, and REVEL=0.978. This variant has an extremely low frequency in ExAC, 1000G, ESP, and gnomAD (MAF=0.00001). . In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP3, PP4.	9012412	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229784/MONDO:0009861/006	45244248-8a0a-4565-9536-b465ac28a4ee
NM_000277.2(PAH):c.194T>A (p.Ile65Asn)	102623	CA229479	NM_000277.2:c.194T>A, NC_000012.12:g.102894893A>T, CM000674.2:g.102894893A>T, NC_000012.11:g.103288671A>T, CM000674.1:g.103288671A>T, NC_000012.10:g.101812801A>T, NG_008690.1:g.27710T>A, NG_008690.2:g.68518T>A, NM_000277.1:c.194T>A, XM_011538422.1:c.194T>A, NM_001354304.1:c.194T>A, XM_017019370.2:c.194T>A, NM_000277.3:c.194T>A, ENST00000307000.7:c.179T>A, ENST00000546844.1:c.194T>A, ENST00000548677.2:n.281T>A, ENST00000548928.1:n.116T>A, ENST00000549111.5:n.290T>A, ENST00000550978.6:n.178T>A, ENST00000551337.5:c.194T>A, ENST00000551988.5:n.283T>A, ENST00000553106.5:c.194T>A, ENST00000635500.1:n.162T>A, NM_000277.2(PAH):c.194T>A (p.Ile65Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		The c.194T>A (p.Ile65Asn) variant was identified in a patient with classic PKU. BH4 deficiency was ruled out. (PMID: 9521426). It was detected in trans with known pathogenic mutation c.143T>C (p.L48S). It has an extremely low frequency in PAGE (0.00026); and is absent from ExAC, 1000 Genomes, gnomAD. Multiple lines of computational evidence support a deleterious effect (SIFT, Polyphen-2, MutationTaster; REVEL=0.957). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4_Moderate, PP3.	9521426, 9521426	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229479/MONDO:0009861/006	a1719899-148c-4be8-9193-1d376d4059d9
NM_000277.2(PAH):c.740G>A (p.Gly247Asp)	102817	CA229734	NM_000277.2:c.740G>A, NC_000012.12:g.102852917C>T, CM000674.2:g.102852917C>T, NC_000012.11:g.103246695C>T, CM000674.1:g.103246695C>T, NC_000012.10:g.101770825C>T, NG_008690.1:g.69686G>A, NG_008690.2:g.110494G>A, NM_000277.1:c.740G>A, XM_011538422.1:c.740G>A, NM_001354304.1:c.740G>A, NM_000277.3:c.740G>A, ENST00000307000.7:c.725G>A, ENST00000549247.6:n.499G>A, ENST00000553106.5:c.740G>A, NM_000277.2(PAH):c.740G>A (p.Gly247Asp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4, PP3	PM5	The c.740G>A (p.Gly247Asp) variant in PAH was reported in 2 patients with classic PKU. PMID: 20920871. This varant is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.975. It has an extremely low frequency in ExAC/gnomAD (MAF 0.00003). In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4, PP3.	20920871	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229734/MONDO:0009861/006	0a85343d-4608-4067-8252-1f3bf74f3cf0
NM_000277.2(PAH):c.739G>C (p.Gly247Arg)	102816	CA229732	NM_000277.2:c.739G>C, NC_000012.12:g.102852918C>G, CM000674.2:g.102852918C>G, NC_000012.11:g.103246696C>G, CM000674.1:g.103246696C>G, NC_000012.10:g.101770826C>G, NG_008690.1:g.69685G>C, NG_008690.2:g.110493G>C, NM_000277.1:c.739G>C, XM_011538422.1:c.739G>C, NM_001354304.1:c.739G>C, NM_000277.3:c.739G>C, ENST00000307000.7:c.724G>C, ENST00000549247.6:n.498G>C, ENST00000553106.5:c.739G>C, NM_000277.2(PAH):c.739G>C (p.Gly247Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2, PP4_Moderate, PP3, PM3_Strong	PM5	The c.739G>C (p.Gly247Arg) variant in PAH has been reported in 3 patients with PAH deficiency, with BH4 deficiency assessed in 2 patients. PMID: 21307867, 18985011, 16256386. It was detected with known pathogenic variants R413P (PMID: 16256386) and V388M (PMID: 18985011). It was absent from ExAC, gnomAD, 1000G, and ESP. This variant is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.981. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PP4_Moderate, PP3.	21307867, 18985011, 16256386, 18985011, 16256386	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229732/MONDO:0009861/006	3b4d8605-fad8-4121-9f56-2b0ecf63eb12
NM_000277.2(PAH):c.739G>A (p.Gly247Ser)	102815	CA229730	NM_000277.2:c.739G>A, NC_000012.12:g.102852918C>T, CM000674.2:g.102852918C>T, NC_000012.11:g.103246696C>T, CM000674.1:g.103246696C>T, NC_000012.10:g.101770826C>T, NG_008690.1:g.69685G>A, NG_008690.2:g.110493G>A, NM_000277.1:c.739G>A, XM_011538422.1:c.739G>A, NM_001354304.1:c.739G>A, NM_000277.3:c.739G>A, ENST00000307000.7:c.724G>A, ENST00000549247.6:n.498G>A, ENST00000553106.5:c.739G>A, NM_000277.2(PAH):c.739G>A (p.Gly247Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4_Moderate, PP3	PM5	The c.739G>A (p.Gly247Ser) variant in PAH was reported in 1 patient with classical PKU, BH4 deficiency excluded. (PMID: 16256386, 25456745) It was detected with T200Nfs, (pathogenic per PAH VCEP). This variant is absent from ExAC, 1000G, gnomAD, and ESP. It is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.981. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PM3, PP3.	25456745, 25456745, 16256386	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229730/MONDO:0009861/006	0a93d02f-63e4-404b-812c-888db7fadaa6
NM_000277.2(PAH):c.706+17G>T	102792	CA229702	NM_000277.2:c.706+17G>T, NC_000012.12:g.102855119C>A, CM000674.2:g.102855119C>A, NC_000012.11:g.103248897C>A, CM000674.1:g.103248897C>A, NC_000012.10:g.101773027C>A, NG_008690.1:g.67484G>T, NG_008690.2:g.108292G>T, NM_000277.1:c.706+17G>T, XM_011538422.1:c.706+17G>T, NM_001354304.1:c.706+17G>T, XM_017019370.2:c.706+17G>T, NM_000277.3:c.706+17G>T, ENST00000307000.7:c.691+17G>T, ENST00000549111.5:n.819G>T, ENST00000553106.5:c.706+17G>T, NM_000277.2(PAH):c.706+17G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Benign	BP4, BS1	PP4	The c.706+17G>T variant in PAH has been reported in the mother of a patient with PKU (not found in the patient). PMID: 11139255. The MAF for this variant is 0.00269, greater than expected. Multiple splicing predictors suggest no impact (HSF: No significant splicing motif alteration detected. This mutation has probably no impact on splicing. MaxEnt: +15.3 % variation). In summary, this variant meets criteria to be classified as likely benign: BS1, BP4.	11139255	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229702/MONDO:0009861/006	42a15d7a-4d52-4cde-a8ef-9abc9e2dcad4
	619163	CA16020843	NM_000277.1:c.697T>A, NC_000012.12:g.102855145A>T, CM000674.2:g.102855145A>T, NC_000012.11:g.103248923A>T, CM000674.1:g.103248923A>T, NC_000012.10:g.101773053A>T, NG_008690.1:g.67458T>A, NG_008690.2:g.108266T>A, XM_011538422.1:c.697T>A, NM_000277.2:c.697T>A, NM_001354304.1:c.697T>A, XM_017019370.2:c.697T>A, NM_000277.3:c.697T>A, ENST00000307000.7:c.682T>A, ENST00000549111.5:n.793T>A, ENST00000553106.5:c.697T>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2, PP3, PS3, PM3_Strong		The c.697T>A (p.Phe233Ile) variant in PAH has been reported in 2 unrelated patients with PKU (BH4 deficiency excluded) and was detected with known pathogenic variants p.R408W and p.V245A. (PP4_Moderate, PM3_Strong; PMID: 23764561). This variant is absent in population databases (PM2). This variant showed no specific activity in functional assay and no response to chaperone co-expression (PS3; PMID: 28653649). Computational prediction tools and conservation analysis suggest this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3_strong, PM2, PP3.	23764561, 28653649, 23764561	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA16020843/MONDO:0009861/006	b990f0f7-2c1b-428d-bfec-28ed05f717f4
	619160	CA16020842	NM_000277.1:c.694C>G, NC_000012.12:g.102855148G>C, CM000674.2:g.102855148G>C, NC_000012.11:g.103248926G>C, CM000674.1:g.103248926G>C, NC_000012.10:g.101773056G>C, NG_008690.1:g.67455C>G, NG_008690.2:g.108263C>G, XM_011538422.1:c.694C>G, NM_000277.2:c.694C>G, NM_001354304.1:c.694C>G, XM_017019370.2:c.694C>G, NM_000277.3:c.694C>G, ENST00000307000.7:c.679C>G, ENST00000549111.5:n.790C>G, ENST00000553106.5:c.694C>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2, PS3	PP3	The c.694C>G (p.Gln232Glu) variant in PAH has not been reported in the literature in individuals with PKU. It has been co-expressed with p.E178G and showed 55.0% enzyme activity. PMID: 26803807. BioPKU reports a 42% enzyme activity for this variant (PS3; PMID: 12501224). This variant is absent in population databases (PM2). Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PS3, PM2.	26803807	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA16020842/MONDO:0009861/006	2d2e4a9f-fe71-4d44-a8d9-cc64cd71145d
	619166	CA16020847	NM_000277.1:c.712A>G, NC_000012.12:g.102852945T>C, CM000674.2:g.102852945T>C, NC_000012.11:g.103246723T>C, CM000674.1:g.103246723T>C, NC_000012.10:g.101770853T>C, NG_008690.1:g.69658A>G, NG_008690.2:g.110466A>G, XM_011538422.1:c.712A>G, NM_000277.2:c.712A>G, NM_001354304.1:c.712A>G, NM_000277.3:c.712A>G, ENST00000307000.7:c.697A>G, ENST00000549247.6:n.471A>G, ENST00000553106.5:c.712A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		The c.712A>G (p.Thr238Ala) variant in PAH has been reported in 2 individuals with PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 23842451, 26503515). This variant is absent in population databases (PM2). This variant was detected with pathogenic variant p.P281L (PM3; PMID: 23842451). Computational evidence support a deleterious effect. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.	23842451, 26503515, 23842451	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA16020847/MONDO:0009861/006	b3f081ca-4251-4be7-a9c4-acd5f05fb2e7
NM_000277.2(PAH):c.650G>A (p.Cys217Tyr)	102772	CA229674	NM_000277.2:c.650G>A, NC_000012.12:g.102855192C>T, CM000674.2:g.102855192C>T, NC_000012.11:g.103248970C>T, CM000674.1:g.103248970C>T, NC_000012.10:g.101773100C>T, NG_008690.1:g.67411G>A, NG_008690.2:g.108219G>A, NM_000277.1:c.650G>A, XM_011538422.1:c.650G>A, NM_001354304.1:c.650G>A, XM_017019370.2:c.650G>A, NM_000277.3:c.650G>A, ENST00000307000.7:c.635G>A, ENST00000549111.5:n.746G>A, ENST00000553106.5:c.650G>A, NM_000277.2(PAH):c.650G>A (p.Cys217Tyr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4_Moderate, PP3	PM5	The c.650G>A (p.Cys217Tyr) variant in PAH was reported in 1 Japanese PKU patient. DHPR activity, biopterin and/or pteridine analysis was performed to rule out other causes of hyperphenylalaninemia. (PMID: 21307867). This variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, Polyphen2, MutationTaster, and REVEL=0.982. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PP3.	21307867	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229674/MONDO:0009861/006	1ca809f3-bf55-4607-8218-009893a28356
	619165	CA16020863	NM_000277.1:c.803A>G, NC_000012.12:g.102852854T>C, CM000674.2:g.102852854T>C, NC_000012.11:g.103246632T>C, CM000674.1:g.103246632T>C, NC_000012.10:g.101770762T>C, NG_008690.1:g.69749A>G, NG_008690.2:g.110557A>G, XM_011538422.1:c.803A>G, NM_000277.2:c.803A>G, NM_001354304.1:c.803A>G, NM_000277.3:c.803A>G, ENST00000307000.7:c.788A>G, ENST00000549247.6:n.562A>G, ENST00000553106.5:c.803A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3	PM5	The c.803A>G (p.Tyr268Cys) variant in PAH has been reported in 1 individual with hyperphenylalaninemia (BH4 deficiency excluded) and was detected with pathogenic variant p.Glu178Gly. (PP4_Moderate, PM3; PMID: 26481238). This variant is absent in population databases (PM2). Computational evidence support a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.	26481238, 26481238	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA16020863/MONDO:0009861/006	547677d3-f246-4f3d-9f34-55a803c2335a
NM_000277.1:c.800A>G	556296	CA16020862	NM_000277.1:c.800A>G, NC_000012.12:g.102852857T>C, CM000674.2:g.102852857T>C, NC_000012.11:g.103246635T>C, CM000674.1:g.103246635T>C, NC_000012.10:g.101770765T>C, NG_008690.1:g.69746A>G, NG_008690.2:g.110554A>G, XM_011538422.1:c.800A>G, NM_000277.2:c.800A>G, NM_001354304.1:c.800A>G, NM_000277.3:c.800A>G, ENST00000307000.7:c.785A>G, ENST00000549247.6:n.559A>G, ENST00000553106.5:c.800A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PP3, PS3	PM5	The c.800A>G (p.Gln267Arg) variant in PAH has been reported in 1 individual with Classic PKU (BH4 deficiency excluded) and was detected with G257V which is pathogenic per the ClinGen PAH VCEP (PP4_Moderate, PM3; PMID: 24401910). This variant is absent in population databases (PM2). This variant has 1.1% enzyme activity (PS3; PMID: 24401910). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM2, PM3, PP3.	24401910, 24401910, 24401910	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA16020862/MONDO:0009861/006	cfc277f3-4908-4b72-91d5-1b6868950557
NM_000277.2(PAH):c.802T>C (p.Tyr268His)	102841	CA229773	NM_000277.2:c.802T>C, NC_000012.12:g.102852855A>G, CM000674.2:g.102852855A>G, NC_000012.11:g.103246633A>G, CM000674.1:g.103246633A>G, NC_000012.10:g.101770763A>G, NG_008690.1:g.69748T>C, NG_008690.2:g.110556T>C, NM_000277.1:c.802T>C, XM_011538422.1:c.802T>C, NM_001354304.1:c.802T>C, NM_000277.3:c.802T>C, ENST00000307000.7:c.787T>C, ENST00000549247.6:n.561T>C, ENST00000553106.5:c.802T>C, NM_000277.2(PAH):c.802T>C (p.Tyr268His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP3	PM5	The c.802T>C (p.Tyr268His) variant in PAH has not been reported in the literature to our knowledge. The reference in BioPKU/PAHdb (Eisensmith, 1996) does not include this variant. It is absent from ExAC, 1000G, and ESP, with Extremely low frequency in gnomAD (0.000004063). A deleterious effect is predicted in SIFT, Polyphen2, MutationTaster, and REVEL=0.977. . In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP3.		Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229773/MONDO:0009861/006	f094cb35-0851-4c83-aa5c-5feea8816db1
NM_000277.2(PAH):c.801G>C (p.Gln267His)	102840	CA229771	NM_000277.2:c.801G>C, NC_000012.12:g.102852856C>G, CM000674.2:g.102852856C>G, NC_000012.11:g.103246634C>G, CM000674.1:g.103246634C>G, NC_000012.10:g.101770764C>G, NG_008690.1:g.69747G>C, NG_008690.2:g.110555G>C, NM_000277.1:c.801G>C, XM_011538422.1:c.801G>C, NM_001354304.1:c.801G>C, NM_000277.3:c.801G>C, ENST00000307000.7:c.786G>C, ENST00000549247.6:n.560G>C, ENST00000553106.5:c.801G>C, NM_000277.2(PAH):c.801G>C (p.Gln267His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4, PP3	PM5	The c.801G>C (p.Gln267His) variant in PAH has been reported in 1 Chinese patient with classical PKU. BH4 deficiencies were not assessed. PMID: 16256386, 19915519. It was detected with a known pathogenic variant p.R252Q. PMID: 16256386. It is absent from population databases. It is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.952. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP3, PP4.	16256386, 19915519, 16256386	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229771/MONDO:0009861/006	88cc7aae-46c6-4cce-a1fb-557f845bdb01
NM_000277.2(PAH):c.799C>G (p.Gln267Glu)	102839	CA229769	NM_000277.2:c.799C>G, NC_000012.12:g.102852858G>C, CM000674.2:g.102852858G>C, NC_000012.11:g.103246636G>C, CM000674.1:g.103246636G>C, NC_000012.10:g.101770766G>C, NG_008690.1:g.69745C>G, NG_008690.2:g.110553C>G, NM_000277.1:c.799C>G, XM_011538422.1:c.799C>G, NM_001354304.1:c.799C>G, NM_000277.3:c.799C>G, ENST00000307000.7:c.784C>G, ENST00000549247.6:n.558C>G, ENST00000553106.5:c.799C>G, NM_000277.2(PAH):c.799C>G (p.Gln267Glu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PM2, PP4, PP3, PS3	PM5	The c.799C>G (p.Gln267Glu) variant in PAH was reported in 2 Chinese PKU patients. BH4 deficiencies not completely ruled out. (PMID: 26600521) This variant was detected with known pathogenic variants p.R111X (PMID: 16256386), and D101N (not in ClinVar, PMID: 26600521). It is absent from ExAC, gnomAD, 1000G, and ESP. This variant is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.935. This variant was expressed in e. coli using a rat Q267E mutant. It has 11% activity of wt. based on duplicate determinations of a single clone. (PMID: 7914195). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PS3, PP3, PP4.	26600521, 16256386, 26600521, 16256386, 9450897, 7914195	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229769/MONDO:0009861/006	3cf6d080-cff7-4ce2-9226-e050a058efd5
NM_000277.2(PAH):c.1147C>T (p.Gln383Ter)	370701	CA16020949	NM_000277.2:c.1147C>T, NC_000012.12:g.102843698G>A, CM000674.2:g.102843698G>A, NC_000012.11:g.103237476G>A, CM000674.1:g.103237476G>A, NC_000012.10:g.101761606G>A, NG_008690.1:g.78905C>T, NG_008690.2:g.119713C>T, NM_000277.1:c.1147C>T, XM_011538422.1:c.1090C>T, NM_001354304.1:c.1147C>T, NM_000277.3:c.1147C>T, ENST00000307000.7:c.1132C>T, ENST00000549247.6:n.906C>T, ENST00000551114.2:n.809C>T, ENST00000553106.5:c.1147C>T, ENST00000635477.1:n.251C>T, ENST00000635528.1:n.662C>T, NM_000277.2(PAH):c.1147C>T (p.Gln383Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PM2, PVS1, PP4		The c.1147C>T (p.Gln383Ter) variant in PAH is a nonsense variant predicted to undergo NMD, present in all biologically relevant transcripts, absent from all populations databases.  It has been identified in a patient with classic PKU as homozygous, and in trans with a pathogenic variant (R408W), although defect in BH4 metabolism was not excluded in either patient. (PMID: 24350308, 22763404). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4.	22763404, 24350308, 22763404, 24350308	Phenylketonuria VCEP		2018-12-09	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020949/MONDO:0009861/006	68a79c42-9ba2-46da-86d0-0f38d4775853
NM_000277.2(PAH):c.1066-2A>T	120258	CA267625	NM_000277.2:c.1066-2A>T, NC_000012.12:g.102843781T>A, CM000674.2:g.102843781T>A, NC_000012.11:g.103237559T>A, CM000674.1:g.103237559T>A, NC_000012.10:g.101761689T>A, NG_008690.1:g.78822A>T, NG_008690.2:g.119630A>T, NM_000277.1:c.1066-2A>T, XM_011538422.1:c.1009-2A>T, NM_001354304.1:c.1066-2A>T, NM_000277.3:c.1066-2A>T, ENST00000307000.7:c.1051-2A>T, ENST00000549247.6:n.825-2A>T, ENST00000551114.2:n.728-2A>T, ENST00000553106.5:c.1066-2A>T, ENST00000635477.1:n.170-2A>T, ENST00000635528.1:n.581-2A>T, NM_000277.2(PAH):c.1066-2A>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PP4_Moderate, PM2		The c.1066-2A>T variant in PAH is absent from all population databases, and has been identified in a patient in which a defect in BH4 metabolism was excluded as a cause of elevated phenylalanine. PMID: 21307867. It is a null variant  where LOF is a known mechanism of disease, exon skipping disrupts reading frame, and is predicted to undergo NMD. Coding exon 11 is present in biologically-relevant transcripts. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PVS1, PM2.	21307867	Phenylketonuria VCEP		2019-04-24	2019-04-24	false	https://erepo.genome.network/evrepo/ui/classification/CA267625/MONDO:0009861/006	b37dff23-d273-465e-ba1b-432ccb787caa
NM_000277.2(PAH):c.632delC (p.Pro211Hisfs)	102767	CA229667	NM_000277.2:c.632delC, NC_000012.12:g.102855211del, CM000674.2:g.102855211del, NC_000012.11:g.103248989del, CM000674.1:g.103248989del, NC_000012.10:g.101773119del, NG_008690.1:g.67393del, NG_008690.2:g.108201del, NM_000277.1:c.632del, XM_011538422.1:c.632del, NM_000277.2:c.632del, NM_001354304.1:c.632del, XM_017019370.2:c.632del, NM_000277.3:c.632del, ENST00000307000.7:c.617del, ENST00000549111.5:n.728del, ENST00000553106.5:c.632del, NM_000277.2(PAH):c.632delC (p.Pro211Hisfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PM2, PP4		The c.632delC (p.Pro211Hisfs) variant in PAH leads to a frameshift at amino acid 211/432. It is identified with low frequency in population databases (1.648e-5).  It has been identified in two individuals with Phenylketonuria as a homozygous variant and in trans with c.1066-11G>A (PMID: 26413448; 26666653).  It has been described in multiple patients with PKU, although a defect in BH4 metabolism has not been excluded as a cause of elevated phenylalanine in any case. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4.	26666653, 26413448, 26666653, 26413448	Phenylketonuria VCEP		2018-12-09	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229667/MONDO:0009861/006	206011ac-8bc7-4dfb-abbb-bbe17ef66221
NM_000277.2(PAH):c.168+1G>A	102604	CA229452	NM_000277.2:c.168+1G>A, NC_000012.12:g.102912790C>T, CM000674.2:g.102912790C>T, NC_000012.11:g.103306568C>T, CM000674.1:g.103306568C>T, NC_000012.10:g.101830698C>T, NG_008690.1:g.9813G>A, NG_008690.2:g.50621G>A, NM_000277.1:c.168+1G>A, XM_011538422.1:c.168+1G>A, NM_001354304.1:c.168+1G>A, XM_017019370.2:c.168+1G>A, NM_000277.3:c.168+1G>A, ENST00000307000.7:c.153+1G>A, ENST00000546844.1:c.168+1G>A, ENST00000548677.2:n.255+1G>A, ENST00000548928.1:n.90+1G>A, ENST00000549111.5:n.264+1G>A, ENST00000550978.6:n.152+1G>A, ENST00000551337.5:c.168+1G>A, ENST00000551988.5:n.257+1G>A, ENST00000553106.5:c.168+1G>A, ENST00000635500.1:n.136+1G>A, NM_000277.2(PAH):c.168+1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PP4_Moderate, PM2		The c.168+1G>A variant in PAH is at a canonical splice site at intron 3, and is absent in all population databases.  It has been identified in trans with a pathogenic variant (Ho, 2014), and as a homozygous variant (PMID: 18294361) in patients with phenylketonuria.  Defects in BH4 metabolism were excluded as a cause of elevated phenylalanine in two patients (PMID: 24368688, 8807331). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4_Moderate.	24368688, 18294361, 8807331, 24368688	Phenylketonuria VCEP		2018-12-09	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229452/MONDO:0009861/006	fd35f7ad-8305-4adf-bce7-3cebca7e1c29
NM_000277.2(PAH):c.1315+2T>C	102588	CA229429	NM_000277.2:c.1315+2T>C, NC_000012.12:g.102840398A>G, CM000674.2:g.102840398A>G, NC_000012.11:g.103234176A>G, CM000674.1:g.103234176A>G, NC_000012.10:g.101758306A>G, NG_008690.1:g.82205T>C, NG_008690.2:g.123013T>C, NM_000277.1:c.1315+2T>C, XM_011538422.1:c.1258+2T>C, NM_001354304.1:c.1315+2T>C, NM_000277.3:c.1315+2T>C, ENST00000307000.7:c.1300+2T>C, ENST00000551114.2:n.977+2T>C, ENST00000553106.5:c.1315+2T>C, ENST00000635477.1:n.419+2T>C, ENST00000635528.1:n.830+2T>C, NM_000277.2(PAH):c.1315+2T>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PM3_Strong	PP3	The c.1315+2T>C variant is at the 3' canonical splice site in the penultimate exon of PAH.  It is absent form population databases and has been identified in trans with pathogenic variants in three independent patients (F39del, Y414C, and R261X; PMID: 9452062; 9521426).  A defect of BH4 metabolism was excluded as a cause of elevated phenylalanine in all patients. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_strong.	9521426, 9452062, 9521426	Phenylketonuria VCEP		2018-12-09	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229429/MONDO:0009861/006	d9c83133-49d7-48ae-af5f-702bc7606dad
NM_000277.2(PAH):c.827T>A (p.Met276Lys)	102857	CA229795	NM_000277.2:c.827T>A, NC_000012.12:g.102852830A>T, CM000674.2:g.102852830A>T, NC_000012.11:g.103246608A>T, CM000674.1:g.103246608A>T, NC_000012.10:g.101770738A>T, NG_008690.1:g.69773T>A, NG_008690.2:g.110581T>A, NM_000277.1:c.827T>A, XM_011538422.1:c.827T>A, NM_001354304.1:c.827T>A, NM_000277.3:c.827T>A, ENST00000307000.7:c.812T>A, ENST00000549247.6:n.586T>A, ENST00000553106.5:c.827T>A, NM_000277.2(PAH):c.827T>A (p.Met276Lys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM3, PM2, PP4_Moderate	PP3	The c.827T>A (p.Met276Lys) variant in PAH is absent from population databases, and found in the same codon as a previously reported pathogenic variant (p.Met276Val).  It has been identified in trans with a known pathogenic variant (I95del), in which a defect of BH4 metabolism was excluded as a cause of elevated phenylalanine (PMID: 25894915).	25894915, 25894915	Phenylketonuria VCEP		2018-12-09	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229795/MONDO:0009861/006	b816d0d3-13ff-424f-a001-bf9ec73622e4
NM_000277.2(PAH):c.826A>G (p.Met276Val)	102856	CA229794	NM_000277.2:c.826A>G, NC_000012.12:g.102852831T>C, CM000674.2:g.102852831T>C, NC_000012.11:g.103246609T>C, CM000674.1:g.103246609T>C, NC_000012.10:g.101770739T>C, NG_008690.1:g.69772A>G, NG_008690.2:g.110580A>G, NM_000277.1:c.826A>G, XM_011538422.1:c.826A>G, NM_001354304.1:c.826A>G, NM_000277.3:c.826A>G, ENST00000307000.7:c.811A>G, ENST00000549247.6:n.585A>G, ENST00000553106.5:c.826A>G, NM_000277.2(PAH):c.826A>G (p.Met276Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2, PP4_Moderate, PM3_Strong	PP3	The c.826A>G (p.Met276Val) variant in PAH is absent from population databases.  It has been identified in trans with pathogenic variants in two patients (A300S and R261Q; PMID: 16198137), and identified in an additional patient in which a defect in BH4 metabolism was excluded as a cause of elevated phenylalanine (PMID: 9634518). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_strong.	9634518, 16198137	Phenylketonuria VCEP		2018-12-09	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229794/MONDO:0009861/006	f085841b-65ba-4950-9a05-678a254062ce
NM_000277.2(PAH):c.824C>G (p.Pro275Arg)	102854	CA229791	NM_000277.2:c.824C>G, NC_000012.12:g.102852833G>C, CM000674.2:g.102852833G>C, NC_000012.11:g.103246611G>C, CM000674.1:g.103246611G>C, NC_000012.10:g.101770741G>C, NG_008690.1:g.69770C>G, NG_008690.2:g.110578C>G, NM_000277.1:c.824C>G, XM_011538422.1:c.824C>G, NM_001354304.1:c.824C>G, NM_000277.3:c.824C>G, ENST00000307000.7:c.809C>G, ENST00000549247.6:n.583C>G, ENST00000553106.5:c.824C>G, NM_000277.2(PAH):c.824C>G (p.Pro275Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM3, PP4_Moderate, PM2, PP3		The c.824C>G (p.Pro275Arg) variant in PAH is absent from population databases and predicted deleterious by multiple in silico algorithms.  It is in the same codon as two previously reported likely pathogenic variants (p.Pro275Ser and p.Pro275Leu).  It has been identified in trans with a pathogenic variant (PMID: 23514811), and a defect in BH4 metabolism was excluded as a cause of elevated phenylalanine in that patient. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PM5, PP3.	23514811, 23514811	Phenylketonuria VCEP		2018-12-09	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229791/MONDO:0009861/006	f7fde206-5b4d-4940-8eec-742dbe7ee761
NM_000277.2(PAH):c.823C>T (p.Pro275Ser)	102853	CA229789	NM_000277.2:c.823C>T, NC_000012.12:g.102852834G>A, CM000674.2:g.102852834G>A, NC_000012.11:g.103246612G>A, CM000674.1:g.103246612G>A, NC_000012.10:g.101770742G>A, NG_008690.1:g.69769C>T, NG_008690.2:g.110577C>T, NM_000277.1:c.823C>T, XM_011538422.1:c.823C>T, NM_001354304.1:c.823C>T, NM_000277.3:c.823C>T, ENST00000307000.7:c.808C>T, ENST00000549247.6:n.582C>T, ENST00000553106.5:c.823C>T, NM_000277.2(PAH):c.823C>T (p.Pro275Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM5, PP4_Moderate, PM2, PP3, PM3_Strong		The c.823C>T (p.Pro275Ser) variant in PAH is absent from all population databases, and is in the same codon as two other likely pathogenic variants.  In silico algorithms agree on a damaging effect.  It has been identified in trans with two independent pathogenic variants (R408W and c.669delC; PMID: 20123475, 24705691), and a defect in BH4 metabolism was excluded as a cause of elevated phenylalanine in multiple patients. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PP4_Moderate, PM5, PP3.	24705691, 20123475, 24705691, 20123475	Phenylketonuria VCEP		2018-12-09	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229789/MONDO:0009861/006	85ea4e16-15ba-4de1-88b7-46e398122a6e
NM_000277.2(PAH):c.796A>C (p.Thr266Pro)	120286	CA267673	NM_000277.2:c.796A>C, NC_000012.12:g.102852861T>G, CM000674.2:g.102852861T>G, NC_000012.11:g.103246639T>G, CM000674.1:g.103246639T>G, NC_000012.10:g.101770769T>G, NG_008690.1:g.69742A>C, NG_008690.2:g.110550A>C, NM_000277.1:c.796A>C, XM_011538422.1:c.796A>C, NM_001354304.1:c.796A>C, NM_000277.3:c.796A>C, ENST00000307000.7:c.781A>C, ENST00000549247.6:n.555A>C, ENST00000553106.5:c.796A>C, NM_000277.2(PAH):c.796A>C (p.Thr266Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3	PM5	The c.796A>C (p.Thr266Pro) variant in PAH is reported in 1 classic PKU patient with BH4 deficiency excluded. (PMID: 26666653, 23430918) It was detected with p.V190A, which is interpreted as pathogenic by our PAH VCEP. (PMID: 23430918) This variant is absent from ExAC, gnomAD, 1000G, and ESP. It is predicted deleterious in SIFT, Polyphen-2, MutationTaster, and REVEL=0.98. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PM3, PP3.	23430918, 26666653, 23430918	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA267673/MONDO:0009861/006	9d15f844-7f1a-47ea-91e3-fa8a96d0342c
	619150	CA16020857	NM_000277.1:c.788T>C, NC_000012.12:g.102852869A>G, CM000674.2:g.102852869A>G, NC_000012.11:g.103246647A>G, CM000674.1:g.103246647A>G, NC_000012.10:g.101770777A>G, NG_008690.1:g.69734T>C, NG_008690.2:g.110542T>C, XM_011538422.1:c.788T>C, NM_000277.2:c.788T>C, NM_001354304.1:c.788T>C, NM_000277.3:c.788T>C, ENST00000307000.7:c.773T>C, ENST00000549247.6:n.547T>C, ENST00000553106.5:c.788T>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PM2, PP4, PP3, PS3		The c.788T>C (p.Phe263Ser) variant in PAH has been reported in 1 patient with hyperphenylalaninemia (BH4 deficiency not excluded) and was detected with known pathogenic variant c.1066-11G>A (PP4, PM3; PMID: 23357515). This variant is absent in population databases (PM2). This variant has 4% enzyme activity (PS3; PMID:20179079). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PS3, PM2, PM3, PP3, PP4.	23357515, 23357515, 20179079	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA16020857/MONDO:0009861/006	ff16e9ce-c14a-43a3-9502-03a9763729f0
NM_000277.2(PAH):c.789C>G (p.Phe263Leu)	102833	CA229760	NM_000277.2:c.789C>G, NC_000012.12:g.102852868G>C, CM000674.2:g.102852868G>C, NC_000012.11:g.103246646G>C, CM000674.1:g.103246646G>C, NC_000012.10:g.101770776G>C, NG_008690.1:g.69735C>G, NG_008690.2:g.110543C>G, NM_000277.1:c.789C>G, XM_011538422.1:c.789C>G, NM_001354304.1:c.789C>G, NM_000277.3:c.789C>G, ENST00000307000.7:c.774C>G, ENST00000549247.6:n.548C>G, ENST00000553106.5:c.789C>G, NM_000277.2(PAH):c.789C>G (p.Phe263Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4_Moderate, PM2, PP3	PM3, PM5	The c.789C>G (p.Phe263Leu) variant in PAH is reported in 1 patient with classical PKU, and 1 Chinese PKU patient. (BH4 deficiency excluded. PMID: 8222245, 26600521) This variant is absent from 1000G and ESP with extremely low frequency in ExAC/gnomAD (MAF=0.00003). It is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.929. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PP3.	26600521, 26600521, 8222245	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229760/MONDO:0009861/006	aa0c5a96-1385-4b9c-ae8b-d8cb6898d847
NM_000277.2(PAH):c.785T>G (p.Val262Gly)	120285	CA267671	NM_000277.2:c.785T>G, NC_000012.12:g.102852872A>C, CM000674.2:g.102852872A>C, NC_000012.11:g.103246650A>C, CM000674.1:g.103246650A>C, NC_000012.10:g.101770780A>C, NG_008690.1:g.69731T>G, NG_008690.2:g.110539T>G, NM_000277.1:c.785T>G, XM_011538422.1:c.785T>G, NM_001354304.1:c.785T>G, NM_000277.3:c.785T>G, ENST00000307000.7:c.770T>G, ENST00000549247.6:n.544T>G, ENST00000553106.5:c.785T>G, NM_000277.2(PAH):c.785T>G (p.Val262Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4, PP3	PM5	The c.785T>G (p.Val262Gly) variant in PAH is observed in 1 patient with classic PKU. BH4 deficiencies were not assessed. It was detected with a known pathogenic variant p.F39L. PMID: 26666653. This variant is absent from ExAC, gnomAD, 1000G, and ESP. It is predicted deleterious in SIFT, Polyphen-2, MutationTaster, and REVEL=0.954. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4, PP3.	26666653, 26666653	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA267671/MONDO:0009861/006	9357bfa1-6426-4f30-9c29-28a74e5240df
	619159	CA16020855	NM_000277.1:c.773T>C, NC_000012.12:g.102852884A>G, CM000674.2:g.102852884A>G, NC_000012.11:g.103246662A>G, CM000674.1:g.103246662A>G, NC_000012.10:g.101770792A>G, NG_008690.1:g.69719T>C, NG_008690.2:g.110527T>C, XM_011538422.1:c.773T>C, NM_000277.2:c.773T>C, NM_001354304.1:c.773T>C, NM_000277.3:c.773T>C, ENST00000307000.7:c.758T>C, ENST00000549247.6:n.532T>C, ENST00000553106.5:c.773T>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PP3, PM3_Supporting	PM5	The c.773T>C (p.Leu258Pro) variant in PAH has been reported in 3 individuals with mild PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 19786003, 23514811). This variant is absent in population databases (PM2). This variant was present in two homozygous patients. Genetic analysis in parents confirmed homozygosity. PMID: 23514811 (PM3-supporting). Computational evidence supports a deleterious effect . In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_supporting, PP3.	19786003, 23514811	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA16020855/MONDO:0009861/006	5bb26a8d-7e21-4fb6-93c4-a25021d88ba1
NM_000277.2(PAH):c.473G>A (p.Arg158Gln)	587	CA251530	NM_000277.2:c.473G>A, NC_000012.12:g.102866632C>T, CM000674.2:g.102866632C>T, NC_000012.11:g.103260410C>T, CM000674.1:g.103260410C>T, NC_000012.10:g.101784540C>T, NG_008690.1:g.55971G>A, NG_008690.2:g.96779G>A, NM_000277.1:c.473G>A, XM_011538422.1:c.473G>A, NM_001354304.1:c.473G>A, XM_017019370.2:c.473G>A, NM_000277.3:c.473G>A, ENST00000307000.7:c.458G>A, ENST00000549111.5:n.569G>A, ENST00000551988.5:n.530+10830G>A, ENST00000553106.5:c.473G>A, NM_000277.2(PAH):c.473G>A (p.Arg158Gln)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM3_Very Strong, PS3	PM2, PS2	PAH-specific ACMG/AMP criteria applied: PS3: R158Q is associated with very low levels (0.2-1.8%) of pah enzyme activity compared to wild-type. (PMID:2014036; PMID:19036622); PP3: tools predict damaging ; PP4_Moderate: BH4 testing showed responsive in a pt, pretreatment 1065uM (PMID:23500595); PM3_VeryStrong: in trans with 4 pathogenic variants: I48S, c.1315+1G>A, P281L, R261Ter. (PMID:23500595; PMID:10479481; PMID:24368688). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PS3, PP3, PP4_Moderate, PM3_VeryStrong).	23500595, 10479481, 24368688, 23500595, 19036622, 2014036	Phenylketonuria VCEP		2018-08-05	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA251530/MONDO:0009861/006	0c42e06b-e66b-4820-b77e-007dbe8b7c6f
NM_000277.1(PAH):c.805A>C (p.Ile269Leu)	102842	CA229775	NM_000277.1:c.805A>C, NC_000012.12:g.102852852T>G, CM000674.2:g.102852852T>G, NC_000012.11:g.103246630T>G, CM000674.1:g.103246630T>G, NC_000012.10:g.101770760T>G, NG_008690.1:g.69751A>C, NG_008690.2:g.110559A>C, XM_011538422.1:c.805A>C, NM_000277.2:c.805A>C, NM_001354304.1:c.805A>C, NM_000277.3:c.805A>C, ENST00000307000.7:c.790A>C, ENST00000549247.6:n.564A>C, ENST00000553106.5:c.805A>C, NM_000277.1(PAH):c.805A>C (p.Ile269Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2, PP4_Moderate, PP3, PM3_Very Strong		The c.805A>C (p.Ile269Leu) variant in PAH has been reported in multiple individuals with PAH deficiency, including non-PKU HPA (BH4 deficiency excluded). (PP4_Moderate; PMID10767174, PMID 2350059). This variant has an extremely low allele frequency in ExAC and gnomAD (PM2; ENF=0.00013). This variant was detected in trans with multiple known pathogenic variants: PMID 9521426: c.842+3G>C; PMID 10767174: R261X; PMID 14726806: E280K; PMID 21871829: IVS10-11G>A (PM3_Very-strong). Computational prediction tools and conservation analysis suggest this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_Very-strong, PP4_Moderate, PM2, PP3.	10767174, 9521426, 21871829, 10767174, 14726806, 9521426	Phenylketonuria VCEP		2018-12-10	2019-05-04	false	https://erepo.genome.network/evrepo/ui/classification/CA229775/MONDO:0009861/006	980fb510-b83f-4177-95ab-dc11302d825a
NM_000277.1(PAH):c.754C>G (p.Arg252Gly)	102823	CA229742	NM_000277.1:c.754C>G, NC_000012.12:g.102852903G>C, CM000674.2:g.102852903G>C, NC_000012.11:g.103246681G>C, CM000674.1:g.103246681G>C, NC_000012.10:g.101770811G>C, NG_008690.1:g.69700C>G, NG_008690.2:g.110508C>G, XM_011538422.1:c.754C>G, NM_000277.2:c.754C>G, NM_001354304.1:c.754C>G, NM_000277.3:c.754C>G, ENST00000307000.7:c.739C>G, ENST00000549247.6:n.513C>G, ENST00000553106.5:c.754C>G, NM_000277.1(PAH):c.754C>G (p.Arg252Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM5, PM2, PP4_Moderate, PP3, PS3		The c.754C>G (p.Arg252Gly) variant in PAH has been reported in multiple individuals with Classic PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 1363786, 9634518). This variant is absent in population databases (PM2). This variant has 3% enzyme activity (PS3; PMID: 9799096). Computational prediction tools and conservation analysis suggest this variant may impact the protein (PP3). This missense change is at an amino acid residue where different pathogenic missense changes have been seen before (p.Arg252Gln/Trp). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM2, PM5, PP3.	9634518, 1363786, 9799096	Phenylketonuria VCEP		2018-12-08	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA229742/MONDO:0009861/006	1e25ace3-fb0d-46cc-a64d-e393e6780847
NM_000277.1(PAH):c.842C>T (p.Pro281Leu)	589	CA220589	NM_000277.1:c.842C>T, NC_000012.12:g.102852815G>A, CM000674.2:g.102852815G>A, NC_000012.11:g.103246593G>A, CM000674.1:g.103246593G>A, NC_000012.10:g.101770723G>A, NG_008690.1:g.69788C>T, NG_008690.2:g.110596C>T, XM_011538422.1:c.842C>T, NM_000277.2:c.842C>T, NM_001354304.1:c.842C>T, NM_000277.3:c.842C>T, ENST00000307000.7:c.827C>T, ENST00000549247.6:n.601C>T, ENST00000553106.5:c.842C>T, ENST00000635477.1:n.3C>T, NM_000277.1(PAH):c.842C>T (p.Pro281Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PP3, PS3	PM2	PAH-specific ACMG/AMP criteria applied: PP3: ; PS3: 2% activity in bioPKU (PAH0309) (PMID:25596310; PMID:17935162); PP4_Moderate: 2 patients with moderate or classical PKU; patients with severe PKU. BH4 deficiency ruled out. (PMID:15503242; PMID:12655553); PM3: IVS4-1G>A (P/LP) (PMID:15503242). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PS3, PP4_Moderate, PM3).	15503242, 12655553, 15503242, 17935162, 25596310	Phenylketonuria VCEP		2018-08-27	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA220589/MONDO:0009861/006	c12aac5a-a84d-4ecc-b66a-d375bf2deb7b
NM_000277.1(PAH):c.841C>T (p.Pro281Ser)	92749	CA220587	NM_000277.1:c.841C>T, NC_000012.12:g.102852816G>A, CM000674.2:g.102852816G>A, NC_000012.11:g.103246594G>A, CM000674.1:g.103246594G>A, NC_000012.10:g.101770724G>A, NG_008690.1:g.69787C>T, NG_008690.2:g.110595C>T, XM_011538422.1:c.841C>T, NM_000277.2:c.841C>T, NM_001354304.1:c.841C>T, NM_000277.3:c.841C>T, ENST00000307000.7:c.826C>T, ENST00000549247.6:n.600C>T, ENST00000553106.5:c.841C>T, ENST00000635477.1:n.2C>T, NM_000277.1(PAH):c.841C>T (p.Pro281Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PP3, PM3_Strong	PM5	PAH-specific ACMG/AMP criteria applied: PM2: 1 allele in ExAC ; PP3: tools predict damaging ; PP4_Moderate: P281S Identified in at least one patient with classic PKU. BH4 deficiency excluded. (PMID:15589814); PM3_Strong: Detected with c.1315+1G>A & p.Arg243Ter, pathogenic in ClinVar (PMID:26666653; PMID:27121329). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong).	15589814, 26666653, 27121329	Phenylketonuria VCEP		2018-08-10	2019-08-17	false	https://erepo.genome.network/evrepo/ui/classification/CA220587/MONDO:0009861/006	4bb0b9e5-fa14-4fb0-bac1-1bcae3cc23b8
NM_030662.3(MAP2K2):c.690G>A (p.Thr230=)	138159	CA291996	NM_030662.3:c.690G>A, LRG_750t1:c.690G>A, XM_006722799.2:c.690G>A, XM_011528133.1:c.120G>A, XM_017026989.1:c.690G>A, XM_017026990.1:c.690G>A, XM_017026991.1:c.690G>A, ENST00000262948.9:c.690G>A, ENST00000394867.8:c.399G>A, ENST00000593364.5:n.637G>A, ENST00000597008.5:n.291G>A, ENST00000597263.5:n.154G>A, ENST00000599021.1:n.14G>A, ENST00000601786.5:n.991G>A, ENST00000602167.5:n.410G>A, NC_000019.10:g.4101034C>T, CM000681.2:g.4101034C>T, NC_000019.9:g.4101032C>T, CM000681.1:g.4101032C>T, NC_000019.8:g.4052032C>T, NG_007996.1:g.28095G>A, LRG_750:g.28095G>A, NM_030662.3(MAP2K2):c.690G>A (p.Thr230=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.690G>A (p.Thr230=) variant in the MAP2K2 gene is 0.1273% for Latino chromosomes by the Exome Aggregation Consortium (3/642 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2018-11-15	2018-12-10	false	https://erepo.genome.network/evrepo/ui/classification/CA291996/MONDO:0021060/004	76788912-f5e9-4ff4-8343-c7b0c152c0b2
NM_000260.3(MYO7A):c.905G>A (p.Arg302His)	11852	CA132454	NM_000260.3:c.905G>A, NC_000011.10:g.77158332G>A, CM000673.2:g.77158332G>A, NC_000011.9:g.76869378G>A, CM000673.1:g.76869378G>A, NC_000011.8:g.76547026G>A, NG_009086.1:g.35069G>A, NM_001127179.2:c.905G>A, NM_001127180.1:c.905G>A, XM_005274012.2:c.905G>A, XM_006718558.2:c.905G>A, XM_006718559.2:c.905G>A, XM_006718560.2:c.905G>A, XM_006718561.2:c.905G>A, XM_011545044.1:c.905G>A, XM_011545045.1:c.905G>A, XM_011545046.1:c.872G>A, XM_011545047.1:c.905G>A, XM_011545048.1:c.905G>A, XM_011545049.1:c.849+940G>A, XM_011545050.1:c.647G>A, XM_011545051.1:c.905G>A, XM_011545052.1:c.905G>A, XR_949938.1:n.1225G>A, XR_949941.1:n.1225G>A, XR_949942.1:n.1227G>A, XR_949943.1:n.1227G>A, XM_011545044.2:c.905G>A, XM_011545046.2:c.995G>A, XM_011545050.2:c.647G>A, XM_017017778.1:c.995G>A, XM_017017779.1:c.995G>A, XM_017017780.1:c.995G>A, XM_017017781.1:c.995G>A, XM_017017782.1:c.995G>A, XM_017017783.1:c.995G>A, XM_017017784.1:c.995G>A, XM_017017785.1:c.939+940G>A, XM_017017786.1:c.995G>A, XM_017017787.1:c.995G>A, XM_017017788.1:c.995G>A, XR_001747885.1:n.1010G>A, XR_001747886.1:n.1010G>A, XR_001747887.1:n.1010G>A, XR_001747888.1:n.1010G>A, XR_001747889.1:n.1010G>A, NM_000260.4:c.905G>A, ENST00000409619.6:c.872G>A, ENST00000409709.7:c.905G>A, ENST00000409893.5:c.905G>A, ENST00000458637.6:c.905G>A, ENST00000620575.4:c.905G>A, NM_000260.3(MYO7A):c.905G>A (p.Arg302His)	MYO7A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Likely Benign	BS1, BP2, BS3_Supporting	BP5	The filtering allele frequency of the c.905G>A (p.Arg302His) variant in the MYO7A gene is 0.4% for European chromosomes by gnomAD (587/126276 with 95% CI), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). While this variant has been reported in several individuals with Usher syndrome, in 2 individuals it was identified in cis with another pathogenic MYO7A variant (BP2; PMID 8900236). This variant has also been reported in at least 2 additional individuals with Usher syndrome who had alternate genetic etiologies identified (PMID: 25468891). In addition, in vitro functional evidence from one study suggests that the Arg302His variant had little effect on motor activity of MYO7A (BS3_Supporting PMID: 18700726). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BS1, BP2, BS3_Supporting.	25468891, 8900236, 18700726	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-10-22	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA132454/MONDO:0019501/005	dc239e28-ecae-44c9-998a-c69771a041f3
NM_022124.6(CDH23):c.6614C>T (p.Pro2205Leu)	46014	CA137541	NM_022124.6:c.6614C>T, NC_000010.11:g.71793542C>T, CM000672.2:g.71793542C>T, NC_000010.10:g.73553299C>T, CM000672.1:g.73553299C>T, NC_000010.9:g.73223305C>T, NG_008835.1:g.401596C>T, ENST00000224721.12:c.6614C>T, ENST00000224721.10:c.6629C>T, ENST00000622827.4:c.6614C>T, NM_022124.5:c.6614C>T, XM_006717940.2:c.6809C>T, XM_006717942.2:c.6743C>T, XM_011540039.1:c.6806C>T, XM_011540040.1:c.6803C>T, XM_011540041.1:c.6749C>T, XM_011540042.1:c.6719C>T, XM_011540043.1:c.6809C>T, XM_011540044.1:c.6674C>T, XM_011540045.1:c.6809C>T, XM_011540046.1:c.6269C>T, XM_011540047.1:c.5627C>T, XM_011540048.1:c.6809C>T, XM_011540049.1:c.6809C>T, XM_011540050.1:c.6809C>T, XM_011540051.1:c.6809C>T, XM_011540052.1:c.3137C>T, XR_945796.1:n.7052C>T, NM_022124.6(CDH23):c.6614C>T (p.Pro2205Leu)	CDH23	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	PP1, PM3, PM2_Supporting	PP3	The variant c.6614C>T (NM_022124.6(CDH23):c.6614C>T (p.Pro2205Leu)) in CDH23 is a missense variant predicted to cause substitution of proline by leucine at amino acid 2205 (p.Pro2205Leu). The highest population minor allele frequency in gnomAD v4.0.0 is 0.000002920 (8/1179896 alleles) in the European (non-Finnish) population, which is lower than the ClinGen Hearing Loss VCEP threshold (<0.00007) for PM2_Supporting, meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.342, which is neither above nor below the thresholds predicting a damaging or benign impact on CDH23 function. This variant has been detected in at least 8 individuals with autosomal recessive hearing loss. All of these individuals were homozygous for the variant (1.0 pts; PMIDs: 28501645, 32747562 & LMM Internal Data (SCV000062934.5); PM3). There was a common haplotype found between five affected individuals from three families, one of which had three affected siblings, including a set of twins. Personal communication confirmed the three siblings were sequenced; however, it was not apparent whether the twins were dizygotic or monozygotic and therefore only one twin was counted toward segregation (PP1_Supporting; 28501645). In summary, this variant meets the criteria to be classified as uncertain significance for autosomal recessive Usher syndrome, based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP (PM2_Supporting, PM3, PP1_Supporting; Version 2; 11/15/23).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-11-15	2024-01-10	false	https://erepo.genome.network/evrepo/ui/classification/CA137541/MONDO:0019501/005	f49b45e9-308a-4c2f-8941-4ed41c897a1b
NM_004086.2(COCH):c.151C>T (p.Pro51Ser)	6611	CA253889	NM_004086.2:c.151C>T, NC_000014.9:g.30877640C>T, CM000676.2:g.30877640C>T, NC_000014.8:g.31346846C>T, CM000676.1:g.31346846C>T, NC_000014.7:g.30416597C>T, NG_008211.2:g.8106C>T, NM_001135058.1:c.151C>T, NR_038356.1:n.1618-1088G>A, XM_011536539.1:c.151C>T, NM_001347720.1:c.346C>T, XM_017021071.1:c.346C>T, XM_024449506.1:c.151C>T, NM_004086.3:c.151C>T, ENST00000216361.8:c.151C>T, ENST00000396618.7:c.151C>T, ENST00000460581.6:c.-186C>T, ENST00000475087.5:c.151C>T, ENST00000553772.5:c.151C>T, ENST00000553833.5:n.305C>T, ENST00000555881.5:c.82+2537C>T, ENST00000556908.5:c.103C>T, ENST00000557065.1:n.67C>T, NM_004086.2(COCH):c.151C>T (p.Pro51Ser)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PP3, PM2, PS4	BS4, BS1, BP5, BP7, BS2, PP4, PM3, PM1, PM4, PM5, PVS1, PM6, BP2, BP3, BP4, BA1, PS2, PS3, PS1	The c.151C>T (p.Pro51Ser) variant in COCH has been reported to segregate with late onset progressive hearing loss and vestibular dysfunction in > 25 family members (PP1_S; PMID: 9931344, 11332404). The variant meets PM2 and has been observed in at least 15 affected probands (PS4, PMID: 28733840, 16151338, 11332404). The allele frequency of the p.Pro51Ser variant is 0.001% (1/111716) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss (PM2). Computational prediction tools and conservation analysis suggest that the p.Pro51Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PP1_S, PS4, PM2, PP3.	24662630, 9931344, 16151338, 24662630, 9931344, 16151338, 11332404, 12928864, 25230692, 26256111, 16481359, 20228067, 28733840, 16151338, 11332404	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-19	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA253889/MONDO:0019497/005	d4782d4a-27b7-4626-acc7-f8758d33384d
NM_004004.6(GJB2):c.677T>G (p.Val226Gly)	447450	CA6904209	NM_004004.6:c.677T>G, NC_000013.11:g.20188905A>C, CM000675.2:g.20188905A>C, NC_000013.10:g.20763044A>C, CM000675.1:g.20763044A>C, NC_000013.9:g.19661044A>C, NG_008358.1:g.9071T>G, ENST00000382844.2:c.677T>G, ENST00000382848.5:c.677T>G, ENST00000382844.1:c.677T>G, ENST00000382848.4:c.677T>G, NM_004004.5:c.677T>G, XM_011535049.1:c.677T>G, XM_011535049.2:c.677T>G, NM_004004.6(GJB2):c.677T>G (p.Val226Gly)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PM2	BS1, BS3, BS4, BP7, BP5, BS2, PP3, PP2, PP4, PP1, PM5, PM4, PM1, PM3, PM6, PVS1, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS2, PS4	The c.677T>G variant in GJB2 is a missense variant predicted to cause substitution of valine to glycine at amino acid 226. The highest population minor allele frequency in gnomAD v2.1.1 is 0.003% (1/35370) in Latino/Admixed American chromosomes, which is below the PM2_Supporting thresholds defined by the ClinGen Hearing Loss Expert Panel (â‰¤0.007%) for autosomal recessive disorders (PM2_Supporting). The computational predictor REVEL gives a score of 0.586 which is neither above nor below the thresholds predicting a damaging or benign impact on USH2A function (no criteria met).  It has been reported in the literature in one heterozygous individual with hearing loss; however, a second variant was not identified and there was no reported family history of hearing loss (no criteria met; PMID: 17666888). This variant has been reported by several clinical laboratories in ClinVar as a variant of uncertain significance (ClinVar Variation ID:  447450). Internal laboratory evidence indicates that the variant has been identified in at least three individuals with hearing loss in the heterozygous state without a second GJB2 variant. One individual was reported to have multiple affected relatives; however, segregation data was not available (no criteria met; SCV000613524.1, SCV000731317.1, SCV002817016.1, SCV002179797.2). In summary, this variant is classified as a variant of uncertain significance based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP; PM2_Supporting. The ClinGen Hearing Loss VCEP Specifications Version 2; 09/26/2023.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-09-26	2023-10-05	false	https://erepo.genome.network/evrepo/ui/classification/CA6904209/MONDO:0019497/005	2b5171d0-5733-4e05-a77e-5d32d43be312
NM_004004.5:c.674C>T	555720	CA387460667	NM_004004.5:c.674C>T, NC_000013.11:g.20188908G>A, CM000675.2:g.20188908G>A, NC_000013.10:g.20763047G>A, CM000675.1:g.20763047G>A, NC_000013.9:g.19661047G>A, NG_008358.1:g.9068C>T, XM_011535049.1:c.674C>T, XM_011535049.2:c.674C>T, NM_004004.6:c.674C>T, ENST00000382844.1:c.674C>T, ENST00000382848.4:c.674C>T	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PM3, PM2	BS4, BS1, BP5, BP7, BS2, PP1, PP4, PP3, PM5, PM1, PM4, PVS1, PM6, BP3, BP2, BP4, BA1, PS1, PS4, PS2, PS3	The p.Pro225Leu variant in GJB2 is absent from the Genome Aggregation Database  (http://gnomad.broadinstitute.org) (PM2). This variant has been detected in 1 patient with hearing loss in trans with pathogenic or suspected-pathogenic variants (PM3; PMID:21112098). In summary, this variant meets criteria to be classified as a variant of uncertain clinical significance for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel:  PM2, PM3.	21112098, 21112098	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-20	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA387460667/MONDO:0019497/005	b93f946a-ef2d-4b2a-9bd3-adc60da6f546
NM_004004.5(GJB2):c.71G>A (p.Trp24Ter)	17002	CA172240	NM_004004.5:c.71G>A, NC_000013.11:g.20189511C>T, CM000675.2:g.20189511C>T, NC_000013.10:g.20763650C>T, CM000675.1:g.20763650C>T, NC_000013.9:g.19661650C>T, NG_008358.1:g.8465G>A, XM_011535049.1:c.71G>A, XM_011535049.2:c.71G>A, NM_004004.6:c.71G>A, ENST00000382844.1:c.71G>A, ENST00000382848.4:c.71G>A, NM_004004.5(GJB2):c.71G>A (p.Trp24Ter)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	BS1, PM3_Very Strong, PVS1, PS3	BS4, BP5, BP7, PP4, PP1, PP3, BS2, PM1, PM4, PM5, PM6, PM2, BP3, BP4, BP2, BA1, PS2, PS4, PS1	The filtering allele frequency of the p.Trp24X variant in the GJB2 gene is 0.38% (137/ 30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). However, the ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs the high allele frequency of the variant in population databases. Therefore, the BS1 code will not contribute to the overall classification. The p.Trp24X variant in GJB2 is predicted to cause a premature stop codon in the only exon of GJB2 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 15070423, 24123366, 18941476, 9139825). A knock-in mouse model demonstrates that the p.Trp24X variant leads to the phenotype (PS3; PMID:18941476).  In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_VS, PS3, BS1.	18941476, 9139825, 15070423, 24123366, 18941476, 9139825, 15070423, 24123366, 18941476	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-17	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA172240/MONDO:0019497/005	b207d225-ce97-42b5-b04a-d9d420ada5eb
NM_000441.1(SLC26A4):c.919-2A>G	4840	CA261445	NM_000441.1:c.919-2A>G, NC_000007.14:g.107683453A>G, CM000669.2:g.107683453A>G, NC_000007.13:g.107323898A>G, CM000669.1:g.107323898A>G, NC_000007.12:g.107111134A>G, NG_008489.1:g.27819A>G, XM_005250425.1:c.919-2A>G, XM_006716025.2:c.919-2A>G, XM_005250425.2:c.919-2A>G, XM_006716025.3:c.919-2A>G, XM_017012318.1:c.919-2A>G, ENST00000265715.7:c.919-2A>G, NM_000441.1(SLC26A4):c.919-2A>G	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PP1_Strong, BS1, PM3_Very Strong, PVS1	BS4, BP5, BP7, BS2, PP4, PP3, PM1, PM5, PM4, PM6, PM2, BP2, BP3, BP4, BA1, PS2, PS4, PS3, PS1	The filtering allele frequency of the c.919-2A>G variant in the SLC26A4 gene is 0.4% for East Asian chromosomes in the Genome Aggregation Database (91/18860 with 95% CI) , which meets the allele frequency threshold defined by the ClinGen Hearing Loss Expert Panel for considering strong evidence against pathogenicity for autosomal recessive hearing loss variants (BS1). However, the c.919-2A>G variant in SLC26A4 is predicted to cause the skipping of a biologically-relevant out-of-frame exon 8. This is then expected to lead to a truncated or absent protein in a gene in which loss-of-function is an established disease mechanism (PVS1; PMID: 30192042). Additionally, this variant has been detected in 16 patients with hearing loss in trans with more than 4 pathogenic variants (PM3_VeryStrong; PMID: 23151025). The c.919-2A>G variant in SLC26A4 has been reported to segregate with hearing loss in at least 6 family members (PP1_Strong; 10874637).  Therefore, the BS1 code will not contribute to the overall classification. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome based on the ACMG/AMP criteria applied: PVS1, PP1_Strong, PM3_VeryStrong, BS1.	10874637, 10874637, 23151025, 23151025	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-20	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA261445/MONDO:0010134/005	cc6044de-e514-40c4-8834-632466dc33f1
NM_004004.5(GJB2):c.167delT (p.Leu56Argfs)	17010	CA172217	NM_004004.5:c.167del, NM_004004.5:c.167delT, NC_000013.11:g.20189415del, CM000675.2:g.20189415del, NC_000013.10:g.20763554del, CM000675.1:g.20763554del, NC_000013.9:g.19661554del, NG_008358.1:g.8561del, XM_011535049.1:c.167del, XM_011535049.2:c.167del, NM_004004.6:c.167del, ENST00000382844.1:c.167del, ENST00000382848.4:c.167del, NM_004004.5(GJB2):c.167delT (p.Leu56Argfs)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PM3_Very Strong, PVS1, BA1	BS4, BS1, BP5, BP7, PP4, PP1, PP3, BS2, PM5, PM1, PM4, PM6, PM2, BP3, BP4, BP2, PS1, PS2, PS4, PS3	The filtering allele frequency of the p.Leu56ArgfsX26 variant in the GJB2 gene is 1.4% (165/10106) of Ashkenazi Jewish chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive nonsyndromic hearing loss variants (BA1). The ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs the high allele frequency of the variant in population databases. Therefore, the BA1 code will not contribute to the overall classification. The p.Leu56ArgfsX26 variant in GJB2 is predicted to cause a premature stop codon in the only coding exon of the gene, leading to an absent protein in a gene in which loss-of-function is an established disease mechanism (PVS1). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 24529908, 26096904, 24158611, 9285800, 17666888). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_VS, BA1.	17666888, 24158611, 26096904, 9285800, 17666888, 24529908, 26096904, 24158611, 9285800, 24529908, 17666888, 24158611, 26096904, 9285800, 17666888, 24529908, 17666888	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-19	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA172217/MONDO:0019497/005	e530bac1-eebd-46fc-a983-e936764ec5dc
NM_004004.6(GJB2):c.-22-2A>C	375406	CA6904346	NM_004004.6:c.-22-2A>C, NC_000013.11:g.20189605T>G, CM000675.2:g.20189605T>G, NC_000013.10:g.20763744T>G, CM000675.1:g.20763744T>G, NC_000013.9:g.19661744T>G, NG_008358.1:g.8371A>C, ENST00000382844.2:c.-24A>C, ENST00000382848.5:c.-22-2A>C, ENST00000382844.1:c.-24A>C, ENST00000382848.4:c.-22-2A>C, NM_004004.5:c.-22-2A>C, XM_011535049.1:c.-22-2A>C, XM_011535049.2:c.-22-2A>C, NM_004004.6(GJB2):c.-22-2A>C	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Likely Pathogenic	BS1, PS3_Supporting, PP1, PM3_Very Strong	BP7, BP5, BS3, BS4, BS2, PP3, PP2, PP4, PM4, PM1, PM5, PM2, PVS1, PM6, BP4, BP1, BP2, BP3, BA1, PS4, PS2, PS1	The filtering allele frequency of the c.-22-2A>C variant in the GJB2 gene is 0.35% for Ashkenazi Jewish chromosomes in gnomAD v2.1.1 (95% CI of 47/10344), which meets the allele frequency threshold defined by the ClinGen Hearing Loss Expert Panel for considering strong evidence against pathogenicity for autosomal recessive hearing loss variants (BS1). However, based on the evidence outlined below, the ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs its high allele frequency in population databases. Therefore, the BS1 code will not contribute to the overall classification. The c.-22-2A>C variant in the GJB2 gene has been detected in at least 9 patients with hearing loss in trans with the pathogenic c.35delG variant (PM3_Very Strong; PMID: 25401782, 24039984, 33096615; Invitae internal data, SCV000935680.2; Childrenâ€™s Hospital of Philadelphia internal data, Molecular Otolaryngology and Renal Research Laboratories internal data) and one individual with the the p.Leu90Pro variant suspected in trans (PMID: 19814620). Phase was confirmed in at least 6 of these 10 observations.This variant has been reported to segregate with hearing loss in at least 2 family members (PP1; PMID: 24039984). It was also identified in the heterozygous state without a second variant in 8 individuals with hearing loss, and in the biallelic state (with c.35delG) in one individual with reportedly normal hearing (GeneDx, ARUP internal data, SCV000680741.2, SCV000603828.1). Of note, the severity of hearing loss is reported to be mild-moderate in affected probands, some with onset in the third to fourth decade, suggesting that this variant may be a hypomorphic allele. RNA analysis using patient cells demonstrated that the c.-22-2A>C variant leads to expression of a novel GJB2 transcript with a slightly longer 5' UTR but otherwise normal coding region. The alternate transcript was shown to have reduced expression, but it is not clear if the lower expression is sufficient to lead to a phenotype (PS3_Supporting; PMID: 24039984). In summary, the VCEP has used expert judgement to classify this variant as likely pathogenic for autosomal recessive hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM3_Very Strong, PP1, PS3_Supporting, BS1.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2021-04-12	2024-01-11	false	https://erepo.genome.network/evrepo/ui/classification/CA6904346/MONDO:0019497/005	09ec9aab-7e7a-4db9-b694-2ff027effd00
NM_000441.1(SLC26A4):c.349C>T	43555	CA132727	NM_000441.1:c.349C>T, NC_000007.14:g.107672182C>T, CM000669.2:g.107672182C>T, NC_000007.13:g.107312627C>T, CM000669.1:g.107312627C>T, NC_000007.12:g.107099863C>T, NG_008489.1:g.16548C>T, ENST00000644269.2:c.349C>T, ENST00000265715.7:c.349C>T, ENST00000440056.1:c.349C>T, XM_005250425.1:c.349C>T, XM_006716025.2:c.349C>T, XM_005250425.2:c.349C>T, XM_006716025.3:c.349C>T, XM_017012318.1:c.349C>T, NM_000441.2:c.349C>T, NM_000441.1(SLC26A4):c.349C>T	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PP1_Strong, PP3, PP4, PM3_Very Strong, BS3_Supporting, BA1	BP7, BP5, BS1, BS4, BS2, PP2, PM5, PM4, PM1, PVS1, PM2, PM6, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	The c.349C>T variant in SLC26A4 is a missense variant predicted to cause substitution of leucine by phenylalanine at amino acid 117. The filtering allele frequency of the p.Leu117Phe variant is 0.005208 (54/10368 alleles) for Ashkenazi Jewish chromosomes in gnomAD v2.1.1, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). The ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for hearing loss outweighs the high allele frequency of the variant in population databases. Therefore, the BA1 code will not contribute to the overall classification. The computational predictor REVEL gives a score of 0.982, which is above the threshold of 0.7, evidence that correlates with impact to SLC26A4 function (PP3). This variant has been detected in 8 individuals with hearing loss. For 5 of those individuals, they were compound heterozygous for the variant and a pathogenic or likely pathogenic variant and all of those were confirmed in trans by (c.1246A>C (p.Thr416Pro), c.1708G>A (p.Val570Ile), c.1522A>G (p.Thr508Ala), c.578C>T (p.Thr193Ile), 5.75 PM3 points, SCV000060146.7, SCV000282017.1). (PM3_VeryStrong). This variant has been identified in patients with EVA, which is a phenotype that was deemed to be highly specific for SLC26A4 by the ClinGen Hearing Loss Expert Panel (LMM) (PP4). The variant has been reported to segregate with hearing loss in at least 5 affected and 4 unaffected family members, across 2 Ashkenazi Jewish families with hearing loss (PP1_Strong; Karen Avraham Lab internal data SCV000282016.1, SCV000282017.1). A functional study demonstrated that this variant may not impact localization or the iodide efflux capacity (BS3_Supporting; PMID: 27771369, 11932316), however, the functional study may not assess all ion transport functions of the protein and/or ensure that the assay reflects the true biological environment and therefore the ClinGen Hearing Loss Expert Panel (HL EP) chose not to consider this evidence fully in conflict with the pathogenic evidence (BS3_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for autosomal recessive Pendred syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: PM3_VS, PP1_S, PP4, PP3, BS3_P (Hearing Loss VCEP specifications version 2; 11/22/2022).	11932316, 16570074, 10700480, 16570074, 26969326, 10700480, 16570074, 26969326, 10700480, 27771369, 11932316, 16570074, 26969326, 10700480	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2022-11-22	2023-01-25	false	https://erepo.genome.network/evrepo/ui/classification/CA132727/MONDO:0010134/005	67c2f97e-385f-494a-b06e-701135ace536
NM_206933.2(USH2A):c.5581G>A (p.Gly1861Ser)	48535	CA262105	NM_206933.2:c.5581G>A, NC_000001.11:g.216073292C>T, CM000663.2:g.216073292C>T, NC_000001.10:g.216246634C>T, CM000663.1:g.216246634C>T, NC_000001.9:g.214313257C>T, NG_009497.1:g.355105G>A, NR_125992.1:n.136+692C>T, NR_125993.1:n.136+692C>T, NM_206933.3:c.5581G>A, ENST00000307340.7:c.5581G>A, NM_206933.2(USH2A):c.5581G>A (p.Gly1861Ser)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP4, PP1, PP3, PM2_Supporting, PS4, PM3_Strong	BP5, BP7, BS4, BS1, BS2, PM1, PM4, PM5, PVS1, PM6, BP3, BP2, BP4, BA1, PS2, PS3, PS1	The allele frequency of the p.Gly1861Ser variant in USH2A is 0.017% (3/17184) of East Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). This variant has been detected in 4 patients with hearing loss in trans with pathogenic or suspected-pathogenic variants (PM3_S; PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). The variant has been reported to segregate with hearing loss in one affected family member (PP1, PMID: 26310143). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). Computational prediction tools and conservation analysis suggest that the p.Gly1861Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PS4, PM2_P, PP3, PM3_S, PP1, PP4.	26310143, 26310143, 26338283, 26310143, 23737954, 25356976, 26338283, 26310143, 23737954, 25356976	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-14	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA262105/MONDO:0019501/005	16f373e0-f3cf-4ebe-91ea-6d1a22e44f9c
NM_004700.3(KCNQ4):c.853G>A (p.Gly285Ser)	6241	CA340532	NM_004700.3:c.853G>A, NC_000001.11:g.40819893G>A, CM000663.2:g.40819893G>A, NC_000001.10:g.41285565G>A, CM000663.1:g.41285565G>A, NC_000001.9:g.41058152G>A, NG_008139.1:g.40882G>A, NG_008139.2:g.40882G>A, NM_172163.2:c.853G>A, XM_011542417.1:c.853G>A, XM_011542418.1:c.853G>A, XM_011542419.1:c.853G>A, XM_011542420.1:c.853G>A, XR_946798.1:n.859G>A, XR_946799.1:n.859G>A, XR_946800.1:n.859G>A, XM_017002792.1:c.-165G>A, NM_004700.4:c.853G>A, ENST00000347132.9:c.853G>A, ENST00000443478.3:n.539G>A, ENST00000506017.1:n.172G>A, ENST00000509682.6:n.853G>A, NM_004700.3(KCNQ4):c.853G>A (p.Gly285Ser)	KCNQ4	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PS3_Supporting, PM1, PM5, PS4_Supporting, PM2	BP5, BP7, BS4, BS1, BS2, PP4, PP3, PM3, PM4, PM6, PVS1, BP2, BP3, BP4, BA1, PS2, PS1	The p.Gly285Ser variant in the KCNQ4 gene was absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org) (PM2). The p.Gly285Ser variant has been reported to segregate with hearing loss in at least 16 family members (PP1_S; PMIDs: 10025409, 25116015). The variant meets PM2 and has been observed in at least 2 affected probands (PS4_P, PMID: 10025409, Partners LMM internal data SCV000198442.4). A different pathogenic missense variant (p.Gly285Cys) has been previously identified at this codon of KCNQ4 which may indicate that this residue is critical to the function of the protein (PM5; ClinVar Variation ID 6244, PMID: 10369879). Furthermore, the variant is in a location that has been defined by the ClinGen Hearing Loss Expert Panel to be a mutational hotspot or domain of KCNQ4 (PM1; PMID: 23717403; https://www.uniprot.org/uniprot/P56696). A functional study demonstrates that this variant may impact protein function (PS3_P; PMID: 10025409, 18786918). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant nonsyndromic hearing loss based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel: PM2, PP1_S, PS4_P, PM5, PM1, PS3_P.	10025409, 25116015, 10025409, 25116015, 18786918, 10025409, 10369879, 8035838, 10025409, 10369879, 8035838	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-11	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA340532/MONDO:0019497/005	a39fbdff-7b49-469e-8890-5baad55ff075
NM_000441.1(SLC26A4):c.1229C>T (p.Thr410Met)	43498	CA261403	NM_000441.1:c.1229C>T, NC_000007.14:g.107690203C>T, CM000669.2:g.107690203C>T, NC_000007.13:g.107330648C>T, CM000669.1:g.107330648C>T, NC_000007.12:g.107117884C>T, NG_008489.1:g.34569C>T, XM_005250425.1:c.1229C>T, XM_006716025.2:c.1229C>T, XM_005250425.2:c.1229C>T, XM_006716025.3:c.1229C>T, XM_017012318.1:c.1229C>T, ENST00000265715.7:c.1229C>T, NM_000441.1(SLC26A4):c.1229C>T (p.Thr410Met)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PP1_Strong, PS3_Supporting, PP4, PP3, PM3_Very Strong, PM2_Supporting	BS4, BS1, BP5, BP7, BS2, PM5, PM1, PM4, PVS1, PM6, BP2, BP3, BP4, BA1, PS4, PS2, PS1	This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VeryStrong; PMID: 25372295, 23638949, 25468468, 24338212, 25394566, 19786220, 19017801, 27541434, 21366435, 17309986, 24007330, 24224479, 21961810, 2844304, 19509082, 15811013). The p.Thr410Met variant in SLC26A4 has been reported to segregate in an autosomal recessive pattern with hearing loss in at least 7 family members (PP1_Strong; PMID: 19017801, 9618167, 15811013). Computational prediction tools and conservation analysis suggest that the p.Thr410Met variant may impact the protein (PP3). At least one patient with a variant in this gene displayed features of EVA or Mondini malformation (PP4; PMID: 15355436, 15811013). The allele frequency of the p.Thr410Met variant in the SLC26A4 gene is 0.062% (19/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss (PM2_Supporting). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM3_VS, PP1_S, PP3, PS3_P, PM2_P, PP4.	9618167, 15811013, 19017801, 9618167, 15811013, 19017801, 23266159, 11932316, 24007330, 15355436, 15811013, 25394566, 27541434, 17309986, 23638949, 28444304, 15355436, 25372295, 25468468, 24338212, 15811013, 19017801, 21366435, 19786220, 24224479, 21961810, 12676893, 24007330, 19509082, 25394566, 27541434, 17309986, 23638949, 28444304, 15355436, 25372295, 25468468, 24338212, 15811013, 19017801, 21366435, 19786220, 24224479, 21961810, 12676893, 24007330, 19509082, 26763877, 15905611, 22412181	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-17	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA261403/MONDO:0010134/005	034f39b8-0469-47c1-b9ac-930299df3dc7
NM_000441.1(SLC26A4):c.412G>T (p.Val138Phe)	4835	CA253312	NM_000441.1:c.412G>T, NC_000007.14:g.107672245G>T, CM000669.2:g.107672245G>T, NC_000007.13:g.107312690G>T, CM000669.1:g.107312690G>T, NC_000007.12:g.107099926G>T, NG_008489.1:g.16611G>T, XM_005250425.1:c.412G>T, XM_006716025.2:c.412G>T, XM_005250425.2:c.412G>T, XM_006716025.3:c.412G>T, XM_017012318.1:c.412G>T, ENST00000265715.7:c.412G>T, NM_000441.1(SLC26A4):c.412G>T (p.Val138Phe)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PP1_Moderate, PS3_Supporting, PP4, PP3, PM3_Very Strong, PM2_Supporting, PS4	BP5, BP7, BS4, BS1, BS2, PM1, PM4, PM5, PVS1, PM6, BP2, BP3, BP4, BA1, PS2, PS1	The p.Val138Phe variant in SLC26A4 has been detected in over 4 patients with Pendred syndrome or hearing loss with enlarged vestibular aqueducts who harbored a pathogenic or suspected pathogenic variant in trans with p.Val138Phe (PM3_VS; PMID: 17503324, 15689455, 20597900, 18285825, 23965030, 24224479, 21551164, 23273637, 12788906, 16570074). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMID: 25999548, 23336812, 26683941). The p.Val138Phe variant in SLC26A4 has been reported to segregate with hearing loss in at least 2 family members (PP1_M; PMID: 12788906). The allele frequency of the p.Val138Phe variant in the SLC26A4 gene is 0.03% (38/126540) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). Computational prediction tools and conservation analysis suggest that the p.Val138Phe variant may impact the protein (PP3). At least one patient with a variant in this gene displayed features of EVA and/or Mondini malformation which are consistent with Pendred syndrome (PP4; PMID: 12788906, 23273637). A functional study performed in HeLa and human embryonic kidney cell lines demonstrated that pendrin harboring the p.Val138Phe variant did not localize to the cell membrane. However, there was no effect on iodide efflux (PS3_P; PMID: 11932316). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome/EVA based on the ACMG/AMP criteria applied: PM3_VS, PS4, PP1_M, PM2_Supporting, PP3, PP4, PS3_P.	12788906, 12788906, 11932316, 23273637, 12788906, 18285825, 21551164, 23965030, 23273637, 16570074, 15689455, 12788906, 24224479, 17503324, 20597900, 18285825, 21551164, 23965030, 23273637, 16570074, 15689455, 12788906, 24224479, 17503324, 20597900, 25999548, 23336812, 26683941	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-19	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA253312/MONDO:0010134/005	c400a0f9-d38a-4d2e-9b96-5829547c6b19
NM_206933.2(USH2A):c.4510dupA (p.Arg1504Lysfs)	166504	CA273289	NM_206933.2:c.4510dupA, NM_206933.2:c.4510_4511insA, NM_007123.5:c.4510dup, NM_206933.2:c.4510dup, NM_206933.3:c.4510dup, ENST00000307340.7:c.4510dup, ENST00000366942.3:c.4510dup, NC_000001.11:g.216175371dup, CM000663.2:g.216175371dup, NC_000001.10:g.216348713dup, CM000663.1:g.216348713dup, NC_000001.9:g.214415336dup, NG_009497.1:g.253028dup, NM_206933.2(USH2A):c.4510dupA (p.Arg1504Lysfs)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP4, PM2, PVS1, PM3_Strong	BS4, BS1, BP5, BP7, BS2, PP1, PP3, PM1, PM4, PM5, PM6, BP2, BP3, BP4, BA1, PS2, PS3, PS4, PS1	The c.4510dupA (p.Arg1504LysX26) variant in USH2A is predicted to cause a premature stop codon in biologically-relevant-exon 21/72 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected in 2 patients with hearing loss in trans with 2 different pathogenic variants (PM3_S; PMID:22135276). The allele frequency of the p.Arg1504LysX26 variant in the USH2A gene is 0.003% (3/111138) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2). At least one patient with a variant in this gene displayed features of retinitis pigmentosa (PP4; PMID: 22135276). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_S, PM2, PP4.	22135276, 22135276, 28041643, 15325563, 10729113	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-10	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA273289/MONDO:0019501/005	34c5d011-929d-4998-ae9a-ef900674144e
NM_007123.5(USH2A):c.4338_4339delCT (p.Cys1447Glnfs)	2353	CA252228	NM_007123.5:c.4338_4339delCT, NC_000001.11:g.216190284_216190285del, CM000663.2:g.216190284_216190285del, NC_000001.10:g.216363626_216363627del, CM000663.1:g.216363626_216363627del, NC_000001.9:g.214430249_214430250del, NG_009497.1:g.238116_238117del, NM_007123.5:c.4338_4339del, NM_206933.2:c.4338_4339del, NM_206933.3:c.4338_4339del, ENST00000307340.7:c.4338_4339del, ENST00000366942.3:c.4338_4339del, NM_007123.5(USH2A):c.4338_4339delCT (p.Cys1447Glnfs)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP1_Moderate, PP4, PM3_Very Strong, PM2, PVS1	BP5, BP7, BS4, BS1, BS2, PP3, PM1, PM4, PM5, PM6, BP2, BP3, BP4, BA1, PS2, PS4, PS3, PS1	The allele frequency of the p.Cys1447GlnfsX29 variant in the USH2A gene is 0.0009% (1/111250) of European (Non-Finnish) chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2). The p.Cys1447GlnfsX29 variant is predicted to cause a premature stop codon in biologically-relevant-exon 20 of 72 that leads to an absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected as compound heterozygous with p.Cys759Phe or p.Glu767SerfsX21 in six Usher syndrome probands, and as homozygous in eight Usher syndrome probands (PM3_VeryStrong; PMID: 9624053, 15325563, 18641288, 18665195, 20440071). The p.Cys1447GlnfsX29 variant in USH2A has been reported to segregate with hearing loss in at least 2 family members (PP1_Moderate; PMID: 20440071, 9624053). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: 9624053, 15325563, 18641288, 18665195, 20440071). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2, PVS1, PM3_VeryStrong, PP1_Moderate, PP4.	9624053, 20440071, 9624053, 20440071, 18665195, 18641288, 9624053, 20440071, 15325563, 18641288, 18665195, 9624053, 20440071, 15325563, 18641288, 18665195, 9624053, 20440071, 15325563, 20613545, 10729113	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-25	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA252228/MONDO:0019501/005	5fc296e5-bbfb-4876-ace3-0e1618efc366
NM_206933.2(USH2A):c.8559-2A>G	48604	CA262122	NM_206933.2:c.8559-2A>G, NC_000001.11:g.215877882T>C, CM000663.2:g.215877882T>C, NC_000001.10:g.216051224T>C, CM000663.1:g.216051224T>C, NC_000001.9:g.214117847T>C, NG_009497.1:g.550515A>G, NM_206933.3:c.8559-2A>G, ENST00000307340.7:c.8559-2A>G, NM_206933.2(USH2A):c.8559-2A>G	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP1_Strong, PP4, PM2_Supporting, PM3_Very Strong, PM4	BS1, BS4, BP7, BP5, BS2, PP3, PM1, PM5, PM6, PVS1, BA1, BP2, BP4, BP3, PS3, PS2, PS4, PS1	The c.8559-2A>G has been detected in >4 patients with Usher syndrome who were compound heterozygous for the this variant in trans with a truncating variant (PM3_VS; PMID: 25356976, 19737284, 26338283, 19023448). Segregation data was also available for two reported families with Usher syndrome. In one family, the variant was identified in trans with a frameshift variant in two affected siblings, and four unaffected siblings were either heterozygous for a single variant or wild-type for both variants. In the second family, an unaffected sibling was heterozygous for a single variant (PP1_Strong, PMID: 19023448). RT-PCR analysis of cells from a patient carrying the variant revealed that the variant causes skipping of exon 43, resulting in a 41 amino acid deletion of the USH2A protein (PM4, PMID: 20596040) The allele frequency of the c.8559-2A>G variant in the USH2A gene is 0.046% (8/17232) of East Asian chromosomes by the Genome Aggregation Database ( http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss and Usher syndrome (PM2_Supporting). Several patients reported to harbor this variant displayed clinical features of Usher syndrome (PP4; PMID: 25356976, 19737284, 26338283, 19023448). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM4, PM3_VS, PP1_S, PP4, PM2_P.	19023448, 19023448, 24853665, 19023448, 25133613, 26338283, 19737284, 25356976, 24853665, 19023448, 25133613, 26338283, 19737284, 25356976, 20596040	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-10-09	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA262122/MONDO:0019501/005	fe785bf9-af38-456e-83ed-6717335dbde4
NM_000441.2(SLC26A4):c.706C>G (p.Leu236Val)	43565	CA132738	NM_000441.2:c.706C>G, NC_000007.14:g.107675050C>G, CM000669.2:g.107675050C>G, NC_000007.13:g.107315495C>G, CM000669.1:g.107315495C>G, NC_000007.12:g.107102731C>G, NG_008489.1:g.19416C>G, ENST00000644269.2:c.706C>G, ENST00000265715.7:c.706C>G, NM_000441.1:c.706C>G, XM_005250425.1:c.706C>G, XM_006716025.2:c.706C>G, XM_005250425.2:c.706C>G, XM_006716025.3:c.706C>G, XM_017012318.1:c.706C>G, NM_000441.2(SLC26A4):c.706C>G (p.Leu236Val)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PP1_Moderate, PP4, PM5, PM3_Very Strong	PP3, PM2	The c.706C>G variant in SLC26A4 is a missense variant predicted to cause substitution of leucine by valine at amino acid 236 (p.Leu236Val). The variant was identified in 0.01833% (11/59998) of admixed American alleles, which is the highest population minor allele frequency in gnomAD v4.1.0 (PM2_Supporting and BS1 are not met). This variant has been detected in 3 probands in trans with a pathogenic variant, in 5 probands in phase unknown with a pathogenic variant, and in the homozygous state in 3 probands, all of whom had hearing loss and/or inner ear malformations consistent with Pendred syndrome. The variant was also identified with a pathogenic splice site variant in 2 probands (PM3_VeryStrong; Partners Laboratory for Molecular Medicine internal data ClinVar SCV000060159.5, ARUP internal data ClinVar SCV000605149.1, Chinese PLA General Hospital internal data, Molecular Otolaryngology and Renal Research Laboratories internal data, Revvity ClinVar SCV002023538.3GeneDx internal data ClinVar SCV001783711.3, Invitae internal data ClinVar SCV002234501.3). This variant was seen in two probands with no second variant identified whose phenotypes were consistent with Pendred syndrome (PMID: 34410491, 34515852), as well as in one proband with enlarged vestibular aqueduct who was compound heterozygous with a likely pathogenic variant in phase unknown (PP4; PMID: 36703223). A different pathogenic missense variant (p.Leu236Pro) has been previously identified at this codon of SLC26A4, which may indicate that this residue is critical to the function of the protein (PM5; ClinVar Variation ID 4817). Additionally, the variant was seen in an adult with deafness who had two pathogenic GJB2 variants in trans (Revvity internal data ClinVar SCV002023538.3).  The variant has been reported to segregate with hearing loss in two affected family members (PP1_Moderate; Partners Laboratory for Molecular Medicine internal data ClinVar SCV000060159.5). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel: PM3_VeryStrong, PM5, PP1_Moderate, PP4. (ClinGen Hearing Loss VCEP specifications version 2; 10/16/2024)	25991456	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2024-10-16	2025-01-06	false	https://erepo.genome.network/evrepo/ui/classification/CA132738/MONDO:0010134/005	f3b84ed4-48e1-4d17-8fda-a9bacc5d12b8
NM_206933.2(USH2A):c.1036A>C (p.Asn346His)	48347	CA262054	NM_206933.2:c.1036A>C, NC_000001.11:g.216325412T>G, CM000663.2:g.216325412T>G, NC_000001.10:g.216498754T>G, CM000663.1:g.216498754T>G, NC_000001.9:g.214565377T>G, NG_009497.1:g.102985A>C, NM_007123.5:c.1036A>C, NM_206933.3:c.1036A>C, ENST00000307340.7:c.1036A>C, ENST00000366942.3:c.1036A>C, NM_206933.2(USH2A):c.1036A>C (p.Asn346His)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP1_Strong, PP3, PP4, PM3_Very Strong, PM2_Supporting	BP7, BP5, BS4, BS1, BS2, PM4, PM1, PM5, PVS1, PM6, BP3, BP4, BP2, BA1, PS3, PS1, PS2, PS4	The allele frequency of the p.Asn346His variant in the USH2A gene is 0.016% (20/126318) of European (Non-Finnish) chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive Usher syndrome (PM2_Supporting). The p.Asn346His variant in USH2A has been reported to segregate with hearing loss in at least 7 families including 13 family members (PP1_S; 10729113, 15241801, 17405132, 25521520, 24160897, 22135276). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 15241801, 24160897, 22135276, 26969326). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: 10729113, 15241801, 17405132, 25521520, 24160897, 22135276). Computational prediction tools and conservation analysis suggest that the p.Asn346His variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting, PP1_S, PM3_VS, PP4, PP3.	15241801, 24160897, 10729113, 17405132, 22135276, 25521520, 15241801, 24160897, 10729113, 17405132, 22135276, 25521520, 15241801, 24160897, 17405132, 10729113, 22135276, 25521520, 15241801, 24160897, 26969326, 22135276, 15241801, 24160897, 26969326, 22135276	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-14	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA262054/MONDO:0019501/005	211c3a9c-3789-42d9-ab55-04892c95f534
NM_206933.2(USH2A):c.8682-9A>G	197510	CA275277	NM_206933.2:c.8682-9A>G, NC_000001.11:g.215867179T>C, CM000663.2:g.215867179T>C, NC_000001.10:g.216040521T>C, CM000663.1:g.216040521T>C, NC_000001.9:g.214107144T>C, NG_009497.1:g.561218A>G, NM_206933.3:c.8682-9A>G, ENST00000307340.7:c.8682-9A>G, NM_206933.2(USH2A):c.8682-9A>G	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PM3_Very Strong	BS4, BS1, BP5, BP7, BS2, PP1, PM4, PM1, PVS1, PM6, BP3, BP4, BP2, BA1, PS3, PS2, PS4	The c.8682-9A>G variant in USH2A has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 27318125, 25425308, 28944237, 23591405). The allele frequency of the c.8682-9A>G variant in the USH2A gene is 0.04% (5/10112) of Ashkenazi Jewish chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). At least one patient with this variant displayed features of retinitis pigmentosa and hearing loss which is consistent with Usher syndrome (PP4; PMID: 27318125, 25425308, 28944237, 23591405). Computational prediction tools and conservation analysis suggest that the c.8682-9A>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM3_VS, PM2_Supporting, PP4, PP3.	27318125, 18273898, 27318125, 25425308, 28944237, 23591405, 27318125, 25425308, 28944237, 23591405	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-24	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA275277/MONDO:0019501/005	b0b1e906-0446-4e9d-a092-fdd3fdce63ef
NM_000441.1(SLC26A4):c.365dupT (p.Ile124Tyrfs)	189148	CA274422	NM_000441.1:c.365dupT, NM_000441.1:c.365dup, XM_005250425.1:c.365dup, XM_006716025.2:c.365dup, XM_005250425.2:c.365dup, XM_006716025.3:c.365dup, XM_017012318.1:c.365dup, ENST00000265715.7:c.365dup, ENST00000440056.1:c.365dup, NC_000007.14:g.107672198dup, CM000669.2:g.107672198dup, NC_000007.13:g.107312643dup, CM000669.1:g.107312643dup, NC_000007.12:g.107099879dup, NG_008489.1:g.16564dup, NM_000441.1(SLC26A4):c.365dupT (p.Ile124Tyrfs)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PM3_Supporting, PP4, PVS1, PM2	BS4, BS1, BP5, BP7, BS2, PP1, PP3, PM5, PM1, PM4, PM6, BP2, BP4, BP3, BA1, PS1, PS2, PS4, PS3	The p.Ile124Tyrfs variant in SLC26A4 is predicted to cause a premature stop codon in biologically-relevant-exon 4/21 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). The allele frequency of the p.Ile124fs variant is in 0.003% (1/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss (PM2). At least one patient with the variant displayed features of enlarged vestibular aqueduct and Mondini malformation which are consistent with Pendred syndrome (PP4; PMID:15679828). This variant has been detected in 2 patients with hearing loss in trans with suspected pathogenic variants (PM3_P, PMID:15679828). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome based on the ACMG/AMP criteria applied: PVS1, PM2, PP4, PM3_P.	15679828, 15679828, 15679828	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-10	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA274422/MONDO:0010134/005	aecfa905-0f27-4b56-9e2b-3672bb807629
NM_000314.6(PTEN):c.97_99delATT (p.Ile33del)	449088	-	NM_000314.6:c.97_99delATT, NM_000314.8(PTEN):c.94ATT[1] (p.Ile33del), NM_000314.6(PTEN):c.97_99delATT (p.Ile33del)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PP1, PS3_Moderate, PM6_Strong, PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PVS1, PP2, PP3, PP4, BS2, PM4, PM1, PM3, PM5, BA1, BP1, BP4, BP3, BP2, PS4, PS2, PS1	PTEN c.97_99delATT (c.94ATT[1]) (p.Ile33del) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3_Moderate: Phosphatase activity â‰¤ -1.11 per Mighell et al. 2018, PMID: 29706350.PM2_Supporting: Absent in large sequenced populations (PMID 27535533).PM6_Strong: An individual with a highly specific phenotype (Internal laboratory contributor SCV000616838.1).PP1: Co-segregation with disease in multiple affected family members, with 5 or 6 meioses observed. (PMID 10234502 , internal laboratory contributor SCV002559099.1)		PTEN VCEP		2023-08-04	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CV449088/MONDO:0017623/003	18b368f7-e2f3-4e09-a961-5f209be89228
NM_000277.2(PAH):c.386A>G (p.Asp129Gly)	102661	CA229527	NM_000277.2:c.386A>G, NC_000012.12:g.102877517T>C, CM000674.2:g.102877517T>C, NC_000012.11:g.103271295T>C, CM000674.1:g.103271295T>C, NC_000012.10:g.101795425T>C, NG_008690.1:g.45086A>G, NG_008690.2:g.85894A>G, NM_000277.1:c.386A>G, XM_011538422.1:c.386A>G, NM_001354304.1:c.386A>G, XM_017019370.2:c.386A>G, NM_000277.3:c.386A>G, ENST00000307000.7:c.371A>G, ENST00000549111.5:n.482A>G, ENST00000550978.6:n.370A>G, ENST00000551337.5:c.386A>G, ENST00000551988.5:n.475A>G, ENST00000553106.5:c.386A>G, NM_000277.2(PAH):c.386A>G (p.Asp129Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		The c.386A>G (p.Asp129Gly) variant in PAH has been reported in multiple individuals with PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 8981952). This variant has extremely low frequency in gnomAD (MAF: 0.00001; PM2). This variant was detected in trans with known pathogenic variant c.1066-11G>A (PM3; PMID: 27121329). Computational evidence supports a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.	23062575, 26666653, 23357515, 27121329, 8981952	Phenylketonuria VCEP		2019-04-05	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229527/MONDO:0009861/006	1c39ee9a-5884-4352-9d86-335d9e4491cb
NM_000277.2(PAH):c.827T>G (p.Met276Arg)	102858	CA229797	NM_000277.2:c.827T>G, NC_000012.12:g.102852830A>C, CM000674.2:g.102852830A>C, NC_000012.11:g.103246608A>C, CM000674.1:g.103246608A>C, NC_000012.10:g.101770738A>C, NG_008690.1:g.69773T>G, NG_008690.2:g.110581T>G, NM_000277.1:c.827T>G, XM_011538422.1:c.827T>G, NM_001354304.1:c.827T>G, NM_000277.3:c.827T>G, ENST00000307000.7:c.812T>G, ENST00000549247.6:n.586T>G, ENST00000553106.5:c.827T>G, NM_000277.2(PAH):c.827T>G (p.Met276Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM2, PP4, PP3		The c.827T>G (p.Met276Arg) variant in PAH is absent from population databases and predicted damaging by in silico models.  It is a novel missense change at an amino acid residue where different pathogenic missense changes have been reported (p.Met276Val is LP in ClinVar, p.Met276Lys is LP via PAH EP). It has been reported in individuals with phenylkeonuria in the literature, although a defect in the metabolism of BH4 has not been excluded as a cause for elevated phenylalanine in any of these patients (PMID: 23932990, 15300621). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM5, PP3.	15300621, 23932990	Phenylketonuria VCEP		2018-12-10	2019-04-05	false	https://erepo.genome.network/evrepo/ui/classification/CA229797/MONDO:0009861/006	81e99b34-e26c-4f1b-af94-b863ba7c1e11
	-	CA16020876	NM_000277.1:c.847A>G, NC_000012.12:g.102851752T>C, CM000674.2:g.102851752T>C, NC_000012.11:g.103245530T>C, CM000674.1:g.103245530T>C, NC_000012.10:g.101769660T>C, NG_008690.1:g.70851A>G, NG_008690.2:g.111659A>G, XM_011538422.1:c.847A>G, NM_000277.2:c.847A>G, NM_001354304.1:c.847A>G, NM_000277.3:c.847A>G, ENST00000307000.7:c.832A>G, ENST00000549247.6:n.606A>G, ENST00000551114.2:n.509A>G, ENST00000553106.5:c.847A>G, ENST00000635477.1:n.8A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM5, PP4_Moderate, PM2	PP3	The c.847A>G (p.Ile283Val) variant in PAH is absent from all population databases, and is at the same amino acid as a previously established pathogenic variant (c.847A>T (p.Ile283Phe)).  It has been identified in a patient with classic PKU (BH4 defect excluded), and in trans with a known pathogenic variant (c.1045T>C, p.Ser349Pro) PMID: 27121329.  Summary evidence using PAH specific ACMG/AMP guidelines :PM2, PM5, PM3, PP4_Moderate.	27121329, 27121329	Phenylketonuria VCEP		2018-12-10	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020876/MONDO:0009861/006	deb05865-1cb0-4972-95ae-59e2da8df3a4
NM_000277.2(PAH):c.168+19T>C	92736	CA145980	NM_000277.2:c.168+19T>C, NC_000012.12:g.102912772A>G, CM000674.2:g.102912772A>G, NC_000012.11:g.103306550A>G, CM000674.1:g.103306550A>G, NC_000012.10:g.101830680A>G, NG_008690.1:g.9831T>C, NG_008690.2:g.50639T>C, NM_000277.1:c.168+19T>C, XM_011538422.1:c.168+19T>C, NM_001354304.1:c.168+19T>C, XM_017019370.2:c.168+19T>C, NM_000277.3:c.168+19T>C, ENST00000307000.7:c.153+19T>C, ENST00000546844.1:c.168+19T>C, ENST00000548677.2:n.255+19T>C, ENST00000548928.1:n.90+19T>C, ENST00000549111.5:n.264+19T>C, ENST00000550978.6:n.152+19T>C, ENST00000551337.5:c.168+19T>C, ENST00000551988.5:n.257+19T>C, ENST00000553106.5:c.168+19T>C, ENST00000635500.1:n.136+19T>C, NM_000277.2(PAH):c.168+19T>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BA1	PP4, BP4	PAH-specific ACMG/AMP criteria applied: BA1: MAF=0.44942 in ExAC. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1).	23690520	Phenylketonuria VCEP		2019-02-26	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA145980/MONDO:0009861/006	99da71a3-d378-4933-bdf6-a67f3d1a4d71
NM_000277.2(PAH):c.969+43G>T	92755	CA145984	NM_000277.2:c.969+43G>T, NC_000012.12:g.102846852C>A, CM000674.2:g.102846852C>A, NC_000012.11:g.103240630C>A, CM000674.1:g.103240630C>A, NC_000012.10:g.101764760C>A, NG_008690.1:g.75751G>T, NG_008690.2:g.116559G>T, NM_000277.1:c.969+43G>T, XM_011538422.1:c.913-2421G>T, NM_001354304.1:c.969+43G>T, NM_000277.3:c.969+43G>T, ENST00000307000.7:c.954+43G>T, ENST00000549247.6:n.728+43G>T, ENST00000551114.2:n.631+43G>T, ENST00000553106.5:c.969+43G>T, ENST00000635477.1:n.74-2421G>T, ENST00000635528.1:n.484+43G>T, NM_000277.2(PAH):c.969+43G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BA1	BP4	PAH-specific ACMG/AMP criteria applied: BA1: MAF=0.49022 in ExAC. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1).		Phenylketonuria VCEP		2019-02-26	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA145984/MONDO:0009861/006	80bf0e7a-2798-48ae-a5a6-cd2f2dea5e41
NM_000277.2(PAH):c.907T>C (p.Ser303Pro)	102889	CA229841	NM_000277.2:c.907T>C, NC_000012.12:g.102851692A>G, CM000674.2:g.102851692A>G, NC_000012.11:g.103245470A>G, CM000674.1:g.103245470A>G, NC_000012.10:g.101769600A>G, NG_008690.1:g.70911T>C, NG_008690.2:g.111719T>C, NM_000277.1:c.907T>C, XM_011538422.1:c.907T>C, NM_001354304.1:c.907T>C, NM_000277.3:c.907T>C, ENST00000307000.7:c.892T>C, ENST00000549247.6:n.666T>C, ENST00000551114.2:n.569T>C, ENST00000553106.5:c.907T>C, ENST00000635477.1:n.68T>C, NM_000277.2(PAH):c.907T>C (p.Ser303Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		The c.907T>C (p.Ser303Pro) variant in PAH has been reported in 1 affected individual (BH4 deficiency excluded). (PP4_Moderate; PMID: 9634518). This variant is absent in population databases (PM2). This variant was detected with p.D282G (LP via PAH workgroup) (PM3; PMID: 16256386). Computational evidence supports a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.	16256386, 9634518	Phenylketonuria VCEP		2019-04-03	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229841/MONDO:0009861/006	f8838359-9b6b-4ebd-bdf6-fbd68f1086cb
NM_000277.2(PAH):c.1271T>C (p.Leu424Ser)	102584	CA229424	NM_000277.2:c.1271T>C, NC_000012.12:g.102840444A>G, CM000674.2:g.102840444A>G, NC_000012.11:g.103234222A>G, CM000674.1:g.103234222A>G, NC_000012.10:g.101758352A>G, NG_008690.1:g.82159T>C, NG_008690.2:g.122967T>C, NM_000277.1:c.1271T>C, XM_011538422.1:c.1214T>C, NM_001354304.1:c.1271T>C, NM_000277.3:c.1271T>C, ENST00000307000.7:c.1256T>C, ENST00000551114.2:n.933T>C, ENST00000553106.5:c.1271T>C, ENST00000635477.1:n.375T>C, ENST00000635528.1:n.786T>C, NM_000277.2(PAH):c.1271T>C (p.Leu424Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP3	PM5, BS2, BA1, PS3, PS1, BS1	The NM_000277.2:c.1271T>C (p.Leu424Ser) variant in PAH has not been reported in the medical literature. This variant is absent from 1000G, ESP, ExAC, and gnomAD. A deleterious effect is predicted in SIFT, Polyphen-2, and REVEL=0.966. Overall, there is not enough evidence to classify the p.Leu424Ser variant with certainty. PAH-specific ACMG/AMP criteria applied: PM2, PP3.		Phenylketonuria VCEP		2019-03-31	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229424/MONDO:0009861/006	047bef50-812a-451d-a05a-87d93f28dbe8
NM_000277.2(PAH):c.350delC (p.Thr117Lysfs)	120274	CA267653	NM_000277.2:c.350delC, NC_000012.12:g.102894737del, CM000674.2:g.102894737del, NC_000012.11:g.103288515del, CM000674.1:g.103288515del, NC_000012.10:g.101812645del, NG_008690.1:g.27866del, NG_008690.2:g.68674del, NM_000277.1:c.350del, XM_011538422.1:c.350del, NM_000277.2:c.350del, NM_001354304.1:c.350del, XM_017019370.2:c.350del, NM_000277.3:c.350del, ENST00000307000.7:c.335del, ENST00000546844.1:c.350del, ENST00000548928.1:n.272del, ENST00000549111.5:n.446del, ENST00000550978.6:n.334del, ENST00000551337.5:c.350del, ENST00000551988.5:n.439del, ENST00000553106.5:c.350del, NM_000277.2(PAH):c.350delC (p.Thr117Lysfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4	BS2, BA1, PS3, BS1	The c.350delC variant in PAH has been previously reported in at least 2 Arab-Israeli probands with classic PKU (PMID: 18299955; PMID: 18294361); BH4 deficiency was not excluded (PP4). The variant is a frameshift variant occurring in exon 3 of 13 in the canonical transcript of PAH, a gene fulfilling the most recent criteria for LOF being a known disease mechanism (PVS1; see PVS1: Recommendations for Interpreting the Loss of Function PVS1 ACMG/AMP Variant Criteria). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and the Greater Middle East Variome (PM2).	18294361, 18299955	Phenylketonuria VCEP		2018-12-22	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA267653/MONDO:0009861/006	df824c1a-6747-41fc-9fc4-cfd843dfe25e
NM_000277.2(PAH):c.46T>C (p.Ser16Pro)	102689	CA229564	NM_000277.2:c.46T>C, NC_000012.12:g.102917085A>G, CM000674.2:g.102917085A>G, NC_000012.11:g.103310863A>G, CM000674.1:g.103310863A>G, NC_000012.10:g.101834993A>G, NG_008690.1:g.5518T>C, NG_008690.2:g.46326T>C, NM_000277.1:c.46T>C, XM_011538422.1:c.46T>C, NM_001354304.1:c.46T>C, XM_017019370.2:c.46T>C, NM_000277.3:c.46T>C, ENST00000307000.7:c.-102T>C, ENST00000546844.1:c.46T>C, ENST00000547319.1:n.357T>C, ENST00000549111.5:n.142T>C, ENST00000550978.6:n.30T>C, ENST00000551337.5:c.46T>C, ENST00000551988.5:n.135T>C, ENST00000553106.5:c.46T>C, ENST00000635500.1:n.29-4187T>C, NM_000277.2(PAH):c.46T>C (p.Ser16Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, BP4		VUS: The c.46T>C (p.S16P) variant in PAH has not been reported in the medical literature. It is tolerated by computation predictors: SIFT, Polyphen, MutationTaster, and REVEL=0.567 (BP4). It is however absent from population databases, including gnomAD, 1000 Genomes, and ESP (PM2). In summary this variant meets the criteria to be classified as uncertain significance. PAH-specific ACMG/AMP criteria applied: BP4, PM2.		Phenylketonuria VCEP		2019-02-26	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229564/MONDO:0009861/006	4126d099-9ee4-4fb2-b057-e8ef788cb645
	-	CA16020719	NM_000277.1:c.47C>A, NC_000012.12:g.102917084G>T, CM000674.2:g.102917084G>T, NC_000012.11:g.103310862G>T, CM000674.1:g.103310862G>T, NC_000012.10:g.101834992G>T, NG_008690.1:g.5519C>A, NG_008690.2:g.46327C>A, XM_011538422.1:c.47C>A, NM_000277.2:c.47C>A, NM_001354304.1:c.47C>A, XM_017019370.2:c.47C>A, NM_000277.3:c.47C>A, ENST00000307000.7:c.-101C>A, ENST00000546844.1:c.47C>A, ENST00000547319.1:n.358C>A, ENST00000549111.5:n.143C>A, ENST00000550978.6:n.31C>A, ENST00000551337.5:c.47C>A, ENST00000551988.5:n.136C>A, ENST00000553106.5:c.47C>A, ENST00000635500.1:n.29-4186C>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4	PP3, BP4	VUS: The c.47C>A (p.S16Y) variant in PAH was reported in one patient in a PKU cohort without segregation, and evidence of BH4 responsiveness (PP4, PMID: 21307867). This variant is absent from population databases, including 1000 Genomes, gnomAD and ESP. Computations predictors SIFT and Polyphen are conflicting, REVEL=0.569. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2.	21307867	Phenylketonuria VCEP		2019-02-26	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020719/MONDO:0009861/006	9ffeebb5-c4e1-48c9-8640-d8d6b0df1676
NM_000277.2(PAH):c.127G>T (p.Glu43Ter)	557124	CA16020729	NM_000277.2:c.127G>T, NC_000012.12:g.102912832C>A, CM000674.2:g.102912832C>A, NC_000012.11:g.103306610C>A, CM000674.1:g.103306610C>A, NC_000012.10:g.101830740C>A, NG_008690.1:g.9771G>T, NG_008690.2:g.50579G>T, NM_000277.1:c.127G>T, XM_011538422.1:c.127G>T, NM_001354304.1:c.127G>T, XM_017019370.2:c.127G>T, NM_000277.3:c.127G>T, ENST00000307000.7:c.112G>T, ENST00000546844.1:c.127G>T, ENST00000548677.2:n.214G>T, ENST00000548928.1:n.49G>T, ENST00000549111.5:n.223G>T, ENST00000550978.6:n.111G>T, ENST00000551337.5:c.127G>T, ENST00000551988.5:n.216G>T, ENST00000553106.5:c.127G>T, ENST00000635500.1:n.95G>T, NM_000277.2(PAH):c.127G>T (p.Glu43Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4		The c.127G>T (p.Glu43*) variant is a nonsense variant in exon 2 of 13 in PAH, predicted to undergo nonsense mediated decay with the truncated region critical to protein function. It has been reported in 2 individuals with PKU (BH4 deficiency not excluded). (PP4; PMID: 26503515). This variant is absent from population databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4.	26503515	Phenylketonuria VCEP		2019-04-03	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA16020729/MONDO:0009861/006	d224fcf5-f7be-4a92-b876-72d31e405d4f
NM_000277.2(PAH):c.58C>T (p.Gln20Ter)	102744	CA229635	NM_000277.2:c.58C>T, NC_000012.12:g.102917073G>A, CM000674.2:g.102917073G>A, NC_000012.11:g.103310851G>A, CM000674.1:g.103310851G>A, NC_000012.10:g.101834981G>A, NG_008690.1:g.5530C>T, NG_008690.2:g.46338C>T, NM_000277.1:c.58C>T, XM_011538422.1:c.58C>T, NM_001354304.1:c.58C>T, XM_017019370.2:c.58C>T, NM_000277.3:c.58C>T, ENST00000307000.7:c.-90C>T, ENST00000546844.1:c.58C>T, ENST00000547319.1:n.369C>T, ENST00000549111.5:n.154C>T, ENST00000550978.6:n.42C>T, ENST00000551337.5:c.58C>T, ENST00000551988.5:n.147C>T, ENST00000553106.5:c.58C>T, ENST00000635500.1:n.29-4175C>T, NM_000277.2(PAH):c.58C>T (p.Gln20Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4		Pathogenic: The c.58C>T (p.Gln20Ter) is a null variant reported in one patient with classic PKU phenotype (PVS1, PP4, PMID: 9391881). This variant is absent from population databases, including gnomAD, 1000 Genomes, and ESP (PM2). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4.	9391881	Phenylketonuria VCEP		2019-02-26	2019-04-06	false	https://erepo.genome.network/evrepo/ui/classification/CA229635/MONDO:0009861/006	0c208e34-37bd-4393-b238-7aeb88c8431e
NM_000277.2(PAH):c.125A>T (p.Lys42Ile)	102581	CA229419	NM_000277.2:c.125A>T, NC_000012.12:g.102912834T>A, CM000674.2:g.102912834T>A, NC_000012.11:g.103306612T>A, CM000674.1:g.103306612T>A, NC_000012.10:g.101830742T>A, NG_008690.1:g.9769A>T, NG_008690.2:g.50577A>T, NM_000277.1:c.125A>T, XM_011538422.1:c.125A>T, NM_001354304.1:c.125A>T, XM_017019370.2:c.125A>T, NM_000277.3:c.125A>T, ENST00000307000.7:c.110A>T, ENST00000546844.1:c.125A>T, ENST00000548677.2:n.212A>T, ENST00000548928.1:n.47A>T, ENST00000549111.5:n.221A>T, ENST00000550978.6:n.109A>T, ENST00000551337.5:c.125A>T, ENST00000551988.5:n.214A>T, ENST00000553106.5:c.125A>T, ENST00000635500.1:n.93A>T, NM_000277.2(PAH):c.125A>T (p.Lys42Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4, PS3	PP3	The c.125A>T (p.Lys42Ile) variant in PAH has been reported in 1 individual with classic PKU (BH4 deficiency not assessed/reported). (PP4; PMID: 9380432; 9781015). This variant is absent in population databases (PM2). This variant was detected with p.E280K (Pathogenic in ClinVar) (PM3). This variant has 12% enzyme activity in vitro (PS3; PMID: 21953985). Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PS3, PP4, PM2, PM3.	9380432, 9781015, 9380432, 11461190, 21953985	Phenylketonuria VCEP		2019-04-07	2019-04-07	false	https://erepo.genome.network/evrepo/ui/classification/CA229419/MONDO:0009861/006	295d33fe-390a-46a8-a5cf-dd0c34df16b9
NM_000277.2(PAH):c.385G>T (p.Asp129Tyr)	102660	CA286503	NM_000277.2:c.385G>T, NC_000012.12:g.102877518C>A, CM000674.2:g.102877518C>A, NC_000012.11:g.103271296C>A, CM000674.1:g.103271296C>A, NC_000012.10:g.101795426C>A, NG_008690.1:g.45085G>T, NG_008690.2:g.85893G>T, NM_000277.1:c.385G>T, XM_011538422.1:c.385G>T, NM_001354304.1:c.385G>T, XM_017019370.2:c.385G>T, NM_000277.3:c.385G>T, ENST00000307000.7:c.370G>T, ENST00000549111.5:n.481G>T, ENST00000550978.6:n.369G>T, ENST00000551337.5:c.385G>T, ENST00000551988.5:n.474G>T, ENST00000553106.5:c.385G>T, NM_000277.2(PAH):c.385G>T (p.Asp129Tyr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM5, PM2, PP3		The c.385G>T (p.Asp129Tyr) variant in PAH has not been reported in the literature to our knowledge. This variant is absent from 1000G, ESP, ExAC and gnomAD (PM2). Multiple lines of computational evidence support a deleterious effect (PP3). There are 2 other missense variants at this residue in ClinVar; p.Asp129Gly is Likely Pathogenic by 1 submitter and PAH EP (PM5). In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM5, PP3.		Phenylketonuria VCEP		2019-04-07	2019-04-07	false	https://erepo.genome.network/evrepo/ui/classification/CA286503/MONDO:0009861/006	0d22d416-20d9-4abc-96d1-031831f71e57
NM_000277.2(PAH):c.464G>A (p.Arg155His)	102686	CA229559	NM_000277.2:c.464G>A, NC_000012.12:g.102866641C>T, CM000674.2:g.102866641C>T, NC_000012.11:g.103260419C>T, CM000674.1:g.103260419C>T, NC_000012.10:g.101784549C>T, NG_008690.1:g.55962G>A, NG_008690.2:g.96770G>A, NM_000277.1:c.464G>A, XM_011538422.1:c.464G>A, NM_001354304.1:c.464G>A, XM_017019370.2:c.464G>A, NM_000277.3:c.464G>A, ENST00000307000.7:c.449G>A, ENST00000549111.5:n.560G>A, ENST00000551988.5:n.530+10821G>A, ENST00000553106.5:c.464G>A, NM_000277.2(PAH):c.464G>A (p.Arg155His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2, PP4_Moderate, PP1, PP3, PM3_Strong	PS3	The c.464G>A (p.Arg155His) has been reported in multiple individuals with mild hyperphenylalaninaemia, with BH4 deficiency excluded including 3 siblings (PP4_moderate, PMID: 9634518; PP1, PMID:18937047). This variant has low frequency in ExAC/gnomad (MAF=0.00012) in EA population (PM2). Multiple lines of computational evidence support a deleterious effect (PP3). This variant has been detected with 3 pathogenic variants: R243Q (PMID: 23932990), R111X (PMID: 24401910), IVS4+5G>T c.441+5G>T (PMID: 26210745) (PM3-strong). Experimental study showed the R155H mutant retained 55% activity, but this is higher than the cutoff set by PAH VCEP for PS3. (PMID: 18937047). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_strong, PM2, PP3, PP1.	9634518, 18937047, 18937047, 26210745, 24401910, 18937047, 23932990	Phenylketonuria VCEP		2019-04-07	2019-04-07	false	https://erepo.genome.network/evrepo/ui/classification/CA229559/MONDO:0009861/006	0857614c-284a-4342-821b-887439f4d6aa
NM_000277.2(PAH):c.493G>A (p.Ala165Thr)	102700	CA229579	NM_000277.2:c.493G>A, NC_000012.12:g.102866612C>T, CM000674.2:g.102866612C>T, NC_000012.11:g.103260390C>T, CM000674.1:g.103260390C>T, NC_000012.10:g.101784520C>T, NG_008690.1:g.55991G>A, NG_008690.2:g.96799G>A, NM_000277.1:c.493G>A, XM_011538422.1:c.493G>A, NM_001354304.1:c.493G>A, XM_017019370.2:c.493G>A, NM_000277.3:c.493G>A, ENST00000307000.7:c.478G>A, ENST00000549111.5:n.589G>A, ENST00000551988.5:n.530+10850G>A, ENST00000553106.5:c.493G>A, NM_000277.2(PAH):c.493G>A (p.Ala165Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP1, PP3		The c.493G>A (p.Ala165Thr) variant in PAH has been reported in multiple individuals with PKU, including siblings (BH4 deficiency excluded). (PP4_Moderate, PMID: 8981952; PP1, PMID: 26666653). This variant has extremely low frequency in gnomAD (MAF=0.00001) (PM2). This variant was detected with c.1066-11G>A (PM3; PMID: 10598814). Multiple lines of computational evidence support a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP1, PP3.	19786003, 10598814, 8981952, 26666653	Phenylketonuria VCEP		2019-04-07	2019-04-07	false	https://erepo.genome.network/evrepo/ui/classification/CA229579/MONDO:0009861/006	08ff348d-98b9-47fa-97c5-2f3d8fb04a8a
NM_000277.2(PAH):c.493G>C (p.Ala165Pro)	102701	CA229581	NM_000277.2:c.493G>C, NC_000012.12:g.102866612C>G, CM000674.2:g.102866612C>G, NC_000012.11:g.103260390C>G, CM000674.1:g.103260390C>G, NC_000012.10:g.101784520C>G, NG_008690.1:g.55991G>C, NG_008690.2:g.96799G>C, NM_000277.1:c.493G>C, XM_011538422.1:c.493G>C, NM_001354304.1:c.493G>C, XM_017019370.2:c.493G>C, NM_000277.3:c.493G>C, ENST00000307000.7:c.478G>C, ENST00000549111.5:n.589G>C, ENST00000551988.5:n.530+10850G>C, ENST00000553106.5:c.493G>C, NM_000277.2(PAH):c.493G>C (p.Ala165Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4, PP3	PM3	The c.493G>C (p.Ala165Pro) variant in PAH has been reported in a French patient with mild PKU with p.Glu390Gly, but parents were not tested (PP4; PMID: 26666653) This variant is absent from 1000G and ESP, and has extremely low frequency in ExAC/gnomAD: MAF 0.00001 (PM2). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.956 (PP3). In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PP3.	26666653, 26666653	Phenylketonuria VCEP		2019-04-07	2019-04-07	false	https://erepo.genome.network/evrepo/ui/classification/CA229581/MONDO:0009861/006	b8695db8-b85f-4831-82d3-e88850f9b494
	-	CA16020800	NM_000277.3:c.494C>A, NC_000012.12:g.102866611G>T, CM000674.2:g.102866611G>T, NC_000012.11:g.103260389G>T, CM000674.1:g.103260389G>T, NC_000012.10:g.101784519G>T, NG_008690.1:g.55992C>A, NG_008690.2:g.96800C>A, NM_000277.1:c.494C>A, XM_011538422.1:c.494C>A, NM_000277.2:c.494C>A, NM_001354304.1:c.494C>A, XM_017019370.2:c.494C>A, ENST00000307000.7:c.479C>A, ENST00000549111.5:n.590C>A, ENST00000551988.5:n.530+10851C>A, ENST00000553106.5:c.494C>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		The c.494C>A (p.Ala165Asp) variant in PAH has been reported in multiple individuals with PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 26503515). This variant is absent in population databases (PM2). This variant was detected with pathogenic variants p.R111X and p.R176X (PM3; PMID: 23225039). Computational evidence support a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.	23225039, 26503515	Phenylketonuria VCEP		2019-04-07	2019-04-08	false	https://erepo.genome.network/evrepo/ui/classification/CA16020800/MONDO:0009861/006	0e6abec4-a4c1-4633-9b93-f5e4f44c8890
NM_000277.2(PAH):c.498C>A (p.Tyr166Ter)	102702	CA229583	NM_000277.2:c.498C>A, NC_000012.12:g.102866607G>T, CM000674.2:g.102866607G>T, NC_000012.11:g.103260385G>T, CM000674.1:g.103260385G>T, NC_000012.10:g.101784515G>T, NG_008690.1:g.55996C>A, NG_008690.2:g.96804C>A, NM_000277.1:c.498C>A, XM_011538422.1:c.498C>A, NM_001354304.1:c.498C>A, XM_017019370.2:c.498C>A, NM_000277.3:c.498C>A, ENST00000307000.7:c.483C>A, ENST00000549111.5:n.594C>A, ENST00000551988.5:n.530+10855C>A, ENST00000553106.5:c.498C>A, NM_000277.2(PAH):c.498C>A (p.Tyr166Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PM2, PP4		The c.498C>A (p.Tyr166Ter) variant in PAH is a nonsense variant in exon 5 of 13 in PAH, predicted to undergo nonsense mediated decay with the truncated region critical to protein function. It has been reported in individuals with Classic PKU in German and Chinese cohorts. (PP4, PMID:16256386; 10394930). This variant is absent from ExAC/gnomAD, 1000 Genomes, and ESP (PM2). This variant was detected with multiple known pathogenic variants (PM3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4.	16256386, 16256386	Phenylketonuria VCEP		2019-04-08	2019-04-08	false	https://erepo.genome.network/evrepo/ui/classification/CA229583/MONDO:0009861/006	76342745-0175-4795-ab71-e314ef54d447
NM_000277.2(PAH):c.521T>C (p.Ile174Thr)	102721	CA229604	NM_000277.2:c.521T>C, NC_000012.12:g.102855321A>G, CM000674.2:g.102855321A>G, NC_000012.11:g.103249099A>G, CM000674.1:g.103249099A>G, NC_000012.10:g.101773229A>G, NG_008690.1:g.67282T>C, NG_008690.2:g.108090T>C, NM_000277.1:c.521T>C, XM_011538422.1:c.521T>C, NM_001354304.1:c.521T>C, XM_017019370.2:c.521T>C, NM_000277.3:c.521T>C, ENST00000307000.7:c.506T>C, ENST00000549111.5:n.617T>C, ENST00000551988.5:n.542T>C, ENST00000553106.5:c.521T>C, NM_000277.2(PAH):c.521T>C (p.Ile174Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PM2, PP4_Moderate, PP3, PS3		The c.521T>C (p.Ile174Thr) variant in PAH has been reported in 2 individuals with PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 9634518). This variant is absent from ExAC/gnomAD, 1000 Genomes, ESP (PM2). This variant has 1-15% enzyme activity (PS3; PMID: 11161839). This variant was detected in with p.F299C (P/LP, 6 submitters) (PM3; PMID: 23842451). Computational prediction tools and conservation analysis suggest that the variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM2, PM3, PP3	23842451, 9634518, 11161839	Phenylketonuria VCEP		2019-04-08	2019-04-08	false	https://erepo.genome.network/evrepo/ui/classification/CA229604/MONDO:0009861/006	e09d3bdc-fa6e-47db-a864-8f62a9e00ee7
NM_000277.2(PAH):c.523C>T (p.Pro175Ser)	555366	CA16020810	NM_000277.2:c.523C>T, NC_000012.12:g.102855319G>A, CM000674.2:g.102855319G>A, NC_000012.11:g.103249097G>A, CM000674.1:g.103249097G>A, NC_000012.10:g.101773227G>A, NG_008690.1:g.67284C>T, NG_008690.2:g.108092C>T, NM_000277.1:c.523C>T, XM_011538422.1:c.523C>T, NM_001354304.1:c.523C>T, XM_017019370.2:c.523C>T, NM_000277.3:c.523C>T, ENST00000307000.7:c.508C>T, ENST00000549111.5:n.619C>T, ENST00000551988.5:n.544C>T, ENST00000553106.5:c.523C>T, NM_000277.2(PAH):c.523C>T (p.Pro175Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		The c.523C>T (p.Pro175Ser) variant in PAH has been reported in 1 individual with classic PKU (BH4 deficiency excluded) in trans with pathogenic variant p.R413P (PP4_Moderate, PM3; PMID: 26322415). This variant is absent in population databases (PM2). Computational evidence support a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.	26322415, 26322415	Phenylketonuria VCEP		2019-04-08	2019-04-08	false	https://erepo.genome.network/evrepo/ui/classification/CA16020810/MONDO:0009861/006	668b6965-0eb2-46ca-a2a6-80d7f55a3bf1
NM_000277.2(PAH):c.143T>C (p.Leu48Ser)	608	CA251539	NM_000277.2:c.143T>C, NC_000012.12:g.102912816A>G, CM000674.2:g.102912816A>G, NC_000012.11:g.103306594A>G, CM000674.1:g.103306594A>G, NC_000012.10:g.101830724A>G, NG_008690.1:g.9787T>C, NG_008690.2:g.50595T>C, NM_000277.1:c.143T>C, XM_011538422.1:c.143T>C, NM_001354304.1:c.143T>C, XM_017019370.2:c.143T>C, NM_000277.3:c.143T>C, ENST00000307000.7:c.128T>C, ENST00000546844.1:c.143T>C, ENST00000548677.2:n.230T>C, ENST00000548928.1:n.65T>C, ENST00000549111.5:n.239T>C, ENST00000550978.6:n.127T>C, ENST00000551337.5:c.143T>C, ENST00000551988.5:n.232T>C, ENST00000553106.5:c.143T>C, ENST00000635500.1:n.111T>C, NM_000277.2(PAH):c.143T>C (p.Leu48Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PP1, PP3, PS3	PM2	The c.143T>C (p.Leu48Ser) variant in PAH has been reported multiple individuals with mild and classic PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 26322415, 16879198, 1679030). This variant has a frequency that is higher than the suggested cutoff for PM2 by the PAH VCEP (MAF=0.00026). This variant has 39% residual activity (PS3, PMID: 17935162). This variant was detected in trans with p.G247R (LP, 2 submitters) PM3, PMID: 26322415). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). Cosegregation with PKU in 2 siblings for 2 unrelated families was reported ( PMID: 23430547). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3, PP1, PP3.	26322415, 26322415, 16879198, 1679030, 23430547, 17935162	Phenylketonuria VCEP		2019-04-08	2019-04-08	false	https://erepo.genome.network/evrepo/ui/classification/CA251539/MONDO:0009861/006	d9c8f867-8d78-48cd-8299-827206594d17
	-	CA16020761	NM_000277.3:c.292T>G, NC_000012.12:g.102894795A>C, CM000674.2:g.102894795A>C, NC_000012.11:g.103288573A>C, CM000674.1:g.103288573A>C, NC_000012.10:g.101812703A>C, NG_008690.1:g.27808T>G, NG_008690.2:g.68616T>G, NM_000277.1:c.292T>G, XM_011538422.1:c.292T>G, NM_000277.2:c.292T>G, NM_001354304.1:c.292T>G, XM_017019370.2:c.292T>G, ENST00000307000.7:c.277T>G, ENST00000546844.1:c.292T>G, ENST00000548928.1:n.214T>G, ENST00000549111.5:n.388T>G, ENST00000550978.6:n.276T>G, ENST00000551337.5:c.292T>G, ENST00000551988.5:n.381T>G, ENST00000553106.5:c.292T>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP4_Moderate	PP3	The c.292T>G (p.Leu98Val) variant in PAH has been reported in multiple individuals with mild PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 26322415, 26503515). This variant is absent in population databases (PM2). This variant was detected in trans with p.R408W (P, 16 submitters) (PM3). Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3.	26322415, 26503515, 26322415	Phenylketonuria VCEP		2019-04-08	2019-04-09	false	https://erepo.genome.network/evrepo/ui/classification/CA16020761/MONDO:0009861/006	cfd0acfb-d16d-459e-b078-1bcf48ce9158
NM_000277.2(PAH):c.843-2A>T	102873	CA229816	NM_000277.2:c.843-2A>T, NC_000012.12:g.102851758T>A, CM000674.2:g.102851758T>A, NC_000012.11:g.103245536T>A, CM000674.1:g.103245536T>A, NC_000012.10:g.101769666T>A, NG_008690.1:g.70845A>T, NG_008690.2:g.111653A>T, NM_000277.1:c.843-2A>T, XM_011538422.1:c.843-2A>T, NM_001354304.1:c.843-2A>T, NM_000277.3:c.843-2A>T, ENST00000307000.7:c.828-2A>T, ENST00000549247.6:n.602-2A>T, ENST00000551114.2:n.503A>T, ENST00000553106.5:c.843-2A>T, ENST00000635477.1:n.4-2A>T, NM_000277.2(PAH):c.843-2A>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4	PM3	The c.843-2A>T variant in PAH has been reported in 1 homozygote individual with classic PKU (PMID: 9452062). This variant disrupts the canonical splice acceptor site of intron 8 where LOF is a known mechanism of disease, exon skipping disrupts reading frame, and is predicted to undergo NMD. Coding exon 8 is present in biologically-relevant transcript. This variant is absent from population databases, including: 1000 Genomes, ESP, and gnomAD. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4.		Phenylketonuria VCEP		2019-04-09	2019-04-09	false	https://erepo.genome.network/evrepo/ui/classification/CA229816/MONDO:0009861/006	0f80f747-69bd-4d63-9cca-27ccf00298b5
NM_000277.2(PAH):c.842+1G>T	102869	CA229812	NM_000277.2:c.842+1G>T, NC_000012.12:g.102852814C>A, CM000674.2:g.102852814C>A, NC_000012.11:g.103246592C>A, CM000674.1:g.103246592C>A, NC_000012.10:g.101770722C>A, NG_008690.1:g.69789G>T, NG_008690.2:g.110597G>T, NM_000277.1:c.842+1G>T, XM_011538422.1:c.842+1G>T, NM_001354304.1:c.842+1G>T, NM_000277.3:c.842+1G>T, ENST00000307000.7:c.827+1G>T, ENST00000549247.6:n.601+1G>T, ENST00000553106.5:c.842+1G>T, ENST00000635477.1:n.3+1G>T, NM_000277.2(PAH):c.842+1G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4		The PAH c.842+1G>T variant has been reported at least once in the literature in a 15 month old patient with moderate PKU in the homozygote state (PP4, PMID: 23220018). This variant is absent from 1000G, ESP, and gnomAD databases. This variant disrupts the canonical splice donor site of intron 7 where LOF is a known mechanism of disease, exon skipping disrupts reading frame, and is predicted to undergo NMD. Coding exon 7 is present in biologically-relevant transcript. In summary, this variant meets criteria to be pathogenic. PAH-specific ACMG/AMP criteria applied: PM2, PP4, PVS1.	23220018	Phenylketonuria VCEP		2019-04-09	2019-04-09	false	https://erepo.genome.network/evrepo/ui/classification/CA229812/MONDO:0009861/006	61b0c352-14e1-4d67-8509-3390ab16ec24
NM_000277.2(PAH):c.440C>T (p.Pro147Leu)	102670	CA229543	NM_000277.2:c.440C>T, NC_000012.12:g.102877463G>A, CM000674.2:g.102877463G>A, NC_000012.11:g.103271241G>A, CM000674.1:g.103271241G>A, NC_000012.10:g.101795371G>A, NG_008690.1:g.45140C>T, NG_008690.2:g.85948C>T, NM_000277.1:c.440C>T, XM_011538422.1:c.440C>T, NM_001354304.1:c.440C>T, XM_017019370.2:c.440C>T, NM_000277.3:c.440C>T, ENST00000307000.7:c.425C>T, ENST00000549111.5:n.536C>T, ENST00000550978.6:n.424C>T, ENST00000551988.5:n.529C>T, ENST00000553106.5:c.440C>T, NM_000277.2(PAH):c.440C>T (p.Pro147Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PP3, PM3_Strong		The c.440C>T (p.Pro147Leu) variant in PAH has been reported in multiple individuals with mild PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 27121329, 26322415, 16527067, 30050108, 28982351). This variant is absent in population databases (PM2). This variant was detected in trans with known pathogenic variants p.R261Ter (PMID: 27121329); c.611A>G (PMID: 30050108); p.S70del (PMID: 28982351) (PM3_strong). Computational evidence supports a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_strong, PP3.	26503515, 26322415, 28982351, 27121329, 26322415, 30050108	Phenylketonuria VCEP		2019-04-09	2019-04-09	false	https://erepo.genome.network/evrepo/ui/classification/CA229543/MONDO:0009861/006	febc80a4-e7d3-4341-8bd4-c26225613b2d
NM_000277.2(PAH):c.559T>C (p.Trp187Arg)	102735	CA229622	NM_000277.2:c.559T>C, NC_000012.12:g.102855283A>G, CM000674.2:g.102855283A>G, NC_000012.11:g.103249061A>G, CM000674.1:g.103249061A>G, NC_000012.10:g.101773191A>G, NG_008690.1:g.67320T>C, NG_008690.2:g.108128T>C, NM_000277.1:c.559T>C, XM_011538422.1:c.559T>C, NM_001354304.1:c.559T>C, XM_017019370.2:c.559T>C, NM_000277.3:c.559T>C, ENST00000307000.7:c.544T>C, ENST00000549111.5:n.655T>C, ENST00000551988.5:n.580T>C, ENST00000553106.5:c.559T>C, NM_000277.2(PAH):c.559T>C (p.Trp187Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PP3, PM3_Strong	BP4, BA1, BS1	The PAH: c.559T>C (p.Trp187Arg) variant was found in two cases in trans with other P/LP alleles: one case with classic PKU (assessed via plasma Phe measurement in trans with the p.R158Q allele (PMID: 18956252) and one case whose PKU sub-phenotype was not mentioned in trans with the p.R261Q allele (PMID: 23074961) (PM3_Strong). It has also been found in trans with the p.Gln419Arg allele, classified as Likely Pathogenic in ClinVar, in 1 case with mild hyperphenylalanemia (BH4 deficiency excluded. PP4_moderate. PMID: 28982351). The variant is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2). It is predicted damaging by multiple lines of computational evidence: SIFT, Polyphen2, Mutation Taster, REVEL = 0.918 (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_strong, PP3.	28982351, 18956252, 23074961, 28982351, 18956252	Phenylketonuria VCEP		2018-12-11	2019-05-04	false	https://erepo.genome.network/evrepo/ui/classification/CA229622/MONDO:0009861/006	c4c72f19-332b-48fb-b8ef-beaa7c0646fb
NM_000277.2(PAH):c.591G>C (p.Leu197Phe)	120280	CA267662	NM_000277.2:c.591G>C, NC_000012.12:g.102855251C>G, CM000674.2:g.102855251C>G, NC_000012.11:g.103249029C>G, CM000674.1:g.103249029C>G, NC_000012.10:g.101773159C>G, NG_008690.1:g.67352G>C, NG_008690.2:g.108160G>C, NM_000277.1:c.591G>C, XM_011538422.1:c.591G>C, NM_001354304.1:c.591G>C, XM_017019370.2:c.591G>C, NM_000277.3:c.591G>C, ENST00000307000.7:c.576G>C, ENST00000549111.5:n.687G>C, ENST00000553106.5:c.591G>C, NM_000277.2(PAH):c.591G>C (p.Leu197Phe)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		The c.591G>C (p.Leu197Phe) variant in PAH has been reported in 3 individuals with classic PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 18299955). This variant is absent in population databases (PM2). This variant was detected with a pathogenic variant (c.168+1G>A) and twice in the homozygous state (PM3). Multiple lines of computational evidence support a deleterious effect (SIFT, PolyPhen2, MutationTaster, REVEL=0.82). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.	18299955, 18299955	Phenylketonuria VCEP		2019-05-04	2019-05-04	false	https://erepo.genome.network/evrepo/ui/classification/CA267662/MONDO:0009861/006	0de1731a-9fea-445e-ac38-11ce147f981a
NM_000277.2(PAH):c.781C>G (p.Arg261Gly)	133314	CA269921	NM_000277.2:c.781C>G, NC_000012.12:g.102852876G>C, CM000674.2:g.102852876G>C, NC_000012.11:g.103246654G>C, CM000674.1:g.103246654G>C, NC_000012.10:g.101770784G>C, NG_008690.1:g.69727C>G, NG_008690.2:g.110535C>G, NM_000277.1:c.781C>G, XM_011538422.1:c.781C>G, NM_001354304.1:c.781C>G, NM_000277.3:c.781C>G, ENST00000307000.7:c.766C>G, ENST00000549247.6:n.540C>G, ENST00000553106.5:c.781C>G, NM_000277.2(PAH):c.781C>G (p.Arg261Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP3		The c.781C>G (p.Arg261Gly) variant in PAH has not been reported in the literature (to our knowledge). This variant is at extremely low frequency in gnomAD (MAF=0.00006, PM2). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.962. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP3.		Phenylketonuria VCEP		2019-05-04	2019-05-04	false	https://erepo.genome.network/evrepo/ui/classification/CA269921/MONDO:0009861/006	4d9ea7aa-408e-4e3d-92b1-c2b52314fc06
NM_000277.2(PAH):c.1092_1094del (p.Leu365del)	597	CA229337	NM_000277.2:c.1092_1094del, NC_000012.12:g.102843753_102843755del, CM000674.2:g.102843753_102843755del, NC_000012.11:g.103237531_103237533del, CM000674.1:g.103237531_103237533del, NC_000012.10:g.101761661_101761663del, NG_008690.1:g.78850_78852del, NG_008690.2:g.119658_119660del, NM_000277.1:c.1092_1094del, XM_011538422.1:c.1035_1037del, NM_001354304.1:c.1092_1094del, NM_000277.3:c.1092_1094del, ENST00000307000.7:c.1077_1079del, ENST00000549247.6:n.851_853del, ENST00000551114.2:n.754_756del, ENST00000553106.5:c.1092_1094del, ENST00000635477.1:n.196_198del, ENST00000635528.1:n.607_609del, NM_000277.2(PAH):c.1092_1094del (p.Leu365del)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM4, PM2, PP4		The c.1092_1094delTCT variant in PAH has been previously reported as a single variant, found in trans with the Pathogenic variant (per internal PAH ClinGen Working Group classification, see ClinVar allele ID 15635) p.Gly272Ter in one proband with classic PKU (PMID: 1975559); phase was confirmed via parental testing (PM3). Apart from stating that the proband was identified via newborn screening further detail is provided regarding the probandâ€™s phenotype, including whether BH4 deficiency was formally excluded (PP4?). The variant is a protein-length changing variant in a non-repeat region (PM4). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2).	1975559, 1975559	Phenylketonuria VCEP		2019-05-04	2019-05-04	false	https://erepo.genome.network/evrepo/ui/classification/CA229337/MONDO:0009861/006	23e1d74c-aefc-440e-983d-80babb89c158
NM_000277.2(PAH):c.1240T>C (p.Tyr414His)	120265	CA267637	NM_000277.2:c.1240T>C, NC_000012.12:g.102840475A>G, CM000674.2:g.102840475A>G, NC_000012.11:g.103234253A>G, CM000674.1:g.103234253A>G, NC_000012.10:g.101758383A>G, NG_008690.1:g.82128T>C, NG_008690.2:g.122936T>C, NM_000277.1:c.1240T>C, XM_011538422.1:c.1183T>C, NM_001354304.1:c.1240T>C, NM_000277.3:c.1240T>C, ENST00000307000.7:c.1225T>C, ENST00000551114.2:n.902T>C, ENST00000553106.5:c.1240T>C, ENST00000635477.1:n.344T>C, ENST00000635528.1:n.755T>C, NM_000277.2(PAH):c.1240T>C (p.Tyr414His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM5, PM2, PP3		The c.1240T>C (p.Tyr414His) variant in PAH has been previously reported Likely Pathogenic by one clinical laboratory in ClinVar (see variant ID 125859); the collection method is stated as â€œliterature onlyâ€ and no further information is provided. To our knowledge, as of 4/29/19, it has not been reported in the published literature. The variant results in the substitution of a highly conserved Tyrosine residue with Histidine, a physiochemically distinct amino acid (nonpolar versus basic side chains), and the amino acid substitution is predicted damaging by multiple lines of computational evidence e.g., Predicted deleterious in SIFT, Polyphen2, Mutation Taster. REVEL= 0.969) (PP3). It is present at extremely low frequency in control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP: the highest MAF reported is 0.00001, in the gnomAD/ExAC Non-Finnish European subpopulation, which falls below the 0.0002 allele frequency cutoff for PAH variants (PM2). Another missense variant at this site, p.Tyr414Cys, has been previously reported Pathogenic, including by the ClinGen PAH working group (see ClinVar variant ID 593) (PM5).		Phenylketonuria VCEP		2019-05-05	2019-05-05	false	https://erepo.genome.network/evrepo/ui/classification/CA267637/MONDO:0009861/006	8aa553b5-7bd0-4681-b391-d6acb0a47cc9
NM_000277.2(PAH):c.168+5G>A	102605	CA229453	NM_000277.2:c.168+5G>A, NC_000012.12:g.102912786C>T, CM000674.2:g.102912786C>T, NC_000012.11:g.103306564C>T, CM000674.1:g.103306564C>T, NC_000012.10:g.101830694C>T, NG_008690.1:g.9817G>A, NG_008690.2:g.50625G>A, NM_000277.1:c.168+5G>A, XM_011538422.1:c.168+5G>A, NM_001354304.1:c.168+5G>A, XM_017019370.2:c.168+5G>A, NM_000277.3:c.168+5G>A, ENST00000307000.7:c.153+5G>A, ENST00000546844.1:c.168+5G>A, ENST00000548677.2:n.255+5G>A, ENST00000548928.1:n.90+5G>A, ENST00000549111.5:n.264+5G>A, ENST00000550978.6:n.152+5G>A, ENST00000551337.5:c.168+5G>A, ENST00000551988.5:n.257+5G>A, ENST00000553106.5:c.168+5G>A, ENST00000635500.1:n.136+5G>A, NM_000277.2(PAH):c.168+5G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PP3, PM3_Strong		The c.168+5G>A variant has been identified in at least 4 probands with phenotypes ranging from mild HPA to classic PKU, with at least 2 probands excluding BH4 deficiency (PMIDs: 9429153, 26413448, 27121329). It has been detected in the homozygous form (PMID: 26413448) as well as in trans with pathogenic variants R297H (PMID: 9429153), I65T, and S349P (PMID: 27121329). This variant is absent from 1000G, ESP, and gnomAD databases. Computational analysis predicts an alteration of the WT donor site, most probably affecting splicing. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_Strong, PM2, PP4_Moderate, PP3.	26413448, 9429153, 27121329, 26413448, 9429153, 27121329	Phenylketonuria VCEP		2019-05-26	2019-05-26	false	https://erepo.genome.network/evrepo/ui/classification/CA229453/MONDO:0009861/006	f91cc9c6-b8c8-4183-a8c9-a7f0c30fd1ba
NM_000277.2(PAH):c.196G>T (p.Glu66Ter)	120270	CA267645	NM_000277.2:c.196G>T, NC_000012.12:g.102894891C>A, CM000674.2:g.102894891C>A, NC_000012.11:g.103288669C>A, CM000674.1:g.103288669C>A, NC_000012.10:g.101812799C>A, NG_008690.1:g.27712G>T, NG_008690.2:g.68520G>T, NM_000277.1:c.196G>T, XM_011538422.1:c.196G>T, NM_001354304.1:c.196G>T, XM_017019370.2:c.196G>T, NM_000277.3:c.196G>T, ENST00000307000.7:c.181G>T, ENST00000546844.1:c.196G>T, ENST00000548677.2:n.283G>T, ENST00000548928.1:n.118G>T, ENST00000549111.5:n.292G>T, ENST00000550978.6:n.180G>T, ENST00000551337.5:c.196G>T, ENST00000551988.5:n.285G>T, ENST00000553106.5:c.196G>T, ENST00000635500.1:n.164G>T, NM_000277.2(PAH):c.196G>T (p.Glu66Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4, PM3_Supporting		The c.196G>T (p.Glu66Ter) variant in PAH has been previously reported in one proband with classic PKU (PMID: 26666653) (PP4). The proband was heterozygous for the variant and also harbor the pathogenic allele (per ClinGen VCEP) c. 1315+1G>A; however, the phase of the variants was not confirmed via parental testing. (PM3_supporting). The sequence change results in a nonsense variant which occurs in exon 3 of 13 in the in the canonical transcript of PAH, a gene fulfilling the most recent criteria for LOF being a known disease mechanism (see PMID: 30192042) (PVS1). It is absent from control databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4, PM3_supporting.	26666653, 26666653	Phenylketonuria VCEP		2019-05-26	2019-05-26	false	https://erepo.genome.network/evrepo/ui/classification/CA267645/MONDO:0009861/006	43d4908f-6cb4-4058-865a-6c3f58dd5dc0
NM_000277.2(PAH):c.504C>A (p.Tyr168Ter)	120277	CA267656	NM_000277.2:c.504C>A, NC_000012.12:g.102866601G>T, CM000674.2:g.102866601G>T, NC_000012.11:g.103260379G>T, CM000674.1:g.103260379G>T, NC_000012.10:g.101784509G>T, NG_008690.1:g.56002C>A, NG_008690.2:g.96810C>A, NM_000277.1:c.504C>A, XM_011538422.1:c.504C>A, NM_001354304.1:c.504C>A, XM_017019370.2:c.504C>A, NM_000277.3:c.504C>A, ENST00000307000.7:c.489C>A, ENST00000549111.5:n.600C>A, ENST00000551988.5:n.530+10861C>A, ENST00000553106.5:c.504C>A, NM_000277.2(PAH):c.504C>A (p.Tyr168Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2, PVS1, PP4, PM3_Supporting		The c.504C>A (p.Tyr168Ter) variant in PAH has been previously reported in one proband with mild hyperphenylalanemia (PMID: 26666653; PP4). The proband was said to be heterozygous for the variant and also harbor the known pathogenic allele (per ClinGen PAH VCEP, see ClinVar ID 92751) c.898G>T (p.Ala300Ser); however, the phase of the variants was not confirmed via parental testing (PM3_supporting).The sequence change results in a nonsense variant which occurs in exon 5 of 13 in the in the canonical transcript of PAH, a gene fulfilling the most recent criteria for LOF being a known disease mechanism (see PMID: 30192042) (PVS1). It is absent from control databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4, PM3_supporting.	26666653, 26666653	Phenylketonuria VCEP		2019-05-26	2019-05-26	false	https://erepo.genome.network/evrepo/ui/classification/CA267656/MONDO:0009861/006	3f6b65dc-2d21-4ed2-80d7-f90aebc846c1
	-	CA16020871	NM_000277.3:c.842+4A>T, NC_000012.12:g.102852811T>A, CM000674.2:g.102852811T>A, NC_000012.11:g.103246589T>A, CM000674.1:g.103246589T>A, NC_000012.10:g.101770719T>A, NG_008690.1:g.69792A>T, NG_008690.2:g.110600A>T, NM_000277.1:c.842+4A>T, XM_011538422.1:c.842+4A>T, NM_000277.2:c.842+4A>T, NM_001354304.1:c.842+4A>T, ENST00000307000.7:c.827+4A>T, ENST00000549247.6:n.601+4A>T, ENST00000553106.5:c.842+4A>T, ENST00000635477.1:n.3+4A>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4, PP3	PM3, PS1	The c.842+4A>T PAH variant has been reported in PKU patients (PMID: 25863075). This variant is absent from 1000G, ESP, and gnomAD databases. This is an intronic variant in a highly conserved nucleotide, and computational analyses predict that this variant abolishes the donor splice site of intron 7.  In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP3, PM2, PP4.	25863075, 25863075	Phenylketonuria VCEP		2019-06-09	2019-06-09	false	https://erepo.genome.network/evrepo/ui/classification/CA16020871/MONDO:0009861/006	7b926e89-1446-46c1-a71b-756e59f310ae
NM_000277.2(PAH):c.895T>C (p.Phe299Leu)	208182	CA275941	NM_000277.2:c.895T>C, NC_000012.12:g.102851704A>G, CM000674.2:g.102851704A>G, NC_000012.11:g.103245482A>G, CM000674.1:g.103245482A>G, NC_000012.10:g.101769612A>G, NG_008690.1:g.70899T>C, NG_008690.2:g.111707T>C, NM_000277.1:c.895T>C, XM_011538422.1:c.895T>C, NM_001354304.1:c.895T>C, NM_000277.3:c.895T>C, ENST00000307000.7:c.880T>C, ENST00000549247.6:n.654T>C, ENST00000551114.2:n.557T>C, ENST00000553106.5:c.895T>C, ENST00000635477.1:n.56T>C, NM_000277.2(PAH):c.895T>C (p.Phe299Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM5, PM2, PP3		The c.895T>C (p.Phe299Leu) variant in PAH is reported as Likely Pathogenic by one clinical laboratory in ClinVar (see variant ID 208182); no further information is provided. At the time of review (5/25/19), the variant does not appear to be reported in the published literature and/or in the BioPKU database. The variant results in the substitution of a highly conserved Phenylalanine residue with Leucine; the amino acid substitution is predicted damaging by multiple lines of computational evidence e.g., predicted deleterious in SIFT, Polyphen2, Mutation Taster; REVEL= 0.96) (PP3). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2). Another missense variant at this site, p.Phe299Cys, has been previously reported Pathogenic/Likely Pathogenic by seven submitters in ClinVar (variant ID 613), where it was noted to be a recurrent allele among Norwegian PKU patients and have in-vitro data supporting that it impaired protein function. Another missense variant at this site, Phe299Ser, has also been reported in the BioPKU database (PAH0800). These reports of those variants support use of PM5.		Phenylketonuria VCEP		2019-06-09	2019-06-09	false	https://erepo.genome.network/evrepo/ui/classification/CA275941/MONDO:0009861/006	9c3f5113-40d4-4491-b303-093c891ae4d2
NM_005343.3(HRAS):c.508A>T (p.Lys170Ter)	40447	CA296052	NM_005343.3:c.508A>T, NC_000011.10:g.532698T>A, CM000673.2:g.532698T>A, NC_000011.9:g.532698T>A, CM000673.1:g.532698T>A, NC_000011.8:g.522698T>A, NG_007666.1:g.7853A>T, NM_001130442.1:c.508A>T, NM_005343.2:c.508A>T, NM_176795.3:c.*77A>T, XM_011519875.1:c.-425+4361T>A, XM_011519877.1:c.-162+4361T>A, XR_242795.1:n.789A>T, NM_001130442.2:c.508A>T, NM_001318054.1:c.271A>T, NM_176795.4:c.*77A>T, XM_011519875.2:c.-425+4361T>A, XM_011519877.2:c.-162+4361T>A, XM_017017167.1:c.-500+4361T>A, XM_017017168.1:c.-500+4361T>A, NM_005343.4:c.508A>T, ENST00000311189.7:c.508A>T, ENST00000397594.5:c.*77A>T, ENST00000397596.6:c.508A>T, ENST00000417302.5:c.*77A>T, ENST00000451590.5:c.508A>T, ENST00000462734.1:n.283A>T, ENST00000478324.5:n.243-68A>T, ENST00000479482.1:n.429A>T, ENST00000493230.5:c.*77A>T, NM_005343.3(HRAS):c.508A>T (p.Lys170Ter)	HRAS	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Uncertain Significance	BS4	PS3, PS4, PS2, PS1, BP5, BP7, BS3, BS1, PM1, PM4, PM5, PM6, PM2, BS2, PP1, PP3, PP2, BP2, BP3, BP4, BP1, BA1	The c.508A>T (p.Lys170Ter) variant in the HRAS gene has been identified in patients with cancer and individuals who underwent testing for RASopathies, however it was also identified in an unaffected parent (BS4; Invitae, GeneDx internal data, GTR Lab ID: 26957, 500031; SCV000207840.14, SCV000635092.3). The filtering allele frequency of the p.Lys170Ter variant is 0.0034% for European (non-Finnish) chromosomes by the gnomAD aggregation database (8/249358 with 95% CI), which is not a high enough frequency to meet thresholds defined by the ClinGen RASopahty Expert panel for autosomal dominant RASopathy variants (BA1/BS1 not met). Furthermore, LOF and/or haploinsufficiency has not been clearly identified as disease mechanisms for these genes relative to the RASopathy spectrum phenotype, therefore the PVS1 rule is not applicable. In summary, the clinical significance of the p.Lys170Ter variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS4.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-06-27	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA296052/MONDO:0009026/004	073e5f90-a343-456a-b175-656a2f84718f
NM_005633.3(SOS1):c.3600C>G (p.Asp1200Glu)	40733	CA297240	NM_005633.3:c.3600C>G, NC_000002.12:g.38986226G>C, CM000664.2:g.38986226G>C, NC_000002.11:g.39213367G>C, CM000664.1:g.39213367G>C, NC_000002.10:g.39066871G>C, NG_007530.1:g.139238C>G, LRG_754:g.139238C>G, LRG_754t1:c.3600C>G, XM_005264515.3:c.3555C>G, XM_011533060.1:c.3693C>G, XM_011533061.1:c.3648C>G, XM_011533062.1:c.3579C>G, XM_011533063.1:c.3576C>G, XM_011533064.1:c.3429C>G, XM_011533065.1:c.3604-863C>G, XM_011533066.1:c.2535C>G, XM_005264515.4:c.3555C>G, XM_011533062.2:c.3579C>G, XM_011533064.2:c.3429C>G, ENST00000395038.6:c.3555C>G, ENST00000402219.6:c.3600C>G, ENST00000426016.5:c.3600C>G, ENST00000469581.1:n.343C>G, NM_005633.3(SOS1):c.3600C>G (p.Asp1200Glu)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1, BP5, BP4	PS1, PS2, PS3, PS4, PM5, PM4, PM1, BS3, BS4, BP7, PM6, PM2, BS2, PP1, PP3, PP2, BP3, BP2, BP1, BA1	The c.3600C>G (p.Asp1200Glu) variant in the SOS1 gene has been identified in at least 6 individuals without detailed phenotypic information as well as one patient with an alternative molecular basis for disease in the BRAF gene (BP5; EGL, Invitae, GeneDx internal data, GTR Lab ID: 500060, 500031, 26957; SCV000854873.1, SCV000553268.3, SCV000209087.11). The filtering allele frequency of the c.3600C>G (p.Asp1200Glu) variant is 0.025% for European (non-Finnish) exomes by the gnomAD database (40/251300 with 95% CI) which is strong evidence to suggest that the variant may be benign based on thresholds defined by the ClinGen RASopathy Expert Panel for autosomal dominant RASopathy variants (BS1). Of note, the c.3600C>A change that also results in p.Asp1200Glu has been identified in one patient with a RASopathy but this variant has not met criteria to be classified as pathogenic and therefore PM5 is not met (Partners LMM internal data; GTR Lab ID: 21766; SCV000062231.5). Computational prediction tools and conservation analysis suggest that the p.Asp1200Glu variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS1, BP4, BP5.	27236105	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-06-27	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA297240/MONDO:0021060/004	9b08e55f-32bb-4cc3-bfff-815c445525b7
NM_005633.3(SOS1):c.1018C>T (p.Pro340Ser)	40664	CA1624660	NM_005633.3:c.1018C>T, NC_000002.12:g.39035268G>A, CM000664.2:g.39035268G>A, NC_000002.11:g.39262409G>A, CM000664.1:g.39262409G>A, NC_000002.10:g.39115913G>A, NG_007530.1:g.90196C>T, LRG_754:g.90196C>T, LRG_754t1:c.1018C>T, XM_005264515.3:c.1018C>T, XM_011533060.1:c.1111C>T, XM_011533061.1:c.1111C>T, XM_011533062.1:c.997C>T, XM_011533063.1:c.994C>T, XM_011533064.1:c.847C>T, XM_011533065.1:c.1111C>T, XM_005264515.4:c.1018C>T, XM_011533062.2:c.997C>T, XM_011533064.2:c.847C>T, ENST00000395038.6:c.1018C>T, ENST00000402219.6:c.1018C>T, ENST00000426016.5:c.1018C>T, ENST00000461545.1:n.368C>T, NM_005633.3(SOS1):c.1018C>T (p.Pro340Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP5, BS4, BS1, PP2	PS3, PS4, PS2, PS1, PM1, PM4, PM5, BP7, BS3, PM6, PM2, BS2, PP1, PP3, BP3, BP2, BP4, BP1, BA1	The c.1018C>T (p.Pro340Ser) variant in the SOS1 gene has been found not to segregate in a family member of a patient who underwent testing for RASopathies as well as another adult who was unaffected (BS4; GeneDx, Invitae internal data; GTR Lab ID: 26957, 500031; SCV000514724.5, SCV000659124.2). This variant has also been identified in a patient with an alternate molecular basis of disease (BP5; PMID 22585553). The filtering allele frequency of the p.Pro340Ser variant is 0.022% for East Asian exomes in the gnomAD database (20/251276 with 95% CI), which is high enough frequency to be considered strong evidence for the variant being benign by the ClinGen RASopathy Expert Panel (BS1). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS4, BP5, BS1.	22585553	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-06-27	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA1624660/MONDO:0021060/004	dc725e41-14fe-44e9-9d51-91ac14a1c2d3
NM_002880.3(RAF1):c.94A>G (p.Ile32Val)	40584	CA241481	NM_002880.3:c.94A>G, NC_000003.12:g.12618628T>C, CM000665.2:g.12618628T>C, NC_000003.11:g.12660127T>C, CM000665.1:g.12660127T>C, NC_000003.10:g.12635127T>C, NG_007467.1:g.50552A>G, LRG_413:g.50552A>G, ENST00000416093.2:c.94A>G, ENST00000423275.6:c.94A>G, ENST00000491290.2:n.471A>G, ENST00000684903.1:c.94A>G, ENST00000685348.1:c.94A>G, ENST00000685437.1:c.94A>G, ENST00000685653.1:c.94A>G, ENST00000685738.1:c.94A>G, ENST00000685740.1:c.94A>G, ENST00000685959.1:c.94A>G, ENST00000686409.1:n.385A>G, ENST00000686455.1:n.457A>G, ENST00000686479.1:n.465A>G, ENST00000686762.1:c.94A>G, ENST00000687257.1:n.429A>G, ENST00000687326.1:c.94A>G, ENST00000687348.1:c.94A>G, ENST00000687923.1:c.94A>G, ENST00000687940.1:n.471A>G, ENST00000688269.1:n.393A>G, ENST00000688444.1:n.420A>G, ENST00000688543.1:c.94A>G, ENST00000688625.1:c.94A>G, ENST00000688753.1:c.94A>G, ENST00000688779.1:n.425A>G, ENST00000688803.1:n.424A>G, ENST00000689033.1:c.94A>G, ENST00000689097.1:c.94A>G, ENST00000689226.1:c.94A>G, ENST00000689389.1:c.94A>G, ENST00000689418.1:c.94A>G, ENST00000689481.1:c.94A>G, ENST00000689540.1:n.244A>G, ENST00000689876.1:c.94A>G, ENST00000689914.1:c.94A>G, ENST00000690397.1:c.94A>G, ENST00000690460.1:c.94A>G, ENST00000690625.1:n.397A>G, ENST00000691396.1:c.94A>G, ENST00000691718.1:c.94A>G, ENST00000691724.1:c.94A>G, ENST00000691779.1:c.94A>G, ENST00000691899.1:c.94A>G, ENST00000692093.1:c.94A>G, ENST00000692311.1:n.467A>G, ENST00000692558.1:n.459A>G, ENST00000692773.1:c.94A>G, ENST00000692777.1:n.422A>G, ENST00000692830.1:c.94A>G, ENST00000692959.1:c.94A>G, ENST00000693069.1:c.94A>G, ENST00000693312.1:c.-18-6566A>G, ENST00000693664.1:c.94A>G, ENST00000693705.1:c.94A>G, ENST00000251849.9:c.94A>G, ENST00000442415.7:c.94A>G, ENST00000251849.8:c.94A>G, ENST00000416093.1:c.94A>G, ENST00000423275.5:c.94A>G, ENST00000442415.6:c.94A>G, LRG_413t1:c.94A>G, XM_005265355.1:c.94A>G, XM_005265357.1:c.94A>G, XM_005265358.3:c.-37A>G, XM_005265359.3:c.-37A>G, XM_005265360.1:c.94A>G, XM_011533974.1:c.94A>G, XM_011533975.1:c.-37A>G, NM_001354689.1:c.94A>G, NM_001354690.1:c.94A>G, NM_001354691.1:c.-37A>G, NM_001354692.1:c.-37A>G, NM_001354693.1:c.94A>G, NM_001354694.1:c.-37A>G, NM_001354695.1:c.-37A>G, NR_148940.1:n.509A>G, NR_148941.1:n.509A>G, NR_148942.1:n.509A>G, XM_011533974.3:c.94A>G, XM_017006966.1:c.94A>G, XR_001740227.1:n.425A>G, NM_001354689.3:c.94A>G, NM_001354690.2:c.94A>G, NM_001354691.2:c.-37A>G, NM_001354692.2:c.-37A>G, NM_001354693.2:c.94A>G, NM_001354694.2:c.-37A>G, NM_001354695.2:c.-37A>G, NR_148940.2:n.425A>G, NR_148941.2:n.425A>G, NR_148942.2:n.425A>G, NM_001354690.3:c.94A>G, NM_001354691.3:c.-37A>G, NM_001354692.3:c.-37A>G, NM_001354693.3:c.94A>G, NM_001354694.3:c.-37A>G, NM_001354695.3:c.-37A>G, NM_002880.4:c.94A>G, NR_148940.3:n.425A>G, NR_148941.3:n.425A>G, NR_148942.3:n.425A>G, NM_002880.3(RAF1):c.94A>G (p.Ile32Val)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BS2, PP2, BP4, BP5, BS1	PM4, PM3, PM1, PVS1, PP1, PP3, PP4, PM2, PM6, BP1, BP3, BP2, BA1, PS4, PS2, PS3, BP7, BS4, BS3	The c.94A>G (p.Ile32Val) variant in the RAF1 gene has been identified in patients who underwent testing for a RASopathy, however it has also been identified in multiple adults who did not have clinical features of a RASopathy (BS2, BP5; Invitae, EGL Diagnostics, GeneDx internal data; GTR Lab ID: 500031, 500060; SCV000287747.4, SCV000227277.5, SCV000209002.14). The filtering allele frequency of the p.Ile32Val variant is 0.017% for European (non-Finnish) genomes in the gnomAD database (8/31404 with 95% CI) which is a high enough frequency to be considered strong evidence that the variant is benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1). Computational prediction tools and conservation analysis suggest that the p.Ile32Val variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS2, BP5, BS1, BP4.		RASopathy VCEP		2019-06-27	2024-08-23	false	https://erepo.genome.network/evrepo/ui/classification/CA241481/MONDO:0021060/040	1128f941-c33c-438d-a44d-f5a0c76c3440
NM_004333.4(BRAF):c.735A>C (p.Leu245Phe)	40347	CA280027	NM_004333.4:c.735A>C, NC_000007.14:g.140801537T>G, CM000669.2:g.140801537T>G, NC_000007.13:g.140501337T>G, CM000669.1:g.140501337T>G, NC_000007.12:g.140147806T>G, NG_007873.3:g.128228A>C, LRG_299:g.128228A>C, LRG_299t1:c.735A>C, XM_005250045.1:c.735A>C, XM_005250046.1:c.735A>C, XM_011516529.1:c.735A>C, XM_011516530.1:c.735A>C, XR_242190.1:n.743A>C, XR_927520.1:n.743A>C, XR_927521.1:n.743A>C, XR_927522.1:n.743A>C, XR_927523.1:n.743A>C, NM_001354609.1:c.735A>C, NM_004333.5:c.735A>C, NR_148928.1:n.1040A>C, XM_017012558.1:c.735A>C, XM_017012559.1:c.735A>C, XR_001744857.1:n.743A>C, XR_001744858.1:n.743A>C, ENST00000288602.10:c.735A>C, ENST00000497784.1:n.770A>C, NM_004333.4(BRAF):c.735A>C (p.Leu245Phe)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM1, PS2_Very Strong, PM2, PP3, PP2, PS4_Supporting	PS1, PS3, PM4, PM5, BS3, BS4, BS1, BP5, BP7, PM6, BS2, PP1, BP3, BP2, BP4, BP1, BA1	The c.735A>C (p.Leu245Phe) variant in BRAF has been reported as a a de novo occurrence, one of which was confirmed in at least 4 patients with clinical features of a RASopathy (PS2_VeryStrong; Partners LMM, GeneDx University Magdeburg GTR Lab ID's 21766, 26957, 506381; ClinVar SCV000061622.5, SCV000057188.16 PMID 19416762). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Leu245Phe variant may impact the protein (PP3). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PM2, PM1, PP2, PP3, PS4_Supporting.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA280027/MONDO:0021060/004	cf6b44e4-40ca-4713-b35e-0ad194eb2f96
NM_004333.4(BRAF):c.735A>T (p.Leu245Phe)	40348	CA280029	NM_004333.4:c.735A>T, NC_000007.14:g.140801537T>A, CM000669.2:g.140801537T>A, NC_000007.13:g.140501337T>A, CM000669.1:g.140501337T>A, NC_000007.12:g.140147806T>A, NG_007873.3:g.128228A>T, LRG_299:g.128228A>T, LRG_299t1:c.735A>T, XM_005250045.1:c.735A>T, XM_005250046.1:c.735A>T, XM_011516529.1:c.735A>T, XM_011516530.1:c.735A>T, XR_242190.1:n.743A>T, XR_927520.1:n.743A>T, XR_927521.1:n.743A>T, XR_927522.1:n.743A>T, XR_927523.1:n.743A>T, NM_001354609.1:c.735A>T, NM_004333.5:c.735A>T, NR_148928.1:n.1040A>T, XM_017012558.1:c.735A>T, XM_017012559.1:c.735A>T, XR_001744857.1:n.743A>T, XR_001744858.1:n.743A>T, ENST00000288602.10:c.735A>T, ENST00000497784.1:n.770A>T, NM_004333.4(BRAF):c.735A>T (p.Leu245Phe)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS1, PM1, PM6, PM2, PP3, PP2, PS4_Supporting	PS2, PS3, PM4, BP7, BP5, BS4, BS3, BS1, BS2, PP1, BP3, BP4, BP1, BP2, BA1	The c.735A>T p.Leu245Phe variant in BRAF has been identified in at least 2 independent occurrences, one of which was de novo, in patients with clinical features of a RASopathy (PM6, PS4_Supporting; Partners LMM, University Magdeburg internal data; GTR Lab IDs: 21766,  506381 PMID: 19206169, 22190897). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Leu245Phe variant may impact the protein (PP3). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Of note, the p.Leu245Phe change has also been reported as a consequence of the c.735A>C variant in BRAF, which has been classified as pathogenic and therefore supports that this residue may be critical to protein function (PS1; ClinVar ID: 40347). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PM6, PM1, PM2, PS1, PP2, PP3.	30820351, 19206169, 23763990, 22190897	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA280029/MONDO:0021060/004	fc4fa86e-060f-49dc-8ade-c259aa8ad24b
	-	CA281951	NR_148928.1:n.1045T>C, NC_000007.14:g.140801532A>G, CM000669.2:g.140801532A>G, NC_000007.13:g.140501332A>G, CM000669.1:g.140501332A>G, NC_000007.12:g.140147801A>G, NG_007873.3:g.128233T>C, LRG_299:g.128233T>C, NM_004333.4:c.740T>C, LRG_299t1:c.740T>C, XM_005250045.1:c.740T>C, XM_005250046.1:c.740T>C, XM_011516529.1:c.740T>C, XM_011516530.1:c.740T>C, XR_242190.1:n.748T>C, XR_927520.1:n.748T>C, XR_927521.1:n.748T>C, XR_927522.1:n.748T>C, XR_927523.1:n.748T>C, NM_001354609.1:c.740T>C, NM_004333.5:c.740T>C, XM_017012558.1:c.740T>C, XM_017012559.1:c.740T>C, XR_001744857.1:n.748T>C, XR_001744858.1:n.748T>C, ENST00000288602.10:c.740T>C, ENST00000497784.1:n.775T>C	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PM1, PM6, PM2, PP3, PP2, PS4_Supporting	PS1, PS3, PS2, BS3, BS4, BS1, BP5, BP7, PM5, PM4, BS2, PP1, BP3, BP2, BP4, BP1, BA1	The c.740T>C (p.Phe247Ser) variant in BRAF has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6, PS4_Supporting; GeneDx internal data; GTR Lab ID: 26957; NOT SUBMITTED TO CLINVAR YET). A different pathogenic missense variant has been previously identified at this codon of BRAF which may indicate that this residue is critical to the function of the protein (PM5 not applied due to PM1 application; ClinVar 55793, 180784). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe247Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PS4_Supporting, PM2, PM1, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA281951/MONDO:0021060/004	7808e324-29b8-43db-85ad-2f63caa01996
NM_004333.4(BRAF):c.739T>C (p.Phe247Leu)	180784	CA295904	NM_004333.4:c.739T>C, NC_000007.14:g.140801533A>G, CM000669.2:g.140801533A>G, NC_000007.13:g.140501333A>G, CM000669.1:g.140501333A>G, NC_000007.12:g.140147802A>G, NG_007873.3:g.128232T>C, LRG_299:g.128232T>C, LRG_299t1:c.739T>C, XM_005250045.1:c.739T>C, XM_005250046.1:c.739T>C, XM_011516529.1:c.739T>C, XM_011516530.1:c.739T>C, XR_242190.1:n.747T>C, XR_927520.1:n.747T>C, XR_927521.1:n.747T>C, XR_927522.1:n.747T>C, XR_927523.1:n.747T>C, NM_001354609.1:c.739T>C, NM_004333.5:c.739T>C, NR_148928.1:n.1044T>C, XM_017012558.1:c.739T>C, XM_017012559.1:c.739T>C, XR_001744857.1:n.747T>C, XR_001744858.1:n.747T>C, ENST00000288602.10:c.739T>C, ENST00000497784.1:n.774T>C, NM_004333.4(BRAF):c.739T>C (p.Phe247Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS1, PS3, PM1, PM6, PM2, PP3, PP2	PS4, PS2, PM5, PM4, BS4, BS3, BS1, BP7, BP5, PP1, BS2, BP4, BP1, BP3, BP2, BA1	The c.739T>C (p.Phe247Leu) variant in BRAF has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; GeneDx internal data; GTR Lab ID: 26957; ClinVar SCV000207748.12). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that the p.Phe247Leu variant may impact protein function (PS3; PMID: 28512244). The c.739T>C variant results in the same amino acid change as the previously established pathogenic c.741T>G (p.Phe247Leu) variant (PS1; ClinVar ID 55793). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe247Leu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PM2, PS3, PS1, PM1, PP2, PP3.	22899370, 26243863, 28512244	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA295904/MONDO:0021060/004	9a18dc91-2016-4b25-ab42-a9f679412ae8
NM_004333.4(BRAF):c.741T>G (p.Phe247Leu)	55793	CA284654	NM_004333.4:c.741T>G, NC_000007.14:g.140801531A>C, CM000669.2:g.140801531A>C, NC_000007.13:g.140501331A>C, CM000669.1:g.140501331A>C, NC_000007.12:g.140147800A>C, NG_007873.3:g.128234T>G, LRG_299:g.128234T>G, LRG_299t1:c.741T>G, XM_005250045.1:c.741T>G, XM_005250046.1:c.741T>G, XM_011516529.1:c.741T>G, XM_011516530.1:c.741T>G, XR_242190.1:n.749T>G, XR_927520.1:n.749T>G, XR_927521.1:n.749T>G, XR_927522.1:n.749T>G, XR_927523.1:n.749T>G, NM_001354609.1:c.741T>G, NM_004333.5:c.741T>G, NR_148928.1:n.1046T>G, XM_017012558.1:c.741T>G, XM_017012559.1:c.741T>G, XR_001744857.1:n.749T>G, XR_001744858.1:n.749T>G, ENST00000288602.10:c.741T>G, ENST00000497784.1:n.776T>G, NM_004333.4(BRAF):c.741T>G (p.Phe247Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS3, PS2, PM1, PM2, PM6, PP3, PP2, PS4_Supporting	PS1, BP7, BP5, BS4, BS1, BS3, PM5, PM4, PP1, BS2, BP3, BP2, BP4, BP1, BA1	The c.741T>G (p.Phe247Leu) variant in BRAF has been reported in the literature as a confirmed and unconfirmed de novo occurrence in 2 patients with clinical features of a RASopathy (PM6, PS2, PS4_Supporting; GeneDx internal data; GTR Lab ID 26957; SCV000077236.10). In vitro functional studies provide some evidence that the p.Phe247Leu variant may impact protein function (PS3; PMID: 28512244). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe247Leu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PS2, PS3, PM1, PM2, PP2, PP3, PS4_Supporting.	28512244	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA284654/MONDO:0021060/004	66924744-6ed6-4985-8479-1c8bab448ed0
NM_004333.4(BRAF):c.739T>G (p.Phe247Val)	44830	CA135140	NM_004333.4:c.739T>G, NC_000007.14:g.140801533A>C, CM000669.2:g.140801533A>C, NC_000007.13:g.140501333A>C, CM000669.1:g.140501333A>C, NC_000007.12:g.140147802A>C, NG_007873.3:g.128232T>G, LRG_299:g.128232T>G, LRG_299t1:c.739T>G, XM_005250045.1:c.739T>G, XM_005250046.1:c.739T>G, XM_011516529.1:c.739T>G, XM_011516530.1:c.739T>G, XR_242190.1:n.747T>G, XR_927520.1:n.747T>G, XR_927521.1:n.747T>G, XR_927522.1:n.747T>G, XR_927523.1:n.747T>G, NM_001354609.1:c.739T>G, NM_004333.5:c.739T>G, NR_148928.1:n.1044T>G, XM_017012558.1:c.739T>G, XM_017012559.1:c.739T>G, XR_001744857.1:n.747T>G, XR_001744858.1:n.747T>G, ENST00000288602.10:c.739T>G, ENST00000497784.1:n.774T>G, NM_004333.4(BRAF):c.739T>G (p.Phe247Val)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PM1, PM2, PP3, PP2, PS4_Supporting	PS2, PS1, PS3, PM4, PM5, BP7, BP5, BS3, BS1, BS4, PM6, BS2, PP1, BP3, BP2, BP4, BP1, BA1	The c.739T>G (p.Phe247Val) variant in BRAF has been identified in at least 2 independent occurrences in patients with clinical features of a RASopathy (PS4_Supporting; Partners LMM, GeneDx internal data; GTR Lab IDs 21766, 26957; ClinVar SCV000061624.5, SCV000330320.6). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). A different pathogenic missense variant (p.Phe247Leu) has been previously identified at this codon of BRAF which may indicate that this residue is critical to the function of the protein (PM5 not usable due to PM1 application; ClinVar 180784, 55793). Computational prediction tools and conservation analysis suggest that the p.Phe247Val variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PM2, PM1, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA135140/MONDO:0021060/004	d691f327-120d-4c5c-b56e-fbfdc3f820f3
NM_002834.4(PTPN11):c.167T>C (p.Ile56Thr)	477669	CA243707917	NM_002834.4:c.167T>C, NC_000012.12:g.112450347T>C, CM000674.2:g.112450347T>C, NC_000012.11:g.112888151T>C, CM000674.1:g.112888151T>C, NC_000012.10:g.111372534T>C, NG_007459.1:g.36616T>C, LRG_614:g.36616T>C, NM_002834.3:c.167T>C, LRG_614t1:c.167T>C, NM_080601.1:c.167T>C, XM_006719526.1:c.167T>C, XM_006719527.1:c.167T>C, XM_011538613.1:c.164T>C, NM_001330437.1:c.167T>C, NM_080601.2:c.167T>C, XM_011538613.2:c.164T>C, XM_017019722.1:c.164T>C, ENST00000351677.6:c.167T>C, ENST00000392597.5:c.167T>C, ENST00000635625.1:n.167T>C, NM_002834.4(PTPN11):c.167T>C (p.Ile56Thr)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PM5, PM2, PP3, PP2, PS4_Supporting	PS3, PS2, PS1, BS3, BS4, BS1, BP5, BP7, PM1, PM4, PM6, BS2, PP1, BP3, BP2, BP4, BP1, BA1	The c.167T>C (p.Ile56Thr) variant in PTPN11 has been identified in 2 related patients with clinical features of a RASopathy (PS4_Supporting, PP1; Invitae internal data; GTR Lab ID 500031; ClinVar SCV000659038.1). A different pathogenic missense variant (p.Ile56Val) has been previously identified at this codon of PTPN11 which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 40485). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Ile56Thr variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PP1, PM2, PM5, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA243707917/MONDO:0021060/004	2a9a7233-77c0-4d04-a2e1-0a1ac478a404
NM_002834.4(PTPN11):c.166A>G (p.Ile56Val)	40485	CA180973	NM_002834.4:c.166A>G, NC_000012.12:g.112450346A>G, CM000674.2:g.112450346A>G, NC_000012.11:g.112888150A>G, CM000674.1:g.112888150A>G, NC_000012.10:g.111372533A>G, NG_007459.1:g.36615A>G, LRG_614:g.36615A>G, NM_002834.3:c.166A>G, LRG_614t1:c.166A>G, NM_080601.1:c.166A>G, XM_006719526.1:c.166A>G, XM_006719527.1:c.166A>G, XM_011538613.1:c.163A>G, NM_001330437.1:c.166A>G, NM_080601.2:c.166A>G, XM_011538613.2:c.163A>G, XM_017019722.1:c.163A>G, ENST00000351677.6:c.166A>G, ENST00000392597.5:c.166A>G, ENST00000635625.1:n.166A>G, NM_002834.4(PTPN11):c.166A>G (p.Ile56Val)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2, PS4, PM2, PP3, PP2	PS1, PS3, PM5, PM4, PM1, BS4, BS3, BS1, BP7, BP5, PM6, BS2, BP3, BP4, BP1, BP2, BA1	The c.166A>G (p.Ile56Val) variant in PTPN11 has been reported as a confirmed de novo occurrence in a patient with clinical features of a RASopathy (PS2; Invitae internal data; GTR Lab ID: 500031; ClinVar SCV000659037.2). The p.Ile56Val variant has been identified in at least 5 independent occurrences in patients with clinical features of a RASopathy (PS4; GeneDx, Partners LMM, Invitae, LabCorp internal data; GTR Lab IDs: 26957, 21766, 500031, 500026; ClinVar SCV SCV000057358.13, SCV000204234.4, SCV000659037.2, SCV000698061.1). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Ile56Val variant may impact the protein (PP3). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS4, PM2, PP3, PP2.	19506109, 26817465, 26817465	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA180973/MONDO:0021060/004	43db1167-715a-4f5d-8517-8487caffe8af
NM_030662.3(MAP2K2):c.692G>A (p.Arg231His)	543999	CA9090854	NM_030662.3:c.692G>A, NC_000019.10:g.4101032C>T, CM000681.2:g.4101032C>T, NC_000019.9:g.4101030C>T, CM000681.1:g.4101030C>T, NC_000019.8:g.4052030C>T, NG_007996.1:g.28097G>A, LRG_750:g.28097G>A, LRG_750t1:c.692G>A, XM_006722799.2:c.692G>A, XM_011528133.1:c.122G>A, XM_017026989.1:c.692G>A, XM_017026990.1:c.692G>A, XM_017026991.1:c.692G>A, ENST00000262948.9:c.692G>A, ENST00000394867.8:c.401G>A, ENST00000593364.5:n.639G>A, ENST00000597008.5:n.293G>A, ENST00000597263.5:n.156G>A, ENST00000599021.1:n.16G>A, ENST00000601786.5:n.993G>A, ENST00000602167.5:n.412G>A, NM_030662.3(MAP2K2):c.692G>A (p.Arg231His)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PP3, PP2	PS1, PS2, PS3, PS4, PM5, PM4, PM1, BP7, BP5, BS4, BS3, BS1, PM6, PM2, PP1, BS2, BP3, BP2, BP4, BP1, BA1	The c.692G>A (p.Arg231His) variant in MAP2K2 has been identified in a patient with clinical features consistent with cardiomyopathy (PS4 not met; Invitae internal data, GTR Lab ID 500031; ClinVar SCV000776886.1). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg231His variant may impact the protein (PP3). In summary, the clinical significance of the p.Arg231His variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-17	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA9090854/MONDO:0021060/004	9f74ed62-a0c3-40e1-b0b2-7aa680c29fe2
NM_030662.3(MAP2K2):c.692G>T (p.Arg231Leu)	40818	CA296133	NM_030662.3:c.692G>T, NC_000019.10:g.4101032C>A, CM000681.2:g.4101032C>A, NC_000019.9:g.4101030C>A, CM000681.1:g.4101030C>A, NC_000019.8:g.4052030C>A, NG_007996.1:g.28097G>T, LRG_750:g.28097G>T, LRG_750t1:c.692G>T, XM_006722799.2:c.692G>T, XM_011528133.1:c.122G>T, XM_017026989.1:c.692G>T, XM_017026990.1:c.692G>T, XM_017026991.1:c.692G>T, ENST00000262948.9:c.692G>T, ENST00000394867.8:c.401G>T, ENST00000593364.5:n.639G>T, ENST00000597008.5:n.293G>T, ENST00000597263.5:n.156G>T, ENST00000599021.1:n.16G>T, ENST00000601786.5:n.993G>T, ENST00000602167.5:n.412G>T, NM_030662.3(MAP2K2):c.692G>T (p.Arg231Leu)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PM2, PP3, PP2, PS4_Supporting	PS2, PS1, PS3, BP7, BP5, BS4, BS3, BS1, PM5, PM4, PM1, PM6, BS2, PP1, BP3, BP2, BP4, BP1, BA1	The c.692G>T (p.Arg231Leu) variant has been identified in at least 2 independent occurrences in patients with clinical features of RASopathies  (PS4_Supporting GeneDx, Invitae internal data, GTR Lab IDs 26957, 500031; ClinVar SCV000207960.9, SCV000551455.2). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg231Leu variant may impact the protein (PP3).In summary, the clinical significance of the p.Arg231Leu variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PM2, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA296133/MONDO:0021060/004	c77c7f8b-de11-4d2a-b1e3-d7190a41ba9f
NM_002834.4(PTPN11):c.1510A>G (p.Met504Val)	40562	CA220140	NM_002834.4:c.1510A>G, NC_000012.12:g.112489086A>G, CM000674.2:g.112489086A>G, NC_000012.11:g.112926890A>G, CM000674.1:g.112926890A>G, NC_000012.10:g.111411273A>G, NG_007459.1:g.75355A>G, LRG_614:g.75355A>G, NM_002834.3:c.1510A>G, LRG_614t1:c.1510A>G, XM_006719526.1:c.1522A>G, XM_006719527.1:c.1408A>G, XM_011538613.1:c.1519A>G, NM_001330437.1:c.1522A>G, XM_011538613.2:c.1519A>G, XM_017019722.1:c.1507A>G, ENST00000351677.6:c.1510A>G, ENST00000635625.1:n.1522A>G, ENST00000635652.1:n.523A>G, NM_002834.4(PTPN11):c.1510A>G (p.Met504Val)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PS3, PP3, PP2, PM6_Strong	PM2	The c.1510A>G (p.Met504Val) variant in PTPN11 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients and 3 independent occurrences in patients with clinical features of a RASopathy (PM6_Strong, PS4; GeneDx internal data; GTR Lab ID: 26957; SCV000057454.12; PMID: 15834506, 17661820, 17020470). In vitro functional studies provide some evidence that the p.Met504Val variant may impact protein function (PS3; PMID: 15834506). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Met504Val variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS3, PM6_Strong, PS4_Moderate, PP2, PP3.	15834506, 17661820, 17020470, 15834506	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA220140/MONDO:0018997/004	e9f2d6d1-62c8-49f8-89ca-4b2438d14afb
NM_002834.5(PTPN11):c.417G>C (p.Glu139Asp)	40513	CA177671	NM_002834.5:c.417G>C, NC_000012.12:g.112453279G>C, CM000674.2:g.112453279G>C, NC_000012.11:g.112891083G>C, CM000674.1:g.112891083G>C, NC_000012.10:g.111375466G>C, NG_007459.1:g.39548G>C, LRG_614:g.39548G>C, ENST00000639857.2:c.417G>C, ENST00000685487.1:c.417G>C, ENST00000687906.1:c.417G>C, ENST00000688597.1:c.417G>C, ENST00000690210.1:c.417G>C, ENST00000692624.1:c.417G>C, ENST00000351677.7:c.417G>C, ENST00000639857.1:c.417G>C, ENST00000351677.6:c.417G>C, ENST00000392597.5:c.417G>C, ENST00000635625.1:c.417G>C, NM_002834.3:c.417G>C, LRG_614t1:c.417G>C, NM_080601.1:c.417G>C, XM_006719526.1:c.417G>C, XM_006719527.1:c.417G>C, XM_011538613.1:c.414G>C, NM_001330437.1:c.417G>C, NM_002834.4:c.417G>C, NM_080601.2:c.417G>C, XM_011538613.2:c.414G>C, XM_017019722.1:c.414G>C, NM_001330437.2:c.417G>C, NM_001374625.1:c.414G>C, NM_080601.3:c.417G>C, NM_002834.5(PTPN11):c.417G>C (p.Glu139Asp)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS4, PS3, PS2_Very Strong, PM2, PP2, PP3		The c.417G>C (p.Glu139Asp) variant in PTPN11 has been reported as a confirmed de novo occurrence in at least 2 patients and at least 5 other independent occurrences in patients with clinical features of a RASopathy (PS2_VeryStrong; PS4; GeneDx, Baylor, BC Children's internal data; SCV000057396.11, SCV000196664.1, SCV000803709.1; GTR Lab ID: 26957, 1006, 249401  PMID: 22315187, 17020470, 11992261). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). In vitro functional studies provide some evidence that the p.Glu139Asp variant may impact protein function (PS3; PMID: 23584145, 15987685, 18372317). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the c.417G>C (p.Glu139Asp) variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS3, PS4, PM2, PP2, PP3.	11992261, 22315187, 17020470, 23584145, 18372317, 15987685	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2024-08-23	false	https://erepo.genome.network/evrepo/ui/classification/CA177671/MONDO:0018997/004	d42e8a4a-ba52-4c29-8f18-11134760c93e
NM_004004.5(GJB2):c.101T>C (p.Met34Thr)	17000	CA172206	NM_004004.5:c.101T>C, NC_000013.11:g.20189481A>G, CM000675.2:g.20189481A>G, NC_000013.10:g.20763620A>G, CM000675.1:g.20763620A>G, NC_000013.9:g.19661620A>G, NG_008358.1:g.8495T>C, XM_011535049.1:c.101T>C, XM_011535049.2:c.101T>C, NM_004004.6:c.101T>C, ENST00000382844.1:c.101T>C, ENST00000382848.4:c.101T>C, NM_004004.5(GJB2):c.101T>C (p.Met34Thr)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PP3, PP1, PM3_Very Strong, PS4	BP5, BP7, BS1, BS4, BS2, PP4, PM4, PM1, PM5, PM6, PM2, PVS1, BP3, BP4, BP2, BA1, PS2, PS3, PS1	The filtering allele frequency (the lower threshold of the 95% CI of 510/25108) of the c.101T>C (p.Met34Thr) variant in the GJB2 gene is 1.46% for European (non-Finnish) genomes in gnomAD. This is a high enough frequency that, in the absence of conflicting data, might warrant a benign classification based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). However, based on the evidence outlined below, the ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs its high allele frequency in population databases. Therefore, the BA1 code will not contribute to the overall classification. The homozygous genotype and compound heterozygous genotype with another variant in GJB2 have shown to be statistically enriched in patients with nonsyndromic sensorineural hearing loss compared to individuals representative of the general population in gnomAD and/or those who underwent carrier screening at Counsyl. (PS4; PMID: 31160754). This study also reported the variant in 27 homozygous affected probands, 17 affected probands with the p.Val37Ile variant in trans, 138 affected probands with a variant asserted to be P/LP in ClinVar, and 78 affected probands with a premature GJB2 termination codon in trans (PM3; PMID 31160754). The REVEL computational prediction analysis tool produced a score of 0.702, which is above the threshold necessary to apply PP3. Most dye transfer and electrical coupling assays support that the variant impacts protein function (PMID: 16849369, 12189493, 10556284, 16300957, 15033936, 12189493); however, some assays showed partial function (PMID: 27884957), and therefore this evidence was not counted. At least 16 segregations of the p.Met34Thr variant in family members have been described (PP1_Strong, PMID: 31160754, 10903123). Of note, the severity of hearing loss is known to be mild on average and there have been multiple accounts of incomplete penetrance of the variant in families/individuals with p.Met34Thr in a biallelic genotype. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic genetic hearing lossbased on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PS4, PP1_Strong, PM3, PP3.	31160754, 14694360, 10903123, 31160754, 31160754, 14694360, 10903123, 31160754, 31160754, 31160754, 31160754, 31160754, 10556284, 15033936, 27884957, 16849369, 12189493, 16300957, 31160754	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-06-24	2019-06-28	false	https://erepo.genome.network/evrepo/ui/classification/CA172206/MONDO:0019497/005	e8b1ce82-bc97-4baf-b442-294c2a6849cd
NM_000277.1(PAH):c.2T>C (p.Met1Thr)	203873	CA312807	NM_000277.1:c.2T>C, NC_000012.12:g.102917129A>G, CM000674.2:g.102917129A>G, NC_000012.11:g.103310907A>G, CM000674.1:g.103310907A>G, NC_000012.10:g.101835037A>G, NG_008690.1:g.5474T>C, NG_008690.2:g.46282T>C, XM_011538422.1:c.2T>C, NM_000277.2:c.2T>C, NM_001354304.1:c.2T>C, XM_017019370.2:c.2T>C, NM_000277.3:c.2T>C, ENST00000307000.7:c.-146T>C, ENST00000546844.1:c.2T>C, ENST00000547319.1:n.313T>C, ENST00000549111.5:n.98T>C, ENST00000551337.5:c.2T>C, ENST00000551988.5:n.91T>C, ENST00000553106.5:c.2T>C, ENST00000635500.1:n.29-4231T>C, NM_000277.1(PAH):c.2T>C (p.Met1Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PVS1, PM2	PP4	c.2T>C (p.Met1Thr) is a null PAH variant (start loss) where LOF is a known mechanism of disease. There are no known alternative start codons in other transcripts. The next in-frame Met is at amino acid 180 in exon 6. There are 49 pathogenic variants in ClinVar upstream of aa 180. The p.Met1Val variant has <3% enzyme activity as compared to wild type (PMID: 9450897), confirming start loss variants lead to loss of function of the PAH enzyme without re-initiation. This variant has an extremely low frequency in ExAC, ESP, gnomAD. However, it has not been reported in the literature to our knowledge. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2.		Phenylketonuria VCEP		2019-07-07	2019-07-07	false	https://erepo.genome.network/evrepo/ui/classification/CA312807/MONDO:0009861/006	44685f9b-a06f-4d15-a65b-2a3632a64ab6
NM_000277.2(PAH):c.3G>C (p.Met1Ile)	585206	CA386303909	NM_000277.2:c.3G>C, NC_000012.12:g.102917128C>G, CM000674.2:g.102917128C>G, NC_000012.11:g.103310906C>G, CM000674.1:g.103310906C>G, NC_000012.10:g.101835036C>G, NG_008690.1:g.5475G>C, NG_008690.2:g.46283G>C, NM_000277.1:c.3G>C, XM_011538422.1:c.3G>C, NM_001354304.1:c.3G>C, XM_017019370.2:c.3G>C, NM_000277.3:c.3G>C, ENST00000307000.7:c.-145G>C, ENST00000546844.1:c.3G>C, ENST00000547319.1:n.314G>C, ENST00000549111.5:n.99G>C, ENST00000551337.5:c.3G>C, ENST00000551988.5:n.92G>C, ENST00000553106.5:c.3G>C, ENST00000635500.1:n.29-4230G>C, NM_000277.2(PAH):c.3G>C (p.Met1Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PVS1, PM2	PM5, PP4, PS1	The c.3G>C (p.Met1Ile) variant in PAH is a null variant (start loss) where LOF is a known mechanism of disease. There are no known alternative start codons in other transcripts. The next in-frame Met is at amino acid 180 in exon 6. There are 49 pathogenic variants in ClinVar upstream of aa 180. The p.Met1Val variant has <3% enzyme activity as compared to wild type (PMID: 9450897), confirming start loss variants lead to loss of function of the PAH enzyme without re-initiation. This variant is absent in population databases (PM2).  This variant has not been reported in an affected individual in the literature to our knowledge. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PVS1.		Phenylketonuria VCEP		2019-07-07	2019-07-07	false	https://erepo.genome.network/evrepo/ui/classification/CA386303909/MONDO:0009861/006	163d78d0-7557-412d-9bdf-155b6085537a
NM_000277.2(PAH):c.1A>T (p.Met1Leu)	102626	CA229482	NM_000277.2:c.1A>T, NC_000012.12:g.102917130T>A, CM000674.2:g.102917130T>A, NC_000012.11:g.103310908T>A, CM000674.1:g.103310908T>A, NC_000012.10:g.101835038T>A, NG_008690.1:g.5473A>T, NG_008690.2:g.46281A>T, NM_000277.1:c.1A>T, XM_011538422.1:c.1A>T, NM_001354304.1:c.1A>T, XM_017019370.2:c.1A>T, NM_000277.3:c.1A>T, ENST00000307000.7:c.-147A>T, ENST00000546844.1:c.1A>T, ENST00000547319.1:n.312A>T, ENST00000549111.5:n.97A>T, ENST00000551337.5:c.1A>T, ENST00000551988.5:n.90A>T, ENST00000553106.5:c.1A>T, ENST00000635500.1:n.29-4232A>T, NM_000277.2(PAH):c.1A>T (p.Met1Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PM2, PP4	PM5	The PAH:p.M1L variant is a predicted start-lost variant in the canonical transcript of PAH (ENST00000553106); There are no other PAH RefSeq transcripts. The next in-frame Met is at amino acid 180 in exon 6. There are 49 pathogenic variants in ClinVar upstream of aa 180. The p.Met1Val variant has <3% enzyme activity as compared to wild type (PMID: 9450897), confirming start loss variants lead to loss of function of the PAH enzyme without re-initiation. This variant was reported in trans with the pathogenic variant p.Arg241His (PM3) in 1 Mexican proband with mild PKU (PMID: 24941924; PP4). It is absent from control databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM3, PVS1.	24941924, 24941924	Phenylketonuria VCEP		2019-07-07	2019-07-07	false	https://erepo.genome.network/evrepo/ui/classification/CA229482/MONDO:0009861/006	a966e463-522a-42df-a6bc-5c03d571d48d
NM_000277.2(PAH):c.2T>G (p.Met1Arg)	102647	CA229509	NM_000277.2:c.2T>G, NC_000012.12:g.102917129A>C, CM000674.2:g.102917129A>C, NC_000012.11:g.103310907A>C, CM000674.1:g.103310907A>C, NC_000012.10:g.101835037A>C, NG_008690.1:g.5474T>G, NG_008690.2:g.46282T>G, NM_000277.1:c.2T>G, XM_011538422.1:c.2T>G, NM_001354304.1:c.2T>G, XM_017019370.2:c.2T>G, NM_000277.3:c.2T>G, ENST00000307000.7:c.-146T>G, ENST00000546844.1:c.2T>G, ENST00000547319.1:n.313T>G, ENST00000549111.5:n.98T>G, ENST00000551337.5:c.2T>G, ENST00000551988.5:n.91T>G, ENST00000553106.5:c.2T>G, ENST00000635500.1:n.29-4231T>G, NM_000277.2(PAH):c.2T>G (p.Met1Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PP4_Moderate, PM2, PVS1	PM5, PP3	The PAH:p.M1R variant is a predicted start-lost variant in the canonical transcript of PAH (ENST00000553106). There are no known alternative start codons in other transcripts. The next in-frame Met is at amino acid 180 in exon 6. There are 49 pathogenic variants in ClinVar upstream of aa 180. The p.Met1Val variant has <3% enzyme activity as compared to wild type (PMID: 9450897), confirming start loss variants lead to loss of function of the PAH enzyme without re-initiation. The variant has been previously reported in 2 unrelated probands with classic PKU, in trans with the pathogenic variant p.R408W (PMID: 10679941; PM3); BH4 deficiency was excluded (PP4_Moderate). The variant is sufficiently rare in control databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3, PM2, PP4_moderate, PVS1.	10679941, 10679941	Phenylketonuria VCEP		2019-07-07	2019-07-07	false	https://erepo.genome.network/evrepo/ui/classification/CA229509/MONDO:0009861/006	ba014c57-1ba6-4480-9f90-191b39ba497e
	-	CA16020886	NM_000277.3:c.890G>T, NC_000012.12:g.102851709C>A, CM000674.2:g.102851709C>A, NC_000012.11:g.103245487C>A, CM000674.1:g.103245487C>A, NC_000012.10:g.101769617C>A, NG_008690.1:g.70894G>T, NG_008690.2:g.111702G>T, NM_000277.1:c.890G>T, XM_011538422.1:c.890G>T, NM_000277.2:c.890G>T, NM_001354304.1:c.890G>T, ENST00000307000.7:c.875G>T, ENST00000549247.6:n.649G>T, ENST00000551114.2:n.552G>T, ENST00000553106.5:c.890G>T, ENST00000635477.1:n.51G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM2, PS3	PM3, PP3	The c.890G>T (p.Arg297Leu) variant in PAH has been reported in at least 1 patient with mild PKU who carried in trans the nonsense variant R243X (BH4 deficiency was not excluded) (PMID: 17096675). This variant is absent from the gnomAD and ESP population databases.  Biochemical assays demonstrate a loss of ~50% enzyme activity (PMID: 18346471 & 21820508). Other amino acid changes at this codon have been reported. Overall, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PS3.	18346471, 17096675, 18346471, 21820508	Phenylketonuria VCEP		2019-07-07	2019-07-07	false	https://erepo.genome.network/evrepo/ui/classification/CA16020886/MONDO:0009861/006	0483fa48-0e0c-4847-9337-62968add6c8f
NM_000277.2(PAH):c.890G>A (p.Arg297His)	92750	CA220590	NM_000277.2:c.890G>A, NC_000012.12:g.102851709C>T, CM000674.2:g.102851709C>T, NC_000012.11:g.103245487C>T, CM000674.1:g.103245487C>T, NC_000012.10:g.101769617C>T, NG_008690.1:g.70894G>A, NG_008690.2:g.111702G>A, NM_000277.1:c.890G>A, XM_011538422.1:c.890G>A, NM_001354304.1:c.890G>A, NM_000277.3:c.890G>A, ENST00000307000.7:c.875G>A, ENST00000549247.6:n.649G>A, ENST00000551114.2:n.552G>A, ENST00000553106.5:c.890G>A, ENST00000635477.1:n.51G>A, NM_000277.2(PAH):c.890G>A (p.Arg297His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2, PP3, PS3, PM3_Strong		The c.890G>A (p.Arg297His) variant in PAH has been reported in 6 patients with PKU, in trans with established pathogenic variants (PMID: 9298832,24401910)  with BH4 deficiency excluded in one (PMIDs 24401910 & 9298832). This variant has an extremely low allele frequency in gnomAD (2/245792). The arginine at position 297 is in the C-terminal aromatic amino acid hydroxylase domain, and computational prediction tools and conservation analysis suggest that the c.890G>A variant may impact the protein function. Mutant enzyme activity is 20% as compared to wild type (PMID:24401910). Overall, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP3, PP4_moderate, PM2, PM3_strong, PS3.	24401910, 9298832, 24401910, 24401910, 9298832	Phenylketonuria VCEP		2019-07-07	2019-07-07	false	https://erepo.genome.network/evrepo/ui/classification/CA220590/MONDO:0009861/006	d5b91f03-15c0-4ffe-9fe6-2a8fca19096a
NM_000277.2(PAH):c.889C>T (p.Arg297Cys)	102885	CA229836	NM_000277.2:c.889C>T, NC_000012.12:g.102851710G>A, CM000674.2:g.102851710G>A, NC_000012.11:g.103245488G>A, CM000674.1:g.103245488G>A, NC_000012.10:g.101769618G>A, NG_008690.1:g.70893C>T, NG_008690.2:g.111701C>T, NM_000277.1:c.889C>T, XM_011538422.1:c.889C>T, NM_001354304.1:c.889C>T, NM_000277.3:c.889C>T, ENST00000307000.7:c.874C>T, ENST00000549247.6:n.648C>T, ENST00000551114.2:n.551C>T, ENST00000553106.5:c.889C>T, ENST00000635477.1:n.50C>T, NM_000277.2(PAH):c.889C>T (p.Arg297Cys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM3, PP4_Moderate, PM2, PP3		The c.889C>T (p.R297C) variant in PAH has been reported in multiple individuals with PAH deficiency (BH4 deficiency excluded: PMID: 8807331, 21307867). It was detected in trans with the pathogenic variant IVS12nt1 (VarID576; PMID 8807331). This variant has an extremely low allele frequency in gnomAD (7/245782). Two other missense variants at the same codon are pathogenic. (92750). Computational prediction tools and conservation analysis suggest that the c.889C>T variant may impact the protein. Overall, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP3, PM2, PM3, PM5, PP4_moderate.	8807331, 27121329, 8807331, 21307867	Phenylketonuria VCEP		2019-07-14	2019-07-14	false	https://erepo.genome.network/evrepo/ui/classification/CA229836/MONDO:0009861/006	d25191fc-95b0-4444-8fc1-9115fe7c811c
NM_000277.2(PAH):c.887A>G (p.Asp296Gly)	120291	CA267682	NM_000277.2:c.887A>G, NC_000012.12:g.102851712T>C, CM000674.2:g.102851712T>C, NC_000012.11:g.103245490T>C, CM000674.1:g.103245490T>C, NC_000012.10:g.101769620T>C, NG_008690.1:g.70891A>G, NG_008690.2:g.111699A>G, NM_000277.1:c.887A>G, XM_011538422.1:c.887A>G, NM_001354304.1:c.887A>G, NM_000277.3:c.887A>G, ENST00000307000.7:c.872A>G, ENST00000549247.6:n.646A>G, ENST00000551114.2:n.549A>G, ENST00000553106.5:c.887A>G, ENST00000635477.1:n.48A>G, NM_000277.2(PAH):c.887A>G (p.Asp296Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP3, PP4, PM3_Supporting	PM5	The c.887A>G (p.Asp296Gly) variant in PAH has been reported in a proband with classic PKU (PMID: 26666653; PP4). The proband was heterozygous for variant; it was found with the known pathogenic (per ClinGen PAH Working Group â€“ see ClinVar variant ID 577) c.1222C > T (p.Arg408Trp) allele; however, the although paper did say that parental samples were collected in the study, it did not explicitly state whether the phase of the variants was confirmed via parental testing. Thus, PM3 is downgraded to supporting. The variant is predicted damaging by multiple lines of computational evidence (PP3). It is absent from ethnically diverse control databases (PM2). Another missense at the site, p.Asp296His, has been previously reported (BioPKU PAH0955) heterozygous in a Chinese proband with PKU; no further information appears to be provided in the manuscript or supplementary information regarding phenotype or second variant (PMID: 26503515). . In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM3_supporting, PP3.	26666653, 26666653	Phenylketonuria VCEP		2019-07-14	2019-07-14	false	https://erepo.genome.network/evrepo/ui/classification/CA267682/MONDO:0009861/006	5cce5177-b984-4bf4-b10c-cc6ae260ddea
	-	CA16020885	NM_000277.3:c.886G>C, NC_000012.12:g.102851713C>G, CM000674.2:g.102851713C>G, NC_000012.11:g.103245491C>G, CM000674.1:g.103245491C>G, NC_000012.10:g.101769621C>G, NG_008690.1:g.70890G>C, NG_008690.2:g.111698G>C, NM_000277.1:c.886G>C, XM_011538422.1:c.886G>C, NM_000277.2:c.886G>C, NM_001354304.1:c.886G>C, ENST00000307000.7:c.871G>C, ENST00000549247.6:n.645G>C, ENST00000551114.2:n.548G>C, ENST00000553106.5:c.886G>C, ENST00000635477.1:n.47G>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PP4_Moderate, PM2, PP3	PM5, PM3	The c.886G>C (p.Asp296His) variant in PAH has been reported in a PKU patient from mainland China, BH4 deficiency assessed (PMID: 26503515). A change to glycine at the same codon has been observed associated with phenylketonuria. This variant is absent from 1000G, ESP, and gnomAD databases. A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.949. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP3, PM2, PP4_moderate.		Phenylketonuria VCEP		2019-07-14	2019-07-14	false	https://erepo.genome.network/evrepo/ui/classification/CA16020885/MONDO:0009861/006	25d719d3-4100-4594-bc0b-e40e47da828c
NM_000277.2(PAH):c.931_932delCT (p.Leu311Glyfs)	120297	CA267689	NM_000277.2:c.931_932del, NC_000012.12:g.102846936_102846937del, CM000674.2:g.102846936_102846937del, NC_000012.11:g.103240714_103240715del, CM000674.1:g.103240714_103240715del, NC_000012.10:g.101764844_101764845del, NG_008690.1:g.75670_75671del, NG_008690.2:g.116478_116479del, NM_000277.1:c.931_932del, XM_011538422.1:c.913-2502_913-2501del, NM_001354304.1:c.931_932del, NM_000277.3:c.931_932del, ENST00000307000.7:c.916_917del, ENST00000549247.6:n.690_691del, ENST00000551114.2:n.593_594del, ENST00000553106.5:c.931_932del, ENST00000635477.1:n.74-2502_74-2501del, ENST00000635528.1:n.446_447del, NM_000277.2(PAH):c.931_932delCT (p.Leu311Glyfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4, PM3_Supporting		The c.931_932del frameshift variant has been identified in at least 1 proband with mild PKU, BH4 deficiency not excluded (PMID: 26666653). It has been detected in trans with the pathogenic variant R241C (PMID: 26666653). This variant is absent from 1000G, Exac, and gnomAD databases. c.931_932delCT generates a frameshift predicted to result in a premature stop codon 4 residues downstream in exon 9 and undergo NMD. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM3_Supporting, PM2, PP4.	26666653, 26666653	Phenylketonuria VCEP		2019-07-14	2019-07-14	false	https://erepo.genome.network/evrepo/ui/classification/CA267689/MONDO:0009861/006	23b3c015-0c55-4a60-a3f3-0d297d4a1b9d
NM_000277.2(PAH):c.837delC (p.Glu280Asnfs)	120288	CA267677	NM_000277.2:c.837del, NC_000012.12:g.102852824del, CM000674.2:g.102852824del, NC_000012.11:g.103246602del, CM000674.1:g.103246602del, NC_000012.10:g.101770732del, NG_008690.1:g.69783del, NG_008690.2:g.110591del, NM_000277.1:c.837del, XM_011538422.1:c.837del, NM_001354304.1:c.837del, NM_000277.3:c.837del, ENST00000307000.7:c.822del, ENST00000549247.6:n.596del, ENST00000553106.5:c.837del, NM_000277.2(PAH):c.837delC (p.Glu280Asnfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PM2, PP4		The c.837del frameshift variant has been identified in at least 2 probands with classic PKU, BH4 deficiency not excluded (PMIDs: 10598814, 26666653). It has been detected in trans with pathogenic variants V388M (PMID: 10598814) and c.1315+1G>A (PMID: 26666653). This variant is absent from 1000G, Exac, and gnomAD databases. C.837delC generates a frameshift predicted to result in a premature stop codon 61 residues downstream in exon 10 and undergo NMD. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM3, PM2, PP4.	10598814, 26666653, 10598814, 26666653	Phenylketonuria VCEP		2019-07-14	2019-07-14	false	https://erepo.genome.network/evrepo/ui/classification/CA267677/MONDO:0009861/006	bcdf79d7-d9f1-457f-a01b-cace787307e1
	637	-	NM_000277.1:c.913_1199del, NM_000277.1(PAH):c.913_1199del (p.Ile306Leufs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PVS1, PM2, PP4		The c.913_1199del (p.Ile306Leufs) variant in PAH has been previously reported in a proband with mild PKU; BH4 deficiency does not appear to have been excluded (PP4). It was found in trans (confirmed via paternal testing) with the known Pathogenic variant p.Glu390Gly (see ClinVar ID 625, PM3). The sequence change results a deletion involving exons 9, 10 and 11 leading to a frameshift variant in the in the canonical transcript of PAH, a gene fulfilling the most recent criteria for LOF being a known disease mechanism (see PMID: 30192042) (PVS1). It is absent from control databases (PM2). ). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4.	10472529	Phenylketonuria VCEP		2019-07-14	2019-07-14	false	https://erepo.genome.network/evrepo/ui/classification/CV637/MONDO:0009861/006	966b80c9-3cc5-47be-99a6-567f7321d534
NM_000277.2(PAH):c.884C>G (p.Ser295Ter)	102884	CA229834	NM_000277.2:c.884C>G, NC_000012.12:g.102851715G>C, CM000674.2:g.102851715G>C, NC_000012.11:g.103245493G>C, CM000674.1:g.103245493G>C, NC_000012.10:g.101769623G>C, NG_008690.1:g.70888C>G, NG_008690.2:g.111696C>G, NM_000277.1:c.884C>G, XM_011538422.1:c.884C>G, NM_001354304.1:c.884C>G, NM_000277.3:c.884C>G, ENST00000307000.7:c.869C>G, ENST00000549247.6:n.643C>G, ENST00000551114.2:n.546C>G, ENST00000553106.5:c.884C>G, ENST00000635477.1:n.45C>G, NM_000277.2(PAH):c.884C>G (p.Ser295Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2, PVS1, PP4	PM3	The c.884C>G (p.S295*) variant in PAH has been reported in 1 individual with PKU, however without indication of complete genotype (PMID:10394930). This variant is absent in  population databases, including 1000 Genomes, Exome Sequencing Project (ESP) and the Genome Aggregation database (gnomAD). This is a nonsense variant in exon 8 of 13 in PAH, predicted to undergo nonsense mediated decay with the truncated region critical to protein function. Overall this variant meets criteria to be classified as pathogenic for PAH. ACMG/AMP criteria applied: PM2, PVS1, PP4.	10394930, 10394930	Phenylketonuria VCEP		2019-07-14	2019-07-14	false	https://erepo.genome.network/evrepo/ui/classification/CA229834/MONDO:0009861/006	6d125790-217d-4bb8-aeab-b6ee4f35be49
	-	CA16020846	NM_000277.3:c.707-2del, NC_000012.12:g.102852952del, CM000674.2:g.102852952del, NC_000012.11:g.103246730del, CM000674.1:g.103246730del, NC_000012.10:g.101770860del, NG_008690.1:g.69651del, NG_008690.2:g.110459del, NM_000277.1:c.707-2del, XM_011538422.1:c.707-2del, NM_000277.2:c.707-2del, NM_001354304.1:c.707-2del, ENST00000307000.7:c.692-2del, ENST00000549247.6:n.464del, ENST00000553106.5:c.707-2del	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM3, PM2, PVS1, PP4		The c.707-2delA variant in PAH has been reported in one patient, who carried a second pathogenic missense variant (p.Pro281Leu; BH4 deficiency not ruled out) (PMID: 19292873). The pre-treatment serum phenylalanine was reported at > 1500 micromolar. This variant is absent from gnomAD and ESP population databases, and disrupts the canonical splice acceptor site of intron 6, resulting in a frameshift and truncated protein (PMID: 19292873). Overall, the c.707-2delA variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PVS1, PP4.	19292873	Phenylketonuria VCEP		2019-07-15	2019-07-15	false	https://erepo.genome.network/evrepo/ui/classification/CA16020846/MONDO:0009861/006	00ac6a3d-eae6-4988-8c79-3396eb3bb017
NM_000277.2(PAH):c.895_897delTTT (p.Phe299del)	102886	CA229837	NM_000277.2:c.895_897del, NC_000012.12:g.102851702_102851704del, CM000674.2:g.102851702_102851704del, NC_000012.11:g.103245480_103245482del, CM000674.1:g.103245480_103245482del, NC_000012.10:g.101769610_101769612del, NG_008690.1:g.70899_70901del, NG_008690.2:g.111707_111709del, NM_000277.1:c.895_897del, XM_011538422.1:c.895_897del, NM_001354304.1:c.895_897del, NM_000277.3:c.895_897del, ENST00000307000.7:c.880_882del, ENST00000549247.6:n.654_656del, ENST00000551114.2:n.557_559del, ENST00000553106.5:c.895_897del, ENST00000635477.1:n.56_58del, NM_000277.2(PAH):c.895_897delTTT (p.Phe299del)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM4, PM2, PP4		The c.895_897del (p.Phe299del) variant in PAH has been reported in 1 individual with PKU without genotype information (BH4 deficiency not ruled out) (PMID: 10541324) . This variant is absent in gnomAD and the ESP population databases. The c.895_897del variant results in an in-frame deletion of phenylalanine 299 in a hydrophobic pocket of the hydroxylase domain of PAH.  In summary, this variant meets the criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM4.	10541324	Phenylketonuria VCEP		2019-07-14	2019-07-15	false	https://erepo.genome.network/evrepo/ui/classification/CA229837/MONDO:0009861/006	e8c15621-e7e7-4110-bab8-054bbe31fd53
	-	CA16020889	NM_000277.3:c.902A>C, NC_000012.12:g.102851697T>G, CM000674.2:g.102851697T>G, NC_000012.11:g.103245475T>G, CM000674.1:g.103245475T>G, NC_000012.10:g.101769605T>G, NG_008690.1:g.70906A>C, NG_008690.2:g.111714A>C, NM_000277.1:c.902A>C, XM_011538422.1:c.902A>C, NM_000277.2:c.902A>C, NM_001354304.1:c.902A>C, ENST00000307000.7:c.887A>C, ENST00000549247.6:n.661A>C, ENST00000551114.2:n.564A>C, ENST00000553106.5:c.902A>C, ENST00000635477.1:n.63A>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2, PP3, PS3, PM3_Supporting		The c.902A>C (p.Gln301Pro) variant in PAH has been reported in at least 1 individual with hyperphenylalaninemia, who carried a second pathogenic variant (p.Leu48Ser) (BH4 deficiency ruled out, parental analysis not performed) (PMID: 19292873, 25757997) . The p.Gln301Pro variant is absent in gnomAD and the ESP population databases. A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.987. In addition the p.Gln301Pro causes a significant reduction of enzyme activity and expression when tested in vitro (PMID: 19292873).  In summary, this variant meets the criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP3, PM2, PM3_supporting, PS3, PP4_moderate.	25757997, 19292873, 19292873, 19292873	Phenylketonuria VCEP		2019-07-14	2019-07-15	false	https://erepo.genome.network/evrepo/ui/classification/CA16020889/MONDO:0009861/006	6b22f5b5-b654-4763-936d-fd132e4d0fbc
	-	CA346365197	NM_005633.3:c.1867T>A, NC_000002.12:g.39014838A>T, CM000664.2:g.39014838A>T, NC_000002.11:g.39241979A>T, CM000664.1:g.39241979A>T, NC_000002.10:g.39095483A>T, NG_007530.1:g.110626T>A, LRG_754:g.110626T>A, LRG_754t1:c.1867T>A, XM_005264515.3:c.1867T>A, XM_011533060.1:c.1960T>A, XM_011533061.1:c.1960T>A, XM_011533062.1:c.1846T>A, XM_011533063.1:c.1843T>A, XM_011533064.1:c.1696T>A, XM_011533065.1:c.1960T>A, XM_011533066.1:c.802T>A, XM_005264515.4:c.1867T>A, XM_011533062.2:c.1846T>A, XM_011533064.2:c.1696T>A, ENST00000395038.6:c.1867T>A, ENST00000402219.6:c.1867T>A, ENST00000426016.5:c.1867T>A	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PS2, PM2, PP2, PP3, PS4_Supporting	PS1, PS3, PM5, PM1, PM4, BP7, BP5, BS3, BS4, BS1, PM6, BS2, PP1, BP3, BP2, BP1, BP4, BA1	The c.1867T>A (p.Phe623Ile) variant in SOS1 has been reported as a confirmed de novo occurrence in a patient with clinical features of Noonan syndrome (PS2; PMID 17586837, 20673819). The p.Phe623Ile variant has also been identified in another independent occurrence in a patient with clinical features of Noonan syndrome (PS4_Supporting; PMID 20673819). This variant was absent from large population studies (PM2; gnomAD; http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Phe623Ile variant may impact the protein (PP3). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Of note, two different pathogenic missense variants have been previously reported at this codon of SOS1 (p.Phe623Val and p.Phe623Glu) which may indicate that this residue is critical to the function of the protein, however these variants have not yet met the criteria to be classified as pathogenic (PM5 not met). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS4_Supporting, PM2, PP2, PP3.	17586837, 11333268, 17586837, 11333268, 17586837, 20673819	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-02-28	2019-07-15	false	https://erepo.genome.network/evrepo/ui/classification/CA346365197/MONDO:0021060/004	e1a27f96-c415-42ee-a544-66d4c7ee7923
	-	CA891862608	NM_005633.3:c.1867_1869delinsGAA, NC_000002.12:g.39014836_39014838delinsTTC, CM000664.2:g.39014836_39014838delinsTTC, NC_000002.11:g.39241977_39241979delinsTTC, CM000664.1:g.39241977_39241979delinsTTC, NC_000002.10:g.39095481_39095483delinsTTC, NG_007530.1:g.110626_110628delinsGAA, LRG_754:g.110626_110628delinsGAA, LRG_754t1:c.1867_1869delinsGAA, XM_005264515.3:c.1867_1869delinsGAA, XM_011533060.1:c.1960_1962delinsGAA, XM_011533061.1:c.1960_1962delinsGAA, XM_011533062.1:c.1846_1848delinsGAA, XM_011533063.1:c.1843_1845delinsGAA, XM_011533064.1:c.1696_1698delinsGAA, XM_011533065.1:c.1960_1962delinsGAA, XM_011533066.1:c.802_804delinsGAA, XM_005264515.4:c.1867_1869delinsGAA, XM_011533062.2:c.1846_1848delinsGAA, XM_011533064.2:c.1696_1698delinsGAA, ENST00000395038.6:c.1867_1869delinsGAA, ENST00000402219.6:c.1867_1869delinsGAA, ENST00000426016.5:c.1867_1869delinsGAA	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PM2, PP2	PS1, PS2, PS3, PS4, PM5, PM4, PM1, BS4, BS3, BS1, BP7, BP5, PM6, PP1, PP3, BS2, BP3, BP2, BP1, BP4, BA1	The c.1867_1869delinsGAA p.Phe623Glu variant in SOS1 has not been reported in patients with clinical features of a RASopathy to date. In vitro functional studies provide some evidence that the p.Phe623Glu variant may impact protein function, however this assay has not been defined by the ClinGen RASopathy Expert panel as criteria for PS3 (PS3 not met; PMID: 11333268). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). Of note, 2 different pathogenic missense variants have been previously reported at this codon of SOS1 (p.Phe623Val and p.Phe623Ile) which may indicate that this residue is critical to the function of the protein, however these variants have not yet met the criteria to be classified as pathogenic (PM5 not met). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, the clinical significance of the p.Phe623Glu variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM2, PP2	11333268, 11333268	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-02-28	2019-07-15	false	https://erepo.genome.network/evrepo/ui/classification/CA891862608/MONDO:0021060/004	9b5591dc-771b-40fd-8445-52363c4cd632
NM_005633.3(SOS1):c.512T>C (p.Val171Ala)	45373	CA261743	NM_005633.3:c.512T>C, NC_000002.12:g.39054822A>G, CM000664.2:g.39054822A>G, NC_000002.11:g.39281963A>G, CM000664.1:g.39281963A>G, NC_000002.10:g.39135467A>G, NG_007530.1:g.70642T>C, LRG_754:g.70642T>C, LRG_754t1:c.512T>C, XM_005264515.3:c.512T>C, XM_011533060.1:c.605T>C, XM_011533061.1:c.605T>C, XM_011533062.1:c.491T>C, XM_011533063.1:c.488T>C, XM_011533064.1:c.341T>C, XM_011533065.1:c.605T>C, XM_005264515.4:c.512T>C, XM_011533062.2:c.491T>C, XM_011533064.2:c.341T>C, ENST00000395038.6:c.512T>C, ENST00000402219.6:c.512T>C, ENST00000426016.5:c.512T>C, NM_005633.3(SOS1):c.512T>C (p.Val171Ala)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PM5, PM2, PM6, PP2, PS4_Supporting	PS1, PS3, PS2, PM1, PM4, BP7, BP5, BS4, BS3, BS1, BS2, PP1, PP3, BP3, BP2, BP1, BP4, BA1	The c.512T>C (p.Val171Ala) variant in SOS1 has been reported as an unconfirmed de novo occurrence in a patient with clinical features of a Noonan spectrum disorder (PM6; Partners LMM internal data; GTR Lab ID: 21766; ClinVar SCV000062240.5). The p.Val171Ala variant has also been identified in another independent occurrences in patients with clinical features of a familial RASopathy (PS4_Supporting; PMID: 29402968). This variant was absent from large population studies (PM2; gnomAD, http://gnomAD.broadinstitute.org). A different pathogenic missense variant (p.Val171Gly) has been previously identified at this codon of SOS1 which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 40654). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PM5, PM2, PS4_Supporting, PP2.	29402968	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-02-28	2019-07-15	false	https://erepo.genome.network/evrepo/ui/classification/CA261743/MONDO:0021060/004	6d026472-974f-4b44-9918-65310c34a46d
NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)	8273	CA279960	NM_030662.3:c.169T>G, NC_000019.10:g.4117553A>C, CM000681.2:g.4117553A>C, NC_000019.9:g.4117551A>C, CM000681.1:g.4117551A>C, NC_000019.8:g.4068551A>C, NG_007996.1:g.11576T>G, LRG_750:g.11576T>G, LRG_750t1:c.169T>G, XM_006722799.2:c.169T>G, XM_017026989.1:c.169T>G, XM_017026990.1:c.169T>G, XM_017026991.1:c.169T>G, ENST00000262948.9:c.169T>G, ENST00000394867.8:c.-123T>G, ENST00000599345.1:n.366T>G, NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM1, PS2_Very Strong, PM2, PP3, PP2		The c.169T>G (p.Phe57Val) variant in MAP2K2 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 18042262). The variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K2 (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe57Val variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PM1, PM2, PP2, PP3.	18042262	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2019-07-15	false	https://erepo.genome.network/evrepo/ui/classification/CA279960/MONDO:0015280/004	ac054f0f-9da0-455d-8a0f-343d2f4ad540
NM_002834.4(PTPN11):c.1403C>T (p.Thr468Met)	13331	CA220134	NM_002834.4:c.1403C>T, NC_000012.12:g.112488466C>T, CM000674.2:g.112488466C>T, NC_000012.11:g.112926270C>T, CM000674.1:g.112926270C>T, NC_000012.10:g.111410653C>T, NG_007459.1:g.74735C>T, LRG_614:g.74735C>T, NM_002834.3:c.1403C>T, LRG_614t1:c.1403C>T, XM_006719526.1:c.1415C>T, XM_006719527.1:c.1301C>T, XM_011538613.1:c.1412C>T, NM_001330437.1:c.1415C>T, XM_011538613.2:c.1412C>T, XM_017019722.1:c.1400C>T, ENST00000351677.6:c.1403C>T, ENST00000635625.1:n.1415C>T, ENST00000635652.1:n.416C>T, NM_002834.4(PTPN11):c.1403C>T (p.Thr468Met)	PTPN11	Noonan syndrome with multiple lentigines	MONDO:0007893	Autosomal dominant inheritance	Pathogenic	PS3, PS4, PP1_Strong, PM1, PP2, PP3, PM6_Strong	PM2	The c.1403C>T (p.Thr468Met) variant in PTPN11 has been reported in the literature in at least 2 unconfirmed de novo occurrences as well as more than 5 other independent occurances of patients with clinical features of a RASopathy (PM6_Strong, PS4; PMID 25884655, 19864201, PMIDs: 20883402, 15520399, 17935252, 24767283, 12058348, 15520399). The c.1403C>T (p.Thr468Met) variant in PTPN11 has been reported in the literature to segregate with clinical features of a RASopathy in at least 7 family members (PP1_Strong; 24767283, 17935252, 15520399, 20883402). In vitro functional studies provide some evidence that the p.Thr468Met variant may impact protein function (PS3; PMID: 24935154, 18372317, 16638574, 18849586). The variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTNP11 (PM1; PMID 29493581). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Thr468Met variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6_Strong, PS4, PP1_Strong, PS3, PM1, PP2, PP3.	24935154, 18849586, 18372317, 16638574, 24767283, 17935252, 12058348, 20883402, 15520399, 24767283, 17935252, 15520399, 20883402, 29493581, 19864201, 25884655	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2019-07-15	false	https://erepo.genome.network/evrepo/ui/classification/CA220134/MONDO:0007893/004	e33078e1-353c-43ad-a6d9-93f2dab20e33
NM_002834.5(PTPN11):c.188A>G (p.Tyr63Cys)	13333	CA220146	NM_002834.5:c.188A>G, NC_000012.12:g.112450368A>G, CM000674.2:g.112450368A>G, NC_000012.11:g.112888172A>G, CM000674.1:g.112888172A>G, NC_000012.10:g.111372555A>G, NG_007459.1:g.36637A>G, LRG_614:g.36637A>G, ENST00000639857.2:c.188A>G, ENST00000685487.1:c.188A>G, ENST00000687906.1:c.188A>G, ENST00000688597.1:c.188A>G, ENST00000690210.1:c.188A>G, ENST00000692624.1:c.188A>G, ENST00000351677.7:c.188A>G, ENST00000639857.1:c.188A>G, ENST00000351677.6:c.188A>G, ENST00000392597.5:c.188A>G, ENST00000635625.1:c.188A>G, NM_002834.3:c.188A>G, LRG_614t1:c.188A>G, NM_080601.1:c.188A>G, XM_006719526.1:c.188A>G, XM_006719527.1:c.188A>G, XM_011538613.1:c.185A>G, NM_001330437.1:c.188A>G, NM_002834.4:c.188A>G, NM_080601.2:c.188A>G, XM_011538613.2:c.185A>G, XM_017019722.1:c.185A>G, NM_001330437.2:c.188A>G, NM_001374625.1:c.185A>G, NM_080601.3:c.188A>G, NM_002834.5(PTPN11):c.188A>G (p.Tyr63Cys)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS3, PS4, PP1_Strong, PM1, PP2, PP3	PM2	The c.188A>G (p.Tyr63Cys) variant in PTPN11 (NM_002834.5(PTPN11):c.188A>G (p.Tyr63Cys)) has been reported in the literature in at least 6 unrelated individuals and has been found to segregate with clinical features of a RASopathy in at least 15 family members (PS4, PP1_Strong; PMID: 16498234, 12634870, 12325025, 11704759). In-vitro functional studies provide some evidence that the p.Tyr63Cys variant may impact protein function (PS3; PMID: 22711529). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Tyr63Cys variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTPN11 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied: PP1_Strong, PS4, PS3, PM1, PP2, PP3 (Version 2.1; 09/17/2024).	22711529, 24219368, 12634870, 12325025, 11704759, 12634870, 16498234, 12325025	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2024-09-17	2024-10-01	false	https://erepo.genome.network/evrepo/ui/classification/CA220146/MONDO:0018997/004	579af108-04e2-4cf7-9a40-35cbaa82b116
NM_004004.6(GJB2):c.107T>C (p.Leu36Pro)	158604	CA172208	NM_004004.6:c.107T>C, NC_000013.11:g.20189475A>G, CM000675.2:g.20189475A>G, NC_000013.10:g.20763614A>G, CM000675.1:g.20763614A>G, NC_000013.9:g.19661614A>G, NG_008358.1:g.8501T>C, ENST00000382844.2:c.107T>C, ENST00000382848.5:c.107T>C, ENST00000382844.1:c.107T>C, ENST00000382848.4:c.107T>C, NM_004004.5:c.107T>C, XM_011535049.1:c.107T>C, XM_011535049.2:c.107T>C, NM_004004.6(GJB2):c.107T>C (p.Leu36Pro)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Likely Pathogenic	PP3, PM3_Very Strong	BS1, BS3, BP7, BP5, PP2, PP4, BS2, PM5, PM4, PM1, PVS1, PM2, BA1, BP1, BP4, BP2, BP3, PS1, PS3	The NM_004004.6:c.107T>C variant in the GJB2 gene is a missense variant predicted to cause substitution of leucine by proline at amino acid 36 (p.Leu36Pro). The highest population minor allele frequency of the variant is 0.01% (2/19954) in the East Asian population in gnomAD v.2.1.1, which does not meet any population codes based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (BA1/BS1/PM2_Supporting not met). The REVEL computational prediction analysis tool produced a score of 0.945, which is above the threshold necessary to apply PP3. This variant has been detected in trans with a pathogenic variant in three patients with hearing loss (4 points, PM3_VeryStrong; PMID:16125251, 16467727, 29605365, 31246659, Invitae internal date (SCV002241983.2)). The variant has also been reported in five individuals with no pathogenic variant reported in trans (PMIDs:17666888, 26043044, 31581539, 31992338). In summary, this variant meets the criteria to be classified as likely pathogenic for autosomal recessive hearing loss. ACMG/AMP criteria applied as specified by the ClinGen Hearing Loss VCEP: PM3_VeryStrong, PP3 (ClinGen Hearing Loss VCEP specifications version 2; 1/18/2022).	17666888, 16125251, 26043044, 17666888, 16125251, 26043044	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2022-01-18	2024-03-28	false	https://erepo.genome.network/evrepo/ui/classification/CA172208/MONDO:0019497/005	e657ec2a-42b6-42fd-94ab-817fd6805f5d
NM_022124.5(CDH23):c.9566G>A (p.Arg3189Gln)	162956	CA175533	NM_022124.5:c.9566G>A, NC_000010.11:g.71812823G>A, CM000672.2:g.71812823G>A, NC_000010.10:g.73572580G>A, CM000672.1:g.73572580G>A, NC_000010.9:g.73242586G>A, NG_008835.1:g.420877G>A, ENST00000224721.12:c.9566G>A, ENST00000642965.1:n.3499G>A, ENST00000647092.1:n.3163G>A, ENST00000224721.10:c.9581G>A, ENST00000398788.4:c.2846G>A, ENST00000475158.1:n.3102G>A, ENST00000619887.4:c.2846G>A, ENST00000622827.4:c.9566G>A, NM_001171933.1:c.2846G>A, NM_001171934.1:c.2846G>A, NM_001171935.1:c.257G>A, NM_001171936.1:c.257G>A, XM_006717940.2:c.9761G>A, XM_006717942.2:c.9695G>A, XM_011540039.1:c.9758G>A, XM_011540040.1:c.9755G>A, XM_011540041.1:c.9701G>A, XM_011540042.1:c.9671G>A, XM_011540043.1:c.9761G>A, XM_011540044.1:c.9626G>A, XM_011540045.1:c.9761G>A, XM_011540046.1:c.9221G>A, XM_011540047.1:c.8579G>A, XM_011540052.1:c.6089G>A, NM_022124.6:c.9566G>A, NM_022124.6(CDH23):c.9566G>A (p.Arg3189Gln), NM_022124.5(CDH23):c.9566G>A (p.Arg3189Gln)	CDH23	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance		BP7, BP5, BS1, BS4, BS3, PP2, PP3, PP4, PP1, BS2, PM1, PM3, PM4, PM5, PM2, PM6, PVS1, BA1, BP1, BP4, BP2, BP3, PS2, PS4, PS3, PS1	The NM_022124.6:c.9566G>A variant in the CDH23 gene is a missense variant predicted to cause substitution of arginine by glutamine at amino acid 3189 (p.Arg3189Gln). This variant has been identified in 1 heterozygous patient with sensorineural hearing loss (Partners LMM internal data, SCV000197429.4). The highest population minor allele frequency of the variant is 0.023% (7/30430) of South Asian alleles in gnomAD v.2.1.1, which does not meet any of the criteria for PM2_P, BA1, and BS1. The REVEL computational prediction analysis tool produced a score of 0.683 which does not meet the criteria for PP3. In summary, this variant meets the criteria to be classified as a variant of uncertain significance for autosomal recessive Usher syndrome. ACMG/AMP criteria applied as specified by the ClinGen Hearing Loss VCEP: None (ClinGen Hearing Loss VCEP specifications version 2; 1/18/2022).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-01-18	2023-02-06	false	https://erepo.genome.network/evrepo/ui/classification/CA175533/MONDO:0019501/005	f7c337df-9d3f-48fe-afac-1a5ce74511bd
NM_005422.2(TECTA):c.3097C>T (p.Arg1033Trp)	178538	CA182517	NM_005422.2:c.3097C>T, NM_005422.2:n.3097C>T, ENST00000264037.2:n.3097C>T, ENST00000392793.5:c.3097C>T, NC_000011.10:g.121137576C>T, CM000673.2:g.121137576C>T, NC_000011.9:g.121008285C>T, CM000673.1:g.121008285C>T, NC_000011.8:g.120513495C>T, NG_011633.1:g.39911C>T, NM_005422.2(TECTA):c.3097C>T (p.Arg1033Trp)	TECTA	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Likely Benign	BS1	BP7, PP3, PM3, PM4, PM5, PM2, PVS1, BA1, BP2, BP3, BP4, PS1	The filtering allele frequency (the lower threshold of the 95% CI of 88/24956) of the p.Arg1033Trp variant in the TECTA gene is 0.29% for African chromosomes by gnomAD, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). The p.Arg1033Trp variant has been identified in one hearing loss patient who carries a second TECTA variant, p.Gln234Arg, that has previously been classified as likely benign by the HL VCEP (PMID 26969326, SCV000840522.3). The variant has also been observed by Partners LMM in one homozygous patient, two heterozygous patients, and two compound heterozygous patients who also carry one or two pathogenic or VUS favor-pathogenic variants. These cases are inconclusive (SCV000204966.4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1.	26969326, 26969326	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-04-29	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA182517/MONDO:0019497/005	7d1da592-1e07-4180-b86b-6fdeb5ee5521
NM_005422.2(TECTA):c.2061C>G (p.Asn687Lys)	45317	CA136024	NM_005422.2:c.2061C>G, NM_005422.2:n.2061C>G, ENST00000264037.2:n.2061C>G, ENST00000392793.5:c.2061C>G, NC_000011.10:g.121128038C>G, CM000673.2:g.121128038C>G, NC_000011.9:g.120998747C>G, CM000673.1:g.120998747C>G, NC_000011.8:g.120503957C>G, NG_011633.1:g.30373C>G, NM_005422.2(TECTA):c.2061C>G (p.Asn687Lys)	TECTA	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Likely Benign	BS1, BP4	PM3, BA1, PS4	The p.Asn687Lys variant in TECTA has been identified in 1 patient with Asperger syndrome who was hypersensitive to sound (PMID: 30675382). However, the filtering allele frequency of the p.Asn687Lys variant is 0.3% for European chromosomes by gnomAD (399/126054, including one homozygous observation, with 95% CI), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss variants (BS1). Additionally, computational prediction analysis using the metapredictor tool REVEL suggests that the variant may not impact the protein (BP4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BS1, BP4.	30675382	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-03-25	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA136024/MONDO:0019497/005	e5864f96-5ffd-461c-9042-b76f2b0d5749
NM_004999.3(MYO6):c.1025C>T (p.Ala342Val)	45131	CA135587	NM_004999.3:c.1025C>T, NC_000006.12:g.75848478C>T, CM000668.2:g.75848478C>T, NC_000006.11:g.76558195C>T, CM000668.1:g.76558195C>T, NC_000006.10:g.76614915C>T, NG_009934.1:g.104287C>T, NG_009934.2:g.104286C>T, NM_001300899.1:c.1025C>T, XM_005248719.2:c.1025C>T, XM_005248720.2:c.1025C>T, XM_005248721.2:c.1025C>T, XM_005248722.2:c.1025C>T, XM_005248724.2:c.1025C>T, XM_005248726.2:c.1025C>T, XM_005248719.4:c.1025C>T, XM_005248720.4:c.1025C>T, XM_005248721.4:c.1025C>T, XM_005248722.4:c.1025C>T, XM_005248724.4:c.1025C>T, XM_005248726.4:c.1025C>T, XM_017010899.2:c.1025C>T, XM_024446447.1:c.1025C>T, XM_024446448.1:c.1025C>T, NM_004999.4:c.1025C>T, ENST00000369975.5:c.1025C>T, ENST00000369977.7:c.1025C>T, ENST00000369981.7:c.1025C>T, ENST00000369985.8:c.1025C>T, ENST00000615563.4:c.1025C>T, ENST00000627432.2:c.1025C>T, NM_004999.3(MYO6):c.1025C>T (p.Ala342Val)	MYO6	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Benign	PP3, BA1	BP7, PP4, PM4, PM5, PM2, PVS1, BP3, BP4, PS4, PS1	The filtering allele frequency of the p.Ala342Val variant in the MYO6 gene is 0.21% for European (non-Finnish) chromosomes by gnomAD (304/129090 with 95% CI), and one homozygous European (Finnish) individual, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1). The REVEL computational prediction analysis tool produced a score of 0.905, however, this information is not predictive of pathogenicity on its own and is not considered in conflict with evidence that supports a benign interpretation. In summary, the HL EP classified this variant as benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BA1.	27068579	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-03-25	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA135587/MONDO:0019497/005	e877db5b-e7aa-4792-865f-538037682cc8
NM_022124.5(CDH23):c.3625A>G (p.Thr1209Ala)	4927	CA137387	NM_022124.5:c.3625A>G, NC_000010.11:g.71730514A>G, CM000672.2:g.71730514A>G, NC_000010.10:g.73490271A>G, CM000672.1:g.73490271A>G, NC_000010.9:g.73160277A>G, NG_008835.1:g.338568A>G, NM_001168390.1:c.-6+7214T>C, NM_001171930.1:c.3625A>G, XM_006717940.2:c.3820A>G, XM_006717942.2:c.3754A>G, XM_011540039.1:c.3820A>G, XM_011540040.1:c.3814A>G, XM_011540041.1:c.3760A>G, XM_011540042.1:c.3820A>G, XM_011540043.1:c.3820A>G, XM_011540044.1:c.3685A>G, XM_011540045.1:c.3820A>G, XM_011540046.1:c.3280A>G, XM_011540047.1:c.2638A>G, XM_011540048.1:c.3820A>G, XM_011540049.1:c.3820A>G, XM_011540050.1:c.3820A>G, XM_011540051.1:c.3820A>G, XM_011540052.1:c.148A>G, XM_011540053.1:c.3820A>G, XR_945796.1:n.4063A>G, ENST00000224721.10:c.3640A>G, ENST00000398786.2:c.-6+7214T>C, ENST00000398792.3:n.317A>G, ENST00000398809.8:c.3622A>G, ENST00000616684.4:c.3625A>G, ENST00000622827.4:c.3625A>G, NM_022124.5(CDH23):c.3625A>G (p.Thr1209Ala)	CDH23	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BP4, BA1, BS3_Supporting	BS4, BS1, BP7, BP5, BS2, PP4, PP1, PP3, PM1, PM5, PM4, PM3, PVS1, PM6, PM2, BP3, BP2, PS2, PS1, PS4, PS3	The filtering allele frequency (the lower threshold of the 95% CI of 3442/23972) of the c.3625A>G (p.Thr1209Ala) variant in the CDH23 gene is 13.15% for African chromosomes by gnomAD, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). A splicing assay did not show any impact to splicing but BS3 was not applied given no assessment of protein function  (PMID:18273900). Computational prediction analysis using the metapredictor tool REVEL did not predict an impact the protein (BP4). Of note, this variant was reported in 3 patients with Usher syndrome (PMID: 15537665, 15660226, 12075507) though without any convincing evidence for pathogenicity (PM3 not met). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BA1, BS3_Supporting, BP4.	19683999, 15660226, 12075507, 15537665, 19683999, 15660226, 12075507, 15537665, 18273900, 16963483, 21569298, 21738395	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-05-28	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA137387/MONDO:0019501/005	dfd4f5fa-53f6-478c-911d-6946d1680d38
NM_004086.2(COCH):c.429A>G (p.Pro143=)	227258	CA7143032	NM_004086.2:c.429A>G, NC_000014.9:g.30879478A>G, CM000676.2:g.30879478A>G, NC_000014.8:g.31348684A>G, CM000676.1:g.31348684A>G, NC_000014.7:g.30418435A>G, NG_008211.2:g.9944A>G, NM_001135058.1:c.429A>G, NR_038356.1:n.1618-2926T>C, XM_011536539.1:c.429A>G, NM_001347720.1:c.624A>G, XM_017021071.1:c.624A>G, XM_024449506.1:c.429A>G, NM_004086.3:c.429A>G, ENST00000216361.8:c.429A>G, ENST00000396618.7:c.429A>G, ENST00000460581.6:c.93A>G, ENST00000475087.5:c.429A>G, ENST00000553772.5:c.240-974A>G, ENST00000553833.5:n.583A>G, ENST00000555881.5:c.83-974A>G, ENST00000556908.5:c.381A>G, ENST00000557065.1:n.211A>G, NM_004086.2(COCH):c.429A>G (p.Pro143=)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency (the lower threshold of the 95% CI of 44/24026) of the c.429A>G (p.Pro143=) variant in the COCH gene is 0.14% for African chromosomes by gnomAD, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-03-25	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA7143032/MONDO:0019497/005	a9f35732-d723-466d-a748-67465ee0c69d
NM_004086.2(COCH):c.629+5C>T	281981	CA7143097	NM_004086.2:c.629+5C>T, NC_000014.9:g.30880739C>T, CM000676.2:g.30880739C>T, NC_000014.8:g.31349945C>T, CM000676.1:g.31349945C>T, NC_000014.7:g.30419696C>T, NG_008211.2:g.11205C>T, NM_001135058.1:c.629+5C>T, NR_038356.1:n.1617+3771G>A, XM_011536539.1:c.629+5C>T, NM_001347720.1:c.824+5C>T, XM_017021071.1:c.824+5C>T, XM_024449506.1:c.629+5C>T, NM_004086.3:c.629+5C>T, ENST00000216361.8:c.629+5C>T, ENST00000396618.7:c.629+5C>T, ENST00000460581.6:c.293+5C>T, ENST00000468826.2:n.148+5C>T, ENST00000475087.5:c.629+5C>T, ENST00000553772.5:c.*189+5C>T, ENST00000555881.5:c.275+5C>T, ENST00000557065.1:n.411+5C>T, NM_004086.2(COCH):c.629+5C>T	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.629+5C>T variant in the COCH gene is 0.1% for European chromosomes by gnomAD (162/126474 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-02-25	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA7143097/MONDO:0019497/005	3a30f66d-ebfc-4ef5-95fc-fb852e05df8a
NM_004086.2(COCH):c.841G>A (p.Asp281Asn)	226529	CA7143202	NM_004086.2:c.841G>A, NC_000014.9:g.30885501G>A, CM000676.2:g.30885501G>A, NC_000014.8:g.31354707G>A, CM000676.1:g.31354707G>A, NC_000014.7:g.30424458G>A, NG_008211.2:g.15967G>A, NM_001135058.1:c.841G>A, NR_038356.1:n.1364C>T, XM_011536539.1:c.841G>A, NM_001347720.1:c.1036G>A, XM_017021071.1:c.1036G>A, XM_024449506.1:c.898G>A, NM_004086.3:c.841G>A, ENST00000216361.8:c.841G>A, ENST00000396618.7:c.841G>A, ENST00000460581.6:c.505G>A, ENST00000468826.2:n.492G>A, ENST00000475087.5:c.841G>A, ENST00000555881.5:c.487G>A, ENST00000557065.1:n.623G>A, NM_004086.2(COCH):c.841G>A (p.Asp281Asn)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.841G>A (p.Asp281Asn) variant in the COCH gene is 0.5% for African chromosomes by gnomAD (145/24032 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-02-25	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA7143202/MONDO:0019497/005	f0ea27ae-e6f6-4144-a4b0-c916b38ecd23
NM_000441.1(SLC26A4):c.1069G>A (p.Ala357Thr)	43491	CA132654	NM_000441.1:c.1069G>A, NC_000007.14:g.107689120G>A, CM000669.2:g.107689120G>A, NC_000007.13:g.107329565G>A, CM000669.1:g.107329565G>A, NC_000007.12:g.107116801G>A, NG_008489.1:g.33486G>A, ENST00000644269.2:c.1069G>A, ENST00000265715.7:c.1069G>A, XM_005250425.1:c.1069G>A, XM_006716025.2:c.1069G>A, XM_005250425.2:c.1069G>A, XM_006716025.3:c.1069G>A, XM_017012318.1:c.1069G>A, NM_000441.2:c.1069G>A, NM_000441.1(SLC26A4):c.1069G>A (p.Ala357Thr)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Likely Benign	BS1, PP3	BP5, PP2, PM5, PM1, PM2, BP1, BP4, BA1, PS1, PS4	The filtering allele frequency of the c.1069G>A (p.Ala357Thr) variant in the SLC26A4 gene is 0.46% for African/African American chromosomes by gnomAD v4.1.0 (489/1613848 with 95% CI), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (HL VCEP) for autosomal recessive hearing loss variants (BS1). The REVEL computational prediction analysis tool produced a score of 0.849, which is above the threshold necessary to apply PP3. The HL VCEP allows classification of variants as likely benign with only BS1 if no other criteria are in conflict. The HL EP reviewed the conflicting evidence (PP3) and felt it did not override the Likely Benign classification inâ€‹ this case as computational scores are error prone, especially when predicting pathogenicity. In summary, the HL VCEP classified this variant as likely benign. (BS1, PP3; Clingen Hearing Loss VCEP Specifications Version 2; 02/19/2025).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2025-02-19	2025-03-18	false	https://erepo.genome.network/evrepo/ui/classification/CA132654/MONDO:0010134/005	ff136dc4-4d43-4577-beb7-70c08e9c04ab
NM_005422.2(TECTA):c.5836T>C (p.Tyr1946His)	165370	CA178113	NM_005422.2:c.5836T>C, NM_005422.2:n.5836T>C, ENST00000264037.2:n.5836T>C, ENST00000392793.5:c.5836T>C, NC_000011.10:g.121168762T>C, CM000673.2:g.121168762T>C, NC_000011.9:g.121039471T>C, CM000673.1:g.121039471T>C, NC_000011.8:g.120544681T>C, NG_011633.1:g.71097T>C, NM_005422.2(TECTA):c.5836T>C (p.Tyr1946His)	TECTA	nonsyndromic genetic deafness	MONDO:0019497		Likely Benign	BS1, PP3		The filtering allele frequency of the c.5836T>C (p.Tyr1946His) variant in the TECTA gene is 0.495% for Ashkenazi Jewish chromosomes by gnomAD (64/10370 with 95% CI), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (HL EP) for autosomal recessive hearing loss variants (BS1). The REVEL computational prediction analysis tool produced a score of 0.8, which is above the threshold necessary to apply PP3. The HL EP allows classification of variants as likely benign with only BS1 if no other criteria are in conflict. The HL EP reviewed the conflicting evidence (PP3) and felt it did not override the Likely Benign classification in this case since computational scores are error prone, especially when predicting pathogenicity. In summary, the HL EP classified this variant as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1, PP3.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-01-28	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA178113/MONDO:0019497/005	4b0e8b50-666a-4b08-ba95-8bb5daecfb6d
NM_005422.2(TECTA):c.3492C>T (p.Thr1164=)	178539	CA182519	NM_005422.2:c.3492C>T, NM_005422.2:n.3492C>T, ENST00000264037.2:n.3492C>T, ENST00000392793.5:c.3492C>T, NC_000011.10:g.121137971C>T, CM000673.2:g.121137971C>T, NC_000011.9:g.121008680C>T, CM000673.1:g.121008680C>T, NC_000011.8:g.120513890C>T, NG_011633.1:g.40306C>T, NM_005422.2(TECTA):c.3492C>T (p.Thr1164=)	TECTA	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Likely Benign	BS1, BP7, BP4	BS4, BP5, BS2, PP4, PP1, PP3, PM5, PM4, PM1, PM3, PM6, PM2, PVS1, BP3, BP2, BA1, PS1, PS3, PS2, PS4	The filtering allele frequency of the c.3492C>T (p.Thr1164=) variant in the TECTA gene is 0.423% for African chromosomes by gnomAD (123/23960) with 95% CI), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss variants (BS1). The silent p.Thr1164= variant in TECTA is not predicted by MaxEntScan to impact splicing (BP7, BP4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1, BP7, BP4.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-02-13	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA182519/MONDO:0019497/005	204ea045-9b19-4698-b5bd-11e5ab2a89f9
NM_000260.4(MYO7A):c.2476G>A (p.Ala826Thr)	177732	CA180669	NM_000260.4:c.2476G>A, NC_000011.10:g.77179843G>A, CM000673.2:g.77179843G>A, NC_000011.9:g.76890889G>A, CM000673.1:g.76890889G>A, NC_000011.8:g.76568537G>A, NG_009086.1:g.56580G>A, NG_009086.2:g.56598G>A, ENST00000409709.9:c.2476G>A, ENST00000409893.6:n.541G>A, ENST00000670577.1:n.317G>A, ENST00000409619.6:c.2443G>A, ENST00000409709.7:c.2476G>A, ENST00000409893.5:c.2476G>A, ENST00000458169.2:n.19G>A, ENST00000458637.6:c.2476G>A, ENST00000481328.7:n.19G>A, ENST00000620575.4:c.2476G>A, NM_000260.3:c.2476G>A, NM_001127179.2:c.2476G>A, NM_001127180.1:c.2476G>A, XM_005274012.2:c.2476G>A, XM_006718558.2:c.2476G>A, XM_006718559.2:c.2476G>A, XM_006718560.2:c.2476G>A, XM_006718561.2:c.2476G>A, XM_011545044.1:c.2476G>A, XM_011545045.1:c.2476G>A, XM_011545046.1:c.2443G>A, XM_011545047.1:c.2476G>A, XM_011545048.1:c.2368-531G>A, XM_011545049.1:c.2245G>A, XM_011545050.1:c.2218G>A, XM_011545051.1:c.2476G>A, XM_011545052.1:c.2476G>A, XR_949938.1:n.2796G>A, XR_949941.1:n.2796G>A, XR_949942.1:n.2798G>A, XR_949943.1:n.2798G>A, XM_011545044.2:c.2476G>A, XM_011545046.2:c.2566G>A, XM_011545050.2:c.2218G>A, XM_017017778.1:c.2566G>A, XM_017017779.1:c.2566G>A, XM_017017780.1:c.2566G>A, XM_017017781.1:c.2566G>A, XM_017017782.1:c.2566G>A, XM_017017783.1:c.2566G>A, XM_017017784.1:c.2566G>A, XM_017017785.1:c.2335G>A, XM_017017786.1:c.2566G>A, XM_017017787.1:c.2566G>A, XM_017017788.1:c.2566G>A, XR_001747885.1:n.2581G>A, XR_001747886.1:n.2581G>A, XR_001747887.1:n.2581G>A, XR_001747888.1:n.2581G>A, XR_001747889.1:n.2581G>A, NM_001127180.2:c.2476G>A, NM_001369365.1:c.2443G>A, NM_000260.4(MYO7A):c.2476G>A (p.Ala826Thr)	MYO7A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	PP1, PP4, PM3, BA1	BS2, PP3, PM5, BP4, PS1, PS4	The variant NM_000260.4:c.2476G>A in MYO7A is a missense variant predicted to cause substitution of alanine by threonine at amino acid 826 (p.Ala826Thr). The filtering allele frequency of the variant is 0.55% for South Asian chromosomes by gnomAD, including 1 homozygous observation (144/22680 with 95% CI), meeting BA1 criteria. The REVEL computational prediction analysis tool produced a score of 0.54, which meets neither PP3 nor BP4 criteria. This variant has been detected in 2 patients with Usher syndrome in trans with pathogenic variants, and has been observed as homozygous in at least 9 cases (PM3; PMID:27460420, 29490346, 23770805, 22135276, 18181211, 9382091). The evidence originally met PM3_Strong criteria, however was downgraded to PM3 by the VCEP due to the high filtering allele frequency of the variant. The variant has also been reported to segregate with Usher syndrome in at least 12 family members (PP1_Strong; 23770805, 9382091). In most of these cases, the patients were documented to have both hearing loss and retinitis pigmentosa (PP4; PMID:27460420, 29490346, 23770805, 22135276, 9382091). In summary, the variant meets criteria to be classified as uncertain significance for AR Usher syndrome. ACMG/AMP criteria met, as specified by the ClinGen Hearing Loss VCEP: BA1, PM3, PP1_Strong, PP4 (ClinGen Hearing Loss VCEP specifications version 2; 1/18/2023).	9382091, 23770805, 9382091, 23770805, 29490346, 18181211, 27460420, 22135276	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-01-18	2023-02-06	false	https://erepo.genome.network/evrepo/ui/classification/CA180669/MONDO:0019501/005	99eea1cf-9c28-4b80-9057-8f3ed2a98c2c
NM_004004.5(GJB2):c.571T>C (p.Phe191Leu)	44760	CA134989	NM_004004.5:c.571T>C, NC_000013.11:g.20189011A>G, CM000675.2:g.20189011A>G, NC_000013.10:g.20763150A>G, CM000675.1:g.20763150A>G, NC_000013.9:g.19661150A>G, NG_008358.1:g.8965T>C, XM_011535049.1:c.571T>C, XM_011535049.2:c.571T>C, NM_004004.6:c.571T>C, ENST00000382844.1:c.571T>C, ENST00000382848.4:c.571T>C, NM_004004.5(GJB2):c.571T>C (p.Phe191Leu)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PM3_Supporting, PS3_Supporting, PP3, BS2, BS1_Supporting	PS4	The c.571T>C (p.Phe191Leu) variant in GJB2 has been reported in over 19 Asian probands in the literature. However, a case control comparison using Chi-squared analysis did not show a statistical significance between cases and controls in the published studies, or between cases and East Asians in gnomAD (case chromosomes= 19/16415, control chromosomes = 6/8626, 36/18870 East Asian chromosomes in gnomAD; PMIDs 19366456, 15700112, 23826813, 27247933, 27792752, 12792423, 12560944, 19043807, 27627659, 20497192 and https://doi.org/10.1016/S1672-2930(07)50004-8). The filtering allele frequency of the p.Phe191Leu variant in the GJB2 gene is 0.14% for East Asian chromosomes in gnomAD (36/18870 with 95% CI), which is a higher frequency than would be expected for an autosomal recessive pathogenic variant based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (BS1_Supporting). This variant has been detected in 1 individual with hearing loss who was homozygous for the variant, and in 4 compound heterozygous individuals who had a second pathogenic GJB2 variant identified (3 with p.Val37Ile and 1 with c.235delC) (Oguchi 2005 PMID: 15700112; ARUP SCV000603821; Partners Lab for Molecular Medicine SCV000061527). Phase was not confirmed for any of these individuals. It is possible that these homozygous and compound heterozygous observations are due to the relatively high allele frequencies of these variants in gnomAD and therefore PM3 was downgraded (PM3_Supporting). In addition, this variant was reported in the homozygous state in a normal hearing parent (BS2, Wattanasirichiagoon 2004, PMID 15479191). Computational prediction analysis using REVEL suggests that the variant may impact the protein (PP3). Two in vitro functional studies demonstrates that this variant resulted in abnormal protein trafficking and retention of the protein in the endoplasmic reticulum; however, further electrical coupling studies were not performed (PS3_Supporting; PMID: 23967136, 26749107). In summary, due to conflicting evidence, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1_Supporting, BS2, PM3_Supporting, PS3_Supporting, PP3.	15700112, 26749107, 25388846, 23967136, 15479191, 19043807, 16840571, 26178431, 12792423, 20497192, 23826813, 24256046, 19043807, 12560944, 27247933, 27627659, 27792752, 15700112, 19366456, 15790391, 16840571	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-24	2019-07-17	false	https://erepo.genome.network/evrepo/ui/classification/CA134989/MONDO:0019497/005	3d336d40-28c9-4f51-b57c-d5a224b55959
NM_000441.1(SLC26A4):c.-103T>C	4838	CA253314	NM_000441.1:c.-103T>C, NC_000007.14:g.107660756T>C, CM000669.2:g.107660756T>C, NC_000007.13:g.107301201T>C, CM000669.1:g.107301201T>C, NC_000007.12:g.107088437T>C, NG_008489.1:g.5122T>C, ENST00000265715.7:c.-103T>C, NR_028137.1:n.198-550A>G, NM_000441.1(SLC26A4):c.-103T>C	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Uncertain Significance	BS1, PS3_Supporting, PP4, PM3	BS3, BS4, BP5, BP7, PP3, PP2, PP1, BS2, PM4, PM5, PM1, PVS1, PM2, PM6, BA1, BP4, BP1, BP3, BP2, PS1, PS2, PS4	The c.-103T>C (NM_000441.2) variant is a substitution in the 5â€™ UTR of SLC26A4. Because the variant is located in the 5â€™ UTR, it is not expected to alter the amino acid sequence. The highest population minor allele frequency in gnomAD v4.0.0 is 0.3% (262/68066 alleles) in the European (non-Finnish) population, which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (HL EP) for autosomal recessive hearing loss variants (BS1). This variant has been detected in 2 individuals with hearing loss and additional features of Pendred syndrome (enlarged vestibular aqueducts (EVA) and Mondini dysplasia) who were compound heterozygous for the variant and a pathogenic variant with phase confirmed in trans in one individual (PMID: 19204907, 25991456). It has also been identified in two additional compound heterozygous individuals with hearing loss, one with a likely pathogenic and one with a variant of uncertain significance, though phase was not confirmed in either individual (SCV000491274.5). However, due to the allele frequency meeting BS1 criteria, PP4 and PM3 were not applied. There have been many reported heterozygous observations in individuals with EVA/Pendred syndrome (PMID:17503324, 23208854, 23965030, 25991456). Functional studies imply that the variant occurs in a binding site that is a major transcriptional regulatory element of SLC26A4 and is necessary for FOXI1-induced transcriptional activation of SLC26A4 (PMID:25910213, 17503324; PS3_Supporting). Due to conflicting evidence, this variant is classified as a variant of uncertain significance for autosomal recessive Pendred syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: BS1, PS3_P (ClinGen Hearing Loss VCEP specifications version 2; 01/17/2024).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2024-01-17	2024-04-01	false	https://erepo.genome.network/evrepo/ui/classification/CA253314/MONDO:0010134/005	52e44005-97e2-4a07-a71a-1f9957307a4b
NM_004004.6(GJB2):c.109G>A (p.Val37Ile)	17023	CA172210	NM_004004.6:c.109G>A, NC_000013.11:g.20189473C>T, CM000675.2:g.20189473C>T, NC_000013.10:g.20763612C>T, CM000675.1:g.20763612C>T, NC_000013.9:g.19661612C>T, NG_008358.1:g.8503G>A, ENST00000382844.2:c.109G>A, ENST00000382848.5:c.109G>A, ENST00000382844.1:c.109G>A, ENST00000382848.4:c.109G>A, NM_004004.5:c.109G>A, XM_011535049.1:c.109G>A, XM_011535049.2:c.109G>A, NM_004004.6(GJB2):c.109G>A (p.Val37Ile)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PP1_Strong, PM3, PS4	BS4, PP3, BS2, BA1, PS3	The filtering allele frequency (the lower threshold of the 95% CI of 143/1558, including 8 homozygous observations) of the c.109G>A (p.Val37Ile) variant in the GJB2 gene is 7.9% for East Asian genomes in gnomAD.This is a high enough frequency that, in the absence of conflicting data, might warrant a benign classification based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). However, based on the evidence outlined below, the ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs its high allele frequency in population databases. Therefore, the BA1 code will not contribute to the overall classification. The homozygous genotype and compound heterozygous genotype with another variant in GJB2 have shown to be statistically enriched in patients with nonsyndromic sensorineural hearing loss compared to individuals representative of the general population in gnomAD and/or those who underwent carrier screening at Counsyl. (PS4; PMID: 31160754). This study also reported the variant in 139 homozygous affected probands, 17 affected probands with the p.Met34Thr variant in trans, 131 affected probands with a variant asserted to be P/LP in ClinVar, and 78 affected probands with a premature GJB2 termination codon in trans. However, because the variant is also very frequent in the general population, this criteria has been applied at the strength of Moderate. (PM3; PMID: 31160754). The p.Val37Ile variant in GJB2 has been reported to segregate with hearing loss in at least 21 family members (PP1_Strong; PMID: 31160754). Although homozygous or compound heterozygous observations have been identified in individuals with normal hearing, it has been suggested that individuals with the p.Val37Ile variant lose hearing at ~1dB/year, suggesting an age-related penetrance (PMID: 27308839). Furthermore, in dye transfer and electrical coupling assays, both functional studies have shown that the variant impacts protein function (PMID: 26088551, 12505163, 16300957) and knock-in mouse model demonstrated that the p.Val37Ile variant leads to the phenotype. However, because the codon for p.Val37 in mouse (GTG) was different from that in human (GTT), c.109G>A in mouse would translate into p.Val37Met, and the dye transfer and coupling assays have limited validation and correlation with pathogenicity, neither was not counted as functional evidence. (PMID: 27623246). Of note, the severity of hearing loss is known to be mild on average and there have been multiple accounts of incomplete penetrance of the variant in families/individuals with p.Val37Ile in a biallelic genotype. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic genetic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PS4, PP1_Strong, PM3.	31160754, 31160754, 31160754	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-06-24	2025-09-23	false	https://erepo.genome.network/evrepo/ui/classification/CA172210/MONDO:0019497/005	69193dd4-e172-4874-984a-28596f644cae
NM_000277.2(PAH):c.1163T>C (p.Val388Ala)	120260	CA267628	NM_000277.2:c.1163T>C, NC_000012.12:g.102843682A>G, CM000674.2:g.102843682A>G, NC_000012.11:g.103237460A>G, CM000674.1:g.103237460A>G, NC_000012.10:g.101761590A>G, NG_008690.1:g.78921T>C, NG_008690.2:g.119729T>C, NM_000277.1:c.1163T>C, XM_011538422.1:c.1106T>C, NM_001354304.1:c.1163T>C, NM_000277.3:c.1163T>C, ENST00000307000.7:c.1148T>C, ENST00000549247.6:n.922T>C, ENST00000551114.2:n.825T>C, ENST00000553106.5:c.1163T>C, ENST00000635477.1:n.267T>C, ENST00000635528.1:n.678T>C, NM_000277.2(PAH):c.1163T>C (p.Val388Ala)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM2, PP4, PP3	PM3	The c.1163T>C (p.Val388Ala) variant in PAH has been previously reported Likely Pathogenic by one clinical laboratory in ClinVar (see variant ID 120260); the collection method is stated as â€œliterature onlyâ€ and no further information is provided. With respect to the published literature, it has been previously reported in a French proband classified as having mild PKU (defined by the authors as plasma phenylalanine levels between 600-1200uL/L) (PMID: 26666653); formal testing to exclude BH4 deficiency was not noted (PP4). The proband was said to be heterozygous for the variant and also harbor the known pathogenic (per ClinGen PAH working group classification, see ClinVar ID 92731) c.1208C>T (Ala403Val); however, the manuscript did not specify whether the phase of the variants was confirmed via parental testing. Thus, at this point, PM3 cannot be applied with full confidence. The variant results in the substitution of a moderately conserved Valine residue with Alanine, a physiochemically similar amino acid. However, the amino acid substitution is predicted damaging by multiple lines of computational evidence e.g., Predicted deleterious in SIFT, Polyphen2, Mutation Taster. REVEL= 0.919) (PP3). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2). Other missense changes at this Valine residue (Val388) have been previously reported Pathogenic or Likely Pathogenic in ClinVar, e.g., p.Val388Met (Pathogenic per internal PAH ClinGen Working Group classification, ClinVar ID 619), as well as p.Val388Leu (PM5). The c.181A>G (p.Asn61Asp) variant in PAH has been reported in 1 individual with mild PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 12501224). This variant is absent in population databases (PM2). This variant was detected with p.R261Q (Pathogenic/likely pathogenic in ClinVar) (PM3; PMID: 12501224). Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM5, PP3.	26666653	Phenylketonuria VCEP		2019-05-05	2019-07-19	false	https://erepo.genome.network/evrepo/ui/classification/CA267628/MONDO:0009861/006	4a58fdc9-98c8-41a1-90fc-e0e94d381492
NM_000314.6(PTEN):c.370T>C (p.Cys124Arg)	7817	CA000422	NM_000314.6:c.370T>C, NC_000010.11:g.87933129T>C, CM000672.2:g.87933129T>C, NC_000010.10:g.89692886T>C, CM000672.1:g.89692886T>C, NC_000010.9:g.89682866T>C, NG_007466.2:g.74691T>C, LRG_311:g.74691T>C, NM_000314.5:c.370T>C, NM_001304717.2:c.889T>C, NM_001304718.1:c.-381T>C, XM_006717926.2:c.325T>C, XM_011539981.1:c.370T>C, XM_011539982.1:c.274T>C, XR_945789.1:n.1082T>C, XR_945790.1:n.1082T>C, XR_945791.1:n.1082T>C, NM_000314.7:c.370T>C, NM_001304717.5:c.889T>C, NM_001304718.2:c.-381T>C, ENST00000371953.7:c.370T>C, ENST00000498703.1:n.196T>C, ENST00000610634.1:c.268T>C, NM_000314.6(PTEN):c.370T>C (p.Cys124Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PM6_Strong, PS4_Supporting, PM1, PS3	PVS1, BS4, BS1, BS3, BP5, BP7, PP1, PP3, BS2, PM4, PM5, BP2, BP4, BA1, PS1, PS2	PTEN c.370T>C (p.Cys124Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 10866302, PMID 29706350)PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (internal laboratory contributor SCV000568254.4)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (internal laboratory contributor SCV000568254.4)	9467011, 9259288, 10234502, 20194734, 10866302, 29785012, 15987703, 29706350	PTEN VCEP		2019-06-25	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA000422/MONDO:0017623/003	b3d1af7f-63db-40b7-9bb6-1937661a6003
NM_000314.6(PTEN):c.740T>C (p.Leu247Ser)	223142	CA16044135	NM_000314.6:c.740T>C, NC_000010.11:g.87957958T>C, CM000672.2:g.87957958T>C, NC_000010.10:g.89717715T>C, CM000672.1:g.89717715T>C, NC_000010.9:g.89707695T>C, NG_007466.2:g.99520T>C, LRG_311:g.99520T>C, ENST00000686459.1:c.*326T>C, ENST00000688158.1:c.*851T>C, ENST00000688308.1:c.740T>C, ENST00000688922.1:c.661T>C, ENST00000693560.1:c.1259T>C, ENST00000371953.8:c.740T>C, ENST00000371953.7:c.740T>C, ENST00000472832.2:c.167T>C, NM_000314.5:c.740T>C, NM_001304717.2:c.1259T>C, NM_001304718.1:c.149T>C, XM_006717926.2:c.695T>C, XM_011539981.1:c.740T>C, XM_011539982.1:c.644T>C, XR_945791.1:n.1310T>C, NM_000314.7:c.740T>C, NM_001304717.5:c.1259T>C, NM_001304718.2:c.149T>C, NM_000314.8:c.740T>C, NM_000314.8(PTEN):c.740T>C (p.Leu247Ser), NM_000314.6(PTEN):c.740T>C (p.Leu247Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PP2, PP3, PS3_Moderate, PM6_Strong, PM2_Supporting	PVS1, BP5, BP7, BS4, BS1, BS3, PP1, PP4, BS2, PM3, PM5, PM4, PM1, BA1, BP2, BP1, BP4, BP3, PS4, PS1, PS2	PTEN c.740T>C (p.Leu247Ser) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2_Supporting: Absent in large sequenced populations (PMID: 27535533).PM6_Strong: One proband with presumed de novo occurrence (maternity/paternity not confirmed) for a patient with highly specific phenotype. (PMIDs: 28086757 and 29752200)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS3_Moderate: Functional studies showing a damaging effect on protein function. Phosphatase activity â‰¤ -1.11 per Mighell et al. 2018 (PMID: 29706350). This variant: score of -1.669765892.PP3: REVEL score > 0.7 (this variant: score=0.918).	28086757, 28086757	PTEN VCEP		2023-08-04	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA16044135/MONDO:0017623/003	33e47859-5909-4f34-ac6c-c5bf41ab8544
NM_000314.6(PTEN):c.388C>G (p.Arg130Gly)	375958	CA16602437	NM_000314.6:c.388C>G, NC_000010.11:g.87933147C>G, CM000672.2:g.87933147C>G, NC_000010.10:g.89692904C>G, CM000672.1:g.89692904C>G, NC_000010.9:g.89682884C>G, NG_007466.2:g.74709C>G, LRG_311:g.74709C>G, NM_000314.5:c.388C>G, NM_001304717.2:c.907C>G, NM_001304718.1:c.-363C>G, XM_006717926.2:c.343C>G, XM_011539981.1:c.388C>G, XM_011539982.1:c.292C>G, XR_945789.1:n.1100C>G, XR_945790.1:n.1100C>G, XR_945791.1:n.1100C>G, NM_000314.7:c.388C>G, NM_001304717.5:c.907C>G, NM_001304718.2:c.-363C>G, ENST00000371953.7:c.388C>G, ENST00000498703.1:n.214C>G, ENST00000610634.1:c.286C>G, NM_000314.6(PTEN):c.388C>G (p.Arg130Gly)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PM5, PM1, PS3	PM6, PVS1, BP5, BP7, BS4, BS3, BS1, BS2, PP1, PP3, PM4, BP2, BP4, BA1, PS1, PS2, PS4	PTEN c.388C>G (p.Arg130Gly) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 10866302, PMID 21828076, PMID 29706350)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations (PMID 27535533).PM5: Missense change at an amino acid residue where a different missense change determined to be pathogenic or likely pathogenic and with equal or lesser BLOSUM62 score has been seen before (ClinVar Variation ID 7829, SCV000840465.2).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	19457929, 25669429, 20926450, 21659347, 24778394, 29785012, 21828076, 19457929, 10866302, 29706350, 20926450	PTEN VCEP		2019-06-25	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA16602437/MONDO:0017623/003	1ff92475-1a3f-42b2-b733-1515bf2a4e10
NM_000314.6(PTEN):c.477G>T (p.Arg159Ser)	375959	CA16602438	NM_000314.6:c.477G>T, NC_000010.11:g.87933236G>T, CM000672.2:g.87933236G>T, NC_000010.10:g.89692993G>T, CM000672.1:g.89692993G>T, NC_000010.9:g.89682973G>T, NG_007466.2:g.74798G>T, LRG_311:g.74798G>T, ENST00000700029.2:c.477G>T, ENST00000710265.1:c.477G>T, ENST00000472832.3:c.477G>T, ENST00000688158.2:n.1212G>T, ENST00000688922.2:c.*307G>T, ENST00000700021.1:c.432G>T, ENST00000700022.1:c.477G>T, ENST00000700029.1:c.311G>T, ENST00000706954.1:c.477G>T, ENST00000706955.1:c.*512G>T, ENST00000686459.1:c.477G>T, ENST00000688158.1:c.*588G>T, ENST00000688308.1:c.477G>T, ENST00000688922.1:c.398G>T, ENST00000693560.1:c.996G>T, ENST00000371953.8:c.477G>T, ENST00000371953.7:c.477G>T, ENST00000498703.1:n.303G>T, ENST00000610634.1:c.375G>T, NM_000314.5:c.477G>T, NM_001304717.2:c.996G>T, NM_001304718.1:c.-274G>T, XM_006717926.2:c.432G>T, XM_011539981.1:c.477G>T, XM_011539982.1:c.381G>T, XR_945789.1:n.1189G>T, XR_945790.1:n.1189G>T, XR_945791.1:n.1189G>T, NM_000314.7:c.477G>T, NM_001304717.5:c.996G>T, NM_001304718.2:c.-274G>T, NM_000314.8:c.477G>T, NM_000314.6(PTEN):c.477G>T (p.Arg159Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PP3, PS3_Moderate, PM2_Supporting	PM6, PVS1, BP7, BP5, BS1, BS3, BS4, PP1, PP4, BS2, PM4, PM1, PM3, BA1, BP1, BP4, BP3, BP2, PS1, PS4, PS2	PTEN c.477G>T (p.Arg159Ser) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	29706350, 29617666	PTEN VCEP		2025-10-03	2025-10-08	false	https://erepo.genome.network/evrepo/ui/classification/CA16602438/MONDO:0017623/003	6ba47371-001e-4be9-8252-885e7e1a5f99
NM_000314.6(PTEN):c.284C>T (p.Pro95Leu)	189403	CA000383	NM_000314.6:c.284C>T, NC_000010.11:g.87933043C>T, CM000672.2:g.87933043C>T, NC_000010.10:g.89692800C>T, CM000672.1:g.89692800C>T, NC_000010.9:g.89682780C>T, NG_007466.2:g.74605C>T, LRG_311:g.74605C>T, NM_000314.5:c.284C>T, NM_001304717.2:c.803C>T, NM_001304718.1:c.-467C>T, XM_006717926.2:c.239C>T, XM_011539981.1:c.284C>T, XM_011539982.1:c.188C>T, XR_945789.1:n.996C>T, XR_945790.1:n.996C>T, XR_945791.1:n.996C>T, NM_000314.7:c.284C>T, NM_001304717.5:c.803C>T, NM_001304718.2:c.-467C>T, ENST00000371953.7:c.284C>T, ENST00000498703.1:n.110C>T, ENST00000610634.1:c.182C>T, NM_000314.6(PTEN):c.284C>T (p.Pro95Leu)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP2, PS4_Supporting, PS3	PVS1, BS4, BS3, BS1, BP5, BP7, PP1, PP3, BS2, PM1, PM5, PM4, BP2, BP4, BA1, PS1, PS2	PTEN c.284C>T (p.Pro95Leu) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 21828076, PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (internal laboratory contributor ClinVar Organization ID 26957)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (internal laboratory contributor ClinVar Organization ID 26957)	21659347, 25669429, 20600018, 21194675, 28526761, 29706350, 21828076	PTEN VCEP		2019-06-25	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA000383/MONDO:0017623/003	43eee6bc-e0e1-4ce0-8d9a-b838428c1884
NM_000314.6(PTEN):c.545T>C (p.Leu182Ser)	187827	CA000177	NM_000314.6:c.545T>C, NC_000010.11:g.87952170T>C, CM000672.2:g.87952170T>C, NC_000010.10:g.89711927T>C, CM000672.1:g.89711927T>C, NC_000010.9:g.89701907T>C, NG_007466.2:g.93732T>C, LRG_311:g.93732T>C, ENST00000686459.1:c.*131T>C, ENST00000688158.1:c.*656T>C, ENST00000688308.1:c.545T>C, ENST00000688922.1:c.466T>C, ENST00000693560.1:c.1064T>C, ENST00000371953.8:c.545T>C, ENST00000371953.7:c.545T>C, NM_000314.5:c.545T>C, NM_001304717.2:c.1064T>C, NM_001304718.1:c.-47T>C, XM_006717926.2:c.500T>C, XM_011539981.1:c.545T>C, XM_011539982.1:c.449T>C, XR_945789.1:n.1416T>C, XR_945790.1:n.1533T>C, XR_945791.1:n.1205-5683T>C, NM_000314.7:c.545T>C, NM_001304717.5:c.1064T>C, NM_001304718.2:c.-47T>C, NM_000314.8:c.545T>C, NM_000314.8(PTEN):c.545T>C (p.Leu182Ser), NM_000314.6(PTEN):c.545T>C (p.Leu182Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PP3, PM2_Supporting	PVS1, PM6, BP7, BP5, BS1, BS3, BS4, BS2, PP1, PP4, PM5, PM4, PM1, PM3, BP1, BP4, BP3, BP2, BA1, PS1, PS4, PS2	PTEN c.545T>C (p.Leu182Ser) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). Of note, this variant may be disease-causing when present in the homozygous state (PMID: 26443266), but this expert panel curation is based on presence in the heterozygous state.  PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PP3: REVEL score > 0.7 (score of this variant =0.972)	29706350, 26443266, 26443266, 28097321, 21194675	PTEN VCEP		2023-12-01	2023-12-14	false	https://erepo.genome.network/evrepo/ui/classification/CA000177/MONDO:0017623/003	37c0f7de-70de-4f9e-93c7-c0ada6770ecc
NM_000314.8(PTEN):c.1061C>T (p.Pro354Leu)	142212	CA000277	NM_000314.8:c.1061C>T, NC_000010.11:g.87965321C>T, CM000672.2:g.87965321C>T, NC_000010.10:g.89725078C>T, CM000672.1:g.89725078C>T, NC_000010.9:g.89715058C>T, NG_007466.2:g.106883C>T, LRG_311:g.106883C>T, ENST00000686459.1:c.*647C>T, ENST00000688158.1:c.*1172C>T, ENST00000688308.1:c.1061C>T, ENST00000688922.1:c.982C>T, ENST00000693560.1:c.1580C>T, ENST00000371953.8:c.1061C>T, ENST00000371953.7:c.1061C>T, NM_000314.5:c.1061C>T, NM_000314.6:c.1061C>T, NM_001304717.2:c.1580C>T, NM_001304718.1:c.470C>T, XM_006717926.2:c.1016C>T, XM_011539982.1:c.965C>T, XR_945791.1:n.1631C>T, NM_000314.7:c.1061C>T, NM_001304717.5:c.1580C>T, NM_001304718.2:c.470C>T, NM_000314.8(PTEN):c.1061C>T (p.Pro354Leu)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PM2_Supporting, BS3_Supporting, BP4	PM6, PVS1, BP7, BP5, BS1, BS4, PP3, PP1, PP4, BS2, PM4, PM5, PM1, PM3, BA1, BP3, BP1, BP2, PS1, PS3, PS4, PS2	PTEN c.1061C>T (p.Pro354Leu) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2_P: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: Well-established functional studies show no deleterious effect: Phosphatase activity >0 (score = 0.1615) per Mighell et al. 2018 (PMID: 29706350).BP4: REVEL score < 0.5 (score=0.402)Using the Bayesian point system (PMID: 29300386) for this variant with conflicting evidence: 2 benign supporting and 2 pathogenic supporting codes get -1*2 + 1*2 points, total is 0 (VUS).	21869887	PTEN VCEP		2023-10-11	2023-10-16	false	https://erepo.genome.network/evrepo/ui/classification/CA000277/MONDO:0017623/003	88bdf077-351e-40ca-bbdf-1299b17f80e5
NM_000314.4(PTEN):c.1078A>G (p.Ser360Gly)	140777	CA000286	NM_000314.4:c.1078A>G, NC_000010.11:g.87965338A>G, CM000672.2:g.87965338A>G, NC_000010.10:g.89725095A>G, CM000672.1:g.89725095A>G, NC_000010.9:g.89715075A>G, NG_007466.2:g.106900A>G, LRG_311:g.106900A>G, ENST00000686459.1:c.*664A>G, ENST00000688158.1:c.*1189A>G, ENST00000688308.1:c.1078A>G, ENST00000688922.1:c.999A>G, ENST00000693560.1:c.1597A>G, ENST00000371953.8:c.1078A>G, ENST00000371953.7:c.1078A>G, NM_000314.5:c.1078A>G, NM_000314.6:c.1078A>G, NM_001304717.2:c.1597A>G, NM_001304718.1:c.487A>G, XM_006717926.2:c.1033A>G, XM_011539982.1:c.982A>G, XR_945791.1:n.1648A>G, NM_000314.7:c.1078A>G, NM_001304717.5:c.1597A>G, NM_001304718.2:c.487A>G, NM_000314.8:c.1078A>G, NM_000314.8(PTEN):c.1078A>G (p.Ser360Gly), NM_000314.4(PTEN):c.1078A>G (p.Ser360Gly)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	PP2, BS1_Supporting, BP4	PM6, PVS1, BP7, BP5, BS3, BS4, PP3, PP1, PP4, BS2, PM4, PM5, PM1, PM3, BA1, BP3, BP1, BP2, PS1, PS3, PS2, PS4	NM_000314.8(PTEN):c.1078A>G (p.Ser360Gly) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS1_P: To be applied for variants with filtering allele frequency of 0.0000043 up to 0.000043 (0.00043% up to 0.0043%) in gnomAD. Popmax FAF of this variant=0.00001171.BP4: REVEL score < 0.5 (score of this variant=0.441).Using the Bayesian point system (PMID: 29300386) for this variant with conflicting evidence: 2 benign supporting and 1 pathogenic supporting codes get (-1*2) + 1 points; total is â€“1 (likely benign).		PTEN VCEP		2023-10-11	2023-10-16	false	https://erepo.genome.network/evrepo/ui/classification/CA000286/MONDO:0017623/003	7447cf4b-3a7e-436e-94f3-5cbeb5f20d28
NM_000314.7(PTEN):c.1093G>A (p.Val365Ile)	237639	CA059160	NM_000314.7:c.1093G>A, NC_000010.11:g.87965353G>A, CM000672.2:g.87965353G>A, NC_000010.10:g.89725110G>A, CM000672.1:g.89725110G>A, NC_000010.9:g.89715090G>A, NG_007466.2:g.106915G>A, LRG_311:g.106915G>A, ENST00000686459.1:c.*679G>A, ENST00000688158.1:c.*1204G>A, ENST00000688308.1:c.1093G>A, ENST00000688922.1:c.1014G>A, ENST00000693560.1:c.1612G>A, ENST00000371953.8:c.1093G>A, ENST00000371953.7:c.1093G>A, NM_000314.5:c.1093G>A, NM_000314.6:c.1093G>A, NM_001304717.2:c.1612G>A, NM_001304718.1:c.502G>A, XM_006717926.2:c.1048G>A, XM_011539982.1:c.997G>A, XR_945791.1:n.1663G>A, NM_001304717.5:c.1612G>A, NM_001304718.2:c.502G>A, NM_000314.8:c.1093G>A, NM_000314.8(PTEN):c.1093G>A (p.Val365Ile), NM_000314.7(PTEN):c.1093G>A (p.Val365Ile)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PM2_Supporting, BP4	PVS1, PM6, BP7, BP5, BS1, BS3, BS4, BS2, PP3, PP1, PP4, PM4, PM5, PM1, PM3, BP3, BP1, BP2, BA1, PS1, PS3, PS4, PS2	PTEN c.1093G>A (p.Val365Ile) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BP4: REVEL score < 0.5 (score=0.441)Using the Bayesian point system (PMID: 29300386) for this variant with conflicting evidence: 1 benign supporting and 2 pathogenic supporting codes get -1 + (1*2) points; total is 1 (VUS).		PTEN VCEP		2023-12-01	2023-12-14	false	https://erepo.genome.network/evrepo/ui/classification/CA059160/MONDO:0017623/003	1ebd3f87-9825-4ccc-aa05-14d1b0b78d24
NM_000314.6(PTEN):c.841C>G (p.Pro281Ala)	184466	CA000211	NM_000314.6:c.841C>G, NC_000010.11:g.87960933C>G, CM000672.2:g.87960933C>G, NC_000010.10:g.89720690C>G, CM000672.1:g.89720690C>G, NC_000010.9:g.89710670C>G, NG_007466.2:g.102495C>G, LRG_311:g.102495C>G, ENST00000686459.1:c.*427C>G, ENST00000688158.1:c.*952C>G, ENST00000688308.1:c.841C>G, ENST00000688922.1:c.762C>G, ENST00000693560.1:c.1360C>G, ENST00000371953.8:c.841C>G, ENST00000371953.7:c.841C>G, ENST00000472832.2:c.268C>G, NM_000314.5:c.841C>G, NM_001304717.2:c.1360C>G, NM_001304718.1:c.250C>G, XM_006717926.2:c.796C>G, XM_011539981.1:c.841C>G, XM_011539982.1:c.745C>G, XR_945791.1:n.1411C>G, NM_000314.7:c.841C>G, NM_001304717.5:c.1360C>G, NM_001304718.2:c.250C>G, NM_000314.8:c.841C>G, NM_000314.8(PTEN):c.841C>G (p.Pro281Ala), NM_000314.6(PTEN):c.841C>G (p.Pro281Ala)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PVS1, PM6, PP3, PP1, PP4, BS2, PM5, PM4, PM1, PM3, BA1, BP1, BP4, BP3, BP2, PS1, PS3, PS4, PS2	NM_000314.8(PTEN):c.841C>G (p.Pro281Ala) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	29785012, 29706350, 29785012, 29706350, 29945567	PTEN VCEP		2023-10-11	2023-10-18	false	https://erepo.genome.network/evrepo/ui/classification/CA000211/MONDO:0017623/003	74ec7748-2294-4f8c-a299-53b2a9c51d35
NM_000314.6(PTEN):c.634+5G>C	427623	CA645509438	NM_000314.6:c.634+5G>C, NC_000010.11:g.87952264G>C, CM000672.2:g.87952264G>C, NC_000010.10:g.89712021G>C, CM000672.1:g.89712021G>C, NC_000010.9:g.89702001G>C, NG_007466.2:g.93826G>C, LRG_311:g.93826G>C, ENST00000686459.1:c.*220+5G>C, ENST00000688158.1:c.*745+5G>C, ENST00000688308.1:c.634+5G>C, ENST00000688922.1:c.555+5G>C, ENST00000693560.1:c.1153+5G>C, ENST00000371953.8:c.634+5G>C, ENST00000371953.7:c.634+5G>C, ENST00000472832.2:c.61+5G>C, NM_000314.5:c.634+5G>C, NM_001304717.2:c.1153+5G>C, NM_001304718.1:c.43+5G>C, XM_006717926.2:c.589+5G>C, XM_011539981.1:c.634+5G>C, XM_011539982.1:c.538+5G>C, XR_945791.1:n.1205-5589G>C, NM_000314.7:c.634+5G>C, NM_001304717.5:c.1153+5G>C, NM_001304718.2:c.43+5G>C, NM_000314.8:c.634+5G>C, NM_000314.8(PTEN):c.634+5G>C, NM_000314.6(PTEN):c.634+5G>C	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PS4_Supporting, PM2_Supporting, PS1, PS3	PVS1, PM6, BP7, BP5, BS1, BS3, BS4, BS2, PP2, PP3, PP1, PP4, PM5, PM4, PM1, PM3, BP1, BP4, BP3, BP2, BA1, PS2	PTEN c.634+5G>C (IVS6+5G>C) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS1: different variant at same nucleotide position as a pathogenic splicing variant, where in silico models predict impact equal to or greater than the known pathogenic variant. PS3: RNA, mini-gene, or other assay shows impact on splicing. (PMID 28677221).PM2_P: Absent in gnomAD (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 28677221).	21659347, 28677221, 28677221	PTEN VCEP		2023-12-01	2023-12-18	false	https://erepo.genome.network/evrepo/ui/classification/CA645509438/MONDO:0017623/003	bb8a0b6c-784c-4603-88f5-dc7102811034
NM_000314.6(PTEN):c.-975G>C	127685	CA000654	NM_000314.6:c.-975G>C, NC_000010.11:g.87863494G>C, CM000672.2:g.87863494G>C, NC_000010.10:g.89623251G>C, CM000672.1:g.89623251G>C, NC_000010.9:g.89613231G>C, NG_007466.2:g.5057G>C, LRG_311:g.5057G>C, NG_033079.1:g.4944C>G, NM_000314.5:c.-975G>C, NM_001304717.2:c.-456G>C, NM_001304718.1:c.-1680G>C, ENST00000371953.7:c.-976G>C, ENST00000610634.1:c.-1078G>C, NM_000314.6(PTEN):c.-975G>C	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP5, BS1	PVS1, PM6, PM2, BP7, BS4, BS3, PP1, PP3, PP2, BS2, PM5, PM1, PM4, BP2, BP4, BA1, PS1, PS2, PS4, PS3	PTEN c.-975G>C (g.89623251G>C) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.006 (0.6%, 21/3466 alleles) in the European (Finnish) subpopulation and 0.002 (0.2%, 30/14,976) in the European (Non-Finnish) subpopulation of the gnomAD cohort. (PMID 27535533)BP5: Variant found in multiple cases with alternate molecular basis for disease. (internal laboratory contributors SCV000187238.1, SCV000149489.5)	22171747, 22171747	PTEN VCEP		2019-06-25	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA000654/MONDO:0017623/003	d5ebdbde-0541-439f-8bbb-2234f7aa3636
NM_000314.6(PTEN):c.320A>T (p.Asp107Val)	372481	CA16042748	NM_000314.6:c.320A>T, NC_000010.11:g.87933079A>T, CM000672.2:g.87933079A>T, NC_000010.10:g.89692836A>T, CM000672.1:g.89692836A>T, NC_000010.9:g.89682816A>T, NG_007466.2:g.74641A>T, LRG_311:g.74641A>T, NM_000314.5:c.320A>T, NM_001304717.2:c.839A>T, NM_001304718.1:c.-431A>T, XM_006717926.2:c.275A>T, XM_011539981.1:c.320A>T, XM_011539982.1:c.224A>T, XR_945789.1:n.1032A>T, XR_945790.1:n.1032A>T, XR_945791.1:n.1032A>T, NM_000314.7:c.320A>T, NM_001304717.5:c.839A>T, NM_001304718.2:c.-431A>T, ENST00000371953.7:c.320A>T, ENST00000498703.1:n.146A>T, ENST00000610634.1:c.218A>T, NM_000314.6(PTEN):c.320A>T (p.Asp107Val)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PP1, PS4_Moderate, PS3	PVS1, BP7, BP5, BS1, BS4, BS3, PP3, BS2, PM5, PM4, PM1, BA1, BP4, BP2, PS1, PS2	PTEN c.320A>T (p.Asp107Val) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type. (PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 25418537)PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 28526761, PMID 23886400, internal laboratory contributor SCV000490750.2)PP1: Co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed. (PMID 28526761, PMID 23886400, internal laboratory contributor SCV000490750.2)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	25418537, 28526761, 23886400, 28526761, 23886400, 28526761, 23886400, 25418537, 29785012, 29706350, 25418537	PTEN VCEP		2019-06-25	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA16042748/MONDO:0017623/003	af7069ee-474b-491e-9317-5e91eeba5b76
NM_000314.6(PTEN):c.1027-1G>A	372482	CA16042723	NM_000314.6:c.1027-1G>A, NC_000010.11:g.87965286G>A, CM000672.2:g.87965286G>A, NC_000010.10:g.89725043G>A, CM000672.1:g.89725043G>A, NC_000010.9:g.89715023G>A, NG_007466.2:g.106848G>A, LRG_311:g.106848G>A, NM_000314.5:c.1027-1G>A, NM_001304717.2:c.1546-1G>A, NM_001304718.1:c.436-1G>A, XM_006717926.2:c.982-1G>A, XM_011539982.1:c.931-1G>A, XR_945791.1:n.1597-1G>A, NM_000314.7:c.1027-1G>A, NM_001304717.5:c.1546-1G>A, NM_001304718.2:c.436-1G>A, ENST00000371953.7:c.1027-1G>A, NM_000314.6(PTEN):c.1027-1G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PVS1	BP5, BP7, BS4, BS3, BS1, BS2, PP1, PP2, PM1, PM4, PM5, BP2, BP4, BA1, PS3, PS4, PS1, PS2	PTEN c.1027-1G>A (IVS8-1G>A) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (Internal laboratory contributor SCV000490754.2)	20962022, 20962022, 27477328, 20962022	PTEN VCEP		2019-06-25	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA16042723/MONDO:0017623/003	1efc38fb-30b6-43c9-b8d5-0f1836b4fb0e
NM_000314.6(PTEN):c.700C>T (p.Arg234Trp)	184844	CA000183	NM_000314.6:c.700C>T, NC_000010.11:g.87957918C>T, CM000672.2:g.87957918C>T, NC_000010.10:g.89717675C>T, CM000672.1:g.89717675C>T, NC_000010.9:g.89707655C>T, NG_007466.2:g.99480C>T, LRG_311:g.99480C>T, ENST00000686459.1:c.*286C>T, ENST00000688158.1:c.*811C>T, ENST00000688308.1:c.700C>T, ENST00000688922.1:c.621C>T, ENST00000693560.1:c.1219C>T, ENST00000371953.8:c.700C>T, ENST00000371953.7:c.700C>T, ENST00000472832.2:c.127C>T, NM_000314.5:c.700C>T, NM_001304717.2:c.1219C>T, NM_001304718.1:c.109C>T, XM_006717926.2:c.655C>T, XM_011539981.1:c.700C>T, XM_011539982.1:c.604C>T, XR_945791.1:n.1270C>T, NM_000314.7:c.700C>T, NM_001304717.5:c.1219C>T, NM_001304718.2:c.109C>T, NM_000314.8:c.700C>T, NM_000314.8(PTEN):c.700C>T (p.Arg234Trp), NM_000314.6(PTEN):c.700C>T (p.Arg234Trp)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PM2_Supporting, BS3_Supporting	BP7, BP5, BS1, BS4, PM6, PVS1, PP3, PP1, BS2, PM4, PM1, PM3, PM5, BP1, BP4, BP3, BP2, BA1, PS3, PS4, PS2, PS1	NM_000314.8(PTEN):c.700C>T (p.Arg234Trp) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: Functional studies showing no damaging effect on protein function. Score of this variant = 0.106334511 (>0, WT-like range) on high throughput phosphatase assay (PMID:29706350).Using the Bayesian point system (PMID: 29300386) for this variant with conflicting evidence: 1 benign supporting and 2 pathogenic supporting codes get -1 + (1*2) points; total is 1 (Uncertain significance).	30039884	PTEN VCEP		2023-10-11	2023-10-16	false	https://erepo.genome.network/evrepo/ui/classification/CA000183/MONDO:0017623/003	45c8d19e-5bfc-4e2d-bc35-187033466d5d
NM_000314.6(PTEN):c.-1195_-1184delAAGCCGCAGCAA	189433	CA163819	NC_000010.11:g.87863274_87863285del, CM000672.2:g.87863274_87863285del, NC_000010.10:g.89623031_89623042del, CM000672.1:g.89623031_89623042del, NC_000010.9:g.89613011_89613022del, NG_007466.2:g.4837_4848del, LRG_311:g.4837_4848del, NG_033079.1:g.5157_5168del, ENST00000706954.1:c.-17+632_-17+643del, ENST00000688308.1:c.-17+161_-17+172del, ENST00000445946.5:c.-794_-783del, ENST00000371953.7:c.-1196_-1185del, ENST00000445946.3:c.-794_-783del, NM_001126049.1:c.-794_-783del, NM_001126049.2:c.-794_-783del, NM_000314.6(PTEN):c.-1195_-1184delAAGCCGCAGCAA	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS4_Supporting, BP5	PM2, PM6, PVS1, BP7, BS1, BS3, PP2, PP3, PP1, BS2, PM4, PM1, PM3, PM5, BA1, BP1, BP4, BP3, BP2, PS4, PS2, PS3, PS1	PTEN c.-1195del12 (NC_000010.10:g.89623031_89623042delAAGCCGCAGCAA) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS4_P: Lack of segregation in affected members of one family. (Internal laboratory contributor SCV SCV000222146.7)BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributors SCV000222146.7, SCV000183826.5)	21532617, 28495237, 28821472, 28157521, 21532617, 25669429, 21194675, 21532617	PTEN VCEP		2019-03-05	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA163819/MONDO:0017623/003	a4de2dba-9fd0-4e69-a9e5-2e6d4ec56af5
NM_000314.6(PTEN):c.698G>A (p.Arg233Gln)	376510	CA060404	NM_000314.6:c.698G>A, NC_000010.11:g.87957916G>A, CM000672.2:g.87957916G>A, NC_000010.10:g.89717673G>A, CM000672.1:g.89717673G>A, NC_000010.9:g.89707653G>A, NG_007466.2:g.99478G>A, LRG_311:g.99478G>A, ENST00000686459.1:c.*284G>A, ENST00000688158.1:c.*809G>A, ENST00000688308.1:c.698G>A, ENST00000688922.1:c.619G>A, ENST00000693560.1:c.1217G>A, ENST00000371953.8:c.698G>A, ENST00000371953.7:c.698G>A, ENST00000472832.2:c.125G>A, NM_000314.5:c.698G>A, NM_001304717.2:c.1217G>A, NM_001304718.1:c.107G>A, XM_006717926.2:c.653G>A, XM_011539981.1:c.698G>A, XM_011539982.1:c.602G>A, XR_945791.1:n.1268G>A, NM_000314.7:c.698G>A, NM_001304717.5:c.1217G>A, NM_001304718.2:c.107G>A, NM_000314.8:c.698G>A, NM_000314.8(PTEN):c.698G>A (p.Arg233Gln), NM_000314.6(PTEN):c.698G>A (p.Arg233Gln)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PM2_Supporting, BS3_Supporting	BP7, BP5, BS1, BS4, PM6, PVS1, PP3, PP1, BS2, PM5, PM4, PM1, PM3, BA1, BP1, BP4, BP3, BP2, PS1, PS3, PS4, PS2	PTEN c.698G>A (p.R233Q) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2_P: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: Well-established functional studies show no deleterious effect: Phosphatase activity >0 (score of this variant = 0.11604447) per Mighell et al. 2018 (PMID: 29706350).Using the Bayesian point system (PMID: 29300386) for this variant with conflicting evidence: 1 benign supporting and 2 pathogenic supporting codes get -1 + 1*2 points; total is 1 (Uncertain significance).	29706350, 27147599	PTEN VCEP		2023-10-11	2023-10-16	false	https://erepo.genome.network/evrepo/ui/classification/CA060404/MONDO:0017623/003	84ca1fb2-bf36-42c2-8262-5a470ed8dfa7
NM_000314.6(PTEN):c.210-7_210-3del5	142397	CA059460	NM_000314.6:c.210-7_210-3delCTTTT, NM_000314.6:c.210-7_210-3del, NC_000010.11:g.87931039_87931043del, CM000672.2:g.87931039_87931043del, NC_000010.10:g.89690796_89690800del, CM000672.1:g.89690796_89690800del, NC_000010.9:g.89680776_89680780del, NG_007466.2:g.72601_72605del, LRG_311:g.72601_72605del, NM_000314.5:c.210-7_210-3del, NM_001304717.2:c.729-7_729-3del, NM_001304718.1:c.-541-7_-541-3del, XM_006717926.2:c.165-7_165-3del, XM_011539981.1:c.210-7_210-3del, XM_011539982.1:c.114-7_114-3del, XR_945789.1:n.922-7_922-3del, XR_945790.1:n.922-7_922-3del, XR_945791.1:n.922-7_922-3del, NM_000314.7:c.210-7_210-3del, NM_001304717.5:c.729-7_729-3del, NM_001304718.2:c.-541-7_-541-3del, ENST00000371953.7:c.210-7_210-3del, ENST00000498703.1:n.36-7_36-3del, ENST00000610634.1:c.108-7_108-3del, NM_000314.6(PTEN):c.210-7_210-3del5	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BS3, BS1	PVS1, PM6, PM2, BS4, BP5, BP7, PP1, PP3, PP2, BS2, PM1, PM4, PM5, BP2, BP4, BA1, PS3, PS2, PS4, PS1	PTEN c.210-7_210-3delCTTTT (IVS3-7_IVS3-3delCTTTT) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.00136 (0.14%, 14/10,306 alleles) in the Ashkenazi Jewish subpopulation of the gnomAD cohort. (PMID 27535533) BS3: Intronic OR synonymous variant with RNA, mini-gene, or other splicing assay demonstrating no splicing impact. (PMID 28677221)	28677221, 27443514, 21659347, 25669429, 11156385, 28677221, 29360161, 27978560, 15589575, 25186627, 22261759, 26976419, 22995991, 16287957	PTEN VCEP		2019-03-05	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA059460/MONDO:0017623/003	48b4a5b9-e1c5-421f-b71f-26b8643652bc
NM_000314.8(PTEN):c.338G>T (p.Ser113Ile)	139567	CA000405	NM_000314.8:c.338G>T, NC_000010.11:g.87933097G>T, CM000672.2:g.87933097G>T, NC_000010.10:g.89692854G>T, CM000672.1:g.89692854G>T, NC_000010.9:g.89682834G>T, NG_007466.2:g.74659G>T, LRG_311:g.74659G>T, ENST00000686459.1:c.338G>T, ENST00000688158.1:c.*449G>T, ENST00000688308.1:c.338G>T, ENST00000688922.1:c.259G>T, ENST00000693560.1:c.857G>T, ENST00000371953.8:c.338G>T, ENST00000371953.7:c.338G>T, ENST00000498703.1:n.164G>T, ENST00000610634.1:c.236G>T, NM_000314.5:c.338G>T, NM_000314.6:c.338G>T, NM_001304717.2:c.857G>T, NM_001304718.1:c.-413G>T, XM_006717926.2:c.293G>T, XM_011539981.1:c.338G>T, XM_011539982.1:c.242G>T, XR_945789.1:n.1050G>T, XR_945790.1:n.1050G>T, XR_945791.1:n.1050G>T, NM_000314.7:c.338G>T, NM_001304717.5:c.857G>T, NM_001304718.2:c.-413G>T, NM_000314.8(PTEN):c.338G>T (p.Ser113Ile)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PP3, PM2_Supporting, BS3_Supporting	PM6, PVS1, BS1, BS4, BP7, BP5, BS2, PP1, PM5, PM4, PM1, PM3, BA1, BP1, BP4, BP3, BP2, PS1, PS3, PS4, PS2	PTEN c.338G>T (p.S113I) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PP3: REVEL score > 0.7 (this variant: score=0.797)BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	29706350, 25248401	PTEN VCEP		2023-08-04	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000405/MONDO:0017623/003	f5fca852-9b72-4798-a482-88fe3941f654
NM_000314.6(PTEN):c.195C>G (p.Tyr65Ter)	237643	CA10582757	NM_000314.6:c.195C>G, NC_000010.11:g.87925543C>G, CM000672.2:g.87925543C>G, NC_000010.10:g.89685300C>G, CM000672.1:g.89685300C>G, NC_000010.9:g.89675280C>G, NG_007466.2:g.67105C>G, LRG_311:g.67105C>G, NM_000314.5:c.195C>G, NM_001304717.2:c.714C>G, NM_001304718.1:c.-541-5503C>G, XM_006717926.2:c.165-5503C>G, XM_011539981.1:c.195C>G, XM_011539982.1:c.99C>G, XR_945789.1:n.907C>G, XR_945790.1:n.907C>G, XR_945791.1:n.907C>G, NM_000314.7:c.195C>G, NM_001304717.5:c.714C>G, NM_001304718.2:c.-541-5503C>G, ENST00000371953.7:c.195C>G, ENST00000498703.1:n.21C>G, ENST00000610634.1:c.93C>G, NM_000314.6(PTEN):c.195C>G (p.Tyr65Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1, PM2, PS4_Supporting	PM6, BS4, BS3, BS1, BP5, BP7, BS2, PP1, PP3, PP2, PM1, PM5, PM4, BP2, BP4, BA1, PS2, PS1	PTEN c.195C>G (p.Y65X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 23335809)	29785012, 29706350, 21194675, 28454995, 23335809	PTEN VCEP		2019-03-05	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA10582757/MONDO:0017623/003	994ade45-e2c0-40c5-9bb6-a646666f386c
NM_000314.6(PTEN):c.507delC (p.Ser170Valfs)	7843	CA000490	NM_000314.6:c.507delC, NC_000010.11:g.87952132del, CM000672.2:g.87952132del, NC_000010.10:g.89711889del, CM000672.1:g.89711889del, NC_000010.9:g.89701869del, NG_007466.2:g.93694del, LRG_311:g.93694del, NM_000314.5:c.507del, NM_000314.6:c.507del, NM_001304717.2:c.1026del, NM_001304718.1:c.-85del, XM_006717926.2:c.462del, XM_011539981.1:c.507del, XM_011539982.1:c.411del, XR_945789.1:n.1378del, XR_945790.1:n.1495del, XR_945791.1:n.1205-5721del, NM_000314.7:c.507del, NM_001304717.5:c.1026del, NM_001304718.2:c.-85del, ENST00000371953.7:c.507del, NM_000314.6(PTEN):c.507delC (p.Ser170Valfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1, PM6, PM2, PS4	BS4, BS3, BS1, BP5, BP7, BS2, PP1, PP2, PP3, PM1, PM4, PM5, BP2, BP4, BA1, PS2, PS3, PS1	PTEN c.507delC (p.Ser170Valfs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 12471211)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 12471211)	12471211, 12938083, 12471211, 12938083, 12471211	PTEN VCEP		2018-07-25	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA000490/MONDO:0017623/003	cda272e6-a64d-4303-8640-80c038c51db1
NM_000314.8(PTEN):c.441_442delinsA (p.Ala148fs)	428216	CA645369482	NM_000314.8:c.441_442delinsA, NC_000010.11:g.87933200_87933201delinsA, CM000672.2:g.87933200_87933201delinsA, NC_000010.10:g.89692957_89692958delinsA, CM000672.1:g.89692957_89692958delinsA, NC_000010.9:g.89682937_89682938delinsA, NG_007466.2:g.74762_74763delinsA, LRG_311:g.74762_74763delinsA, ENST00000686459.1:c.441_442delinsA, ENST00000688158.1:c.*552_*553delinsA, ENST00000688308.1:c.441_442delinsA, ENST00000688922.1:c.362_363delinsA, ENST00000693560.1:c.960_961delinsA, ENST00000371953.8:c.441_442delinsA, ENST00000371953.7:c.441_442delinsA, ENST00000498703.1:n.267_268delinsA, ENST00000610634.1:c.339_340delinsA, NM_000314.5:c.441_442delinsA, NM_000314.6:c.441_442delinsA, NM_001304717.2:c.960_961delinsA, NM_001304718.1:c.-310_-309delinsA, XM_006717926.2:c.396_397delinsA, XM_011539981.1:c.441_442delinsA, XM_011539982.1:c.345_346delinsA, XR_945789.1:n.1153_1154delinsA, XR_945790.1:n.1153_1154delinsA, XR_945791.1:n.1153_1154delinsA, NM_000314.7:c.441_442delinsA, NM_001304717.5:c.960_961delinsA, NM_001304718.2:c.-310_-309delinsA, NM_000314.8(PTEN):c.441_442delinsA (p.Ala148fs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1, PM2_Supporting	PM6, BS1, BS3, BS4, BP7, BP5, BS2, PP3, PP2, PP1, PP4, PM5, PM4, PM1, PM3, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	NM_000314.8(PTEN):c.441_442delinsA (p.Ala148HisfsTer5) variant meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.8). PM2_P: Absent in large sequenced populations in the gnomAD cohort (PMID:27535533).	10400993, 22261759, 27477328, 25669429	PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA645369482/MONDO:0017623/003	6c80a1d5-39c5-49ee-915e-3b6840f8d492
NM_000314.8(PTEN):c.-862G>T	7845	CA000612	NM_000314.8:c.-862G>T, NC_000010.11:g.87863608G>T, CM000672.2:g.87863608G>T, NC_000010.10:g.89623365G>T, CM000672.1:g.89623365G>T, NC_000010.9:g.89613345G>T, NG_007466.2:g.5171G>T, LRG_311:g.5171G>T, NG_033079.1:g.4830C>A, ENST00000706954.1:c.-16-846G>T, ENST00000688308.1:c.-17+495G>T, ENST00000692337.1:c.50G>T, ENST00000693560.1:c.-342G>T, ENST00000371953.7:c.-862G>T, ENST00000610634.1:c.-964G>T, NM_000314.5:c.-861G>T, NM_000314.6:c.-861G>T, NM_001304717.2:c.-342G>T, NM_001304718.1:c.-1566G>T, NM_000314.8(PTEN):c.-862G>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2_Supporting	PVS1, PM6, BP7, BP5, BS3, BS1, BS4, PP3, PP2, PP1, PP4, BS2, PM5, PM4, PM1, PM3, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS4, PS2	PTEN c.-861G>T (NC_000010.10:g.89623365G>T) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).	17847000, 17847000	PTEN VCEP		2025-06-06	2025-10-08	false	https://erepo.genome.network/evrepo/ui/classification/CA000612/MONDO:0017623/003	b7d1c7bd-f00c-4e8d-a6a5-e83fed03f5df
NM_000314.6(PTEN):c.512dup (p.Arg172Glufs)	428206	CA645369422	NM_000314.6:c.512dup, NC_000010.11:g.87952137dup, CM000672.2:g.87952137dup, NC_000010.10:g.89711894dup, CM000672.1:g.89711894dup, NC_000010.9:g.89701874dup, NG_007466.2:g.93699dup, LRG_311:g.93699dup, NM_000314.5:c.512dup, NM_001304717.2:c.1031dup, NM_001304718.1:c.-80dup, XM_006717926.2:c.467dup, XM_011539981.1:c.512dup, XM_011539982.1:c.416dup, XR_945789.1:n.1383dup, XR_945790.1:n.1500dup, XR_945791.1:n.1205-5716dup, NM_000314.7:c.512dup, NM_001304717.5:c.1031dup, NM_001304718.2:c.-80dup, ENST00000371953.7:c.512dup, NM_000314.6(PTEN):c.512dup (p.Arg172Glufs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1, PM2, PS4_Supporting	PM6, BS4, BS3, BS1, BP5, BP7, BS2, PP1, PP3, PP2, PM1, PM4, PM5, BP2, BP4, BA1, PS2, PS3, PS1	PTEN c.512dup (p.R172Efs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 17526801)	17526801, 21659347, 20962022, 21194675, 21956414, 22261759, 20600018, 25669429, 21190448, 27477328	PTEN VCEP		2019-03-05	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA645369422/MONDO:0017623/003	df053db0-9ad9-48ee-aea1-550cda8b3586
NM_000314.6(PTEN):c.104T>G (p.Met35Arg)	7825	CA000268	NM_000314.6:c.104T>G, NC_000010.11:g.87894049T>G, CM000672.2:g.87894049T>G, NC_000010.10:g.89653806T>G, CM000672.1:g.89653806T>G, NC_000010.9:g.89643786T>G, NG_007466.2:g.35611T>G, LRG_311:g.35611T>G, NM_000314.5:c.104T>G, NM_001304717.2:c.623T>G, NM_001304718.1:c.-602T>G, XM_006717926.2:c.104T>G, XM_011539981.1:c.104T>G, XM_011539982.1:c.68+13611T>G, XR_945789.1:n.816T>G, XR_945790.1:n.816T>G, XR_945791.1:n.816T>G, NM_000314.7:c.104T>G, NM_001304717.5:c.623T>G, NM_001304718.2:c.-602T>G, ENST00000371953.7:c.104T>G, ENST00000462694.1:n.106T>G, ENST00000610634.1:c.2T>G, NM_000314.6(PTEN):c.104T>G (p.Met35Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PS2, PS3	PM6, PVS1, BP5, BP7, BS4, BS3, BS1, BS2, PP1, PP3, PM1, PM4, PM5, BP2, BP4, BA1, PS4, PS1	PTEN c.104T>G (p.Met35Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (PMID 9425889)PS3: Phosphatase activity <50% of wild type. (PMID 21828076, 25875300)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	9425889, 9425889, 25875300, 21828076	PTEN VCEP		2018-07-25	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA000268/MONDO:0017623/003	2374c339-e2d7-4496-9d9a-d33c1abd8dce
NM_000314.6(PTEN):c.492+2T>G	7821	CA000475	NM_000314.6:c.492+2T>G, NC_000010.11:g.87933253T>G, CM000672.2:g.87933253T>G, NC_000010.10:g.89693010T>G, CM000672.1:g.89693010T>G, NC_000010.9:g.89682990T>G, NG_007466.2:g.74815T>G, LRG_311:g.74815T>G, ENST00000686459.1:c.492+2T>G, ENST00000688158.1:c.*603+2T>G, ENST00000688308.1:c.492+2T>G, ENST00000688922.1:c.413+2T>G, ENST00000693560.1:c.1011+2T>G, ENST00000371953.8:c.492+2T>G, ENST00000371953.7:c.492+2T>G, ENST00000498703.1:n.320T>G, ENST00000610634.1:c.390+2T>G, NM_000314.5:c.492+2T>G, NM_001304717.2:c.1011+2T>G, NM_001304718.1:c.-259+2T>G, XM_006717926.2:c.447+2T>G, XM_011539981.1:c.492+2T>G, XM_011539982.1:c.396+2T>G, XR_945789.1:n.1204+2T>G, XR_945790.1:n.1204+2T>G, XR_945791.1:n.1204+2T>G, NM_000314.7:c.492+2T>G, NM_001304717.5:c.1011+2T>G, NM_001304718.2:c.-259+2T>G, NM_000314.8:c.492+2T>G, NM_000314.8(PTEN):c.492+2T>G, NM_000314.6(PTEN):c.492+2T>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1, PS4_Supporting, PM2_Supporting, PS2	PM6, BS1, BS4, BS3, BP7, BP5, BS2, PP3, PP2, PP1, PP4, PM5, PM4, PM1, PM3, BA1, BP4, BP1, BP3, BP2, PS1, PS3	NM_000314.8(PTEN):c.492+2T>G variant meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.8). PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (SCV002821528.2). PM2_P: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533). PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (SCV001499809.1)		PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000475/MONDO:0017623/003	97d2ac8e-89b9-466c-a53a-4e15d173a70a
NM_000314.6(PTEN):c.696delA (p.Arg233Aspfs)	7822	CA000548	NM_000314.6:c.696delA, NC_000010.11:g.87957914del, CM000672.2:g.87957914del, NC_000010.10:g.89717671del, CM000672.1:g.89717671del, NC_000010.9:g.89707651del, NG_007466.2:g.99476del, LRG_311:g.99476del, ENST00000686459.1:c.*282del, ENST00000688158.1:c.*807del, ENST00000688308.1:c.696del, ENST00000688922.1:c.617del, ENST00000693560.1:c.1215del, ENST00000371953.8:c.696del, ENST00000371953.7:c.696del, ENST00000472832.2:c.123del, NM_000314.5:c.696del, NM_000314.6:c.696del, NM_001304717.2:c.1215del, NM_001304718.1:c.105del, XM_006717926.2:c.651del, XM_011539981.1:c.696del, XM_011539982.1:c.600del, XR_945791.1:n.1266del, NM_000314.7:c.696del, NM_001304717.5:c.1215del, NM_001304718.2:c.105del, NM_000314.8:c.696del, NM_000314.8(PTEN):c.696del (p.Arg233fs), NM_000314.6(PTEN):c.696delA (p.Arg233Aspfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1, PM2_Supporting	PM6, BP5, BP7, BS4, BS3, BS1, PP1, PP4, PP3, PP2, BS2, PM3, PM5, PM4, PM1, BP2, BP4, BP1, BP3, BA1, PS4, PS2, PS3, PS1	NM_000314.8(PTEN):c.696del (p.Arg233AspfsTer23) variant meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.8). PM2_P: Absent in large sequenced populations in the gnomAD cohort (PMID:27535533).	9425889	PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000548/MONDO:0017623/003	b5898872-dd1b-462b-9884-a69944868912
NM_000314.6(PTEN):c.701G>A (p.Arg234Gln)	7840	CA000551	NM_000314.6:c.701G>A, NC_000010.11:g.87957919G>A, CM000672.2:g.87957919G>A, NC_000010.10:g.89717676G>A, CM000672.1:g.89717676G>A, NC_000010.9:g.89707656G>A, NG_007466.2:g.99481G>A, LRG_311:g.99481G>A, ENST00000686459.1:c.*287G>A, ENST00000688158.1:c.*812G>A, ENST00000688308.1:c.701G>A, ENST00000688922.1:c.622G>A, ENST00000693560.1:c.1220G>A, ENST00000371953.8:c.701G>A, ENST00000371953.7:c.701G>A, ENST00000472832.2:c.128G>A, NM_000314.5:c.701G>A, NM_001304717.2:c.1220G>A, NM_001304718.1:c.110G>A, XM_006717926.2:c.656G>A, XM_011539981.1:c.701G>A, XM_011539982.1:c.605G>A, XR_945791.1:n.1271G>A, NM_000314.7:c.701G>A, NM_001304717.5:c.1220G>A, NM_001304718.2:c.110G>A, NM_000314.8:c.701G>A, NM_000314.8(PTEN):c.701G>A (p.Arg234Gln), NM_000314.6(PTEN):c.701G>A (p.Arg234Gln)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PM2_Supporting	BP7, BP5, BS1, BS3, BS4, PM6, PVS1, PP3, PP4, PP1, BS2, PM5, PM4, PM1, PM3, BP4, BP1, BP3, BP2, BA1, PS1, PS3, PS2, PS4	NM_000314.8(PTEN):c.701G>A (p.Arg234Gln) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2_Supporting: Absent in large sequenced populations in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	29706350, 12085208, 29785012, 12085208, 28755079, 29706350, 12085208, 29785012	PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000551/MONDO:0017623/003	5fe899fa-c13c-4145-9397-0b200e380e4c
NM_000314.6(PTEN):c.304A>C (p.Lys102Gln)	186427	CA000139	NM_000314.6:c.304A>C, NC_000010.11:g.87933063A>C, CM000672.2:g.87933063A>C, NC_000010.10:g.89692820A>C, CM000672.1:g.89692820A>C, NC_000010.9:g.89682800A>C, NG_007466.2:g.74625A>C, LRG_311:g.74625A>C, ENST00000686459.1:c.304A>C, ENST00000688158.1:c.*415A>C, ENST00000688308.1:c.304A>C, ENST00000688922.1:n.225A>C, ENST00000693560.1:c.823A>C, ENST00000371953.8:c.304A>C, ENST00000371953.7:c.304A>C, ENST00000498703.1:n.130A>C, ENST00000610634.1:c.202A>C, NM_000314.5:c.304A>C, NM_001304717.2:c.823A>C, NM_001304718.1:c.-447A>C, XM_006717926.2:c.259A>C, XM_011539981.1:c.304A>C, XM_011539982.1:c.208A>C, XR_945789.1:n.1016A>C, XR_945790.1:n.1016A>C, XR_945791.1:n.1016A>C, NM_000314.7:c.304A>C, NM_001304717.5:c.823A>C, NM_001304718.2:c.-447A>C, NM_000314.8:c.304A>C, NM_000314.8(PTEN):c.304A>C (p.Lys102Gln), NM_000314.6(PTEN):c.304A>C (p.Lys102Gln)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2, PP2, BS3_Supporting	PVS1, PM6, BP7, BP5, BS1, BS4, PP3, PP1, PP4, BS2, PM4, PM5, PM1, PM3, BA1, BP3, BP4, BP1, BP2, PS1, PS3, PS4, PS2	PTEN c.304A>C (p.Lys102Gln) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	29706350	PTEN VCEP		2021-06-04	2022-09-30	false	https://erepo.genome.network/evrepo/ui/classification/CA000139/MONDO:0017623/003	db32e75a-9a54-4922-9aaf-03a6bf68097e
NM_000314.6(PTEN):c.314G>A (p.Cys105Tyr)	142261	CA000393	NM_000314.6:c.314G>A, NC_000010.11:g.87933073G>A, CM000672.2:g.87933073G>A, NC_000010.10:g.89692830G>A, CM000672.1:g.89692830G>A, NC_000010.9:g.89682810G>A, NG_007466.2:g.74635G>A, LRG_311:g.74635G>A, ENST00000686459.1:c.314G>A, ENST00000688158.1:c.*425G>A, ENST00000688308.1:c.314G>A, ENST00000688922.1:n.235G>A, ENST00000693560.1:c.833G>A, ENST00000371953.8:c.314G>A, ENST00000371953.7:c.314G>A, ENST00000498703.1:n.140G>A, ENST00000610634.1:c.212G>A, NM_000314.5:c.314G>A, NM_001304717.2:c.833G>A, NM_001304718.1:c.-437G>A, XM_006717926.2:c.269G>A, XM_011539981.1:c.314G>A, XM_011539982.1:c.218G>A, XR_945789.1:n.1026G>A, XR_945790.1:n.1026G>A, XR_945791.1:n.1026G>A, NM_000314.7:c.314G>A, NM_001304717.5:c.833G>A, NM_001304718.2:c.-437G>A, NM_000314.8:c.314G>A, NM_000314.8(PTEN):c.314G>A (p.Cys105Tyr), NM_000314.6(PTEN):c.314G>A (p.Cys105Tyr)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2, PM6, PP2, PS4_Supporting	BP7, BP5, BS1, BS3, BS4, PVS1, PP3, PP4, PP1, BS2, PM5, PM4, PM1, PM3, BA1, BP4, BP1, BP3, BP2, PS1, PS3, PS2	PTEN c.314G>A (p.Cys105Tyr) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (internal laboratory contributor ClinVar Organization ID 26957)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (internal laboratory contributor ClinVar Organization ID 26957)	15987703, 29706350, 10400993, 15987703, 29706350	PTEN VCEP		2021-06-04	2022-09-30	false	https://erepo.genome.network/evrepo/ui/classification/CA000393/MONDO:0017623/003	dce7b398-e447-420b-8da1-a51cbf6a8e69
NM_000314.6(PTEN):c.364A>G (p.Ile122Val)	186161	CA000147	NM_000314.6:c.364A>G, NC_000010.11:g.87933123A>G, CM000672.2:g.87933123A>G, NC_000010.10:g.89692880A>G, CM000672.1:g.89692880A>G, NC_000010.9:g.89682860A>G, NG_007466.2:g.74685A>G, LRG_311:g.74685A>G, ENST00000686459.1:c.364A>G, ENST00000688158.1:c.*475A>G, ENST00000688308.1:c.364A>G, ENST00000688922.1:n.285A>G, ENST00000693560.1:c.883A>G, ENST00000371953.8:c.364A>G, ENST00000371953.7:c.364A>G, ENST00000498703.1:n.190A>G, ENST00000610634.1:c.262A>G, NM_000314.5:c.364A>G, NM_001304717.2:c.883A>G, NM_001304718.1:c.-387A>G, XM_006717926.2:c.319A>G, XM_011539981.1:c.364A>G, XM_011539982.1:c.268A>G, XR_945789.1:n.1076A>G, XR_945790.1:n.1076A>G, XR_945791.1:n.1076A>G, NM_000314.7:c.364A>G, NM_001304717.5:c.883A>G, NM_001304718.2:c.-387A>G, NM_000314.8:c.364A>G, NM_000314.8(PTEN):c.364A>G (p.Ile122Val), NM_000314.6(PTEN):c.364A>G (p.Ile122Val)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	BS3, PM2, PP2	BP7, BP5, BS4, BS1, PVS1, PM6, BS2, PP3, PP1, PP4, PM4, PM5, PM1, PM3, BP3, BP4, BP1, BP2, BA1, PS1, PS3, PS4, PS2	PTEN c.364A>G (p.Ile122Val) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3: Missense variants with both lipid phosphatase activity AND results from a second assay appropriate to the protein domain demonstrating no statistically significant difference from wild type. (PMID 21828076, 29706350, 29785012)	21828076, 29785012, 29706350	PTEN VCEP		2021-06-04	2022-09-30	false	https://erepo.genome.network/evrepo/ui/classification/CA000147/MONDO:0017623/003	c4bf5c74-cf88-47c3-812d-89a0c0e7f110
NM_000314.6(PTEN):c.715A>G (p.Met239Val)	184878	CA000189	NM_000314.6:c.715A>G, NC_000010.11:g.87957933A>G, CM000672.2:g.87957933A>G, NC_000010.10:g.89717690A>G, CM000672.1:g.89717690A>G, NC_000010.9:g.89707670A>G, NG_007466.2:g.99495A>G, LRG_311:g.99495A>G, ENST00000686459.1:c.*301A>G, ENST00000688158.1:c.*826A>G, ENST00000688308.1:c.715A>G, ENST00000688922.1:c.636A>G, ENST00000693560.1:c.1234A>G, ENST00000371953.8:c.715A>G, ENST00000371953.7:c.715A>G, ENST00000472832.2:c.142A>G, NM_000314.5:c.715A>G, NM_001304717.2:c.1234A>G, NM_001304718.1:c.124A>G, XM_006717926.2:c.670A>G, XM_011539981.1:c.715A>G, XM_011539982.1:c.619A>G, XR_945791.1:n.1285A>G, NM_000314.7:c.715A>G, NM_001304717.5:c.1234A>G, NM_001304718.2:c.124A>G, NM_000314.8:c.715A>G, NM_000314.8(PTEN):c.715A>G (p.Met239Val), NM_000314.6(PTEN):c.715A>G (p.Met239Val)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PP2, PM2_Supporting, BP4	PM6, PVS1, BP7, BP5, BS1, BS3, BS4, PP1, PP4, PP3, BS2, PM4, PM5, PM1, PM3, BA1, BP3, BP2, BP1, PS1, PS3, PS4, PS2	NM_000314.8(PTEN):c.715A>G (p.Met239Val) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2_Supporting: Absent in large sequenced populations in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BP4: REVEL score < 0.5 (score=0.421).Using the Bayesian point system (PMID: 29300386) for this variant with conflicting evidence: 1 benign supporting = -1. 2 pathogenic supporting = 2. Total = 1 (VUS).		PTEN VCEP		2023-06-14	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000189/MONDO:0017623/003	dd41683a-d4b5-4e1a-aafb-d6cbe064561e
NM_000314.6(PTEN):c.-734G>A	127672	CA10602385	NM_000314.6:c.-734G>A, NC_000010.11:g.87863735G>A, CM000672.2:g.87863735G>A, NC_000010.10:g.89623492G>A, CM000672.1:g.89623492G>A, NC_000010.9:g.89613472G>A, NG_007466.2:g.5298G>A, LRG_311:g.5298G>A, NG_033079.1:g.4703C>T, ENST00000688158.1:c.-735G>A, ENST00000688308.1:c.-17+622G>A, ENST00000693560.1:c.-215G>A, ENST00000371953.8:c.-735G>A, ENST00000371953.7:c.-735G>A, ENST00000610634.1:c.-837G>A, NM_000314.5:c.-734G>A, NM_001304717.2:c.-215G>A, NM_001304718.1:c.-1439G>A, NM_000314.7:c.-734G>A, NM_001304717.5:c.-215G>A, NM_001304718.2:c.-1439G>A, NM_000314.8:c.-735G>A, NM_000314.8(PTEN):c.-735G>A, NM_000314.6(PTEN):c.-734G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS1	BP5, BP7, BS3, BS4, PM2, PM6, PVS1, PP2, PP3, PP4, PP1, BS2, PM3, PM4, PM1, PM5, BP1, BP4, BP2, BP3, BA1, PS3, PS4, PS2, PS1	NM_000314.8(PTEN):c.-735G>A meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: To be applied for variants with filtering allele frequency (FAF) of 0.000043 up to 0.00056 (0.0043% up to 0.056%) in gnomAD. Popmax FAF in gnomAD for South Asians: 0.01758%.Per ClinGen PTEN Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PTEN Version 3, 1 Benign Strong = Likely Benign.		PTEN VCEP		2023-08-04	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA10602385/MONDO:0017623/003	ffaaa038-c2bf-425c-b1d9-29e7adab495b
NM_000314.8(PTEN):c.882T>G (p.Ser294Arg)	127693	CA000618	NM_000314.8:c.882T>G, NC_000010.11:g.87960974T>G, CM000672.2:g.87960974T>G, NC_000010.10:g.89720731T>G, CM000672.1:g.89720731T>G, NC_000010.9:g.89710711T>G, NG_007466.2:g.102536T>G, LRG_311:g.102536T>G, ENST00000686459.1:c.*468T>G, ENST00000688158.1:c.*993T>G, ENST00000688308.1:c.882T>G, ENST00000688922.1:c.803T>G, ENST00000693560.1:c.1401T>G, ENST00000371953.8:c.882T>G, ENST00000371953.7:c.882T>G, ENST00000472832.2:c.309T>G, NM_000314.5:c.882T>G, NM_000314.6:c.882T>G, NM_001304717.2:c.1401T>G, NM_001304718.1:c.291T>G, XM_006717926.2:c.837T>G, XM_011539981.1:c.882T>G, XM_011539982.1:c.786T>G, XR_945791.1:n.1452T>G, NM_000314.7:c.882T>G, NM_001304717.5:c.1401T>G, NM_001304718.2:c.291T>G, NM_000314.8(PTEN):c.882T>G (p.Ser294Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS1, PP2, BP4	PM2, PM6, PVS1, BS3, BS4, BP5, BP7, BS2, PP3, PP1, PP4, PM5, PM3, PM4, PM1, BA1, BP1, BP2, BP3, PS1, PS3, PS4, PS2	NM_000314.8(PTEN):c.882T>G (p.Ser294Arg) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1: Filtering allele frequency of 0.0002887 (0.02887%, 13/24922 African/African American alleles) in gnomAD. BP4: REVEL score = 0.365. PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.Variant with benign and pathogenic codes. Classification based on application of Bayesian Classification Framework (PMID: 29300386): BS1 (-4 pts), BP4 (-1 pt), PP2 (+1 pt) = -4 pts total (Likely Benign).		PTEN VCEP		2023-08-04	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000618/MONDO:0017623/003	ea71ad62-785a-426a-b9bd-7ffff8b8a049
NM_000314.6(PTEN):c.914G>A (p.Ser305Asn)	127696	CA000632	NM_000314.6:c.914G>A, NC_000010.11:g.87961006G>A, CM000672.2:g.87961006G>A, NC_000010.10:g.89720763G>A, CM000672.1:g.89720763G>A, NC_000010.9:g.89710743G>A, NG_007466.2:g.102568G>A, LRG_311:g.102568G>A, NM_000314.5:c.914G>A, NM_001304717.2:c.1433G>A, NM_001304718.1:c.323G>A, XM_006717926.2:c.869G>A, XM_011539981.1:c.914G>A, XM_011539982.1:c.818G>A, XR_945791.1:n.1484G>A, NM_000314.7:c.914G>A, NM_001304717.5:c.1433G>A, NM_001304718.2:c.323G>A, ENST00000371953.7:c.914G>A, ENST00000472832.2:n.341G>A, NM_000314.6(PTEN):c.914G>A (p.Ser305Asn)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2, PP2, BS3_Supporting	PVS1, PM6, BP5, BP7, BS4, BS1, PP1, PP3, BS2, PM1, PM4, PM5, BP2, BP4, BA1, PS2, PS4, PS3, PS1	PTEN c.914G>A (p.S305N) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	29706350	PTEN VCEP		2019-03-05	2019-07-23	false	https://erepo.genome.network/evrepo/ui/classification/CA000632/MONDO:0017623/003	59aacee3-4abf-400b-9713-4c28e3258b75
NM_000314.8(PTEN):c.892C>G (p.Gln298Glu)	127695	CA000623	NM_000314.8:c.892C>G, NC_000010.11:g.87960984C>G, CM000672.2:g.87960984C>G, NC_000010.10:g.89720741C>G, CM000672.1:g.89720741C>G, NC_000010.9:g.89710721C>G, NG_007466.2:g.102546C>G, LRG_311:g.102546C>G, ENST00000686459.1:c.*478C>G, ENST00000688158.1:c.*1003C>G, ENST00000688308.1:c.892C>G, ENST00000688922.1:c.813C>G, ENST00000693560.1:c.1411C>G, ENST00000371953.8:c.892C>G, ENST00000371953.7:c.892C>G, ENST00000472832.2:c.319C>G, NM_000314.5:c.892C>G, NM_000314.6:c.892C>G, NM_001304717.2:c.1411C>G, NM_001304718.1:c.301C>G, XM_006717926.2:c.847C>G, XM_011539981.1:c.892C>G, XM_011539982.1:c.796C>G, XR_945791.1:n.1462C>G, NM_000314.7:c.892C>G, NM_001304717.5:c.1411C>G, NM_001304718.2:c.301C>G, NM_000314.8(PTEN):c.892C>G (p.Gln298Glu)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	PP2, BS1_Supporting, BS3_Supporting, BP4	PM2, PM6, PVS1, BP7, BP5, BS4, PP3, PP1, BS2, PM5, PM4, PM1, PM3, BP1, BP3, BP2, BA1, PS1, PS4, PS2, PS3	NM_000314.8(PTEN):c.892C>G (p.Gln298Glu) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1_Supporting: Filtering allele frequency of 0.00002132 (0.002132%, 4/24900 African/African American alleles) in gnomAD. BS3_Supporting: Massively parallel functional assay interrogating phosphatase activity demonstrating no statistically significant difference from wild type (PMID: 29706350). BP4: REVEL score = 0.229. PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.Variant with benign and pathogenic codes. Classification based on application of Bayesian Classification Framework (PMID: 29300386): BS1_P (-1 pt1), BS3_P (-1 pt), BP4 (-1 pt), PP2 (+1 pt) = -2 pts total (Likely Benign).	25980754, 29706350, 29785012	PTEN VCEP		2023-08-04	2023-10-19	false	https://erepo.genome.network/evrepo/ui/classification/CA000623/MONDO:0017623/003	304beaf9-04a8-47e9-859a-ceb4b54a57fa
NM_030662.3(MAP2K2):c.919+4C>T	40834	CA9090795	NM_030662.3:c.919+4C>T, NC_000019.10:g.4099197G>A, CM000681.2:g.4099197G>A, NC_000019.9:g.4099195G>A, CM000681.1:g.4099195G>A, NC_000019.8:g.4050195G>A, NG_007996.1:g.29932C>T, LRG_750:g.29932C>T, LRG_750t1:c.919+4C>T, XM_006722799.2:c.705+1822C>T, XM_011528133.1:c.349+4C>T, XM_017026989.1:c.919+4C>T, XM_017026990.1:c.705+1822C>T, ENST00000262948.9:c.919+4C>T, ENST00000394867.8:c.628+4C>T, ENST00000593364.5:n.870C>T, ENST00000595715.1:n.734+4C>T, ENST00000597263.5:n.169+1822C>T, ENST00000599021.1:n.29+1822C>T, ENST00000600584.5:n.1479+4C>T, ENST00000601786.5:n.1220+4C>T, NM_030662.3(MAP2K2):c.919+4C>T	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP7, BP4	BS1, BS2	The  variant c.919+4C>T is an intronic variant at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP7). Also, computational prediction tools and conservation analysis suggests that the variant does not impact the protein (BP4). In summary, the clinical significance of the c.919+4C>T variant is likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BP4, BP7.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-07-25	2019-12-03	false	https://erepo.genome.network/evrepo/ui/classification/CA9090795/MONDO:0021060/004	246061da-c54d-4473-bf35-633ebf160104
NM_005343.3(HRAS):c.412G>A (p.Gly138Ser)	45304	CA135988	NM_005343.3:c.412G>A, NC_000011.10:g.533491C>T, CM000673.2:g.533491C>T, NC_000011.9:g.533491C>T, CM000673.1:g.533491C>T, NC_000011.8:g.523491C>T, NG_007666.1:g.7060G>A, NM_001130442.1:c.412G>A, NM_005343.2:c.412G>A, NM_176795.3:c.412G>A, XM_011519875.1:c.-424-5107C>T, XM_011519877.1:c.-162+5154C>T, XR_242795.1:n.611G>A, NM_001130442.2:c.412G>A, NM_001318054.1:c.93G>A, NM_176795.4:c.412G>A, XM_011519875.2:c.-424-5107C>T, XM_011519877.2:c.-162+5154C>T, XM_017017167.1:c.-499-5032C>T, XM_017017168.1:c.-499-5032C>T, NM_005343.4:c.412G>A, ENST00000311189.7:c.412G>A, ENST00000397594.5:c.412G>A, ENST00000397596.6:c.412G>A, ENST00000417302.5:c.412G>A, ENST00000451590.5:c.412G>A, ENST00000462734.1:n.105G>A, ENST00000478324.5:n.122G>A, ENST00000479482.1:n.333G>A, ENST00000493230.5:c.412G>A, NM_005343.3(HRAS):c.412G>A (p.Gly138Ser)	HRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PP2	PS4, PM2	The c.412G>A (p.Gly138Ser) variant in the HRAS gene has been identified in 1 Asian woman with Noonan Syndrome and 1 Asian man with Costello Syndrome (Laboratory for Molecular Medicine internal data). It has been also identified in 1 patient who had a combined cardiac panel (GeneDx internal data) and was observed in 3 unrelated women with breast cancer and 1 woman with uterine cancer (Invitae internal data). PS4_Supporting not met due to conflicting phenotypes between the identified patients. HRAS has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, the clinical significance of the p.Gly138Ser variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-07-25	2019-12-03	false	https://erepo.genome.network/evrepo/ui/classification/CA135988/MONDO:0021060/004	7b1915f1-7c70-4f7b-afa5-d08962f3c012
NM_002880.3(RAF1):c.-267G>A	40575	CA181005	NM_002880.3:c.-267G>A, NC_000003.12:g.12664053C>T, CM000665.2:g.12664053C>T, NC_000003.11:g.12705552C>T, CM000665.1:g.12705552C>T, NC_000003.10:g.12680552C>T, NG_007467.1:g.5127G>A, LRG_413:g.5127G>A, LRG_413t1:c.-267G>A, XM_005265357.1:c.-267G>A, XM_005265358.3:c.-397G>A, XM_005265359.3:c.-397G>A, XM_005265360.1:c.-267G>A, XM_011533974.1:c.-360G>A, XM_011533975.1:c.-490G>A, NM_001354689.1:c.-267G>A, NM_001354691.1:c.-490G>A, NM_001354692.1:c.-397G>A, NM_001354693.1:c.-267G>A, NM_001354694.1:c.-397G>A, NM_001354695.1:c.-397G>A, NR_148940.1:n.149G>A, NR_148941.1:n.149G>A, NR_148942.1:n.149G>A, XM_011533974.3:c.-360G>A, XR_001740227.1:n.65G>A, ENST00000251849.8:c.-267G>A, ENST00000416093.1:c.-267G>A, ENST00000423275.5:c.-267G>A, ENST00000442415.6:c.-267G>A, NM_002880.3(RAF1):c.-267G>A	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP7, BP5, BP4, BA1		The c.-267G>A variant was identified in the RAF1 gene. The filtering allele frequency for the c.-267G>A is 6.32% for African chromosomes in gnomAD (68/8706 with 95% CI) (https://gnomad.broadinstitute.org/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). The variant has also been identified in a patient with an alternate molecular basis for disease (BP5; Laboratory for Molecular Medicine internal data). In summary, the c.-267G>A variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-07-25	2019-12-03	false	https://erepo.genome.network/evrepo/ui/classification/CA181005/MONDO:0021060/004	8ca8203f-7106-4509-94f8-6bfbd5481879
	-	CA16020890	NM_000277.3:c.903G>T, NC_000012.12:g.102851696C>A, CM000674.2:g.102851696C>A, NC_000012.11:g.103245474C>A, CM000674.1:g.103245474C>A, NC_000012.10:g.101769604C>A, NG_008690.1:g.70907G>T, NG_008690.2:g.111715G>T, NM_000277.1:c.903G>T, XM_011538422.1:c.903G>T, NM_000277.2:c.903G>T, NM_001354304.1:c.903G>T, ENST00000307000.7:c.888G>T, ENST00000549247.6:n.662G>T, ENST00000551114.2:n.565G>T, ENST00000553106.5:c.903G>T, ENST00000635477.1:n.64G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM5, PM2, PP4_Moderate, PP3	PM3	The c.903G>T (p.Gln301His) variant in PAH has been reported in at least 1 individual with PKU however without indication of the genotype (BH4 deficiency ruled out) (PMID: 21307867) . The p.Gln301His variant is absent in gnomAD and the ESP population databases. A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.831.  This variant is located in the C-terminal aromatic amino acid hydroxylase domain and a different amino acid change at the same codon has been reported (PMID: 19292873 ).  Overall, the c.903G>T variant is classified as likely pathogenic. PAH-specific ACMG/AMP criteria applied: PP3, PM2, PP4_M, PM5.		Phenylketonuria VCEP		2019-08-02	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA16020890/MONDO:0009861/006	818a5909-77d6-409a-950b-67263a6bce83
NM_001754.4(RUNX1):c.601C>T (p.Arg201Ter)	376018	CA16602487	NM_001754.4:c.601C>T, NC_000021.9:g.34859486G>A, CM000683.2:g.34859486G>A, NC_000021.8:g.36231783G>A, CM000683.1:g.36231783G>A, NC_000021.7:g.35153653G>A, NG_011402.2:g.1130226C>T, LRG_482:g.1130226C>T, ENST00000675419.1:c.601C>T, ENST00000300305.7:c.601C>T, ENST00000344691.8:c.520C>T, ENST00000358356.9:c.520C>T, ENST00000399237.6:c.565C>T, ENST00000399240.5:c.520C>T, ENST00000437180.5:c.601C>T, ENST00000467577.1:n.93C>T, ENST00000482318.5:c.*191C>T, NM_001001890.2:c.520C>T, NM_001122607.1:c.520C>T, LRG_482t1:c.601C>T, XM_005261068.3:c.565C>T, XM_005261069.3:c.601C>T, XM_011529766.1:c.601C>T, XM_011529767.1:c.562C>T, XM_011529768.1:c.562C>T, XM_011529770.1:c.601C>T, XR_937576.1:n.780C>T, XM_005261069.4:c.601C>T, XM_011529766.2:c.601C>T, XM_011529767.2:c.562C>T, XM_011529768.2:c.562C>T, XM_011529770.2:c.601C>T, XM_017028487.1:c.448C>T, XR_937576.2:n.827C>T, NM_001001890.3:c.520C>T, NM_001122607.2:c.520C>T, NM_001754.5:c.601C>T, NM_001754.4(RUNX1):c.601C>T (p.Arg201Ter)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PVS1, PM2_Supporting	PS1, PS3, PS2, BP3, BP1, BP4, BP2, BA1, BP7, BP5, BS3, BS4, BS1, PM6, PM5, PM1, PM4, PM3, PP2, PP3, PP4, BS2	The NM_001754.4:c.601C>T (p.Arg201Ter) variant is a nonsense variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant has been reported in four probands meeting at least one of the RUNX1-phenotypic criteria (PS4; PMIDs: 10508512; 19387465; 20549580; 28513614). The variant was found to co-segregate with disease in multiple affected family members, with 14 meioses observed in across 4 families (PP1_Strong; PMID: 10508512; 19387465; 20549580; 28513614). The variant is absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PS4, PP1_Strong, PM2_supporting.	10508512, 19387465, 20549580, 28513614	Myeloid Malignancy VCEP		2024-09-04	2024-09-04	false	https://erepo.genome.network/evrepo/ui/classification/CA16602487/MONDO:0011071/008	86145d7f-0d2f-4234-81b7-bd179ea8e91f
NM_001754.5(RUNX1):c.679G>T (p.Glu227Ter)	545522	CA410206910	NM_001754.5:c.679G>T, NC_000021.9:g.34834536C>A, CM000683.2:g.34834536C>A, NC_000021.8:g.36206833C>A, CM000683.1:g.36206833C>A, NC_000021.7:g.35128703C>A, NG_011402.2:g.1155176G>T, LRG_482:g.1155176G>T, ENST00000675419.1:c.679G>T, ENST00000300305.7:c.679G>T, ENST00000344691.8:c.598G>T, ENST00000358356.9:c.598G>T, ENST00000399237.6:c.643G>T, ENST00000399240.5:c.532+24938G>T, ENST00000437180.5:c.679G>T, ENST00000469087.1:n.215G>T, ENST00000482318.5:c.*269G>T, NM_001001890.2:c.598G>T, NM_001122607.1:c.598G>T, NM_001754.4:c.679G>T, LRG_482t1:c.679G>T, XM_005261068.3:c.643G>T, XM_005261069.3:c.613+24938G>T, XM_011529766.1:c.679G>T, XM_011529767.1:c.640G>T, XM_011529768.1:c.574+24938G>T, XM_011529770.1:c.679G>T, XR_937576.1:n.858G>T, XM_005261069.4:c.613+24938G>T, XM_011529766.2:c.679G>T, XM_011529767.2:c.640G>T, XM_011529768.2:c.574+24938G>T, XM_011529770.2:c.679G>T, XM_017028487.1:c.526G>T, XR_937576.2:n.905G>T, NM_001001890.3:c.598G>T, NM_001122607.2:c.598G>T, NM_001754.5(RUNX1):c.679G>T (p.Glu227Ter)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PS4_Supporting, PM2_Supporting	PS3, PS1, PS2, BA1, BP1, BP4, BP3, BP2, PM6, BS3, BS1, BS4, BP7, BP5, PM4, PM1, PM3, BS2, PP2, PP3, PP1, PP4	The NM_001001890.2:c.598G>T (p.Glu200Ter) variant is a nonsense variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This variant is a nonsense/frameshift variants that is downstream of c.98 (PM5_Supporting). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 30990344). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2_supporting, PS4_Supporting, PM5_supporting.	30990344	Myeloid Malignancy VCEP		2024-03-26	2024-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA410206910/MONDO:0011071/008	1c4b6804-f641-4dd6-931b-84e1443249f2
NM_001754.5(RUNX1):c.861C>A (p.Tyr287Ter)	14467	CA248619	NM_001754.5:c.861C>A, NC_000021.9:g.34799407G>T, CM000683.2:g.34799407G>T, NC_000021.8:g.36171704G>T, CM000683.1:g.36171704G>T, NC_000021.7:g.35093574G>T, NG_011402.2:g.1190305C>A, LRG_482:g.1190305C>A, ENST00000675419.1:c.861C>A, ENST00000300305.7:c.861C>A, ENST00000344691.8:c.780C>A, ENST00000399240.5:c.588C>A, ENST00000437180.5:c.861C>A, ENST00000482318.5:c.*451C>A, NM_001001890.2:c.780C>A, NM_001754.4:c.861C>A, LRG_482t1:c.861C>A, XM_005261068.3:c.825C>A, XM_005261069.3:c.669C>A, XM_011529766.1:c.861C>A, XM_011529767.1:c.822C>A, XM_011529768.1:c.630C>A, XR_937576.1:n.1040C>A, XM_005261069.4:c.669C>A, XM_011529766.2:c.861C>A, XM_011529767.2:c.822C>A, XM_011529768.2:c.630C>A, XM_017028487.1:c.708C>A, XR_937576.2:n.1087C>A, NM_001001890.3:c.780C>A, NM_001754.5(RUNX1):c.861C>A (p.Tyr287Ter)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PM5_Supporting, PVS1, PS4_Supporting, PM2_Supporting	PS3, PS1, PS2, BA1, BP1, BP4, BP3, BP2, PM6, BS3, BS1, BS4, BP7, BP5, PM4, PM1, PM3, PP2, PP3, PP4, BS2	The NM_001754.4:c.861C>A (p.Tyr287Ter) variant is a nonsense variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant was found to co-segregate with disease in multiple affected family members, with seven meioses observed in one family (PP1_Strong; PMID: 11830488). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This variant is a nonsense/frameshift variants that is downstream of c.98 (PM5_Supporting). The variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting;  PMID: 11830488). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PP1_Strong, PM2_supporting, PS4_Supporting.	11830488, 11830488, 11830488	Myeloid Malignancy VCEP		2024-03-26	2024-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA248619/MONDO:0011071/008	fed802a7-8c1d-4396-89f1-65546e996764
NM_001754.4(RUNX1):c.1163C>A (p.Ser388Ter)	561222	CA410147908	NM_001754.4:c.1163C>A, NC_000021.9:g.34792415G>T, CM000683.2:g.34792415G>T, NC_000021.8:g.36164712G>T, CM000683.1:g.36164712G>T, NC_000021.7:g.35086582G>T, NG_011402.2:g.1197297C>A, LRG_482:g.1197297C>A, ENST00000675419.1:c.1163C>A, ENST00000300305.7:c.1163C>A, ENST00000344691.8:c.1082C>A, ENST00000399240.5:c.890C>A, ENST00000437180.5:c.1163C>A, ENST00000482318.5:c.*753C>A, NM_001001890.2:c.1082C>A, LRG_482t1:c.1163C>A, XM_005261068.3:c.1127C>A, XM_005261069.3:c.971C>A, XM_011529766.1:c.1163C>A, XM_011529767.1:c.1124C>A, XM_011529768.1:c.932C>A, XM_005261069.4:c.971C>A, XM_011529766.2:c.1163C>A, XM_011529767.2:c.1124C>A, XM_011529768.2:c.932C>A, XM_017028487.1:c.1010C>A, NM_001001890.3:c.1082C>A, NM_001754.5:c.1163C>A, NM_001754.4(RUNX1):c.1163C>A (p.Ser388Ter)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	PVS1_Strong, PS3_Supporting, PS4_Supporting, PM2_Supporting	PS1, PS2, BP1, BP4, BP3, BP2, BA1, BP7, BP5, BS3, BS4, BS1, PM6, PM4, PM1, PM5, PM3, BS2, PP2, PP3, PP1, PP4	The NM_001754.4:c.1163C>A (p.Ser388Ter) variant is a nonsense variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). Transactivation assays demonstrate enhanced transactivation (>115% of wt) (PS3_Supporting; PMID: 20846103). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_Supporting; PMID: 20846103). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2_supporting, PS3_Supporting, PS4_Supporting.	20846103, 20846103, 20846103, 20846103	Myeloid Malignancy VCEP		2024-09-10	2024-09-10	false	https://erepo.genome.network/evrepo/ui/classification/CA410147908/MONDO:0011071/008	37cf5142-fd3f-4896-9da9-ca4c54b542ea
NM_001754.5(RUNX1):c.328A>G (p.Lys110Glu)	14465	CA248613	NM_001754.5:c.328A>G, NC_000021.9:g.34886866T>C, CM000683.2:g.34886866T>C, NC_000021.8:g.36259163T>C, CM000683.1:g.36259163T>C, NC_000021.7:g.35181033T>C, NG_011402.2:g.1102846A>G, LRG_482:g.1102846A>G, ENST00000675419.1:c.328A>G, ENST00000300305.7:c.328A>G, ENST00000344691.8:c.247A>G, ENST00000358356.9:c.247A>G, ENST00000399237.6:c.292A>G, ENST00000399240.5:c.247A>G, ENST00000437180.5:c.328A>G, ENST00000455571.5:c.289A>G, ENST00000482318.5:c.59-6153A>G, NM_001001890.2:c.247A>G, NM_001122607.1:c.247A>G, NM_001754.4:c.328A>G, LRG_482t1:c.328A>G, XM_005261068.3:c.292A>G, XM_005261069.3:c.328A>G, XM_011529766.1:c.328A>G, XM_011529767.1:c.289A>G, XM_011529768.1:c.289A>G, XM_011529770.1:c.328A>G, XR_937576.1:n.507A>G, XM_005261069.4:c.328A>G, XM_011529766.2:c.328A>G, XM_011529767.2:c.289A>G, XM_011529768.2:c.289A>G, XM_011529770.2:c.328A>G, XM_017028487.1:c.175A>G, XR_937576.2:n.554A>G, NM_001001890.3:c.247A>G, NM_001122607.2:c.247A>G, NM_001754.5(RUNX1):c.328A>G (p.Lys110Glu)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PS3, PP1_Strong, PM5_Supporting, PM1, PM2_Supporting, PS4_Supporting, PP3	PS1, PS2, BA1, BP1, BP4, BP3, BP2, PM6, PVS1, BS3, BS1, BS4, BP7, BP5, PM4, PM3, PP2, PP4, BS2	Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.328A>G (p.Lys110Glu) variant and data from secondary assays demonstrate altered DNA binding, CBFÎ² binding and sub-cellular localization (PS3; PMID: 23848403; 17290219; 11830488). This variant was found to co-segregate with disease in multiple affected family members, with 7 meioses observed in one pedigree (PP1_Strong; PMID: 11830488). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This missense variant has a REVEL score >0.75 (0.953) (PP3). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_Supporting; PMID: 11830488). This variant is a missense change at the same residue (p.K110) where a different missense change has been previously established as a pathogenic variant (ClinVar ID 1518631, 14465) based on MM-VCEP rules for RUNX1 and RNA data or agreement in splicing predictors (SSF and MES) show no splicing effects (PM5_Supporting). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PP1_Strong, PM1, PM2_supporting, PP3, PS4_Supporting, PM5_supporting.	23848403, 17290219, 11830488, 11830488, 11830488, 11830488	Myeloid Malignancy VCEP		2024-03-26	2024-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA248613/MONDO:0011071/008	37efba9c-0430-4e4f-a3ce-fc8c501d717a
NM_001754.5(RUNX1):c.367G>C (p.Asp123His)	429813	CA10014524	NM_001754.5:c.367G>C, NC_000021.9:g.34880698C>G, CM000683.2:g.34880698C>G, NC_000021.8:g.36252995C>G, CM000683.1:g.36252995C>G, NC_000021.7:g.35174865C>G, NG_011402.2:g.1109014G>C, LRG_482:g.1109014G>C, ENST00000675419.1:c.367G>C, ENST00000300305.7:c.367G>C, ENST00000344691.8:c.286G>C, ENST00000358356.9:c.286G>C, ENST00000399237.6:c.331G>C, ENST00000399240.5:c.286G>C, ENST00000437180.5:c.367G>C, ENST00000455571.5:c.328G>C, ENST00000482318.5:c.74G>C, NM_001001890.2:c.286G>C, NM_001122607.1:c.286G>C, NM_001754.4:c.367G>C, LRG_482t1:c.367G>C, XM_005261068.3:c.331G>C, XM_005261069.3:c.367G>C, XM_011529766.1:c.367G>C, XM_011529767.1:c.328G>C, XM_011529768.1:c.328G>C, XM_011529770.1:c.367G>C, XR_937576.1:n.546G>C, XM_005261069.4:c.367G>C, XM_011529766.2:c.367G>C, XM_011529767.2:c.328G>C, XM_011529768.2:c.328G>C, XM_011529770.2:c.367G>C, XM_017028487.1:c.214G>C, XR_937576.2:n.593G>C, NM_001001890.3:c.286G>C, NM_001122607.2:c.286G>C, NM_001754.5(RUNX1):c.367G>C (p.Asp123His)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	PM1_Supporting, BS3_Supporting, PS4_Supporting, PP3, PP1	PS1, PS3, PS2, BA1, BP1, BP4, BP3, BP2, PVS1, PM2, PM6, BP7, BP5, BS1, BS4, PM5, PM4, PM3, PP2, PP4, BS2	The NM_001754.5(RUNX1):c.367G>C (p.Asp123His) is a missense variant. Transactivation assays demonstrating normal transactivation (80-115% of wt) (BS3_Supporting; PMID: 35026845). This variant was found to co-segregate with disease in multiple affected family members, with three or four (4) meioses observed in one family (PP1; PMID: 18723428). This missense variant has a REVEL score â‰¥ 0.88 (0.943) (PP3). This variant affects one of the other residues (AA 89-204) within the RHD (PM1_Supporting). This variant has been reported in two or three probands (2) meeting at least one of the RUNX1-phenotypic criteria (PS4_Moderate; PMID: 18723428, 35026845). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS3_supporting, PP1, PP3, PM1_supporting, PS4_supporting.		Myeloid Malignancy VCEP		2025-02-24	2025-02-24	false	https://erepo.genome.network/evrepo/ui/classification/CA10014524/MONDO:0011071/008	7e5378c7-f9d9-470d-9323-32fe9a5a69f7
NM_001754.5(RUNX1):c.400G>C (p.Ala134Pro)	14468	CA248623	NM_001754.5:c.400G>C, NC_000021.9:g.34880665C>G, CM000683.2:g.34880665C>G, NC_000021.8:g.36252962C>G, CM000683.1:g.36252962C>G, NC_000021.7:g.35174832C>G, NG_011402.2:g.1109047G>C, LRG_482:g.1109047G>C, ENST00000675419.1:c.400G>C, ENST00000300305.7:c.400G>C, ENST00000344691.8:c.319G>C, ENST00000358356.9:c.319G>C, ENST00000399237.6:c.364G>C, ENST00000399240.5:c.319G>C, ENST00000437180.5:c.400G>C, ENST00000455571.5:c.361G>C, ENST00000482318.5:c.107G>C, NM_001001890.2:c.319G>C, NM_001122607.1:c.319G>C, NM_001754.4:c.400G>C, LRG_482t1:c.400G>C, XM_005261068.3:c.364G>C, XM_005261069.3:c.400G>C, XM_011529766.1:c.400G>C, XM_011529767.1:c.361G>C, XM_011529768.1:c.361G>C, XM_011529770.1:c.400G>C, XR_937576.1:n.579G>C, XM_005261069.4:c.400G>C, XM_011529766.2:c.400G>C, XM_011529767.2:c.361G>C, XM_011529768.2:c.361G>C, XM_011529770.2:c.400G>C, XM_017028487.1:c.247G>C, XR_937576.2:n.626G>C, NM_001001890.3:c.319G>C, NM_001122607.2:c.319G>C, NM_001754.5(RUNX1):c.400G>C (p.Ala134Pro)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PS3, PM5_Supporting, PM1, PM2_Supporting, PS4_Supporting, PP3, PP1	PS1, PS2, BP1, BP4, BP3, BP2, BA1, PM6, PVS1, BS3, BS1, BS4, BP7, BP5, PM4, PM3, PP2, PP4, BS2	Transactivation assays demonstrate altered transactivation (<20% of wt) for the missense variant, NM_001754.4:c.400G>C (p.Ala134Pro) and data from secondary assays demonstrate altered CBFÎ² binding and sub-cellular localization.(PS3; PMID: 23848403). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). It has a REVEL score >0.75 (0.945) (PP3). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 12060124). It was found to co-segregate with disease in multiple affected family members, with three meioses observed in one family (PP1; PMID: 12060124). This variant is a missense change at the same residue (p.A134) where a different missense change has been previously established as a likely pathogenic variant (ClinVar ID 1484777) based on MM-VCEP rules for RUNX1 and RNA data or agreement in splicing predictors (SSF and MES) show no splicing effects (PM5_Supporting). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PM1, PM2_supporting, PP1, PP3, PS4_Supporting, PM5_Supporting.	23848403, 12060124, 12060124, 12060124	Myeloid Malignancy VCEP		2024-03-26	2024-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA248623/MONDO:0011071/008	d5e03ae0-3ff2-428d-87e3-ae93412f6bf1
NM_001754.5(RUNX1):c.467C>A (p.Ala156Glu)	14471	CA248628	NM_001754.5:c.467C>A, NC_000021.9:g.34880598G>T, CM000683.2:g.34880598G>T, NC_000021.8:g.36252895G>T, CM000683.1:g.36252895G>T, NC_000021.7:g.35174765G>T, NG_011402.2:g.1109114C>A, LRG_482:g.1109114C>A, ENST00000675419.1:c.467C>A, ENST00000300305.7:c.467C>A, ENST00000344691.8:c.386C>A, ENST00000358356.9:c.386C>A, ENST00000399237.6:c.431C>A, ENST00000399240.5:c.386C>A, ENST00000437180.5:c.467C>A, ENST00000482318.5:c.*57C>A, NM_001001890.2:c.386C>A, NM_001122607.1:c.386C>A, NM_001754.4:c.467C>A, LRG_482t1:c.467C>A, XM_005261068.3:c.431C>A, XM_005261069.3:c.467C>A, XM_011529766.1:c.467C>A, XM_011529767.1:c.428C>A, XM_011529768.1:c.428C>A, XM_011529770.1:c.467C>A, XR_937576.1:n.646C>A, XM_005261069.4:c.467C>A, XM_011529766.2:c.467C>A, XM_011529767.2:c.428C>A, XM_011529768.2:c.428C>A, XM_011529770.2:c.467C>A, XM_017028487.1:c.314C>A, XR_937576.2:n.693C>A, NM_001001890.3:c.386C>A, NM_001122607.2:c.386C>A, NM_001754.5(RUNX1):c.467C>A (p.Ala156Glu)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	PM1_Supporting, PP1_Strong, PS4_Supporting, PM2_Supporting, PP3	PS1, PS3, PS2, BA1, BP1, BP4, BP3, BP2, PM6, BP7, BP5, BS3, BS1, BS4, PVS1, PM5, PM4, PM3, PP2, PP4, BS2	The NM_001754.4:c.467C>A (p.Ala156Glu) variant was found to co-segregate with disease in multiple affected family members, with seven meioses observed in one family (PP1_Strong; PMID: 19357396, 27112265). It has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 19357396, 27112265). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). It affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This missense variant has a REVEL score >0.75 (0.906) (PP3). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PP1_Strong, PM2_supporting, PP3, PM1_Supporting, PS4_Supporting.	27112265, 19357396, 27112265, 19357396, 27112265, 19357396	Myeloid Malignancy VCEP		2024-06-24	2024-06-24	false	https://erepo.genome.network/evrepo/ui/classification/CA248628/MONDO:0011071/008	1023c045-33cc-4c4b-9297-ea4832be8def
NM_001754.4(RUNX1):c.497G>A (p.Arg166Gln)	417961	CA16616941	NM_001754.4:c.497G>A, NC_000021.9:g.34880568C>T, CM000683.2:g.34880568C>T, NC_000021.8:g.36252865C>T, CM000683.1:g.36252865C>T, NC_000021.7:g.35174735C>T, NG_011402.2:g.1109144G>A, LRG_482:g.1109144G>A, ENST00000675419.1:c.497G>A, ENST00000300305.7:c.497G>A, ENST00000344691.8:c.416G>A, ENST00000358356.9:c.416G>A, ENST00000399237.6:c.461G>A, ENST00000399240.5:c.416G>A, ENST00000437180.5:c.497G>A, ENST00000482318.5:c.*87G>A, NM_001001890.2:c.416G>A, NM_001122607.1:c.416G>A, LRG_482t1:c.497G>A, XM_005261068.3:c.461G>A, XM_005261069.3:c.497G>A, XM_011529766.1:c.497G>A, XM_011529767.1:c.458G>A, XM_011529768.1:c.458G>A, XM_011529770.1:c.497G>A, XR_937576.1:n.676G>A, XM_005261069.4:c.497G>A, XM_011529766.2:c.497G>A, XM_011529767.2:c.458G>A, XM_011529768.2:c.458G>A, XM_011529770.2:c.497G>A, XM_017028487.1:c.344G>A, XR_937576.2:n.723G>A, NM_001001890.3:c.416G>A, NM_001122607.2:c.416G>A, NM_001754.5:c.497G>A, NM_001754.4(RUNX1):c.497G>A (p.Arg166Gln)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PS3, PS4_Moderate, PM6_Supporting, PM1, PM2_Supporting, PP3, PP1	PS1, PS2, BP1, BP4, BP3, BP2, BA1, PVS1, BP7, BP5, BS3, BS4, BS1, PM5, PM4, PM3, PP2, PP4, BS2	Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.497G>A (p.Arg166Gln) variant and data from a secondary assays demonstrate altered DNA binding, CBFÎ² binding and sub-cellular localization (PS3; PMID: 11830488,  25840971, 23848403). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). This variant has been reported in three probands meeting at least one of the RUNX1-phenotypic criteria (PS4_Moderate; PMID: 10508512, 28960434, 26175287). This variant is absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). It has a REVEL score >0.75 (0.962) (PP3). There are two unrelated probands meeting at least one of the RUNX1- phenotypic criteria with assumed de novo occurrence (without confirmation of maternity and paternity) (PM6_ Supporting; PMID: 8960434, 26175287). This variant was found to co-segregate with disease in multiple affected family members, with three meioses observed in one family (PP1; PMID: 10508512). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PM1, PS4_Moderate, PM2_supporting, PP3,  PM6_Supporting, PP1.	23848403, 25840971, 11830488, 28960434, 26175287, 28960434, 10508512, 26175287, 28960434, 26175287, 10508512, 10508512	Myeloid Malignancy VCEP		2024-09-10	2024-09-10	false	https://erepo.genome.network/evrepo/ui/classification/CA16616941/MONDO:0011071/008	ba8c0c9c-028c-473b-9259-a8316db5b16d
NM_001754.4(RUNX1):c.557T>A (p.Val186Asp)	212089	CA248819	NM_001754.4:c.557T>A, NC_000021.9:g.34859530A>T, CM000683.2:g.34859530A>T, NC_000021.8:g.36231827A>T, CM000683.1:g.36231827A>T, NC_000021.7:g.35153697A>T, NG_011402.2:g.1130182T>A, LRG_482:g.1130182T>A, ENST00000675419.1:c.557T>A, ENST00000300305.7:c.557T>A, ENST00000344691.8:c.476T>A, ENST00000358356.9:c.476T>A, ENST00000399237.6:c.521T>A, ENST00000399240.5:c.476T>A, ENST00000437180.5:c.557T>A, ENST00000467577.1:n.49T>A, ENST00000482318.5:c.*147T>A, NM_001001890.2:c.476T>A, NM_001122607.1:c.476T>A, LRG_482t1:c.557T>A, XM_005261068.3:c.521T>A, XM_005261069.3:c.557T>A, XM_011529766.1:c.557T>A, XM_011529767.1:c.518T>A, XM_011529768.1:c.518T>A, XM_011529770.1:c.557T>A, XR_937576.1:n.736T>A, XM_005261069.4:c.557T>A, XM_011529766.2:c.557T>A, XM_011529767.2:c.518T>A, XM_011529768.2:c.518T>A, XM_011529770.2:c.557T>A, XM_017028487.1:c.404T>A, XR_937576.2:n.783T>A, NM_001001890.3:c.476T>A, NM_001122607.2:c.476T>A, NM_001754.5:c.557T>A, NM_001754.4(RUNX1):c.557T>A (p.Val186Asp)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	PM1_Supporting, PM2_Supporting, PP3	PS3, PS1, PS4, PS2, BP1, BP4, BP3, BP2, BA1, PM6, PVS1, BP7, BP5, BS3, BS1, BS4, PM4, PM5, PM3, BS2, PP2, PP1, PP4	NM_001754.4(RUNX1):c.557T>A (p.Val186Asp) is a missense variant which is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). It has a REVEL score of 0.953 (> 0.75), supporting PP3. This variant is located within the Runt Homology Domain (RHD), affecting one of the residues (AA 105-204) but not an established hotspot residue (PM1_supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, PP3, PM1_supporting.		Myeloid Malignancy VCEP		2025-01-15	2025-01-15	false	https://erepo.genome.network/evrepo/ui/classification/CA248819/MONDO:0011071/008	3ff9a59f-f463-4e1a-942e-a60afc15686a
NM_001754.4(RUNX1):c.602G>A (p.Arg201Gln)	14464	CA248610	NM_001754.4:c.602G>A, NC_000021.9:g.34859485C>T, CM000683.2:g.34859485C>T, NC_000021.8:g.36231782C>T, CM000683.1:g.36231782C>T, NC_000021.7:g.35153652C>T, NG_011402.2:g.1130227G>A, LRG_482:g.1130227G>A, NM_001001890.2:c.521G>A, NM_001122607.1:c.521G>A, LRG_482t1:c.602G>A, XM_005261068.3:c.566G>A, XM_005261069.3:c.602G>A, XM_011529766.1:c.602G>A, XM_011529767.1:c.563G>A, XM_011529768.1:c.563G>A, XM_011529770.1:c.602G>A, XR_937576.1:n.781G>A, XM_005261069.4:c.602G>A, XM_011529766.2:c.602G>A, XM_011529767.2:c.563G>A, XM_011529768.2:c.563G>A, XM_011529770.2:c.602G>A, XM_017028487.1:c.449G>A, XR_937576.2:n.828G>A, ENST00000300305.7:c.602G>A, ENST00000344691.8:c.521G>A, ENST00000358356.9:c.521G>A, ENST00000399237.6:c.566G>A, ENST00000399240.5:c.521G>A, ENST00000437180.5:c.602G>A, ENST00000467577.1:n.94G>A, ENST00000482318.5:c.*192G>A, NM_001754.4(RUNX1):c.602G>A (p.Arg201Gln)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PS4, PS3, PM2, PM1, PP1, PP3	PS1, BP2, BP4, BA1, PVS1, PM6, BP7, BS1, BS4, BS3, PM5, PM4	Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.602G>A (p.Arg201Gln) variant  and data from a secondary assays demonstrate altered DNA binding, CBFÎ² binding and sub-cellular localization (PS3; PMID: 17290219, 11830488, 23817177, 22318203, 25840971,  23848403). This variant has been reported in four probands meeting at least one of the RUNX1-phenotypic criteria (PS4; PMID: 27112265, 28748566, 10508512). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). The variant has a REVEL score >0.75 (0.94) (PP3). It was found to co-segregate with disease in multiple affected family members, with four meioses observed in across 3 families (PP1; PMID:  27112265, 28748566, 10508512). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PS4, PM1, PM2, PP1, PP3.	10508512, 28748566, 27112265, 23817177, 11830488, 22318203, 23848403, 17290219, 25840971, 28748566, 10508512, 27112265, 28748566, 10508512, 27112265	Myeloid Malignancy VCEP		2019-07-30	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA248610/MONDO:0011071/008	52b9ca56-4641-4652-8c86-bee9650bacf2
NM_001754.4:c.1395C>A	666273	CA410146870	NM_001754.4:c.1395C>A, NC_000021.9:g.34792183G>T, CM000683.2:g.34792183G>T, NC_000021.8:g.36164480G>T, CM000683.1:g.36164480G>T, NC_000021.7:g.35086350G>T, NG_011402.2:g.1197529C>A, LRG_482:g.1197529C>A, ENST00000675419.1:c.1395C>A, ENST00000300305.7:c.1395C>A, ENST00000344691.8:c.1314C>A, ENST00000399240.5:c.1122C>A, ENST00000437180.5:c.1395C>A, ENST00000482318.5:c.*985C>A, NM_001001890.2:c.1314C>A, LRG_482t1:c.1395C>A, XM_005261068.3:c.1359C>A, XM_005261069.3:c.1203C>A, XM_011529766.1:c.1395C>A, XM_011529767.1:c.1356C>A, XM_011529768.1:c.1164C>A, XM_005261069.4:c.1203C>A, XM_011529766.2:c.1395C>A, XM_011529767.2:c.1356C>A, XM_011529768.2:c.1164C>A, XM_017028487.1:c.1242C>A, NM_001001890.3:c.1314C>A, NM_001754.5:c.1395C>A	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BP4, PM2_Supporting	PS1, PS3, PS4, PS2, BP1, BP3, BP2, BA1, PM6, PVS1, BP7, BP5, BS3, BS1, BS4, PM4, PM5, PM1, PM3, BS2, PP2, PP3, PP1, PP4	NM_001754.5(RUNX1):c.1395C>A (p.Asn465Lys) is a missense variant which is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This variant has a REVEL score of 0.108 (< 0.15), and SSF and MES predict no change in the canonical splice site score, with no creation of putative cryptic splice sites, supporting BP4. The variant is reported in an individual with MDS in PMID: 26884589; however, a germline sample was not used for genetic testing, so the evidence does not meet the criteria for PS4_supporting. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, BP4.		Myeloid Malignancy VCEP		2025-01-15	2025-01-15	false	https://erepo.genome.network/evrepo/ui/classification/CA410146870/MONDO:0011071/008	49879cb4-10b0-44b7-a695-0af82d9e37d5
NM_001754.5(RUNX1):c.215_216dup (p.Ser73fs)	463988	CA658656806	NM_001754.5:c.215_216dup, NC_000021.9:g.34886978_34886979dup, CM000683.2:g.34886978_34886979dup, NC_000021.8:g.36259275_36259276dup, CM000683.1:g.36259275_36259276dup, NC_000021.7:g.35181145_35181146dup, NG_011402.2:g.1102733_1102734dup, LRG_482:g.1102733_1102734dup, ENST00000675419.1:c.215_216dup, ENST00000300305.7:c.215_216dup, ENST00000344691.8:c.134_135dup, ENST00000358356.9:c.134_135dup, ENST00000399237.6:c.179_180dup, ENST00000399240.5:c.134_135dup, ENST00000437180.5:c.215_216dup, ENST00000455571.5:c.176_177dup, ENST00000482318.5:c.59-6266_59-6265dup, NM_001001890.2:c.134_135dup, NM_001122607.1:c.134_135dup, NM_001754.4:c.215_216dup, LRG_482t1:c.215_216dup, XM_005261068.3:c.179_180dup, XM_005261069.3:c.215_216dup, XM_011529766.1:c.215_216dup, XM_011529767.1:c.176_177dup, XM_011529768.1:c.176_177dup, XM_011529770.1:c.215_216dup, XR_937576.1:n.394_395dup, XM_005261069.4:c.215_216dup, XM_011529766.2:c.215_216dup, XM_011529767.2:c.176_177dup, XM_011529768.2:c.176_177dup, XM_011529770.2:c.215_216dup, XM_017028487.1:c.62_63dup, XR_937576.2:n.441_442dup, NM_001001890.3:c.134_135dup, NM_001122607.2:c.134_135dup, NM_001754.5(RUNX1):c.215_216dup (p.Ser73fs)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PM2_Supporting, PS4_Supporting	PS1, PS3, PS2, BP1, BP4, BP3, BP2, BA1, PM6, BP7, BP5, BS3, BS1, BS4, PM4, PM1, PM3, BS2, PP2, PP3, PP1, PP4	The NM_001754.4:c.215_216dup (p.Ser73Glyfs) variant is a frameshift variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This variant is a nonsense/frameshift variants that is downstream of c.98 (PM5_Supporting). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; SCV000638134.1). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2_supporting, PS4_Supporting, PM5_supporting.		Myeloid Malignancy VCEP		2024-03-26	2024-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA658656806/MONDO:0011071/008	1d884ce0-9d6e-40e7-a2aa-6f0ff56bae4c
NM_001754.5(RUNX1):c.442_449del (p.Thr148fs)	14470	CA248627	NM_001754.5:c.442_449del, NC_000021.9:g.34880616_34880623del, CM000683.2:g.34880616_34880623del, NC_000021.8:g.36252913_36252920del, CM000683.1:g.36252913_36252920del, NC_000021.7:g.35174783_35174790del, NG_011402.2:g.1109089_1109096del, LRG_482:g.1109089_1109096del, ENST00000675419.1:c.442_449del, ENST00000300305.7:c.442_449del, ENST00000344691.8:c.361_368del, ENST00000358356.9:c.361_368del, ENST00000399237.6:c.406_413del, ENST00000399240.5:c.361_368del, ENST00000437180.5:c.442_449del, ENST00000455571.5:c.403_410del, ENST00000482318.5:c.*32_*39del, NM_001001890.2:c.361_368del, NM_001122607.1:c.361_368del, NM_001754.4:c.442_449del, LRG_482t1:c.442_449del, XM_005261068.3:c.406_413del, XM_005261069.3:c.442_449del, XM_011529766.1:c.442_449del, XM_011529767.1:c.403_410del, XM_011529768.1:c.403_410del, XM_011529770.1:c.442_449del, XR_937576.1:n.621_628del, XM_005261069.4:c.442_449del, XM_011529766.2:c.442_449del, XM_011529767.2:c.403_410del, XM_011529768.2:c.403_410del, XM_011529770.2:c.442_449del, XM_017028487.1:c.289_296del, XR_937576.2:n.668_675del, NM_001001890.3:c.361_368del, NM_001122607.2:c.361_368del, NM_001754.5(RUNX1):c.442_449del (p.Thr148fs)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PM2_Supporting, PS4_Supporting	PS1, PS3, PS2, BP1, BP4, BP3, BP2, BA1, PM6, BP7, BP5, BS3, BS1, BS4, PM4, PM1, PM3, PP2, PP3, PP1, PP4, BS2	The NM_001754.4(RUNX1):c.442_449delACCGCAGC (p.Thr148Hisfs) variant is a frameshift variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This variant is a nonsense/frameshift variants that is downstream of c.98 (PM5_Supporting). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting;  PMID: 27112265). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2_supporting, PS4_Supporting, PM5_supporting.	27112265, 27112265, 27112265	Myeloid Malignancy VCEP		2024-03-26	2024-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA248627/MONDO:0011071/008	029c6661-002e-49de-a67f-e2903b825e5b
NM_001754.5(RUNX1):c.352-1G>A	436616	CA410202793	NM_001754.5:c.352-1G>A, NC_000021.9:g.34880714C>T, CM000683.2:g.34880714C>T, NC_000021.8:g.36253011C>T, CM000683.1:g.36253011C>T, NC_000021.7:g.35174881C>T, NG_011402.2:g.1108998G>A, LRG_482:g.1108998G>A, ENST00000675419.1:c.352-1G>A, ENST00000300305.7:c.352-1G>A, ENST00000344691.8:c.271-1G>A, ENST00000358356.9:c.271-1G>A, ENST00000399237.6:c.316-1G>A, ENST00000399240.5:c.271-1G>A, ENST00000437180.5:c.352-1G>A, ENST00000455571.5:c.313-1G>A, ENST00000482318.5:c.59-1G>A, NM_001001890.2:c.271-1G>A, NM_001122607.1:c.271-1G>A, NM_001754.4:c.352-1G>A, LRG_482t1:c.352-1G>A, XM_005261068.3:c.316-1G>A, XM_005261069.3:c.352-1G>A, XM_011529766.1:c.352-1G>A, XM_011529767.1:c.313-1G>A, XM_011529768.1:c.313-1G>A, XM_011529770.1:c.352-1G>A, XR_937576.1:n.531-1G>A, XM_005261069.4:c.352-1G>A, XM_011529766.2:c.352-1G>A, XM_011529767.2:c.313-1G>A, XM_011529768.2:c.313-1G>A, XM_011529770.2:c.352-1G>A, XM_017028487.1:c.199-1G>A, XR_937576.2:n.578-1G>A, NM_001001890.3:c.271-1G>A, NM_001122607.2:c.271-1G>A, NM_001754.5(RUNX1):c.352-1G>A	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PVS1, PS4_Supporting, PM2_Supporting, PP1	PS1, PS3, PS2, BA1, BP1, BP4, BP3, BP2, PM6, BS3, BS1, BS4, BP7, BP5, PM5, PM4, PM1, PM3, BS2, PP2, PP3, PP4	The NM_001754.4:c.352-1G>A variant is a canonical splice site variant that is predicted to introduce a frameshift and premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_Supporting). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 26175287). This variant was found to co-segregate with disease in multiple affected family members, with three meioses observed in one family (PP1; PMID: 26175287). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2_supporting, PS4_Supporting, PP1.	26175287, 26175287, 26175287	Myeloid Malignancy VCEP		2024-03-26	2024-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA410202793/MONDO:0011071/008	bacb4dd5-65e9-43dd-9c45-b3d9b6a59f6d
NM_001754.4(RUNX1):c.352-1G>T	14463	CA248609	NM_001754.4:c.352-1G>T, NC_000021.9:g.34880714C>A, CM000683.2:g.34880714C>A, NC_000021.8:g.36253011C>A, CM000683.1:g.36253011C>A, NC_000021.7:g.35174881C>A, NG_011402.2:g.1108998G>T, LRG_482:g.1108998G>T, NM_001001890.2:c.271-1G>T, NM_001122607.1:c.271-1G>T, LRG_482t1:c.352-1G>T, XM_005261068.3:c.316-1G>T, XM_005261069.3:c.352-1G>T, XM_011529766.1:c.352-1G>T, XM_011529767.1:c.313-1G>T, XM_011529768.1:c.313-1G>T, XM_011529770.1:c.352-1G>T, XR_937576.1:n.531-1G>T, XM_005261069.4:c.352-1G>T, XM_011529766.2:c.352-1G>T, XM_011529767.2:c.313-1G>T, XM_011529768.2:c.313-1G>T, XM_011529770.2:c.352-1G>T, XM_017028487.1:c.199-1G>T, XR_937576.2:n.578-1G>T, ENST00000300305.7:c.352-1G>T, ENST00000344691.8:c.271-1G>T, ENST00000358356.9:c.271-1G>T, ENST00000399237.6:c.316-1G>T, ENST00000399240.5:c.271-1G>T, ENST00000437180.5:c.352-1G>T, ENST00000455571.5:c.313-1G>T, ENST00000482318.5:c.59-1G>T, NM_001754.4(RUNX1):c.352-1G>T	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PVS1, PM2, PS4_Supporting	PS3, PS1, BP2, BP4, BA1, PM6, BS4, BS1, BS3, BP7, PM1, PM4, PM5, PP3	The NM_001754.4:c.352-1G>T variant is a canonical splice site variant that is predicted to introduce a frameshift and a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1; PMID: 10508512). This variant was found to co-segregate with disease in multiple affected family members, with more than seven meioses (at least 25 affected individuals) observed in one family/across X families (PP1_Strong; 10508512). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 11830488). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PP1_Strong, PM2, PS4_Supporting.		Myeloid Malignancy VCEP		2019-08-01	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA248609/MONDO:0011071/008	582e74ff-583d-43ab-9de0-41f6d60d889b
NM_001754.5(RUNX1):c.351+1G>C	409822	CA16616270	NM_001754.5:c.351+1G>C, NC_000021.9:g.34886842C>G, CM000683.2:g.34886842C>G, NC_000021.8:g.36259139C>G, CM000683.1:g.36259139C>G, NC_000021.7:g.35181009C>G, NG_011402.2:g.1102870G>C, LRG_482:g.1102870G>C, ENST00000675419.1:c.351+1G>C, ENST00000300305.7:c.351+1G>C, ENST00000344691.8:c.270+1G>C, ENST00000358356.9:c.270+1G>C, ENST00000399237.6:c.315+1G>C, ENST00000399240.5:c.270+1G>C, ENST00000437180.5:c.351+1G>C, ENST00000455571.5:c.312+1G>C, ENST00000482318.5:c.59-6129G>C, NM_001001890.2:c.270+1G>C, NM_001122607.1:c.270+1G>C, NM_001754.4:c.351+1G>C, LRG_482t1:c.351+1G>C, XM_005261068.3:c.315+1G>C, XM_005261069.3:c.351+1G>C, XM_011529766.1:c.351+1G>C, XM_011529767.1:c.312+1G>C, XM_011529768.1:c.312+1G>C, XM_011529770.1:c.351+1G>C, XR_937576.1:n.530+1G>C, XM_005261069.4:c.351+1G>C, XM_011529766.2:c.351+1G>C, XM_011529767.2:c.312+1G>C, XM_011529768.2:c.312+1G>C, XM_011529770.2:c.351+1G>C, XM_017028487.1:c.198+1G>C, XR_937576.2:n.577+1G>C, NM_001001890.3:c.270+1G>C, NM_001122607.2:c.270+1G>C, NM_001754.5(RUNX1):c.351+1G>C	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	PVS1, PM2_Supporting	PS1, PS3, PS4, PS2, BA1, BP1, BP4, BP3, BP2, PM6, BS3, BS1, BS4, BP7, BP5, PM5, PM4, PM1, PM3, BS2, PP2, PP3, PP1, PP4	The NM_001754.4(RUNX1):c.351+1G>C variant is a canonical splice site variant that is predicted to introduce a frameshift and a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2_supporting.		Myeloid Malignancy VCEP		2025-04-16	2025-04-16	false	https://erepo.genome.network/evrepo/ui/classification/CA16616270/MONDO:0011071/008	5671cfda-4808-4020-8702-22f1816745bd
NM_001754.4(RUNX1):c.508+3delA	14466	CA248618	NM_001754.4:c.508+3delA, NC_000021.9:g.34880554del, CM000683.2:g.34880554del, NC_000021.8:g.36252851del, CM000683.1:g.36252851del, NC_000021.7:g.35174721del, NG_011402.2:g.1109158del, LRG_482:g.1109158del, ENST00000675419.1:c.508+3del, ENST00000300305.7:c.508+3del, ENST00000344691.8:c.427+3del, ENST00000358356.9:c.427+3del, ENST00000399237.6:c.472+3del, ENST00000399240.5:c.427+3del, ENST00000437180.5:c.508+3del, ENST00000482318.5:c.*98+3del, NM_001001890.2:c.427+3del, NM_001122607.1:c.427+3del, NM_001754.4:c.508+3del, LRG_482t1:c.508+3del, XM_005261068.3:c.472+3del, XM_005261069.3:c.508+3del, XM_011529766.1:c.508+3del, XM_011529767.1:c.469+3del, XM_011529768.1:c.469+3del, XM_011529770.1:c.508+3del, XR_937576.1:n.687+3del, XM_005261069.4:c.508+3del, XM_011529766.2:c.508+3del, XM_011529767.2:c.469+3del, XM_011529768.2:c.469+3del, XM_011529770.2:c.508+3del, XM_017028487.1:c.355+3del, XR_937576.2:n.734+3del, NM_001001890.3:c.427+3del, NM_001122607.2:c.427+3del, NM_001754.5:c.508+3del, NM_001754.4(RUNX1):c.508+3delA	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PS3, PP1_Strong, PS4_Supporting, PM2_Supporting, PP3	PS1, PS2, BP1, BP4, BP3, BP2, BA1, PVS1, BP7, BP5, BS3, BS1, BS4, PM6, PM4, PM1, PM5, PM3, PP2, PP4, BS2	There is RT-PCR assay evidence demonstrating that the NM_001754.4:c.508+3delA variant creates a cryptic splice donor site that is used and results in a frameshift and introduction of premature termination codon (PS3; PMID: 11830488). This variant was found to co-segregate with disease in multiple affected family members, with eight meioses observed in one family (PP1_Strong; PMID: 11830488). It is absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This intronic variant (in intron 5) is located in reference to the exon at positions +3 for donor splice site and has a predicted decrease in the score of the canonical splice site by at least 75% (measured by both MES and SSF). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_Supporting; PMID: 11830488). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PP1_Strong, PM2_supporting, PP3, PS4_Supporting.	11830488, 11830488, 11830488, 11830488	Myeloid Malignancy VCEP		2024-09-10	2024-09-10	false	https://erepo.genome.network/evrepo/ui/classification/CA248618/MONDO:0011071/008	d7a48ae9-bd50-426d-bb9f-589c53013a9b
NM_001754.4(RUNX1):c.654C>T (p.Ser218=)	239052	CA10014384	NM_001754.4:c.654C>T, NC_000021.9:g.34834561G>A, CM000683.2:g.34834561G>A, NC_000021.8:g.36206858G>A, CM000683.1:g.36206858G>A, NC_000021.7:g.35128728G>A, NG_011402.2:g.1155151C>T, LRG_482:g.1155151C>T, NM_001001890.2:c.573C>T, NM_001122607.1:c.573C>T, LRG_482t1:c.654C>T, XM_005261068.3:c.618C>T, XM_005261069.3:c.613+24913C>T, XM_011529766.1:c.654C>T, XM_011529767.1:c.615C>T, XM_011529768.1:c.574+24913C>T, XM_011529770.1:c.654C>T, XR_937576.1:n.833C>T, XM_005261069.4:c.613+24913C>T, XM_011529766.2:c.654C>T, XM_011529767.2:c.615C>T, XM_011529768.2:c.574+24913C>T, XM_011529770.2:c.654C>T, XM_017028487.1:c.501C>T, XR_937576.2:n.880C>T, ENST00000300305.7:c.654C>T, ENST00000344691.8:c.573C>T, ENST00000358356.9:c.573C>T, ENST00000399237.6:c.618C>T, ENST00000399240.5:c.532+24913C>T, ENST00000437180.5:c.654C>T, ENST00000469087.1:n.190C>T, ENST00000482318.5:c.*244C>T, NM_001754.4(RUNX1):c.654C>T (p.Ser218=)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP4, BS1	PS3, PS1, PS4, BP2, BA1, PM6, PM2, PVS1, BP7, BS3, BS4, PM1, PM4, PM5, PP3, PP1	The MAF of the synonymous variant, NM_001754.4:c.654C>T (p.Ser218=), is 0.00105 (0.1%, 36/34418 alleles) in the Latino subpopulation of the gnomAD cohort, which is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). This synonymous variant is predicted by SSF and MES to lead to an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% AND no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, BP4.		Myeloid Malignancy VCEP		2019-08-02	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014384/MONDO:0011071/008	4b6d6bcb-da2e-42b4-886e-38565501ee4a
NM_001754.5(RUNX1):c.1269C>T (p.Arg423=)	239042	CA10014189	NM_001754.5:c.1269C>T, NC_000021.9:g.34792309G>A, CM000683.2:g.34792309G>A, NC_000021.8:g.36164606G>A, CM000683.1:g.36164606G>A, NC_000021.7:g.35086476G>A, NG_011402.2:g.1197403C>T, LRG_482:g.1197403C>T, ENST00000675419.1:c.1269C>T, ENST00000300305.7:c.1269C>T, ENST00000344691.8:c.1188C>T, ENST00000399240.5:c.996C>T, ENST00000437180.5:c.1269C>T, ENST00000482318.5:c.*859C>T, NM_001001890.2:c.1188C>T, NM_001754.4:c.1269C>T, LRG_482t1:c.1269C>T, XM_005261068.3:c.1233C>T, XM_005261069.3:c.1077C>T, XM_011529766.1:c.1269C>T, XM_011529767.1:c.1230C>T, XM_011529768.1:c.1038C>T, XM_005261069.4:c.1077C>T, XM_011529766.2:c.1269C>T, XM_011529767.2:c.1230C>T, XM_011529768.2:c.1038C>T, XM_017028487.1:c.1116C>T, NM_001001890.3:c.1188C>T, NM_001754.5(RUNX1):c.1269C>T (p.Arg423=)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP4, BS1, BP7	PS1, PS3, PS4, PS2, BP1, BP3, BP2, BA1, PVS1, PM6, PM2, BS3, BS4, BP5, PM4, PM5, PM1, PM3, BS2, PP2, PP3, PP1, PP4	NM_001754.5(RUNX1):c.1269C>T (p.Arg423=) is a synonymous variant which has a MAF of 0.0003400 (0.034%, 23/67652 alleles) in the European non-Finnish subpopulation of the gnomAD v3 cohort, meeting the threshold for BS1. This variant has a SpliceAI score â‰¤ 0.20 (0.0) (BP4), and evolutionary conservation algorithms predict the site as not being conserved (PhyloP score â‰¤ 2.0 (0.62)) (BP7). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, BP4, BP7.		Myeloid Malignancy VCEP		2025-05-02	2025-05-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014189/MONDO:0011071/008	35a9e328-f29e-49b8-8ad9-03779bd95996
NM_001754.5(RUNX1):c.1389C>G (p.Pro463=)	258184	CA10014178	NM_001754.5:c.1389C>G, NC_000021.9:g.34792189G>C, CM000683.2:g.34792189G>C, NC_000021.8:g.36164486G>C, CM000683.1:g.36164486G>C, NC_000021.7:g.35086356G>C, NG_011402.2:g.1197523C>G, LRG_482:g.1197523C>G, ENST00000675419.1:c.1389C>G, ENST00000300305.7:c.1389C>G, ENST00000344691.8:c.1308C>G, ENST00000399240.5:c.1116C>G, ENST00000437180.5:c.1389C>G, ENST00000482318.5:c.*979C>G, NM_001001890.2:c.1308C>G, NM_001754.4:c.1389C>G, LRG_482t1:c.1389C>G, XM_005261068.3:c.1353C>G, XM_005261069.3:c.1197C>G, XM_011529766.1:c.1389C>G, XM_011529767.1:c.1350C>G, XM_011529768.1:c.1158C>G, XM_005261069.4:c.1197C>G, XM_011529766.2:c.1389C>G, XM_011529767.2:c.1350C>G, XM_011529768.2:c.1158C>G, XM_017028487.1:c.1236C>G, NM_001001890.3:c.1308C>G, NM_001754.5(RUNX1):c.1389C>G (p.Pro463=)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP4, BP2, BA1, BP7	PS1, PS3, PS2, PS4, BP1, BP3, PVS1, PM6, PM2, BP5, BS3, BS4, BS1, PM5, PM4, PM1, PM3, PP2, PP3, PP1, PP4, BS2	NM_001754.4(RUNX1):c.1389C>G (p.Pro463=) is a synonymous variant which has a minor allele frequency of 0.1206 (1976/16382 alleles) in the African subpopulation of the gnomAD cohort, meeting the threshold for BA1. It is detected in a homozygous state in 202 individuals in gnomAD (BP2). Splicing predictors SSF and MES indicate no significant impact on the canonical splice site, and no cryptic splice sites are created (BP4). Evolutionary conservation algorithms predict the site as not being conserved (BP7). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2, BP4, BP7.	27106701	Myeloid Malignancy VCEP		2025-05-02	2025-05-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014178/MONDO:0011071/008	9ae68387-9090-4f9d-933e-8799521dac42
NM_001754.4(RUNX1):c.18A>G (p.Ile6Met)	463989	CA10014733	NM_001754.4:c.18A>G, NC_000021.9:g.35048882T>C, CM000683.2:g.35048882T>C, NC_000021.8:g.36421179T>C, CM000683.1:g.36421179T>C, NC_000021.7:g.35343049T>C, NG_011402.2:g.940830A>G, LRG_482:g.940830A>G, LRG_482t1:c.18A>G, XM_005261069.3:c.18A>G, XM_011529766.1:c.18A>G, XM_011529767.1:c.18A>G, XM_011529768.1:c.18A>G, XM_011529770.1:c.18A>G, XR_937576.1:n.197A>G, XM_005261069.4:c.18A>G, XM_011529766.2:c.18A>G, XM_011529767.2:c.18A>G, XM_011529768.2:c.18A>G, XM_011529770.2:c.18A>G, XR_937576.2:n.244A>G, ENST00000300305.7:c.18A>G, ENST00000416754.1:c.18A>G, ENST00000437180.5:c.18A>G, ENST00000455571.5:c.18A>G, ENST00000475045.6:c.18A>G, ENST00000482318.5:c.18A>G, NM_001754.4(RUNX1):c.18A>G (p.Ile6Met)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BS1	PS4, PS3, PS1, BP2, BP4, BA1, PM6, PM2, PVS1, BP7, BS4, BS3, PM1, PM4, PM5, PP1, PP3	MAF for NM_001754.4:c.18A>G (p.Ile6Met) variant is 0.00025 (0.02%, 17/66732 Alleles) in the non-Finnish European subpopulation of ExAC database, which is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). Note: The variant is classified as likely benign based on BS1 alone with no contradictory evidence supporting pathogenicity. In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1.		Myeloid Malignancy VCEP		2019-08-02	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014733/MONDO:0011071/008	ff29e264-e204-4efc-bb2e-f3f16e5d88d0
NM_001754.5(RUNX1):c.65T>A (p.Ile22Lys)	464002	CA10014634	NM_001754.5:c.65T>A, NC_000021.9:g.34892957A>T, CM000683.2:g.34892957A>T, NC_000021.8:g.36265254A>T, CM000683.1:g.36265254A>T, NC_000021.7:g.35187124A>T, NG_011402.2:g.1096755T>A, LRG_482:g.1096755T>A, ENST00000675419.1:c.65T>A, ENST00000300305.7:c.65T>A, ENST00000416754.1:c.65T>A, ENST00000437180.5:c.65T>A, ENST00000455571.5:c.59-5861T>A, ENST00000475045.6:c.65T>A, ENST00000482318.5:c.59-12244T>A, NM_001754.4:c.65T>A, LRG_482t1:c.65T>A, XM_005261069.3:c.65T>A, XM_011529766.1:c.65T>A, XM_011529767.1:c.59-5861T>A, XM_011529768.1:c.59-5861T>A, XM_011529770.1:c.65T>A, XR_937576.1:n.244T>A, XM_005261069.4:c.65T>A, XM_011529766.2:c.65T>A, XM_011529767.2:c.59-5861T>A, XM_011529768.2:c.59-5861T>A, XM_011529770.2:c.65T>A, XR_937576.2:n.291T>A, NM_001754.5(RUNX1):c.65T>A (p.Ile22Lys)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1, BP4	PS1, PS3, PS4, PS2, BP1, BP3, BP2, PVS1, PM2, PM6, BP7, BP5, BS3, BS1, BS4, PM5, PM4, PM1, PM3, BS2, PP2, PP3, PP1, PP4	NM_001754.4(RUNX1):c.65T>A (p.Ile22Lys) is a missense variant which has a MAF of 0.001593 (56/35158 alleles) in the Latino subpopulation in gnomAD v2.1.1, meeting the threshold for BA1. It also has a REVEL score < 0.50 (0.271) and a SpliceAI score â‰¤ 0.20 (0.04) (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP4.		Myeloid Malignancy VCEP		2025-05-02	2025-05-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014634/MONDO:0011071/008	6426c4e0-697d-4b39-a0dd-56f81c978e1a
NM_001754.5(RUNX1):c.824C>T (p.Pro275Leu)	464009	CA10014287	NM_001754.5:c.824C>T, NC_000021.9:g.34799444G>A, CM000683.2:g.34799444G>A, NC_000021.8:g.36171741G>A, CM000683.1:g.36171741G>A, NC_000021.7:g.35093611G>A, NG_011402.2:g.1190268C>T, LRG_482:g.1190268C>T, ENST00000675419.1:c.824C>T, ENST00000300305.7:c.824C>T, ENST00000344691.8:c.743C>T, ENST00000399240.5:c.551C>T, ENST00000437180.5:c.824C>T, ENST00000482318.5:c.*414C>T, NM_001001890.2:c.743C>T, NM_001754.4:c.824C>T, LRG_482t1:c.824C>T, XM_005261068.3:c.788C>T, XM_005261069.3:c.632C>T, XM_011529766.1:c.824C>T, XM_011529767.1:c.785C>T, XM_011529768.1:c.593C>T, XR_937576.1:n.1003C>T, XM_005261069.4:c.632C>T, XM_011529766.2:c.824C>T, XM_011529767.2:c.785C>T, XM_011529768.2:c.593C>T, XM_017028487.1:c.671C>T, XR_937576.2:n.1050C>T, NM_001001890.3:c.743C>T, NM_001754.5(RUNX1):c.824C>T (p.Pro275Leu)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP4, BA1	PS1, PS3, PS4, PS2, BP1, BP3, BP2, PVS1, PM2, PM6, BP7, BP5, BS3, BS1, BS4, PM5, PM4, PM1, PM3, PP2, PP3, PP1, PP4, BS2	NM_001754.5(RUNX1):c.824C>T (p.Pro275Leu) is a missense variant which has a minor allele frequency (MAF) of 0.00225 (0.2%, 26/11,566 alleles) in the Latino subpopulation of the ExAC cohort, which is â‰¥ 0.0015 (0.15%) (BA1). This variant also has a REVEL score < 0.15 (0.146) (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP4.		Myeloid Malignancy VCEP		2025-03-25	2025-03-25	false	https://erepo.genome.network/evrepo/ui/classification/CA10014287/MONDO:0011071/008	ed562b68-0918-4a40-899c-7000d16d5da8
NM_001754.4(RUNX1):c.1005G>T (p.Gln335His)	239039	CA10014223	NM_001754.4:c.1005G>T, NC_000021.9:g.34792573C>A, CM000683.2:g.34792573C>A, NC_000021.8:g.36164870C>A, CM000683.1:g.36164870C>A, NC_000021.7:g.35086740C>A, NG_011402.2:g.1197139G>T, LRG_482:g.1197139G>T, NM_001001890.2:c.924G>T, LRG_482t1:c.1005G>T, XM_005261068.3:c.969G>T, XM_005261069.3:c.813G>T, XM_011529766.1:c.1005G>T, XM_011529767.1:c.966G>T, XM_011529768.1:c.774G>T, XR_937576.1:n.4609G>T, XM_005261069.4:c.813G>T, XM_011529766.2:c.1005G>T, XM_011529767.2:c.966G>T, XM_011529768.2:c.774G>T, XM_017028487.1:c.852G>T, XR_937576.2:n.4656G>T, ENST00000300305.7:c.1005G>T, ENST00000344691.8:c.924G>T, ENST00000399240.5:c.732G>T, ENST00000437180.5:c.1005G>T, ENST00000482318.5:c.*595G>T, NM_001754.4(RUNX1):c.1005G>T (p.Gln335His)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1	PS4, PS3, PS1, BP2, BP4, PVS1, PM6, PM2, BS4, BS1, BS3, BP7, PM1, PM4, PM5, PP1, PP3	The NM_001754.4:c.1005G>T (p.Gln335His) variant has a MAF of 0.00357 (0.357%, 15/4,206 alleles) in the East Asian subpopulation of the ExAC cohort that is â‰¥ 0.0015 (0.15%) (BA1). This missense variant has a REVEL score 0.4. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1.		Myeloid Malignancy VCEP		2019-07-26	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014223/MONDO:0011071/008	1ef12dd0-41cd-4ff0-897f-dd0a414457bc
NM_001754.4(RUNX1):c.1355T>G (p.Val452Gly)	339875	CA10014181	NM_001754.4:c.1355T>G, NC_000021.9:g.34792223A>C, CM000683.2:g.34792223A>C, NC_000021.8:g.36164520A>C, CM000683.1:g.36164520A>C, NC_000021.7:g.35086390A>C, NG_011402.2:g.1197489T>G, LRG_482:g.1197489T>G, NM_001001890.2:c.1274T>G, LRG_482t1:c.1355T>G, XM_005261068.3:c.1319T>G, XM_005261069.3:c.1163T>G, XM_011529766.1:c.1355T>G, XM_011529767.1:c.1316T>G, XM_011529768.1:c.1124T>G, XM_005261069.4:c.1163T>G, XM_011529766.2:c.1355T>G, XM_011529767.2:c.1316T>G, XM_011529768.2:c.1124T>G, XM_017028487.1:c.1202T>G, ENST00000300305.7:c.1355T>G, ENST00000344691.8:c.1274T>G, ENST00000399240.5:c.1082T>G, ENST00000437180.5:c.1355T>G, ENST00000482318.5:c.*945T>G, NM_001754.4(RUNX1):c.1355T>G (p.Val452Gly)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP4, BA1, BS3	PS4, PS3, PS1, BP2, PM6, PM2, PVS1, BP7, BS4, BS1, PM1, PM4, PM5, PP1, PP3	The NM_001754.4:c.1355T>G (p.Val452Gly) variant has a MAF of 0.00177 (0.177%, 22/12,406 alleles) in the East Asian subpopulation of the gnomAD cohort that is â‰¥ 0.0015 (0.15%) (BA1). Transactivation assays demonstrating normal transactivation (80-115% of wt) and data from secondary assays demonstrate normal DNA binding and CBFÎ² binding (BS3; PMID: 25840971). This missense variant has a REVEL score <0.15 (0.046) and SSF and MES predict either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BS3, BP4.	25840971	Myeloid Malignancy VCEP		2019-07-26	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014181/MONDO:0011071/008	1b105287-c135-44f7-b0a1-0719b8f91b20
NM_001754.4(RUNX1):c.351+15A>G	258185	CA10014545	NM_001754.4:c.351+15A>G, NC_000021.9:g.34886828T>C, CM000683.2:g.34886828T>C, NC_000021.8:g.36259125T>C, CM000683.1:g.36259125T>C, NC_000021.7:g.35180995T>C, NG_011402.2:g.1102884A>G, LRG_482:g.1102884A>G, NM_001001890.2:c.270+15A>G, NM_001122607.1:c.270+15A>G, LRG_482t1:c.351+15A>G, XM_005261068.3:c.315+15A>G, XM_005261069.3:c.351+15A>G, XM_011529766.1:c.351+15A>G, XM_011529767.1:c.312+15A>G, XM_011529768.1:c.312+15A>G, XM_011529770.1:c.351+15A>G, XR_937576.1:n.530+15A>G, XM_005261069.4:c.351+15A>G, XM_011529766.2:c.351+15A>G, XM_011529767.2:c.312+15A>G, XM_011529768.2:c.312+15A>G, XM_011529770.2:c.351+15A>G, XM_017028487.1:c.198+15A>G, XR_937576.2:n.577+15A>G, ENST00000300305.7:c.351+15A>G, ENST00000344691.8:c.270+15A>G, ENST00000358356.9:c.270+15A>G, ENST00000399237.6:c.315+15A>G, ENST00000399240.5:c.270+15A>G, ENST00000437180.5:c.351+15A>G, ENST00000455571.5:c.312+15A>G, ENST00000482318.5:c.59-6115A>G, NM_001754.4(RUNX1):c.351+15A>G	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP2, BP4, BA1, BP7	PS4, PS3, PS1, PVS1, PM6, PM2, BS4, BS1, BS3, PM1, PM4, PM5, PP1, PP3	The NM_001754.4:c.351+15A>G variant has a MAF of 0.00809 (0.809%, 524/64,760 alleles) in the European (Non-Finnish) subpopulation of the ExAC cohort that is â‰¥ 0.0015 (0.15%) (BA1). This variant is detected in homozygous state (8) in gnomAD population database (BP2). This intronic variant is predicted by SSF and MES to lead to either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In addition, evolutionary conservation prediction algorithms predict the site as not being highly conserved (PhyloP score -1.34728 < 0.1) (BP7). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2, BP4, BP7.		Myeloid Malignancy VCEP		2019-07-26	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014545/MONDO:0011071/008	94e6e157-486c-4c38-a2be-d9aa1387bd45
NM_001754.4(RUNX1):c.614-34C>T	258186	CA10014405	NM_001754.4:c.614-34C>T, NC_000021.9:g.34834635G>A, CM000683.2:g.34834635G>A, NC_000021.8:g.36206932G>A, CM000683.1:g.36206932G>A, NC_000021.7:g.35128802G>A, NG_011402.2:g.1155077C>T, LRG_482:g.1155077C>T, NM_001001890.2:c.533-34C>T, NM_001122607.1:c.533-34C>T, LRG_482t1:c.614-34C>T, XM_005261068.3:c.578-34C>T, XM_005261069.3:c.613+24839C>T, XM_011529766.1:c.614-34C>T, XM_011529767.1:c.575-34C>T, XM_011529768.1:c.574+24839C>T, XM_011529770.1:c.614-34C>T, XR_937576.1:n.793-34C>T, XM_005261069.4:c.613+24839C>T, XM_011529766.2:c.614-34C>T, XM_011529767.2:c.575-34C>T, XM_011529768.2:c.574+24839C>T, XM_011529770.2:c.614-34C>T, XM_017028487.1:c.461-34C>T, XR_937576.2:n.840-34C>T, ENST00000300305.7:c.614-34C>T, ENST00000344691.8:c.533-34C>T, ENST00000358356.9:c.533-34C>T, ENST00000399237.6:c.578-34C>T, ENST00000399240.5:c.532+24839C>T, ENST00000437180.5:c.614-34C>T, ENST00000469087.1:n.150-34C>T, ENST00000482318.5:c.*204-34C>T, NM_001754.4(RUNX1):c.614-34C>T	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1, BP4, BP2	PS3, PS1, PS4, PVS1, PM2, PM6, BS3, BS1, BS4, BP7, PM4, PM1, PM5, PP3, PP1	The NM_001754.4:c.614-34C>T variant has a MAF of 1 (100%) in gnomAD cohort that is â‰¥ 0.0015 (0.15%) (BA1). This variant is detected in homozygous state in gnomAD population database (BP2). This intronic variant is predicted by SSF and MES to lead to either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2, BP4.		Myeloid Malignancy VCEP		2019-07-26	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014405/MONDO:0011071/008	e7c466ba-2630-4273-adcf-da7d8ca99b52
NM_001754.4(RUNX1):c.167T>C (p.Leu56Ser)	239045	CA10014578	NM_001754.4:c.167T>C, NC_000021.9:g.34887027A>G, CM000683.2:g.34887027A>G, NC_000021.8:g.36259324A>G, CM000683.1:g.36259324A>G, NC_000021.7:g.35181194A>G, NG_011402.2:g.1102685T>C, LRG_482:g.1102685T>C, NM_001001890.2:c.86T>C, NM_001122607.1:c.86T>C, LRG_482t1:c.167T>C, XM_005261068.3:c.131T>C, XM_005261069.3:c.167T>C, XM_011529766.1:c.167T>C, XM_011529767.1:c.128T>C, XM_011529768.1:c.128T>C, XM_011529770.1:c.167T>C, XR_937576.1:n.346T>C, XM_005261069.4:c.167T>C, XM_011529766.2:c.167T>C, XM_011529767.2:c.128T>C, XM_011529768.2:c.128T>C, XM_011529770.2:c.167T>C, XM_017028487.1:c.14T>C, XR_937576.2:n.393T>C, ENST00000300305.7:c.167T>C, ENST00000344691.8:c.86T>C, ENST00000358356.9:c.86T>C, ENST00000399237.6:c.131T>C, ENST00000399240.5:c.86T>C, ENST00000437180.5:c.167T>C, ENST00000455571.5:c.128T>C, ENST00000482318.5:c.59-6314T>C, NM_001754.4(RUNX1):c.167T>C (p.Leu56Ser)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP2, BA1, BS3	PS4, PS3, PS1, BP4, PM6, PM2, PVS1, BP7, BS4, BS1, PM1, PM4, PM5, PP1, PP3	The NM_001754.4:c.167T>C (p.Leu56Ser) variant has a MAF of 0.03259 (3.259%, 518/15,894 alleles) in the South Asian subpopulation of the ExAC cohort that is â‰¥ 0.0015 (0.15%) (BA1). This variant is detected in homozygous state (56) in gnomAD population database (BP2). Transactivation assays demonstrating normal transactivation (80-115% of wt) and data from secondary assays demonstrate normal DNA binding, CBFÎ² binding and sub-cellular localization (BS3; PMID: 23817177). Two patients reported in PMID:29365323 with AML. But PS4 can not apply in combined with BA1. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BS3, BP2.	23817177	Myeloid Malignancy VCEP		2019-07-26	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014578/MONDO:0011071/008	36a19c90-310a-4c8f-ad1d-8f186170daaa
	532664	-	NM_001754.5:c.1412_1413dup, NM_001754.5(RUNX1):c.1412_1413dup (p.Leu472fs)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PVS1_Strong, PP1_Strong, PM5_Supporting, PS4_Supporting, PS3_Moderate, PM2_Supporting	PS1, PS2, BP1, BP4, BP3, BP2, BA1, PM6, BP7, BP5, BS3, BS1, BS4, PM4, PM1, PM3, BS2, PP2, PP3, PP4	The NM_001754.4:c.1412_1413dup (p.Leu472Alafs) variant is a frameshift variant that is not expected to result in nonsense-mediated mRNA decay, but the predicted truncated/altered region (removes aa 472-480, including the VWRPY motif) is critical to protein function (PVS1_Strong). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This variant is a nonsense/frameshift variants that is downstream of c.98 (PM5_Supporting). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 24353905). This variant was found to co-segregate with disease in multiple affected family members, with seven meioses observed in one family (PP1_Strong; PMID: 24353905). There is evidence of abnormal protein expression of this variant allele as a functional consequence of incorrect protein products (PS3_Moderate; PMID: 24353905). PS3_Moderate is applied because the variant meets PVS1_Strong. In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1_strong, PP1_strong, PS3_moderate, PM2_supporting, PS4_supporting, PM5_supporting.	24353905, 24353905, 24353905, 24353905	Myeloid Malignancy VCEP		2024-03-26	2024-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CV532664/MONDO:0011071/008	d4e4778b-1537-485e-88bb-36c15bebe04c
NM_001754.4(RUNX1):c.698G>A (p.Arg233His)	415832	CA10014373	NM_001754.4:c.698G>A, NC_000021.9:g.34834517C>T, CM000683.2:g.34834517C>T, NC_000021.8:g.36206814C>T, CM000683.1:g.36206814C>T, NC_000021.7:g.35128684C>T, NG_011402.2:g.1155195G>A, LRG_482:g.1155195G>A, NM_001001890.2:c.617G>A, NM_001122607.1:c.617G>A, LRG_482t1:c.698G>A, XM_005261068.3:c.662G>A, XM_005261069.3:c.613+24957G>A, XM_011529766.1:c.698G>A, XM_011529767.1:c.659G>A, XM_011529768.1:c.574+24957G>A, XM_011529770.1:c.698G>A, XR_937576.1:n.877G>A, XM_005261069.4:c.613+24957G>A, XM_011529766.2:c.698G>A, XM_011529767.2:c.659G>A, XM_011529768.2:c.574+24957G>A, XM_011529770.2:c.698G>A, XM_017028487.1:c.545G>A, XR_937576.2:n.924G>A, ENST00000300305.7:c.698G>A, ENST00000344691.8:c.617G>A, ENST00000358356.9:c.617G>A, ENST00000399237.6:c.662G>A, ENST00000399240.5:c.532+24957G>A, ENST00000437180.5:c.698G>A, ENST00000469087.1:n.234G>A, ENST00000482318.5:c.*288G>A, NM_001754.4(RUNX1):c.698G>A (p.Arg233His)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BS1	PS4, PS3, PS1, BP2, BP4, BA1, PM6, PM2, PVS1, BP7, BS4, BS3, PM1, PM4, PM5, PP1, PP3	The NM_001754.4:c.698G>A (p.Arg233His) variant has a MAF of 0.00142 (0.142%, 34/23,970 alleles) in the African subpopulation of the gnomAD cohort that is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). We allow a variant to reach a likely benign classification based on BS1 alone if there is no contradictory evidence supporting pathogenicity. In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1.		Myeloid Malignancy VCEP		2019-07-26	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014373/MONDO:0011071/008	52a12148-1cdf-4d95-bf36-4dfae2e0e6e7
NM_001754.5(RUNX1):c.444C>T (p.Thr148=)	339877	CA10014514	NM_001754.5:c.444C>T, NC_000021.9:g.34880621G>A, CM000683.2:g.34880621G>A, NC_000021.8:g.36252918G>A, CM000683.1:g.36252918G>A, NC_000021.7:g.35174788G>A, NG_011402.2:g.1109091C>T, LRG_482:g.1109091C>T, ENST00000675419.1:c.444C>T, ENST00000300305.7:c.444C>T, ENST00000344691.8:c.363C>T, ENST00000358356.9:c.363C>T, ENST00000399237.6:c.408C>T, ENST00000399240.5:c.363C>T, ENST00000437180.5:c.444C>T, ENST00000455571.5:c.405C>T, ENST00000482318.5:c.*34C>T, NM_001001890.2:c.363C>T, NM_001122607.1:c.363C>T, NM_001754.4:c.444C>T, LRG_482t1:c.444C>T, XM_005261068.3:c.408C>T, XM_005261069.3:c.444C>T, XM_011529766.1:c.444C>T, XM_011529767.1:c.405C>T, XM_011529768.1:c.405C>T, XM_011529770.1:c.444C>T, XR_937576.1:n.623C>T, XM_005261069.4:c.444C>T, XM_011529766.2:c.444C>T, XM_011529767.2:c.405C>T, XM_011529768.2:c.405C>T, XM_011529770.2:c.444C>T, XM_017028487.1:c.291C>T, XR_937576.2:n.670C>T, NM_001001890.3:c.363C>T, NM_001122607.2:c.363C>T, NM_001754.5(RUNX1):c.444C>T (p.Thr148=)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP4, BP7	PS3, PS1, PS4, PS2, BA1, BP1, BP3, BP2, PM2, PM6, PVS1, BP5, BS3, BS1, BS4, PM4, PM1, PM5, PM3, PP2, PP3, PP1, PP4, BS2	NM_001754.5(RUNX1):c.444C>T (p.Thr148=) is a synonymous variant which has a SpliceAI score of 0.00 and a PhyloP score of -6.58, indicating no predicted impact on splicing and lack of conservation (BP4, BP7). This variant is present in gnomAD but not at an elevated frequency, so no population codes were applied. In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BP4, BP7.		Myeloid Malignancy VCEP		2025-03-26	2025-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CA10014514/MONDO:0011071/008	2a26c020-4ebb-4160-a16b-4c5b8b5b9440
NM_001754.4(RUNX1):c.253C>A (p.His85Asn)	14469	CA123975	NM_001754.4:c.253C>A, NC_000021.9:g.34886941G>T, CM000683.2:g.34886941G>T, NC_000021.8:g.36259238G>T, CM000683.1:g.36259238G>T, NC_000021.7:g.35181108G>T, NG_011402.2:g.1102771C>A, LRG_482:g.1102771C>A, NM_001001890.2:c.172C>A, NM_001122607.1:c.172C>A, LRG_482t1:c.253C>A, XM_005261068.3:c.217C>A, XM_005261069.3:c.253C>A, XM_011529766.1:c.253C>A, XM_011529767.1:c.214C>A, XM_011529768.1:c.214C>A, XM_011529770.1:c.253C>A, XR_937576.1:n.432C>A, XM_005261069.4:c.253C>A, XM_011529766.2:c.253C>A, XM_011529767.2:c.214C>A, XM_011529768.2:c.214C>A, XM_011529770.2:c.253C>A, XM_017028487.1:c.100C>A, XR_937576.2:n.479C>A, ENST00000300305.7:c.253C>A, ENST00000344691.8:c.172C>A, ENST00000358356.9:c.172C>A, ENST00000399237.6:c.217C>A, ENST00000399240.5:c.172C>A, ENST00000437180.5:c.253C>A, ENST00000455571.5:c.214C>A, ENST00000482318.5:c.59-6228C>A, NM_001754.4(RUNX1):c.253C>A (p.His85Asn)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BS1, BS3, PP3	PS4, PS3, PS1, BP2, BP4, BA1, PVS1, PM2, PM6, BS4, BP7, PM1, PM4, PM5, PP1	The NM_001754.4:c.253C>A (p.His85Asn) variant has a MAF of 0.00043 (0.043%, 8/18,768 alleles) in the East Asian subpopulation of the gnomAD cohort that is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). This missense variant has a REVEL score >0.75 (0.852) (PP3). Transactivation assays demonstrating normal transactivation (80-115% of wt) and data from secondary assays demonstrate normal DNA binding, CBFÎ² binding and sub-cellular localization (BS3; PMID: 23817177, PMID: 10068652). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, BS3, PP3.	10068652, 12200707, 10068652, 23817177	Myeloid Malignancy VCEP		2019-07-26	2019-08-02	false	https://erepo.genome.network/evrepo/ui/classification/CA123975/MONDO:0011071/008	c3870801-0fcc-45c8-9383-0ae10065097d
NM_001754.5(RUNX1):c.1422G>T (p.Glu474Asp)	339874	CA10652929	NM_001754.5:c.1422G>T, NC_000021.9:g.34792156C>A, CM000683.2:g.34792156C>A, NC_000021.8:g.36164453C>A, CM000683.1:g.36164453C>A, NC_000021.7:g.35086323C>A, NG_011402.2:g.1197556G>T, LRG_482:g.1197556G>T, ENST00000675419.1:c.1422G>T, ENST00000300305.7:c.1422G>T, ENST00000344691.8:c.1341G>T, ENST00000399240.5:c.1149G>T, ENST00000437180.5:c.1422G>T, ENST00000482318.5:c.*1012G>T, NM_001001890.2:c.1341G>T, NM_001754.4:c.1422G>T, LRG_482t1:c.1422G>T, XM_005261068.3:c.1386G>T, XM_005261069.3:c.1230G>T, XM_011529766.1:c.1422G>T, XM_011529767.1:c.1383G>T, XM_011529768.1:c.1191G>T, XM_005261069.4:c.1230G>T, XM_011529766.2:c.1422G>T, XM_011529767.2:c.1383G>T, XM_011529768.2:c.1191G>T, XM_017028487.1:c.1269G>T, NM_001001890.3:c.1341G>T, NM_001754.5(RUNX1):c.1422G>T (p.Glu474Asp)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	PM2_Supporting	PS4, PS2, PS1, PS3, BA1, BP2, BP1, BP4, BP3, BP5, BP7, BS1, BS4, BS3, PM6, PVS1, PM3, PM5, PM4, PM1, PP1, PP2, PP3, PP4, BS2	The NM_001754.4:c.1422G>T (p.Glu474Asp) variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This missense variant has a REVEL score 0.312. In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting.		Myeloid Malignancy VCEP		2024-09-11	2024-09-11	false	https://erepo.genome.network/evrepo/ui/classification/CA10652929/MONDO:0011071/008	272c05cd-977f-4310-b29b-61bd0a72da18
NM_001754.4(RUNX1):c.1257G>A (p.Val419=)	436611	CA512341177	NM_001754.4:c.1257G>A, NC_000021.9:g.34792321C>T, CM000683.2:g.34792321C>T, NC_000021.8:g.36164618C>T, CM000683.1:g.36164618C>T, NC_000021.7:g.35086488C>T, NG_011402.2:g.1197391G>A, LRG_482:g.1197391G>A, ENST00000675419.1:c.1257G>A, ENST00000300305.7:c.1257G>A, ENST00000344691.8:c.1176G>A, ENST00000399240.5:c.984G>A, ENST00000437180.5:c.1257G>A, ENST00000482318.5:c.*847G>A, NM_001001890.2:c.1176G>A, LRG_482t1:c.1257G>A, XM_005261068.3:c.1221G>A, XM_005261069.3:c.1065G>A, XM_011529766.1:c.1257G>A, XM_011529767.1:c.1218G>A, XM_011529768.1:c.1026G>A, XM_005261069.4:c.1065G>A, XM_011529766.2:c.1257G>A, XM_011529767.2:c.1218G>A, XM_011529768.2:c.1026G>A, XM_017028487.1:c.1104G>A, NM_001001890.3:c.1176G>A, NM_001754.5:c.1257G>A, NM_001754.4(RUNX1):c.1257G>A (p.Val419=)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP4, BP7, BS1	PS1, PS3, PS4, PS2, BA1, BP1, BP3, BP2, PVS1, PM2, PM6, BP5, BS3, BS4, PM5, PM4, PM1, PM3, PP2, PP3, PP1, PP4, BS2	NM_001754.5(RUNX1):c.1257G>A (p.Val419=) is a synonymous variant which meets criteria for likely benign classification. The MAF is 0.0001369 (0.01369%, 7/51146 alleles) in the Admixed American subpopulation of the gnomAD v4.1.0 cohort, which is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). It has a SpliceAI score â‰¤ 0.20 (Donor gain Î” score 0.01) (BP4), and evolutionary conservation algorithms predict the site as not being conserved (PhyloP score â‰¤ 2.0 (0.370)) (BP7). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, BP4, BP7.		Myeloid Malignancy VCEP		2025-01-15	2025-01-15	false	https://erepo.genome.network/evrepo/ui/classification/CA512341177/MONDO:0011071/008	45e8489f-6a97-40c0-8875-ebee7b797ef2
NM_001754.5(RUNX1):c.1160G>C (p.Gly387Ala)	532662	CA410147917	NM_001754.5:c.1160G>C, NC_000021.9:g.34792418C>G, CM000683.2:g.34792418C>G, NC_000021.8:g.36164715C>G, CM000683.1:g.36164715C>G, NC_000021.7:g.35086585C>G, NG_011402.2:g.1197294G>C, LRG_482:g.1197294G>C, ENST00000675419.1:c.1160G>C, ENST00000300305.7:c.1160G>C, ENST00000344691.8:c.1079G>C, ENST00000399240.5:c.887G>C, ENST00000437180.5:c.1160G>C, ENST00000482318.5:c.*750G>C, NM_001001890.2:c.1079G>C, NM_001754.4:c.1160G>C, LRG_482t1:c.1160G>C, XM_005261068.3:c.1124G>C, XM_005261069.3:c.968G>C, XM_011529766.1:c.1160G>C, XM_011529767.1:c.1121G>C, XM_011529768.1:c.929G>C, XM_005261069.4:c.968G>C, XM_011529766.2:c.1160G>C, XM_011529767.2:c.1121G>C, XM_011529768.2:c.929G>C, XM_017028487.1:c.1007G>C, NM_001001890.3:c.1079G>C, NM_001754.5(RUNX1):c.1160G>C (p.Gly387Ala)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BP4, PS4_Supporting	PS2, PS1, PS3, BP2, BP1, BP3, BA1, PVS1, PM2, PM6, BP5, BP7, BS1, BS4, BS3, PM3, PM5, PM4, PM1, BS2, PP1, PP4, PP2, PP3	The NM_001754.4:c.1160G>C (p.Gly387Ala) variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 27210295). This missense variant has a REVEL score <0.15 (0.141) and SSF and MES predict either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). This variant is present at a MAF of 0.000001727 (0.0001727%) in gnomADv4.1.0. In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS4_ supporting, BP4.	27210295	Myeloid Malignancy VCEP		2025-02-24	2025-02-24	false	https://erepo.genome.network/evrepo/ui/classification/CA410147917/MONDO:0011071/008	796f47f4-6c31-4833-8a66-03f0dc55514a
NM_001754.4(RUNX1):c.1098_1103dupCGGCAT (p.Gly367_Met368insIleGly)	239040	-	NM_001754.4:c.1098_1103dup6, NM_001754.4:c.1098_1103dupCGGCAT, NM_001754.5(RUNX1):c.1092CGGCAT[3] (p.364IG[3]), NM_001754.4(RUNX1):c.1098_1103dupCGGCAT (p.Gly367_Met368insIleGly)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BS1	PS4, PS2, PS1, PS3, BA1, BP2, BP1, BP4, BP3, PM6, PM2, PVS1, BS4, BS3, BP5, BP7, PM3, PM5, PM4, PM1, PP1, PP4, PP2, PP3, BS2	The NM_001754.5(RUNX1):c.1098_1103dup (p.Ile366_Gly367dup) variant has a highest MAF 0.0001618 (11 out of 67990 alleles) in European (non-Finnish) subpopulation of gnomAD v3.1 (BS1). In summary, the clinical significance of this variant is Likely Benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1.	27210295, 28659335	Myeloid Malignancy VCEP		2021-02-20	2023-11-13	false	https://erepo.genome.network/evrepo/ui/classification/CV239040/MONDO:0011071/008	06359166-e7e4-4c6e-8e13-8246247788c2
NM_001754.4(RUNX1):c.259G>T (p.Gly87Cys)	436618	CA10014559	NM_001754.4:c.259G>T, NC_000021.9:g.34886935C>A, CM000683.2:g.34886935C>A, NC_000021.8:g.36259232C>A, CM000683.1:g.36259232C>A, NC_000021.7:g.35181102C>A, NG_011402.2:g.1102777G>T, LRG_482:g.1102777G>T, ENST00000675419.1:c.259G>T, ENST00000300305.7:c.259G>T, ENST00000344691.8:c.178G>T, ENST00000358356.9:c.178G>T, ENST00000399237.6:c.223G>T, ENST00000399240.5:c.178G>T, ENST00000437180.5:c.259G>T, ENST00000455571.5:c.220G>T, ENST00000482318.5:c.59-6222G>T, NM_001001890.2:c.178G>T, NM_001122607.1:c.178G>T, LRG_482t1:c.259G>T, XM_005261068.3:c.223G>T, XM_005261069.3:c.259G>T, XM_011529766.1:c.259G>T, XM_011529767.1:c.220G>T, XM_011529768.1:c.220G>T, XM_011529770.1:c.259G>T, XR_937576.1:n.438G>T, XM_005261069.4:c.259G>T, XM_011529766.2:c.259G>T, XM_011529767.2:c.220G>T, XM_011529768.2:c.220G>T, XM_011529770.2:c.259G>T, XM_017028487.1:c.106G>T, XR_937576.2:n.485G>T, NM_001001890.3:c.178G>T, NM_001122607.2:c.178G>T, NM_001754.5:c.259G>T, NM_001754.4(RUNX1):c.259G>T (p.Gly87Cys)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	PP3	PS1, PS3, PS4, PS2, BP1, BP4, BP3, BP2, BA1, PVS1, PM2, PM6, BP7, BP5, BS3, BS1, BS4, PM5, PM4, PM1, PM3, BS2, PP2, PP1, PP4	NM_001754.4(RUNX1):c.259G>T (p.Gly87Cys) is a missense variant which has a REVEL score â‰¥ 0.88 (0.918) (PP3). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PP3.		Myeloid Malignancy VCEP		2025-01-15	2025-01-15	false	https://erepo.genome.network/evrepo/ui/classification/CA10014559/MONDO:0011071/008	9b53e7f3-6c92-4c63-95f0-3c9f51ca59e4
NM_001754.5(RUNX1):c.155T>A (p.Met52Lys)	239044	CA10014581	NM_001754.5:c.155T>A, NC_000021.9:g.34887039A>T, CM000683.2:g.34887039A>T, NC_000021.8:g.36259336A>T, CM000683.1:g.36259336A>T, NC_000021.7:g.35181206A>T, NG_011402.2:g.1102673T>A, LRG_482:g.1102673T>A, ENST00000675419.1:c.155T>A, ENST00000300305.7:c.155T>A, ENST00000344691.8:c.74T>A, ENST00000358356.9:c.74T>A, ENST00000399237.6:c.119T>A, ENST00000399240.5:c.74T>A, ENST00000437180.5:c.155T>A, ENST00000455571.5:c.116T>A, ENST00000482318.5:c.59-6326T>A, NM_001001890.2:c.74T>A, NM_001122607.1:c.74T>A, NM_001754.4:c.155T>A, LRG_482t1:c.155T>A, XM_005261068.3:c.119T>A, XM_005261069.3:c.155T>A, XM_011529766.1:c.155T>A, XM_011529767.1:c.116T>A, XM_011529768.1:c.116T>A, XM_011529770.1:c.155T>A, XR_937576.1:n.334T>A, XM_005261069.4:c.155T>A, XM_011529766.2:c.155T>A, XM_011529767.2:c.116T>A, XM_011529768.2:c.116T>A, XM_011529770.2:c.155T>A, XM_017028487.1:c.2T>A, XR_937576.2:n.381T>A, NM_001001890.3:c.74T>A, NM_001122607.2:c.74T>A, NM_001754.5(RUNX1):c.155T>A (p.Met52Lys)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP2, BS1	PS1, PS3, PS4, PS2, BP1, BP4, BP3, BA1, PVS1, PM2, PM6, BP7, BP5, BS3, BS4, PM5, PM4, PM1, PM3, BS2, PP2, PP3, PP1, PP4	NM_001754.4(RUNX1):c.155T>A (p.Met52Lys) is a missense variant which has a MAF of 0.0007121 (0.071%, 840/1,179,678 alleles, including 1 homozygote) in the European (non-Finnish) subpopulation of the gnomAD v4.1.0 cohort, meeting the threshold for BS1 and BP2. In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, BP2.	29365323	Myeloid Malignancy VCEP		2025-05-02	2025-05-02	false	https://erepo.genome.network/evrepo/ui/classification/CA10014581/MONDO:0011071/008	4ceacdfa-56c1-4933-a48a-f8c97e4f92e9
NM_001754.4(RUNX1):c.97+4T>G	339878	CA10014626	NC_000021.9:g.34892921A>C, CM000683.2:g.34892921A>C, NC_000021.8:g.36265218A>C, CM000683.1:g.36265218A>C, NC_000021.7:g.35187088A>C, NG_011402.2:g.1096791T>G, LRG_482:g.1096791T>G, ENST00000675419.1:c.97+4T>G, ENST00000300305.7:c.97+4T>G, ENST00000437180.5:c.97+4T>G, ENST00000455571.5:c.59-5825T>G, ENST00000475045.6:c.97+4T>G, ENST00000482318.5:c.59-12208T>G, NM_001754.4:c.97+4T>G, LRG_482t1:c.97+4T>G, XM_005261069.3:c.97+4T>G, XM_011529766.1:c.97+4T>G, XM_011529767.1:c.59-5825T>G, XM_011529768.1:c.59-5825T>G, XM_011529770.1:c.97+4T>G, XR_937576.1:n.276+4T>G, XM_005261069.4:c.97+4T>G, XM_011529766.2:c.97+4T>G, XM_011529767.2:c.59-5825T>G, XM_011529768.2:c.59-5825T>G, XM_011529770.2:c.97+4T>G, XR_937576.2:n.323+4T>G, NM_001754.5:c.97+4T>G, NM_001754.4(RUNX1):c.97+4T>G	N/A	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP4, BP7	PS1, PS3, PS4, PS2, BP1, BP3, BP2, BA1, PVS1, PM6, PM2, BP5, BS3, BS4, BS1, PM5, PM4, PM1, PM3, PP2, PP3, PP1, PP4, BS2	The NM_001754.5(RUNX1):c.97+4T>G is an intronic variant. This intronic variant has a SpliceAI score â‰¤ 0.20 (0.02 donor gain; 0.01 acceptor gain) (BP4). This variant has a SpliceAI score â‰¤ 0.20 (0.02/0.01) and evolutionary conservation algorithms predict the site as not being conserved (PhyloP score â‰¤ 2.0 (0.640) (BP7). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BP4, BP7.		Myeloid Malignancy VCEP		2025-01-15	2025-01-15	false	https://erepo.genome.network/evrepo/ui/classification/CA10014626/MONDO:0011071/008	bdea36eb-db13-4ea7-9d70-efa5d6e16c01
NM_001754.4(RUNX1):c.563C>G (p.Thr188Ser)	532659	CA410208042	NM_001754.4:c.563C>G, NC_000021.9:g.34859524G>C, CM000683.2:g.34859524G>C, NC_000021.8:g.36231821G>C, CM000683.1:g.36231821G>C, NC_000021.7:g.35153691G>C, NG_011402.2:g.1130188C>G, LRG_482:g.1130188C>G, ENST00000675419.1:c.563C>G, ENST00000300305.7:c.563C>G, ENST00000344691.8:c.482C>G, ENST00000358356.9:c.482C>G, ENST00000399237.6:c.527C>G, ENST00000399240.5:c.482C>G, ENST00000437180.5:c.563C>G, ENST00000467577.1:n.55C>G, ENST00000482318.5:c.*153C>G, NM_001001890.2:c.482C>G, NM_001122607.1:c.482C>G, LRG_482t1:c.563C>G, XM_005261068.3:c.527C>G, XM_005261069.3:c.563C>G, XM_011529766.1:c.563C>G, XM_011529767.1:c.524C>G, XM_011529768.1:c.524C>G, XM_011529770.1:c.563C>G, XR_937576.1:n.742C>G, XM_005261069.4:c.563C>G, XM_011529766.2:c.563C>G, XM_011529767.2:c.524C>G, XM_011529768.2:c.524C>G, XM_011529770.2:c.563C>G, XM_017028487.1:c.410C>G, XR_937576.2:n.789C>G, NM_001001890.3:c.482C>G, NM_001122607.2:c.482C>G, NM_001754.5:c.563C>G, NM_001754.4(RUNX1):c.563C>G (p.Thr188Ser)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	PM1_Supporting, PM2_Supporting, PP3	PS1, PS3, PS4, PS2, BP1, BP4, BP3, BP2, BA1, PVS1, PM6, BP7, BP5, BS3, BS1, BS4, PM5, PM4, PM3, BS2, PP2, PP1, PP4	NM_001754.4:c.563C>G (p.Thr188Ser) is a missense variant which is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This missense variant is located within the Runt Homology Domain (AA 89-204) but does not occur in an established hotspot residue (PM1_supporting). It has a REVEL score >0.75 (0.922) (PP3). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, PP3, PM1_supporting.		Myeloid Malignancy VCEP		2025-01-15	2025-01-15	false	https://erepo.genome.network/evrepo/ui/classification/CA410208042/MONDO:0011071/008	cf85a4a4-1e5d-4f72-b064-0a7bbcc1e78e
NM_001754.5(RUNX1):c.532A>C (p.Thr178Pro)	561246	CA410208110	NM_001754.5:c.532A>C, NC_000021.9:g.34859555T>G, CM000683.2:g.34859555T>G, NC_000021.8:g.36231852T>G, CM000683.1:g.36231852T>G, NC_000021.7:g.35153722T>G, NG_011402.2:g.1130157A>C, LRG_482:g.1130157A>C, ENST00000675419.1:c.532A>C, ENST00000300305.7:c.532A>C, ENST00000344691.8:c.451A>C, ENST00000358356.9:c.451A>C, ENST00000399237.6:c.496A>C, ENST00000399240.5:c.451A>C, ENST00000437180.5:c.532A>C, ENST00000467577.1:n.24A>C, ENST00000482318.5:c.*122A>C, NM_001001890.2:c.451A>C, NM_001122607.1:c.451A>C, NM_001754.4:c.532A>C, LRG_482t1:c.532A>C, XM_005261068.3:c.496A>C, XM_005261069.3:c.532A>C, XM_011529766.1:c.532A>C, XM_011529767.1:c.493A>C, XM_011529768.1:c.493A>C, XM_011529770.1:c.532A>C, XR_937576.1:n.711A>C, XM_005261069.4:c.532A>C, XM_011529766.2:c.532A>C, XM_011529767.2:c.493A>C, XM_011529768.2:c.493A>C, XM_011529770.2:c.532A>C, XM_017028487.1:c.379A>C, XR_937576.2:n.758A>C, NM_001001890.3:c.451A>C, NM_001122607.2:c.451A>C, NM_001754.5(RUNX1):c.532A>C (p.Thr178Pro)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	PM1_Supporting, PM2_Supporting, PS4_Supporting, PP3	PS1, PS3, PS2, BA1, BP1, BP4, BP3, BP2, PVS1, PM6, BP7, BP5, BS3, BS1, BS4, PM5, PM4, PM3, PP2, PP1, PP4, BS2	NM_001754.4:c.532A>C (p.Thr178Pro) is a missense variant which affects one of the residues within the Runt Homology Domain (AA 105-204) (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This missense variant has a REVEL score >0.75 (0.971) (PP3). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; SCV000807789.1). In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, PP3, PS4_ supporting, PM1_supporting.		Myeloid Malignancy VCEP		2024-10-29	2024-10-29	false	https://erepo.genome.network/evrepo/ui/classification/CA410208110/MONDO:0011071/008	c1eaabe2-0120-42d8-8111-750503fe2b65
NM_001754.5(RUNX1):c.502G>A (p.Gly168Arg)	561243	CA410202479	NM_001754.5:c.502G>A, NC_000021.9:g.34880563C>T, CM000683.2:g.34880563C>T, NC_000021.8:g.36252860C>T, CM000683.1:g.36252860C>T, NC_000021.7:g.35174730C>T, NG_011402.2:g.1109149G>A, LRG_482:g.1109149G>A, ENST00000675419.1:c.502G>A, ENST00000300305.7:c.502G>A, ENST00000344691.8:c.421G>A, ENST00000358356.9:c.421G>A, ENST00000399237.6:c.466G>A, ENST00000399240.5:c.421G>A, ENST00000437180.5:c.502G>A, ENST00000482318.5:c.*92G>A, NM_001001890.2:c.421G>A, NM_001122607.1:c.421G>A, NM_001754.4:c.502G>A, LRG_482t1:c.502G>A, XM_005261068.3:c.466G>A, XM_005261069.3:c.502G>A, XM_011529766.1:c.502G>A, XM_011529767.1:c.463G>A, XM_011529768.1:c.463G>A, XM_011529770.1:c.502G>A, XR_937576.1:n.681G>A, XM_005261069.4:c.502G>A, XM_011529766.2:c.502G>A, XM_011529767.2:c.463G>A, XM_011529768.2:c.463G>A, XM_011529770.2:c.502G>A, XM_017028487.1:c.349G>A, XR_937576.2:n.728G>A, NM_001001890.3:c.421G>A, NM_001122607.2:c.421G>A, NM_001754.5(RUNX1):c.502G>A (p.Gly168Arg)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	PS4_Moderate, PM1_Supporting, PM2_Supporting, PP3, PP1	PS1, PS3, PS2, BA1, BP1, BP4, BP3, BP2, PVS1, PM6, BS3, BS1, BS4, BP7, BP5, PM5, PM4, PM3, BS2, PP2, PP4	NM_001754.4:c.502G>A (p.Gly168Arg) is a missense variant which affects a residue within the Runt Homology domain (AA 89-204) but does not affect an established hotspot residue (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This missense variant has a REVEL score >0.75 (0.947) (PP3). This variant has been identified in two families with thrombocytopenia, abnormal bleeding and bruising (PS4_moderate) and has been observed in 3 meioses across 2 families (PP1) (PMID:39375928, NIH RUNX1 Natural History Study unpublished). In summary, the clinical significance of this variant is Likely Pathogenic (LP). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, PP3, PM1_supporting, PS4_moderate, PP1.		Myeloid Malignancy VCEP		2025-01-27	2025-01-27	false	https://erepo.genome.network/evrepo/ui/classification/CA410202479/MONDO:0011071/008	d6e9b950-bdb2-405a-b288-176c8db7a1c5
NM_001754.4(RUNX1):c.391A>G (p.Thr131Ala)	463994	CA410202714	NM_001754.4:c.391A>G, NC_000021.9:g.34880674T>C, CM000683.2:g.34880674T>C, NC_000021.8:g.36252971T>C, CM000683.1:g.36252971T>C, NC_000021.7:g.35174841T>C, NG_011402.2:g.1109038A>G, LRG_482:g.1109038A>G, ENST00000675419.1:c.391A>G, ENST00000300305.7:c.391A>G, ENST00000344691.8:c.310A>G, ENST00000358356.9:c.310A>G, ENST00000399237.6:c.355A>G, ENST00000399240.5:c.310A>G, ENST00000437180.5:c.391A>G, ENST00000455571.5:c.352A>G, ENST00000482318.5:c.98A>G, NM_001001890.2:c.310A>G, NM_001122607.1:c.310A>G, LRG_482t1:c.391A>G, XM_005261068.3:c.355A>G, XM_005261069.3:c.391A>G, XM_011529766.1:c.391A>G, XM_011529767.1:c.352A>G, XM_011529768.1:c.352A>G, XM_011529770.1:c.391A>G, XR_937576.1:n.570A>G, XM_005261069.4:c.391A>G, XM_011529766.2:c.391A>G, XM_011529767.2:c.352A>G, XM_011529768.2:c.352A>G, XM_011529770.2:c.391A>G, XM_017028487.1:c.238A>G, XR_937576.2:n.617A>G, NM_001001890.3:c.310A>G, NM_001122607.2:c.310A>G, NM_001754.5:c.391A>G, NM_001754.4(RUNX1):c.391A>G (p.Thr131Ala)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	PM1_Supporting, PM2_Supporting, PP3	PS3, PS1, PS4, PS2, BP1, BP4, BP3, BP2, BA1, PVS1, PM6, BP7, BP5, BS3, BS1, BS4, PM4, PM5, PM3, PP2, PP1, PP4, BS2	NM_001754.4:c.391A>G (p.Thr131Ala) is a missense variant which is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This missense variant is located within the Runt Homology Domain (AA 89-204) but does not occur in an established hotspot residue (PM1_supporting). It has a REVEL score >0.75 (0.942) (PP3). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, PP3, PM1_supporting.		Myeloid Malignancy VCEP		2025-01-15	2025-01-15	false	https://erepo.genome.network/evrepo/ui/classification/CA410202714/MONDO:0011071/008	1030c6f6-46f9-4881-bc0c-32d4bcfd2b33
NM_001754.4(RUNX1):c.331A>G (p.Thr111Ala)	532671	CA410203415	NM_001754.4:c.331A>G, NC_000021.9:g.34886863T>C, CM000683.2:g.34886863T>C, NC_000021.8:g.36259160T>C, CM000683.1:g.36259160T>C, NC_000021.7:g.35181030T>C, NG_011402.2:g.1102849A>G, LRG_482:g.1102849A>G, ENST00000675419.1:c.331A>G, ENST00000300305.7:c.331A>G, ENST00000344691.8:c.250A>G, ENST00000358356.9:c.250A>G, ENST00000399237.6:c.295A>G, ENST00000399240.5:c.250A>G, ENST00000437180.5:c.331A>G, ENST00000455571.5:c.292A>G, ENST00000482318.5:c.59-6150A>G, NM_001001890.2:c.250A>G, NM_001122607.1:c.250A>G, LRG_482t1:c.331A>G, XM_005261068.3:c.295A>G, XM_005261069.3:c.331A>G, XM_011529766.1:c.331A>G, XM_011529767.1:c.292A>G, XM_011529768.1:c.292A>G, XM_011529770.1:c.331A>G, XR_937576.1:n.510A>G, XM_005261069.4:c.331A>G, XM_011529766.2:c.331A>G, XM_011529767.2:c.292A>G, XM_011529768.2:c.292A>G, XM_011529770.2:c.331A>G, XM_017028487.1:c.178A>G, XR_937576.2:n.557A>G, NM_001001890.3:c.250A>G, NM_001122607.2:c.250A>G, NM_001754.5:c.331A>G, NM_001754.4(RUNX1):c.331A>G (p.Thr111Ala)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	PM1_Supporting, PM2_Supporting, PP3	PS3, PS1, PS4, PS2, BP1, BP4, BP3, BP2, BA1, PVS1, PM6, BP7, BP5, BS3, BS1, BS4, PM4, PM5, PM3, BS2, PP2, PP1, PP4	NM_001754.4(RUNX1):c.331A>G (p.Thr111Ala) is a missense variant that affects one of the residues (AA 105-204) within the Runt Homology Domain (RHD), but does not occur in an established hotspot residue (PM1_supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). It has a REVEL score of 0.939 (> 0.75), supporting PP3. In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, PP3, PM1_supporting.		Myeloid Malignancy VCEP		2025-01-15	2025-01-15	false	https://erepo.genome.network/evrepo/ui/classification/CA410203415/MONDO:0011071/008	1823619f-a990-4590-a95b-0a7edb3671c1
NM_001754.4(RUNX1):c.316T>A (p.Trp106Arg)	436617	CA410203508	NM_001754.4:c.316T>A, NC_000021.9:g.34886878A>T, CM000683.2:g.34886878A>T, NC_000021.8:g.36259175A>T, CM000683.1:g.36259175A>T, NC_000021.7:g.35181045A>T, NG_011402.2:g.1102834T>A, LRG_482:g.1102834T>A, ENST00000675419.1:c.316T>A, ENST00000300305.7:c.316T>A, ENST00000344691.8:c.235T>A, ENST00000358356.9:c.235T>A, ENST00000399237.6:c.280T>A, ENST00000399240.5:c.235T>A, ENST00000437180.5:c.316T>A, ENST00000455571.5:c.277T>A, ENST00000482318.5:c.59-6165T>A, NM_001001890.2:c.235T>A, NM_001122607.1:c.235T>A, LRG_482t1:c.316T>A, XM_005261068.3:c.280T>A, XM_005261069.3:c.316T>A, XM_011529766.1:c.316T>A, XM_011529767.1:c.277T>A, XM_011529768.1:c.277T>A, XM_011529770.1:c.316T>A, XR_937576.1:n.495T>A, XM_005261069.4:c.316T>A, XM_011529766.2:c.316T>A, XM_011529767.2:c.277T>A, XM_011529768.2:c.277T>A, XM_011529770.2:c.316T>A, XM_017028487.1:c.163T>A, XR_937576.2:n.542T>A, NM_001001890.3:c.235T>A, NM_001122607.2:c.235T>A, NM_001754.5:c.316T>A, NM_001754.4(RUNX1):c.316T>A (p.Trp106Arg)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	PM1_Supporting, PS3, PM2_Supporting, PP3	PS1, PS4, PS2, BA1, BP1, BP4, BP3, BP2, BS3, BS1, BS4, BP7, BP5, PM6, PVS1, PM5, PM4, PM3, BS2, PP2, PP1, PP4	The NM_001754.4:c.316T>A (p.Trp106Arg) variant affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). Transactivation assays demonstrating altered transactivation (<20% of wt, and/or reduced to levels similar to well-established pathogenic variants such as R201Q or R166Q) and data from secondary assay demonstrate altered DNA binding (PS3; PMID: 25840971). This missense variant has a REVEL score >0.75 (0.976) (PP3). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PM2_supporting, PP3, PM1_supporting.	25840971	Myeloid Malignancy VCEP		2024-09-10	2024-09-10	false	https://erepo.genome.network/evrepo/ui/classification/CA410203508/MONDO:0011071/008	8f98e7f4-4645-4121-8da3-bcf507754b5c
NM_001754.5(RUNX1):c.314A>C (p.His105Pro)	561233	CA410203519	NM_001754.5:c.314A>C, NC_000021.9:g.34886880T>G, CM000683.2:g.34886880T>G, NC_000021.8:g.36259177T>G, CM000683.1:g.36259177T>G, NC_000021.7:g.35181047T>G, NG_011402.2:g.1102832A>C, LRG_482:g.1102832A>C, ENST00000675419.1:c.314A>C, ENST00000300305.7:c.314A>C, ENST00000344691.8:c.233A>C, ENST00000358356.9:c.233A>C, ENST00000399237.6:c.278A>C, ENST00000399240.5:c.233A>C, ENST00000437180.5:c.314A>C, ENST00000455571.5:c.275A>C, ENST00000482318.5:c.59-6167A>C, NM_001001890.2:c.233A>C, NM_001122607.1:c.233A>C, NM_001754.4:c.314A>C, LRG_482t1:c.314A>C, XM_005261068.3:c.278A>C, XM_005261069.3:c.314A>C, XM_011529766.1:c.314A>C, XM_011529767.1:c.275A>C, XM_011529768.1:c.275A>C, XM_011529770.1:c.314A>C, XR_937576.1:n.493A>C, XM_005261069.4:c.314A>C, XM_011529766.2:c.314A>C, XM_011529767.2:c.275A>C, XM_011529768.2:c.275A>C, XM_011529770.2:c.314A>C, XM_017028487.1:c.161A>C, XR_937576.2:n.540A>C, NM_001001890.3:c.233A>C, NM_001122607.2:c.233A>C, NM_001754.5(RUNX1):c.314A>C (p.His105Pro)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	PM1_Supporting, PM5_Supporting, PM2_Supporting, PS4_Supporting, PP3	PS1, PS3, PS2, BA1, BP1, BP4, BP3, BP2, PVS1, PM6, BP7, BP5, BS3, BS1, BS4, PM4, PM3, PP2, PP1, PP4, BS2	NM_001754.4(RUNX1):c.314A>C (p.His105Pro) is a missense variant that affects one of the residues (AA 105-204) within the Runt Homology Domain (RHD), though not an established hotspot residue (PM1_supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). It has a REVEL score of 0.953 (> 0.75), supporting PP3. Additionally, this variant represents a missense change at the same residue (p.His105) where a different missense change has been previously established as a likely pathogenic variant (ClinVar ID 666274), meeting PM5_supporting. This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_supporting; SCV000807773.1). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting, PP3, PM1_supporting, PM5_supporting, PS4_supporting.		Myeloid Malignancy VCEP		2025-01-15	2025-01-15	false	https://erepo.genome.network/evrepo/ui/classification/CA410203519/MONDO:0011071/008	42a3f999-4991-4180-8cb2-0e8975c5e5bb
NM_001754.4:c.315C>A	666274	CA410203511	NM_001754.4:c.315C>A, NC_000021.9:g.34886879G>T, CM000683.2:g.34886879G>T, NC_000021.8:g.36259176G>T, CM000683.1:g.36259176G>T, NC_000021.7:g.35181046G>T, NG_011402.2:g.1102833C>A, LRG_482:g.1102833C>A, ENST00000675419.1:c.315C>A, ENST00000300305.7:c.315C>A, ENST00000344691.8:c.234C>A, ENST00000358356.9:c.234C>A, ENST00000399237.6:c.279C>A, ENST00000399240.5:c.234C>A, ENST00000437180.5:c.315C>A, ENST00000455571.5:c.276C>A, ENST00000482318.5:c.59-6166C>A, NM_001001890.2:c.234C>A, NM_001122607.1:c.234C>A, LRG_482t1:c.315C>A, XM_005261068.3:c.279C>A, XM_005261069.3:c.315C>A, XM_011529766.1:c.315C>A, XM_011529767.1:c.276C>A, XM_011529768.1:c.276C>A, XM_011529770.1:c.315C>A, XR_937576.1:n.494C>A, XM_005261069.4:c.315C>A, XM_011529766.2:c.315C>A, XM_011529767.2:c.276C>A, XM_011529768.2:c.276C>A, XM_011529770.2:c.315C>A, XM_017028487.1:c.162C>A, XR_937576.2:n.541C>A, NM_001001890.3:c.234C>A, NM_001122607.2:c.234C>A, NM_001754.5:c.315C>A	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	PM1_Supporting, PS3, PM2_Supporting, PP3	PS1, PS4, PS2, BA1, BP1, BP4, BP3, BP2, BP7, BP5, BS3, BS1, BS4, PM6, PVS1, PM5, PM4, PM3, PP2, PP1, PP4, BS2	The NM_001754.4:c.315C>A (p.His105Gln) variant affects one of the residues (AA 105-204) within the RHD which is not an established hotspot residue (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). Transactivation assays demonstrating altered transactivation (<20% of wt, and/or reduced to levels similar to well-established pathogenic variants such as R201Q or R166Q) and data from secondary assays demonstrate altered DNA binding and functional consequences in mouse model. (PS3; PMID: 22318203; PMID: 25840971). This missense variant has a REVEL score >0.75 (0.901) (PP3). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PM2_supporting, PP3, PM1_supporting.	22318203, 25840971	Myeloid Malignancy VCEP		2024-09-10	2024-09-10	false	https://erepo.genome.network/evrepo/ui/classification/CA410203511/MONDO:0011071/008	f6a20713-2a4b-4e08-91db-86f46749c256
NC_000021.9:g.(?_34787801)_(34799462_?)del	417477	-	NC_000021.9:g.(?_34787801)_(34799462_?)del	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	PS4_Moderate, PVS1_Strong, PM2	PS1, PS3, PS2, BP1, BP4, BP3, BP2, BA1, BP7, BP5, BS3, BS1, BS4, PM6, PM5, PM4, PM1, PM3, PP2, PP3, PP1, PP4, BS2	This deletion of exons 8+9 of RUNX1 affects critical protein domains (TAD, VWRPY-motif). Despite the unknown impact on the reading frame and no NMD-prediction, PVS1_Strong can be applied based on the impact on critical protein domains. In addition, the variant is absent from population databases (PM2) and 2 probands have been reported and met FPD/AML phenotype criteria (SCV000563938.2 and internal laboratories) (PS4_Moderate). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1_Strong, PM2, PS4_Moderate.		Myeloid Malignancy VCEP		2019-08-07	2019-08-07	false	https://erepo.genome.network/evrepo/ui/classification/CV417477/MONDO:0011071/008	66e7e1cc-4845-45b7-8b92-31aa70fc169b
NC_000021.9:g.(?_35048836)_(35048905_?)del	463975	-	NC_000021.9:g.(?_35048836)_(35048905_?)del	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PS4, PVS1_Moderate, PP1_Strong, PM5_Supporting, PM2_Supporting	PS1, PS3, PS2, BA1, BP1, BP4, BP3, BP2, PM6, BP7, BP5, BS3, BS1, BS4, PM4, PM1, PM3, PP2, PP3, PP4, BS2	The deletion of exons 1 (non-coding) and 2 or exons 1, 2, and 3, all affecting presumedly exclusively RUNX1 isoform C, are common in FPD/AML patients and currently represent the most common pathogenic CNV in RUNX1. Multiple probands have been reported. These deletions only affect the N-terminal region of isoform C which is not shared by isoforms A and B. Despite the N-terminal region being a functionally unknown part of the protein, isoform C is biologically important und deletions are absent in the population which warrants application of PVS1_Moderate and PM2_supporting. This variant is a nonsense/frameshift variants that is downstream of c.98 (PM5_Supporting). Probands and affected family members show the typical FPD/AML phenotype and the deletion segregates with disease in multiple affected family members across multiple families (PP1_Strong). In addition, PS4 can be applied due to 5 probands with FPD/AML were reported from internal laboratories. In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS4, PP1_Strong, PVS1_Moderate, PM2_supporting, PM5_supporting.	29666006	Myeloid Malignancy VCEP		2024-03-26	2024-03-26	false	https://erepo.genome.network/evrepo/ui/classification/CV463975/MONDO:0011071/008	5d15c32f-47fc-4ba9-8d74-b998374ee11d
NM_001754.4(RUNX1):c.509-?_613+?del	254081	-	NM_001754.4(RUNX1):c.509-?_613+?del	N/A	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	PVS1_Strong, PS4_Supporting, PM2_Supporting, PP1	PS3, PS1, PS2, BP1, BP4, BP3, BP2, BA1, BS3, BS1, BS4, BP7, BP5, PM6, PM4, PM1, PM5, PM3, PP2, PP3, PP4, BS2	NM_001754.4(RUNX1):c.509-?_613+?del is an in-frame deletion of exon 6 of RUNX1 which disrupts the critical Runt homology DNA-binding domain, affecting a crucial functional domain (PVS1_Strong). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). One proband shows a typical FPD/AML phenotype (PS4_supporting), and there is evidence of segregation of the deletion with disease in affected family members (PP1). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1_Strong, PM2_supporting, PP1, PS4_supporting.		Myeloid Malignancy VCEP		2024-08-28	2024-08-28	false	https://erepo.genome.network/evrepo/ui/classification/CV254081/MONDO:0011071/008	aa38c2db-b62c-4b9a-969f-cd66d4dc9b0f
NM_001754.4(RUNX1):c.613+8C>T	339876	CA10014475	NM_001754.4:c.613+8C>T, NC_000021.9:g.34859466G>A, CM000683.2:g.34859466G>A, NC_000021.8:g.36231763G>A, CM000683.1:g.36231763G>A, NC_000021.7:g.35153633G>A, NG_011402.2:g.1130246C>T, LRG_482:g.1130246C>T, NM_001001890.2:c.532+8C>T, NM_001122607.1:c.532+8C>T, LRG_482t1:c.613+8C>T, XM_005261068.3:c.577+8C>T, XM_005261069.3:c.613+8C>T, XM_011529766.1:c.613+8C>T, XM_011529767.1:c.574+8C>T, XM_011529768.1:c.574+8C>T, XM_011529770.1:c.613+8C>T, XR_937576.1:n.792+8C>T, XM_005261069.4:c.613+8C>T, XM_011529766.2:c.613+8C>T, XM_011529767.2:c.574+8C>T, XM_011529768.2:c.574+8C>T, XM_011529770.2:c.613+8C>T, XM_017028487.1:c.460+8C>T, XR_937576.2:n.839+8C>T, ENST00000300305.7:c.613+8C>T, ENST00000344691.8:c.532+8C>T, ENST00000358356.9:c.532+8C>T, ENST00000399237.6:c.577+8C>T, ENST00000399240.5:c.532+8C>T, ENST00000437180.5:c.613+8C>T, ENST00000467577.1:n.105+8C>T, ENST00000482318.5:c.*203+8C>T, NM_001754.4(RUNX1):c.613+8C>T	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1, BP4, BP2, BP7	PS3, PS1, PS4, PM2, PM6, PVS1, BS3, BS1, BS4, PM1, PM4, PM5, PP3, PP1	The NM_001754.4:c.613+8C>T variant has a MAF of 0.00151 (0.151%, 101/66,722 alleles) in the European (Non-Finnish) subpopulation of the ExAC cohort that is â‰¥ 0.0015 (0.15%) (BA1). This variant is detected in homozygous state (15) in gnomAD population database (BP2). This intronic variant is predicted by SSF and MES to lead to either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In addition, evolutionary conservation prediction algorithms predict the site as not being highly conserved (PhyloP score -1.2534 < 0.1) (BP7). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2, BP4, BP7.		Myeloid Malignancy VCEP		2019-08-06	2019-08-06	false	https://erepo.genome.network/evrepo/ui/classification/CA10014475/MONDO:0011071/008	a5b1509f-a41a-4e1f-8abf-f00dfd44bcf5
NM_000277.2(PAH):c.441+6T>A	120275	CA267654	NM_000277.2:c.441+6T>A, NC_000012.12:g.102877456A>T, CM000674.2:g.102877456A>T, NC_000012.11:g.103271234A>T, CM000674.1:g.103271234A>T, NC_000012.10:g.101795364A>T, NG_008690.1:g.45147T>A, NG_008690.2:g.85955T>A, NM_000277.1:c.441+6T>A, XM_011538422.1:c.441+6T>A, NM_001354304.1:c.441+6T>A, XM_017019370.2:c.441+6T>A, NM_000277.3:c.441+6T>A, ENST00000307000.7:c.426+6T>A, ENST00000549111.5:n.537+6T>A, ENST00000550978.6:n.431T>A, ENST00000551988.5:n.530+6T>A, ENST00000553106.5:c.441+6T>A, NM_000277.2(PAH):c.441+6T>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PP3, PM3_Strong		The c.441+6T>A variant in PAH has been reported in at least 2 patients with PKU (BH4 deficiency ruled out), who carried pathogenic variants (ClinVar IDs: 589 & 576)  (PMID: 22526846). This variant is absent from 1000G and ESP, and has an extremely low frequency in gnomAD (MAF= 0.000004). This intronic variant changes a moderately conserved nucleotide, and computational analyses (Alamut) predict that this variant may weaken (~60%) the splice donor site of intron 4. Based on the available information, this variant is considered to be likely pathogenic. PAH-specific ACMG/AMP criteria applied: PP3, PP4_M, PM2, PM3_S.	22526846, 22526846	Phenylketonuria VCEP		2019-08-06	2019-08-07	false	https://erepo.genome.network/evrepo/ui/classification/CA267654/MONDO:0009861/006	f4d1a114-f822-49f7-aec3-f445c0174a02
NM_000277.2(PAH):c.912G>A (p.Gln304=)	102892	CA229845	NM_000277.2:c.912G>A, NC_000012.12:g.102851687C>T, CM000674.2:g.102851687C>T, NC_000012.11:g.103245465C>T, CM000674.1:g.103245465C>T, NC_000012.10:g.101769595C>T, NG_008690.1:g.70916G>A, NG_008690.2:g.111724G>A, NM_000277.1:c.912G>A, XM_011538422.1:c.912G>A, NM_001354304.1:c.912G>A, NM_000277.3:c.912G>A, ENST00000307000.7:c.897G>A, ENST00000549247.6:n.671G>A, ENST00000551114.2:n.574G>A, ENST00000553106.5:c.912G>A, ENST00000635477.1:n.73G>A, NM_000277.2(PAH):c.912G>A (p.Gln304=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PP4_Moderate, PM2, PP3, PM3_Strong		The c.912G>A (p.Gln304Gln) variant in PAH has been reported in multiple PKU patients  (BH4 deficiency excluded in some) (PMID: 23514811). This variant is absent from 1000G and ESP, and has an extremely low frequency in gnomAD (MAF=0.000004).  This is a synonymous variant that occurs at the junction of exon8/intron8, and computational analyses (Alamut v.2.11) predict that this variant may impact splicing by reducing (~20%) the canonical donor site.  p.Gln304= has been detected with multiple pathogenic variants without confirmation of parental testing to determine phase: R241H (VarID102804, PMID: 27413125); K363fsdelG (c.1089delG, VarID102518, PMID: 8659548); I65T (VarID636) and A300S (VarID92751, PMID: 2351481); p.R176L (VarID631, PMID: 23500595). In summary, this variant meets criteria to be classified as likely pathogenic for PAH.  PAH-specific ACMG/AMP criteria applied: PP3, PM2, PM3_strong, PP4_moderate.	23514811, 7766951, 26413448, 23500595, 24941924, 27413125, 23514811, 8659548	Phenylketonuria VCEP		2019-08-06	2019-08-07	false	https://erepo.genome.network/evrepo/ui/classification/CA229845/MONDO:0009861/006	264d0ad0-d6e2-476b-bd24-bbdc8f2ccd05
	-	CA16020877	NM_000277.1:c.868C>T, NC_000012.12:g.102851731G>A, CM000674.2:g.102851731G>A, NC_000012.11:g.103245509G>A, CM000674.1:g.103245509G>A, NC_000012.10:g.101769639G>A, NG_008690.1:g.70872C>T, NG_008690.2:g.111680C>T, XM_011538422.1:c.868C>T, NM_000277.2:c.868C>T, NM_001354304.1:c.868C>T, NM_000277.3:c.868C>T, ENST00000307000.7:c.853C>T, ENST00000549247.6:n.627C>T, ENST00000551114.2:n.530C>T, ENST00000553106.5:c.868C>T, ENST00000635477.1:n.29C>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PP4_Moderate, PM2, PP3		The c.868C>T (p.His290Tyr) variant in PAH has been reported in 1 individual with PKU (BH4 deficiency excluded) detected in trans with p.R408E (Pathogenic in ClinVar; PP4_Moderate, PM3; PMID: 22526846). This variant is absent in population databases (PM2). Computational evidence suggests a damaging effect. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.	22526846	Phenylketonuria VCEP		2019-08-11	2019-08-11	false	https://erepo.genome.network/evrepo/ui/classification/CA16020877/MONDO:0009861/006	651457c2-ed3e-4bdf-ab55-fdb60566927d
NM_000277.2(PAH):c.505C>T (p.Arg169Cys)	125436	CA267693	NM_000277.2:c.505C>T, NC_000012.12:g.102866600G>A, CM000674.2:g.102866600G>A, NC_000012.11:g.103260378G>A, CM000674.1:g.103260378G>A, NC_000012.10:g.101784508G>A, NG_008690.1:g.56003C>T, NG_008690.2:g.96811C>T, NM_000277.1:c.505C>T, XM_011538422.1:c.505C>T, NM_001354304.1:c.505C>T, XM_017019370.2:c.505C>T, NM_000277.3:c.505C>T, ENST00000307000.7:c.490C>T, ENST00000549111.5:n.601C>T, ENST00000551988.5:n.530+10862C>T, ENST00000553106.5:c.505C>T, NM_000277.2(PAH):c.505C>T (p.Arg169Cys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2, PP4_Moderate, PM3_Strong	PP3	The c.505C>T (p.Arg169Cys) PAH variant has been identified in at least 3 compound heterozygous probands with mild HPA to classic PKU, with at least 1 proband excluding BH4 deficiency (PMIDs: 28771436, 30050108, 30747360). It has been detected in trans with pathogenic variants Arg243Gln (ClinVar 591), Arg408Gln (ClinVar 577), and c.208_210del (ClinVar 102632). This variant occurs and a very low frequency of 0.00001194 in gnomAD. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_Strong, PM2, PP4_Moderate.	30050108, 30747360, 28771436, 30050108	Phenylketonuria VCEP		2019-08-11	2019-08-11	false	https://erepo.genome.network/evrepo/ui/classification/CA267693/MONDO:0009861/006	1010c67c-c106-47a5-840d-1ea31f14b69a
NM_000277.2(PAH):c.547_548delGAinsTT (p.Glu183Leu)	120278	CA267658	NM_000277.2:c.547_548delGAinsTT, NM_000277.1:c.547_548delinsTT, XM_011538422.1:c.547_548delinsTT, NM_000277.2:c.547_548delinsTT, NM_001354304.1:c.547_548delinsTT, XM_017019370.2:c.547_548delinsTT, NM_000277.3:c.547_548delinsTT, ENST00000307000.7:c.532_533delinsTT, ENST00000549111.5:n.643_644delinsTT, ENST00000551988.5:n.568_569delinsTT, ENST00000553106.5:c.547_548delinsTT, NC_000012.12:g.102855294_102855295delinsAA, CM000674.2:g.102855294_102855295delinsAA, NC_000012.11:g.103249072_103249073delinsAA, CM000674.1:g.103249072_103249073delinsAA, NC_000012.10:g.101773202_101773203delinsAA, NG_008690.1:g.67308_67309delinsTT, NG_008690.2:g.108116_108117delinsTT, NM_000277.2(PAH):c.547_548delGAinsTT (p.Glu183Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM3, PM2, PP3, PP4		The c.547_548delGAinsTT PAH variant has been identified in at least one patient with classic PKU (PMID: 26666653). It was detected in trans with the pathogenic variant c.143T>C; p.Leu48Ser (ClinVar 608). This variant is absent from 1000G, ESP, and gnomAD databases. It is predicted deleterious in multiple in silico models. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM3, PP3.	26666653, 26666653	Phenylketonuria VCEP		2019-08-11	2019-08-11	false	https://erepo.genome.network/evrepo/ui/classification/CA267658/MONDO:0009861/006	3e905683-806d-4709-8aaf-b71562b3bf03
NM_000277.1(PAH):c.782G>C (p.Arg261Pro)	102832	CA229759	NM_000277.1:c.782G>C, NC_000012.12:g.102852875C>G, CM000674.2:g.102852875C>G, NC_000012.11:g.103246653C>G, CM000674.1:g.103246653C>G, NC_000012.10:g.101770783C>G, NG_008690.1:g.69728G>C, NG_008690.2:g.110536G>C, XM_011538422.1:c.782G>C, NM_000277.2:c.782G>C, NM_001354304.1:c.782G>C, NM_000277.3:c.782G>C, ENST00000307000.7:c.767G>C, ENST00000549247.6:n.541G>C, ENST00000553106.5:c.782G>C, NM_000277.1(PAH):c.782G>C (p.Arg261Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM5, PM2, PP3, PP4, PM3_Strong		The PAH c.782G>C (p.Arg261Pro) variant has been reported in multiple affected individuals (PMID: 26666653, Bh4 deficiency not ruled out, PP4). It has been detected with 5 known pathogenic variants (PM3_S). It is absent from ExAC/gnomAD. Computational evidence supports a deleterious effect. Also, p.R261Q is interpreted as pathogenic. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_S, PM2, PM5, PP4, PP3.	26666653, 26666653	Phenylketonuria VCEP		2019-08-11	2019-08-11	false	https://erepo.genome.network/evrepo/ui/classification/CA229759/MONDO:0009861/006	e50d8620-443e-4dd4-949e-81a67d4b702d
	-	CA16020720	NM_000277.1:c.48dup, NC_000012.12:g.102917083dup, CM000674.2:g.102917083dup, NC_000012.11:g.103310861dup, CM000674.1:g.103310861dup, NC_000012.10:g.101834991dup, NG_008690.1:g.5520dup, NG_008690.2:g.46328dup, XM_011538422.1:c.48dup, NM_000277.2:c.48dup, NM_001354304.1:c.48dup, XM_017019370.2:c.48dup, NM_000277.3:c.48dup, ENST00000307000.7:c.-100dup, ENST00000546844.1:c.48dup, ENST00000547319.1:n.359dup, ENST00000549111.5:n.144dup, ENST00000550978.6:n.32dup, ENST00000551337.5:c.48dup, ENST00000551988.5:n.137dup, ENST00000553106.5:c.48dup, ENST00000635500.1:n.29-4185dup	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1, PM2, PP4, PM3_Supporting		Pathogenic: The c.48dup (p.D17*) variant has been reported in one individual with classic PKU, who carried a second pathogenic variant in PAH (p.L48S) (PM3, PP4; PMID: 18299955). This variant is absent from gnomAD, 1000 Genomes, and ESP databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM3-supporting, PM2, PP4.	18299955, 18299955	Phenylketonuria VCEP		2019-08-11	2019-08-11	false	https://erepo.genome.network/evrepo/ui/classification/CA16020720/MONDO:0009861/006	1eae3b8a-7f13-4ed6-a03c-e9edf537ff1d
NM_000277.2(PAH):c.59A>T (p.Gln20Leu)	102749	CA229641	NM_000277.2:c.59A>T, NC_000012.12:g.102917072T>A, CM000674.2:g.102917072T>A, NC_000012.11:g.103310850T>A, CM000674.1:g.103310850T>A, NC_000012.10:g.101834980T>A, NG_008690.1:g.5531A>T, NG_008690.2:g.46339A>T, NM_000277.1:c.59A>T, XM_011538422.1:c.59A>T, NM_001354304.1:c.59A>T, XM_017019370.2:c.59A>T, NM_000277.3:c.59A>T, ENST00000307000.7:c.-89A>T, ENST00000546844.1:c.59A>T, ENST00000547319.1:n.370A>T, ENST00000549111.5:n.155A>T, ENST00000550978.6:n.43A>T, ENST00000551337.5:c.59A>T, ENST00000551988.5:n.148A>T, ENST00000553106.5:c.59A>T, ENST00000635500.1:n.29-4174A>T, NM_000277.2(PAH):c.59A>T (p.Gln20Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2, PP4, PM3_Supporting	PP3	VUS:The c.59A>T (p.Q20L) variant was detected in trans with a known pathogenic variant (c.1315+1G>A) in a patient with hyperphenylalaninemia (parental testing not reported) (PP4, PM3-supporting; PMID: 10679941). This variant is absent from population databases including, gnomAD, ESP, and 1000 Genomes (PM2). Computation predictors on protein structure and function indicate conflicting results (SIFT: tolerated, Polyphen: Benign, MutationTaster: Disease causing, REVEL=0.582). In summary this variant meets the criteria  to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3-supporting, PP4.	10679941, 106799